
<html lang="en"     class="pb-page"  data-request-id="f7a89857-c310-4891-ab5b-0bea209eb10c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b01780;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-5"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="The Other Angiotensin II Receptor: AT2R as a Therapeutic Target" /></meta><meta name="dc.Creator" content="Lucienne  Juillerat-Jeanneret" /></meta><meta name="dc.Description" content="The active hormone of the renin–angiotensin system (RAS), angiotensin II (Ang II), is involved in several human diseases, driving the development and clinical use of several therapeutic drugs, most..." /></meta><meta name="Description" content="The active hormone of the renin–angiotensin system (RAS), angiotensin II (Ang II), is involved in several human diseases, driving the development and clinical use of several therapeutic drugs, most..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 7, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01780" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01780" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01780" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01780" /></link>
        
    
    

<title>The Other Angiotensin II Receptor: AT2R as a Therapeutic Target | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01780" /></meta><meta property="og:title" content="The Other Angiotensin II Receptor: AT2R as a Therapeutic Target" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0013.jpeg" /></meta><meta property="og:description" content="The active hormone of the renin–angiotensin system (RAS), angiotensin II (Ang II), is involved in several human diseases, driving the development and clinical use of several therapeutic drugs, mostly angiotensin I converting enzyme (ACE) inhibitors and angiotensin receptor type I (AT1R) antagonists. However, angiotensin peptides can also bind to receptors different from AT1R, in particular, angiotensin receptor type II (AT2R), resulting in biological and physiological effects different, and sometimes antagonistic, of their binding to AT1R. In the present Perspective, the components of the RAS and the therapeutic tools developed to control it will be reviewed. In particular, the characteristics of AT2R and tools to modulate its functions will be discussed. Agonists or antagonists to AT2R are potential therapeutics in cardiovascular diseases, for agonists, and in the control of pain, for antagonists, respectively. However, controlling their binding properties and their targeting to the target tissues must be optimized." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The active hormone of the renin–angiotensin system (RAS), angiotensin II (Ang II), is involved in several human diseases, driving the development and clinical use of several therapeutic drugs, mostly angiotensin I converting enzyme (ACE) inhibitors and angiotensin receptor type I (AT1R) antagonists. However, angiotensin peptides can also bind to receptors different from AT1R, in particular, angiotensin receptor type II (AT2R), resulting in biological and physiological effects different, and sometimes antagonistic, of their binding to AT1R. In the present Perspective, the components of the RAS and the therapeutic tools developed to control it will be reviewed. In particular, the characteristics of AT2R and tools to modulate its functions will be discussed. Agonists or antagonists to AT2R are potential therapeutics in cardiovascular diseases, for agonists, and in the control of pain, for antagonists, respectively. However, controlling their binding properties and their targeting to the target tissues must be optimized." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0013.jpeg" /></meta><meta name="twitter:title" content="The Other Angiotensin II Receptor: AT2R as a Therapeutic Target" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01780"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01780">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01780&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01780&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01780&amp;href=/doi/10.1021/acs.jmedchem.9b01780" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 1978-1995</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01623" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b02014" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Other Angiotensin II Receptor: AT<sub>2</sub>R as a Therapeutic Target</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Lucienne Juillerat-Jeanneret</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lucienne Juillerat-Jeanneret</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Transplantation Center, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Chemin des Boveresses 155, CH1011 Lausanne, Switzerland</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +41 21 314 7214, +41 21 314 7117. Email: <a href="/cdn-cgi/l/email-protection#68041d0b010d06060d46021d0104040d1a091c280b001d1e460b00"><span class="__cf_email__" data-cfemail="402c352329252e2e256e2a35292c2c2532213400232835366e2328">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lucienne++Juillerat-Jeanneret">Lucienne Juillerat-Jeanneret</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8039-7882" title="Orcid link">http://orcid.org/0000-0002-8039-7882</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01780&amp;href=/doi/10.1021%2Facs.jmedchem.9b01780" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 1978–1995</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 7, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 October 2019</li><li><span class="item_label"><b>Published</b> online</span>7 February 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01780" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01780</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1978%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLucienne%2BJuillerat-Jeanneret%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D5%26contentID%3Dacs.jmedchem.9b01780%26title%3DThe%2BOther%2BAngiotensin%2BII%2BReceptor%253A%2BAT2R%2Bas%2Ba%2BTherapeutic%2BTarget%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1995%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01780"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1019</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01780" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Other Angiotensin II Receptor: AT2R as a Therapeutic Target&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Lucienne&quot;,&quot;last_name&quot;:&quot;Juillerat-Jeanneret&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;1978-1995&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01780&quot;},&quot;abstract&quot;:&quot;The active hormone of the renin–angiotensin system (RAS), angiotensin II (Ang II), is involved in several human diseases, driving the development and clinical use of several therapeutic drugs, mostly angiotensin I converting enzyme (ACE) inhibitors and angiotensin receptor type I (AT1R) antagonists. However, angiotensin peptides can also bind to receptors different from AT1R, in particular, angiotensin receptor type II (AT2R), resulting in biological and physiological effects different, and sometimes antagonistic, of their binding to AT1R. In the present Perspective, the components of the RAS and the therapeutic tools developed to control it will be reviewed. In particular, the characteristics of AT2R and tools to modulate its functions will be discussed. Agonists or antagonists to AT2R are potential therapeutics in cardiovascular diseases, for agonists, and in the control of pain, for antagonists, respectively. However, controlling their binding properties and their targeting to the target tissues must be op&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01780&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01780" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01780&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01780" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01780&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01780" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01780&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01780&amp;href=/doi/10.1021/acs.jmedchem.9b01780" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01780" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01780" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01780%26sid%3Dliteratum%253Aachs%26pmid%3D32030982%26genre%3Darticle%26aulast%3DJuillerat-Jeanneret%26date%3D2020%26atitle%3DThe%2BOther%2BAngiotensin%2BII%2BReceptor%253A%2BAT2R%2Bas%2Ba%2BTherapeutic%2BTarget%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D5%26spage%3D1978%26epage%3D1995%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/5" title="Go to Volume 63, Issue 5"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/jmcmar.2020.63.issue-5/20200312/jmcmar.2020.63.issue-5.largecover.jpg" alt="Go to Volume 63, Issue 5"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The active hormone of the renin–angiotensin system (RAS), angiotensin II (Ang II), is involved in several human diseases, driving the development and clinical use of several therapeutic drugs, mostly angiotensin I converting enzyme (ACE) inhibitors and angiotensin receptor type I (AT<sub>1</sub>R) antagonists. However, angiotensin peptides can also bind to receptors different from AT<sub>1</sub>R, in particular, angiotensin receptor type II (AT<sub>2</sub>R), resulting in biological and physiological effects different, and sometimes antagonistic, of their binding to AT<sub>1</sub>R. In the present Perspective, the components of the RAS and the therapeutic tools developed to control it will be reviewed. In particular, the characteristics of AT<sub>2</sub>R and tools to modulate its functions will be discussed. Agonists or antagonists to AT<sub>2</sub>R are potential therapeutics in cardiovascular diseases, for agonists, and in the control of pain, for antagonists, respectively. However, controlling their binding properties and their targeting to the target tissues must be optimized.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/5"><issue-title>Women in Medicinal Chemistry</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> The Renin–Angiotensin System</h3><div class="NLM_p">From angiotensinogen, a member of the serpin family, the proteases of the renin–angiotensin system (RAS) generate several angiotensin (Ang) peptide hormones. Ang peptides then bind to cell-surface receptors, generating distinct cellular signals which induce physiological responses. Historically, the RAS has been described as a circulating system involving renal and vascular mechanisms.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The classical RAS is mainly known for regulating blood pressure and fluid balance, mediated by the interaction of Ang II with its type 1 receptor (AT<sub>1</sub>R). However, in addition to these classical functions, the RAS also controls other biologically important pathways, mediated by Ang II and/or its metabolites, involving AT<sub>1</sub>R and Ang receptors other than AT<sub>1</sub>R. Local tissue RAS, including intracellular RAS, has been found in a number of cells, tissues, and organs, including the kidneys, adrenal glands, the heart, the vascular and nervous systems, the reproductive and digestive organs, and the skin. These local RAS have a variety of functions, in association with or independently of the systemic RAS, including noncardiovascular functions, and are responsible for numerous biological and physiological effects of Ang peptides.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a></div><div class="NLM_p">In the classical RAS cascade, the enzyme renin (EC 3.4.23.15) converts the precursor angiotensinogen released by the liver to Ang I, which is subsequently converted to Ang II by angiotensin-converting enzyme (ACE, EC 3.4.15.1) found on the surface of vascular endothelial cells, predominantly but not exclusively, of the lungs. Ang II binding to AT<sub>1</sub>R results in vasoconstriction and retention of sodium and water, leading to an increase in blood pressure. Alternatively, an intracellular RAS was also shown to play important roles in mammalian cell function in normal situations and has also been involved in the pathogenesis of human diseases such as hypertension, diabetes, inflammation, fibrosis, arrhythmias, and kidney diseases. However, in addition to the classical effectors of the RAS, Ang II and AT<sub>1</sub>R, other angiotensin metabolite peptides, such as Ang III, Ang IV, and Ang(1–7), released from Ang I/II by alternate enzymes including aminopeptidase A (APA, EC 3.4.11.7), aminopeptidase B (APB, EC 3.4.11.6), aminopeptidase N (APN, EC 3.4.11.2), and ACE2 (EC 3.4.17.23) control the RAS in a counter-regulatory fashion.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Receptors for Ang peptides other than AT<sub>1</sub>R, such as AT<sub>2</sub>R and Mas receptor (MasR), have biological and physiological functions.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.) These mostly beneficial effects of Ang metabolites and alternate receptors include improving cardiovascular and renal dysfunctions, inflammation, tissue regeneration, brain function, cancer, and fibrosis, in particular kidney and heart fibrosis. In addition, a bypass loop by the lysosomal cathepsins, cathepsins B, D, and G, can also produce Ang active peptides.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> A brain RAS has been demonstrated, working independently of peripheral organs and encompassing all components of the RAS,<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> in particular in brain-derived cancer cells, which express angiotensinogen and the AT<sub>1</sub>R/AT<sub>2</sub>R.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Extended RAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Many disorders are associated with dysregulation of the RAS. Therefore, drugs that interrupt and/or modify different steps in this cascade have been developed to control blood pressure as well as heart and kidney failure. Presently, in current medical practice, overactivity of the RAS, and the resultant hypertension and cardiovascular disorders, is clinically controlled using either ACE inhibitors (ACEI) or AT<sub>1</sub>R blockers (ARBs). However, drugs aimed at interfering with the systemic RAS may also affect the functions of local systems, beneficially or adversely. Therapeutic approaches are also complicated by counterbalancing<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> as well as feedback mechanisms, such as the well-known rebound and rise in renin during chronic blockade of the RAS. As renin is the rate limiting component of the RAS, this rebound will translate into an increase of Ang peptides. Below, the characteristics of the components of the classical RAS as well as the components of the nonclassical RAS, and their associated chemotherapeutics in clinical use or under clinical development, will be briefly reviewed, focusing mainly on the Ang alternate receptor AT<sub>2</sub>R. As understanding the biological, physiological, and biomedical functions of the components of the RAS other than AT<sub>2</sub>R is necessary to discuss the potential role of this receptor as a target for therapeutic strategies, I will first provide a brief overview of the main components of the RAS and of the compounds that have allowed to better define AT<sub>2</sub>R as a therapeutic target.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Inhibitors of the Enzymes of the Classical RAS</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Renin and Renin Antagonism</h3><div class="NLM_p">Renin is a 37 kDa enzyme of the aspartyl protease family secreted mainly, but not exclusively, by the kidney. Human renin is released as pro-renin either by constitutive or regulated pathways, in response to three stimuli: a decrease in arterial blood pressure, a decrease in sodium load delivered to the distal tubule, and sympathetic nervous system activity. Pro-renin needs activation by proteolytic removal of its pro-fragment. Active renin hydrolyzes angiotensinogen secreted by the liver to the peptide Ang I. Pro-renin and renin can also bind to ATP6AP2 (ATPase H(+)-transporting lysosomal accessory protein 2), a transmembrane protein that is an essential accessory component of the vacuolar ATPase required for lysosomal degradative functions and autophagy, thus behaving as a hormone, which results in an increase in the conversion of angiotensinogen to Ang I and phosphorylation of serine and tyrosine residues of ATP6AP2. Renin regulates arterial blood pressure and mediates extracellular fluid volume (blood plasma, lymph, and interstitial fluid). Renin inhibitors have been developed for the treatment of cardiovascular diseases (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> These therapeutic inhibitors prevent the formation of Ang I and consequently also of Ang II and other angiotensin metabolites such as Ang III and Ang (1–7).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Renin inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The <i>N</i>-acyl-pentapeptide pepstatin/isovaleryl-<span class="smallcaps smallerCapital">l</span>-valyl-<span class="smallcaps smallerCapital">l</span>-valyl-statyl-<span class="smallcaps smallerCapital">l</span>-alanyl-statine was the first synthetic renin inhibitor, displaying poor specificity for renin over the other aspartyl proteases. First-generation inhibitors, such as H142 (<b>1</b>), were peptide analogues and consisted of two groups of compounds, either analogues of the pro-segment of renin or of the amino-terminal part of the substrate angiotensinogen, but they displayed poor bioavailability, short duration of action, and low potencies. Second-generation inhibitors such as remikiren (<b>2</b>) were peptide mimetics and were more potent and more stable, with longer durations of action. However, clinical development was terminated due to poor oral bioavailability and activity in lowering blood pressure. Third-generation nonpeptide inhibitors, such as aliskiren (<b>3</b>), were orally active, however quite poorly absorbed. Aliskiren was the first drug in its class to be approved for clinical use. However, possible risks exist, in particular the development of angioedema and elevated risks for acute kidney injury and hyperkalemia, when using aliskiren with ACEI and ARBs in patients with diabetes or renal impairment.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> ACE and ACE Antagonism</h3><div class="NLM_p">Following hydrolysis of angiotensinogen by renin, the inactive Ang I is further converted by ACE to the active peptide Ang II by removing the C-term dipeptide His-Leu. ACE also hydrolyzes other vasoactive peptides, including bradykinin. ACE is found in endothelial cells of the lungs and of other organs as well as on epithelial cells of the kidney and colon. ACEI are widely used for the treatment of cardiovascular diseases, diabetic nephropathy, and type 2 diabetes mellitus.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> ACE is a zinc metalloenzyme which is inhibited by metal-chelating agents. Thus, the first ACE inhibitor used in clinics, captopril (<b>4</b>), was a thiol compound able to chelate the catalytic zinc. Then, several molecules with various structures have been developed and accepted for clinical use, including enalapril (<b>5</b>), benazepril (<b>6</b>), and perindopril (<b>7</b>), among many others (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Some examples of ACE inhibitors in clinical use.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">ACEIs inhibit ACE competitively, decreasing the generation of Ang II, the secretion of aldosterone, and the degradation of bradykinin. ACEIs decrease arterial blood pressure and water and sodium reabsorption and reduce extracellular fluid volume. However, ACEIs also display side effects because ACE hydrolyses peptides other than Ang I, thus the development of antagonists to Ang receptor(s) was attempted to improve therapeutic selectivity and to control the off-targets and side effects of ACEI.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Modulators of the Classical and Alternative RAS</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Ang Peptides and Receptors and Alternative Pathways</h3><div class="NLM_p">Ang II is a potent constrictor of all blood vessels, active on smooth muscle cells, increasing vessel resistance. Ang II also acts on the adrenal glands, releasing aldosterone, which stimulates epithelial cells of the distal tubules and collecting ducts of the kidneys to increase reabsorption of sodium and water, leading to raised blood volume. Ang II has also been shown to be involved in oxidative stress and mitochondrial dysfunction.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> However, although Ang II has been previously viewed as a bloodborne hormone produced in the circulation, it is now established that Ang II is also formed locally in many tissues, such as the brain, kidney, and heart and blood vessel walls, and functions as a paracrine and autocrine hormone. Many of the physiological functions of Ang II are mediated by the AT<sub>1</sub>R, however, Ang II may also bind to AT<sub>2</sub>R. In addition to Ang II, other Ang metabolites with biological functions are known.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> From Ang I, in association with ACE, or from Ang II the zinc peptidase APA produce Ang III (desAsp-Ang II). Ang II and Ang III have the same affinity for AT<sub>1</sub>R and AT<sub>2</sub>R. Whereas Ang III can bind to AT<sub>1</sub>R and AT<sub>2</sub>R, Ang III stimulates aldosterone secretion from adrenal gland only via AT<sub>2</sub>R. We have previously shown that APA is increased in diseased brain and kidney, an effect mediated by the transforming growth factor (TGF)-β and that pro-drugs of therapeutic agents designed as APA substrates can selectively deliver their targets to APA-positive tissues.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Ang III can be further converted to Ang IV (desArg-Ang III) by APB or APN. Nonspecific APA/APB/APN inhibitors (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), such as amastatin (<b>8</b>) and bestatin (<b>9</b>), have been described, however, the specific role of each of these enzymes could not be precisely determined using these compounds. The development of the more specific APA and APN inhibitors,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> EC33 (<b>10</b>) and PC18 (<b>11</b>), respectively, has allowed to more precisely define their role in the RAS, in particular in the central nervous system (CNS), which expresses all components of the RAS. In the brain, Ang II is converted to Ang III by APA, whereas Ang III is inactivated by APN. Inhibition of APA by intracerebral injection, but not intravascular injection, of <b>10</b> blocked the pressor response to Ang II, an effect mediated by the axis Ang III/AT<sub>1</sub>R.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. APA and APN inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Evidence for a distinct Ang III receptor, i.e., AT<sub>3</sub>R, is controversial and the characteristics of AT<sub>3</sub>R are poorly defined. Ang IV specifically binds to AT<sub>4</sub>R, which has been identified as the transmembrane enzyme, insulin-regulated aminopeptidase/Leu-<i>N</i>-exopeptidase (IRAP, EC 3.4.11.3), a type II integral membrane spanning protein belonging to the M1 family of aminopeptidases. Ang IV acts as an inhibitor of IRAP. IRAP is unable to bind Ang II and its analogues and antagonists. Small molecule IRAP inhibitors, including HFI419 (<b>12</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), have been developed<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> but have not yet reached clinical trials. AT<sub>4</sub>R is predominantly located in the brain, heart, kidney, and blood vessels. AT<sub>4</sub>R signaling mechanisms are not well-defined, but AT<sub>4</sub>R influences local blood flow and is associated with cognitive processes and sensory and motor functions. The AT<sub>3</sub>R and AT<sub>4</sub>R will not be discussed further in this Perspective.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. IRAP, ACE2, and MasR modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">ACE2 catalyzes the conversion of Ang I to Ang(1–9) or of Ang II to the Ang(1–7), active on AT<sub>2</sub>R or the MasR, respectively,<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> inducing the production of arachidonic acid and activation of NO synthase, predominantly in the brain. ACE2 main physiological effects in the context of the RAS may be related to metabolically reducing Ang II levels and thus enhancing the beneficial effects of ACEI. Thus, enhancers of ACE2 activity and levels are likely to be therapeutically more interesting than inhibitors. (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) For example, the ACE2 inhibitor MLN-4760 (<b>13</b>) (IC<sub>50</sub> = 440 pM), aggravated kidney dysfunction, cardiac hypertrophy, and fibrosis. MasR coupling with the Gα<sub>i</sub>-adenylate cyclase pathway negatively modulates cAMP levels.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Ang(1–7) in addition to binding to MasR, can also bind to AT<sub>2</sub>R, with relevant effects, however, with a 5× lower affinity than Ang II, but cannot bind to AT<sub>1</sub>R. The selective MasR agonist AVE 0991 (<b>14</b>) (IC<sub>50</sub> = 21 nM) competes with Ang(1–7) for binding. AT<sub>2</sub>R and MasR mediate very similar protective functions and can heterodimerize, mediated by Cys<sup>35</sup> on AT<sub>2</sub>R. Heterodimers maintain functional responses to AT<sub>2</sub>R antagonists and agonists as well as to the MasR antagonist A-779 (Asp-Arg-Val-Tyr-Ile-His-<span class="smallcaps smallerCapital">d</span>-Ala, IC<sub>50</sub> = 0.3 nM, with a negligible affinity for AT<sub>1</sub>R and AT<sub>2</sub>R). Therefore, whereas AT<sub>1</sub>R/AT<sub>2</sub>R and AT<sub>1</sub>R/MasR heterodimerization leads to suppression of the AT<sub>1</sub>R signaling, AT<sub>2</sub>R/MasR heterodimers are functionally active.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Modulators of Ang Receptors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Within the RAS, Ang II activates two membrane glycoprotein members of the seven-transmembrane-domain (7TM) G protein-coupled receptor superfamily (GPCR): AT<sub>1</sub>R and AT<sub>2</sub>R,<a onclick="showRef(event, 'ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31">(28−31)</a> responsible for the signal transduction of Ang II, but with vastly different functions (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. AT<sub>1</sub>R and AT<sub>2</sub>R cellular signaling and effects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">AT<sub>1</sub>R and AT<sub>2</sub>R are phylogenetically old and found in all vertebrate classes. The human genome contains single genes for AT<sub>1</sub>R and AT<sub>2</sub>R. Although sequence homology between AT<sub>1</sub>R and AT<sub>2</sub>R is only 30%, the natural ligand Ang II and peptide antagonists, such as [Sar<sup>1</sup>, Ile<sup>8</sup>]Ang II, do not distinguish between the two receptors. However, binding of Ang II to each receptor elicits very different responses, and in addition to Ang II, Ang receptors can also bind Ang III. These receptors selectively and specifically but differently regulate many of the cardiovascular, hemodynamic, renal, neurological, and endothelial functions, cell proliferation and survival, inflammation, and cell-matrix interactions of the RAS. For example, a more important role for AT<sub>2</sub>R than AT<sub>1</sub>R has been shown in fetal development, while AT<sub>1</sub>R is more involved than AT<sub>2</sub>R in mediating Ang II effects for renal function in the postnatal development, maturation, and adaptation.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Ang receptors are classified by their gene sequences, structures of the proteins, ligand-binding affinities, agonist and antagonist efficacies, and signal transduction mechanisms. Pharmacologically, AT<sub>1</sub>R is sensitive to biphenylimidazole, such as the members of the “sartan” family of ARBs, and insensitive to AT<sub>2</sub>R ligands such as tetrahydroimidazopyridines. AT<sub>1</sub>R is inactivated by thiols, whereas AT<sub>2</sub>R is activated by thiols.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The development of specific nonpeptide receptor agonists and antagonists of both receptors has led to major advances in the physiology, pharmacology, and therapy of the RAS.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> However, in comparison with AT<sub>1</sub>R, the functions of AT<sub>2</sub>R are much less well-known.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> AT<sub>1</sub>R and AT<sub>1</sub>R Antagonism</h3><div class="NLM_p">AT<sub>1</sub>R is the best characterized Ang receptor. AT<sub>1</sub>R is ubiquitously expressed, including in vascular smooth muscle, liver, kidney, heart, lung, adrenal cortex, pituitary, and the brain. AT<sub>1</sub>R is the receptor subtype that is mainly responsible for the classical physiological actions of the RAS. AT<sub>1</sub>R has vasopressor effects and regulates vascular smooth muscle cell proliferation, renal functions and sodium reuptake, cardiac contractility, and extracellular matrix formation as well as aldosterone secretion and regulation of fluid volume in the cardiovascular system. AT<sub>1</sub>R can form heterodimers, in particular with the bradykinin B2 receptor, involved in preeclampsia hypertension in pregnant women.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">In humans, the gene encoding AT<sub>1</sub>R is located on chromosome 3q21–3q25. Mutations disrupting AT<sub>1</sub>R functions are not known, however, genetic variants of the <i>AGTR1</i> gene resulting from single nucleotide polymorphisms in the noncoding regions are documented. The molecular mass of human AT<sub>1</sub>R is ≈41 kDa and contains three <i>N</i>-glycosylation sites, eight phosphorylation sites, and six cysteine residues. The three-dimensional structure of AT<sub>1</sub>R is maintained by two disulfide bridges. The receptor binding sites for agonist and nonpeptide antagonist ligands have been defined. Amino acid residues of the extracellular and transmembrane regions of AT<sub>1</sub>R determine the binding affinities of Ang II; the binding sites of nonpeptide AT<sub>1</sub>R antagonists overlap with the Ang II binding pocket. The crystal structure of the human AT<sub>1</sub>R<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> confirmed the 7TM α-helical architecture of AT<sub>1</sub>R, showing three extracellular loops and three intracellular loops and a disordered C-terminal region. The second extracellular loop exhibits a secondary β-hairpin structure. The crystal structure and molecular docking studies indicated that Tyr<sup>35</sup>, Thr<sup>84</sup>, and Arg<sup>167</sup> are critical binding residues. AT<sub>1</sub>R is inactivated by thiol reagents.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Pharmacologically, the typical features of AT<sub>1</sub>R are their selective affinity for ARBs of the biphenylimidazole class and their insensitivity to AT<sub>2</sub>R antagonists of the tetrahydroimidazopyridine class, allowing to perform selective antagonism between the two Ang II receptors.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">Several nonselective or partially selective AT<sub>1</sub>R/AT<sub>2</sub>R ligands are known (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), such as L-162,313 (<b>15</b>) (<i>K</i><sub>i</sub> = 3.9 nM for AT<sub>1</sub>R, <i>K</i><sub>i</sub> = 2.8 nM for AT<sub>2</sub>R) or L-163,491 (<b>16</b>) (IC<sub>50</sub> = 1.4 nM for AT<sub>1</sub>R, IC<sub>50</sub> = 101 nM for AT<sub>2</sub>R), and have allowed to define the biological effects of Ang receptors. However, selectivity was sometimes controversial, and recently, <b>15</b> was shown to be a more selective AT<sub>2</sub>R than AT<sub>1</sub>R agonist.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Agonist binding to the AT<sub>1</sub>R leads to the recruitment of heterotrimeric G proteins and/or kinases, stimulating multiple intracellular signaling pathways. AT<sub>1</sub>R is predominantly coupled to G<sub>q/11</sub> and signal through phospholipases A, C, D, inositol phosphates, formation of prostaglandins and prostanoids, and calcium channels, which in turn triggers cellular responses such as stimulation of protein kinase C, inhibition of adenylate cyclase, and activation of various serine/threonine and tyrosine kinases. AT<sub>1</sub>R has been shown to also interact with zinc finger and BTB (Broad-Complex, Tramtrack, and Bric-a-Brac) domain-containing proteins. Cell specific effects have also been described. Many AT<sub>1</sub>R-induced growth responses are mediated by transactivation of growth factor receptors. Ang II, like many growth factors, promotes activation of tyrosine kinases such as pp60src, JAK-STAT, mitogen-activated protein kinase (MAPK), and nuclear factor kappaB (NF<sub>k</sub>B) pathways. Drugs that antagonize AT<sub>1</sub>R, such as losartan (<b>17</b>), valsartan (<b>18</b>), or candesartan (<b>19</b>), are largely used clinical therapeutics for the treatment of hypertension, congestive heart failure, and nephropathies. Therapeutic AT<sub>1</sub>R antagonists, the ARBs “sartans” family of therapeutics (some examples are shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), have been developed and are used clinically to prevent AT<sub>1</sub>R-mediated cardiovascular and renal effects of Ang II. Other beneficial effects of ARBs have been demonstrated. For example, <b>17</b> was shown to reduce collagen levels mediated by the axis Ang II-TGF-β1,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> an interesting effect for the control of fibrotic disorders. The axis Ang II-AT<sub>1</sub>R regulates hypertrophy of vascular smooth muscle cells through an autophagy mechanism, inhibited by a <b>17-</b>dependent/RhoA/Rho kinase-dependent signaling.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Ang II-induced fibrosis is associated with fibroblast differentiation into myofibroblasts and is triggered by macrophages through a TGF-β1/Smad signaling. Curcumin, a natural antioxidant, anti-inflammatory, and antifibrosis compound, was shown to attenuate myocardial fibrosis by decreasing AT<sub>1</sub>R and increasing AT<sub>2</sub>R levels associated with decreased TGF-β and collagen levels as well as reducing macrophage and myofibroblast populations.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> As most of the classical functions of Ang II are mediated through the AT<sub>1</sub>R, more pharmacological agents targeting AT<sub>1</sub>R compared to AT<sub>2</sub>R have been developed. AT<sub>1</sub>R antagonists, the ARBs, are at least as effective as ACEI in cardiovascular diseases, but are better tolerated.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. AT<sub>1</sub>R agonists and antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In summary, compounds designed to modulate the classical RAS have different consequences. Inhibitors of the RAS-associated enzymes, renin and ACE, involved in the production of Ang II induce a decrease of the level of this hormone and, consequently, a decrease of the activation of its receptors. On the contrary, antagonists to AT<sub>1</sub>R and inhibitors of the enzymes involved in the further processing of Ang II to its metabolites, the aminopeptidases APA, APB, and APN and ACE2 will result in an increase of Ang II levels and an increased bioavailability of this hormone to activate AT<sub>2</sub>R (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Consequences of modulating the Ang II production pathways in the classical RAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As a consequence, part of the beneficial effects of AT<sub>1</sub>R blockade by ARBs have been attributed to increased availability of Ang II and/or Ang III for the activation of AT<sub>2</sub>R, an effect which does not exist with ACEI.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> AT<sub>2</sub>R and AT<sub>2</sub>R Agonists and Antagonists</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> General Considerations</h4><div class="NLM_p">AT<sub>2</sub>R was first described in 1989 as the thiol-potentiated Ang II receptor. AT<sub>2</sub>R shares only 34% sequence homology with AT<sub>1</sub>R and differs from AT<sub>1</sub>R in terms of gene structure, characteristics and expression, protein sequence, tissue expression, signaling and pharmacological functions, and regulation.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> The gene coding for human AT<sub>2</sub>R is located on chromosome Xq22–Xq23, which results in sex differences in its expression and function. Mutations disrupting AT<sub>2</sub>R structure and/or signaling have been reported associated with X-linked mental retardation and related disorders as well as heart and renal structural abnormalities.<a onclick="showRef(event, 'ref44 ref45 ref46 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46 ref47 ref48 ref49">(44−49)</a> AT<sub>2</sub>R is an integral membrane protein of 363 amino acids and ≈41 kDa molecular weight belonging to the family 1 of 7TM GPCR. The receptor contains five <i>N</i>-glycosylation sites, five phosphorylation sites, and 14 cysteine residues, forming two disulfide bridges in its extracellular domain. Reduction of one of the two disulfide bridges is enough for modifying AT<sub>2</sub>R affinity and avidity for ligands.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> Structural features of AT<sub>2</sub>R explains its poor coupling to G proteins and lack of phosphorylation by kinases and of desensitization following Ang II binding.<a onclick="showRef(event, 'ref26 ref35 ref42 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref26 ref35 ref42 ref52 ref53 ref54">(26,35,42,52−54)</a> The pharmacophore of AT<sub>2</sub>R is distinct from AT<sub>1</sub>R, however, Ang II binds with equal affinity to AT<sub>1</sub>R and AT<sub>2</sub>R, and both Ang II and Ang III bind to AT<sub>2</sub>R with affinity in the nM range.</div><div class="NLM_p">In cells, the physiological functions and signal transduction mechanisms of AT<sub>2</sub>R are presently not completely defined. They are complex and diverse, depending on the biological context, as well as the cell and tissue types. AT<sub>2</sub>R has been shown to engage pathways different of AT<sub>1</sub>R upon Ang II binding. To identify the molecular determinants involved in AT<sub>2</sub>R activation, the structure of AT<sub>2</sub>R has been studied. The initial results showed that ligand binding induces an active conformation of the receptor, suggesting that AT<sub>2</sub>R does not bind to G proteins/β-arrestins.<a onclick="showRef(event, 'ref47 ref54'); return false;" href="javascript:void(0);" class="ref ref47 ref54">(47,54)</a> The crystal structure of human AT<sub>2</sub>R binding the peptide ligand and AT<sub>2</sub>R agonist<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> [Sar<sup>1</sup>, Ile<sup>8</sup>]Ang II and a stabilizing specific antibody fragment was solved at 3.2 Å resolution. [Sar<sup>1</sup>, Ile<sup>8</sup>]Ang II interacts with both the core binding domain of small AT<sub>1</sub>R and AT<sub>2</sub>R ligands, the extended binding domain, stabilized by the antibody fragment, functioning as a positive allosteric modulator. The differences observed between AT<sub>1</sub>R and AT<sub>2</sub>R for the binding modes and the amino acids engaged in the receptors in part explain that the active conformation of AT<sub>2</sub>R is constitutively more stable than AT<sub>1</sub>R.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> A series of AT<sub>1</sub>R/AT<sub>2</sub>R receptor chimeras allowed characterization of the structural determinants of AT<sub>2</sub>R signaling. The results suggested that the amino acid residues of the C-terminal domain of AT<sub>2</sub>R are compatible with canonical GPCR signaling. However, the atypical positioning of helix VIII due to the increased polarity of intracellular loop 1, but not the amino acid residues of helix VIII, impedes the engagement of classical GPCR effectors.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p">On the basis of its conformational characteristics, AT<sub>2</sub>R was proposed to display constitutive activity in the absence of ligands, suggesting that altered expression of AT<sub>2</sub>R by itself, and not ligand binding, mediates some of the biological functions of AT<sub>2</sub>R. In cells, AT<sub>2</sub>R transduction signaling is different from AT<sub>1</sub>R. AT<sub>1</sub>R signaling pathways, depending on tissue origin, involve heterotrimeric G-proteins, phosphorylation-dependent desensitization, and internalization, effects not observed for AT<sub>2</sub>R. AT<sub>2</sub>R displays ligand-independent constitutive activity, Ang II binding being not affected by guanosine triphosphate (GTP).<a onclick="showRef(event, 'ref30 ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref30 ref56 ref57 ref58">(30,56−58)</a> However, AT<sub>2</sub>R pertussis toxin-sensitive coupling to G<sub>i</sub>/G<sub>o</sub> has also been reported to participate in the signal transduction mechanism of AT<sub>2</sub>R. AT<sub>2</sub>R signaling involves serine and tyrosine protein phosphatases (such as dual specificity protein phosphatase 1/MAP kinase phosphatase 1/DUSP1/MKP-1, protein phosphatase 2A/PP2A, and Src homology phosphatase-1/SHP-1), whose activity is controlled by cellular redox mechanisms, limiting kinase signaling. The control of the phosphatase activity involves bradykinin, nitric oxide (NO), and cyclic guanosine monophosphate (cGMP) formation.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Thus, some of the beneficial effects of AT<sub>2</sub>R are mediated via the bradykinin and NO/cGMP systems, also observed in the presence of the AT<sub>1</sub>R blocker <b>17</b>, which allows for enhanced AT<sub>2</sub>R activation.<a onclick="showRef(event, 'ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61">(59−61)</a> We have shown that in the coronary microcirculation, AT<sub>2</sub>R-dependent vasodilation was endothelium-dependent and mediated by NO and bradykinin and that the beneficial effects of ARBs, but not of ACEI, were dependent on AT<sub>2</sub>R stimulation.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> AT<sub>2</sub>R also signals through several ion channel or phospholipases such as phospholipase A<sub>2</sub>.</div><div class="NLM_p">AT<sub>2</sub>R counteracts several of the growth responses initiated by AT<sub>1</sub>R and other growth factor receptors. Transactivation by AT<sub>2</sub>R of EGF, PDGF, and IGF receptors by direct interaction has been reported, AT<sub>2</sub>R acting as a negative regulator of cell kinase signaling and antagonizing growth stimulation by Ang II, EGF, PDGF, and IGF. AT<sub>2</sub>R also interacts with the transcription factors AT-rich binding protein ATBP/AT+P, which inhibits Erk phosphorylation in the absence of Ang II, or with the promyelocytic leukemia zinc finger protein PLZF, essential for protein synthesis. Depending on the tissue origin, AT<sub>2</sub>R activation stimulates intracellular mechanisms leading to the inactivation of AT<sub>1</sub>R-activated and growth factor-activated kinases. These effects result in antiproliferation, promotion of apoptosis, modulation of cation channels, and ultimately vasodilation. Agonist stimulation of AT<sub>2</sub>R does not increase cAMP, InsP<sub>3</sub>, and diacylglycerol (DAG) formation even if the sequence motifs involved in GPCR activation are retained. AT<sub>2</sub>R does not undergo agonist-induced receptor phosphorylation.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Thus, even if AT<sub>2</sub>R belongs to the GPCR family, which usually couple to G-proteins, AT<sub>2</sub>R associates directly, but alternatively, with other pathways, resulting in different signaling mechanisms, depending on the circumstances. Effects mediated by AT<sub>2</sub>R are context and cell- and tissue-dependent and include regulation of DNA and protein synthesis, cytostasis and apoptosis, tissue hypertrophy, vasodilation, and natriuresis. However, a clear picture of AT<sub>2</sub>R cellular and/or biological effects has not yet been provided.</div><div class="NLM_p">Physiological effects mediated by AT<sub>2</sub>R include fetal tissue development, vascular cell growth, cardiovascular functions, regulation of extracellular matrix (ECM), apoptosis, differentiation, and neuronal regeneration.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> The expression of AT<sub>2</sub>R is developmentally regulated, at both the transcriptional and translational levels. AT<sub>2</sub>R is abundantly and ubiquitously expressed in fetal and neonate tissues then decreases after birth under normal physiological circumstances, contrary to AT<sub>1</sub>R, which is ubiquitously found in adult tissues. AT<sub>2</sub>R can be re-expressed or up-regulated in pathological conditions, such as fibrosis and inflammation, vascular injury, myocardial infarction, cardiac failure, or wound healing, possibly reflecting reactivation of a fetal genetic program. However, in adults, AT<sub>2</sub>R is still expressed at low levels in the normal cardiovascular system, adrenal gland, kidney, brain, uterine myometrium, and skin.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> For example, in the kidney, AT<sub>2</sub>R represents up to 20% of Ang II binding capacity, in particular in the preglomerular vessels. AT<sub>2</sub>R is found on vascular endothelial cells<a onclick="showRef(event, 'ref65 ref57'); return false;" href="javascript:void(0);" class="ref ref65 ref57">(65,57)</a> and also on inflammatory/immune cells, including monocytes and T-cells.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> AT<sub>2</sub>R has also been suggested to protect the lungs from hypertension and fibrosis<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> and to participate to neuronal regeneration.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> In some tissues, AT<sub>1</sub>R and AT<sub>2</sub>R coexist. Tissue-specific expression of AT<sub>2</sub>R depends on several enhancers in the promoter region of AT<sub>2</sub>R gene. Species differences have been observed.</div><div class="NLM_p">The biomedical role of AT<sub>2</sub>R in human disorders has been studied, in particular in the cardiovascular system. The RAS and Ang II play a pivotal role in normal physiology, but dysregulation of the RAS results in chronic cardiovascular pathologies, mediated by increased signaling via the AT<sub>1</sub>R. Thus, inhibiting Ang II production using ACEI or Ang II binding to AT<sub>1</sub>R with ARBs is used to treat chronic cardiovascular diseases. It has to be noted that a reduction in Ang II levels by ACEIs will suppress the feedback loops on the RAS, but blockade of AT<sub>1</sub>R by ARBs can increase the availability of Ang II for AT<sub>2</sub>R and indirectly unmask hidden effects of AT<sub>2</sub>R activity. AT<sub>1</sub>R blockade also increases AT<sub>2</sub>R expression related to increased Ang II circulating levels, suggesting that AT<sub>2</sub>R participate to the beneficial effects of ARBs; therefore, ARBs are also cardioprotective through increased availability of Ang II for AT<sub>2</sub>R activation.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Thus, AT<sub>2</sub>R inhibits AT<sub>1</sub>R-mediated cellular signaling, resulting in antihypertensive, antiproliferative, antifibrotic, and anti-inflammatory effects.<a onclick="showRef(event, 'ref71 ref72 ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73 ref74 ref75">(71−75)</a> As preclinical in vitro and in vivo studies have shown that AT<sub>2</sub>R counterbalances the effects of AT<sub>1</sub>R, it has been proposed that AT<sub>2</sub>R action is beneficial not only in cardiovascular diseases but also in fibrotic disorders.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> AT<sub>2</sub>R antagonism or AT<sub>2</sub>R inactivation exacerbates renal fibrosis suggesting an antifibrotic role in this organ.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> In rodents, AT<sub>2</sub>R modulators have demonstrated an antidiuretic and antinatriuretic effect of AT<sub>2</sub>R.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Activation of AT<sub>2</sub>R may inhibit the expression and function of insulin receptor in renal cells depending on the hypertension status.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> AT<sub>2</sub>R also plays a major role in CNS. Human sensory neurons selectively express only AT<sub>2</sub>R. Stimulation of AT<sub>2</sub>R is neuroprotective and neuroregenerative, in particular after stroke and ischemia. Recent studies using an AT<sub>2</sub>R nonpeptide agonist in spinal cord injuries demonstrated a potential beneficial role beyond blood pressure regulation. Very recently, it was reported that AT<sub>1</sub>R expression decreased in metastatic melanoma compared to primary melanoma, due to promoter methylation, AT<sub>1</sub>R inhibition resulting in increased proliferation. AT<sub>2</sub>R activation by Ang II or Tyr<sup>6</sup>-Ang II, a specific AT<sub>2</sub>R agonist, resulted in enhanced proliferation of melanoma cells, whereas AT<sub>2</sub>R antagonism inhibited melanoma growth. Thus, pharmacological inhibition of AT<sub>2</sub>R may provide new therapeutic options for melanoma treatment.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div><div class="NLM_p last">The AT<sub>2</sub>R-mediated effects, in particular in the kidney and brain, may require local conversion of Ang II to Ang III, indicating that APA-mediated production of Ang III plays an important role in the activation of AT<sub>2</sub>R.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> We have very recently shown that the antioxidant mitochondria-active tetrapeptide SS-31 (<span class="smallcaps smallerCapital">d</span>-Arg-dimethylTyr-Lys-Phe-NH<sub>2</sub>) can down-regulate AT<sub>1</sub>R mRNA level following acute tubular and/or glomerular damage in animal models of kidney diseases. At the same time, SS-31 increased the expression of AT<sub>2</sub>R, which may contribute to limit renal damage. SS-31-based prodrugs developed as APA substrates also regulated APA,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> suggesting the involvement of Ang III in the beneficial effects of antioxidant compounds. Mitochondria are the main producers of oxidative stress in cells. A functional AT<sub>2</sub>R is present in the mitochondrial inner membrane, its level being enhanced by the ARB <b>17</b>.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Intracellular Ang II receptors in mitochondria and nucleus protect cells during chronic stimulation of the local tissue RAS in neurons, fibroblasts, renal cells, and cardiomyocytes. Nuclear AT<sub>1</sub>R signaling was shown to promote AT<sub>2</sub>R-dependent processes in mitochondria following its translocation to this organelle, stimulating mitochondrial AT<sub>2</sub>R and MasR signaling cascades, and enhancing mitochondrial biogenesis and cell protection against oxidative stress.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> High levels of AT<sub>2</sub>R in the mitochondria of renal tubular cells were shown to protect these cells from reactive oxygen species (ROS) production and metabolic reprogramming in the early stages of diabetes in a murine experimental model.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> AT<sub>2</sub>R has been shown to interact with the C-terminal domain of microtubule-associated scaffold protein 1, encoding a mitochondrial protein that acts as a tumor suppressor and participates in AT<sub>2</sub>R signaling pathways. The axis Ang II-AT<sub>1</sub>R stimulates oxidative stress and the production of proinflammatory and fibrotic molecules, whereas the axis Ang II/Ang III-AT<sub>2</sub>R results in anti-inflammatory and antifibrotic responses. AT<sub>2</sub>R regulates the NF<sub>κ</sub>B pathway and interferes with inflammatory and oxidative processes, reducing AT<sub>1</sub>R and increasing AT<sub>2</sub>R protein levels. Tissue RAS has been involved in remodeling processes, including ECM production.<a onclick="showRef(event, 'ref77 ref86'); return false;" href="javascript:void(0);" class="ref ref77 ref86">(77,86)</a> Increased AT<sub>2</sub>R expression is observed in response to tissue inflammatory stress and remodeling,<a onclick="showRef(event, 'ref67 ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref67 ref87 ref88 ref89">(67,87−89)</a> playing a protective role in tissue repair and regeneration. For example, AT<sub>2</sub>R mediates cardiac homing of c-kit<sup>+</sup> progenitor cells and promotes repair of infarcted tissue, possibly mediated by the Erk1/Erk2MAP kinases. Experimental studies in tissue repair and regeneration also suggest a protective action of AT<sub>2</sub>R on macrophages and myofibroblasts associated with reduced levels of TGF-β1, Smad2/3, and collagen I, resulting in reduced myocardial fibrosis.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Finally, as already stated, AT<sub>2</sub>R can form heterodimers, functioning dependently of each other, with either MasR<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> maintaining functional AT<sub>2</sub>R effects or with AT<sub>1</sub>R,<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> which results in disruption of AT<sub>2</sub>R signaling. Interaction between the renal D<sub>1</sub>R (dopamine D<sub>1</sub>-like receptor) and AT<sub>2</sub>R in human renal proximal tubule cells regulates renal Na<sup>+</sup> transport and blood pressure. D<sub>1</sub>R activation induces apical plasma membrane recruitment of AT<sub>2</sub>R, while AT<sub>2</sub>R stimulation with Ang III leads to the apical plasma membrane recruitment of the D<sub>1</sub>R, providing evidence for trans-regulation between these two receptors in the kidney.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Thus, depending on the cellular signaling and tissue involved, AT<sub>2</sub>R functions are anti-inflammatory, antiproliferative, antifibrotic, or antiapoptotic and are cardiovascular and renal protective as well as neuroprotective. In conclusion, there is increasing evidence that Ang II or Ang III through binding to AT<sub>2</sub>R have beneficial effects in various physiological and pathological situations.</div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">AT<sub>2</sub>R Agonists or Antagonists as Therapeutics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As the functions of AT<sub>2</sub>R, when activated, may be beneficial or detrimental depending on the physiological and medical context it was important to define, according to the context, whether the use of agonists, which would activate AT<sub>2</sub>R as do the natural Ang ligands, or on the contrary antagonists, which would block AT<sub>2</sub>R functions, are more appropriate. Therefore, both AT<sub>2</sub>R agonists and antagonists were developed and evaluated in various physiological contexts.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Agonists and Antagonists</h3><div class="NLM_p">Several AT<sub>2</sub>R agonists, including Compound 21 (C 21 (<b>20</b>), CGP 42112A (<b>21</b>) or 5,5-bicyclic thiazabicycloalkane Ang II (<b>22</b>), and antagonists, including PD123319 (<b>23</b>), PD123177 (<b>24</b>) or EMA-401 (<b>25</b>) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), were designed, prepared, and evaluated and have allowed to define in more detail the biological and physiological functions of AT<sub>2</sub>R and to evaluate the clinical and therapeutic interest of some selected compounds. The information that no individual residue in Ang II is critical for binding affinity explains the ability of AT<sub>2</sub>R to bind analogues and metabolites of Ang II.<a onclick="showRef(event, 'ref56 ref93'); return false;" href="javascript:void(0);" class="ref ref56 ref93">(56,93)</a> Thus, the first compounds prepared were Ang II analogues,<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> including Ang peptides analogues, shorter endogenous Ang II peptides, or unrelated endogenous peptides such as the AT<sub>2</sub>R agonist adrenal gland-derived peptide vasoconstriction-inhibiting peptide, which inhibits Ang II-induced phosphorylation,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> then nonpeptide compounds with improved pharmacokinetic properties were designed and further refined.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Some examples of AT<sub>2</sub>R agonists and antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b><i>Ang analogues and first-generation compounds</i></b> included Ang peptides analogues, displaying nanomolar affinity for AT<sub>2</sub>R and able to discriminate between AT<sub>1</sub>R and AT<sub>2</sub>R, such as <i>p</i>-amino-Phe<sup>6</sup>-Ang II,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> AT<sub>2</sub>R-selective agonist Ang II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics (<b>22</b>),<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Ang III analogues,<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> or even Ang-unrelated peptides, such as novokinin (RPLKPW).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Two aromatic histidine-related scaffolds or analogues missing the phenylalanyl residue were synthesized and introduced in tripeptides corresponding to the C-terminal region of Ang II providing peptidomimetics which exhibited selective, nanomolar affinity for AT<sub>2</sub>R as lead compounds for future development of novel classes of selective AT<sub>2</sub>R agonists.<a onclick="showRef(event, 'ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref101 ref102">(101,102)</a> The peptide CGP42112A (<i>N</i>-α-nicotinoyl-Tyr-Lys-(<i>N</i>-α-Z-Arg)-His-Pro-Ile, <b>21</b>), developed by Ciba-Geigy, is a partial agonist with high binding affinity but low potency,<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> it is also an AT<sub>1</sub>R agonist at high concentrations (<i>K</i><sub>i</sub> = 1.7 μM), therefore producing results ambiguous to interpret because the threshold was difficult to define. Stimulation of AT<sub>2</sub>R by <b>21</b> increased mucosal NO production and in isolated mitochondria, <b>21</b> decreased oxygen consumption.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a><b>21</b> added at reperfusion onset attenuated infarct following cerebral ischemia in mice.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> AT<sub>2</sub>R activation by <b>21</b> after experimental traumatic brain injury in mice improved neuroprotection as well as cognitive and motor functions, mediated by Akt and Erk1/2 activation and an increase of nerve growth factors.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> In murine fetal neurons in culture under glucose deprivation, <b>21</b> reduced cell death at low concentration, an effect lost at high concentration, likely due to uncomplete selectivity and AT<sub>1</sub>R activation. This effect was antagonized by the ARB <b>19</b> or by coadministration of the nonpeptide AT<sub>2</sub>R-selective antagonist <b>23</b>/EMA-200 (<i>K</i><sub>i</sub> = ∼12 nM for AT<sub>2</sub>R, ∼120 μM for AT<sub>1</sub>R). The AT<sub>2</sub>R agonist peptide analogue NP-6A4 (Novopyrix)<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> increased the expression of AT<sub>2</sub>R mRNA and protein levels, activating a positive feedback loop for AT<sub>2</sub>R signaling without induced cytotoxicity. NP-6A4 increased cell growth, mitochondrial respiration, ATP synthesis, and NO production, suggesting enhanced mitochondrial energy dynamics. NP-6A4 also suppressed ROS production and Jun-N-terminal phosphorylation over long-term cell exposure to doxorubicin and Ang II. NP-6A4, like <b>20</b> and <b>21</b>, is protective for cardiomyocytes, human coronary artery vascular smooth muscle, and endothelial cells. In these cells, NP-6A4 increased AT<sub>2</sub>R mRNA and protein levels, an effect suppressed by pretreatment with the AT<sub>2</sub>R antagonist <b>23</b> or an anti-AT<sub>2</sub>R siRNA. AT<sub>2</sub>R activation by Ang II induced cell dysfunction, cell growth arrest, and apoptosis, an effect inhibited by the antagonist <b>23</b>.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> AT<sub>2</sub>R activation is neuroprotective in the CNS. Microglia produce ROS and induce inflammatory stress, mediated by NADPH oxidase and antagonized by the AT<sub>2</sub>R agonist <b>21</b>, its protective effect being attenuated by the AT<sub>2</sub>R antagonist <b>23</b>.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The AT<sub>2</sub>R antagonist <b>23</b> also attenuated the protective effects of AT<sub>2</sub>R against corticosteroid/salt-induced hypertension in female, but not in male rats, an effect mediated by the regulation of brain RAS and proinflammatory cytokines.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Several AT<sub>2</sub>R antagonists (EMA200/<b>23</b>, EMA300/PD-121,981, EMA400/PD-126,055, L-159,686, L-161,638, and L-163,579, structures not provided) have interesting analgesic properties for the treatment of neuropathic pain.<a onclick="showRef(event, 'ref110 ref111 ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref110 ref111 ref112 ref113">(110−113)</a> Ang II-induced excitability in neuronal cells in culture and hindpaw sensitivity in a rat model of neuropathic pain was reduced by <b>23</b>. A major step forward was achieved when a [Phe]<sup>6</sup>-Ang II analogue was designed and shown to be a highly selective (18000-fold higher selectivity for AT<sub>2</sub>R versus AT<sub>1</sub>R), high affinity AT<sub>2</sub>R agonist (<i>K</i><sub>i</sub> = 3 nM), and a negative regulator of AT<sub>1</sub>R signaling, with anticancer properties.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> In conclusion, first-generation compounds provided leads to develop families of potential therapeutics of biomedical interest in cardiovascular, fibrogenic, inflammatory, oncologic, and neuronal disorders.</div><div class="NLM_p"><b><i>Second-generation nonpeptidomimetic AT</i><sub>2</sub><i>R agonists and antagonists</i></b> include mainly the antagonist EMA401 (<b>25</b>) and the agonist compound 21 (C21, <b>20</b>), chemical structures in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, which have shown interesting and valuable biological and physiological properties.<a onclick="showRef(event, 'ref113 ref115'); return false;" href="javascript:void(0);" class="ref ref113 ref115">(113,115)</a> AT<sub>2</sub>R blockade by <b>23</b> or <b>25</b> was shown to reduce sensitivity to pain.<a onclick="showRef(event, 'ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref116 ref117">(116,117)</a> Therefore, AT<sub>2</sub>R antagonism became a target for the treatment of neuropathic pain and pain control.<a onclick="showRef(event, 'ref112 ref118'); return false;" href="javascript:void(0);" class="ref ref112 ref118">(112,118)</a> AT<sub>2</sub>R agonism with <b>20</b> also displayed beneficial anti-inflammatory, antiproliferative, and antifibrotic effects in several diseases.</div><div class="NLM_p">EMA401: 4,5,6,7-Tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine and substituted 1,2,3,4-tetrahydro-isoquinoline derivatives were the first compounds described to have antagonizing properties for AT<sub>2</sub>R. From the series of compounds of the tetrahydroisoquinoline class (EMA200/<b>23</b>, EMA300/PD-121,981, and EMA400/PD-126,055), designed, prepared, and patented in 2003 by Parke-Davis, EMA-400 (IC<sub>50</sub> = 75.2 nM for rat AT<sub>2</sub>R; IC<sub>50</sub> = 2.9 × 10<sup>6</sup> nM for rat AT<sub>1</sub>R) was the most promising AT<sub>2</sub>R antagonist, displaying the best antinociceptive pain properties. The racemate EMA400 was then separated into the <i>S</i>-enantiomer <b>25</b> ((<i>S</i>)-2-(diphenylacetyl)-l,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid sodium salt) and the <i>R</i>-enantiomer EMA402. The highly AT<sub>2</sub>R-selective competitive antagonist <b>25</b> (IC<sub>50</sub> = 39 nM for human AT<sub>2</sub>R; IC<sub>50</sub> > 10000 nM for AT<sub>1</sub>R) proved better than EMA402 (IC<sub>50</sub> = 1100 nM for human AT<sub>2</sub>R) for treating nociceptive pain. Therefore, <b>25</b> was selected as the candidate drug for the clinical development of neuropathic pain treatment. The therapeutic development of <b>25</b> in the context of pain control has been recently reviewed in detail<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> and will be only summarized here. Doses of <b>25</b> up to 400 mg were safe in healthy male adults and was administered orally in both men and women at 100 mg twice daily in a phase II clinical trial.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a><b>25</b> reached a steady-state drug plasma concentration by the eighth day of drug intake and does not accumulate in the blood. <b>25</b> has shown efficacy in relieving pain in several preclinical models<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> and has been evaluated in phases I and II clinical trials for pain relief.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Following supportive results for the indication of peripheral neuropathies of a phase I trial by Spinifex Pharmaceuticals, the first clinical phase IIa trial, randomized, placebo-controlled, included 183 participants with postherpetic neuralgia, a chronic neuropathic pain, given either <b>25</b> orally or placebo for 28 days.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> No serious adverse effects have been determined that directly associates with <b>25</b>, only headache frequency was higher in patients receiving <b>25</b> for pain control over placebo in both phase I and phase II clinical trials.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Patients receiving <b>25</b> reported significant pain improvement compared to those under placebo. A nonrandomized phase II study of <b>25</b> for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy was approved and is currently underway. A further phase IIb/III trial was withdrawn without detailed explanation. <b>25</b> was initially developed by the Australian biotechnology company Spinifex Pharmaceuticals, then Novartis took over Spinifex in 2015, but no schedule is presently available for further clinical trials.</div><div class="NLM_p">Neuropathic pain is long-lasting pain that develops when the peripheral and the central nervous systems are sensitized following injury, while nociceptive pain is immediate pain felt as a result of injury inflicted to tissue.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a><b>23</b> and its analogues EMA200, EMA300 as well as <b>25</b> were studied as selective AT<sub>2</sub>R antagonists in the context of nociceptive pain. All components of the RAS, including AT<sub>1</sub>R and AT<sub>2</sub>R, are selectively expressed in cells of the adult CNS. Microglia produce ROS and induce inflammatory stress.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> AT<sub>1</sub>R is widely distributed, but mostly restricted to glial cells,<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> and is not involved with nociception. AT<sub>2</sub>R is mostly expressed by neurons in specific regions of the adult brain.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> AT<sub>2</sub>R antagonists, such as <b>25</b>, inhibit p38 and p42/p44 MAPK and capsaicin-evoked calcium influx in human sensory neurons which selectively express AT<sub>2</sub>R and not AT<sub>1</sub>R.<a onclick="showRef(event, 'ref28 ref110 ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref28 ref110 ref111 ref112">(28,110−112)</a> In the brain, excessive stimulation of AT<sub>1</sub>R mediates detrimental actions in cerebrovascular diseases, whereas activation of AT<sub>2</sub>R partly offsets the effects of AT<sub>1</sub>R and is protective. However, blockade of AT<sub>1</sub>R may also be protective as it results in increased binding of Ang II to AT<sub>2</sub>R. Following ischemic insult, AT<sub>2</sub>R may be upregulated in neuronal tissues, AT<sub>2</sub>R activation being neuroprotective in the CNS.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> As <b>25</b> does not cross the blood–brain barrier (BBB), it cannot have any direct effect in the CNS. Therefore, other mechanisms of action were studied in the context of neuropathies. <b>25</b> was shown in 2004 to reduce sensitization induced by Ang II of the transient receptor potential cation channel subfamily V member 1 (TRPV1).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Injured nerves and painful neuromas display higher AT<sub>2</sub>R expression compared to normal undamaged nerves.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Peripheral nerve damage results in the recruitment of macrophages, chronic inflammation, and neuropathic pain. AT<sub>2</sub>R is locally produced in tissues under nociceptive conditions<i>;</i><a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> however, in these tissues, AT<sub>2</sub>R is expressed by macrophages but not by sensory nociceptive neurons which express only AT<sub>1</sub>R, not AT<sub>2</sub>R. Macrophages express several other components of the RAS including angiotensinogen, renin, and ACE<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> and thus can produce Ang II. Activation of AT<sub>2</sub>R by Ang II in murine macrophages that infiltrate damaged sensory neurons induced the release of ROS, resulting in the activation of the TRPV1 pain-inducing ion channel expressed by neurons. Thus, AT<sub>2</sub>R on macrophages and the ion channel TRPV1 in neurons are required for Ang II-induced pain sensitization, demonstrating that interaction between both cells are necessary. TRPV1 is a ligand-gated nonselective cation channel found in sensory neurons that allows the sensation and perception of heat and other noxious stimuli. In clinical conditions of chronic pain, TRPV1 expression is up-regulated. Macrophage infiltration and AT<sub>2</sub>R activation by Ang II/Ang III or an AT<sub>2</sub>R agonist induced ROS production, resulting in TRPV1 activation in neurons via cysteine modification. ROS production was shown to be blocked by an AT<sub>2</sub>R, but not an AT<sub>1</sub>R, antagonist.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Ang II colocalization with substance P and calcitonin gene-related peptide suggests a role for these peptides in nociception,<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> implying the presence of an intrinsic angiotensinergic system. <b>25</b> has been implicated in alleviating pain associated with a host of neural abnormalities, including excessive damaged nerve sprouting, shingles, diabetes, osteoarthritis, diseases associated with human immunodeficiency virus (HIV)-1 infection, and chemotherapy, without displaying side effects in the CNS. Thus, the Ang II–AT<sub>2</sub>R pathway contributes to neuropathic pain by potentiating pathways in pain detecting neurons through kinase activation and sensitization of voltage-gated ion channels,<a onclick="showRef(event, 'ref110 ref111 ref112 ref120 ref123 ref126'); return false;" href="javascript:void(0);" class="ref ref110 ref111 ref112 ref120 ref123 ref126">(110−112,120,123,126)</a> increased cAMP levels, resulting in increased TRPV1 phosphorylation.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a><b>25</b> inhibits AT<sub>2</sub>R activation and cAMP increase in a dose dependent manner, producing analgesia.</div><div class="NLM_p">C21 and analogues: In 2004, Wan et al. at the Medicinal Chemistry group of Uppsala University synthesized the first selective orally active nonpeptide AT<sub>2</sub>R agonist, C21 (<b>20</b>) (<i>K</i><sub>i</sub> > 10 000 nM for AT<sub>1</sub>R; <i>K</i><sub>i</sub> = 0.4 nM for AT<sub>2</sub>R).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><b>20</b> was selected as the best representative of a series of compounds obtained by modifications of the nonselective AT<sub>1</sub>R/AT<sub>2</sub>R agonist <b>15</b>. In their initial publication, the authors demonstrated that <b>20</b> induced the outgrowth of neurites in cells expressing only the AT<sub>2</sub>R, an effect similar to Ang II, and mediated by Erk42/44 phosphorylation and inhibited by <b>23</b>. <b>20</b> is an orally active, nonpeptide and highly selective AT<sub>2</sub>R agonist, which allowed to convincingly define the functions of AT<sub>2</sub>R, pointing to a mainly dominant anti-inflammatory mechanism for its beneficial actions.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a><b>20</b> has been shown to be protective in many tissues, including the brain, vasculature, kidney, and heart in animal experimental models.<a onclick="showRef(event, 'ref129 ref130 ref131 ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref129 ref130 ref131 ref132 ref133">(129−133)</a><b>20</b> improved the consequences of postmyocardial infarction, vasodepressor effects, and ischemic stroke in animal models.<a onclick="showRef(event, 'ref134 ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref134 ref135 ref136">(134−136)</a> Ischemic stroke occurs when blood supply to the brain is decreased, depriving the brain of oxygen and nutrients, and causing immediate, irreversible necrosis within the core of the ischemic area but more delayed and potentially reversible neuronal damage in the surrounding brain tissue, the penumbra. The few currently approved therapies for ischemic stroke are only effective for a minority of patients and do not completely restore neurological deficits. Preclinical evidence in various animal models indicated that AT<sub>2</sub>R agonists, such as <b>20</b>, exerted significant neuroprotective effects, in particular by their regenerative, anti-inflammatory, and antioxidative properties, improving cerebral blood flow. However, delivering them across the BBB to the infarcted areas of the brain is challenging.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Thus, AT<sub>2</sub>R agonists have a neuroprotective potential in a stroke model.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><div class="NLM_p">The RAS regulates tissue remodeling processes and ECM production,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> mediated by activation of AT<sub>1</sub>R, resulting in oxidative stress, inflammation, fibrosis, and preventing apoptosis, proteolysis, and normal ECM regeneration.<a onclick="showRef(event, 'ref139 ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref139 ref140 ref141">(139−141)</a> In vivo, AT<sub>2</sub>R stimulation by <b>20</b>, in addition to decreasing mean arterial blood pressure in SHR rats, ameliorated cardiac fibrosis by diminishing TGF-β and matrix-metalloproteinases (MMP)2/9-mediated proteolysis.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> In an experimental hypertensive rat model, <b>20</b> reduced vascular injury and myocardial fibrosis, alone or in combination with <b>17</b>.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> In an experimental model of elastase-induced abdominal aneurysm, <b>20</b> prevented aneurysm progression, independently of cardiovascular functions. Expression of IL-1β, NFκB, MMP9, and TGF-β1, a hormone induced by AT<sub>1</sub>R activation, were down-regulated in the aorta, preventing ECM degradation, maintaining vascular integrity, and decreasing inflammatory cell infiltration,<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> thus being antiproliferative, antiatherosclerotic, and antifibrotic in the vasculature. <b>20</b> was shown to inhibit the NFκB and TGF-β pathways via NO/cGMP production in regulating fibrosis.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> In an experimental model of type 1 diabetes, <b>20</b> was protective against diabetic nephropathy and hypertensive neuropathy by inhibiting oxidative stress, inflammation, cardiomyopathy, and idiopathic pulmonary fibrosis.<a onclick="showRef(event, 'ref72 ref129 ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref72 ref129 ref144 ref145">(72,129,144,145)</a> Chronic administration of <b>20</b> was shown to positively improve the sensitivity to insulin in mice, dependent on Erk1/2 phosphorylation.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Thus, inducing AT<sub>2</sub>R expression and activation with agonists such as <b>20</b> has beneficial cardiovascular effects and is an anti-inflammatory, antiproliferative, and antifibrotic strategy with therapeutic potential in pathologic fibrosis. However, it was speculated that, under some circumstances, <b>20</b> effects may be off-target effects.<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147,148)</a></div><div class="NLM_p">The presumed structural requirements necessary for ligand binding of compounds designed as AT<sub>2</sub>R agonists or antagonists, respectively, have been studied and discussed.<a onclick="showRef(event, 'ref96 ref149'); return false;" href="javascript:void(0);" class="ref ref96 ref149">(96,149)</a> Systematic modifications and structure–activity relationships (SAR) of the sulfonylcarbamate derivative <b>20</b>, encompassing a phenylthiofen scaffold, were performed, mostly by the Hallberg/Larhed Medicinal Chemistry group at Uppsala University. Different scaffolds and functional groups attached to these scaffolds have been designed, prepared, and evaluated. However, these more recent molecules have not yet been evaluated in preclinical animal models. Below, a summary of these attempts at designing potential therapeutic drugs with improved biomedical properties is provided for the most promising potential therapeutic compounds.</div><div class="NLM_p">Structural alterations in the A-, B-, and/or C-positions of <b>20</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>)<a onclick="showRef(event, 'ref150 ref151 ref152 ref153 ref154 ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref150 ref151 ref152 ref153 ref154 ref155 ref156">(150−156)</a> have been performed. The modified compounds included butyloxyphenyl and propylthienyl derivatives in position C,<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> the replacement of the imidazole group in position A by a noncyclic moiety,<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> a series of substituted benzamide analogues in position C and isobutyl substituent in position B.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> The imidazole ring system in position A is a strong determinant of AT<sub>2</sub>R selectivity, most analogues maintaining AT<sub>2</sub>R affinity, AT<sub>2</sub>R/AT<sub>1</sub>R selectivity, and the capacity to induce neurite elongation in neuronal cells, comparable to Ang II. The imidazole moiety, responsible for the inhibition of CYP 450 by <b>20</b>, was replaced in position A by various heterocycles or carbonyl functionalities at the benzylic position providing AT<sub>2</sub>R agonists with high selectivity and affinity and reduced inhibition of the CYP 450.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Two series of compounds with a meta substitution pattern of the phenyl ring in position A have been synthesized and evaluated, providing compounds with high affinity (<i>K</i><sub>i</sub> = 2 to 100 nM) and selectivity for AT<sub>2</sub>R. Very interestingly, some of the compounds, represented by C38 (<b>26</b>), also acted as potent AT<sub>2</sub>R <i>antagonists</i>, being more effective than <b>23</b>, thus representing potential new leads. The properties of the two related and selective drug-like nonpeptide AT<sub>2</sub>R ligands, the agonist <b>20</b> and the antagonist <b>26</b>, were compared using neurite outgrowth in neuronal NG108-15 cells. <b>20</b>-induced or Ang II-induced neurite outgrowth and Erkp42/p44<sup>mapk</sup> activation in cells was inhibited by <b>26</b>, comparable to <b>23</b>.<a onclick="showRef(event, 'ref154 ref155'); return false;" href="javascript:void(0);" class="ref ref154 ref155">(154,155)</a> However, the authors used only a binding assay and one cell line, the NG108-15 cells (a hybrid between mouse neuroblastoma and rat glioma brain tumor cells) and neurite outgrowth, to evaluate their compounds, with no use of nontumoral cells or cells of various tissue origin. No detailed information has been provided concerning the mechanisms involved, in particular in the context of cell signaling, and no preclinical information is available. Thus, presently, without more detailed preclinical information, it is not possible to predict which compound would be the most interesting and relevant for further evaluation.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structural modifications of <b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Therefore, from the nonselective AT<sub>1</sub>R/AT<sub>2</sub>R agonist <b>15</b>, the high affinity AT<sub>2</sub>R selective agonist <b>20</b> was developed, which became the high affinity AT<sub>2</sub>R antagonist <b>26</b> through the moving of the imidazole ring in position A from a para to a meta position (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. From a nonspecific AT<sub>1</sub>R/AT<sub>2</sub>R agonist to a selective AT<sub>2</sub>R agonist to a selective AT<sub>2</sub>R antagonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These compounds are thought to mimic the three C-terminal amino acids His-Pro-Phe of Ang II. Detailed molecular models explaining AT<sub>2</sub>R selectivity resulting from these minor structural changes, the relative position of the imidazole group and the isobutyl substituent on the thiophene ring of this series of nonpeptide ligands, provoking different functional activities and selectivity for the different conformations of the receptor, have been discussed in more detail at a molecular level, using modeling of AT<sub>2</sub>R in its active and inactive conformations.<a onclick="showRef(event, 'ref156 ref143'); return false;" href="javascript:void(0);" class="ref ref156 ref143">(156,143)</a> On the basis of docking data, a tentative model of the binding modes of ligand analogues compared to the prototype AT<sub>2</sub>R antagonist <b>26</b> was also proposed.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> The differences in the predicted binding modes between agonists and antagonists in the active or inactive conformation of AT<sub>2</sub>R provide a possible explanation for the different biological behavior of the compounds.</div><div class="NLM_p last">More recently, two series of compounds were synthesized as ligands of AT<sub>2</sub>R and investigated. The first series explored the effects of adding small substituents to the phenyl ring of the AT<sub>2</sub>R antagonist <b>26</b>. These changes were well tolerated, generating only small shifts in AT<sub>2</sub>R affinity and similar kinetic solubility and stability in human liver microsomes as <b>26</b>. The second series was comprised of new bicyclic derivatives. One of these compounds exhibited a 5-fold improved affinity for AT<sub>2</sub>R as compared to <b>26</b>. However, most compounds in the second series were inferior to <b>26</b> with regard to stability in human microsomes. Thus, ligands with shorter carbamate alkyl chains demonstrated slightly improved stability in microsomes. Then, using transesterification reactions, several <b>26</b> analogues, in which the sulfonyl carbamate tail was varied, were synthesized as AT<sub>2</sub>R ligands for treating neuropathic pain, with potency equivalent to <b>26</b> and high AT<sub>2</sub>R/AT<sub>1</sub>R selectivity but with increased stability in human liver microsomes for the compounds with reduced size of the alkyl chain.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions and Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Several molecules, summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, have been designed, prepared, and evaluated for controlling the RAS, and in particular the receptors for the Ang peptides. These ligands displayed various affinities and selectivity for the different receptors of the RAS.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Angiotensin Receptors and Agonists and Antagonists</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">AT<sub>1</sub>R</th><th class="colsep0 rowsep0" align="center">AT<sub>2</sub>R</th><th class="colsep0 rowsep0" align="center">MasR</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left"><b>angiotensin peptides ligands</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ang I Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ang II Asp-Arg-Val-Tyr-Ile-His-Pro-Phe</td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">(±)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ang III Arg-Val-Tyr-Ile-His-Pro-Phe</td><td class="colsep0 rowsep0" align="center">++</td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ang(1–7) Asp-Arg-Val-Tyr-Ile-His-Pro</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">+++</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left"><b>AT<sub>1</sub>R and AT<sub>2</sub>R receptor agonists</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ang II/Ang III analogues</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">+</td><td class="colsep0 rowsep0" align="center">+++</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left"><b>AT<sub>1</sub>R and AT<sub>2</sub>R receptor antagonists</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ang II/Ang III analogues</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sartans/ARBs <b>17</b>, <b>18</b>, <b>19</b></td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">++</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">+++</td><td class="colsep0 rowsep0" align="center">–</td></tr></tbody></table></div></div><div class="NLM_p">AT<sub>1</sub>R antagonists, the ARBs/“sartans”, are in clinical use for several years to control cardiovascular and renal diseases. The search for AT<sub>2</sub>R ligands able to modify, either activate or antagonize, the functions of AT<sub>2</sub>R, started only recently. Whereas selectivity between AT<sub>1</sub>R/AT<sub>2</sub>R and MasR was easily achieved, it was more difficult to obtain selectivity between AT<sub>1</sub>R and AT<sub>2</sub>R, or selectivity of the compounds between agonism and antagonism for the receptors. However, they allowed definition in some more detail of the biological and physiological role of AT<sub>2</sub>R. A few compounds as AT<sub>2</sub>R ligands have been described, but only two nonpeptidomimetic small molecule compounds have shown selectivity for AT<sub>2</sub>R over the other receptors of Ang peptides, the agonist <b>20</b> and the antagonist <b>25</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), and have reached clinical evaluation. Presently, no AT<sub>2</sub>R agonist or antagonist is clinically approved, but in addition to the agonist <b>20</b> and its analogues and the antagonist <b>25</b>, the peptide analogue NP-6A4 (Novopyrix) is under clinical trial, but very scarce information exists. The AT<sub>2</sub>R <i>antagonist</i><b>25</b> is in phase II clinical trial for peripheral neuropathic pain. The AT<sub>2</sub>R <i>agonist</i><b>20</b> is entering phase II clinical trial as a potential treatment for fibrotic diseases of the lung and possibly other organs. To be efficient, these drugs ideally should also increase the level of AT<sub>2</sub>R, which is low in nonstressed nonpathological adult tissues. Thus, agonists and antagonists of AT<sub>2</sub>R produce different and partly opposing physiological effects. AT<sub>2</sub>R agonists promote tissue protective effects in cardiovascular, renal, and neuronal disorders, while AT<sub>2</sub>R antagonists reduce neuropathic pain (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Therapeutic interest of AT<sub>2</sub>R modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This means that their use may result in unwanted off-targets, sometimes potentially deleterious, side effects. This also means that their cell, tissue, and organ distribution in specific diseases must be carefully controlled. As AT<sub>2</sub>R expression is context-specific and cell- and tissue-selective, it will probably be necessary to design compounds with increased tissue/cell selectivity and specificity using addressing tools. In this context, we have shown in the murine models of kidney diseases that using prodrugs as substrates for enzymes with increased expression in the diseases results in improved biodistribution of the drugs to the diseased organs. Pro-drugs of inhibitors for the enzyme γ-secretase as substrates for the enzyme γ-glutamyl-transpeptidase were able to selectively decrease Notch activation in diseased kidneys.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Pro-drugs of the mitochondria antioxidant peptide SS-31 as substrates for the enzyme APA induced expression of AT<sub>2</sub>R in diseased kidney.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Such approaches could be considered for selectively delivering AT<sub>2</sub>R agonists or antagonists to diseased tissues and cells.</div><div class="NLM_p last">As the presently developed modulators of AT<sub>2</sub>R cannot cross the BBB, it might also be necessary to design compounds and/or means to cross the BBB for the treatment of diseases of the CNS. One possibility may be an osmotic shock or ultrasounds to open the BBB, direct injection into the CNS, however, both possibilities are too invasive to be acceptable in humans. Embedding the compounds into nanoparticles (NPs) able to cross the BBB, nose to brain injection, chemical modifications of the compounds to make them more lipophilic, conjugation with ligands for receptors, or transporters to force their transport across the nonperturbed BBB, may also be options. In cardiovascular disorders, chronic use of ACEI or ARBs induces a rebound effect on renin production, and thus of Ang II levels, and thus a less than perfect control of hypertension and associated disorders. Thus, the use of AT<sub>2</sub>R agonist may be of interest for cardiovascular treatment-refractory diseases. However, for the treatment of chronic diseases, improved biodistribution and long-term biological stability of the compounds must be achieved.</div></div><div class="NLM_back"><div class="NLM_notes" id="notes1"><p class="first last">The author declares no competing financial interest.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01780" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42466" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42466" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lucienne Juillerat-Jeanneret</span> - <span class="hlFld-Affiliation affiliation">Transplantation Center, Department
of Medicine, Centre Hospitalier Universitaire
Vaudois (CHUV) and University of Lausanne (UNIL), Chemin des Boveresses 155, CH1011 Lausanne, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8039-7882" title="Orcid link">http://orcid.org/0000-0002-8039-7882</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#28445d4b414d46464d06425d4144444d5a495c684b405d5e064b40"><span class="__cf_email__" data-cfemail="7a160f19131f14141f54100f1316161f081b0e3a19120f0c541912">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The author declares no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Lucienne Juillerat-Jeanneret</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=BIO-d7e3052-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lucienne Juillerat-Jeanneret</b> obtained her Ph.D. from the University of Geneva, Switzerland. After postdoctoral experiences at the University of Geneva and the University Hospital of Lausanne (CHUV-UNIL), she joined the University Institute of Pathology and Transplantation Center of CHUV-UNIL as a tenured senior lecturer and a teacher at the University of Lausanne (UNIL) and the Swiss Federal Institute of Technology of Lausanne (EPFL). Her research interests are focused at the interface between biomedicine, chemistry, and biomaterials to design and develop innovative devices or modified drugs to more selectively deliver therapeutics. She is involved in the development of novel strategies for diagnosis and tissue engineering, including the design and evaluation of nanotherapeutics and targeted therapeutics for the treatment of cancer, inflammatory, fibrotic, and degenerative diseases.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACE(I)</td><td class="NLM_def"><p class="first last">angiotensin converting enzyme (inhibitor)</p></td></tr><tr><td class="NLM_term">ACE2</td><td class="NLM_def"><p class="first last">angiotensin converting enzyme 2</p></td></tr><tr><td class="NLM_term">Ang</td><td class="NLM_def"><p class="first last">angiotensin</p></td></tr><tr><td class="NLM_term">APA, APB, APN</td><td class="NLM_def"><p class="first last">aminopeptidases A, B, N</p></td></tr><tr><td class="NLM_term">ARB</td><td class="NLM_def"><p class="first last">angiotensin receptor type 1 blockers</p></td></tr><tr><td class="NLM_term">AT<sub>1</sub>R, AT<sub>2</sub>R</td><td class="NLM_def"><p class="first last">angiotensin receptor type 1, type 2</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">HIV-1</td><td class="NLM_def"><p class="first last">human immunodeficiency virus (HIV)-1</p></td></tr><tr><td class="NLM_term">IRAP</td><td class="NLM_def"><p class="first last">insulin-regulated aminopeptidase</p></td></tr><tr><td class="NLM_term">MasR</td><td class="NLM_def"><p class="first last">Mas receptor</p></td></tr><tr><td class="NLM_term">NFκB</td><td class="NLM_def"><p class="first last">nuclear factor kappa B</p></td></tr><tr><td class="NLM_term">RAS</td><td class="NLM_def"><p class="first last">renin angiotensin system</p></td></tr><tr><td class="NLM_term">TGF-β</td><td class="NLM_def"><p class="first last">transforming growth factor-β</p></td></tr><tr><td class="NLM_term">TRPV</td><td class="NLM_def"><p class="first last">transient receptor otential cation channel subfamily V</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56500" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56500" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 160 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurley, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirotsou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffman, T. M.</span></span> <span> </span><span class="NLM_article-title">Classical renin-angiotensin in kidney physiology</span>. <i>Compr. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1201</span>– <span class="NLM_lpage">1228</span>, <span class="refDoi"> DOI: 10.1002/cphy.c130040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fcphy.c130040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24944035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC2cfjvFygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1201-1228&author=M.+A.+Sparksauthor=S.+D.+Crowleyauthor=S.+B.+Gurleyauthor=M.+Mirotsouauthor=T.+M.+Coffman&title=Classical+renin-angiotensin+in+kidney+physiology&doi=10.1002%2Fcphy.c130040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Classical Renin-Angiotensin system in kidney physiology</span></div><div class="casAuthors">Sparks Matthew A; Crowley Steven D; Gurley Susan B; Mirotsou Maria; Coffman Thomas M</div><div class="citationInfo"><span class="NLM_cas:title">Comprehensive Physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1201-28</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The renin-angiotensin system has powerful effects in control of the blood pressure and sodium homeostasis.  These actions are coordinated through integrated actions in the kidney, cardiovascular system and the central nervous system.  Along with its impact on blood pressure, the renin-angiotensin system also influences a range of processes from inflammation and immune responses to longevity.  Here, we review the actions of the "classical" renin-angiotensin system, whereby the substrate protein angiotensinogen is processed in a two-step reaction by renin and angiotensin converting enzyme, resulting in the sequential generation of angiotensin I and angiotensin II, the major biologically active renin-angiotensin system peptide, which exerts its actions via type 1 and type 2 angiotensin receptors.  In recent years, several new enzymes, peptides, and receptors related to the renin-angiotensin system have been identified, manifesting a complexity that was previously unappreciated.  While the functions of these alternative pathways will be reviewed elsewhere in this journal, our focus here is on the physiological role of components of the "classical" renin-angiotensin system, with an emphasis on new developments and modern concepts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShV0-YwFOzpBwLZxei1HN8fW6udTcc2eYK2YBICVoBd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfjvFygtw%253D%253D&md5=4a7268d31366074c46226401b0d8ecc4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fcphy.c130040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcphy.c130040%26sid%3Dliteratum%253Aachs%26aulast%3DSparks%26aufirst%3DM.%2BA.%26aulast%3DCrowley%26aufirst%3DS.%2BD.%26aulast%3DGurley%26aufirst%3DS.%2BB.%26aulast%3DMirotsou%26aufirst%3DM.%26aulast%3DCoffman%26aufirst%3DT.%2BM.%26atitle%3DClassical%2520renin-angiotensin%2520in%2520kidney%2520physiology%26jtitle%3DCompr.%2520Physiol.%26date%3D2014%26volume%3D4%26spage%3D1201%26epage%3D1228%26doi%3D10.1002%2Fcphy.c130040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Mello, W. C.</span></span> <span> </span><span class="NLM_article-title">Is an intracellular renin-angiotensin system involved in control of cell communication in heart?</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1097/00005344-199404000-00018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2F00005344-199404000-00018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=7516016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2cXitlOjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1994&pages=640-646&author=W.+C.+De%0AMello&title=Is+an+intracellular+renin-angiotensin+system+involved+in+control+of+cell+communication+in+heart%3F&doi=10.1097%2F00005344-199404000-00018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Is an intracellular renin-angiotensin system involved in control of cell communication in heart?</span></div><div class="casAuthors">De Mello, Walmor C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">640-6</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    </div><div class="casAbstract">The possible influence of an intracellular renin-angiotensin system (RAS) on control of cell communication in heart muscle was investigated in cell pairs isolated from adult rats.  Junctional conductance (gj) was measured with 2 sepd. voltage-clamp circuits.  Intracellular dialysis of angiotensin I (AI 10-8M) caused a decrease in gj of 76% (SE) in 7 min.  The effect of AI appears to be due mainly to its conversion to AII because enalaprilat (10-9M) dialyzed into the cell caused an appreciable redn. in the effect of AI.  AII (10-8M) alone caused a decrease in gj of 60% in 45 s.  The effect of AII on gj was suppressed by previous inhibition of protein kinase C (PKC), but enalaprilat could not alter the effect of the peptide.  Apparently, synthesis of AII inside cardiac myocytes plays an important role in modulation of gj and consequently on propagation of the elec. impulse in heart.  The effect of AII on gj was blocked by DuP 753 (10-9M) administered intracellularly, whereas [Sar1Val5Ala8]AII also caused a slight decrease (1.97%) in gj.  Apparently, an intracellular receptor is involved in the effect of the peptide on gj.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLRkecRWDulbVg90H21EOLACvtfcHk0lh6eI3qfIuhTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlOjsL8%253D&md5=af3da8836140a7f7d855105ff19759ea</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1097%2F00005344-199404000-00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199404000-00018%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BMello%26aufirst%3DW.%2BC.%26atitle%3DIs%2520an%2520intracellular%2520renin-angiotensin%2520system%2520involved%2520in%2520control%2520of%2520cell%2520communication%2520in%2520heart%253F%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1994%26volume%3D23%26spage%3D640%26epage%3D646%26doi%3D10.1097%2F00005344-199404000-00018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filipeanu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henning, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zeeuw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelemans, A.</span></span> <span> </span><span class="NLM_article-title">Intracellular angiotensin II and cell growth of vascular smooth muscle cells</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1596</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0703984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fsj.bjp.0703984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11264254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVahsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2001&pages=1590-1596&author=C.+M.+Filipeanuauthor=R.+H.+Henningauthor=D.+de+Zeeuwauthor=A.+Nelemans&title=Intracellular+angiotensin+II+and+cell+growth+of+vascular+smooth+muscle+cells&doi=10.1038%2Fsj.bjp.0703984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular angiotensin II and cell growth of vascular smooth muscle cells</span></div><div class="casAuthors">Filipeanu, Catalin M.; Henning, Robert H.; De Zeeuw, Dick; Nelemans, Adriaan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1590-1596</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors recently demonstrated that intracellular application of Angiotensin II (Angiotensin IIintr) induces rat aorta contraction independent of plasma membrane Angiotensin II receptors.  In this study the authors investigated the effects of Angiotensin IIintr on cell growth in A7r5 smooth muscle cells.  DNA-synthesis was increased dose-dependently by liposomes filled with Angiotensin II as measured by [3H]-thymidine incorporation at high (EC50=27±6 pM) and low (EC50=14±5 nM) affinity binding sites with increases in Emax of 58±4 and 37±4% above quiescent cells, resp.  Cell growth was corroborated by an increase in cell no.  Extracellular Angiotensin II (10 pM-10 μM) did not modify [3H]-thymidine incorporation.  Growth effects of Angiotensin IIintr mediated via high affinity sites were inhibited by liposomes filled with 1 μM of the non-peptidergic antagonists losartan (AT1-receptor) or PD123319 (AT2-receptor) or with the peptidergic agonist CGP42112A (AT2-receptor).  Emax values were decreased to 30±3, 29±4 and 4±2%, resp., without changes in EC50.  The Angiotensin IIintr effect via low affinity sites was only antagonized by CGP42112A (Emax=11±3%), while losartan and PD123319 increased Emax to 69±4%.  Intracellular applications were ineffective in the absence of Angiotensin IIintr.  Neither intracellular nor extracellular Angiotensin I (1 μM) were effective.  The Angiotensin IIintr induced growth response was blocked by selective inhibition of phosphatidylinositol 3-kinase (PI-3K) by wortmannin (1 μM) and of the mitogen-activated protein kinase (MAPK/ERK) pathway by PD98059 (1 μM) to 61±14 and 4±8% of control, resp.  These data demonstrate that Angiotensin IIintr induces cell growth through atypical AT-receptors via a PI-3K and MAPK/ERK -sensitive pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3QZwKuHmCHLVg90H21EOLACvtfcHk0lh6eI3qfIuhTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVahsbw%253D&md5=68092180d26771ac89e02304830209c1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703984%26sid%3Dliteratum%253Aachs%26aulast%3DFilipeanu%26aufirst%3DC.%2BM.%26aulast%3DHenning%26aufirst%3DR.%2BH.%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DNelemans%26aufirst%3DA.%26atitle%3DIntracellular%2520angiotensin%2520II%2520and%2520cell%2520growth%2520of%2520vascular%2520smooth%2520muscle%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D132%26spage%3D1590%26epage%3D1596%26doi%3D10.1038%2Fsj.bjp.0703984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Re, R.</span></span> <span> </span><span class="NLM_article-title">Intracellular renin-angiotensin system: the tip of the intracrine physiology iceberg</span>. <i>Am. J. Physiol., Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">H905</span>– <span class="NLM_lpage">H906</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00552.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajpheart.00552.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=17526648" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2007&pages=H905-H906&author=R.+Re&title=Intracellular+renin-angiotensin+system%3A+the+tip+of+the+intracrine+physiology+iceberg&doi=10.1152%2Fajpheart.00552.2007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00552.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00552.2007%26sid%3Dliteratum%253Aachs%26aulast%3DRe%26aufirst%3DR.%26atitle%3DIntracellular%2520renin-angiotensin%2520system%253A%2520the%2520tip%2520of%2520the%2520intracrine%2520physiology%2520iceberg%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Heart%2520Circ.%2520Physiol.%26date%3D2007%26volume%3D293%26spage%3DH905%26epage%3DH906%26doi%3D10.1152%2Fajpheart.00552.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paz
Ocaranza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riquelme, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalil, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandero, S.</span></span> <span> </span><span class="NLM_article-title">Counter-regulatory renin–angiotensin system in cardiovascular disease</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1038/s41569-019-0244-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fs41569-019-0244-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=31427727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BB3MvpsVKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=116-129&author=M.+Paz%0AOcaranzaauthor=J.+A.+Riquelmeauthor=L.+Garc%C3%ADaauthor=J.+E.+Jalilauthor=M.+Chiongauthor=R.+A.+S.+Santosauthor=S.+Lavandero&title=Counter-regulatory+renin%E2%80%93angiotensin+system+in+cardiovascular+disease&doi=10.1038%2Fs41569-019-0244-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Counter-regulatory renin-angiotensin system in cardiovascular disease</span></div><div class="casAuthors">Paz Ocaranza Maria; Jalil Jorge E; Riquelme Jaime A; Garcia Lorena; Chiong Mario; Lavandero Sergio; Santos Robson A S; Lavandero Sergio; Lavandero Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Cardiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The renin-angiotensin system is an important component of the cardiovascular system.  Mounting evidence suggests that the metabolic products of angiotensin I and II - initially thought to be biologically inactive - have key roles in cardiovascular physiology and pathophysiology.  This non-canonical axis of the renin-angiotensin system consists of angiotensin 1-7, angiotensin 1-9, angiotensin-converting enzyme 2, the type 2 angiotensin II receptor (AT2R), the proto-oncogene Mas receptor and the Mas-related G protein-coupled receptor member D.  Each of these components has been shown to counteract the effects of the classical renin-angiotensin system.  This counter-regulatory renin-angiotensin system has a central role in the pathogenesis and development of various cardiovascular diseases and, therefore, represents a potential therapeutic target.  In this Review, we provide the latest insights into the complexity and interplay of the components of the non-canonical renin-angiotensin system, and discuss the function and therapeutic potential of targeting this system to treat cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3XOEtE4JzWbrIbt-tGZmxfW6udTcc2eYhPeu_L52Lc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvpsVKktg%253D%253D&md5=03e0ead60a2c6139e470b69b364f1338</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fs41569-019-0244-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41569-019-0244-8%26sid%3Dliteratum%253Aachs%26aulast%3DPaz%2BOcaranza%26aufirst%3DM.%26aulast%3DRiquelme%26aufirst%3DJ.%2BA.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DL.%26aulast%3DJalil%26aufirst%3DJ.%2BE.%26aulast%3DChiong%26aufirst%3DM.%26aulast%3DSantos%26aufirst%3DR.%2BA.%2BS.%26aulast%3DLavandero%26aufirst%3DS.%26atitle%3DCounter-regulatory%2520renin%25E2%2580%2593angiotensin%2520system%2520in%2520cardiovascular%2520disease%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2020%26volume%3D17%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fs41569-019-0244-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2014.59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fnrcardio.2014.59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24776703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslGitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=413-426&author=F.+Jiangauthor=J.+Yangauthor=Y.+Zhangauthor=M.+Dongauthor=S.+Wangauthor=Q.+Zhangauthor=F.+F.+Liuauthor=K.+Zhangauthor=C.+Zhang&title=Angiotensin-converting+enzyme+2+and+angiotensin+1%E2%80%937%3A+novel+therapeutic+targets&doi=10.1038%2Fnrcardio.2014.59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets</span></div><div class="casAuthors">Jiang, Fan; Yang, Jianmin; Zhang, Yongtao; Dong, Mei; Wang, Shuangxi; Zhang, Qunye; Liu, Fang Fang; Zhang, Kai; Zhang, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">413-426</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The renin-angiotensin system (RAS) has pivotal roles in the regulation of normal physiol. and the pathogenesis of cardiovascular disease.  Angiotensin-converting enzyme (ACE) 2, and its product angiotensin 1-7, are thought to have counteracting effects against the adverse actions of other, better known and understood, members of the RAS.  The physiol. and pathol. importance of ACE2 and angiotensin 1-7 in the cardiovascular system are not completely understood, but numerous exptl. studies have indicated that these components have protective effects in the heart and blood vessels.  Here, we provide an overview on the basic properties of ACE2 and angiotensin 1-7 and a summary of the evidence from exptl. and clin. studies of various pathol. conditions, such as hypertension, atherosclerosis, myocardial remodelling, heart failure, ischemic stroke, and diabetes mellitus.  ACE2-mediated catabolism of angiotensin II is likely to have a major role in cardiovascular protection, whereas the relevant functions and signalling mechanisms of actions induced by angiotensin 1-7 have not been conclusively detd.  The ACE2-angiotensin 1-7 pathway, however, might provide a useful therapeutic target for the treatment of cardiovascular disease, esp. in patients with overactive RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraCy0GZ3yFW7Vg90H21EOLACvtfcHk0lgxC_le2cyO0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslGitLs%253D&md5=07d420f3ada328a490033348ac01b7ac</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2014.59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2014.59%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DF.%2BF.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DAngiotensin-converting%2520enzyme%25202%2520and%2520angiotensin%25201%25E2%2580%25937%253A%2520novel%2520therapeutic%2520targets%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2014%26volume%3D11%26spage%3D413%26epage%3D426%26doi%3D10.1038%2Fnrcardio.2014.59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickremesekera, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itinteang, T.</span></span> <span> </span><span class="NLM_article-title">Renin-angiotensin system and cancer: a review</span>. <i>Integr. Cancer Sci. Therap.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">231</span>, <span class="refDoi"> DOI: 10.15761/ICST.1000231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.15761%2FICST.1000231" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=231&author=M.+J.+Munroauthor=A.+C.+Wickremesekeraauthor=P.+F.+Davisauthor=R.+Marshauthor=S.+T.+Tanauthor=T.+Itinteang&title=Renin-angiotensin+system+and+cancer%3A+a+review&doi=10.15761%2FICST.1000231"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.15761%2FICST.1000231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15761%252FICST.1000231%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DM.%2BJ.%26aulast%3DWickremesekera%26aufirst%3DA.%2BC.%26aulast%3DDavis%26aufirst%3DP.%2BF.%26aulast%3DMarsh%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DS.%2BT.%26aulast%3DItinteang%26aufirst%3DT.%26atitle%3DRenin-angiotensin%2520system%2520and%2520cancer%253A%2520a%2520review%26jtitle%3DIntegr.%2520Cancer%2520Sci.%2520Therap.%26date%3D2017%26volume%3D4%26spage%3D231%26doi%3D10.15761%2FICST.1000231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKinley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albiston, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathai, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S. Y.</span></span> <span> </span><span class="NLM_article-title">The brain renin-angiotensin system: location and physiological roles</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">901</span>– <span class="NLM_lpage">918</span>, <span class="refDoi"> DOI: 10.1016/S1357-2725(02)00306-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS1357-2725%2802%2900306-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12676175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFShu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2003&pages=901-918&author=M.+J.+McKinleyauthor=A.+L.+Albistonauthor=A.+M.+Allenauthor=M.+L.+Mathaiauthor=C.+N.+Mayauthor=R.+M.+McAllenauthor=B.+J.+Oldfieldauthor=F.+A.+Mendelsohnauthor=S.+Y.+Chai&title=The+brain+renin-angiotensin+system%3A+location+and+physiological+roles&doi=10.1016%2FS1357-2725%2802%2900306-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The brain renin-angiotensin system: location and physiological roles</span></div><div class="casAuthors">McKinley, M. J.; Albiston, A. L.; Allen, A. M.; Mathai, M. L.; May, C. N.; McAllen, R. M.; Oldfield, B. J.; Mendelsohn, F. A. O.; Chai, S. Y.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">901-918</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiotensinogen, the precursor mol. for angiotensins I, II and III, and the enzymes renin, angiotensin-converting enzyme (ACE), and aminopeptidases A and N may all be synthesized within the brain.  Angiotensin (Ang) AT1, AT2 and AT4 receptors are also plentiful in the brain.  AT1 receptors are found in several brain regions, such as the hypothalamic paraventricular and supraoptic nuclei, the lamina terminalis, lateral parabrachial nucleus, ventrolateral medulla and nucleus of the solitary tract (NTS), which are known to have roles in the regulation of the cardiovascular system and/or body fluid and electrolyte balance.  Immunohistochem. and neuropharmacol. studies suggest that angiotensinergic neural pathways utilize Ang II and/or Ang III as a neurotransmitter or neuromodulator in the aforementioned brain regions.  Angiotensinogen is synthesized predominantly in astrocytes, but the processes by which Ang II is generated or incorporated in neurons for utilization as a neurotransmitter is unknown.  Centrally administered AT1 receptor antagonists or angiotensinogen antisense oligonucleotides inhibit sympathetic activity and reduce arterial blood pressure in certain physiol. or pathophysiol. conditions, as well as disrupting water drinking and sodium appetite, vasopressin secretion, sodium excretion, renin release and thermoregulation.  The AT4 receptor is identical to insulin-regulated aminopeptidase (IRAP) and plays a role in memory mechanisms.  In conclusion, angiotensinergic neural pathways and angiotensin peptides are important in neural function and may have important homeostatic roles, particularly related to cardiovascular function, osmoregulation and thermoregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA4nXg_hNM-LVg90H21EOLACvtfcHk0lh1br0YGkSYjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFShu7o%253D&md5=2fb9f3ee2d618990f6703c347e833e2a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS1357-2725%2802%2900306-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-2725%252802%252900306-0%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinley%26aufirst%3DM.%2BJ.%26aulast%3DAlbiston%26aufirst%3DA.%2BL.%26aulast%3DAllen%26aufirst%3DA.%2BM.%26aulast%3DMathai%26aufirst%3DM.%2BL.%26aulast%3DMay%26aufirst%3DC.%2BN.%26aulast%3DMcAllen%26aufirst%3DR.%2BM.%26aulast%3DOldfield%26aufirst%3DB.%2BJ.%26aulast%3DMendelsohn%26aufirst%3DF.%2BA.%26aulast%3DChai%26aufirst%3DS.%2BY.%26atitle%3DThe%2520brain%2520renin-angiotensin%2520system%253A%2520location%2520and%2520physiological%2520roles%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2003%26volume%3D35%26spage%3D901%26epage%3D918%26doi%3D10.1016%2FS1357-2725%2802%2900306-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohlender, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imboden, H.</span></span> <span> </span><span class="NLM_article-title">Angiotensinergic neurotransmission in the peripheral autonomic nervous system</span>. <i>Front. Biosci., Landmark Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2419</span>– <span class="NLM_lpage">2432</span>, <span class="refDoi"> DOI: 10.2741/4062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2741%2F4062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22652789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSksbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=2419-2432&author=J.+Bohlenderauthor=H.+Imboden&title=Angiotensinergic+neurotransmission+in+the+peripheral+autonomic+nervous+system&doi=10.2741%2F4062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensinergic neurotransmission in the peripheral autonomic nervous system</span></div><div class="casAuthors">Bohlender, Jurgen; Imboden, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience, Landmark Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2419-2432, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Angiotensin (Ang) II has for long been identified as a neuropeptide located within neurons and pathways of the central nervous system involved in the control of thirst and cardio-vascular homeostasis.  The presence of Ang II in ganglionic neurons of celiac, dorsal root and trigeminal ganglia has only recently been described in humans and rats.  Ang II-contg. fibers were also found in the mesenteric artery and the heart together with intrinsic Ang II-contg. cardiac neurons.  Ganglionic neurons express angiotensinogen and co-localize it with Ang II.  Its intraneuronal prodn. as a neuropeptide appears to involve angiotensinogen processing enzymes other than renin.  Immunocytochem. and gene expression data suggest that neuronal Ang II acts as a neuromodulatory peptide and co-transmitter in the peripheral autonomic and also sensory nervous system.  Neuronal Ang II probably competes with humoral Ang II for effector cell activtation.  Its functional role, however, still remains to be detd.  Angiotensinergic neurotransmission in the autonomic nervous system is a potential new target for therapeutic interventions in many common diseases such as essential hypertension, heart failure and cardiac arrhythmia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvJWhOr8t8ArVg90H21EOLACvtfcHk0lh1br0YGkSYjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSksbrK&md5=03e5319967fe00ab3e5cc3c618ca2c1d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2741%2F4062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F4062%26sid%3Dliteratum%253Aachs%26aulast%3DBohlender%26aufirst%3DJ.%26aulast%3DImboden%26aufirst%3DH.%26atitle%3DAngiotensinergic%2520neurotransmission%2520in%2520the%2520peripheral%2520autonomic%2520nervous%2520system%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2012%26volume%3D17%26spage%3D2419%26epage%3D2432%26doi%3D10.2741%2F4062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Célérier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuis Bernasconi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maerki, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzer, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvol, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasc, J. M.</span></span> <span> </span><span class="NLM_article-title">Renin and angiotensinogen expression and function in growth and apoptosis of human glioblastoma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1068</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6601646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fsj.bjc.6601646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=14997208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhslWrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=1059-1068&author=L.+Juillerat-Jeanneretauthor=J.+C%C3%A9l%C3%A9rierauthor=C.+Chapuis+Bernasconiauthor=G.+Nguyenauthor=W.+Wostlauthor=H.+P.+Maerkiauthor=R.+C.+Janzerauthor=P.+Corvolauthor=J.+M.+Gasc&title=Renin+and+angiotensinogen+expression+and+function+in+growth+and+apoptosis+of+human+glioblastoma&doi=10.1038%2Fsj.bjc.6601646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma</span></div><div class="casAuthors">Juillerat-Jeanneret, L.; Celerier, J.; Chapuis Bernasconi, C.; Nguyen, G.; Wostl, W.; Maerki, H. P.; Janzer, R-C.; Corvol, P.; Gasc, J-M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1059-1068</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The expression and function in growth and apoptosis of the renin-angiotensin system (RAS) was evaluated in human glioblastoma.  Renin and angiotensinogen (AGT) mRNAs and proteins were found by in situ hybridization and immunohistochem. in glioblastoma cells.  Angiotensinogen was present in glioblastoma cystic fluids.  Thus, human glioblastoma cells produce renin and AGT and secrete AGT.  Human glioblastoma and glioblastoma cells expressed renin, AGT, renin receptor, AT2 and/or AT1 mRNAs and proteins detd. by RT-PCR and/or Western blotting, resp.  The function of the RAS in glioblastoma was studied using human glioblastoma cells in culture.  Angiotensinogen, des(Ang I)AGT, tetradecapeptide renin substrate (AGT1-14), Ang I, Ang II or Ang III, added to glioblastoma cells in culture, did not modulate their proliferation, survival or death.  Angiotensin-converting enzyme inhibitors did not diminish glioblastoma cell proliferation.  However, the addn. of selective synthetic renin inhibitors to glioblastoma cells decreased DNA synthesis and viable tumor cell no., and induced apoptosis.  This effect was not counterbalanced by concomitant addn. of Ang II.  In conclusion, the complete RAS is expressed by human glioblastomas and glioblastoma cells in culture.  Inhibition of renin in glioblastoma cells may be a potential approach to control glioblastoma cell proliferation and survival, and glioblastoma progression in combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEViTYIexQ4LVg90H21EOLACvtfcHk0lh990yMTCtNxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhslWrsbo%253D&md5=39005a7561f49040844dfd5e82dbe151</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601646%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DC%25C3%25A9l%25C3%25A9rier%26aufirst%3DJ.%26aulast%3DChapuis%2BBernasconi%26aufirst%3DC.%26aulast%3DNguyen%26aufirst%3DG.%26aulast%3DWostl%26aufirst%3DW.%26aulast%3DMaerki%26aufirst%3DH.%2BP.%26aulast%3DJanzer%26aufirst%3DR.%2BC.%26aulast%3DCorvol%26aufirst%3DP.%26aulast%3DGasc%26aufirst%3DJ.%2BM.%26atitle%3DRenin%2520and%2520angiotensinogen%2520expression%2520and%2520function%2520in%2520growth%2520and%2520apoptosis%2520of%2520human%2520glioblastoma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2004%26volume%3D90%26spage%3D1059%26epage%3D1068%26doi%3D10.1038%2Fsj.bjc.6601646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staessen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richart, T.</span></span> <span> </span><span class="NLM_article-title">Oral renin inhibitors</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1456</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(06)69442-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0140-6736%2806%2969442-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=17055947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSntb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1449-1456&author=J.+A.+Staessenauthor=Y.+Liauthor=T.+Richart&title=Oral+renin+inhibitors&doi=10.1016%2FS0140-6736%2806%2969442-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Oral renin inhibitors</span></div><div class="casAuthors">Staessen, Jan A.; Li, Yan; Richart, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">9545</span>),
    <span class="NLM_cas:pages">1449-1456</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Use of drugs that inhibit the renin-angiotensin system is an effective way to intervene in the pathogenesis of cardiovascular and renal disorders.  The idea of blocking the renin system at its origin by inhibition of renin has existed for more than 30 years.  Renin inhibition suppresses the generation of the active peptide angiotensin II.  The first generation of orally active renin inhibitors were never used clin. because of low bioavailability and weak blood-pressure-lowering activity.  At present, aliskiren is the first non-peptide orally active renin inhibitor to progress to phase-III clin. trials.  It might become the first renin inhibitor with indications for the treatment of hypertension and cardiovascular and renal disorders.  Novel compds. with improved oral bioavailability, specificity, and efficacy are now in preclin. development.  This Review summarizes the development of oral renin inhibitors and their pharmacokinetic and pharmacodynamic properties, with a focus on aliskiren.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3x7KVdYm_4rVg90H21EOLACvtfcHk0lh990yMTCtNxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSntb3M&md5=a6867b4cea28566aa719c8633257a983</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969442-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969442-7%26sid%3Dliteratum%253Aachs%26aulast%3DStaessen%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRichart%26aufirst%3DT.%26atitle%3DOral%2520renin%2520inhibitors%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1449%26epage%3D1456%26doi%3D10.1016%2FS0140-6736%2806%2969442-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, C. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.1998.tb03121.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fj.1875-9114.1998.tb03121.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9620109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1cXkt1KjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=588-599&author=C.+M.+White&title=Pharmacologic%2C+pharmacokinetic%2C+and+therapeutic+differences+among+ACE+inhibitors&doi=10.1002%2Fj.1875-9114.1998.tb03121.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors</span></div><div class="casAuthors">White, C. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">588-599</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Pharmacotherapy Publications</span>)
        </div><div class="casAbstract">A review with 84 refs.  Angiotensin-converting enzyme (ACE) inhibitors are a heterogeneous group of agents, and important pharmacol., pharmacokinetic, and therapeutic differences among them must be understood to obtain optimal therapy.  For patients with severe liver disease, lisinopril and captopril are not prodrugs (e.g., do not require hepatic activation), and lisinopril has almost solely renal elimination.  Enalaprilat, the i.v. formulation of enalapril, is the only i.v. available ACE inhibitor and can be given to patients with severe liver dysfunction as it is also not a prodrug.  Fosinopril is the only drug with compensatory dual routes of elimination, and it does not require dosage adjustment in patients with reduced renal function, as other ACE inhibitors do.  Captopril and moexipril have potential drug-food interactions and are the only agents that should be spaced from meals.  The ACE inhibitors also differ in their dialyzability, half-life, lipophilicity, trough:peak ratios, approved indications, and therapeutic information available for many indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF-b_6jQNBqbVg90H21EOLACvtfcHk0lh2_FVAyiygdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt1KjtLs%253D&md5=4a57f9ba8f2dc75886fb07e69ed899de</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.1998.tb03121.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.1998.tb03121.x%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DC.%2BM.%26atitle%3DPharmacologic%252C%2520pharmacokinetic%252C%2520and%2520therapeutic%2520differences%2520among%2520ACE%2520inhibitors%26jtitle%3DPharmacotherapy%26date%3D1998%26volume%3D18%26spage%3D588%26epage%3D599%26doi%3D10.1002%2Fj.1875-9114.1998.tb03121.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaten, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monte, A. A.</span></span> <span> </span><span class="NLM_article-title">The pharmacogenomic and metabolomic predictors of ACE inhibitor and angiotensin II receptor blocker effectiveness and safety</span>. <i>Cardiovasc. Drugs Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1007/s10557-017-6733-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs10557-017-6733-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28741243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WqsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=471-482&author=H.+K.+Flatenauthor=A.+A.+Monte&title=The+pharmacogenomic+and+metabolomic+predictors+of+ACE+inhibitor+and+angiotensin+II+receptor+blocker+effectiveness+and+safety&doi=10.1007%2Fs10557-017-6733-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety</span></div><div class="casAuthors">Flaten, Hania K.; Monte, Andrew A.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drugs and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-482</span>CODEN:
                <span class="NLM_cas:coden">CDTHET</span>;
        ISSN:<span class="NLM_cas:issn">0920-3206</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Hypertension (HTN) is the most common chronic disease in the USA.  Hypertensive patients frequently require repeat primary care visits to find an effective drug or drug combination to control their disease.  Currently, patients are prescribed drugs for HTN based on race, age, and comorbidities and although the current guidelines are reasonable starting points for prescribing, 50% of hypertensive patients still fail to achieve target blood pressures.  Despite numerous strategies to improve compliance, drug effectiveness, and optimization of initial drug choice, effectiveness has remained largely unchanged over the past two decades.  Therefore, it is important to pursue alternative strategies to more effectively treat patients and to decrease medical costs.  Addnl. precision medicine work is needed to identify factors assocd. with effectiveness of commonly used antihypertensive medications.  The objective of this manuscript is to present a comprehensive review of the pharmacogenomic and metabolomic factors assocd. with ACEI and ARB effectiveness and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHCu01oUJnWLVg90H21EOLACvtfcHk0lh2_FVAyiygdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WqsL3I&md5=e8ea9afebdf21a9950a8162b3225dea7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10557-017-6733-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10557-017-6733-2%26sid%3Dliteratum%253Aachs%26aulast%3DFlaten%26aufirst%3DH.%2BK.%26aulast%3DMonte%26aufirst%3DA.%2BA.%26atitle%3DThe%2520pharmacogenomic%2520and%2520metabolomic%2520predictors%2520of%2520ACE%2520inhibitor%2520and%2520angiotensin%2520II%2520receptor%2520blocker%2520effectiveness%2520and%2520safety%26jtitle%3DCardiovasc.%2520Drugs%2520Ther.%26date%3D2017%26volume%3D31%26spage%3D471%26epage%3D482%26doi%3D10.1007%2Fs10557-017-6733-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, J. H.</span></span> <span> </span><span class="NLM_article-title">Angiotensin converting enzyme inhibitor</span>. <i>Am. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1093/ajh/3.4.331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1093%2Fajh%2F3.4.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=2189445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK3cXkslSntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1990&pages=331-337&author=J.+H.+Bauer&title=Angiotensin+converting+enzyme+inhibitor&doi=10.1093%2Fajh%2F3.4.331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-converting enzyme inhibitors</span></div><div class="casAuthors">Bauer, John H.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hypertension</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">331-7</span>CODEN:
                <span class="NLM_cas:coden">AJHYE6</span>;
        ISSN:<span class="NLM_cas:issn">0895-7061</span>.
    </div><div class="casAbstract">A review, with 133 refs., of the use of the title drugs, in hypertension.  Mechanisms of action, general pharmacol., renal effects, side effects, and efficacy are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGzlB_5FlRgrVg90H21EOLACvtfcHk0lh2_FVAyiygdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkslSntr0%253D&md5=4e3a7ab9b3999abfca751cb674803997</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fajh%2F3.4.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fajh%252F3.4.331%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DJ.%2BH.%26atitle%3DAngiotensin%2520converting%2520enzyme%2520inhibitor%26jtitle%3DAm.%2520J.%2520Hypertens.%26date%3D1990%26volume%3D3%26spage%3D331%26epage%3D337%26doi%3D10.1093%2Fajh%2F3.4.331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarco, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endlich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter-Katalinić, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weide, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavenstädt, H.</span></span> <span> </span><span class="NLM_article-title">Downregulation of the antioxidant protein peroxiredoxin 2 contributes to angiotensin II-mediated podocyte apoptosis</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">969</span>, <span class="refDoi"> DOI: 10.1038/ki.2011.250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fki.2011.250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=21814176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaiurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=959-969&author=H.+H.+Hsuauthor=S.+Hoffmannauthor=G.+S.+DiMarcoauthor=N.+Endlichauthor=J.+Peter-Katalini%C4%87author=T.+Weideauthor=H.+Pavenst%C3%A4dt&title=Downregulation+of+the+antioxidant+protein+peroxiredoxin+2+contributes+to+angiotensin+II-mediated+podocyte+apoptosis&doi=10.1038%2Fki.2011.250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Downregulation of the antioxidant protein peroxiredoxin 2 contributes to angiotensin II-mediated podocyte apoptosis</span></div><div class="casAuthors">Hsu, Hsiang-Hao; Hoffmann, Sigrid; Di Marco, Giovana S.; Endlich, Nicole; Peter-Katalinic, Jasna; Weide, Thomas; Pavenstaedt, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">959-969</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Podocytes have a significant role in establishing selective permeability of the glomerular filtration barrier.  Sustained renin-angiotensin-aldosterone system activation is crucial to the pathogenesis of podocyte injury, but the mechanisms by which angiotensin II modulates podocyte survival due to physiol. or injurious stimuli remain unclear.  Here, we used proteomic anal. to find new mediators of angiotensin II-induced podocyte injury.  Antioxidant protein peroxiredoxin 2 expression was decreased in cultured podocytes stimulated with angiotensin II.  Peroxiredoxin 2 was found to be expressed in podocytes in vivo, and its expression was decreased in the glomeruli of rats transgenic for angiotensin II type 1 receptors in a podocyte-specific manner, or in rats infused with angiotensin II.  Downregulation of peroxiredoxin 2 in podocytes resulted in increased reactive oxygen species release, protein overoxidn., and inhibition of the Akt pathway.  Both treatment with angiotensin II and downregulation of peroxiredoxin 2 expression led to apoptosis of podocytes.  Thus, peroxiredoxin 2 is an important modulator of angiotensin II-induced podocyte injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhhBhn7s4kPLVg90H21EOLACvtfcHk0lggeZwyXLIe7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaiurzJ&md5=c0c97123a42c3f206098108d6b05375b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fki.2011.250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2011.250%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DHoffmann%26aufirst%3DS.%26aulast%3DDiMarco%26aufirst%3DG.%2BS.%26aulast%3DEndlich%26aufirst%3DN.%26aulast%3DPeter-Katalini%25C4%2587%26aufirst%3DJ.%26aulast%3DWeide%26aufirst%3DT.%26aulast%3DPavenst%25C3%25A4dt%26aufirst%3DH.%26atitle%3DDownregulation%2520of%2520the%2520antioxidant%2520protein%2520peroxiredoxin%25202%2520contributes%2520to%2520angiotensin%2520II-mediated%2520podocyte%2520apoptosis%26jtitle%3DKidney%2520Int.%26date%3D2011%26volume%3D80%26spage%3D959%26epage%3D969%26doi%3D10.1038%2Fki.2011.250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grobe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elased, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cool, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M.</span></span> <span> </span><span class="NLM_article-title">Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney</span>. <i>Am. J. Physiol., Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>302</i></span>,  <span class="NLM_fpage">E1016</span>– <span class="NLM_lpage">E1024</span>, <span class="refDoi"> DOI: 10.1152/ajpendo.00515.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajpendo.00515.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22318946" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2012&pages=E1016-E1024&author=N.+Grobeauthor=K.+M.+Elasedauthor=D.+R.+Coolauthor=M.+Morris&title=Mass+spectrometry+for+the+molecular+imaging+of+angiotensin+metabolism+in+kidney&doi=10.1152%2Fajpendo.00515.2011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1152%2Fajpendo.00515.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpendo.00515.2011%26sid%3Dliteratum%253Aachs%26aulast%3DGrobe%26aufirst%3DN.%26aulast%3DElased%26aufirst%3DK.%2BM.%26aulast%3DCool%26aufirst%3DD.%2BR.%26aulast%3DMorris%26aufirst%3DM.%26atitle%3DMass%2520spectrometry%2520for%2520the%2520molecular%2520imaging%2520of%2520angiotensin%2520metabolism%2520in%2520kidney%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Endocrinol.%2520Metab.%26date%3D2012%26volume%3D302%26spage%3DE1016%26epage%3DE1024%26doi%3D10.1152%2Fajpendo.00515.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, J. D.</span></span> <span> </span><span class="NLM_article-title">Targeted γ-secretase inhibition to control the Notch pathway in renal diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8097</span>– <span class="NLM_lpage">8109</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8097-8109&author=L.+Juillerat-Jeanneretauthor=A.+Flohrauthor=M.+Schneiderauthor=I.+Walterauthor=J.+C.+Wyssauthor=R.+Kumarauthor=D.+Golshayanauthor=J.+D.+Aebi&title=Targeted+%CE%B3-secretase+inhibition+to+control+the+Notch+pathway+in+renal+diseases&doi=10.1021%2Facs.jmedchem.5b00912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted γ-Secretase Inhibition To Control the Notch Pathway in Renal Diseases</span></div><div class="casAuthors">Juillerat-Jeanneret, Lucienne; Flohr, Alexander; Schneider, Manfred; Walter, Isabelle; Wyss, Jean-Christophe; Kumar, Rajesh; Golshayan, Dela; Aebi, Johannes D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8097-8109</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Notch is a membrane inserted protein activated by the membrane-inserted γ-secretase proteolytic complex.  The Notch pathway is a potential therapeutic target for the treatment of renal diseases but also controls the function of other cells, requiring cell-targeting of Notch antagonists.  Toward selective targeting, we have developed the γ-secretase inhibitor-based prodrugs 13a and 15a as substrates for γ-glutamyltranspeptidase (γ-GT) and/or γ-glutamylcyclotransferase (γ-GCT) as well as aminopeptidase A (APA), which are overexpressed in renal diseases, and have evaluated them in exptl. in vitro and in vivo models.  In nondiseased mice, the cleavage product from Ac-γ-Glu-γ-secretase inhibitor prodrug 13a (γ-GT-targeting and γ-GCT-targeting) but not from Ac-α-Glu-γ-secretase inhibitor prodrug 15a (APA-targeting) accumulated in kidneys when compared to blood and liver.  Potential nephroprotective effects of the γ-secretase inhibitor targeted prodrugs were investigated in vivo in a mouse model of acute kidney injury, demonstrating that the expression of Notch1 and cleaved Notch1 could be selectively down-regulated upon treatment with the Ac-γ-Glu-γ-secretase-inhibitor 13a.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpJIYcUrrK37Vg90H21EOLACvtfcHk0lh_xnz2gR9_rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7rN&md5=a2084cbd458203f5b0c061aae1c51cb3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00912%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DFlohr%26aufirst%3DA.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DWalter%26aufirst%3DI.%26aulast%3DWyss%26aufirst%3DJ.%2BC.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DGolshayan%26aufirst%3DD.%26aulast%3DAebi%26aufirst%3DJ.%2BD.%26atitle%3DTargeted%2520%25CE%25B3-secretase%2520inhibition%2520to%2520control%2520the%2520Notch%2520pathway%2520in%2520renal%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8097%26epage%3D8109%26doi%3D10.1021%2Facs.jmedchem.5b00912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">David-Basei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournié-Zaluski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span> <span> </span><span class="NLM_article-title">Aminopeptidase A inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1517/13543776.11.3.431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1517%2F13543776.11.3.431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslSis74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=431-444&author=C.+David-Baseiauthor=M.+C.+Fourni%C3%A9-Zaluskiauthor=B.+P.+Roques&title=Aminopeptidase+A+inhibitors&doi=10.1517%2F13543776.11.3.431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Aminopeptidase A inhibitors</span></div><div class="casAuthors">David-Basei, Christelle; Fournie-Zaluski, Marie-Claude; Roques, Bernard P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">431-444</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">Potent and specific aminopeptidase A (APA; glutamylaminopeptidase, EC 3.4.11.7) inhibitors could be useful as powerful tools in the study of the physiol. involvement of this enzyme in the metab. of various peptides.  Thus, using newly designed selective APA inhibitors, APA has been shown to participate in the metab. of cholecystokinin and to be responsible for the conversion of angiotensin II (Ang II), a peripheral vasoconstrictor peptide, into Ang III, which has been recently shown to induce an increase in blood pressure and in vasopressin release in rat brain.  Moreover, APA was shown to be overexpressed in several types of malignant tumors, probably by inducing the formation of as yet unidentified cell proliferating active peptide(s).  This review with 57 refs. highlights advances in the structure and functions of APA and in the design of very potent and selective inhibitors of this zinc metallopeptidase.  These compds. could have interesting applications in the treatment of essential hypertension and their usefulness in cancer chemotherapy warrants further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-WYMYLLXElLVg90H21EOLACvtfcHk0lh_xnz2gR9_rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslSis74%253D&md5=2776e6e05e45075a78b800c04d097189</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F13543776.11.3.431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.11.3.431%26sid%3Dliteratum%253Aachs%26aulast%3DDavid-Basei%26aufirst%3DC.%26aulast%3DFourni%25C3%25A9-Zaluski%26aufirst%3DM.%2BC.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26atitle%3DAminopeptidase%2520A%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2001%26volume%3D11%26spage%3D431%26epage%3D444%26doi%3D10.1517%2F13543776.11.3.431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournie-Zaluski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvol, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Cortes, C.</span></span> <span> </span><span class="NLM_article-title">Aminopeptidase A inhibitors as potential central antihypertensive agents</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">13415</span>– <span class="NLM_lpage">13420</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.23.13415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1073%2Fpnas.96.23.13415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10557335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1MXns1Gmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=13415-13420&author=A.+Reauxauthor=M.+C.+Fournie-Zaluskiauthor=C.+Davidauthor=S.+Ziniauthor=B.+P.+Roquesauthor=P.+Corvolauthor=C.+Llorens-Cortes&title=Aminopeptidase+A+inhibitors+as+potential+central+antihypertensive+agents&doi=10.1073%2Fpnas.96.23.13415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Aminopeptidase A inhibitors as potential central antihypertensive agents</span></div><div class="casAuthors">Reaux, Annabelle; Fournie-Zaluski, Marie Claude; David, Christelle; Zini, Sylvie; Roques, Bernard P.; Corvol, Pierre; Llorens-Cortes, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">13415-13420</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Overactivity of the brain renin-angiotensin system (RAS) has been implicated in the development and maintenance of hypertension in several exptl. models, such as spontaneously hypertensive rats and transgenic mice expressing both human renin and human angiotensinogen transgenes.  We recently reported that, in the murine brain, angiotensin II (AngII) is converted to angiotensin III (AngIII) by aminopeptidase A (APA), whereas AngIII is inactivated by aminopeptidase N (APN).  If injected into cerebral ventricles (ICV), AngII and AngIII cause similar pressor responses.  Because AngII is metabolized in vivo into AngIII, the exact nature of the active peptide is not precisely detd.  Here we report that, in rats, ICV injection of the selective APA inhibitor EC33 [(S)-3-amino-4-mercaptobutyl sulfonic acid] blocked the pressor response of exogenous AngII, suggesting that the conversion of AngII to AngIII is required to increase blood pressure (BP).  Furthermore, ICV injection, but not i.v. injection, of EC33 alone caused a dose-dependent decrease in BP by blocking the formation of brain but not systemic AngIII.  This is corroborated by the fact that the selective APN inhibitor, PC18 (2-amino-4-methylsulfonyl butane thiol), administered alone via the ICV route, increases BP.  This pressor response was blocked by prior treatment with the angiotensin type 1 (AT1) receptor antagonist, losartan, showing that blocking the action of APN on AngIII metab. leads to an increase in endogenous AngIII levels, resulting in BP increase, through interaction with AT1 receptors.  These data demonstrate that AngIII is a major effector peptide of the brain RAS, exerting tonic stimulatory control over BP.  Thus, APA, the enzyme responsible for the formation of brain AngIII, represents a potential central therapeutic target that justifies the development of APA inhibitors as central antihypertensive agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLqu7dS3hsm7Vg90H21EOLACvtfcHk0li5pFDPRKCMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1Gmtbo%253D&md5=61de1e121e2db47d7174203dbaa42b78</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.23.13415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.23.13415%26sid%3Dliteratum%253Aachs%26aulast%3DReaux%26aufirst%3DA.%26aulast%3DFournie-Zaluski%26aufirst%3DM.%2BC.%26aulast%3DDavid%26aufirst%3DC.%26aulast%3DZini%26aufirst%3DS.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26aulast%3DCorvol%26aufirst%3DP.%26aulast%3DLlorens-Cortes%26aufirst%3DC.%26atitle%3DAminopeptidase%2520A%2520inhibitors%2520as%2520potential%2520central%2520antihypertensive%2520agents%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D13415%26epage%3D13420%26doi%3D10.1073%2Fpnas.96.23.13415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Padia, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournie-Zaluski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R.</span></span> <span> </span><span class="NLM_article-title">Conversion of renal angiotensin II to angiotensin III is critical for AT<sub>2</sub> receptor–mediated natriuresis in rats</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">460</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.107.103242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.107.103242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=18158338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1KrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=460-465&author=S.+H.+Padiaauthor=B.+A.+Kempauthor=N.+L.+Howellauthor=M.+C.+Fournie-Zaluskiauthor=B.+P.+Roquesauthor=R.+Carey&title=Conversion+of+renal+angiotensin+II+to+angiotensin+III+is+critical+for+AT2+receptor%E2%80%93mediated+natriuresis+in+rats&doi=10.1161%2FHYPERTENSIONAHA.107.103242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Conversion of Renal Angiotensin II to Angiotensin III Is Critical for AT2 Receptor-Mediated Natriuresis In Rats</span></div><div class="casAuthors">Padia, Shetal H.; Kemp, Brandon A.; Howell, Nancy L.; Fournie-Zaluski, Marie-Claude; Roques, Bernard P.; Carey, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2, Pt. 2</span>),
    <span class="NLM_cas:pages">460-465</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">In the kidney, angiotensin II (Ang II) is metabolized to angiotensin III (Ang III) by aminopeptidase A (APA).  In turn, Ang III is metabolized to angiotensin IV by aminopeptidase N (APN).  Renal interstitial (RI) infusion of Ang III, but not Ang II, results in angiotensin type-2 receptor (AT2R)-mediated natriuresis.  This response is augmented by coinfusion of PC-18, a specific inhibitor of APN.  The present study addresses the hypotheses that Ang II conversion to Ang III is crit. for the natriuretic response.  Sprague-Dawley rats received systemic angiotensin type-1 receptor (AT1R) blockade with candesartan (CAND; 0.01 mg/kg/min) for 24 h before and during the expt.  After a control period, rats received either RI infusion of Ang II or Ang II + PC-18.  The contralateral kidney received a RI infusion of vehicle in all rats.  Mean arterial pressure (MAP) was monitored, and urinary sodium excretion rate (UNaV) was calcd. sep. from exptl. and control kidneys for each period.  In contrast to Ang II-infused kidneys, UNaV from Ang II + PC-18-infused kidneys increased from a baseline of 0.03 ± 0.01 to 0.09 ± 0.02 μmol/min (P < 0.05).  MAP was unchanged by either infusion.  RI addn. of PD-123319, an AT2R antagonist, inhibited the natriuretic response.  Furthermore, RI addn. of EC-33, a selective APA inhibitor, abolished the natriuretic response to Ang II + PC-18.  These data demonstrate that RI addn. of PC-18 to Ang II enables natriuresis mediated by the AT2R, and that conversion of Ang II to Ang III is crit. for this response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPlVJK5sD7R7Vg90H21EOLACvtfcHk0li5pFDPRKCMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1KrsQ%253D%253D&md5=ee931985a31c6e2ca26d1afc8a496b42</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.107.103242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.107.103242%26sid%3Dliteratum%253Aachs%26aulast%3DPadia%26aufirst%3DS.%2BH.%26aulast%3DKemp%26aufirst%3DB.%2BA.%26aulast%3DHowell%26aufirst%3DN.%2BL.%26aulast%3DFournie-Zaluski%26aufirst%3DM.%2BC.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26aulast%3DCarey%26aufirst%3DR.%26atitle%3DConversion%2520of%2520renal%2520angiotensin%2520II%2520to%2520angiotensin%2520III%2520is%2520critical%2520for%2520AT2%2520receptor%25E2%2580%2593mediated%2520natriuresis%2520in%2520rats%26jtitle%3DHypertension%26date%3D2008%26volume%3D51%26spage%3D460%26epage%3D465%26doi%3D10.1161%2FHYPERTENSIONAHA.107.103242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donoghue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baronas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godbout, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosselin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagliano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaseelan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitbart, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, S.</span></span> <span> </span><span class="NLM_article-title">A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">e1</span>– <span class="NLM_lpage">e9</span>, <span class="refDoi"> DOI: 10.1161/01.RES.87.5.e1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.RES.87.5.e1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10969042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2000&pages=e1-e9&author=M.+Donoghueauthor=F.+Hsiehauthor=E.+Baronasauthor=K.+Godboutauthor=M.+Gosselinauthor=N.+Staglianoauthor=M.+Donovanauthor=B.+Woolfauthor=K.+Robisonauthor=R.+Jeyaseelanauthor=R.+E.+Breitbartauthor=S.+Acton&title=A+novel+angiotensin-converting+enzyme-related+carboxypeptidase+%28ACE2%29+converts+angiotensin+I+to+angiotensin+1%E2%80%939&doi=10.1161%2F01.RES.87.5.e1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9</span></div><div class="casAuthors">Donoghue, Mary; Hsieh, Frank; Baronas, Elizabeth; Godbout, Kevin; Gosselin, Michael; Stagliano, Nancy; Donovan, Michael; Woolf, Betty; Robison, Keith; Jeyaseelan, Raju; Breitbart, Roger E.; Acton, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e1-e9</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">ACE2, the first known human homolog of angiotensin-converting enzyme (ACE), was identified from 5' sequencing of a human heart failure ventricle cDNA library.  ACE2 has an apparent signal peptide, a single metalloprotease active site, and a transmembrane domain.  The metalloprotease catalytic domains of ACE2 and ACE are 42% identical, and comparison of the genomic structures indicates that the two genes arose through duplication.  In contrast to the more ubiquitous ACE, ACE2 transcripts are found only in heart, kidney, and testis of 23 human tissues examd.  Immunohistochem. shows ACE2 protein predominantly in the endothelium of coronary and intrarenal vessels and in renal tubular epithelium.  Active ACE2 enzyme is secreted from transfected cells by cleavage N-terminal to the transmembrane domain.  Recombinant ACE2 hydrolyzes the carboxy terminal leucine from angiotensin I to generate angiotensin 1-9, which is converted to smaller angiotensin peptides by ACE in vitro and by cardiomyocytes in culture.  ACE2 can also cleave des-Arg bradykinin and neurotensin but not bradykinin or 15 other vasoactive and hormonal peptides tested.  ACE2 is not inhibited by lisinopril or captopril.  The organ- and cell-specific expression of ACE2 and its unique cleavage of key vasoactive peptides suggest an essential role for ACE2 in the local renin-angiotensin system of the heart and kidney.  The full text of this article is available at http://www.circresaha.org.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd1c3AtR1RlLVg90H21EOLACvtfcHk0liPnPwHd8D6sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslOisr8%253D&md5=094beb0d23cddb94676e14559946a790</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1161%2F01.RES.87.5.e1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.87.5.e1%26sid%3Dliteratum%253Aachs%26aulast%3DDonoghue%26aufirst%3DM.%26aulast%3DHsieh%26aufirst%3DF.%26aulast%3DBaronas%26aufirst%3DE.%26aulast%3DGodbout%26aufirst%3DK.%26aulast%3DGosselin%26aufirst%3DM.%26aulast%3DStagliano%26aufirst%3DN.%26aulast%3DDonovan%26aufirst%3DM.%26aulast%3DWoolf%26aufirst%3DB.%26aulast%3DRobison%26aufirst%3DK.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DBreitbart%26aufirst%3DR.%2BE.%26aulast%3DActon%26aufirst%3DS.%26atitle%3DA%2520novel%2520angiotensin-converting%2520enzyme-related%2520carboxypeptidase%2520%2528ACE2%2529%2520converts%2520angiotensin%2520I%2520to%2520angiotensin%25201%25E2%2580%25939%26jtitle%3DCirc.%2520Res.%26date%3D2000%26volume%3D87%26spage%3De1%26epage%3De9%26doi%3D10.1161%2F01.RES.87.5.e1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanga, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sävmarker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åqvist, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutiérrez-de-Terán, H.</span></span> <span> </span><span class="NLM_article-title">Structural basis of inhibition of human insulin-regulated aminopeptidase (IRAP) by aryl sulfonamides</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">4509</span>– <span class="NLM_lpage">4521</span>, <span class="refDoi"> DOI: 10.1021/acsomega.8b00595</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.8b00595" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFOgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=4509-4521&author=S.+R.+Vangaauthor=J.+S%C3%A4vmarkerauthor=L.+Ngauthor=M.+Larhedauthor=M.+Hallbergauthor=J.+%C3%85qvistauthor=A.+Hallbergauthor=S.+Y.+Chaiauthor=H.+Guti%C3%A9rrez-de-Ter%C3%A1n&title=Structural+basis+of+inhibition+of+human+insulin-regulated+aminopeptidase+%28IRAP%29+by+aryl+sulfonamides&doi=10.1021%2Facsomega.8b00595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides</span></div><div class="casAuthors">Vanga, Sudarsana Reddy; Saevmarker, Jonas; Ng, Leelee; Larhed, Mats; Hallberg, Mathias; Aaqvist, Johan; Hallberg, Anders; Chai, Siew Yeen; Gutierrez-de-Teran, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">4509-4521</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The insulin-regulated aminopeptidase (IRAP) is a membrane-bound zinc metallopeptidase with many important regulatory functions.  It has been demonstrated that inhibition of IRAP by angiotensin IV (Ang IV) and other peptides, as well as more druglike inhibitors, improves cognition in several rodent models.  The authors recently reported a series of aryl sulfonamides as small-mol. IRAP inhibitors and a promising scaffold for pharmacol. intervention.  The authors have now expanded with a no. of derivs., report their stability in liver microsomes, and characterize the activity of the whole series in a new assay performed on recombinant human IRAP.  Several compds., such as the new fluorinated deriv. I, present submicromolar affinity and high metabolic stability.  Starting from the two binding modes previously proposed for the sulfonamide scaffold, the authors systematically performed mol. dynamics simulations and binding affinity estn. with the linear interaction energy method for the full compd. series.  The significant agreement with exptl. affinities suggests one of the binding modes, which was further confirmed by the excellent correlation for binding affinity differences between the selected pair of compds. obtained by rigorous free energy perturbation calcns.  The new exptl. data and the computationally derived structure-activity relationship of the sulfonamide series provide valuable information for further lead optimization of novel IRAP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmyxsMeum5hLVg90H21EOLACvtfcHk0liPnPwHd8D6sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFOgsrY%253D&md5=6efee8267a1ed6f5a7f535a5beeb8dad</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsomega.8b00595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.8b00595%26sid%3Dliteratum%253Aachs%26aulast%3DVanga%26aufirst%3DS.%2BR.%26aulast%3DS%25C3%25A4vmarker%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DL.%26aulast%3DLarhed%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3D%25C3%2585qvist%26aufirst%3DJ.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DChai%26aufirst%3DS.%2BY.%26aulast%3DGuti%25C3%25A9rrez-de-Ter%25C3%25A1n%26aufirst%3DH.%26atitle%3DStructural%2520basis%2520of%2520inhibition%2520of%2520human%2520insulin-regulated%2520aminopeptidase%2520%2528IRAP%2529%2520by%2520aryl%2520sulfonamides%26jtitle%3DACS%2520Omega%26date%3D2018%26volume%3D3%26spage%3D4509%26epage%3D4521%26doi%3D10.1021%2Facsomega.8b00595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keidar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamliel-Lazarovich, A.</span></span> <span> </span><span class="NLM_article-title">ACE2 of the heart: from angiotensin I to angiotensin (1–7)</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/j.cardiores.2006.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.cardiores.2006.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=17049503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=463-469&author=S.+Keidarauthor=M.+Kaplanauthor=A.+Gamliel-Lazarovich&title=ACE2+of+the+heart%3A+from+angiotensin+I+to+angiotensin+%281%E2%80%937%29&doi=10.1016%2Fj.cardiores.2006.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">ACE2 of the heart: From angiotensin I to angiotensin (1-7)</span></div><div class="casAuthors">Keidar, Shlomo; Kaplan, Marielle; Gamliel-Lazarovich, Aviva</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Angiotensin II (Ang II), a bioactive peptide of the renin-angiotensin system (RAAS), plays an important role in the development of cardiovascular diseases (CVD).  Pharmacol. inhibition of angiotensin-converting enzyme (ACE), the Ang II forming enzyme, or specific blockade of Ang II binding to angiotensin type 1 receptor (AT1R) through which it exerts its deleterious effects, were shown to provide some protection against progression of CVD.  The ACE-Ang II-AT1R axis has been challenged over the last few years with RAAS components able to counterbalance the effects of the main axis.  The ACE homolog ACE2 efficiently hydrolyzes Ang II to form Ang (1-7), a peptide that exerts actions opposite to those of Ang II.  In contrast to the Ang II axis, the role of the ACE2-Ang (1-7) axis in cardiac function is largely obscure.  Ang (1-7) is present in the viable myocardium, and its formation depends on Ang II as a substrate.  The expression of this peptide is assocd. with cardiac remodeling: it is lost in the infarcted area and significantly increased in the border area.  Low doses of Ang (1-7) improve cardiac output and antagonize Ang II-induced vasoconstriction.  The type of Ang (1-7) biol. activity is tissue specific and dose dependent.  These findings point to a possible protective role for Ang (1-7) in abating the Ang II-induced actions.  The elevated expression of Ang (1-7) in failing heart tissue paralleled the expression of its forming enzyme, ACE2.  Several observations and exptl. evidence suggest a beneficial role for ACE2 in cardiovascular function.  Elevated ACE2 expression at the initial stage of several pathologies which decline with progression of disease might indicate a protective role for ACE2.  Genetic manipulation of ACE2 expression, either targeted disruption or overexpression, point to the possible significance of this enzyme in cardiac function.  Based on the above, a therapeutic approach that will amplify the ACE2-Ang (1-7) axis could provide further protection against the development of CVD.  It turns out that the merits of currently used drugs - ACE inhibitors, AT1R blockers and mineralocorticoid receptor blockers (MRB) - lay beyond their direct effects on suppression of the ACE-Ang II-AT1R axis as they also increase cardiac ACE2 and Ang (1-7) significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJej3xhxIFg7Vg90H21EOLACvtfcHk0ljcxnWFmUKHsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVSqsg%253D%253D&md5=a24c864385617f5ebb6c284936a98820</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2006.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2006.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DKeidar%26aufirst%3DS.%26aulast%3DKaplan%26aufirst%3DM.%26aulast%3DGamliel-Lazarovich%26aufirst%3DA.%26atitle%3DACE2%2520of%2520the%2520heart%253A%2520from%2520angiotensin%2520I%2520to%2520angiotensin%2520%25281%25E2%2580%25937%2529%26jtitle%3DCardiovasc.%2520Res.%26date%3D2007%26volume%3D73%26spage%3D463%26epage%3D469%26doi%3D10.1016%2Fj.cardiores.2006.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burghi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echeverría, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiroga, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monczor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominici, F. P.</span></span> <span> </span><span class="NLM_article-title">Participation of Gα<sub>i</sub>-adenylate cyclase and ERK1/2 in Mas receptor signaling pathways</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">146</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffphar.2019.00146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30853914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlagtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=146&author=V.+Burghiauthor=E.+B.+Echeverr%C3%ADaauthor=M.+H.+Sosaauthor=D.+T.+Quirogaauthor=M.+C.+Mu%C3%B1ozauthor=C.+Davioauthor=F.+Monczorauthor=N.+C.+Fern%C3%A1ndezauthor=F.+P.+Dominici&title=Participation+of+G%CE%B1i-adenylate+cyclase+and+ERK1%2F2+in+Mas+receptor+signaling+pathways&doi=10.3389%2Ffphar.2019.00146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Participation of Gαi-adenylate cyclase and ERK1/2 in mas receptor signaling pathways</span></div><div class="casAuthors">Burghi, Valeria; Echeverria, Emiliana B.; Sosa, Maximo H.; Quiroga, Diego T.; Munoz, Marina C.; Davio, Carlos; Monczor, Federico; Fernandez†, Natalia C.; Dominici, Fernando P.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">146</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The MasR receptor (MasR) is an orphan G protein-coupled receptor proposed as a candidate for mediating the angiotensin (Ang)-converting enzyme 2-Ang-(1-7) protective axis of renin-angiotensin system.  This receptor has been suggested to participate in several physiol. processes including cardio- and reno-protection and regulation of the central nervous system function.  Although the knowledge of the signaling mechanisms assocd. with MasR is essential for therapeutic purposes, these are still poorly understood.  Accordingly, in the current study we aimed to characterize the signaling pathways triggered by the MasR.  To do that, we measured cAMP and Ca2+ levels in both na.ovrddot.ive and MasR transfected cells in basal conditions and upon incubation with putative MasR ligands.  Besides, we evaluated activation of ERK1/2 by Ang-(1-7) in MasR transfected cells.  Results indicated the existence of a high degree of MasR constitutive activity toward cAMP modulation.  This effect was not mediated by the PDZ-binding motif of the MasR but by receptor coupling to Gαi-adenylyl cyclase signaling pathway.  Incubation of MasR transfected cells with Ang-(1-7) or the synthetic ligand AVE 0991 amplified MasR neg. modulation of cAMP levels.  On the other hand, we provided evidence for lack of MasR-assocd. modulation of Ca2+ levels by Ang-(1-7).  Finally, it was detd. that the MasR attenuated Ang-(1-7)-induced ERK1/2 phosphorylation mediated by AT1R.  We provided further characterization of MasR signaling mechanisms regarding its constitutive activity and response to putative ligands.  This information could prove useful to better describe MasR physiol. role and development of therapeutic agents that could modulate its action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQBooqdyJTabVg90H21EOLACvtfcHk0ljcxnWFmUKHsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlagtrnN&md5=74d3eba4de3a588d5000e2221075dbf2</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00146%26sid%3Dliteratum%253Aachs%26aulast%3DBurghi%26aufirst%3DV.%26aulast%3DEcheverr%25C3%25ADa%26aufirst%3DE.%2BB.%26aulast%3DSosa%26aufirst%3DM.%2BH.%26aulast%3DQuiroga%26aufirst%3DD.%2BT.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%2BC.%26aulast%3DDavio%26aufirst%3DC.%26aulast%3DMonczor%26aufirst%3DF.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DN.%2BC.%26aulast%3DDominici%26aufirst%3DF.%2BP.%26atitle%3DParticipation%2520of%2520G%25CE%25B1i-adenylate%2520cyclase%2520and%2520ERK1%252F2%2520in%2520Mas%2520receptor%2520signaling%2520pathways%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D146%26doi%3D10.3389%2Ffphar.2019.00146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, T.</span></span> <span> </span><span class="NLM_article-title">Dimerization of AT<sub>2</sub> and Mas receptors in control of blood pressure</span>. <i>Curr. Hypertens. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.1007/s11906-018-0845-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs11906-018-0845-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29717388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC1MjovVyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=41&author=S.+Patelauthor=T.+Hussain&title=Dimerization+of+AT2+and+Mas+receptors+in+control+of+blood+pressure&doi=10.1007%2Fs11906-018-0845-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Dimerization of AT2 and Mas Receptors in Control of Blood Pressure</span></div><div class="casAuthors">Patel Sanket; Hussain Tahir</div><div class="citationInfo"><span class="NLM_cas:title">Current hypertension reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Angiotensin type 2 receptor (AT2R) and receptor Mas (MasR) are part of the "protective arm" of the renin angiotensin system.  Gene and pharmacological manipulation studies reveal that AT2R and MasR are involved in natriuretic, vasodilatory, and anti-inflammatory responses and in lowering blood pressure in various animal models under normal and pathological conditions such as salt-sensitive hypertension, obesity, and diabetes.  The scope of this review is to discuss co-localization and heterodimerization as potential molecular mechanisms of AT2R- and MasR-mediated functions including antihypertensive activities.  RECENT FINDINGS:  Accumulating evidences show that AT2R and MasR are co-localized, make a heterodimer, and are functionally interdependent in producing their physiological responses.  Moreover, ang-(1-7) preferably may be an AT1R-biased agonist while acting as a MasR agonist.  The physical interactions of AT2R and MasR appear to be an important mechanism by which these receptors are involved in blood pressure regulation and antihypertensive activity.  Whether heteromers of these receptors influence affinity or efficacy of endogenous or synthetic agonists remains a question to be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKJWY6AT4bBqcY7HFp97qMfW6udTcc2eaNKVkQfsiGLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjovVyqtQ%253D%253D&md5=6aee7c9c20816e913a50db999b688d5b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs11906-018-0845-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11906-018-0845-3%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DHussain%26aufirst%3DT.%26atitle%3DDimerization%2520of%2520AT2%2520and%2520Mas%2520receptors%2520in%2520control%2520of%2520blood%2520pressure%26jtitle%3DCurr.%2520Hypertens.%2520Rep.%26date%3D2018%26volume%3D20%26spage%3D41%26doi%3D10.1007%2Fs11906-018-0845-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Ferrer, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heringer-Walther, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gembardt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheiss, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, T.</span></span> <span> </span><span class="NLM_article-title">G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1806</span>– <span class="NLM_lpage">1812</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000160867.23556.7D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.CIR.0000160867.23556.7D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=15809376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFelur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2005&pages=1806-1812&author=E.+Kostenisauthor=G.+Milliganauthor=A.+Christopoulosauthor=C.+F.+Sanchez-Ferrerauthor=S.+Heringer-Waltherauthor=P.+M.+Sextonauthor=F.+Gembardtauthor=E.+Kellettauthor=L.+Martiniauthor=P.+Vanderheydenauthor=H.+P.+Schultheissauthor=T.+Walther&title=G-protein-coupled+receptor+Mas+is+a+physiological+antagonist+of+the+angiotensin+II+type+1+receptor&doi=10.1161%2F01.CIR.0000160867.23556.7D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">G-Protein-Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor</span></div><div class="casAuthors">Kostenis, Evi; Milligan, Graeme; Christopoulos, Arthur; Sanchez-Ferrer, Carlos F.; Heringer-Walther, Silvia; Sexton, Patrick M.; Gembardt, Florian; Kellett, Elaine; Martini, Lene; Vanderheyden, Patrick; Schultheiss, Heinz-Peter; Walther, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1806-1813</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background- We previously identified the G-protein-coupled receptor Mas, encoded by the Mas proto-oncogene, as an endogenous receptor for the heptapeptide angiotensin-(1-7); however, the receptor is also suggested to be involved in actions of angiotensin II.  We therefore tested whether this could be mediated indirectly through an interaction with the angiotensin II type 1 receptor, AT1.  Methods and Results- In transfected mammalian cells, Mas was not activated by angiotensin II; however, AT1 receptor-mediated, angiotensin II-induced prodn. of inositol phosphates and mobilization of intracellular Ca2+ was diminished by 50% after coexpression of Mas, despite a concomitant increase in angiotensin II binding capacity.  Mas and the AT1 receptor formed a constitutive hetero-oligomeric complex that was unaffected by the presence of agonists or antagonists of the 2 receptors.  In vivo, Mas acts as an antagonist of the AT1 receptor; mice lacking the Mas gene show enhanced angiotensin II-mediated vasoconstriction in mesenteric microvessels.  Conclusions- These results demonstrate that Mas can hetero-oligomerize with the AT1 receptor and by so doing inhibit the actions of angiotensin II.  This is a novel demonstration that a G-protein-coupled receptor acts as a physiol. antagonist of a previously characterized receptor.  Consequently, the AT1-Mas complex could be of great importance as a target for pharmacol. intervention in cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhYEOYRiMOrrVg90H21EOLACvtfcHk0lhUNsVJ1WIkZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFelur4%253D&md5=bede82574eb0570dd9127280e2d1cdcd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000160867.23556.7D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000160867.23556.7D%26sid%3Dliteratum%253Aachs%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DMilligan%26aufirst%3DG.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSanchez-Ferrer%26aufirst%3DC.%2BF.%26aulast%3DHeringer-Walther%26aufirst%3DS.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DGembardt%26aufirst%3DF.%26aulast%3DKellett%26aufirst%3DE.%26aulast%3DMartini%26aufirst%3DL.%26aulast%3DVanderheyden%26aufirst%3DP.%26aulast%3DSchultheiss%26aufirst%3DH.%2BP.%26aulast%3DWalther%26aufirst%3DT.%26atitle%3DG-protein-coupled%2520receptor%2520Mas%2520is%2520a%2520physiological%2520antagonist%2520of%2520the%2520angiotensin%2520II%2520type%25201%2520receptor%26jtitle%3DCirculation%26date%3D2005%26volume%3D111%26spage%3D1806%26epage%3D1812%26doi%3D10.1161%2F01.CIR.0000160867.23556.7D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leonhardt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villela, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teichmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Münter, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namsolleck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alenina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multhaup, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schülein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span> <span> </span><span class="NLM_article-title">Evidence for heterodimerization and functional interaction of the angiotensin type 2 receptor and the receptor MAS</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.116.08814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.116.08814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28461604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlyis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=1128-1135&author=J.+Leonhardtauthor=D.+C.+Villelaauthor=A.+Teichmannauthor=L.+M.+M%C3%BCnterauthor=M.+C.+Mayerauthor=M.+Mardahlauthor=S.+Kirschauthor=P.+Namsolleckauthor=K.+Luchtauthor=V.+Benzauthor=N.+Aleninaauthor=N.+Daniellauthor=M.+Horiuchiauthor=M.+Iwaiauthor=G.+Multhaupauthor=R.+Sch%C3%BCleinauthor=M.+Baderauthor=R.+A.+Santosauthor=T.+Ungerauthor=U.+M.+Steckelings&title=Evidence+for+heterodimerization+and+functional+interaction+of+the+angiotensin+type+2+receptor+and+the+receptor+MAS&doi=10.1161%2FHYPERTENSIONAHA.116.08814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for Heterodimerization and Functional Interaction of the Angiotensin Type 2 Receptor and the Receptor MAS</span></div><div class="casAuthors">Leonhardt, Julia; Villela, Daniel C.; Teichmann, Anke; Muenter, Lisa-Marie; Mayer, Magnus C.; Mardahl, Maibritt; Kirsch, Sebastian; Namsolleck, Pawel; Lucht, Kristin; Benz, Verena; Alenina, Natalia; Daniell, Nicholas; Horiuchi, Masatsugu; Iwai, Masaru; Multhaup, Gerhard; Schuelein, Ralf; Bader, Michael; Santos, Robson A.; Unger, Thomas; Steckelings, Ulrike Muscha</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1128-1135</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The angiotensin type 2 receptor (AT2R) and the receptor MAS are receptors of the protective arm of the renin-angiotensin system.  They mediate strikingly similar actions.  Moreover, in various studies, AT2R antagonists blocked the effects of MAS agonists and vice versa.  Such cross-inhibition may indicate heterodimerization of these receptors.  Therefore, this study investigated the mol. and functional interplay between MAS and the AT2R.  Mol. interactions were assessed by fluorescence resonance energy transfer and by cross correlation spectroscopy in human embryonic kidney-293 cells transfected with vectors encoding fluorophore-tagged MAS or AT2R.  Functional interaction of AT2R and MAS was studied in astrocytes with CX3C chemokine receptor-1 mRNA expression as readout.  Coexpression of fluorophore-tagged AT2R and MAS resulted in a fluorescence resonance energy transfer efficiency of 10.8 ± 0.8%, indicating that AT2R and MAS are capable to form heterodimers.  Heterodimerization was verified by competition expts. using untagged AT2R and MAS.  Specificity of dimerization of AT2R and MAS was supported by lack of dimerization with the transient receptor potential cation channel, subfamily C-member 6.  Dimerization of the AT2R was abolished when it was mutated at cysteine residue 35.  AT2R and MAS stimulation with the resp. agonists, Compd. 21 or angiotensin-(1-7), significantly induced CX3C chemokine receptor-1 mRNA expression.  Effects of each agonist were blocked by an AT2R antagonist (PD123319) and also by a MAS antagonist (A-779).  Knockout of a single of these receptors made astrocytes unresponsive for both agonists.  Our results suggest that MAS and the AT2R form heterodimers and that-at least in astrocytes-both receptors functionally depend on each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokeH4MMXUihbVg90H21EOLACvtfcHk0ljwRJIq6jnvGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlyis7Y%253D&md5=699eafec991f0245f80c741b6736a62a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.116.08814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.116.08814%26sid%3Dliteratum%253Aachs%26aulast%3DLeonhardt%26aufirst%3DJ.%26aulast%3DVillela%26aufirst%3DD.%2BC.%26aulast%3DTeichmann%26aufirst%3DA.%26aulast%3DM%25C3%25BCnter%26aufirst%3DL.%2BM.%26aulast%3DMayer%26aufirst%3DM.%2BC.%26aulast%3DMardahl%26aufirst%3DM.%26aulast%3DKirsch%26aufirst%3DS.%26aulast%3DNamsolleck%26aufirst%3DP.%26aulast%3DLucht%26aufirst%3DK.%26aulast%3DBenz%26aufirst%3DV.%26aulast%3DAlenina%26aufirst%3DN.%26aulast%3DDaniell%26aufirst%3DN.%26aulast%3DHoriuchi%26aufirst%3DM.%26aulast%3DIwai%26aufirst%3DM.%26aulast%3DMulthaup%26aufirst%3DG.%26aulast%3DSch%25C3%25BClein%26aufirst%3DR.%26aulast%3DBader%26aufirst%3DM.%26aulast%3DSantos%26aufirst%3DR.%2BA.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26atitle%3DEvidence%2520for%2520heterodimerization%2520and%2520functional%2520interaction%2520of%2520the%2520angiotensin%2520type%25202%2520receptor%2520and%2520the%2520receptor%2520MAS%26jtitle%3DHypertension%26date%3D2017%26volume%3D69%26spage%3D1128%26epage%3D1135%26doi%3D10.1161%2FHYPERTENSIONAHA.116.08814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anand, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yiangou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korchev, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons</span>. <i>Eur. J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1026</span>, <span class="refDoi"> DOI: 10.1002/j.1532-2149.2012.00269.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fj.1532-2149.2012.00269.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23255326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKhsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1012-1026&author=U.+Anandauthor=P.+Facerauthor=Y.+Yiangouauthor=M.+Sinisiauthor=M.+Foxauthor=T.+McCarthyauthor=C.+Bountraauthor=Y.+E.+Korchevauthor=P.+Anand&title=Angiotensin+II+type+2+receptor+%28AT2+R%29+localization+and+antagonist-mediated+inhibition+of+capsaicin+responses+and+neurite+outgrowth+in+human+and+rat+sensory+neurons&doi=10.1002%2Fj.1532-2149.2012.00269.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons</span></div><div class="casAuthors">Anand, U.; Facer, P.; Yiangou, Y.; Sinisi, M.; Fox, M.; McCarthy, T.; Bountra, C.; Korchev, Y. E.; Anand, P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pain (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1012-1026</span>CODEN:
                <span class="NLM_cas:coden">EJPAFJ</span>;
        ISSN:<span class="NLM_cas:issn">1090-3801</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : The angiotensin II (AngII) receptor subtype 2 (AT2R) is expressed in sensory neurons and may play a role in nociception and neuronal regeneration.  Methods : We used immunostaining with characterized antibodies to study the localization of AT2R in cultured human and rat dorsal root ganglion (DRG) neurons and a range of human tissues.  The effects of AngII and AT2R antagonist EMA401 on capsaicin responses in cultured human and rat (DRG) neurons were measured with calcium imaging, on neurite length and d. with Gap43 immunostaining, and on cyclic adenosine monophosphate (cAMP) expression using immunofluorescence.  Results : AT2R expression was localized in small-/medium-sized cultured neurons of human and rat DRG.  Treatment with the AT2R antagonist EMA401 resulted in dose-related functional inhibition of capsaicin responses (IC50=10nmol/L), which was reversed by 8-bromo-cAMP, and reduced neurite length and d.; AngII treatment significantly enhanced capsaicin responses, cAMP levels and neurite outgrowth.  The AT1R antagonist losartan had no effect on capsaicin responses.  AT2R was localized in sensory neurons of human DRG, and nerve fibers in peripheral nerves, skin, urinary bladder and bowel.  A majority sub-population (60%) of small-/medium-diam. neuronal cells were immunopos. in both control post-mortem and avulsion-injured human DRG; some very small neurons appeared to be intensely immunoreactive, with TRPV1 co-localization.  While AT2R levels were reduced in human limb peripheral nerve segments proximal to injury, they were preserved in painful neuromas.  Conclusions : AT2R antagonists could be particularly useful in the treatment of chronic pain and hypersensitivity assocd. with abnormal nerve sprouting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXE7j5pUExILVg90H21EOLACvtfcHk0ljwRJIq6jnvGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKhsrnF&md5=9550c73afcb055fb9144251b1f7d1872</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fj.1532-2149.2012.00269.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1532-2149.2012.00269.x%26sid%3Dliteratum%253Aachs%26aulast%3DAnand%26aufirst%3DU.%26aulast%3DFacer%26aufirst%3DP.%26aulast%3DYiangou%26aufirst%3DY.%26aulast%3DSinisi%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DM.%26aulast%3DMcCarthy%26aufirst%3DT.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DKorchev%26aufirst%3DY.%2BE.%26aulast%3DAnand%26aufirst%3DP.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor%2520%2528AT2%2520R%2529%2520localization%2520and%2520antagonist-mediated%2520inhibition%2520of%2520capsaicin%2520responses%2520and%2520neurite%2520outgrowth%2520in%2520human%2520and%2520rat%2520sensory%2520neurons%26jtitle%3DEur.%2520J.%2520Pain%26date%3D2013%26volume%3D17%26spage%3D1012%26epage%3D1026%26doi%3D10.1002%2Fj.1532-2149.2012.00269.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Gasparo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catt, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">International union of pharmacology. XXIII. The angiotensin II receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10977869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2000&pages=415-472&author=M.+de%0AGasparoauthor=K.+J.+Cattauthor=T.+Inagamiauthor=J.+W.+Wrightauthor=T.+Unger&title=International+union+of+pharmacology.+XXIII.+The+angiotensin+II+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">International union of pharmacology. XXIII. The angiotensin II receptors</span></div><div class="casAuthors">De Gasparo, M.; Catt, K. J.; Inagami, T.; Wright, J. W.; Unger, Th.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">415-472</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review with 741 refs.  The cardiovascular and other actions of angiotensin II (Ang II) are mediated by AT1 and AT2 receptors, which are seven transmembrane glycoproteins with 30% sequence similarity.  Most species express a single autosomal AT1 gene, but two related AT1A and AT1B receptor genes are expressed in rodents.  AT1 receptors are predominantly coupled to Gq/11, and signal through phospholipases A, C, D, inositol phosphates, calcium channels, and a variety of serine/threonine and tyrosine kinases.  Many AT1-induced growth responses are mediated by transactivation of growth factor receptors.  The receptor binding sites for agonist and nonpeptide antagonist ligands have been defined.  The latter compds. are as effective as angiotensin converting enzyme inhibitors in cardiovascular diseases but are better tolerated.  The AT2 receptor is expressed at high d. during fetal development.  It is much less abundant in adult tissues and is up-regulated in pathol. conditions.  Its signaling pathways include serine and tyrosine phosphatases, phospholipase A2, nitric oxide, and cyclic guanosine monophosphate.  The AT2 receptor counteracts several of the growth responses initiated by the AT1 and growth factor receptors.  The AT4 receptor specifically binds Ang IV (Ang 3-8), and is located in brain and kidney.  Its signaling mechanisms are unknown, but it influences local blood flow and is assocd. with cognitive processes and sensory and motor functions.  Although AT1 receptors mediate most of the known actions of Ang II, the AT2 receptor contributes to the regulation of blood pressure and renal function.  The development of specific nonpeptide receptor antagonists has led to major advances in the physiol., pharmacol., and therapy of the renin-angiotensin system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSSYESfE8nPrVg90H21EOLACvtfcHk0ljwRJIq6jnvGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbk%253D&md5=6abc5466d51de53202ecf1fd9ba3c186</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BGasparo%26aufirst%3DM.%26aulast%3DCatt%26aufirst%3DK.%2BJ.%26aulast%3DInagami%26aufirst%3DT.%26aulast%3DWright%26aufirst%3DJ.%2BW.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DInternational%2520union%2520of%2520pharmacology.%2520XXIII.%2520The%2520angiotensin%2520II%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2000%26volume%3D52%26spage%3D415%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirupula, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, P.</span></span> <span> </span><span class="NLM_article-title">International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1124/pr.114.010454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1124%2Fpr.114.010454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26315714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWhsr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=754-819&author=S.+S.+Karnikauthor=H.+Unalauthor=J.+R.+Kempauthor=K.+C.+Tirupulaauthor=W.+Thomasauthor=S.+Eguchiauthor=P.+Vanderheyden&title=International+Union+of+Basic+and+Clinical+Pharmacology.+XCIX.+Angiotensin+receptors%3A+interpreters+of+pathophysiological+angiotensinergic+stimuli&doi=10.1124%2Fpr.114.010454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">International union of basic and clinical pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli</span></div><div class="casAuthors">Karnik, Sadashiva S.; Unal, Hamiyet; Kemp, Jacqueline R.; Tirupula, Kalyan C.; Eguchi, Satoru; Vanderheyden, Patrick M. L.; Thomas, Walter G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">754-820</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The renin angiotensin system (RAS) produced hormone peptides regulate many vital body functions.  Dysfunctional signaling by receptors for RAS peptides leads to pathol. states.  Nearly half of humanity today would likely benefit from modern drugs targeting these receptors.  The receptors for RAS peptides consist of three G-protein-coupled receptors- the angiotensin II type 1 receptor (AT1 receptor), the angiotensin II type 2 receptor (AT2 receptor), the MAS receptor-and a type II trans-membrane zinc protein- the candidate angiotensin IV receptor (AngIV binding site).  The prorenin receptor is a relatively new contender for consideration, but is not included here because the role of prorenin receptor as an independent endocrine mediator is presently unclear.  The full spectrum of biol. characteristics of these receptors is still evolving, but there is evidence establishing unique roles of each receptor in cardiovascular, hemodynamic, neurol., renal, and endothelial functions, as well as in cell proliferation, survival,matrix-cell interaction, and inflammation.  Therapeutic agents targeted to these receptors are either in active use in clin. intervention of major common diseases or under evaluation for repurposing in many other disorders.  Broad-spectrum influence these receptors produce in complex pathophysiol. context in our body highlights their role as precise interpreters of distinctive angiotensinergic peptide cues.  This review article summarizes findings published in the last 15 years on the structure, pharmacol., signaling, physiol., and disease states related to angiotensin receptors.  We also discuss the challenges the pharmacologist presently faces in formally accepting newer members as established angiotensin receptors and emphasize necessary future developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhBn_d6p-zR7Vg90H21EOLACvtfcHk0ljnJVuvgIq5aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWhsr%252FI&md5=0ec13e7282e81d8fb02cdc505592fbc0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.010454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.010454%26sid%3Dliteratum%253Aachs%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26aulast%3DUnal%26aufirst%3DH.%26aulast%3DKemp%26aufirst%3DJ.%2BR.%26aulast%3DTirupula%26aufirst%3DK.%2BC.%26aulast%3DThomas%26aufirst%3DW.%26aulast%3DEguchi%26aufirst%3DS.%26aulast%3DVanderheyden%26aufirst%3DP.%26atitle%3DInternational%2520Union%2520of%2520Basic%2520and%2520Clinical%2520Pharmacology.%2520XCIX.%2520Angiotensin%2520receptors%253A%2520interpreters%2520of%2520pathophysiological%2520angiotensinergic%2520stimuli%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D754%26epage%3D819%26doi%3D10.1124%2Fpr.114.010454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhanachandra
Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span> <span> </span><span class="NLM_article-title">Angiotensin receptors: structure, function, signaling and clinical applications</span>. <i>J. Cell Signal.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.4172/2576-1471.1000111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.4172%2F2576-1471.1000111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=111&author=K.+Dhanachandra%0ASinghauthor=S.+S.+Karnik&title=Angiotensin+receptors%3A+structure%2C+function%2C+signaling+and+clinical+applications&doi=10.4172%2F2576-1471.1000111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4172%2F2576-1471.1000111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2576-1471.1000111%26sid%3Dliteratum%253Aachs%26aulast%3DDhanachandra%2BSingh%26aufirst%3DK.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26atitle%3DAngiotensin%2520receptors%253A%2520structure%252C%2520function%252C%2520signaling%2520and%2520clinical%2520applications%26jtitle%3DJ.%2520Cell%2520Signal.%26date%3D2017%26volume%3D1%26spage%3D111%26doi%3D10.4172%2F2576-1471.1000111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vinturache, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, F. G.</span></span> <span> </span><span class="NLM_article-title">Renal effects of angiotensin II in the newborn period: role of type 1 and type 2 receptors</span>. <i>BMC Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/s12899-016-0022-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1186%2Fs12899-016-0022-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=27090941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtV2rsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=3&author=A.+E.+Vinturacheauthor=F.+G.+Smith&title=Renal+effects+of+angiotensin+II+in+the+newborn+period%3A+role+of+type+1+and+type+2+receptors&doi=10.1186%2Fs12899-016-0022-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Renal effects of angiotensin II in the newborn period: role of type 1 and type 2 receptors</span></div><div class="casAuthors">Vinturache, Angela E.; Smith, Francine G.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Physiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3/1-3/10</span>CODEN:
                <span class="NLM_cas:coden">BPMHCV</span>;
        ISSN:<span class="NLM_cas:issn">1472-6793</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Evidence suggests a crit. role for the renin-angiotensin system in regulating renal function during postnatal development.  Methods: The renal effects of the selective antagonist to AT1R, ZD 7155 and to AT2R, PD 1233319 were evaluated in two groups of conscious chronically instrumented lambs aged ∼ one week (N = 8) and ∼ six weeks (N = 10).  Two expts. were carried out in each animal and consisted of the assessment of renal variables including glomerular and tubular function, for 30 min before (Control) and 60 min after infusion of ZD 7155 and PD 123319, resp.  Results: ZD 7155 infusion was assocd. with a significant decrease in glomerular filtration rate and filtration fraction at one but not six weeks; urinary flow rate decreased significantly in older animals, whereas sodium excretion and free water clearance were not altered.  There was an age-dependent effect on potassium handling along the nephron, potassium excretion decreasing after ZD 7155 infusion in younger but not in older lambs.  PD 123319 had no significant effects on glomerular filtration rate and tubular function in either age group.  Conclusions: These results provide evidence to support an important role for AT1Rs in mediating the renal effects of angiotensin II during postnatal maturation in conscious developing animals.  In contrast to a role for AT2Rs later in life, there appears to be no role for AT2Rs in influencing the renal effects of Angiotensin II in the postnatal period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq82BkTygQ1n7Vg90H21EOLACvtfcHk0ljnJVuvgIq5aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtV2rsbk%253D&md5=2e395b6d6e43ee6075315b938af34c50</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1186%2Fs12899-016-0022-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12899-016-0022-3%26sid%3Dliteratum%253Aachs%26aulast%3DVinturache%26aufirst%3DA.%2BE.%26aulast%3DSmith%26aufirst%3DF.%2BG.%26atitle%3DRenal%2520effects%2520of%2520angiotensin%2520II%2520in%2520the%2520newborn%2520period%253A%2520role%2520of%2520type%25201%2520and%2520type%25202%2520receptors%26jtitle%3DBMC%2520Physiol.%26date%3D2016%26volume%3D16%26spage%3D3%26doi%3D10.1186%2Fs12899-016-0022-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span> <span> </span><span class="NLM_article-title">Developmental expression patterns for angiotensin receptors in mouse skin and brain</span>. <i>JRAAS</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1177/1470320312467557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1177%2F1470320312467557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=139-149&author=L.+Yuauthor=C.+Shaoauthor=L.+Gao&title=Developmental+expression+patterns+for+angiotensin+receptors+in+mouse+skin+and+brain&doi=10.1177%2F1470320312467557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Developmental expression patterns for angiotensin receptors in mouse skin and brain</span></div><div class="casAuthors">Yu, Li; Shao, Chunhong; Gao, Lie</div><div class="citationInfo"><span class="NLM_cas:title">JRAAS</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-149, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JRAAAG</span>;
        ISSN:<span class="NLM_cas:issn">1470-3203</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Two G-protein-coupled receptors, angiotensin type 1 receptor (AT1R) and type 2 receptor (AT2R), mediate the majority of angiotensin II (Ang II) effects.  It has long been believed that the AT2R is reduced to extremely low levels in adulthood but is abundantly expressed in the fetus.  However, recent data from rats and mice do not support this notion.  Employing Western blot anal., we found a gradual increase in AT2R protein expression from fetal life to adulthood in brain, heart, lung, liver, and kidney.  The reason for the discrepancy between our observations and the conventional concept is unknown.  Evidence supporting a regression of the AT2R during maturation is derived largely from autoradiog. signals that were confined to the outline of fetal rats, implying that the previously reported high AT2R expression in the fetus might be valid only for skin.  We therefore hypothesized that the ontogeny of angiotensin receptors in skin is opposite that in other organs.  In the current expt., we employed Western blot anal. to compare AT2R and AT1R protein expressions in skin with that in the brainstem of fetal and adult mice.  Fetal brainstem expressed lower AT2R and higher AT1R protein compared to adult brainstem (AT2R/GAPDH: 0.08 ± 0.2 in fetus vs 7.6 ± 0.9 in adult, p < 0.05; AT1R/GAPDH: 5.9 ± 0.8 in fetus vs 0.7 ± 0.3 in adult, p < 0.05).  In contrast, fetal skin expresses higher AT2R and lower AT1R protein compared to adult skin (AT2R/GAPDH: 0.95 ± 0.4 in fetus vs 0.04 ± 0.2 in adult, p < 0.05; AT1R/GAPDH: 0.6 ± 0.2 in fetus vs 2.1 ± 0.5 in adult, p < 0.05).  This expression profile was also confirmed by immunofluorescence.  Using real-time RT-PCR, we could not detect any significant differences in mRNA of these two receptors in brainstem between fetal and adult mice.  However, we found a higher AT2R mRNA and lower AT1R mRNA in the fetal skin compared to adult skin.  The above results confirm our hypothesis that skin displays an expression profile of angiotensin receptors opposite that of other organs during development, suggesting that the currently held view concerning AT2R maturation is suitable only for skin.  In other organs and tissues, adults express higher AT2R protein than does the fetus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP8lMRg1Fgx7Vg90H21EOLACvtfcHk0ljnJVuvgIq5aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWgu77F&md5=331eee1b6fe64ee8bf447b7036993db4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1177%2F1470320312467557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1470320312467557%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DL.%26aulast%3DShao%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DL.%26atitle%3DDevelopmental%2520expression%2520patterns%2520for%2520angiotensin%2520receptors%2520in%2520mouse%2520skin%2520and%2520brain%26jtitle%3DJRAAS%26date%3D2014%26volume%3D15%26spage%3D139%26epage%3D149%26doi%3D10.1177%2F1470320312467557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quitterer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AbdAlla, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of pathologic GPCR aggregation</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">9</span>, <span class="refDoi"> DOI: 10.3389/fmed.2019.00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffmed.2019.00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BB3cfjtFynsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=9&author=U.+Quittererauthor=S.+AbdAlla&title=Discovery+of+pathologic+GPCR+aggregation&doi=10.3389%2Ffmed.2019.00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pathologic GPCR Aggregation</span></div><div class="casAuthors">Quitterer Ursula; AbdAlla Said; Quitterer Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9</span>
        ISSN:<span class="NLM_cas:issn">2296-858X</span>.
    </div><div class="casAbstract">The family of G-protein-coupled receptors (GPCRs) is one of the most important drug targets.  Mechanisms underlying GPCR activation and signaling are therefore of great pharmacologic interest.  It was long thought that GPCRs exist and function as monomers.  This feature was considered to distinguish GPCRs from other membrane receptors such as receptor tyrosine kinases or cytokine receptors, which signal from dimeric receptor complexes.  But during the last two decades it was increasingly recognized that GPCRs can undergo aggregation to form dimers and higher order oligomers, resulting in homomeric and/or heteromeric protein complexes with different stoichiometries.  Moreover, this protein complex formation could modify GPCR signaling and function.  We contributed to this paradigm shift in GPCR pharmacology by the discovery of the first pathologic GPCR aggregation, which is the protein complex formation between the angiotensin II AT1 receptor and the bradykinin B2 receptor.  Increased AT1-B2 heteromerization accounts for the angiotensin II hypersensitivity of pregnant women with preeclampsia hypertension.  Since the discovery of AT1-B2, other pathologic GPCR aggregates were found, which contribute to atherosclerosis, neurodegeneration and Alzheimer's disease.  As a result of our findings, pathologic GPCR aggregation appears as an independent and disease-specific process, which is increasingly considered as a novel target for pharmacologic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-TR1YbDmoryA3UY9EwTNrfW6udTcc2eZeouLm93MiKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfjtFynsA%253D%253D&md5=7bc88e11ff82a30b54e9e55e33607374</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2019.00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2019.00009%26sid%3Dliteratum%253Aachs%26aulast%3DQuitterer%26aufirst%3DU.%26aulast%3DAbdAlla%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520pathologic%2520GPCR%2520aggregation%26jtitle%3DFront.%2520Med.%26date%3D2019%26volume%3D6%26spage%3D9%26doi%3D10.3389%2Ffmed.2019.00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zatsepin, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weierstall, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawaya, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messerschmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yefanov, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirupula, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnoyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span> <span> </span><span class="NLM_article-title">Structure of the angiotensin receptor revealed by serial femtosecond crystallography</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">833</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2015.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.cell.2015.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25913193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFKjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2015&pages=833-844&author=H.+Zhangauthor=H.+Unalauthor=C.+Gatiauthor=G.+W.+Hanauthor=W.+Liuauthor=N.+A.+Zatsepinauthor=D.+Jamesauthor=D.+Wangauthor=G.+Nelsonauthor=U.+Weierstallauthor=M.+R.+Sawayaauthor=Q.+Xuauthor=M.+Messerschmidtauthor=G.+J.+Williamsauthor=S.+Boutetauthor=O.+M.+Yefanovauthor=T.+A.+Whiteauthor=C.+Wangauthor=A.+Ishchenkoauthor=K.+C.+Tirupulaauthor=R.+Desnoyerauthor=J.+Coeauthor=C.+Conradauthor=P.+Frommeauthor=R.+C.+Stevensauthor=V.+Katritchauthor=S.+S.+Karnikauthor=V.+Cherezov&title=Structure+of+the+angiotensin+receptor+revealed+by+serial+femtosecond+crystallography&doi=10.1016%2Fj.cell.2015.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography</span></div><div class="casAuthors">Zhang, Haitao; Unal, Hamiyet; Gati, Cornelius; Han, Gye Won; Liu, Wei; Zatsepin, Nadia A.; James, Daniel; Wang, Dingjie; Nelson, Garrett; Weierstall, Uwe; Sawaya, Michael R.; Xu, Qingping; Messerschmidt, Marc; Williams, Garth J.; Boutet, Sebastien; Yefanov, Oleksandr M.; White, Thomas A.; Wang, Chong; Ishchenko, Andrii; Tirupula, Kalyan C.; Desnoyer, Russell; Coe, Jesse; Conrad, Chelsie E.; Fromme, Petra; Stevens, Raymond C.; Katritch, Vsevolod; Karnik, Sadashiva S.; Cherezov, Vadim</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">833-844</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Angiotensin II type 1 receptor (AT1R) is a G protein-coupled receptor that serves as a primary regulator for blood pressure maintenance.  Although several anti-hypertensive drugs have been developed as AT1R blockers (ARBs), the structural basis for AT1R ligand-binding and regulation has remained elusive, mostly due to the difficulties of growing high-quality crystals for structure detn. using synchrotron radiation.  By applying the recently developed method of serial femtosecond crystallog. at an X-ray free-electron laser, we successfully detd. the room-temp. crystal structure of the human AT1R in complex with its selective antagonist ZD 7155 at 2.9-Å resoln.  The AT1R-ZD 7155 complex structure revealed key structural features of AT1R and crit. interactions for ZD7155 binding.  Docking simulations of the clin. used ARBs into the AT1R structure further elucidated both the common and distinct binding modes for these anti-hypertensive drugs.  Our results thereby provide fundamental insights into AT1R structure-function relationship and structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9DHOZJVeyA7Vg90H21EOLACvtfcHk0lhd0AnwepKRvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFKjsLw%253D&md5=ac870c42fb32992de4398f5da440af15</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DUnal%26aufirst%3DH.%26aulast%3DGati%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZatsepin%26aufirst%3DN.%2BA.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DNelson%26aufirst%3DG.%26aulast%3DWeierstall%26aufirst%3DU.%26aulast%3DSawaya%26aufirst%3DM.%2BR.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMesserschmidt%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DG.%2BJ.%26aulast%3DBoutet%26aufirst%3DS.%26aulast%3DYefanov%26aufirst%3DO.%2BM.%26aulast%3DWhite%26aufirst%3DT.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DIshchenko%26aufirst%3DA.%26aulast%3DTirupula%26aufirst%3DK.%2BC.%26aulast%3DDesnoyer%26aufirst%3DR.%26aulast%3DCoe%26aufirst%3DJ.%26aulast%3DConrad%26aufirst%3DC.%26aulast%3DFromme%26aufirst%3DP.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26aulast%3DCherezov%26aufirst%3DV.%26atitle%3DStructure%2520of%2520the%2520angiotensin%2520receptor%2520revealed%2520by%2520serial%2520femtosecond%2520crystallography%26jtitle%3DCell%26date%3D2015%26volume%3D161%26spage%3D833%26epage%3D844%26doi%3D10.1016%2Fj.cell.2015.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnoyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structural basis for ligand recognition and functional selectivity at angiotensin receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">29127</span>– <span class="NLM_lpage">29139</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.689000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1074%2Fjbc.M115.689000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26420482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGku77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=29127-29139&author=H.+Zhangauthor=H.+Unalauthor=R.+Desnoyerauthor=G.+W.+Hanauthor=N.+Patelauthor=V.+Katritchauthor=S.+S.+Karnikauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structural+basis+for+ligand+recognition+and+functional+selectivity+at+angiotensin+receptor&doi=10.1074%2Fjbc.M115.689000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor</span></div><div class="casAuthors">Zhang, Haitao; Unal, Hamiyet; Desnoyer, Russell; Han, Gye Won; Patel, Nilkanth; Katritch, Vsevolod; Karnik, Sadashiva S.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">29127-29139</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Angiotensin II type 1 receptor (AT1R) is the primary blood pressure regulator.  AT1R blockers (ARBs) have been widely used in clin. settings as anti-hypertensive drugs and share a similar chem. scaffold, although even minor variations can lead to distinct therapeutic efficacies toward cardiovascular etiologies.  The structural basis for AT1R modulation by different peptide and non-peptide ligands has remained elusive.  Here, we report the crystal structure of the human AT1R in complex with an inverse agonist olmesartan (BenicarTM), a highly potent anti-hypertensive drug.  Olmesartan is anchored to the receptor primarily by the residues Tyr-351.39, Trp-842.60, and Arg-167ECL2, similar to the antagonist ZD 7155, corroborating a common binding mode of different ARBs.  Using docking simulations and site-directed mutagenesis, we identified specific interactions between AT1R and different ARBs, including olmesartan derivs. with inverse agonist, neutral antagonist, or agonist activities.  We further obsd. that the mutation N1113.35A in the putative sodium-binding site affects binding of the endogenous peptide agonist angiotensin II but not the β-arrestin-biased peptide TRV 120027.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIxvG2W4XcgLVg90H21EOLACvtfcHk0lhq6XsCX-qepg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGku77P&md5=a7f4963798b4eeb805064460d01ef33e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.689000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.689000%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DUnal%26aufirst%3DH.%26aulast%3DDesnoyer%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructural%2520basis%2520for%2520ligand%2520recognition%2520and%2520functional%2520selectivity%2520at%2520angiotensin%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D29127%26epage%3D29139%26doi%3D10.1074%2Fjbc.M115.689000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kellici, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavromoustakos, T.</span></span> <span> </span><span class="NLM_article-title">Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3868</span>– <span class="NLM_lpage">3897</span>, <span class="refDoi"> DOI: 10.3390/molecules20033868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3390%2Fmolecules20033868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25738535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksFegtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=3868-3897&author=T.+F.+Kelliciauthor=A.+G.+Tzakosauthor=T.+Mavromoustakos&title=Rational+drug+design+and+synthesis+of+molecules+targeting+the+angiotensin+II+type+1+and+type+2+receptors&doi=10.3390%2Fmolecules20033868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 Receptors</span></div><div class="casAuthors">Kellici, Tahsin F.; Tzakos, Andreas G.; Mavromoustakos, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">3868-3897</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The angiotensin II (Ang II) type 1 and type 2 receptors (AT1R and AT2R) orchestrate an array of biol. processes that regulate human health.  Aberrant function of these receptors triggers pathophysiol. responses that can ultimately lead to death.  Therefore, it is important to design and synthesize compds. that affect beneficially these two receptors.  Cardiovascular disease, which is attributed to the overactivation of the vasoactive peptide hormone Ang II, can now be treated with com. AT1R antagonists.  Herein, recent achievements in rational drug design and synthesis of mols. acting on the two AT receptors are reviewed.  Quant. structure activity relationships (QSAR) and mol. modeling on the two receptors aim to assist the search for new active compds.  As AT1R and AT2R are GPCRs and drug action is localized in the transmembrane region the role of membrane bilayers is exploited.  The future perspectives in this field are outlined.  Tremendous progress in the field is expected if the two receptors are crystd., as this will assist the structure based screening of the chem. space and lead to new potent therapeutic agents in cardiovascular and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoote0qZSQyH7Vg90H21EOLACvtfcHk0lhq6XsCX-qepg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksFegtL4%253D&md5=b09be77448fa09ff43eb37baa7009cb2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3390%2Fmolecules20033868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules20033868%26sid%3Dliteratum%253Aachs%26aulast%3DKellici%26aufirst%3DT.%2BF.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26aulast%3DMavromoustakos%26aufirst%3DT.%26atitle%3DRational%2520drug%2520design%2520and%2520synthesis%2520of%2520molecules%2520targeting%2520the%2520angiotensin%2520II%2520type%25201%2520and%2520type%25202%2520receptors%26jtitle%3DMolecules%26date%3D2015%26volume%3D20%26spage%3D3868%26epage%3D3897%26doi%3D10.3390%2Fmolecules20033868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudry, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botoros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fändriks, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of the first selective nonpeptide AT<sub>2</sub> receptor agonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">5995</span>– <span class="NLM_lpage">6008</span>, <span class="refDoi"> DOI: 10.1021/jm049715t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049715t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1WjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=5995-6008&author=Y.+Wanauthor=C.+Wallinderauthor=B.+Plouffeauthor=H.+Beaudryauthor=A.+K.+Mahalingamauthor=X.+Wuauthor=B.+Johanssonauthor=M.+Holmauthor=M.+Botorosauthor=A.+Karl%C3%A9nauthor=A.+Petterssonauthor=F.+Nybergauthor=L.+F%C3%A4ndriksauthor=N.+Gallo-Payetauthor=A.+Hallbergauthor=M.+Alterman&title=Design%2C+synthesis%2C+and+biological+evaluation+of+the+first+selective+nonpeptide+AT2+receptor+agonist&doi=10.1021%2Fjm049715t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT2 Receptor Agonist</span></div><div class="casAuthors">Wan, Yiqian; Wallinder, Charlotta; Plouffe, Bianca; Beaudry, Helene; Mahalingam, A. K.; Wu, Xiongyu; Johansson, Berndt; Holm, Mathias; Botoros, Milad; Karlen, Anders; Pettersson, Anders; Nyberg, Fred; Faendriks, Lars; Gallo-Payet, Nicole; Hallberg, Anders; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5995-6008</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first druglike selective angiotensin II AT2 receptor agonist (21) with a Ki value of 0.4 nM for the AT2 receptor and a Ki >10 μM for the AT1 receptor is reported.  Compd. 21, with a bioavailability of 20-30% after oral administration and a half-life estd. to 4 h in rat, induces outgrowth of neurite cells, stimulates p42/p44mapk, enhances in vivo duodenal alk. secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats.  Thus, the peptidomimetic 21 (I) exerts a similar biol. response as the endogenous peptide angiotensin II after selective activation of the AT2 receptor.  Compd. 21, derived from the prototype nonselective AT1/AT2 receptor agonist L-162,313 will serve as a valuable research tool, enabling studies of the function of the AT2 receptor in more detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryZC-ZeMQYarVg90H21EOLACvtfcHk0lhq6XsCX-qepg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1WjsLg%253D&md5=cf2ffe7214ce8912d3dd51035c65a50a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm049715t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049715t%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DY.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DBeaudry%26aufirst%3DH.%26aulast%3DMahalingam%26aufirst%3DA.%2BK.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJohansson%26aufirst%3DB.%26aulast%3DHolm%26aufirst%3DM.%26aulast%3DBotoros%26aufirst%3DM.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DPettersson%26aufirst%3DA.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DF%25C3%25A4ndriks%26aufirst%3DL.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520the%2520first%2520selective%2520nonpeptide%2520AT2%2520receptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D5995%26epage%3D6008%26doi%3D10.1021%2Fjm049715t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diop-Frimpong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span> <span> </span><span class="NLM_article-title">Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">2909</span>– <span class="NLM_lpage">2914</span>, <span class="refDoi"> DOI: 10.1073/pnas.1018892108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1073%2Fpnas.1018892108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=21282607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitl2lsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=2909-2914&author=B.+Diop-Frimpongauthor=V.+P.+Chauhanauthor=S.+Kraneauthor=Y.+Boucherauthor=R.+K.+Jain&title=Losartan+inhibits+collagen+I+synthesis+and+improves+the+distribution+and+efficacy+of+nanotherapeutics+in+tumors&doi=10.1073%2Fpnas.1018892108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors</span></div><div class="casAuthors">Diop-Frimpong, Benjamin; Chauhan, Vikash P.; Krane, Stephen; Boucher, Yves; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2909-2914, S2909/1-S2909/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The dense collagen network in tumors significantly reduces the penetration and efficacy of nanotherapeutics.  We tested whether losartan - a clin. approved angiotensin II receptor antagonist with noted antifibrotic activity - can enhance the penetration and efficacy of nanomedicine.  We found that losartan inhibited collagen I prodn. by carcinoma-assocd. fibroblasts isolated from breast cancer biopsies.  Addnl., it led to a dose-dependent redn. in stromal collagen in desmoplastic models of human breast pancreatic, and skin tumors in mice.  Furthermore, losartan improved the distribution and therapeutic efficacy of intratumorally injected oncolytic herpes simplex viruses.  Finally, it also enhanced the efficacy of i.v. injected pegylated liposomal doxorubicin (Doxil).  Thus, losartan has the potential to enhance the efficacy of nanotherapeutics in patients with desmoplastic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHM20w3PNOLVg90H21EOLACvtfcHk0lg44F_b9Wc9cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitl2lsb8%253D&md5=20046ce2bab341bff6d8b5514df8327e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1018892108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1018892108%26sid%3Dliteratum%253Aachs%26aulast%3DDiop-Frimpong%26aufirst%3DB.%26aulast%3DChauhan%26aufirst%3DV.%2BP.%26aulast%3DKrane%26aufirst%3DS.%26aulast%3DBoucher%26aufirst%3DY.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DLosartan%2520inhibits%2520collagen%2520I%2520synthesis%2520and%2520improves%2520the%2520distribution%2520and%2520efficacy%2520of%2520nanotherapeutics%2520in%2520tumors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D2909%26epage%3D2914%26doi%3D10.1073%2Fpnas.1018892108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondaca-Ruff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riquelme, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiroga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norambuena-Soto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanhueza-Olivares, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villar-Fincheira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Díaz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancino-Arenas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiong, M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II-regulated autophagy is required for vascular smooth muscle cell hypertrophy</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1553</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffphar.2018.01553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30804791" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1553&author=D.+Mondaca-Ruffauthor=J.+A.+Riquelmeauthor=C.+Quirogaauthor=I.+Norambuena-Sotoauthor=F.+Sanhueza-Olivaresauthor=P.+Villar-Fincheiraauthor=T.+Hern%C3%A1ndez-D%C3%ADazauthor=N.+Cancino-Arenasauthor=A.+San+Martinauthor=L.+Garc%C3%ADaauthor=S.+Lavanderoauthor=M.+Chiong&title=Angiotensin+II-regulated+autophagy+is+required+for+vascular+smooth+muscle+cell+hypertrophy&doi=10.3389%2Ffphar.2018.01553"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01553%26sid%3Dliteratum%253Aachs%26aulast%3DMondaca-Ruff%26aufirst%3DD.%26aulast%3DRiquelme%26aufirst%3DJ.%2BA.%26aulast%3DQuiroga%26aufirst%3DC.%26aulast%3DNorambuena-Soto%26aufirst%3DI.%26aulast%3DSanhueza-Olivares%26aufirst%3DF.%26aulast%3DVillar-Fincheira%26aufirst%3DP.%26aulast%3DHern%25C3%25A1ndez-D%25C3%25ADaz%26aufirst%3DT.%26aulast%3DCancino-Arenas%26aufirst%3DN.%26aulast%3DSan%2BMartin%26aufirst%3DA.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DL.%26aulast%3DLavandero%26aufirst%3DS.%26aulast%3DChiong%26aufirst%3DM.%26atitle%3DAngiotensin%2520II-regulated%2520autophagy%2520is%2520required%2520for%2520vascular%2520smooth%2520muscle%2520cell%2520hypertrophy%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D9%26spage%3D1553%26doi%3D10.3389%2Ffphar.2018.01553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKallip, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">6043</span>– <span class="NLM_lpage">6054</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S95333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2147%2FDDDT.S95333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26648693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1Sjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=6043-6054&author=X.+F.+Pangauthor=L.+H.+Zhangauthor=F.+Baiauthor=N.+P.+Wangauthor=R.+E.+Garnerauthor=R.+J.+McKallipauthor=Z.+Q.+Zhao&title=Attenuation+of+myocardial+fibrosis+with+curcumin+is+mediated+by+modulating+expression+of+angiotensin+II+AT1%2FAT2+receptors+and+ACE2+in+rats&doi=10.2147%2FDDDT.S95333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats</span></div><div class="casAuthors">Pang, Xue-Fen; Zhang, Li-Hui; Bai, Feng; Wang, Ning-Ping; Garner, Ron E.; McKallip, Robert J.; Zhao, Zhi-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6043-6054</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Curcumin is known to improve cardiac function by balancing degrdn. and synthesis of collagens after myocardial infarction.  This study tested the hypothesis that inhibition of myocardial fibrosis by curcumin is assocd. with modulating expression of angiotensin II (Ang II) receptors and angiotensin-converting enzyme 2 (ACE2).  Male Sprague Dawley rats were subjected to Ang II infusion (500 ng/kg/min) using osmotic minipumps for 2 and 4 wk, resp., and curcumin (150 mg/kg/day) was fed by gastric gavage during Ang II infusion.  Compared to the animals with Ang II infusion, curcumin significantly decreased the mean arterial blood pressure during the course of the observation.  The protein level of the Ang II type 1 (AT1) receptor was reduced, and the Ang II type 2 (AT2) receptor was up-regulated, evidenced by an increased ratio of the AT2 receptor over the AT1 receptor in the curcumin group (1.2±0.02%) vs in the Ang II group (0.7±0.03%, P<0.05).  These changes were coincident with less locally expressed AT1 receptor and enhanced AT2 receptor in the intracardiac vessels and intermyocardium.  Along with these modulations, curcumin significantly decreased the populations of macrophages and alpha smooth muscle actin-expressing myofibroblasts, which were accompanied by reduced expression of transforming growth factor beta 1 and phosphorylated-Smad2/3.  Collagen I synthesis was inhibited, and tissue fibrosis was attenuated, as demonstrated by less extensive collagen-rich fibrosis.  Furthermore, curcumin increased protein level of ACE2 and enhanced its expression in the intermyocardium relative to the Ang II group.  These results suggest that curcumin could be considered as an add-on therapeutic agent in the treatment of fibrosis-derived heart failure patient who is intolerant of ACE inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhKyEygGyjVLVg90H21EOLACvtfcHk0lg44F_b9Wc9cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1Sjtr4%253D&md5=87d58358354203eb8ebb40422a86fb5f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S95333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S95333%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DX.%2BF.%26aulast%3DZhang%26aufirst%3DL.%2BH.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DN.%2BP.%26aulast%3DGarner%26aufirst%3DR.%2BE.%26aulast%3DMcKallip%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DZ.%2BQ.%26atitle%3DAttenuation%2520of%2520myocardial%2520fibrosis%2520with%2520curcumin%2520is%2520mediated%2520by%2520modulating%2520expression%2520of%2520angiotensin%2520II%2520AT1%252FAT2%2520receptors%2520and%2520ACE2%2520in%2520rats%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D6043%26epage%3D6054%26doi%3D10.2147%2FDDDT.S95333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzau, V. J.</span></span> <span> </span><span class="NLM_article-title">Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">24539</span>– <span class="NLM_lpage">24542</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=8227010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2cXisVahtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=24539-24542&author=M.+Mukoyamaauthor=M.+Nakajimaauthor=M.+Horiuchiauthor=H.+Sasamuraauthor=R.+E.+Prattauthor=V.+J.+Dzau&title=Expression+cloning+of+type+2+angiotensin+II+receptor+reveals+a+unique+class+of+seven-transmembrane+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors</span></div><div class="casAuthors">Mukoyama, Masashi; Nakajima, Masatoshi; Horiuchi, Masatsugu; Sasamura, Hiroyuki; Pratt, Richard E.; Dzau, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">24539-42</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Angiotensin II acts on at least two distinct receptor subtypes (AT1 and AT2).  Most known effects of angiotensin II in adult tissues are attributable to the AT1 receptor.  The function of AT2 receptor is undefined, but its abundant expressions in fetal tissues, immature brain, skin wound, and atretic ovarian follicles suggest a role in growth and development.  Previous studies suggested that AT2 receptor may not be G protein-coupled.  Here, from a rat fetus expression library, the authors cloned a cDNA encoding a unique 363-amino acid protein with pharmacol. specificity, tissue distribution, and developmental pattern of the AT2 receptor.  It is 34% identical in sequence to the AT1 receptor, sharing a seven-transmembrane domain topol.  A review of prior data on other receptors suggests that this receptor may belong to a unique class of seven-transmembrane receptors (including somatostatin SSTR1, dopamine D3, and frizzled protein Fz) for which G protein coupling has not been demonstrated.  All members of this class exhibit fetal and developmental and/or neuronal-specific expression.  A conserved motif in the third intracellular loop, distinguishing this class from "classical" G protein-coupled receptors, may mediate novel intracellular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS1rHYpNLNBLVg90H21EOLACvtfcHk0ljoJvhk0K_vfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXisVahtw%253D%253D&md5=05318096e5998d5da30e0b7f42d221ca</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMukoyama%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DHoriuchi%26aufirst%3DM.%26aulast%3DSasamura%26aufirst%3DH.%26aulast%3DPratt%26aufirst%3DR.%2BE.%26aulast%3DDzau%26aufirst%3DV.%2BJ.%26atitle%3DExpression%2520cloning%2520of%2520type%25202%2520angiotensin%2520II%2520receptor%2520reveals%2520a%2520unique%2520class%2520of%2520seven-transmembrane%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D24539%26epage%3D24542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kambayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamakubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagami, T.</span></span> <span> </span><span class="NLM_article-title">Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">24543</span>– <span class="NLM_lpage">24546</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=8227011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2cXitlOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=24543-24546&author=Y.+Kambayashiauthor=S.+Bardhanauthor=K.+Takahashiauthor=S.+Tsuzukiauthor=H.+Inuiauthor=T.+Hamakuboauthor=T.+Inagami&title=Molecular+cloning+of+a+novel+angiotensin+II+receptor+isoform+involved+in+phosphotyrosine+phosphatase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition</span></div><div class="casAuthors">Kambayashi, Yoshikazu; Bardhan, Smriti; Takahashi, Kyoko; Tsuzuki, Satoshi; Inui, Hiroshi; Hamakubo, Takao; Inagami, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">24543-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">There are two major isoforms of the angiotensin II receptor, type 1 (AT1) and type 2 (AT2).  AT2 is distinguished from AT1 with respect to its ligand selectivity, its insensitivity to non-hydrolyzable GTP analogs, and its as yet unidentified biol. functions.  In the present study the authors have expression-cloned AT2 cDNA from a cDNA library of a rat pheochromocytoma cell line (PC12w).  Rat AT2 cDNA encodes a 363-amino acid protein that has seven transmembrane domains.  AT1 is the closest in homol. to AT2 but with only a 32% identity of amino acid sequence.  Stably expressed in COS-7 cells, the receptor showed selective binding to AT2-specific ligands PD 123319 and CGP 42112A but not to the AT1-specific ligand, losartan.  Northern blot anal. revealed that the mRNA of rat AT2 was expressed not only in PC12w cells but also in the adrenal glands and in the inferior olive of the brain, both of which are known to contain AT2 type binding sites.  The expressed AT2 receptor mediated angiotensin II-induced inhibition of protein tyrosine phosphatase, an action that was dependent on a pertussis toxin-sensitive G-protein-coupled mechanism in COS-7 cells.  The AT2-specific ligand CGP42112A was an agonist rather than antagonist in the inhibition of phosphotyrosine phosphatase.  AT2 did not cause a decrease in cGMP in PC12w or COS-7 cells expressing AT2 stably.  The results indicate that the AT2 receptor is structurally and functionally different from AT1 and suggest novel functional roles of the renin-angiotensin system in cross-talk with phosphotyrosine signaling by modulating protein phosphotyrosine levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz2Bf_VYyqKrVg90H21EOLACvtfcHk0ljoJvhk0K_vfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlOhsQ%253D%253D&md5=978c3de28dc0233e85fa46ab37c07075</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKambayashi%26aufirst%3DY.%26aulast%3DBardhan%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DTsuzuki%26aufirst%3DS.%26aulast%3DInui%26aufirst%3DH.%26aulast%3DHamakubo%26aufirst%3DT.%26aulast%3DInagami%26aufirst%3DT.%26atitle%3DMolecular%2520cloning%2520of%2520a%2520novel%2520angiotensin%2520II%2520receptor%2520isoform%2520involved%2520in%2520phosphotyrosine%2520phosphatase%2520inhibition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D24543%26epage%3D24546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vervoort, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beachem, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Mollerat, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuPont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. K.</span></span> <span> </span><span class="NLM_article-title">AGTR2 mutations in X-linked mental retardation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">2401</span>– <span class="NLM_lpage">2403</span>, <span class="refDoi"> DOI: 10.1126/science.1072191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1126%2Fscience.1072191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12089445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38XltFWksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=2401-2403&author=V.+S.+Vervoortauthor=M.+A.+Beachemauthor=P.+S.+Edwardsauthor=S.+Laddauthor=K.+E.+Millerauthor=X.+de+Molleratauthor=K.+Clarksonauthor=B.+DuPontauthor=C.+E.+Schwartzauthor=R.+E.+Stevensonauthor=E.+Boydauthor=A.+K.+Srivastava&title=AGTR2+mutations+in+X-linked+mental+retardation&doi=10.1126%2Fscience.1072191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">AGTR2 mutations in X-linked mental retardation</span></div><div class="casAuthors">Vervoort, Virginie S.; Beachem, Michael A.; Edwards, Penny S.; Ladd, Sydney; Miller, Karin E.; de Mollerat, Xavier; Clarkson, Katie; DuPont, Barbara; Schwartz, Charles E.; Stevenson, Roger E.; Boyd, Ellen; Srivastava, Anand K.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5577</span>),
    <span class="NLM_cas:pages">2401-2403</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Two angiotensin II (Ang II)-specific receptors, AGTR1 and AGTR2, are expressed in the mammalian brain.  Ang II actions on blood pressure regulation, water electrolyte balance, and hormone secretion are primarily mediated by AGTR1.  The function of AGTR2 remains unclear.  Here, the authors show that expression of the AGTR2 gene was absent in a female patient with mental retardation (MR) who had a balanced X;7 chromosomal translocation.  Addnl., 8 of 590 unrelated male patients with MR were found to have sequence changes in the AGTR2 gene, including one frameshift and three missense mutations.  These findings indicate a role for AGTR2 in brain development and cognitive function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX_YkE6B52SrVg90H21EOLACvtfcHk0ljoJvhk0K_vfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltFWksrg%253D&md5=23bfdc50f2369cc5efeb3becd5058856</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1126%2Fscience.1072191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1072191%26sid%3Dliteratum%253Aachs%26aulast%3DVervoort%26aufirst%3DV.%2BS.%26aulast%3DBeachem%26aufirst%3DM.%2BA.%26aulast%3DEdwards%26aufirst%3DP.%2BS.%26aulast%3DLadd%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DK.%2BE.%26aulast%3Dde%2BMollerat%26aufirst%3DX.%26aulast%3DClarkson%26aufirst%3DK.%26aulast%3DDuPont%26aufirst%3DB.%26aulast%3DSchwartz%26aufirst%3DC.%2BE.%26aulast%3DStevenson%26aufirst%3DR.%2BE.%26aulast%3DBoyd%26aufirst%3DE.%26aulast%3DSrivastava%26aufirst%3DA.%2BK.%26atitle%3DAGTR2%2520mutations%2520in%2520X-linked%2520mental%2520retardation%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D2401%26epage%3D2403%26doi%3D10.1126%2Fscience.1072191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bienvenu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Esch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraine, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryns, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ropers, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beldjord, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yntema, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chelly, J.</span></span> <span> </span><span class="NLM_article-title">Rare polymorphic variants of the AGTR2 gene in boys with non-specific mental retardation</span>. <i>J. Med. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1136/jmg.40.5.357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1136%2Fjmg.40.5.357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12746399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1Gksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2003&pages=357-359&author=T.+Bienvenuauthor=K.+Poirierauthor=H.+Van+Eschauthor=B.+Hamelauthor=C.+Moraineauthor=J.+P.+Frynsauthor=H.+H.+Ropersauthor=C.+Beldjordauthor=H.+G.+Yntemaauthor=J.+Chelly&title=Rare+polymorphic+variants+of+the+AGTR2+gene+in+boys+with+non-specific+mental+retardation&doi=10.1136%2Fjmg.40.5.357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Rare polymorphic variants of the AGTR2 gene in boys with non-specific mental retardation</span></div><div class="casAuthors">Bienvenu, T.; Poirier, K.; Van Esch, H.; Hamel, B.; Moraine, C.; Fryns, J. P.; Ropers, H. H.; Beldjord, C.; Yntema, H. G.; Chelly, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">357-359</span>CODEN:
                <span class="NLM_cas:coden">JMDGAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-2593</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Mutation anal. of the angiotensin II specific receptor (AGTR2) gene was performed in 15 large families with mental retardation-linked to Xq24, in a panel of 101 clin. well characterized small families with at least two boys affected with MR, and in 244 sporadic cases of non-specific MR.  Denaturing high pressure liq. chromatog. anal. of the entire coding region detected no deleterious mutations in the 360 patients.  A novel C117F amino acid substitution was identified as a non-pathogenic rare genetic variant.  Results suggest that AGTR2 is rarely involved in non-specific MR but could be involved in more specific forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofGtYu1SFuRbVg90H21EOLACvtfcHk0ljRYdqPNhdZXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1Gksb4%253D&md5=83658f4d64d62665a48885390cc50523</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1136%2Fjmg.40.5.357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjmg.40.5.357%26sid%3Dliteratum%253Aachs%26aulast%3DBienvenu%26aufirst%3DT.%26aulast%3DPoirier%26aufirst%3DK.%26aulast%3DVan%2BEsch%26aufirst%3DH.%26aulast%3DHamel%26aufirst%3DB.%26aulast%3DMoraine%26aufirst%3DC.%26aulast%3DFryns%26aufirst%3DJ.%2BP.%26aulast%3DRopers%26aufirst%3DH.%2BH.%26aulast%3DBeldjord%26aufirst%3DC.%26aulast%3DYntema%26aufirst%3DH.%2BG.%26aulast%3DChelly%26aufirst%3DJ.%26atitle%3DRare%2520polymorphic%2520variants%2520of%2520the%2520AGTR2%2520gene%2520in%2520boys%2520with%2520non-specific%2520mental%2520retardation%26jtitle%3DJ.%2520Med.%2520Genet.%26date%3D2003%26volume%3D40%26spage%3D357%26epage%3D359%26doi%3D10.1136%2Fjmg.40.5.357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pescucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meloni, I.</span></span> <span> </span><span class="NLM_article-title">Non-syndronic X-linked mental retardation from a molecular to a clinical point of view</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1002/jcp.20296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fjcp.20296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=15690397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2005&pages=8-20&author=A.+Renieriauthor=C.+Pescucciauthor=I.+Longoauthor=F.+Arianiauthor=F.+Mariauthor=I.+Meloni&title=Non-syndronic+X-linked+mental+retardation+from+a+molecular+to+a+clinical+point+of+view&doi=10.1002%2Fjcp.20296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Non-syndromic X-linked mental retardation: From a molecular to a clinical point of view</span></div><div class="casAuthors">Renieri, A.; Pescucci, C.; Longo, I.; Ariani, F.; Mari, F.; Meloni, I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-20</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">This review focuses on the 19 identified genes involved in X-linked "non-syndromic" mental retardation (MR) and defines the signaling pathways in which they are involved, focusing on emerging common mechanisms.  The majority of proteins are involved in three distinct pathways:.  (1) Rho GTPases pathway modulating neuronal differentiation and synaptic plasticity;.  (2) Rab GTPases pathway regulating synaptic vesicle cycling;.  (3) Gene expression regulation.  The function of four proteins (ACSL4, AT2, SLC6A8, and SAP102) could not be reconciled to a common pathway.  From a clin. point of view, the review discusses whether some common dysmorphic features can be identified even in non-syndromic MR patients and whether it is correct to maintain the distinction between "non-syndromic" and "syndromic" MR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0rBVhNgR64rVg90H21EOLACvtfcHk0ljRYdqPNhdZXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr8%253D&md5=81ec0ffa6bf7c0bd10bf19cc766ec045</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fjcp.20296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.20296%26sid%3Dliteratum%253Aachs%26aulast%3DRenieri%26aufirst%3DA.%26aulast%3DPescucci%26aufirst%3DC.%26aulast%3DLongo%26aufirst%3DI.%26aulast%3DAriani%26aufirst%3DF.%26aulast%3DMari%26aufirst%3DF.%26aulast%3DMeloni%26aufirst%3DI.%26atitle%3DNon-syndronic%2520X-linked%2520mental%2520retardation%2520from%2520a%2520molecular%2520to%2520a%2520clinical%2520point%2520of%2520view%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2005%26volume%3D204%26spage%3D8%26epage%3D20%26doi%3D10.1002%2Fjcp.20296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmieder, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regitz-Zagrosek, V.</span></span> <span> </span><span class="NLM_article-title">Effect of the angiotensin II type 2-receptor gene (11675 G/A) on left ventricular structure in humans</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/S0735-1097(00)01063-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0735-1097%2800%2901063-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11153734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVKjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=175-182&author=R.+E.+Schmiederauthor=J.+Erdmannauthor=C.+Dellesauthor=J.+Jacobiauthor=E.+Fleckauthor=K.+Hilgersauthor=V.+Regitz-Zagrosek&title=Effect+of+the+angiotensin+II+type+2-receptor+gene+%2811675+G%2FA%29+on+left+ventricular+structure+in+humans&doi=10.1016%2FS0735-1097%2800%2901063-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans</span></div><div class="casAuthors">Schmieder, Roland E.; Erdmann, Jeanette; Delles, Christian; Jacobi, Johannes; Fleck, Eckart; Hilgers, Karl; Regitz-Zagrosek, Vera</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-182</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The authors' study goal was to analyze whether gene variants of angiotensin II type 2-receptor (AT2-R) modulate the effects of angiotensin II on the left ventricle (LV).  Exptl. data suggest that angiotensin II modifies ventricular growth responses via angiotensin II type 1-receptors (AT1-R) and AT2-R.  In 120 white, young male subjects with normal or mildly elevated blood pressure, the authors assessed plasma angiotensin II and aldosterone concns. (RIA), 24-h urinary sodium excretion, 24-h ambulatory blood pressure and LV structure (two-dimensional guided M-mode echocardiog.).  The intronic + 1675 G/A polymorphism of the X-chromosomal located AT2-R gene was investigated by single-strand conformational polymorphism anal. and DNA-sequencing.  Hypertensive subjects with the A-allele had a greater LV posterior (11.0 vs. 9 mm), septal (11.8 vs. 10.1 mm) and relative wall thickness (0.44 vs. 39) as well as LV mass index (138 vs. 120 g/M2) than those with the G-allele.  Confounding factors (i.e., body mass index and surface area, plasma angiotensin II, sodium excretion, systolic and diastolic ambulatory blood pressure) were similar between the two genotypes.  In normotensive subjects, relative wall thickness (0.36 vs. 35) and LV mass index (115 vs. 112 g/M2) were nearly identical across the two genotypes, with similar confounding variables.  The authors' data indicate that the X-chromosomal located + 1675 G/A-polymorphism of the AT2-R gene is assocd. with LV structure in young male humans with early structural changes of the heart due to arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAtSvQmwEReLVg90H21EOLACvtfcHk0ljRYdqPNhdZXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVKjuw%253D%253D&md5=55e09808707bb8d354b14573d3dabc08</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0735-1097%2800%2901063-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0735-1097%252800%252901063-9%26sid%3Dliteratum%253Aachs%26aulast%3DSchmieder%26aufirst%3DR.%2BE.%26aulast%3DErdmann%26aufirst%3DJ.%26aulast%3DDelles%26aufirst%3DC.%26aulast%3DJacobi%26aufirst%3DJ.%26aulast%3DFleck%26aufirst%3DE.%26aulast%3DHilgers%26aufirst%3DK.%26aulast%3DRegitz-Zagrosek%26aufirst%3DV.%26atitle%3DEffect%2520of%2520the%2520angiotensin%2520II%2520type%25202-receptor%2520gene%2520%252811675%2520G%252FA%2529%2520on%2520left%2520ventricular%2520structure%2520in%2520humans%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2001%26volume%3D37%26spage%3D175%26epage%3D182%26doi%3D10.1016%2FS0735-1097%2800%2901063-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titze, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreutz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgers, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaich, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmieder, R. E.</span></span> <span> </span><span class="NLM_article-title">High sodium intake modulates left ventricular mass in patients with Gexpression of + 1675 G/A angiotensin receptor type 2 gene</span>. <i>J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1627</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1097/HJH.0b013e3281cd40f5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2FHJH.0b013e3281cd40f5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=17620959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVCrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1627-1632&author=C.+Ottauthor=S.+I.+Titzeauthor=T.+K.+Schwarzauthor=R.+Kreutzauthor=K.+F.+Hilgersauthor=B.+M.+Schmidtauthor=M.+P.+Schlaichauthor=R.+E.+Schmieder&title=High+sodium+intake+modulates+left+ventricular+mass+in+patients+with+Gexpression+of+%2B+1675+G%2FA+angiotensin+receptor+type+2+gene&doi=10.1097%2FHJH.0b013e3281cd40f5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene</span></div><div class="casAuthors">Ott, Christian; Titze, Stephanie I.; Schwarz, Thomas K.; Kreutz, Reinhold; Hilgers, Karl F.; Schmidt, Bernhard M. W.; Schlaich, Markus P.; Schmieder, Roland E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1627-1632</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">In patients with hypertension left ventricular hypertrophy (LVH) is assocd. with genetic variations of the angiotensin type 2 receptor (AT2R).  Hypertension and LVH are often aggravated by salt intake.  The authors' objective was to assess the relationship between AT2R gene variation and salt intake and their impact on left ventricular mass (LVM).  In 205 subjects with normal or mildly elevated blood pressure, the authors assessed sodium intake and left ventricular structure and function by echocardiog.  Intronic +1675 G/A polymorphism of the AT2R gene was investigated.  A-allele carriers had a greater LVM (P = 0.049) than G-allele carriers.  Independent of diet, septal wall thickness was higher in A-allele carriers (P = 0.001).  Fractional fiber shortening was greater in A-allele carriers (P = 0.034), and the velocity of circumferential fiber shortening tended to be greater in A-allele carriers (P = 0.057).  When the 2 groups were stratified according to their salt intake, only G-allele carriers displayed a modulating effect of salt intake on LVM.  Covariance anal. revealed that there was a trend towards a modulating effect of salt intake on LVM, even after taking blood pressure into account (P = 0.054).  The authors' data clearly support the notion that LVM is influenced by AT2R polymorphisms.  Furthermore, G-allele carriers in particular appear to be susceptible to a modifying effect of increased salt intake on LVM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt5lFcNbqXirVg90H21EOLACvtfcHk0li0_meXhswBXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVCrs7s%253D&md5=53ead8878c84f4958f7d47c38285615e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1097%2FHJH.0b013e3281cd40f5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHJH.0b013e3281cd40f5%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DC.%26aulast%3DTitze%26aufirst%3DS.%2BI.%26aulast%3DSchwarz%26aufirst%3DT.%2BK.%26aulast%3DKreutz%26aufirst%3DR.%26aulast%3DHilgers%26aufirst%3DK.%2BF.%26aulast%3DSchmidt%26aufirst%3DB.%2BM.%26aulast%3DSchlaich%26aufirst%3DM.%2BP.%26aulast%3DSchmieder%26aufirst%3DR.%2BE.%26atitle%3DHigh%2520sodium%2520intake%2520modulates%2520left%2520ventricular%2520mass%2520in%2520patients%2520with%2520Gexpression%2520of%2520%252B%25201675%2520G%252FA%2520angiotensin%2520receptor%2520type%25202%2520gene%26jtitle%3DJ.%2520Hypertens.%26date%3D2007%26volume%3D25%26spage%3D1627%26epage%3D1632%26doi%3D10.1097%2FHJH.0b013e3281cd40f5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hohenfellner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunley, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schloemer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerkes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zepp, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kon, V.</span></span> <span> </span><span class="NLM_article-title">Angiotensin type 2 receptor is important in the normal development of the ureter</span>. <i>Pediatr. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1007/s004670050589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs004670050589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10353402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADyaK1M3nvFynsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=187-191&author=K.+Hohenfellnerauthor=T.+E.+Hunleyauthor=C.+Schloemerauthor=W.+Brennerauthor=E.+Yerkesauthor=F.+Zeppauthor=J.+W.+Brockauthor=V.+Kon&title=Angiotensin+type+2+receptor+is+important+in+the+normal+development+of+the+ureter&doi=10.1007%2Fs004670050589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin type 2 receptor is important in the normal development of the ureter</span></div><div class="casAuthors">Hohenfellner K; Hunley T E; Schloemer C; Brenner W; Yerkes E; Zepp F; Brock J W 3rd; Kon V</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric nephrology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-91</span>
        ISSN:<span class="NLM_cas:issn">0931-041X</span>.
    </div><div class="casAbstract">In humans, the actions of angiotensin II are transduced through the AT1 and AT2 receptors which have recently been implicated in renal organogenesis.  Polymorphisms in the human angiotensin II receptor genes have been linked to cardiovascular and nephrological disorders.  In this study we evaluated 35 patients with either primary obstructive megaureter or posterior urethral valves.  Each was genotyped for the A1166 AT1 polymorphism and the recently described A-1332G AT2 transition.  The incidence of these genetic variants was also evaluated in normal controls without any ultrasonographic urological abnormalities.  Similar to our previous findings in congenital urological abnormalities, the AT1 receptor genotype distribution did not differ between patients with either primary obstructive megaureter or posterior urethral valves versus controls.  In contrast, compared with normal controls, there was a dramatic increase in the occurrence of the AT2 A-1332G transition in patients with primary obstructive megaureter (75.0% vs. 41.9% in controls, P<0.025).  In patients with posterior urethral valves, there was no difference in the occurrence of the transition versus controls (36.9%, P=NS).  Thus, there is no correlation between the AT1 receptor gene polymorphism and urological abnormalities.  However there is an increased incidence in the AT2 genetic variant in patients with primary obstructive megaureter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4E-NO8velOynGiHuhFGv8fW6udTcc2eYu0r2UiHui-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3nvFynsA%253D%253D&md5=ff24b491e6dbcd1c1ec0578142fcdcb9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs004670050589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs004670050589%26sid%3Dliteratum%253Aachs%26aulast%3DHohenfellner%26aufirst%3DK.%26aulast%3DHunley%26aufirst%3DT.%2BE.%26aulast%3DSchloemer%26aufirst%3DC.%26aulast%3DBrenner%26aufirst%3DW.%26aulast%3DYerkes%26aufirst%3DE.%26aulast%3DZepp%26aufirst%3DF.%26aulast%3DBrock%26aufirst%3DJ.%2BW.%26aulast%3DKon%26aufirst%3DV.%26atitle%3DAngiotensin%2520type%25202%2520receptor%2520is%2520important%2520in%2520the%2520normal%2520development%2520of%2520the%2520ureter%26jtitle%3DPediatr.%2520Nephrol.%26date%3D1999%26volume%3D13%26spage%3D187%26epage%3D191%26doi%3D10.1007%2Fs004670050589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speth, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grove, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saylor, D.</span></span> <span> </span><span class="NLM_article-title">Sulfhydril reducing agents distinguish two subtypes of angiotensin II receptors in the rat brain</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>548</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(91)91098-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2F0006-8993%2891%2991098-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1868325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK3MXks1Gntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=548&publication_year=1991&pages=1-8&author=R.+C.+Spethauthor=B.+P.+Roweauthor=K.+L.+Groveauthor=M.+R.+Carterauthor=D.+Saylor&title=Sulfhydril+reducing+agents+distinguish+two+subtypes+of+angiotensin+II+receptors+in+the+rat+brain&doi=10.1016%2F0006-8993%2891%2991098-L"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfhydryl reducing agents distinguish two subtypes of angiotensin II receptors in the rat brain</span></div><div class="casAuthors">Speth, Robert C.; Rowe, Brian P.; Grove, Kevin L.; Carter, Michelle R.; Saylor, David</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">548</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">Two angiotensin II receptor subtypes were distinguished in the rat brain using in vitro receptor autoradiog. based on the differential effects of sulfhydryl reducing agents on 125I-sarcosine1, isoleucine8 angiotensin II binding in various brain nuclei.  At several nuclei, e.g. the hypothalamus, circumventricular organs, and the dorsal medulla, 125I-sarcosine1, isoleucine8 angiotensin II binding was strongly inhibited by 30 mM β-mercaptoethanol or 5 mM dithiothreitol, whereas at other nuclei, e.g. the lateral septum, colliculi, locus ceruleus, and medial amygdala, sulfhydryl reducing agents had either little effect on radioligand binding or enhanced the binding.  The distribution of the sulfhydryl reducing agent inactivated subtype corresponds exactly with the distribution of DuP 743 sensitive (designated as AIIα) 125I-sarcosine1, isoleucine8 angiotensin II binding sites.  The subtype not inhibited by sulfhydryl reducing agents corresponds with the DuP 753 insensitive (designated as AIIβ) sites in the brain.  The sulfhydryl reducing agent effect on brain angiotensin II receptor subtypes is similar to that seen in angiotensin II receptor subtypes in peripheral tissues.  These observations indicate that many previous studies of brain angiotensin II receptor binding that included 5 mM dithiothreitol in the assay medium overlooked the sulfhydryl reducing agent inactivated (AIIα) receptor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpghcvSM9y_L7Vg90H21EOLACvtfcHk0liRBRrhtvzZ-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXks1Gntbs%253D&md5=f581b397bbb7e43658529f9362b4da3c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2891%2991098-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252891%252991098-L%26sid%3Dliteratum%253Aachs%26aulast%3DSpeth%26aufirst%3DR.%2BC.%26aulast%3DRowe%26aufirst%3DB.%2BP.%26aulast%3DGrove%26aufirst%3DK.%2BL.%26aulast%3DCarter%26aufirst%3DM.%2BR.%26aulast%3DSaylor%26aufirst%3DD.%26atitle%3DSulfhydril%2520reducing%2520agents%2520distinguish%2520two%2520subtypes%2520of%2520angiotensin%2520II%2520receptors%2520in%2520the%2520rat%2520brain%26jtitle%3DBrain%2520Res.%26date%3D1991%26volume%3D548%26spage%3D1%26epage%3D8%26doi%3D10.1016%2F0006-8993%2891%2991098-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span> <span> </span><span class="NLM_article-title">Reversible inactivation of AT(2) angiotensin II receptor from cysteine-disulfide bond exchange</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>484</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(00)02141-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0014-5793%2800%2902141-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11068047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVamuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=484&publication_year=2000&pages=133-138&author=Y.+H.+Fengauthor=Y.+Saadauthor=S.+S.+Karnik&title=Reversible+inactivation+of+AT%282%29+angiotensin+II+receptor+from+cysteine-disulfide+bond+exchange&doi=10.1016%2FS0014-5793%2800%2902141-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible inactivation of AT2 angiotensin II receptor from cysteine-disulfide bond exchange</span></div><div class="casAuthors">Feng, Y.-H.; Saad, Y.; Karnik, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">484</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-138</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Dithiothreitol (DTT) treatment of angiotensin II (Ang II) type 2 (AT2) receptor potentiates ligand binding, but the underlying mechanism is not known.  Two disulfide bonds proposed in the extracellular domain were examd. in this report.  Based on the anal. of ligand affinity of cysteine (Cys, C) to alanine (Ala, A) substitution mutants, we provide evidence that Cys35-Cys290 and Cys117-Cys195 disulfide bonds are formed in the wild-type AT2 receptor.  Disruption of the highly conserved Cys117-Cys195 disulfide bond linking the second and third extracellular segments leads to inactivation of the receptor.  The Cys35-Cys290 bond is highly sensitive to DTT.  Its breakage results in an increased binding affinity for both Ang II and the AT2 receptor-specific antagonist PD123319.  Surprisingly, in the single Cys mutants, C35A and C290A, a labile population of receptors is produced which can be re-folded to high-affinity state by DTT treatment.  These results suggest that the free -SH group of Cys35 or Cys290 competes with the disulfide bond formation between Cys117 and Cys195.  This Cys-disulfide bond exchange results in prodn. of the inactive population of the mutant receptors through formation of a non-native disulfide bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVLBM8_Lm1LrVg90H21EOLACvtfcHk0liRBRrhtvzZ-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVamuro%253D&md5=40c807c66eb03ea9d6eb4f87f1ea922f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2800%2902141-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252800%252902141-4%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%2BH.%26aulast%3DSaad%26aufirst%3DY.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26atitle%3DReversible%2520inactivation%2520of%2520AT%25282%2529%2520angiotensin%2520II%2520receptor%2520from%2520cysteine-disulfide%2520bond%2520exchange%26jtitle%3DFEBS%2520Lett.%26date%3D2000%26volume%3D484%26spage%3D133%26epage%3D138%26doi%3D10.1016%2FS0014-5793%2800%2902141-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holleran, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillargeon, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavigne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leduc, R.</span></span> <span> </span><span class="NLM_article-title">Interplay between intracellular loop 1 and helix VIII of the angiotensin II type 2 receptor controls its activation</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bcp.2019.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=31348898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWmurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=330-338&author=A.+Connollyauthor=B.+J.+Holleranauthor=E.+Simardauthor=J.-P.+Baillargeonauthor=P.+Lavigneauthor=R.+Leduc&title=Interplay+between+intracellular+loop+1+and+helix+VIII+of+the+angiotensin+II+type+2+receptor+controls+its+activation&doi=10.1016%2Fj.bcp.2019.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Interplay between intracellular loop 1 and helix VIII of the angiotensin II type 2 receptor controls its activation</span></div><div class="casAuthors">Connolly, Alexandre; Holleran, Brian J.; Simard, Elie; Baillargeon, Jean-Patrice; Lavigne, Pierre; Leduc, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">330-338</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The signaling mechanisms of the angiotensin II type 2 receptor (AT2R), a heptahelical receptor, have not yet been clearly and completely defined.  In the present contribution, we set out to identify the mol. determinants involved in AT2R activation.  Although AT2R has not been shown to engage Gq/11, G12, Gi2, and β-arrestin (βarr) pathways as does the AT1R upon angiotensin II (AngII) stimulation, the atypical positioning of helix VIII in the recently published AT2R structure may play a role in the receptor's capacity to couple to downstream effectors.  In the AT2R structure, helix VIII points inwards and towards intracellular loop 3 (ICL3) to form tertiary interactions with transmembrane domain 6 (TM6), possibly impeding access to signaling effectors.  On the other hand, in most class A GPCRs, helix VIII is found to be engaged in tertiary interactions with ICL1 and away from the effector binding site.  Upon closer examn. of the AT2R structure, we found that the residues contained within intracellular loop 1 (ICL1) may be involved in driving this unusual conformation of helix VIII.  To explore this hypothesis, we designed a series of AT1R/AT2R receptor chimeras to validate the roles of ICL1 and helix VIII in AT2R signaling.  Substituting the AT1R ICL1 into AT2R led to a mutant receptor that coupled to Gi2.  The substitution of the helix VIII and C-terminal domains of AT2R into the AT1R backbone led to a mutant receptor that retained AT1R-like signaling properties.  These results suggest that the C-terminal portion of AT2R is compatible with canonical GPCR signaling and that ICL1 of AT2R is involved in repositioning helix VIII, which impedes engagement of classical GPCR effectors such as G proteins or βarrs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcgci_00VRNrVg90H21EOLACvtfcHk0lhKFCe7B6S7yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWmurnO&md5=767016b28eeeef5bb755dcedfb3a4940</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DA.%26aulast%3DHolleran%26aufirst%3DB.%2BJ.%26aulast%3DSimard%26aufirst%3DE.%26aulast%3DBaillargeon%26aufirst%3DJ.-P.%26aulast%3DLavigne%26aufirst%3DP.%26aulast%3DLeduc%26aufirst%3DR.%26atitle%3DInterplay%2520between%2520intracellular%2520loop%25201%2520and%2520helix%2520VIII%2520of%2520the%2520angiotensin%2520II%2520type%25202%2520receptor%2520controls%2520its%2520activation%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2019%26volume%3D168%26spage%3D330%26epage%3D338%26doi%3D10.1016%2Fj.bcp.2019.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiroishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamakubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusano-Arai, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, S.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">570</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0079-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fs41594-018-0079-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29967536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=570-576&author=H.+Asadaauthor=S.+Horitaauthor=K.+Hirataauthor=M.+Shiroishiauthor=Y.+Shiimuraauthor=H.+Iwanariauthor=T.+Hamakuboauthor=T.+Shimamuraauthor=N.+Nomuraauthor=O.+Kusano-Araiauthor=T.+Uemuraauthor=C.+Sunoauthor=T.+Kobayashiauthor=S.+Iwata&title=Crystal+structure+of+the+human+angiotensin+II+type+2+receptor+bound+to+an+angiotensin+II+analog&doi=10.1038%2Fs41594-018-0079-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog</span></div><div class="casAuthors">Asada, Hidetsugu; Horita, Shoichiro; Hirata, Kunio; Shiroishi, Mitsunori; Shiimura, Yuki; Iwanari, Hiroko; Hamakubo, Takao; Shimamura, Tatsuro; Nomura, Norimichi; Kusano-Arai, Osamu; Uemura, Tomoko; Suno, Chiyo; Kobayashi, Takuya; Iwata, So</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">570-576</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Angiotensin II (AngII) plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngII and the G-protein-coupled receptors (GPCRs) AngII type 1 receptor (AT1R) and AngII type 2 receptor (AT2R).  We have solved the crystal structure of human AT2R binding the peptide ligand [Sar1, Ile8]AngII and its specific antibody at 3.2-Å resoln. [Sar1, Ile8]AngII interacts with both the 'core' binding domain, where the small-mol. ligands of AT1R and AT2R bind, and the 'extended' binding domain, which is equiv. to the allosteric modulator binding site of muscarinic acetylcholine receptor.  We generated an antibody fragment to stabilize the extended binding domain that functions as a pos. allosteric modulator.  We also identified a signature pos. charged cluster, which is conserved among peptide-binding receptors, to locate C termini at the bottom of the binding pocket.  The reported results should help with designing ligands for angiotensin receptors and possibly to other peptide GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYfv71Hv599bVg90H21EOLACvtfcHk0lhKFCe7B6S7yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7fM&md5=27fefcc3b51c9cb881e7b47a4e0064c2</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0079-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0079-8%26sid%3Dliteratum%253Aachs%26aulast%3DAsada%26aufirst%3DH.%26aulast%3DHorita%26aufirst%3DS.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DShiroishi%26aufirst%3DM.%26aulast%3DShiimura%26aufirst%3DY.%26aulast%3DIwanari%26aufirst%3DH.%26aulast%3DHamakubo%26aufirst%3DT.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DKusano-Arai%26aufirst%3DO.%26aulast%3DUemura%26aufirst%3DT.%26aulast%3DSuno%26aufirst%3DC.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DIwata%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520angiotensin%2520II%2520type%25202%2520receptor%2520bound%2520to%2520an%2520angiotensin%2520II%2520analog%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D570%26epage%3D576%26doi%3D10.1038%2Fs41594-018-0079-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batyuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadybekov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamlynny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenstein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstikova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weierstall, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babaoglu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Calvo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span> <span> </span><span class="NLM_article-title">Structural basis for selectivity and diversity in angiotensin II receptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>544</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1038/nature22035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fnature22035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28379944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVKhs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=544&publication_year=2017&pages=327-332&author=H.+Zhangauthor=G.+W.+Hanauthor=A.+Batyukauthor=A.+Ishchenkoauthor=K.+L.+Whiteauthor=N.+Patelauthor=A.+Sadybekovauthor=B.+Zamlynnyauthor=M.+T.+Ruddauthor=K.+Hollensteinauthor=A.+Tolstikovaauthor=T.+A.+Whiteauthor=M.+S.+Hunterauthor=U.+Weierstallauthor=W.+Liuauthor=K.+Babaogluauthor=E.+L.+Mooreauthor=R.+D.+Katzauthor=J.+M.+Shipmanauthor=M.+Garcia-Calvoauthor=S.+Sharmaauthor=P.+Shethauthor=S.+M.+Soissonauthor=R.+C.+Stevensauthor=V.+Katritchauthor=V.+Cherezov&title=Structural+basis+for+selectivity+and+diversity+in+angiotensin+II+receptors&doi=10.1038%2Fnature22035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for selectivity and diversity in angiotensin II receptors</span></div><div class="casAuthors">Zhang, Haitao; Han, Gye Won; Batyuk, Alexander; Ishchenko, Andrii; White, Kate L.; Patel, Nilkanth; Sadybekov, Anastasiia; Zamlynny, Beata; Rudd, Michael T.; Hollenstein, Kaspar; Tolstikova, Alexandra; White, Thomas A.; Hunter, Mark S.; Weierstall, Uwe; Liu, Wei; Babaoglu, Kerim; Moore, Eric L.; Katz, Ryan D.; Shipman, Jennifer M.; Garcia-Calvo, Margarita; Sharma, Sujata; Sheth, Payal; Soisson, Stephen M.; Stevens, Raymond C.; Katritch, Vsevolod; Cherezov, Vadim</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">544</span>
        (<span class="NLM_cas:issue">7650</span>),
    <span class="NLM_cas:pages">327-332</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The angiotensin II receptors AT1R and AT2R serve as key components of the renin-angiotensin-aldosterone system.  AT1R has a central role in the regulation of blood pressure, but the function of AT2R is unclear and it has a variety of reported effects.  To identify the mechanisms that underlie the differences in function and ligand selectivity between these receptors, here the authors report crystal structures of human AT2R bound to an AT2R-selective ligand and to an AT1R/AT2R dual ligand, capturing the receptor in an active-like conformation.  Unexpectedly, helix VIII was found in a non-canonical position, stabilizing the active-like state, but at the same time preventing the recruitment of G proteins or β-arrestins, in agreement with the lack of signaling responses in std. cellular assays.  Structure-activity relationship, docking and mutagenesis studies revealed the crucial interactions for ligand binding and selectivity.  The authors' results thus provide insights into the structural basis of the distinct functions of the angiotensin receptors, and may guide the design of new selective ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonEzSnnYnMorVg90H21EOLACvtfcHk0lh4yiIj9Ds1IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVKhs7c%253D&md5=4473fb24c39c800b2126b1303c02afec</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnature22035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22035%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DBatyuk%26aufirst%3DA.%26aulast%3DIshchenko%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DSadybekov%26aufirst%3DA.%26aulast%3DZamlynny%26aufirst%3DB.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DHollenstein%26aufirst%3DK.%26aulast%3DTolstikova%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DT.%2BA.%26aulast%3DHunter%26aufirst%3DM.%2BS.%26aulast%3DWeierstall%26aufirst%3DU.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBabaoglu%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DE.%2BL.%26aulast%3DKatz%26aufirst%3DR.%2BD.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DGarcia-Calvo%26aufirst%3DM.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSheth%26aufirst%3DP.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DCherezov%26aufirst%3DV.%26atitle%3DStructural%2520basis%2520for%2520selectivity%2520and%2520diversity%2520in%2520angiotensin%2520II%2520receptors%26jtitle%3DNature%26date%3D2017%26volume%3D544%26spage%3D327%26epage%3D332%26doi%3D10.1038%2Fnature22035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guimond, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span> <span> </span><span class="NLM_article-title">Saralasin and sarile are AT2 receptor agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1132</span>, <span class="refDoi"> DOI: 10.1021/ml500278g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500278g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlynu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1129-1132&author=M.+O.+Guimondauthor=M.+Hallbergauthor=N.+Gallo-Payetauthor=C.+Wallinder&title=Saralasin+and+sarile+are+AT2+receptor+agonists&doi=10.1021%2Fml500278g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Saralasin and Sarile Are AT2 Receptor Agonists</span></div><div class="casAuthors">Guimond, Marie-Odile; Hallberg, Mathias; Gallo-Payet, Nicole; Wallinder, Charlotta</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1129-1132</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Saralasin and sarile, extensively studied over the past 40 years as angiotensin II (Ang II) receptor blockers, induce neurite outgrowth in a NG108-15 cell assay to a similar extent as the endogenous Ang II.  In their undifferentiated state, these cells express mainly the AT2 receptor.  The neurite outgrowth was inhibited by preincubation with the AT2 receptor selective antagonist PD 123,319, which suggests that the obsd. outgrowth was mediated by the AT2 receptor.  Neither saralasin nor sarile reduced the neurite outgrowth induced by Ang II proving that the two octapeptides do not act as antagonists at the AT2 receptor and may be considered as AT2 receptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Y9fqgIPsgLVg90H21EOLACvtfcHk0lhqkKuYqxgxKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlynu7rE&md5=2417e096b8cb64f4dfe0e2aaf7c13755</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fml500278g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500278g%26sid%3Dliteratum%253Aachs%26aulast%3DGuimond%26aufirst%3DM.%2BO.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DWallinder%26aufirst%3DC.%26atitle%3DSaralasin%2520and%2520sarile%2520are%2520AT2%2520receptor%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1129%26epage%3D1132%26doi%3D10.1021%2Fml500278g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition</span>. <i>J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1097/00004872-199917030-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2F00004872-199917030-00013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10100078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1MXjsVOgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=397-404&author=S.+Miuraauthor=S.+S.+Karnik&title=Angiotensin+II+type+1+and+type+2+receptors+bind+angiotensin+II+through+different+types+of+epitope+recognition&doi=10.1097%2F00004872-199917030-00013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition</span></div><div class="casAuthors">Miura, Shin-Ichiro; Karnik, Sadashiva S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-404</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This study was designed to demonstrate that the principle of mol. recognition underlying high-affinity binding of angiotensin II to the type 2 (AT2) receptor is distinct from that of the type 1 (AT1) receptor.  In general, the same functional pharmacophores in hormones are used to bind and activate different subtypes of cell surface receptors.  However, the binding of angiotensin II to the AT2 receptor is distinct from that of the AT1 receptor.  To systematically evaluate the effect of modification of angiotensin II side chains on binding to both the receptors, several analogs of angiotensin II were synthesized.  Rat AT1 or AT2 receptors expressed in COS1 cell membranes were used to det. the affinity of analogs using radioligand competition binding expts. under equil. conditions.  Modifications of all angiotensin II side chains affected binding to the AT2 receptor to nearly similar extents.  In contrast, binding to the AT1 receptor was significantly affected by modifications at side chain positions 2, 4, 6 and 7.  In accordance with previous observations that Tyr4- or Phe8-modified angiotensin II analogs antagonized vasoconstriction mediated exclusively by the AT1 receptor, binding to the AT1 receptor was significantly dependent on Tyr4 or Phe8 of angiotensin II, whereas binding to the AT2 receptor was not.  Rather surprisingly, the affinity profile of several angiotensin II analogs towards the AT2 receptor was similar to the measured affinity of the constitutively active N111G mutant AT1 receptor.  These results suggest that the AT2-receptor pharmacophore is very distinct from that of the AT1 receptor.  The AT1 receptor is in a constrained conformation and is activated only when bound to angiotensin II.  In contrast, the AT2 receptor is relaxed in that no single interaction is crit. for binding, like the N111G mutant AT1 receptor, which is constitutively active.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHKqce7-EWg7Vg90H21EOLACvtfcHk0lhqkKuYqxgxKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsVOgsbg%253D&md5=dbbe4d8e9ed840e8df09703519408e9d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1097%2F00004872-199917030-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004872-199917030-00013%26sid%3Dliteratum%253Aachs%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26atitle%3DAngiotensin%2520II%2520type%25201%2520and%2520type%25202%2520receptors%2520bind%2520angiotensin%2520II%2520through%2520different%2520types%2520of%2520epitope%2520recognition%26jtitle%3DJ.%2520Hypertens.%26date%3D1999%26volume%3D17%26spage%3D397%26epage%3D404%26doi%3D10.1097%2F00004872-199917030-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span> <span> </span><span class="NLM_article-title">Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane helix-2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">24299</span>– <span class="NLM_lpage">24305</span>, <span class="refDoi"> DOI: 10.1074/jbc.M202743200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1074%2Fjbc.M202743200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11983705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlOhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=24299-24305&author=S.+Miuraauthor=S.+S.+Karnik&title=Constitutive+activation+of+angiotensin+II+type+1+receptor+alters+the+orientation+of+transmembrane+helix-2&doi=10.1074%2Fjbc.M202743200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane helix-2</span></div><div class="casAuthors">Miura, Shin-Ichiro; Karnik, Sadashiva S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">24299-24305</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A key step in transmembrane (TM) signal transduction by G-protein-coupled receptors (GPCRs) is the ligand-induced conformational change of the receptor, which triggers the activation of a guanine nucleotide-binding protein.  GPCRs contain a seven-TM helical structure essential for signal transduction in response to a large variety of sensory and hormonal signals.  Primary structure comparison of GPCRs has shown that the second TM helix contains a highly conserved Asp residue, which is crit. for agonist activation in these receptors.  How conformational changes in TM2 relate to signal transduction by a GPCR is not known, because activation-induced conformational changes in TM2 helix have not been measured.  Here we use modification of reporter cysteines to measure water accessibility at specific residues in TM2 of the type 1 receptor for the octapeptide hormone angiotensin II.  Activation-dependent changes in the accessibility of Cys76 on TM2 were measured in constitutively activated mutants.  These changes were directly correlated with measurement of function, establishing the link between phys. changes in TM2 and function.  Accessibility changes were measured at several consecutive residues on TM2, which suggest that TM2 undergoes a transmembrane movement in response to activation.  This is the first report of in situ measurement of TM2 movement in a GPCR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr88wlFJzPET7Vg90H21EOLACvtfcHk0lhqkKuYqxgxKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlOhsL4%253D&md5=aaf855e11ac5bfb5c0cf993a1c7b8ade</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M202743200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M202743200%26sid%3Dliteratum%253Aachs%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26atitle%3DConstitutive%2520activation%2520of%2520angiotensin%2520II%2520type%25201%2520receptor%2520alters%2520the%2520orientation%2520of%2520transmembrane%2520helix-2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D24299%26epage%3D24305%26doi%3D10.1074%2Fjbc.M202743200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span> <span> </span><span class="NLM_article-title">Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4026</span>– <span class="NLM_lpage">4035</span>, <span class="refDoi"> DOI: 10.1093/emboj/19.15.4026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1093%2Femboj%2F19.15.4026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10921883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVKqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=4026-4035&author=S.+Miuraauthor=S.+S.+Karnik&title=Ligand-independent+signals+from+angiotensin+II+type+2+receptor+induce+apoptosis&doi=10.1093%2Femboj%2F19.15.4026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis</span></div><div class="casAuthors">Miura, Shin-Ichiro; Karnik, Sadashiva S.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4026-4035</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Conventional models of ligand-receptor regulation predict that agonists enhance the tone of signals generated by the receptor in the absence of ligand.  Contrary to this paradigm, stimulation of the type 2 (AT2) receptor by angiotensin II (Ang II) is not required for induction of apoptosis but the level of receptor protein expression is crit.  The authors compared Ang II-dependent and -independent AT2 receptor signals involved in regulating apoptosis of cultured fibroblasts, epithelial cells and vascular smooth muscle cells.  The authors found that induction of apoptosis-blocked by pharmacol. inhibition of p38 mitogen-activated protein kinase and caspase 3-is a constitutive function of the AT2 receptor.  Biochem. and genetic studies suggest that the level of AT2 receptor expression is crit. for physiol. ontogenesis and its expression is restricted postnatally, coinciding with cessation of developmental apoptosis.  Re-expression of the AT2 receptor in remodeling tissues in the adult is linked to control of tissue growth and regeneration.  Therefore, the authors propose that overexpression of the AT2 receptor itself is a signal for apoptosis that does not require the renin-angiotensin system hormone Ang II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5kbZxTVjwUrVg90H21EOLACvtfcHk0ljvnc7bwJHXyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVKqu78%253D&md5=c3c1c2305ef3084e3ec04f548094a381</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.15.4026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.15.4026%26sid%3Dliteratum%253Aachs%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26atitle%3DLigand-independent%2520signals%2520from%2520angiotensin%2520II%2520type%25202%2520receptor%2520induce%2520apoptosis%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D4026%26epage%3D4035%26doi%3D10.1093%2Femboj%2F19.15.4026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharov, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nass, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbah, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, O. A.</span></span> <span> </span><span class="NLM_article-title">Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1926</span>– <span class="NLM_lpage">1935</span>, <span class="refDoi"> DOI: 10.1172/JCI119360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1172%2FJCI119360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9109437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2sXisF2qu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1997&pages=1926-1935&author=Y.+H.+Liuauthor=X.+P.+Yangauthor=V.+G.+Sharovauthor=O.+Nassauthor=H.+N.+Sabbahauthor=E.+Petersonauthor=O.+A.+Carretero&title=Effects+of+angiotensin-converting+enzyme+inhibitors+and+angiotensin+II+type+1+receptor+antagonists+in+rats+with+heart+failure.+Role+of+kinins+and+angiotensin+II+type+2+receptors&doi=10.1172%2FJCI119360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors</span></div><div class="casAuthors">Liu, Yun-He; Yang, Xiao-Ping; Sharov, Victor G.; Nass, Omar; Sabbah, Hani N.; Peterson, Edward; Carretero, Oscar A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1926-1935</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Angiotensin-converting enzyme inhibitors (ACEi) improve cardiac function and remodeling and prolong survival in patients with heart failure (HF).  Blockade of the renin-angiotensin system (RAS) with an angiotensin II type 1 receptor antagonist (AT1-ant) may have a similar beneficial effect.  In addn. to inhibition of the RAS, ACEi may also act by inhibiting kinin destruction, whereas AT1-ant may block the RAS at the level of the AT1 receptor and activate the angiotensin II type 2 (AT2) receptor.  Using a model of HF induced by myocardial infarction (MI) in rats, we studied the role of kinins in the cardioprotective effect of ACEi.  We also investigated whether an AT1-ant has a similar effect and whether these effects are partly due to activation of the AT2 receptor.  Two months after MI, rats were treated for 2 mo with: (a) vehicle; (b) the ACEi ramipril, with and without the B2 receptor antagonist icatibant (B2-ant); or (c) an AT1-ant with and without an AT2-antagonist (AT2-ant) or B2-ant.  Vehicle-treated rats had a significant increase in left ventricular end-diastolic (LVEDV) and end-systolic vol. (LVESV) as well as interstitial collagen deposition and cardiomyocyte size, whereas ejection fraction was decreased.  Left ventricular remodeling and cardiac function were improved by the ACEi and AT1-ant.  The B2-ant blocked most of the cardioprotective effect of the ACEi, whereas the effect of the AT1-ant was blocked by the AT2-ant.  The decreases in LVEDV and LVESV caused by the AT1-ant were also partially blocked by the B2-ant.  We concluded that (a) in HF both ACEi and AT1-ant have a cardioprotective effect, which could be due to either a direct action on the heart or secondary to altered hemodynamics, or both; and (b) the effect of the ACEi is mediated in part by kinins, whereas that of the AT1-ant is triggered by activation of the AT2 receptor and is also mediated in part by kinins.  We speculate that in HF, blockade of AT1 receptors increases both renin and angiotensins; these angiotensins stimulate the AT2 receptor, which in turn may play an important role in the therapeutic effect of the AT1-ant via kinins and other autacoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkxavfJUkJrrVg90H21EOLACvtfcHk0ljvnc7bwJHXyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisF2qu7g%253D&md5=81f7f7fad69b2467e6c1a751b5fbab91</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1172%2FJCI119360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI119360%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BH.%26aulast%3DYang%26aufirst%3DX.%2BP.%26aulast%3DSharov%26aufirst%3DV.%2BG.%26aulast%3DNass%26aufirst%3DO.%26aulast%3DSabbah%26aufirst%3DH.%2BN.%26aulast%3DPeterson%26aufirst%3DE.%26aulast%3DCarretero%26aufirst%3DO.%2BA.%26atitle%3DEffects%2520of%2520angiotensin-converting%2520enzyme%2520inhibitors%2520and%2520angiotensin%2520II%2520type%25201%2520receptor%2520antagonists%2520in%2520rats%2520with%2520heart%2520failure.%2520Role%2520of%2520kinins%2520and%2520angiotensin%2520II%2520type%25202%2520receptors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1997%26volume%3D99%26spage%3D1926%26epage%3D1935%26doi%3D10.1172%2FJCI119360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gohlke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pees, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.31.1.349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.HYP.31.1.349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9453327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1cXptF2ntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1998&pages=349-355&author=P.+Gohlkeauthor=C.+Peesauthor=T.+Unger&title=AT2+receptor+stimulation+increases+aortic+cyclic+GMP+in+SHRSP+by+a+kinin-dependent+mechanism&doi=10.1161%2F01.HYP.31.1.349"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism</span></div><div class="casAuthors">Gohlke, Peter; Pees, Christiane; Unger, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1, Pt. 2</span>),
    <span class="NLM_cas:pages">349-355</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">In the present study we tested the hypothesis whether an angiotensin AT2 receptor-mediated stimulation of the bradykinin (BK)/nitric oxide (NO) system can account for the effects of AT1 receptor antagonism on aortic cGMP described previously in SHRSP.  Adult SHRSP were treated for 4 h with angiotensin II (ANG II) (30 ng/kg per min i.v.) or vehicle (0.9% NaCl i.v.).  Animals were pretreated with vehicle, losartan (100 mg/kg p.o.), PD 123319 (30 mg/kg i.v.), losartan plus PD 123319, icatibant (500 μg/kg i.v.), NG-nitro-L-arginine Me ester (L-NAME; 1 mg/kg i.v.), or minoxidil (3 mg/kg i.v.).  Mean arterial blood pressure (MAP) was continuously monitored over the 4-h exptl. period, and plasma ANG II and aortic cGMP were measured by RIA at the end of the study.  ANG II infusion over 4 h raised MAP by about 20 mm Hg.  Losartan alone or losartan plus ANG II as well as minoxidil plus ANG II markedly reduced blood pressure when compared to vehicle-treated or ANG II-treated animals, resp.  Plasma levels of ANG II were increased 2-fold by ANG II infusion alone or by ANG II in combination with icatibant, L-NAME, or minoxidil.  The increase in plasma ANG II levels was even more pronounced after losartan treatment.  Aortic cGMP content was significantly increased by ANG II, losartan, losartan plus ANG II, and minoxidil plus ANG II by 60%, 45%, 68%, and 52%, resp.  The effects of ANG II and of losartan plus ANG II on aortic cGMP content were both blocked by cotreatment with the AT2 receptor antagonist PD 123319.  Icatibant and L-NAME abolished the effects of ANG II on aortic cGMP.  Our results demonstrate the following: (1) ANG II increases aortic cGMP by an AT2 receptor-mediated action because the effect could be prevented by an AT2 receptor antagonist; (2) the effect of ANG II was not secondary to blood pressure increase because it remained under redn. of MAP with minoxidil; (3) losartan increased aortic cGMP most likely by increasing plasma ANG II levels with a subsequent stimulation of AT2 receptor; and (4) the effects of AT2 receptor stimulation are mediated by BK and, subsequently, NO because they were abolished by B2 receptor blockade as well as by NO synthase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-f9ZtGY8CmbVg90H21EOLACvtfcHk0ljif6oOnpqhXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXptF2ntA%253D%253D&md5=dfcbb507c01312b422657d202fd54071</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.31.1.349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.31.1.349%26sid%3Dliteratum%253Aachs%26aulast%3DGohlke%26aufirst%3DP.%26aulast%3DPees%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DAT2%2520receptor%2520stimulation%2520increases%2520aortic%2520cyclic%2520GMP%2520in%2520SHRSP%2520by%2520a%2520kinin-dependent%2520mechanism%26jtitle%3DHypertension%26date%3D1998%26volume%3D31%26spage%3D349%26epage%3D355%26doi%3D10.1161%2F01.HYP.31.1.349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fushiki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, K.</span></span> <span> </span><span class="NLM_article-title">Contrasting effects of angiotensin type 1 and 2 receptors on nitric oxide release under pressure</span>. <i>Hypertens. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1291/hypres.25.779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1291%2Fhypres.25.779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12452333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlSltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2002&pages=779-786&author=S.+Haradaauthor=T.+Nakataauthor=A.+Oguniauthor=H.+Kidoauthor=T.+Hattaauthor=R.+Fukuyamaauthor=S.+Fushikiauthor=S.+Sasakiauthor=K.+Takeda&title=Contrasting+effects+of+angiotensin+type+1+and+2+receptors+on+nitric+oxide+release+under+pressure&doi=10.1291%2Fhypres.25.779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Contrasting effects of angiotensin type 1 and 2 receptors on nitric oxide release under pressure</span></div><div class="casAuthors">Harada, Sanae; Nakata, Tetsuo; Oguni, Atsuhiko; Kido, Hidenori; Hatta, Tsuguru; Fukuyama, Ryuichi; Fushiki, Shinji; Sasaki, Susumu; Takeda, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">HRESE4</span>;
        ISSN:<span class="NLM_cas:issn">0916-9636</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Hypertension</span>)
        </div><div class="casAbstract">This study was designed to test the hypothesis that increased pressure itself could cause endothelial dysfunction and lead to decreased nitric oxide (NO) release, partly through effects on the tissue renin angiotensin system in hypertension.  Cultured endothelial cells (ECs) isolated from the aortas of WKY rats were continuously exposed to a pressure of 150 mmHg in a CO2 incubator for 72 h using a pressure system, and the NOx (NO2 and NO3) and angiotensin II (Ang II) concns. in the supernatant were measured.  An Ang II type 1 receptor (AT1R) antagonist (losartan) and an Ang II type 2 receptor (AT2R) antagonist (PD 123319) were added to the medium.  The expression of AT1R and AT2R mRNAs was also examd.  Pressure loading significantly decreased the NO release from ECs.  Concomitant administration of losartan restored NO release to the level before the application of pressure.  This effect of losartan was blocked by simultaneous administration of PD 123319, bradykinin type 2 receptor antagonist, and NO synthase inhibitor.  The Ang II concn. was increased by pressure and was further increased by losartan.  The gene expression of AT1R was not changed by pressure, but AT2R mRNA was increased almost 2-fold.  These results indicate that high pressure itself attenuates NO release from ECs, and that losartan improves NO release by activating the bradykinin system via AT2R stimulation.  In addn., the increase of AT2R gene expression in ECs during exposure to pressure may compensate for the redn. of NO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrncBdSbx7Y7LVg90H21EOLACvtfcHk0ljif6oOnpqhXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlSltb4%253D&md5=14d5437ff95524855095e6097e76ae53</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1291%2Fhypres.25.779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1291%252Fhypres.25.779%26sid%3Dliteratum%253Aachs%26aulast%3DHarada%26aufirst%3DS.%26aulast%3DNakata%26aufirst%3DT.%26aulast%3DOguni%26aufirst%3DA.%26aulast%3DKido%26aufirst%3DH.%26aulast%3DHatta%26aufirst%3DT.%26aulast%3DFukuyama%26aufirst%3DR.%26aulast%3DFushiki%26aufirst%3DS.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DTakeda%26aufirst%3DK.%26atitle%3DContrasting%2520effects%2520of%2520angiotensin%2520type%25201%2520and%25202%2520receptors%2520on%2520nitric%2520oxide%2520release%2520under%2520pressure%26jtitle%3DHypertens.%2520Res.%26date%3D2002%26volume%3D25%26spage%3D779%26epage%3D786%26doi%3D10.1291%2Fhypres.25.779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Batenburg, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrelds, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, C.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kats, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danser, A. H. J.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor-mediated vasodilatation in human coronary microarteries</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2296</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000128696.12245.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.CIR.0000128696.12245.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=15117835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslOru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2004&pages=2296-2301&author=W.+W.+Batenburgauthor=I.+M.+Garreldsauthor=C.C.+Bernasconiauthor=L.+Juillerat-Jeanneretauthor=J.+P.+van+Katsauthor=P.+R.+Saxenaauthor=A.+H.+J.+Danser&title=Angiotensin+II+type+2+receptor-mediated+vasodilatation+in+human+coronary+microarteries&doi=10.1161%2F01.CIR.0000128696.12245.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II Type 2 Receptor-Mediated Vasodilation in Human Coronary Microarteries</span></div><div class="casAuthors">Batenburg, Wendy W.; Garrelds, Ingrid M.; Bernasconi, Catherine Chapuis; Juillerat-Jeanneret, Lucienne; Van Kats, Jorge P.; Saxena, Pramod R.; Danser, A. H. Jan</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2296-2301</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background- Angiotensin (Ang) II type 2 (AT2) receptor stimulation results in coronary vasodilation in the rat heart.  In contrast, AT2 receptor-mediated vasodilation could not be obsd. in large human coronary arteries.  We studied Ang II-induced vasodilation of human coronary microarteries (HCMAs).  Methods and Results- HCMAs (diam., 160 to 500 μm) were obtained from 49 heart valve donors (age, 3 to 65 yr).  Ang II constricted HCMAs, mounted in Mulvany myographs, in a concn.-dependent manner (pEC50, 8.6; maximal effect [Emax], 79% of the contraction to 100 mmol/L K+).  The Ang II type 1 receptor antagonist irbesartan prevented this vasoconstriction, whereas the AT2 receptor antagonist PD 123319 increased Emax to 97%.  The increase in Emax was larger in older donors (correlation ΔEmax vs. age, r=0.47).  The PD 123319-induced potentiation was not obsd. in the presence of the NO synthase inhibitor L-NAME, the bradykinin type 2 (B2) receptor antagonist Hoe 140, or after removal of the endothelium.  Ang II relaxed U 46619-preconstricted HCMAs in the presence of irbesartan by maximally 49%, and PD 123319 prevented this relaxation.  Finally, radioligand binding studies and reverse transcription-polymerase chain reaction confirmed the expression of AT2 receptors in HCMAs.  Conclusions- AT2 receptor-mediated vasodilation in the human heart appears to be limited to coronary microarteries and is mediated by B2 receptors and NO.  Most likely, AT2 receptors are located on endothelial cells, and their contribution increases with age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRYo8y3N9J27Vg90H21EOLACvtfcHk0ljSdrq2DFmpJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslOru7c%253D&md5=0dcd1f98b6c7fac4e516f64585ce81e6</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000128696.12245.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000128696.12245.57%26sid%3Dliteratum%253Aachs%26aulast%3DBatenburg%26aufirst%3DW.%2BW.%26aulast%3DGarrelds%26aufirst%3DI.%2BM.%26aulast%3DBernasconi%26aufirst%3DC.C.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3Dvan%2BKats%26aufirst%3DJ.%2BP.%26aulast%3DSaxena%26aufirst%3DP.%2BR.%26aulast%3DDanser%26aufirst%3DA.%2BH.%2BJ.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor-mediated%2520vasodilatation%2520in%2520human%2520coronary%2520microarteries%26jtitle%3DCirculation%26date%3D2004%26volume%3D109%26spage%3D2296%26epage%3D2301%26doi%3D10.1161%2F01.CIR.0000128696.12245.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozono, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siragy, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R. M.</span></span> <span> </span><span class="NLM_article-title">Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.32.1.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.HYP.32.1.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9674641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVOlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1998&pages=78-83&author=Z.+Q.+Wangauthor=A.+F.+Mooreauthor=R.+Ozonoauthor=H.+M.+Siragyauthor=R.+M.+Carey&title=Immunolocalization+of+subtype+2+angiotensin+II+%28AT2%29+receptor+protein+in+rat+heart&doi=10.1161%2F01.HYP.32.1.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart</span></div><div class="casAuthors">Wang, Zhi-Qin; Moore, Allan F.; Ozono, Ryoji; Siragy, Helmy M.; Carey, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-83</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The expression and localization of AT2 receptor protein in the rat heart was investigated using an antipeptide polyclonal antibody against the native rat AT2 receptor by light microscopic immunocytochem. and Western blot anal.  In frozen tissue sections, pos. immunostaining was obsd. in the myocardium and coronary vessels throughout the ventricle and atrium of neonatal and young rat hearts.  Coronary vessels of the neonatal heart were more intensely stained compared with the surrounding myocardium.  Pos. immunoreactivity in the coronary vessels of young rats was localized to vascular endothelium but not in the smooth muscle cells.  Preadsorption controls were all neg.  Western blot anal. showed that the AT2 receptor protein (≈44 kDa) was detectable from the AT2 receptor-transfected COS-7 cells and neonatal rat cardiac myocytes but not from fibroblasts or young rat aortic smooth muscle cells.  The neonatal rat heart expressed significantly more AT2 receptors than young rat heart.  These data provide the 1st direct evidence for the expression and localization of AT2 receptor protein in the rat heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosaV_hcPuYkLVg90H21EOLACvtfcHk0ljSdrq2DFmpJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVOlu7Y%253D&md5=48345b749af4413818bd427760967838</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.32.1.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.32.1.78%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%2BQ.%26aulast%3DMoore%26aufirst%3DA.%2BF.%26aulast%3DOzono%26aufirst%3DR.%26aulast%3DSiragy%26aufirst%3DH.%2BM.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26atitle%3DImmunolocalization%2520of%2520subtype%25202%2520angiotensin%2520II%2520%2528AT2%2529%2520receptor%2520protein%2520in%2520rat%2520heart%26jtitle%3DHypertension%26date%3D1998%26volume%3D32%26spage%3D78%26epage%3D83%26doi%3D10.1161%2F01.HYP.32.1.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, A. W.</span></span> <span> </span><span class="NLM_article-title">Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">F437</span>– <span class="NLM_lpage">F446</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.1999.277.3.F437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajprenal.1999.277.3.F437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10484527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1MXmt1Gisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1999&pages=F437-F446&author=N.+Miyataauthor=F.+Parkauthor=X.+F.+Liauthor=A.+W.+Cowley&title=Distribution+of+angiotensin+AT1+and+AT2+receptor+subtypes+in+the+rat+kidney&doi=10.1152%2Fajprenal.1999.277.3.F437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney</span></div><div class="casAuthors">Miyata, Noriyuki; Park, Frank; Li, Xiao Feng; Cowley, Allen W., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">3, Pt. 2</span>),
    <span class="NLM_cas:pages">F437-F446</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">ANG II contributes importantly to the regulation of renal vascular resistance, glomerular filtration, and tubular epithelial transport, yet there remains a paucity of information regarding the localization of the ANG II type 1 and 2 (AT1 and AT2) receptors within the rat kidney particularly within the vasculature.  The present study was designed to localize the transcriptional and translational site(s) of AT1 and AT2 receptor (AT1R and AT2R, resp.) expression within the rat kidney.  Using immunohistochem., the authors detected the AT1R translational sites throughout the kidney, with the strongest labeling found in the vasculature of the renal cortex and the proximal tubules of the outer medulla.  The AT2R protein expression was found throughout the rat kidney, although there was little to no expression found in the glomerulus and medullary thick ascending limbs of Henle (TAL).  Gene-specific primers were then designed to distinguish between the receptor subtypes within microdissected renal tubular and vascular segments using RT-PCR.  AT1AR, AT1BR, and AT2R mRNA were found within the renal vasculature (afferent arterioles, arcuate artery, and outer medullary descending vasa recta).  The mRNA for both the AT1R isoforms was also detected in the glomeruli and the renal tubules (proximal tubules, TAL, and collecting ducts); however, no AT2R mRNA was detected within the glomerulus and was inconsistently found within the medullary TAL (MTAL).  Taken together, these data show that mRNA for the AT1R subtypes was located in all of the renal tubular and vascular segments.  Evidence for AT2R mRNA was also found in all but two of the vascular and tubular segments, the MTAL, and the glomeruli.  These results are consistent with the whole tissue immunohistochem. localized receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6N5uZmO-x2LVg90H21EOLACvtfcHk0ljSdrq2DFmpJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt1Gisb0%253D&md5=cf3b91f9d223a835f927d86697124493</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.1999.277.3.F437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.1999.277.3.F437%26sid%3Dliteratum%253Aachs%26aulast%3DMiyata%26aufirst%3DN.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DX.%2BF.%26aulast%3DCowley%26aufirst%3DA.%2BW.%26atitle%3DDistribution%2520of%2520angiotensin%2520AT1%2520and%2520AT2%2520receptor%2520subtypes%2520in%2520the%2520rat%2520kidney%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1999%26volume%3D277%26spage%3DF437%26epage%3DF446%26doi%3D10.1152%2Fajprenal.1999.277.3.F437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span> <span> </span><span class="NLM_article-title">Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion</span>. <i>J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1075</span>– <span class="NLM_lpage">1081</span>, <span class="refDoi"> DOI: 10.1097/00004872-200106000-00012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2F00004872-200106000-00012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11403356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlSqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=1075-1081&author=F.+Bonnetauthor=M.+E.+Cooperauthor=R.+M.+Careyauthor=D.+Casleyauthor=Z.+Cao&title=Vascular+expression+of+angiotensin+type+2+receptor+in+the+adult+rat%3A+influence+of+angiotensin+II+infusion&doi=10.1097%2F00004872-200106000-00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion</span></div><div class="casAuthors">Bonnet, Fabrice; Cooper, Mark E.; Carey, Robert M.; Casley, David; Cao, Zemin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1075-1081</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The aim of this study was to investigate the relative role of the angiotensin type 1 (AT1) and type 2 (AT2) receptors in mediating angiotensin II-induced regulation of AT2 receptor in mesenteric artery.  Sprague-Dawley rats were infused with either angiotensin II or vehicle for 14 days at a dose of 58.3 ng/min.  Ang II-infused rats were allocated to receive either an AT1 antagonist, valsartan at a dose of 30 mg/kg per day or the AT2 receptor antagonist PD123319 at a dose of 830 ng/min.  Gene and protein expression of the AT2 receptor in the mesenteric vasculature was assessed by quant. reverse transcriptase polymerase chain reaction, immunohistochem. and by in vitro autoradiog. with a specific radioligand, 125I-CGP 42112B.  The AT2 receptor mRNA and protein were detected in the mesenteric artery from adult rats.  Both nuclear emulsion and immunohistochem. staining showed expression of the AT2 receptor in the adventitial and medial layers.  Compared to control rats, angiotensin II infusion was assocd. with a significant increase in the AT2 receptor expression.  Valsartan treatment significantly reduced AT2 receptor gene expression, with no significant effect of PD123319 on this parameter.  This study confirms that the presence of the AT2 receptor in mesenteric arteries in adult rats, shows an up-regulation of the AT2 receptor following angiotensin II infusion and suggests a role for the AT1 receptor in this regulation.  In view of the recently demonstrated effects of the AT2 receptor, these findings may be relevant to the role of the AT2 receptor in the pathophysiol. of vascular remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9d57rNnrFLVg90H21EOLACvtfcHk0lhskP11_5f6uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlSqs7c%253D&md5=61acfa50273553f0a1eb53624693b00b</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1097%2F00004872-200106000-00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004872-200106000-00012%26sid%3Dliteratum%253Aachs%26aulast%3DBonnet%26aufirst%3DF.%26aulast%3DCooper%26aufirst%3DM.%2BE.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26aulast%3DCasley%26aufirst%3DD.%26aulast%3DCao%26aufirst%3DZ.%26atitle%3DVascular%2520expression%2520of%2520angiotensin%2520type%25202%2520receptor%2520in%2520the%2520adult%2520rat%253A%2520influence%2520of%2520angiotensin%2520II%2520infusion%26jtitle%3DJ.%2520Hypertens.%26date%3D2001%26volume%3D19%26spage%3D1075%26epage%3D1081%26doi%3D10.1097%2F00004872-200106000-00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nahmod, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raiden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamone, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamberale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Calotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahmod, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geffner, J. R.</span></span> <span> </span><span class="NLM_article-title">Control of dendritic cell differentiation by angiotensin II</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1096/fj.02-0755fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1096%2Ffj.02-0755fje" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12514109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFaquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=491-493&author=K.+A.+Nahmodauthor=M.+E.+Vermeulenauthor=S.+Raidenauthor=G.+A.+Salamoneauthor=R.+Gamberaleauthor=P.+Fernandez-Calottiauthor=A.+Alvarezauthor=V.+Nahmodauthor=M.+Giordanoauthor=J.+R.+Geffner&title=Control+of+dendritic+cell+differentiation+by+angiotensin+II&doi=10.1096%2Ffj.02-0755fje"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Control of dendritic cell differentiation by angiotensin II</span></div><div class="casAuthors">Nahmod, Karen A.; Vermeulen, Monica E.; Radien, Silvina; Salamone, Gabriela; Gamberale, Romina; Fernandez-Calotti, Paula; Alvarez, Azucena; Nahmod, Victor; Giordano, Mirta; Geffner, Jorge R.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">491-493, 10.1096/fj.02-0755fje</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Here the authors analyze the role of the angiotensinergic system in the differentiation of dendritic cells (DC).  The authors found that human monocytes produce angiotensin II (AII) and express AT1 and AT2 receptors for AII.  DC differentiated from human monocytes in the presence of AT1 receptor antagonists losartan or candesartan show very low levels of CD1a expression and poor endocytic and allostimulatory activities.  By contrast, DC differentiation in the presence of either the AT2 receptor antagonist PD 123319 or exogenous AII results in the development of nonadherent cells with CD1a expression and endocytic and allostimulatory activities higher than control DC.  Similar contrasting effects were obsd. in mouse DC obtained from bone marrow cultures supplemented with granulocyte-monocyte colony-stimulating factor.  DC differentiated in the presence of the AT1 receptor antagonist losartan express lower levels of CD11c, CD40, and Ia and display a lower ability to endocyte horseradish peroxidase (HRP) and to induce antibody responses in vivo, compared with controls.  By contrast, DC differentiation in the presence of either the AT2 receptor antagonist PD 123319 or exogenous AII results in cells with high levels of CD11c, CD40, and Ia, as well as high ability to endocyte HRP and to induce antibody responses in vivo.  The authors' results support the notion that the differentiation of DC is regulated by AII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyQ116_bflLVg90H21EOLACvtfcHk0lhskP11_5f6uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFaquro%253D&md5=8fd0d8cfbadb117e39b12eca80724c4c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1096%2Ffj.02-0755fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.02-0755fje%26sid%3Dliteratum%253Aachs%26aulast%3DNahmod%26aufirst%3DK.%2BA.%26aulast%3DVermeulen%26aufirst%3DM.%2BE.%26aulast%3DRaiden%26aufirst%3DS.%26aulast%3DSalamone%26aufirst%3DG.%2BA.%26aulast%3DGamberale%26aufirst%3DR.%26aulast%3DFernandez-Calotti%26aufirst%3DP.%26aulast%3DAlvarez%26aufirst%3DA.%26aulast%3DNahmod%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DM.%26aulast%3DGeffner%26aufirst%3DJ.%2BR.%26atitle%3DControl%2520of%2520dendritic%2520cell%2520differentiation%2520by%2520angiotensin%2520II%26jtitle%3DFASEB%2520J.%26date%3D2003%26volume%3D17%26spage%3D491%26epage%3D493%26doi%3D10.1096%2Ffj.02-0755fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altarche-Xifró, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miteva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imboden, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Identification of noncytotoxic and IL-10–producing CD8<sup>+</sup>AT2R<sup>+</sup> T cell population in response to ischemic heart injury</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">6286</span>– <span class="NLM_lpage">6293</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0903681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.4049%2Fjimmunol.0903681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=20935205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlOhsbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2010&pages=6286-6293&author=C.+Curatoauthor=S.+Slavicauthor=J.+Dongauthor=A.+Skorskaauthor=W.+Altarche-Xifr%C3%B3author=K.+Mitevaauthor=E.+Kaschinaauthor=A.+Thielauthor=H.+Imbodenauthor=J.+Wangauthor=U.+Steckelingsauthor=G.+Steinhoffauthor=T.+Ungerauthor=J.+Li&title=Identification+of+noncytotoxic+and+IL-10%E2%80%93producing+CD8%2BAT2R%2B+T+cell+population+in+response+to+ischemic+heart+injury&doi=10.4049%2Fjimmunol.0903681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Noncytotoxic and IL-10-Producing CD8+AT2R+ T Cell Population in Response to Ischemic Heart Injury</span></div><div class="casAuthors">Curato, Caterina; Slavic, Svetlana; Dong, Jun; Skorska, Anna; Altarche-Xifro, Wassim; Miteva, Kapka; Kaschina, Elena; Thiel, Andreas; Imboden, Hans; Wang, Jianan; Steckelings, Ulrike; Steinhoff, Gustav; Unger, Thomas; Li, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6286-6293</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Emerging evidence suggests a cardioprotective role of the angiotensin AT2R, albeit the underlying cellular mechanisms are not well understood.  We aimed in this article to elucidate a potential role of cardiac angiotensin AT2R in regulating cellular immune response to ischemic heart injury.  Seven days after myocardial infarction in rats, double-immunofluorescence staining showed that AT2R was detected in a fraction of CD8+ T cells infiltrating in the peri-infarct myocardium.  We developed a method that allowed the isolation of myocardial infiltrating CD8+AT2R+ T cells using modified MACS, and further characterization and purifn. with flow cytometry.  Although the CD8+AT2R- T cells exhibited potent cytotoxicity to both adult and fetal cardiomyocytes (CMs), the CD8+AT2R+ T cells were noncytotoxic to these CMs.  The CD8+AT2R+ T cells were characterized by upregulated IL-10 and downregulated IL-2 and INF-γ expression when compared with CD8+AT2R- T cells.  We further showed that IL-10 gene expression was enhanced in CD8+ T cells on in vitro AT2R stimulation.  Importantly, in vivo AT2R activation engendered an increment of CD8+AT2R+ T cells and IL-10 prodn. in the ischemic myocardium.  In addn., intramyocardial transplantation of CD8+AT2R+ T cells (vs. CD8+AT2R-) led to reduced ischemic heart injury.  Moreover, the CD8+AT2R+ T cell population was also demonstrated in human peripheral blood.  Thus, we have defined the cardioprotective CD8+AT2R+ T cell population, which increases during ischemic heart injury and contributes to maintaining CM viability and providing IL-10, hence revealing an AT2R-mediated cellular mechanism in modulating adaptive immune response in the heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdJEWH0cF9s7Vg90H21EOLACvtfcHk0lhskP11_5f6uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlOhsbnE&md5=76935cde3daf859a59a36d50e7c86131</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0903681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0903681%26sid%3Dliteratum%253Aachs%26aulast%3DCurato%26aufirst%3DC.%26aulast%3DSlavic%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DSkorska%26aufirst%3DA.%26aulast%3DAltarche-Xifr%25C3%25B3%26aufirst%3DW.%26aulast%3DMiteva%26aufirst%3DK.%26aulast%3DKaschina%26aufirst%3DE.%26aulast%3DThiel%26aufirst%3DA.%26aulast%3DImboden%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSteckelings%26aufirst%3DU.%26aulast%3DSteinhoff%26aufirst%3DG.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520noncytotoxic%2520and%2520IL-10%25E2%2580%2593producing%2520CD8%252BAT2R%252B%2520T%2520cell%2520population%2520in%2520response%2520to%2520ischemic%2520heart%2520injury%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D185%26spage%3D6286%26epage%3D6293%26doi%3D10.4049%2Fjimmunol.0903681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathinasabapathy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espejo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oswalt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raizada, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumners, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katovich, M. J.</span></span> <span> </span><span class="NLM_article-title">Selective activation of angiotensin AT<sub>2</sub> receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">2219</span>– <span class="NLM_lpage">2231</span>, <span class="refDoi"> DOI: 10.1111/bph.13044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2Fbph.13044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25522140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVentrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=2219-2231&author=E.+Bruceauthor=V.+Shenoyauthor=A.+Rathinasabapathyauthor=A.+Espejoauthor=A.+Horowitzauthor=A.+Oswaltauthor=J.+Francisauthor=A.+Nairauthor=T.+Ungerauthor=M.+K.+Raizadaauthor=U.+M.+Steckelingsauthor=C.+Sumnersauthor=M.+J.+Katovich&title=Selective+activation+of+angiotensin+AT2+receptors+attenuates+progression+of+pulmonary+hypertension+and+inhibits+cardiopulmonary+fibrosis&doi=10.1111%2Fbph.13044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis</span></div><div class="casAuthors">Bruce, E.; Shenoy, V.; Rathinasabapathy, A.; Espejo, A.; Horowitz, A.; Oswalt, A.; Francis, J.; Nair, A.; Unger, T.; Raizada, M. K.; Steckelings, U. M.; Sumners, C.; Katovich, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2219-2231</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Pulmonary hypertension (PH) is a devastating disease characterized by increased pulmonary arterial pressure, which progressively leads to right-heart failure and death.  A dys-regulated renin angiotensin system (RAS) has been implicated in the development and progression of PH.  However, the role of the angiotensin AT2 receptor in PH has not been fully elucidated.  We have taken advantage of a recently identified non-peptide AT2 receptor agonist, Compd. 21 (C21), to investigate its effects on the well-established monocrotaline (MCT) rat model of PH.  Exptl. Approach : A single s.c. injection of MCT (50 mg·kg-1) was used to induce PH in 8-wk-old male Sprague Dawley rats.  After 2 wk of MCT administration, a subset of animals began receiving either 0.03 mg·kg-1 C21, 3 mg·kg-1 PD-123319 or 0.5 mg·kg-1 A779 for an addnl. 2 wk, after which right ventricular haemodynamic parameters were measured and tissues were collected for gene expression and histol. analyses.  Key Results : Initiation of C21 treatment significantly attenuated much of the pathophysiol. assocd. with MCT-induced PH.  Most notably, C21 reversed pulmonary fibrosis and prevented right ventricular fibrosis.  These beneficial effects were assocd. with improvement in right heart function, decreased pulmonary vessel wall thickness, reduced pro-inflammatory cytokines and favorable modulation of the lung RAS.  Conversely, co-administration of the AT2 receptor antagonist, PD-123319, or the Mas antagonist, A779, abolished the protective actions of C21.  Conclusions and Implications : Taken together, our results suggest that the AT2 receptor agonist, C21, may hold promise for patients with PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJWqeNKOlr-7Vg90H21EOLACvtfcHk0lgKm1vKlnRnng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVentrbN&md5=18540b3c5040756c43d8fb60a5dcf35f</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1111%2Fbph.13044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13044%26sid%3Dliteratum%253Aachs%26aulast%3DBruce%26aufirst%3DE.%26aulast%3DShenoy%26aufirst%3DV.%26aulast%3DRathinasabapathy%26aufirst%3DA.%26aulast%3DEspejo%26aufirst%3DA.%26aulast%3DHorowitz%26aufirst%3DA.%26aulast%3DOswalt%26aufirst%3DA.%26aulast%3DFrancis%26aufirst%3DJ.%26aulast%3DNair%26aufirst%3DA.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DRaizada%26aufirst%3DM.%2BK.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DSumners%26aufirst%3DC.%26aulast%3DKatovich%26aufirst%3DM.%2BJ.%26atitle%3DSelective%2520activation%2520of%2520angiotensin%2520AT2%2520receptors%2520attenuates%2520progression%2520of%2520pulmonary%2520hypertension%2520and%2520inhibits%2520cardiopulmonary%2520fibrosis%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D2219%26epage%3D2231%26doi%3D10.1111%2Fbph.13044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namsolleck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlöf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">Non-peptide AT2-receptor agonists</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2010.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.coph.2010.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=21167778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFymsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=187-192&author=U.+M.+Steckelingsauthor=M.+Larhedauthor=A.+Hallbergauthor=R.+E.+Widdopauthor=E.+S.+Jonesauthor=C.+Wallinderauthor=P.+Namsolleckauthor=B.+Dahl%C3%B6fauthor=T.+Unger&title=Non-peptide+AT2-receptor+agonists&doi=10.1016%2Fj.coph.2010.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Non-peptide AT2-receptor agonists</span></div><div class="casAuthors">Steckelings, U. Muscha; Larhed, Mats; Hallberg, Anders; Widdop, Robert E.; Jones, Emma S.; Wallinder, Charlotta; Namsolleck, Pawel; Dahloef, Bjoern; Unger, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-192</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The renin-angiotensin-system harbours two main receptor subtypes binding angiotensin II which are the AT1-receptor and the AT2-receptor.  While the AT1-receptor has been a drug target in cardiovascular disease for many years, the AT2-receptor was only a subject of academic interest.  This has changed with the design and synthesis of a first non-peptide, orally active AT2-receptor agonist, compd. 21 (C21).  First data using C21 revealed tissue protective effects and functional improvement after myocardial infarction and in hypertension-induced end organ damage, notably in a blood-pressure independent way.  In all of these models, AT2-receptor mediated anti-inflammation seemed an important underlying mechanism.  C21 is awaited to enter a phase I clin. study in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI57AJFDrpYLVg90H21EOLACvtfcHk0lgKm1vKlnRnng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFymsLg%253D&md5=6134dd4d3aa5e97993939bd4cf4d7bc7</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2010.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2010.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DLarhed%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DJones%26aufirst%3DE.%2BS.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DNamsolleck%26aufirst%3DP.%26aulast%3DDahl%25C3%25B6f%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DNon-peptide%2520AT2-receptor%2520agonists%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D187%26epage%3D192%26doi%3D10.1016%2Fj.coph.2010.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moudgil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musat-Marcu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jugdutt, B. I.</span></span> <span> </span><span class="NLM_article-title">Increased AT(2)R protein expression but not increased apoptosis during cardioprotection induced by AT(1)R blockade</span>. <i>Can. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12420045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt12htLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=1107-1116&author=R.+Moudgilauthor=S.+Musat-Marcuauthor=Y.+Xuauthor=D.+Kumarauthor=B.+I.+Jugdutt&title=Increased+AT%282%29R+protein+expression+but+not+increased+apoptosis+during+cardioprotection+induced+by+AT%281%29R+blockade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade</span></div><div class="casAuthors">Moudgil, Rohit; Musat-Marcu, Sorin; Xu, Yi; Kumar, Dinender; Jugdutt, Bodh I.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Cardiology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1107-1116</span>CODEN:
                <span class="NLM_cas:coden">CJCAEX</span>;
        ISSN:<span class="NLM_cas:issn">0828-282X</span>.
    
            (<span class="NLM_cas:orgname">Pulsus Group</span>)
        </div><div class="casAbstract">The angiotensin II type 2 receptor (AT2R) is considered to be antigrowth and to mediate apoptosis in several cell types.  Whether AT2R upregulation, assocd. with angiotensin II type 1 receptor (AT1R) blockade and cardioprotection after ischemia-reperfusion (IR), might not result in increased cardiomyocyte (CM) apoptosis has not been documented.  To det. whether increased AT2R protein expression, during AT1R blockade after acute IR, is assocd. with no increase in CM apoptosis.  The recovery of left ventricular (LV) mech. function after acute IR (30 min of ischemia, 40 min of reperfusion) was measured in isolated Langendorff rat hearts following pretreatment with the AT1R antagonist candesartan (CN) (CN 10 nmol/L) for 40 min before ischemia.  The authors established with an initial dose-response curve using escalating concns. of CN that 10 nmol/L abrogated vasoconstriction induced by angiotensin II (0.1 μmol/L).  AT1R and AT2R protein expression (Western immunoblot), CM apoptosis (terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick end-labeling assay and nuclear morphol.) and apoptotic markers (Bax, Bcl-2, caspase-3, p53) were assessed in LV tissue.  Compared with IR controls, CN improved peak systolic pressure, LV developed pressure and pos. dp/dt, and increased AT2R (not AT1R) protein, but did not change the level of apoptosis or the expression of Bax, Bcl-2, caspase-3 or p53.  CN also increased AT2R protein after ischemia alone but did not change CM apoptosis or expression of the markers.  Increased AT2R protein expression during AT1R blockade after IR in the isolated Langendorff rat heart is assocd. with cardioprotection but no increase in CM apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpip-YLtsjh_7Vg90H21EOLACvtfcHk0liDhxD2TcYsUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt12htLk%253D&md5=38719fd04fb61e48fdf44122aa8491d7</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoudgil%26aufirst%3DR.%26aulast%3DMusat-Marcu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DJugdutt%26aufirst%3DB.%2BI.%26atitle%3DIncreased%2520AT%25282%2529R%2520protein%2520expression%2520but%2520not%2520increased%2520apoptosis%2520during%2520cardioprotection%2520induced%2520by%2520AT%25281%2529R%2520blockade%26jtitle%3DCan.%2520J.%2520Cardiol.%26date%3D2002%26volume%3D18%26spage%3D1107%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulakat, L.</span></span> <span> </span><span class="NLM_article-title">Identification of the region of AT2 receptor needed for inhibition of the AT1 receptor-mediated inositol 1,4,5-triphosphate generation</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(02)03713-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0014-5793%2802%2903713-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12482596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlCqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2002&pages=379-386&author=V.+Kumarauthor=D.+Knowleauthor=N.+Gaviniauthor=L.+Pulakat&title=Identification+of+the+region+of+AT2+receptor+needed+for+inhibition+of+the+AT1+receptor-mediated+inositol+1%2C4%2C5-triphosphate+generation&doi=10.1016%2FS0014-5793%2802%2903713-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the region of AT2 receptor needed for inhibition of the AT1 receptor-mediated inositol 1,4,5-triphosphate generation</span></div><div class="casAuthors">Kumar, Vikas; Knowle, Dieter; Gavini, Narasaiah; Pulakat, Lakshmidevi</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">379-386</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Increase in the intracellular inositol triphosphate (IP3) levels in Xenopus oocytes in response to expression and activation of rat angiotensin II (Ang II) receptor AT1 was inhibited by co-expression of rat AT2 receptor.  To identify which region of the AT2 was involved in this inhibition, ability of three AT2 mutants to abolish this inhibition was analyzed.  Deletion of the C-terminus of the AT2 did not abolish this inhibition.  Replacing Ile249 in the third intracellular loop (3rd ICL) of the AT2 with proline, corresponding amino acid in the AT1, in the mutant M6, resulted in slightly reduced affinity to [125I]Ang II (Kd=0.259 nM), however, did not abolish the inhibition.  In contrast, replacing eight more amino acids in the 3rd ICL of the AT2 (at positions 241-244, 250-251 and 255-256) with that of the AT1 in the mutant M8, not only increased the affinity of the AT2 receptor to [125I]Ang II (Kd=0.038 nM) but also abolished AT2-mediated inhibition.  Interestingly, activation of the M8 by Ang II binding also resulted in increase in the intracellular IP3 levels in oocytes.  These results imply that the region of the 3rd ICL of AT2 spanning amino acids 241-256 is sufficient for the AT2-mediated inhibition of AT1-stimulated IP3 generation.  Moreover, these nine mutations are also sufficient to render the AT2 with the ability to activate phospholipase C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwjQTZUkVyq7Vg90H21EOLACvtfcHk0liDhxD2TcYsUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlCqtbw%253D&md5=12beb8c7c58fa1058ad4e04f87b6ea8d</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2802%2903713-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252802%252903713-4%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DKnowle%26aufirst%3DD.%26aulast%3DGavini%26aufirst%3DN.%26aulast%3DPulakat%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520the%2520region%2520of%2520AT2%2520receptor%2520needed%2520for%2520inhibition%2520of%2520the%2520AT1%2520receptor-mediated%2520inositol%25201%252C4%252C5-triphosphate%2520generation%26jtitle%3DFEBS%2520Lett.%26date%3D2002%26volume%3D532%26spage%3D379%26epage%3D386%26doi%3D10.1016%2FS0014-5793%2802%2903713-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shesely, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhaleb, N.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-P.</span></span> <span> </span><span class="NLM_article-title">Effects of cardiac overexpression of the angiotensin II type 2 receptor on remodeling and dysfunction in mice post-myocardial infarction</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.114.03247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.114.03247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24732892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Kqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2014&pages=1251-1259&author=J.+Xuauthor=Y.+Sunauthor=O.+A.+Carreteroauthor=L.+Zhuauthor=P.+Hardingauthor=E.+G.+Sheselyauthor=X.+Daiauthor=N.-E.+Rhalebauthor=E.+Petersonauthor=X.-P.+Yang&title=Effects+of+cardiac+overexpression+of+the+angiotensin+II+type+2+receptor+on+remodeling+and+dysfunction+in+mice+post-myocardial+infarction&doi=10.1161%2FHYPERTENSIONAHA.114.03247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Cardiac Overexpression of the Angiotensin II Type 2 Receptor on Remodeling and Dysfunction in Mice Post-Myocardial Infarction</span></div><div class="casAuthors">Xu, Jiang; Sun, Ying; Carretero, Oscar A.; Zhu, Liping; Harding, Pamela; Shesely, Edward G.; Dai, Xiangguo; Rhaleb, Nour-Eddine; Peterson, Edward; Yang, Xiao-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1251-1259</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The activation of angiotensin II type 2 receptor (AT2R) has been considered cardioprotective.  However, there are controversial findings regarding the role of overexpressing AT2R in the heart.  Using transgenic mice with different levels of AT2R gene overexpression in the heart (1, 4, or 9 copies of the AT2R transgene: Tg, Tg, or Tg), we studied the effect of AT2R overexpression on left ventricular remodeling and dysfunction post-myocardial infarction (MI).  Tg, Tg, Tg, and their wild-type littermates were divided into (1) sham MI, (2) MI plus vehicle, and (3) MI plus AT2R antagonist.  Treatments were started 4 wk after MI and continued for 8 wk.  AT2R protein and mRNA expression in the heart was significantly increased in transgenic mice, and the increase pos. correlated with copies of the transgene.  AT1R protein and mRNA expression remained unchanged in Tg and Tg but slightly increased in Tg mice.  Systolic blood pressure and cardiac phenotypes did not differ among strains under basal conditions.  MI caused myocardial hypertrophy, interstitial fibrosis, ventricular dilatation, and dysfunction assocd. with increased protein expression of Nox2 and transforming growth factor β1.  These pathol. responses were diminished in Tg and Tg mice.  Moreover, the protective effects of AT2R were abolished by AT2R antagonist and also absent in Tg mice.  We thus conclude that whether overexpression of AT2R is beneficial or detrimental to the heart is largely dependent on expression levels and possibly via regulations of Nox2 and transforming growth factor β1 signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7ORJ7CYzkebVg90H21EOLACvtfcHk0ljxre43SIm_Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Kqs74%253D&md5=f7522d78a65fb30ca9e65f8aa9d0d29b</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.114.03247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.114.03247%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DCarretero%26aufirst%3DO.%2BA.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DHarding%26aufirst%3DP.%26aulast%3DShesely%26aufirst%3DE.%2BG.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DRhaleb%26aufirst%3DN.-E.%26aulast%3DPeterson%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DX.-P.%26atitle%3DEffects%2520of%2520cardiac%2520overexpression%2520of%2520the%2520angiotensin%2520II%2520type%25202%2520receptor%2520on%2520remodeling%2520and%2520dysfunction%2520in%2520mice%2520post-myocardial%2520infarction%26jtitle%3DHypertension%26date%3D2014%26volume%3D63%26spage%3D1251%26epage%3D1259%26doi%3D10.1161%2FHYPERTENSIONAHA.114.03247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannan, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, T. A.</span></span> <span> </span><span class="NLM_article-title">Angiotensin AT2 receptors: cardiovascular: hope or hype?</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">824</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0705448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fsj.bjp.0705448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=14530223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1eksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2003&pages=809-824&author=R.+E.+Widdopauthor=E.+S.+Jonesauthor=R.+E.+Hannanauthor=T.+A.+Gaspari&title=Angiotensin+AT2+receptors%3A+cardiovascular%3A+hope+or+hype%3F&doi=10.1038%2Fsj.bjp.0705448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin AT2 receptors: Cardiovascular hope or hype?</span></div><div class="casAuthors">Widdop, Robert E.; Jones, Emma S.; Hannan, Ruth E.; Gaspari, Tracey A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">809-824</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review is given on the pharmacol. and pathophysiol. role of angiotensin AT2 receptors.  The authors describe anatomical distribution, signaling pathways, angiotensin AT2 receptor-mediated relaxation/vasodilatation, structural effects mediated by angiotensin AT2 receptors, and the role of angiotensin AT2 receptors in cardiovascular action of angiotensin AT1 receptor blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAh_C4WE_cbLVg90H21EOLACvtfcHk0ljxre43SIm_Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1eksrw%253D&md5=0ceb805540aaf7d91a17d45cbfae41e9</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705448%26sid%3Dliteratum%253Aachs%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DJones%26aufirst%3DE.%2BS.%26aulast%3DHannan%26aufirst%3DR.%2BE.%26aulast%3DGaspari%26aufirst%3DT.%2BA.%26atitle%3DAngiotensin%2520AT2%2520receptors%253A%2520cardiovascular%253A%2520hope%2520or%2520hype%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D140%26spage%3D809%26epage%3D824%26doi%3D10.1038%2Fsj.bjp.0705448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">AT2 receptors: functional relevance in cardiovascular disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2008.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.pharmthera.2008.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=18804122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2008&pages=292-316&author=E.+S.+Jonesauthor=A.+Vinhauthor=C.+A.+McCarthyauthor=T.+A.+Gaspariauthor=R.+E.+Widdop&title=AT2+receptors%3A+functional+relevance+in+cardiovascular+disease&doi=10.1016%2Fj.pharmthera.2008.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">AT2 receptors: Functional relevance in cardiovascular disease</span></div><div class="casAuthors">Jones, Emma S.; Vinh, Antony; McCarthy, Claudia A.; Gaspari, Tracey A.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-316</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The renin angiotensin system (RAS) is intricately involved in normal cardiovascular homeostasis.  Excessive stimulation by the octapeptide angiotensin II contributes to a range of cardiovascular pathologies and diseases via angiotensin type 1 receptor (AT1R) activation.  On the other hand, the angiotensin type 2 receptor (AT2R) is thought to counter-regulate AT1R function.  In this review, we describe the enhanced expression and function of AT2R in various cardiovascular disease settings.  In addn., we illustrate that the RAS consists of a family of angiotensin peptides that exert cardiovascular effects that are often distinct from those of Ang II.  During cardiovascular disease, there is likely to be an increased functional importance of AT2R, stimulated by Ang II, or even shorter angiotensin peptide fragments, to limit AT1R-mediated overactivity and cardiovascular pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1mCsfGWYR07Vg90H21EOLACvtfcHk0liP6tih-IlI2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsL7N&md5=5ba08b8428ce0bad39a8f3df3eea768d</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2008.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2008.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DE.%2BS.%26aulast%3DVinh%26aufirst%3DA.%26aulast%3DMcCarthy%26aufirst%3DC.%2BA.%26aulast%3DGaspari%26aufirst%3DT.%2BA.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DAT2%2520receptors%253A%2520functional%2520relevance%2520in%2520cardiovascular%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2008%26volume%3D120%26spage%3D292%26epage%3D316%26doi%3D10.1016%2Fj.pharmthera.2008.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">The regenerative potential of angiotensin AT2 receptor in cardiac repair</span>. <i>Can. J. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1139/y11-108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1139%2Fy11-108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22364522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlCktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2012&pages=287-293&author=M.+Ludwigauthor=G.+Steinhoffauthor=J.+Li&title=The+regenerative+potential+of+angiotensin+AT2+receptor+in+cardiac+repair&doi=10.1139%2Fy11-108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">The regenerative potential of angiotensin AT2 receptor in cardiac repair</span></div><div class="casAuthors">Ludwig, Marion; Steinhoff, Gustav; Li, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-293</span>CODEN:
                <span class="NLM_cas:coden">CJPPA3</span>;
        ISSN:<span class="NLM_cas:issn">0008-4212</span>.
    
            (<span class="NLM_cas:orgname">Canadian Science Publishing</span>)
        </div><div class="casAbstract">A review.  Angiotensin II, the main effector peptide of the renin-angiotensin system, interferes with cardiac remodeling and repair through its receptors, including AT1 and AT2 receptor (R).  The functional relevance of the previously neglected AT2R is currently intensively studied.  Pharmacol. therapies with AT1R blockers have improved outcomes in patients with ischemic heart injury, probably involving an indirect stimulation of AT2R.  Previous exptl. studies have clearly shown a protective action of AT2R in tissue repair and regeneration.  We have recently identified the c-kit+AT2R+ progenitor cell population in rat heart and bone marrow, which increases after induction of myocardial infarction.  Further exptl. evidence demonstrates that AT2R mediates cardiac homing and repair process of the c-kit+ progenitor cells.  AT2R stimulation through AT1R blockers or directly by AT2R agonist or both in combination may potentially offer the translational options to improve the regenerative potentials of stem/progenitor cells derived from patients with cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorRPtiDwP_4LVg90H21EOLACvtfcHk0liP6tih-IlI2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlCktr0%253D&md5=0b35422e2c3b6826477b590a34b2524b</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1139%2Fy11-108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fy11-108%26sid%3Dliteratum%253Aachs%26aulast%3DLudwig%26aufirst%3DM.%26aulast%3DSteinhoff%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DThe%2520regenerative%2520potential%2520of%2520angiotensin%2520AT2%2520receptor%2520in%2520cardiac%2520repair%26jtitle%3DCan.%2520J.%2520Physiol.%2520Pharmacol.%26date%3D2012%26volume%3D90%26spage%3D287%26epage%3D293%26doi%3D10.1139%2Fy11-108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saku, K.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2009.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bbrc.2009.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19896468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFSi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2010&pages=85-90&author=S.+Miuraauthor=Y.+Matsuoauthor=Y.+Kiyaauthor=S.+S.+Karnikauthor=K.+Saku&title=Molecular+mechanisms+of+the+antagonistic+action+between+AT1+and+AT2+receptors&doi=10.1016%2Fj.bbrc.2009.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors</span></div><div class="casAuthors">Miura, Shin-ichiro; Matsuo, Yoshino; Kiya, Yoshihiro; Karnik, Sadashiva S.; Saku, Keijiro</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-90</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Although angiotensin II (Ang II) binds to Ang II type 1 (AT1) and type 2 (AT2) receptors, AT1 and AT2 receptors have antagonistic actions with regard to cell signaling.  The mol. mechanisms that underlie this antagonism are not well understood.  We examd. AT1 and AT2 receptor-induced signal cross-talk in the cytoplasm and the importance of the hetero-dimerization of AT1 receptor with AT2 receptor on the cell surface.  AT1 and AT2 receptors showed antagonistic effects toward inositol phosphate prodn.  AT1 receptors mainly formed homo-dimers, rather than hetero-dimers with AT2 receptor, on the cell surface as detd. by immunopptn., and subsequently induced cell signals.  AT2 receptor mainly formed homo-dimers, rather than hetero-dimers with AT1 receptor, on the cell surface.  The expression levels of homo-dimerized AT1 receptor or AT2 receptor on the cell surface did not change after treatment with Ang II, the AT1 receptor antagonist telmisartan or the AT2 receptor antagonist PD 123319.  Finally, AT1 and AT2 receptor-induced signals antagonized phospholipase C-β3 phosphorylation.  In conclusion, Ang II-induced AT1 receptor signals may be mainly blocked by AT2 receptor signals through their neg. cross-talk in the cytoplasm rather than by the hetero-dimerization of both receptors on the cell surface.  The proper balance of the expression levels of AT1 and AT2 receptors might be crit. for the antagonistic action between these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMnbObAVyCn7Vg90H21EOLACvtfcHk0lg5sk9QDACOJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFSi&md5=ec8dea407037f02e6ad86c8dae4bee50</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2009.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2009.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DMatsuo%26aufirst%3DY.%26aulast%3DKiya%26aufirst%3DY.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26aulast%3DSaku%26aufirst%3DK.%26atitle%3DMolecular%2520mechanisms%2520of%2520the%2520antagonistic%2520action%2520between%2520AT1%2520and%2520AT2%2520receptors%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2010%26volume%3D391%26spage%3D85%26epage%3D90%26doi%3D10.1016%2Fj.bbrc.2009.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benessiano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrion, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duriez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poitevin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, J. L.</span></span> <span> </span><span class="NLM_article-title">Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1172/JCI118807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1172%2FJCI118807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=8755652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK28XksFCltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1996&pages=418-425&author=B.+I.+Levyauthor=J.+Benessianoauthor=D.+Henrionauthor=L.+Caputoauthor=C.+Heymesauthor=M.+Duriezauthor=P.+Poitevinauthor=J.+L.+Samuel&title=Chronic+blockade+of+AT2-subtype+receptors+prevents+the+effect+of+angiotensin+II+on+the+rat+vascular+structure&doi=10.1172%2FJCI118807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure</span></div><div class="casAuthors">Levy, Bernard I.; Benessiano, Joelle; Henrion, Daniel; Caputo, Lidia; Heymes, Christophe; Duriez, Micheline; Poitevin, Pierre; Samuel, Jane Lise</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-425</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II) is both a vasoactive and a potent growth-promoting factor for vascular smooth muscle cells.  Little is known about the in vivo contribution of AT1 and AT2 receptor activation to the biol. action of Ang II.  Therefore, we investigated the effect of AT1 or AT2 subtype receptor chronic blockade by losartan or PD 123319 on the vascular hypertrophy in rats with Ang II-induced hypertension.  Normotensive rats received for 3 wk s.c. infusions of Ang II (120 ng/kg per min), or Ang II + PD 123319 (30 mg/kg per d), or Ang II + losartan (10 mg/kg per d) or PD 123319 alone, and were compared with control animals.  In normotensive animals, chronic blockade of AT2 receptors did not affect the plasma level of angiotensin II and the vascular reactivity to angiotensin II mediated by the AT1 receptor.  Chronic blockade of AT1 in rats receiving Ang II resulted in normal arterial pressure, but it induced significant aortic hypertrophy and fibrosis.  Chronic blockade of AT2 receptors in Ang II-induced hypertensive rats had no effect on arterial pressure, but antagonized the effect of Ang II on arterial hypertrophy and fibrosis, suggesting that in vivo vasotrophic effects of Ang II are at least partially mediated via AT2 subtype receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm9-du4uXMvrVg90H21EOLACvtfcHk0lg5sk9QDACOJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFCltr4%253D&md5=a94ce425856b8a0d71e222cd19349787</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1172%2FJCI118807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI118807%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DB.%2BI.%26aulast%3DBenessiano%26aufirst%3DJ.%26aulast%3DHenrion%26aufirst%3DD.%26aulast%3DCaputo%26aufirst%3DL.%26aulast%3DHeymes%26aufirst%3DC.%26aulast%3DDuriez%26aufirst%3DM.%26aulast%3DPoitevin%26aufirst%3DP.%26aulast%3DSamuel%26aufirst%3DJ.%2BL.%26atitle%3DChronic%2520blockade%2520of%2520AT2-subtype%2520receptors%2520prevents%2520the%2520effect%2520of%2520angiotensin%2520II%2520on%2520the%2520rat%2520vascular%2520structure%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1996%26volume%3D98%26spage%3D418%26epage%3D425%26doi%3D10.1172%2FJCI118807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benndorf, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch-Hoffmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwedhelm, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cieslar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Haupt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Schwesinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaiss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmchen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehmke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böger, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, U. O.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1038/ki.2009.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fki.2009.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19212419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlt1Sltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2009&pages=1039-1049&author=R.+A.+Benndorfauthor=C.+Krebsauthor=B.+Hirsch-Hoffmannauthor=E.+Schwedhelmauthor=G.+Cieslarauthor=R.+Schmidt-Hauptauthor=O.+M.+Steinmetzauthor=C.+Meyer-Schwesingerauthor=F.+Thaissauthor=M.+Haddadauthor=S.+Fehrauthor=A.+Heilmannauthor=U.+Helmchenauthor=L.+Heinauthor=H.+Ehmkeauthor=R.+A.+Stahlauthor=R.+H.+B%C3%B6gerauthor=U.+O.+Wenzel&title=Angiotensin+II+type+2+receptor+deficiency+aggravates+renal+injury+and+reduces+survival+in+chronic+kidney+disease+in+mice&doi=10.1038%2Fki.2009.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice</span></div><div class="casAuthors">Benndorf, Ralf A.; Krebs, Christian; Hirsch-Hoffmann, Birgit; Schwedhelm, Edzard; Cieslar, Gabriele; Schmidt-Haupt, Robin; Steinmetz, Oliver M.; Meyer-Schwesinger, Catherine; Thaiss, Friedrich; Haddad, Munif; Fehr, Susanne; Heilmann, Andreas; Helmchen, Udo; Hein, Lutz; Ehmke, Heimo; Stahl, Rolf A.; Boeger, Rainer H.; Wenzel, Ulrich O.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1039-1049</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II) activates at least two receptors, AT1 and AT2, with the majority of its effects-such as vasoconstriction, inflammation, and matrix deposition-mediated by the AT1 receptor.  It is thought that the AT2 receptor counteracts these processes; however, recent studies have found proinflammatory and hypertrophic effects of this receptor subtype.  To identify the physiol. roles of the AT2 receptor in chronic kidney disease, we performed renal ablation in AT2 receptor knockout and wild-type mice.  Renal injury caused a greater impairment of renal function, glomerular injury, albuminuria, and mortality in the knockout mice than in the wild-type mice.  There was increased fibronectin expression and inflammation in the knockout mice, as shown by augmented monocyte/macrophage infiltration and higher chemokine monocyte chemotactic protein-1 (MCP-1) and RANTES expression in the remnant kidney.  The higher mortality and renal morbidity of the knockout mice was not due to differences in systemic blood pressure, glomerular vol., AT1 receptor, renin, or endothelial nitric oxide synthase expression.  Whether activation of the AT2 receptor will have therapeutic benefit in chronic kidney disease will require further study.  Kidney International (2009) 75, 1039-1049; doi:10.1038/ki.2009.2; published online 11 Feb. 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOjqjoqy37FLVg90H21EOLACvtfcHk0lgg0iHJlo8K3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlt1Sltbc%253D&md5=94b41c37e45555d4c11f8748f1a02d66</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fki.2009.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2009.2%26sid%3Dliteratum%253Aachs%26aulast%3DBenndorf%26aufirst%3DR.%2BA.%26aulast%3DKrebs%26aufirst%3DC.%26aulast%3DHirsch-Hoffmann%26aufirst%3DB.%26aulast%3DSchwedhelm%26aufirst%3DE.%26aulast%3DCieslar%26aufirst%3DG.%26aulast%3DSchmidt-Haupt%26aufirst%3DR.%26aulast%3DSteinmetz%26aufirst%3DO.%2BM.%26aulast%3DMeyer-Schwesinger%26aufirst%3DC.%26aulast%3DThaiss%26aufirst%3DF.%26aulast%3DHaddad%26aufirst%3DM.%26aulast%3DFehr%26aufirst%3DS.%26aulast%3DHeilmann%26aufirst%3DA.%26aulast%3DHelmchen%26aufirst%3DU.%26aulast%3DHein%26aufirst%3DL.%26aulast%3DEhmke%26aufirst%3DH.%26aulast%3DStahl%26aufirst%3DR.%2BA.%26aulast%3DB%25C3%25B6ger%26aufirst%3DR.%2BH.%26aulast%3DWenzel%26aufirst%3DU.%2BO.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor%2520deficiency%2520aggravates%2520renal%2520injury%2520and%2520reduces%2520survival%2520in%2520chronic%2520kidney%2520disease%2520in%2520mice%26jtitle%3DKidney%2520Int.%26date%3D2009%26volume%3D75%26spage%3D1039%26epage%3D1049%26doi%3D10.1038%2Fki.2009.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padia, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R. M.</span></span> <span> </span><span class="NLM_article-title">AT2 receptor activation induces natriuresis and lowers blood pressure</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.115.304110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FCIRCRESAHA.115.304110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24903104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOlt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2014&pages=388-399&author=B.+A.+Kempauthor=N.+L.+Howellauthor=J.+J.+Gildeaauthor=S.+R.+Kellerauthor=S.+H.+Padiaauthor=R.+M.+Carey&title=AT2+receptor+activation+induces+natriuresis+and+lowers+blood+pressure&doi=10.1161%2FCIRCRESAHA.115.304110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">AT2 Receptor Activation Induces Natriuresis and Lowers Blood Pressure</span></div><div class="casAuthors">Kemp, Brandon A.; Howell, Nancy L.; Gildea, John J.; Keller, Susanna R.; Padia, Shetal H.; Carey, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">388-399</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: Compd. 21 (C-21) is a highly selective nonpeptide AT2 receptor (AT2R) agonist.  Objective: To test the hypothesis that renal proximal tubule AT2Rs induce natriuresis and lower blood pressure in Sprague-Dawley rats and mice.  Methods and results: In rats, AT2R activation with i.v. C-21 increased urinary sodium excretion by 10-fold (P<0.0001); this natriuresis was abolished by direct renal interstitial infusion of specific AT2R antagonist PD-123319.  C-21 increased fractional excretion of Na (P<0.05) and lithium (P<0.01) without altering renal hemodynamic function.  AT2R activation increased renal proximal tubule cell apical membrane AT2R protein (P<0.001) without changing total AT2R expression and internalized/inactivated Na-H exchanger-3 and Na/KATPase.  C-21-induced natriuresis was accompanied by an increase in renal interstitial cGMP (P<0.01); C-21-induced increases in urinary sodium excretion and renal interstitial cGMP were abolished by renal interstitial nitric oxide synthase inhibitor L-N-nitroarginine Me ester or bradykinin B2 receptor antagonist icatibant.  Renal AT2R activation with C-21 prevented Na retention and lowered blood pressure in the angiotensin II infusion model of exptl. hypertension.  Conclusions: AT2R activation initiates its translocation to the renal proximal tubule cell apical membrane and the internalization of Na-H exchanger-3 and Na/KATPase, inducing natriuresis in a bradykinin-nitric oxide-cGMP-dependent manner.  Intrarenal AT2R activation prevents Na retention and lowers blood pressure in angiotensin II-dependent hypertension.  AT2R activation holds promise as a renal proximal tubule natriuretic/diuretic target for the treatment of fluid-retaining states and hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhMcuc8Fsbo7Vg90H21EOLACvtfcHk0lgg0iHJlo8K3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOlt77L&md5=eff0d06d331c7afa584ce27e8900edfb</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.115.304110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.115.304110%26sid%3Dliteratum%253Aachs%26aulast%3DKemp%26aufirst%3DB.%2BA.%26aulast%3DHowell%26aufirst%3DN.%2BL.%26aulast%3DGildea%26aufirst%3DJ.%2BJ.%26aulast%3DKeller%26aufirst%3DS.%2BR.%26aulast%3DPadia%26aufirst%3DS.%2BH.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26atitle%3DAT2%2520receptor%2520activation%2520induces%2520natriuresis%2520and%2520lowers%2520blood%2520pressure%26jtitle%3DCirc.%2520Res.%26date%3D2014%26volume%3D115%26spage%3D388%26epage%3D399%26doi%3D10.1161%2FCIRCRESAHA.115.304110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jose, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor inhibits expression and function of insulin receptor in rat renal proximal tubule cells</span>. <i>J. Am. Soc. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1016/j.jash.2017.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.jash.2017.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29289466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFyktb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=135-145&author=Y.+Yangauthor=C.+Chenauthor=C.+Fuauthor=Z.+Xuauthor=C.+Lanauthor=Y.+Zengauthor=Z.+Chenauthor=P.+A.+Joseauthor=Y.+Zhangauthor=C.+Zeng&title=Angiotensin+II+type+2+receptor+inhibits+expression+and+function+of+insulin+receptor+in+rat+renal+proximal+tubule+cells&doi=10.1016%2Fj.jash.2017.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II type 2 receptor inhibits expression and function of insulin receptor in rat renal proximal tubule cells</span></div><div class="casAuthors">Yang, Yang; Chen, Caiyu; Fu, Chunjiang; Xu, Zaicheng; Lan, Cong; Zeng, Yongchun; Chen, Zhi; Jose, Pedro A.; Zhang, Ye; Zeng, Chunyu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Hypertension</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-145</span>CODEN:
                <span class="NLM_cas:coden">JASHCA</span>;
        ISSN:<span class="NLM_cas:issn">1878-7436</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Both renin-angiotensin systems and insulin participate in kidney-involved blood pressure regulation.  Activation of angiotensin II type 2 receptor (AT2R) decreases sodium reabsorption in renal proximal tubule (RPT) cells, whereas insulin produces the opposite effect.  We presume that AT2R has an inhibitory effect on insulin receptor expression in RPT cells, which may affect renal sodium transport and therefore be of physiol. or pathol. significance.  Our present study found that activation of AT2R inhibited insulin receptor expression in a concn. and time-dependent manner in RPT cells from Wistar-Kyoto (WKY) rats.  In the presence of a protein kinase C (PKC) inhibitor (PKC inhibitor peptide 19-31, 10-6 mol/L) or a phosphatidylinositol 3 kinase inhibitor (wortmannin, 10-6 mol/L), the inhibitory effect of AT2R on insulin receptor was blocked, indicating that both PKC and phosphatidylinositol 3 kinase were involved in the signaling pathway.  There was a linkage between AT2R and insulin receptor which was detd. by both laser confocal microscopy and coimmunopptn.  However, the effect of AT2R activation on insulin receptor expression was different in RPT cells from spontaneously hypertensive rats (SHRs).  Being contrary to the effect in WKY RPT cells, AT2R stimulation increased insulin receptor in SHR RPT cells.  Insulin (10-7 mol/L, 15 min) enhanced Na+-K+-ATPase activity in both WKY and SHR RPT cells.  Pretreatment with CGP42112 decreased the stimulatory effect of insulin on Na+-K+-ATPase activity in WKY RPT cells, whereas pretreatment with CGP42112 increased it in SHR RPT cells.  It is suggested that activation of AT2R inhibits insulin receptor expression and function in RPT cells.  The lost inhibitory effect of AT2R on insulin receptor expression may contribute to the pathophysiol. of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxuYrFY-ZAILVg90H21EOLACvtfcHk0lg1XPANqsRwcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFyktb7P&md5=1143c43065e9b8513c774babfbe22c03</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.jash.2017.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jash.2017.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DFu%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLan%26aufirst%3DC.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJose%26aufirst%3DP.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DC.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor%2520inhibits%2520expression%2520and%2520function%2520of%2520insulin%2520receptor%2520in%2520rat%2520renal%2520proximal%2520tubule%2520cells%26jtitle%3DJ.%2520Am.%2520Soc.%2520Hypertens.%26date%3D2018%26volume%3D12%26spage%3D135%26epage%3D145%26doi%3D10.1016%2Fj.jash.2017.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renziehausen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Nigro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lattanzio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega-Rioja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Carranco, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harwood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szlosarek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proby, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, T.</span></span> <span> </span><span class="NLM_article-title">The Renin Angiotensin System (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2320</span>– <span class="NLM_lpage">2336</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0563-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fs41388-018-0563-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30478450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSqsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=2320-2336&author=A.+Renziehausenauthor=H.+Wangauthor=B.+Raoauthor=L.+Weirauthor=C.+Lo+Nigroauthor=L.+Lattanzioauthor=M.+Merlanoauthor=A.+Vega-Riojaauthor=M.+C.+Fernandez-Carrancoauthor=N.+Hajjiauthor=R.+Matinauthor=C.+Harwoodauthor=S.+Liauthor=V.+R.+Simauthor=K.+O%E2%80%99Neillauthor=A.+Evansauthor=A.+Thompsonauthor=P.+Szlosarekauthor=C.+Flemingauthor=J.+Stebbingauthor=C.+Probyauthor=A.+G.+Tzakosauthor=N.+Syedauthor=T.+Crook&title=The+Renin+Angiotensin+System+%28RAS%29+mediates+bifunctional+growth+regulation+in+melanoma+and+is+a+novel+target+for+therapeutic+intervention&doi=10.1038%2Fs41388-018-0563-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention</span></div><div class="casAuthors">Renziehausen, Alexander; Wang, Hexiao; Rao, Bhavya; Weir, Lynda; Nigro, Cristiana Lo; Lattanzio, Laura; Merlano, Marco; Vega-Rioja, Antonio; del Carmen Fernandez-Carranco, Maria; Hajji, Nabil; Matin, Rubeta; Harwood, Catherine; Li, Su; Sim, Van Ren; O'Neill, Kevin; Evans, Alan; Thompson, Alastair; Szlosarek, Peter; Fleming, Colin; Stebbing, Justin; Proby, Charlotte; Tzakos, Andreas G.; Syed, Nelofer; Crook, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2320-2336</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Despite emergence of new systemic therapies, metastatic melanoma remains a challenging and often fatal form of skin cancer.  The renin-angiotensin system (RAS) is a major physiol. regulatory pathway controlling salt-water equil., intravascular vol. and blood pressure.  Biol. effects of the RAS are mediated by the vasoactive hormone angiotensin II (AngII) via two receptor subtypes, AT1R (encoded by AGTR1) and AT2R (encoded by AGTR2).  We report decreasing expression and increasing CpG island methylation of AGTR1 in metastatic vs. primary melanoma and detection in serum of methylated genomic DNA from the AGTR1 CpG island in metastatic melanoma implying that AGTR1 encodes a tumor suppressor function in melanoma.  Consistent with this hypothesis, antagonism of AT1R using losartan or shRNA-mediated knockdown in melanoma cell lines expressing AGTR1 resulted in acquisition of the ability to proliferate in serum-free conditions.  Conversely, ectopic expression of AGTR1 in cell lines lacking endogenous expression inhibits proliferation irresp. of the presence of AngII implying a ligand-independent suppressor function for AT1R.  Treatment of melanoma cell lines expressing endogenous AT2R with either AngII or the AT2R-selective agonist Y6AII induces proliferation in serum-free conditions whereas the AT2R-specific antagonists PD123319 and EMA401 inhibit melanoma growth and angiogenesis and potentiate inhibitors of BRAF and MEK in cells with BRAF V600 mutations.  Our results demonstrate that the RAS has both oncogenic and tumor suppressor functions in melanoma.  Pharmacol. inhibition of AT2R may provide therapeutic opportunities in melanomas expressing this receptor and AGTR1 CpG island methylation in serum may serve as a novel biomarker of metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocfJXsr7oKIbVg90H21EOLACvtfcHk0lg1XPANqsRwcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSqsbnK&md5=923bbfd8618a30af04c25ba8cb7d82b8</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0563-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0563-y%26sid%3Dliteratum%253Aachs%26aulast%3DRenziehausen%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRao%26aufirst%3DB.%26aulast%3DWeir%26aufirst%3DL.%26aulast%3DLo%2BNigro%26aufirst%3DC.%26aulast%3DLattanzio%26aufirst%3DL.%26aulast%3DMerlano%26aufirst%3DM.%26aulast%3DVega-Rioja%26aufirst%3DA.%26aulast%3DFernandez-Carranco%26aufirst%3DM.%2BC.%26aulast%3DHajji%26aufirst%3DN.%26aulast%3DMatin%26aufirst%3DR.%26aulast%3DHarwood%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DSim%26aufirst%3DV.%2BR.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DK.%26aulast%3DEvans%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DSzlosarek%26aufirst%3DP.%26aulast%3DFleming%26aufirst%3DC.%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DProby%26aufirst%3DC.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26aulast%3DSyed%26aufirst%3DN.%26aulast%3DCrook%26aufirst%3DT.%26atitle%3DThe%2520Renin%2520Angiotensin%2520System%2520%2528RAS%2529%2520mediates%2520bifunctional%2520growth%2520regulation%2520in%2520melanoma%2520and%2520is%2520a%2520novel%2520target%2520for%2520therapeutic%2520intervention%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D2320%26epage%3D2336%26doi%3D10.1038%2Fs41388-018-0563-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mary, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Differential effects of the mitochondria-active tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) and its peptidase-targeted prodrugs in experimental acute kidney injury</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1209</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.01209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffphar.2019.01209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=31780923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BB3MfksFaltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1209&author=J.+C.+Wyssauthor=R.+Kumarauthor=J.+Mikulicauthor=M.+Schneiderauthor=J.+L.+Maryauthor=J.+D.+Aebiauthor=L.+Juillerat-Jeanneretauthor=D.+Golshayan&title=Differential+effects+of+the+mitochondria-active+tetrapeptide+SS-31+%28D-Arg-dimethylTyr-Lys-Phe-NH2%29+and+its+peptidase-targeted+prodrugs+in+experimental+acute+kidney+injury&doi=10.3389%2Ffphar.2019.01209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Effects of the Mitochondria-Active Tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) and Its Peptidase-Targeted Prodrugs in Experimental Acute Kidney Injury</span></div><div class="casAuthors">Wyss Jean-Christophe; Kumar Rajesh; Mikulic Josip; Juillerat-Jeanneret Lucienne; Golshayan Dela; Schneider Manfred; Mary Jean-Luc; Aebi Johannes D; Juillerat-Jeanneret Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1209</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">The mitochondria-active tetrapeptide SS-31 can control oxidative tissue damage in kidney diseases.  To investigate other potential beneficial nephroprotective effects of SS-31, in vivo murine models of acute tubular injury and glomerular damage were developed.  Reduction of acute kidney injury was demonstrated in mice treated with SS-31.  The expression of mRNAs involved in acute inflammatory and oxidative stress responses in the diseased kidneys confirmed that SS-31 could regulate these pathways in our in vivo models.  Furthermore, ex vivo histoenzymography of mouse kidneys showed that aminopeptidase A (APA), the enzyme involved in the processing of angiotensin (Ang) II to Ang III, was induced in the diseased kidneys, and its activity was inhibited by SS-31.  As the renin-angiotensin system (RAS) is a main regulator of kidney functions, the modulation of Ang receptors (ATR) and APA by SS-31 was further investigated using mRNAs extracted from diseased kidneys.  Following acute tubular and/or glomerular damage, the expression of the AT1R mRNA was upregulated, which could be selectively downregulated upon SS-31 administration to the animals.  At the same time, SS-31 was able to increase the expression of the AT2R, which may contribute to limit renal damage.  Consequently, SS-31-based prodrugs were developed as substrates and/or inhibitors for APA and were screened using cells expressing high levels of APA, showing its selective regulation by α-Glu-SS-31.  Thus, a link between SS-31 and the RAS opens new therapeutic implications for SS-31 in kidney diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsJPizEcy1hAHqQV89nF-2fW6udTcc2eZEfg5kGbCt0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfksFaltg%253D%253D&md5=017f0a2adfc05b8937ff5e1a9817d76b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01209%26sid%3Dliteratum%253Aachs%26aulast%3DWyss%26aufirst%3DJ.%2BC.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DMikulic%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DMary%26aufirst%3DJ.%2BL.%26aulast%3DAebi%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DDifferential%2520effects%2520of%2520the%2520mitochondria-active%2520tetrapeptide%2520SS-31%2520%2528D-Arg-dimethylTyr-Lys-Phe-NH2%2529%2520and%2520its%2520peptidase-targeted%2520prodrugs%2520in%2520experimental%2520acute%2520kidney%2520injury%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1209%26doi%3D10.3389%2Ffphar.2019.01209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abadir, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucker, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedarko, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walston, J. D.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of a functional mitochondrial angiotensin system</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">14849</span>– <span class="NLM_lpage">14854</span>, <span class="refDoi"> DOI: 10.1073/pnas.1101507108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1073%2Fpnas.1101507108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=21852574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFyktLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=14849-14854&author=P.+M.+Abadirauthor=D.+B.+Fosterauthor=M.+Crowauthor=C.+A.+Cookeauthor=J.+J.+Ruckerauthor=A.+Jainauthor=B.+J.+Smithauthor=T.+N.+Burksauthor=R.+D.+Cohnauthor=N.+S.+Fedarkoauthor=R.+M.+Careyauthor=B.+O%E2%80%99Rourkeauthor=J.+D.+Walston&title=Identification+and+characterization+of+a+functional+mitochondrial+angiotensin+system&doi=10.1073%2Fpnas.1101507108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization if a functional mitochondrial angiotensin system</span></div><div class="casAuthors">Abadir, Peter M.; Foster, D. Brian; Crow, Michael; Cooke, Carol A.; Rucker, Jasma J.; Jain, Alka; Smith, Barbara J.; Burks, Tyesha N.; Cohn, Ronald D.; Fedarko, Neal S.; Carey, Robert M.; O'Rourke, Brian; Walston, Jeremy D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">14849-14854, S14849/1-S14849/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The renin-angiotensin (Ang) system regulates multiple physiol. functions through Ang II type 1 and type 2 receptors.  Prior studies suggest an intracellular pool of Ang II that may be released in an autocrine manner upon stretch to activate surface membrane Ang receptors.  Alternatively, an intracellular renin-Ang system has been proposed, with a primary focus on nuclear Ang receptors.  A mitochondrial Ang system has not been previously described.  Here we report that functional Ang II type 2 receptors are present on mitochondrial inner membranes and are colocalized with endogenous Ang.  We demonstrate that activation of the mitochondrial Ang system is coupled to mitochondrial nitric oxide prodn. and can modulate respiration.  In addn., we present evidence of age-related changes in mitochondrial Ang receptor expression, i.e., increased mitochondrial Ang II type 1 receptor and decreased type 2 receptor d. that is reversed by chronic treatment with the Ang II type 1 receptor blocker losartan.  The presence of a functional Ang system in human mitochondria provides a foundation for understanding, the interaction between mitochondria and chronic disease states and reveals potential therapeutic targets for optimizing mitochondrial function and decreasing chronic disease burden with aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbLv-W_FnS0bVg90H21EOLACvtfcHk0lhVjQRzOWFm9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFyktLfJ&md5=de6176eab577214fab3c06b6b0149acd</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1101507108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1101507108%26sid%3Dliteratum%253Aachs%26aulast%3DAbadir%26aufirst%3DP.%2BM.%26aulast%3DFoster%26aufirst%3DD.%2BB.%26aulast%3DCrow%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DC.%2BA.%26aulast%3DRucker%26aufirst%3DJ.%2BJ.%26aulast%3DJain%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DBurks%26aufirst%3DT.%2BN.%26aulast%3DCohn%26aufirst%3DR.%2BD.%26aulast%3DFedarko%26aufirst%3DN.%2BS.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DB.%26aulast%3DWalston%26aufirst%3DJ.%2BD.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520a%2520functional%2520mitochondrial%2520angiotensin%2520system%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D14849%26epage%3D14854%26doi%3D10.1073%2Fpnas.1101507108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escobales, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javadov, S.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial angiotensin receptors and cardioprotective pathways</span>. <i>Am. J. Physiol., Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">H1426</span>– <span class="NLM_lpage">H1438</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00772.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajpheart.00772.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30978131" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2019&pages=H1426-H1438&author=N.+Escobalesauthor=R.+E.+Nu%C3%B1ezauthor=S.+Javadov&title=Mitochondrial+angiotensin+receptors+and+cardioprotective+pathways&doi=10.1152%2Fajpheart.00772.2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00772.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00772.2018%26sid%3Dliteratum%253Aachs%26aulast%3DEscobales%26aufirst%3DN.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DR.%2BE.%26aulast%3DJavadov%26aufirst%3DS.%26atitle%3DMitochondrial%2520angiotensin%2520receptors%2520and%2520cardioprotective%2520pathways%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Heart%2520Circ.%2520Physiol.%26date%3D2019%26volume%3D316%26spage%3DH1426%26epage%3DH1438%26doi%3D10.1152%2Fajpheart.00772.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micakovic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papagiannarou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzay, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramovic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sticht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawroth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammes, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alenina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gröne, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, S. C.</span></span> <span> </span><span class="NLM_article-title">The angiotensin II type 2 receptors protect renal tubule mitochondria in early stages of diabetes mellitus</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1016/j.kint.2018.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.kint.2018.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30190172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1eku7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2018&pages=937-950&author=T.+Micakovicauthor=S.+Papagiannarouauthor=E.+Clarkauthor=Y.+Kuzayauthor=K.+Abramovicauthor=J.+Petersauthor=C.+Stichtauthor=N.+Volkauthor=T.+Flemingauthor=P.+Nawrothauthor=H.+P.+Hammesauthor=N.+Aleninaauthor=H.+J.+Gr%C3%B6neauthor=S.+C.+Hoffmann&title=The+angiotensin+II+type+2+receptors+protect+renal+tubule+mitochondria+in+early+stages+of+diabetes+mellitus&doi=10.1016%2Fj.kint.2018.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The angiotensin II type 2 receptors protect renal tubule mitochondria in early stages of diabetes mellitus</span></div><div class="casAuthors">Micakovic, Tamara; Papagiannarou, Stamatia; Clark, Euan; Kuzay, Yalcin; Abramovic, Katarina; Peters, Joerg; Sticht, Carsten; Volk, Nadine; Fleming, Thomas; Nawroth, Peter; Hammes, Hans-Peter; Alenina, Natalia; Groene, Hermann-Josef; Hoffmann, Sigrid Christa</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">937-950</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Diabetic nephropathy correlates more closely to defective mitochondria and increased oxidative stress in the kidney than to hyperglycemia.  A key driving factor of diabetic nephropathy is angiotensin II acting via the G-protein-coupled cell membrane type 1 receptor.  The present study aimed to investigate the role of the angiotensin II type 2 receptor (AT2R) at the early stages of diabetic nephropathy.  Using receptor binding studies and immunohistochem. we found that the mitochondria in renal tubules contain high-affinity AT2Rs.  Increased renal mitochondrial AT2R d. by transgenic overexpression was assocd. with reduced superoxide prodn. of isolated mitochondria from non-diabetic rats.  Streptozotocin-induced diabetes (28 days) caused a drop in the ATP/oxygen ratio and an increase in the superoxide prodn. of isolated renal mitochondria from wild-type diabetic rats.  This correlated with changes in the renal expression profile and increased tubular epithelial cell proliferation.  AT2R overexpression in tubular epithelial cells inhibited all diabetes-induced renal changes including a drop in mitochondrial bioenergetics efficiency, a rise in mitochondrial superoxide prodn., metabolic reprogramming, and increased proliferation.  Thus, AT2Rs translocate to mitochondria and can contribute to reno-protective effects at early stages of diabetes.  Hence, targeted AT2R overexpression in renal cells may open new avenues to develop novel types of drugs preventing diabetic nephropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKqUgcGZoHm7Vg90H21EOLACvtfcHk0lhVjQRzOWFm9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1eku7jM&md5=afd0172f5344a7d5ac07218eb13ffff9</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.kint.2018.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.kint.2018.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DMicakovic%26aufirst%3DT.%26aulast%3DPapagiannarou%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DE.%26aulast%3DKuzay%26aufirst%3DY.%26aulast%3DAbramovic%26aufirst%3DK.%26aulast%3DPeters%26aufirst%3DJ.%26aulast%3DSticht%26aufirst%3DC.%26aulast%3DVolk%26aufirst%3DN.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DNawroth%26aufirst%3DP.%26aulast%3DHammes%26aufirst%3DH.%2BP.%26aulast%3DAlenina%26aufirst%3DN.%26aulast%3DGr%25C3%25B6ne%26aufirst%3DH.%2BJ.%26aulast%3DHoffmann%26aufirst%3DS.%2BC.%26atitle%3DThe%2520angiotensin%2520II%2520type%25202%2520receptors%2520protect%2520renal%2520tubule%2520mitochondria%2520in%2520early%2520stages%2520of%2520diabetes%2520mellitus%26jtitle%3DKidney%2520Int.%26date%3D2018%26volume%3D94%26spage%3D937%26epage%3D950%26doi%3D10.1016%2Fj.kint.2018.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Te
Riet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Esch, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roks, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Meiracker, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danser, A. H.</span></span> <span> </span><span class="NLM_article-title">Hypertension: renin-angiotensin-aldosterone system alterations</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">975</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.116.303587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FCIRCRESAHA.116.303587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25767283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktlSisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2015&pages=960-975&author=L.+Te%0ARietauthor=J.+H.+van+Eschauthor=A.+J.+Roksauthor=A.+H.+van+den+Meirackerauthor=A.+H.+Danser&title=Hypertension%3A+renin-angiotensin-aldosterone+system+alterations&doi=10.1161%2FCIRCRESAHA.116.303587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Hypertension: Renin-Angiotensin-Aldosterone System Alterations</span></div><div class="casAuthors">te Riet, Luuk; van Esch, Joep H. M.; Roks, Anton J. M.; van den Meiracker, Anton H.; Danser, A. H. Jan</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">960-975</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Blockers of the renin-angiotensin-aldosterone system (RAAS), i.e., renin inhibitors, angiotensin (Ang)-converting enzyme (ACE) inhibitors, Ang II type 1 receptor antagonists, and mineralocorticoid receptor antagonists, are a cornerstone in the treatment of hypertension.  How exactly they exert their effect, in particular in patients with low circulating RAAS activity, also taking into consideration the so-called Ang II/aldosterone escape that often occurs after initial blockade, is still incompletely understood.  Multiple studies have tried to find parameters that predict the response to RAAS blockade, allowing a personalized treatment approach.  Consequently, the question should now be answered on what basis (eg, sex, ethnicity, age, salt intake, baseline renin, ACE or aldosterone, and genetic variance) a RAAS blocker can be chosen to treat an individual patient.  Are all blockers equal Does optimal blockade imply max. RAAS blockade, for example, by combining ≥2 RAAS blockers or by simply increasing the dose of 1 blocker Exciting recent investigations reveal a range of unanticipated extrarenal effects of aldosterone, as well as a detailed insight in the genetic causes of primary aldosteronism, and mineralocorticoid receptor blockers have now become an important treatment option for resistant hypertension.  Finally, apart from the deleterious ACE-Ang II-Ang II type 1 receptor arm, animal studies support the existence of protective aminopeptidase A-Ang III-Ang II type 2 receptor and ACE2-Ang-(1 to 7)-Mas receptor arms, paving the way for multiple new treatment options.  This review provides an update about all these aspects, critically discussing the many controversies and allowing the reader to obtain a full understanding of what we currently know about RAAS alterations in hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlvyUVPG2x27Vg90H21EOLACvtfcHk0ljJXxj0iLHPJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktlSisLc%253D&md5=40292de9f623880fc37fc2a6d82a4e4d</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.116.303587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.116.303587%26sid%3Dliteratum%253Aachs%26aulast%3DTe%2BRiet%26aufirst%3DL.%26aulast%3Dvan%2BEsch%26aufirst%3DJ.%2BH.%26aulast%3DRoks%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2Bden%2BMeiracker%26aufirst%3DA.%2BH.%26aulast%3DDanser%26aufirst%3DA.%2BH.%26atitle%3DHypertension%253A%2520renin-angiotensin-aldosterone%2520system%2520alterations%26jtitle%3DCirc.%2520Res.%26date%3D2015%26volume%3D116%26spage%3D960%26epage%3D975%26doi%3D10.1161%2FCIRCRESAHA.116.303587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akishita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakami, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzau, V. J.</span></span> <span> </span><span class="NLM_article-title">Inflammation influences vascular remodeling through AT2 receptor expression and signaling</span>. <i>Physiol. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1152/physiolgenomics.2000.2.1.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fphysiolgenomics.2000.2.1.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11015577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltFGktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=13-20&author=M.+Akishitaauthor=M.+Horiuchiauthor=H.+Yamadaauthor=L.+Zhangauthor=G.+Shirakamiauthor=K.+Tamuraauthor=Y.+Ouchiauthor=V.+J.+Dzau&title=Inflammation+influences+vascular+remodeling+through+AT2+receptor+expression+and+signaling&doi=10.1152%2Fphysiolgenomics.2000.2.1.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation influences vascular remodeling through AT2 receptor expression and signaling</span></div><div class="casAuthors">Akishita, Masahiro; Horiuchi, Masatsugu; Yamada, Hiroyuki; Zhang, Lunan; Shirakami, Gotaro; Tamura, Rouichi; Ouchi, Yasuyoshi; Dzau, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Genomics [online computer file]</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-20</span>CODEN:
                <span class="NLM_cas:coden">PHGEFP</span>;
        ISSN:<span class="NLM_cas:issn">1094-8341</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">The AT2 receptor, which exerts growth inhibitory effects in cell culture, is present scantily in the adult vasculature but is reexpressed after vascular injury.  To examine the in vivo role of this receptor in vascular diseases, we developed a mouse model of vascular remodeling and compared the responses in wild-type (Agtr2+) and AT2 receptor knockout (Agtr2-) mice.  Polyethylene cuff placement on the femoral artery led to the vascular expression of cytokines, the transcriptional factor interferon regulatory factor-1 (IRF-1), and both the AT1 and AT2 receptors.  Although the expressions of IRF-1 and AT1 receptor were induced to comparable levels in both the Agtr2+ and Agtr2- mice, the neointimal lesion size and the smooth muscle cell proliferation were twice greater in the Agtr2- than in the Agtr2+ mouse.  Correlated with this difference, AT2 receptor expression was induced predominantly in the smooth muscle cells of Agtr2+ mouse.  These results demonstrate that the AT2 receptor plays an important role in nonocclusive inflammatory injury by mediating the effects of inflammation on vascular smooth muscle growth inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwqFpQOpyqbbVg90H21EOLACvtfcHk0lgVZ_n5gidvrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltFGktbo%253D&md5=6a6845a2d9c3f5ede256150a891757f9</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1152%2Fphysiolgenomics.2000.2.1.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysiolgenomics.2000.2.1.13%26sid%3Dliteratum%253Aachs%26aulast%3DAkishita%26aufirst%3DM.%26aulast%3DHoriuchi%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShirakami%26aufirst%3DG.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DOuchi%26aufirst%3DY.%26aulast%3DDzau%26aufirst%3DV.%2BJ.%26atitle%3DInflammation%2520influences%2520vascular%2520remodeling%2520through%2520AT2%2520receptor%2520expression%2520and%2520signaling%26jtitle%3DPhysiol.%2520Genomics%26date%3D2000%26volume%3D2%26spage%3D13%26epage%3D20%26doi%3D10.1152%2Fphysiolgenomics.2000.2.1.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortnagl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blume, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirnagl, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1096/fj.04-2960fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1096%2Ffj.04-2960fje" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=15665034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFaks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=617-619&author=J.+Liauthor=J.+Culmanauthor=H.+Hortnaglauthor=Y.+Zhaoauthor=N.+Gerovaauthor=M.+Timmauthor=A.+Blumeauthor=K.+Zimmermannauthor=K.+Seidelauthor=U.+Dirnaglauthor=T.+Unger&title=Angiotensin+AT2+receptor+protects+against+cerebral+ischemia-induced+neuronal+injury&doi=10.1096%2Ffj.04-2960fje"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury</span></div><div class="casAuthors">Li, Jun; Culman, Juraj; Hoertnagl, Heide; Zhao, Yi; Gerova, Nadezhda; Timm, Melanie; Blume, Annegret; Zimmermann, Mathias; Seidel, Kerstin; Dirnagl, Ulrich; Unger, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">617-619, 10.1096/fj.04-2960fje</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Several lines of clin. and exptl. evidence suggest an important role of the renin-angiotensin system in ischemic brain injury although the cellular regulation of the angiotensin AT1 and AT2 receptors and their potential relevance in this condition have not yet been clearly defined.  We first assessed the regulation of brain AT1 and AT2 receptors in response to transient unilateral medial cerebral artery occlusion in rats by real-time RT-PCR, Western blot, and immunofluorescence labeling.  AT2 receptors in the peri-infarct zone were significantly upregulated 2 days after transient focal cerebral ischemia.  Increased AT2 receptors, which were abundantly distributed in a large no. of brain regions adjacent to the infarct area including cerebral frontal cortex, piriform cortex, striatum, and hippocampus, were exclusively expressed in neurons.  By contrast, AT1 receptors, which remained unaltered, were mainly expressed in astrocytes.  In neurons of ischemic striatum, increased AT2 receptors were assocd. with intense neurite outgrowth.  Blockade of central AT2 receptors with PD123177 abolished the neuroprotective effects of central AT1 receptor blockade with irbesartan on infarct size and neurol. outcome.  In primary cortical neurons, stimulation of AT2 receptors supported neuronal survival and neurite outgrowth.  Our data indicate that cerebral AT2 receptors exert neuroprotective actions in response to ischemia-induced neuronal injury, possibly by supporting neuronal survival and neurite outgrowth in peri-ischemic brain areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcchA7MJUAE7Vg90H21EOLACvtfcHk0lgVZ_n5gidvrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFaks7o%253D&md5=0f6b46627af09be20244e0f4c409e4fb</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1096%2Ffj.04-2960fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.04-2960fje%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCulman%26aufirst%3DJ.%26aulast%3DHortnagl%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGerova%26aufirst%3DN.%26aulast%3DTimm%26aufirst%3DM.%26aulast%3DBlume%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DSeidel%26aufirst%3DK.%26aulast%3DDirnagl%26aufirst%3DU.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DAngiotensin%2520AT2%2520receptor%2520protects%2520against%2520cerebral%2520ischemia-induced%2520neuronal%2520injury%26jtitle%3DFASEB%2520J.%26date%3D2005%26volume%3D19%26spage%3D617%26epage%3D619%26doi%3D10.1096%2Ffj.04-2960fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altarche-Xifro, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imboden, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Cardiac c-kitCAT2C cell population is increased in response to ischemic injury and supports cardiomyocyte performance</span>. <i>Stem Cells</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2488</span>– <span class="NLM_lpage">2497</span>, <span class="refDoi"> DOI: 10.1002/stem.171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fstem.171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19591228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFenur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=2488-2497&author=W.+Altarche-Xifroauthor=C.+Curatoauthor=E.+Kaschinaauthor=A.+Grzesiakauthor=S.+Slavicauthor=J.+Dongauthor=K.+Kappertauthor=M.+Steckelingsauthor=H.+Imbodenauthor=T.+Ungerauthor=J.+Li&title=Cardiac+c-kitCAT2C+cell+population+is+increased+in+response+to+ischemic+injury+and+supports+cardiomyocyte+performance&doi=10.1002%2Fstem.171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac c-kit+AT2+ cell population is increased in response to ischemic injury and supports cardiomyocyte performance</span></div><div class="casAuthors">Altarche-Xifro, Wassim; Curato, Caterina; Kaschina, Elena; Grzesiak, Aleksandra; Slavic, Svetlana; Dong, Jun; Kappert, Kai; Steckelings, Muscha; Imboden, Hans; Unger, Thomas; Li, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells (Durham, NC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2488-2497</span>CODEN:
                <span class="NLM_cas:coden">STCEEJ</span>;
        ISSN:<span class="NLM_cas:issn">1066-5099</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">The expression pattern of angiotensin AT2 receptors with predominance during fetal life and upregulation under pathol. conditions during tissue injury/repair process suggests that AT2 receptors may exert an important action in injury/repair adaptive mechanisms.  Less is known about AT2 receptors in acute ischemia-induced cardiac injury.  We aimed here to elucidate the role of AT2 receptors after acute myocardial infarction.  Double immunofluorescence staining showed that cardiac AT2 receptors were mainly detected in clusters of small c-kit+ cells accumulating in peri-infarct zone and c-kit+AT2+ cells increased in response to acute cardiac injury.  Further, we isolated cardiac c-kit+AT2+ cell population by modified magnetic activated cell sorting and fluorescence activated cell sorting.  These cardiac c-kit+AT2+ cells, represented ∼0.19% of total cardiac cells in infarcted heart, were characterized by upregulated transcription factors implicated in cardiogenic differentiation (Gata-4, Notch-2, Nkx-2.5) and genes required for self-renewal (Tbx-3, c-Myc, Akt).  When adult cardiomyocytes and cardiac c-kit+AT2+ cells isolated from infarcted rat hearts were cocultured, AT2 receptor stimulation in vitro inhibited apoptosis of these cocultured cardiomyocytes.  Moreover, in vivo AT2 receptor stimulation led to an increased c-kit+AT2+ cell population in the infarcted myocardium and reduced apoptosis of cardiomyocytes in rats with acute myocardial infarction.  These data suggest that cardiac c-kit+AT2+ cell population exists and increases after acute ischemic injury.  AT2 receptor activation supports performance of cardiomyocytes, thus contributing to cardioprotection via cardiac c-kit+AT2+ cell population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKQ78A4B4itbVg90H21EOLACvtfcHk0ljKC-m3iP6ebA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFenur%252FI&md5=56bda5978285a7f7c05187e01f373b17</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1002%2Fstem.171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fstem.171%26sid%3Dliteratum%253Aachs%26aulast%3DAltarche-Xifro%26aufirst%3DW.%26aulast%3DCurato%26aufirst%3DC.%26aulast%3DKaschina%26aufirst%3DE.%26aulast%3DGrzesiak%26aufirst%3DA.%26aulast%3DSlavic%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DKappert%26aufirst%3DK.%26aulast%3DSteckelings%26aufirst%3DM.%26aulast%3DImboden%26aufirst%3DH.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DCardiac%2520c-kitCAT2C%2520cell%2520population%2520is%2520increased%2520in%2520response%2520to%2520ischemic%2520injury%2520and%2520supports%2520cardiomyocyte%2520performance%26jtitle%3DStem%2520Cells%26date%3D2009%26volume%3D27%26spage%3D2488%26epage%3D2497%26doi%3D10.1002%2Fstem.171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Edavarone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3019</span>– <span class="NLM_lpage">3033</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S144807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2147%2FDDDT.S144807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29081650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSkt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=3019-3033&author=W.+W.+Zhangauthor=F.+Baiauthor=J.+Wangauthor=R.+H.+Zhengauthor=L.+W.+Yangauthor=E.+A.+Jamesauthor=Z.+Q.+Zhao&title=Edavarone+inhibits+pressure+overload-induced+cardiac+fibrosis+and+dysfunction+by+reducing+expression+of+angiotensin+II+AT1+receptor&doi=10.2147%2FDDDT.S144807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor</span></div><div class="casAuthors">Zhang, Wei-Wei; Bai, Feng; Wang, Jin; Zheng, Rong-Hua; Yang, Li-Wang; James, Erskine A.; Zhao, Zhi-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3019-3033</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II) is known to be involved in the progression of ventricular dysfunction and heart failure by eliciting cardiac fibrosis.  The purpose of this study was to demonstrate whether treatment with an antioxidant compd., edaravone, reduces cardiac fibrosis and improves ventricular function by inhibiting Ang II AT1 receptor.  The study was conducted in a rat model of transverse aortic constriction (TAC).  In control, rats were subjected to 8 wk of TAC.  In treated rats, edaravone (10 mg/kg/day) or Ang II AT1 receptor blocker, telmisartan (10 mg/kg/day) was administered by i.p. injection or gastric gavage, resp., during TAC.  Relative to the animals with TAC, edaravone reduced myocardial malonaldehyde level and increased superoxide dismutase activity.  Protein level of the AT1 receptor was reduced and the AT2 receptor was upregulated, as evidenced by the reduced ratio of AT1 over AT2 receptor (0.57±0.2 vs 3.16±0.39, p<0.05) and less locally expressed AT1 receptor in the myocardium.  Furthermore, the protein level of angiotensin converting enzyme 2 was upregulated.  In coincidence with these changes, edaravone significantly decreased the populations of macrophages and myofibroblasts in the myocardium, which were accompanied by reduced levels of transforming growth factor beta 1 and Smad2/3.  Collagen I synthesis was inhibited and collagen-rich fibrosis was attenuated.  Relative to the TAC group, cardiac systolic function was preserved, as shown by increased left ventricular systolic pressure (204±51 vs 110±19 mmHg, p<0.05) and ejection fraction (82%±3% vs 60%±5%, p<0.05).  Treatment with telmisartan provided a comparable level of protection as compared with edaravone in all the parameters measured.  Taken together, edaravone treatment ameliorates cardiac fibrosis and improves left ventricular function in the pressure overload rat model, potentially via suppressing the AT1 receptor-mediated signaling pathways.  These data indicate that edaravone might be selected in combination with other existing drugs in preventing progression of cardiac dysfunction in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdgiWC1QUkDLVg90H21EOLACvtfcHk0ljKC-m3iP6ebA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSkt7nE&md5=b869850a0f306239e13dcc3ae3991cb9</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S144807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S144807%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%2BW.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DR.%2BH.%26aulast%3DYang%26aufirst%3DL.%2BW.%26aulast%3DJames%26aufirst%3DE.%2BA.%26aulast%3DZhao%26aufirst%3DZ.%2BQ.%26atitle%3DEdavarone%2520inhibits%2520pressure%2520overload-induced%2520cardiac%2520fibrosis%2520and%2520dysfunction%2520by%2520reducing%2520expression%2520of%2520angiotensin%2520II%2520AT1%2520receptor%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D3019%26epage%3D3033%26doi%3D10.2147%2FDDDT.S144807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">AbdAlla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lother, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Tawab, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quitterer, U.</span></span> <span> </span><span class="NLM_article-title">The angiotensin II AT2 receptor is an AT1 receptor antagonist</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">39721</span>– <span class="NLM_lpage">39726</span>, <span class="refDoi"> DOI: 10.1074/jbc.M105253200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1074%2Fjbc.M105253200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11507095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotFGit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=39721-39726&author=S.+AbdAllaauthor=H.+Lotherauthor=A.+M.+Abdel-Tawabauthor=U.+Quitterer&title=The+angiotensin+II+AT2+receptor+is+an+AT1+receptor+antagonist&doi=10.1074%2Fjbc.M105253200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The angiotensin II AT2 receptor is an AT1 receptor antagonist</span></div><div class="casAuthors">AbdAlla, Said; Lother, Heinz; Abdel-Tawab, Ahmed M.; Quitterer, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">39721-39726</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The vasopressor angiotensin II activates AT1 and AT2 receptors.  Most of the known in vivo effects of angiotensin II are mediated by AT1 receptors while the biol. functions of AT2 receptors are less clear.  We report here that the AT2 receptor binds directly to the AT1 receptor and thereby antagonizes the function of the AT1 receptor.  The AT1-specific antagonism of the AT2 receptor was independent of AT2 receptor activation and signaling, and it was effective on different cells and on human myometrial biopsies with AT1/AT2 receptor expression.  Thus, the AT2 receptor is the first identified example of a G-protein-coupled receptor which acts as a receptor-specific antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKCbYkE9odorVg90H21EOLACvtfcHk0ljKC-m3iP6ebA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotFGit7s%253D&md5=e08a9974752dbf40ddecd2b993265f16</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M105253200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M105253200%26sid%3Dliteratum%253Aachs%26aulast%3DAbdAlla%26aufirst%3DS.%26aulast%3DLother%26aufirst%3DH.%26aulast%3DAbdel-Tawab%26aufirst%3DA.%2BM.%26aulast%3DQuitterer%26aufirst%3DU.%26atitle%3DThe%2520angiotensin%2520II%2520AT2%2520receptor%2520is%2520an%2520AT1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D39721%26epage%3D39726%26doi%3D10.1074%2Fjbc.M105253200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gildea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jose, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, R. A.</span></span> <span> </span><span class="NLM_article-title">The dopamine D<sub>1</sub> receptor and angiotensin II Type-2 receptor are required for inhibition of sodium transport through a protein phosphatase 2A pathway</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1258</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.119.12705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.119.12705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=31030607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlegtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2019&pages=1258-1265&author=J.+J.+Gildeaauthor=P.+Xuauthor=B.+A.+Kempauthor=R.+M.+Careyauthor=P.+A.+Joseauthor=R.+A.+Felder&title=The+dopamine+D1+receptor+and+angiotensin+II+Type-2+receptor+are+required+for+inhibition+of+sodium+transport+through+a+protein+phosphatase+2A+pathway&doi=10.1161%2FHYPERTENSIONAHA.119.12705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">The Dopamine D1 Receptor and Angiotensin II Type-2 Receptor are Required for Inhibition of Sodium Transport Through a Protein Phosphatase 2A Pathway</span></div><div class="casAuthors">Gildea, John J.; Xu, Peng; Kemp, Brandon A.; Carey, Robert M.; Jose, Pedro A.; Felder, Robin A.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1258-1265</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Activation of the renal D1R (dopamine D1-like receptor) or AT2R (angiotensin II type-2 receptor), individually or both, simultaneously, is necessary in the normal regulation of renal sodium (Na) transport and blood pressure.  However, little is known regarding the precise mechanism of this interaction.  Pharmacol. stimulation, membrane biotinylation, and cell surface immunofluorescence were used to study the effect of the D1R/AT2R interaction in human renal proximal tubule cells.  D1R activation of GαS stimulates AC (adenylyl cyclase) and induces apical plasma membrane recruitment of AT2Rs.  We now show for the first time the reciprocal reaction, AT2R stimulation with Ang III (angiotensin III) leads to the apical plasma membrane recruitment of the D1R.  The cell-permeable second messenger analogs of cAMP (8-Br-cAMP) or cGMP (8-Br-cGMP) induce translocation of both D1R and AT2R to the plasma membrane.  Inhibition of PKA (protein kinase A) with Rp-cAMPS and PKG (protein kinase G) with Rp-8-CPT-cGMPS blocks D1R and AT2R recruitment, resp., indicating that both PKA and PKG are necessary for D1R and AT2R trafficking.  Both 8-Br-cAMP and 8-Br-cGMP activate PP2A (protein phosphatase 2A), which is necessary for both plasma membrane recruitment of D1R and AT2R and the inhibition of sodium hydrogen exchanger 3-dependent Na transport.  These studies provide insights into the D1R/AT2R transregulation mechanisms that play a crucial role in maintaining Na and ultimately blood pressure homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp9ShHdQD2_7Vg90H21EOLACvtfcHk0lgNOsYkboRNLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlegtLk%253D&md5=25ffaf7075ce2446d67d4447958224ed</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.119.12705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.119.12705%26sid%3Dliteratum%253Aachs%26aulast%3DGildea%26aufirst%3DJ.%2BJ.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DKemp%26aufirst%3DB.%2BA.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26aulast%3DJose%26aufirst%3DP.%2BA.%26aulast%3DFelder%26aufirst%3DR.%2BA.%26atitle%3DThe%2520dopamine%2520D1%2520receptor%2520and%2520angiotensin%2520II%2520Type-2%2520receptor%2520are%2520required%2520for%2520inhibition%2520of%2520sodium%2520transport%2520through%2520a%2520protein%2520phosphatase%25202A%2520pathway%26jtitle%3DHypertension%26date%3D2019%26volume%3D73%26spage%3D1258%26epage%3D1265%26doi%3D10.1161%2FHYPERTENSIONAHA.119.12705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenström, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sköld, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and AT<sub>2</sub> receptor-binding properties of angiotensin II analogues</span>. <i>J. Pept. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.2004.00184.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2Fj.1399-3011.2004.00184.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=15485557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BD2crmt1yqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=194-201&author=U.+Rosenstr%C3%B6mauthor=C.+Sk%C3%B6ldauthor=G.+Lindebergauthor=M.+Botrosauthor=F.+Nybergauthor=A.+Hallbergauthor=A.+Karl%C3%A9n&title=Synthesis+and+AT2+receptor-binding+properties+of+angiotensin+II+analogues&doi=10.1111%2Fj.1399-3011.2004.00184.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and AT2 receptor-binding properties of angiotensin II analogues</span></div><div class="casAuthors">Rosenstrom U; Skold C; Lindeberg G; Botros M; Nyberg F; Hallberg A; Karlen A</div><div class="citationInfo"><span class="NLM_cas:title">The journal of peptide research : official journal of the American Peptide Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">194-201</span>
        ISSN:<span class="NLM_cas:issn">1397-002X</span>.
    </div><div class="casAbstract">The present study investigates the importance of the amino acid side chains in the octapeptide angiotensin II (Ang II) for binding to the AT2 receptor.  A Gly scan was performed where each amino acid in Ang II was substituted one-by-one with glycine.  The resulting set of peptides was tested for affinity to the AT2 receptor (porcine myometrial membranes).  For a comparison, the peptides were also tested for affinity to the AT1 receptor (rat liver membranes).  Only the substitution of Arg2 reduced affinity to the AT2 receptor considerably (92-fold when compared with Ang II).  For the other Gly-substituted analogues the affinity to the AT2 receptor was only moderately affected.  To further investigate the role of the Arg2 side chain for receptor binding, we synthesized some N-terminally modified Ang II analogues.  According to these studies a positive charge in the N-terminal end of angiotensin III [Ang II (2-8)] is not required for high AT2 receptor affinity but seems to be more important in Ang II.  With respect to the AT1 receptor, [Gly2]Ang II and [Gly8]Ang II lacked binding affinity (Ki > 10 microM).  Replacement of the Val3 or Ile5 residues with Gly produced only a slight decrease in affinity.  Interestingly, substitution of Tyr4 or His6, which are known to be very important for AT1 receptor binding, resulted in only 48 and 14 times reduction in affinity, respectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTL9YyCCETfREH3Rlp_k91zfW6udTcc2ebpkpqJ8uJCh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crmt1yqug%253D%253D&md5=2f9c1144fd6316505092015d81c61fc2</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.2004.00184.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.2004.00184.x%26sid%3Dliteratum%253Aachs%26aulast%3DRosenstr%25C3%25B6m%26aufirst%3DU.%26aulast%3DSk%25C3%25B6ld%26aufirst%3DC.%26aulast%3DLindeberg%26aufirst%3DG.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520AT2%2520receptor-binding%2520properties%2520of%2520angiotensin%2520II%2520analogues%26jtitle%3DJ.%2520Pept.%2520Res.%26date%3D2004%26volume%3D64%26spage%3D194%26epage%3D201%26doi%3D10.1111%2Fj.1399-3011.2004.00184.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sävmarker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span> <span> </span><span class="NLM_article-title">Angiotensin peptides as AT2 receptor agonists</span>. <i>Curr. Protein Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.2174/1389203718666170203150344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2174%2F1389203718666170203150344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28164758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVShtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=809-818&author=M.+Hallbergauthor=J.+S%C3%A4vmarkerauthor=A.+Hallberg&title=Angiotensin+peptides+as+AT2+receptor+agonists&doi=10.2174%2F1389203718666170203150344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin Peptides as AT2 Receptor Agonists</span></div><div class="casAuthors">Hallberg, Mathias; Saevmarker, Jonas; Hallberg, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Current Protein and Peptide Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">809-818</span>CODEN:
                <span class="NLM_cas:coden">CPPSCM</span>;
        ISSN:<span class="NLM_cas:issn">1389-2037</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In 2004, the first nonpeptide selective angiotensin II type 2 receptor (AT2R) agonist was reported.  This nonpeptide (C21), which, exerts anti-inflammatory and antifibrotic actions in vivo, has been extensively explored and is currently in clin. trials.  Subsequently, a large no. of related drug-like AT2R agonists have been disclosed.  Reviews that summarize known structure-activity relationships (SAR) of nonpeptide AT2R agonists have recently appeared in the literature; however, very few reviews discuss the role of angiotensin peptides as AT2R agonists.  Furthermore, to date, there have been no reports focusing on the medicinal chem. perspective of peptide AT2R agonists.  In the present review, reports on linear and conformationally constrained Ang II analogs, with a focus on AT2R selective ligands that are proven to act as agonists at the AT2 receptor are summarized.  The impact of truncations and macrocyclizations of Ang II analogs and of incorporation of scaffolds that mimic secondary structures into Ang II related peptides is highlighted.  A survey of the efforts to transform the nonselective octapeptide Ang II to more drug-like selective AT2R agonists is presented.  The relationship between the structures of the AT2R agonists and their affinity to the AT2R is briefly discussed and common pharmacophore elements of AT2R selective Ang II peptide analogs and selective nonpeptide AT2R agonists are compared.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr860hLK9E6sLVg90H21EOLACvtfcHk0lie7yntnqlR1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVShtrjP&md5=f6b91646608c02bbbe32d593c30755fb</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.2174%2F1389203718666170203150344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389203718666170203150344%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DS%25C3%25A4vmarker%26aufirst%3DJ.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DAngiotensin%2520peptides%2520as%2520AT2%2520receptor%2520agonists%26jtitle%3DCurr.%2520Protein%2520Pept.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D809%26epage%3D818%26doi%3D10.2174%2F1389203718666170203150344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asare, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liehn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raya-Bermudez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda-Martos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Castañeda, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinze, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zidek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowski, J.</span></span> <span> </span><span class="NLM_article-title">Identification of the vasoconstriction-inhibiting factor (VIF), a potent endogenous cofactor of angiotensin II acting on the angiotensin II type 2 receptor</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1426</span>– <span class="NLM_lpage">1434</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.114.013168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FCIRCULATIONAHA.114.013168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25810338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFSgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2015&pages=1426-1434&author=S.+Salemauthor=V.+Jankowskiauthor=Y.+Asareauthor=E.+Liehnauthor=P.+Welkerauthor=A.+Raya-Bermudezauthor=C.+Pineda-Martosauthor=M.+Rodriguezauthor=J.+R.+Mu%C3%B1oz-Casta%C3%B1edaauthor=H.+Bruckauthor=N.+Marxauthor=F.+B.+Machadoauthor=M.+Staudtauthor=G.+Heinzeauthor=W.+Zidekauthor=J.+Jankowski&title=Identification+of+the+vasoconstriction-inhibiting+factor+%28VIF%29%2C+a+potent+endogenous+cofactor+of+angiotensin+II+acting+on+the+angiotensin+II+type+2+receptor&doi=10.1161%2FCIRCULATIONAHA.114.013168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the Vasoconstriction-Inhibiting Factor (VIF), a Potent Endogenous Cofactor of Angiotensin II Acting on the Angiotensin II Type 2 Receptor</span></div><div class="casAuthors">Salem, Silvia; Jankowski, Vera; Asare, Yaw; Liehn, Elisa; Welker, Pia; Raya-Bermudez, Ana; Pineda-Martos, Carmen; Rodriguez, Mariano; Munoz-Castaneda, Juan Rafael; Bruck, Heike; Marx, Nikolaus; Machado, Fernanda B.; Staudt, Mareike; Heinze, Georg; Zidek, Walter; Jankowski, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1426-1434</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND-: The renin-angiotensin system and esp. the angiotensin peptides play a central role in blood pressure regulation.  Here, we hypothesize that an as-yet unknown peptide is involved in the action of angiotensin II modulating the vasoregulatory effects as a cofactor.  METHODS AND RESULTS-: The peptide with vasodilatory properties was isolated from adrenal glands chromatog.  The effects of this peptide were evaluated in vitro and in vivo, and the receptor affinity was analyzed.  The plasma concn. in humans was quantified in patients with chronic kidney disease, patients with heart failure, and healthy control subjects.  The amino acid sequence of the peptide from bovine adrenal glands was HSSYEDELSEVL EKPNDQAE PKEVTEEVSSKDAAE, which is a degrdn. product of chromogranin A.  The sequence of the peptide isolated from human plasma was HSGFEDELSEVLENQSSQAELKEAVEEPSSKDVME.  Both peptides diminished significantly the vasoconstrictive effect of angiotensin II in vitro.  Therefore, we named the peptide vasoconstriction-inhibiting factor (VIF).  The vasoregulatory effects of VIF are mediated by the angiotensin II type 2 receptor.  VIF impairs angiotensin II-induced phosphorylation of the p38 mitogen-activated protein kinase pathway but not of extracellular-regulated kinase 1/2.  The vasodilatory effects were confirmed in vivo.  The plasma concn. was significantly increased in renal patients and patients with heart failure.  CONCLUSIONS-: VIF is a vasoregulatory peptide that modulates the vasoconstrictive effects of angiotensin II by acting on the angiotensin II type 2 receptor.  It is likely that the increase in VIF may serve as a counterregulatory effect to defend against hypertension.  The identification of this target may help us to understand the pathophysiol. of renal and heart failure and may form a basis for the development of new strategies for the prevention and treatment of cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBu2Pwyj6Oo7Vg90H21EOLACvtfcHk0lie7yntnqlR1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFSgtLg%253D&md5=a05ad402a8bbe135c3a2522f0980e35a</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.114.013168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.114.013168%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DS.%26aulast%3DJankowski%26aufirst%3DV.%26aulast%3DAsare%26aufirst%3DY.%26aulast%3DLiehn%26aufirst%3DE.%26aulast%3DWelker%26aufirst%3DP.%26aulast%3DRaya-Bermudez%26aufirst%3DA.%26aulast%3DPineda-Martos%26aufirst%3DC.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DMu%25C3%25B1oz-Casta%25C3%25B1eda%26aufirst%3DJ.%2BR.%26aulast%3DBruck%26aufirst%3DH.%26aulast%3DMarx%26aufirst%3DN.%26aulast%3DMachado%26aufirst%3DF.%2BB.%26aulast%3DStaudt%26aufirst%3DM.%26aulast%3DHeinze%26aufirst%3DG.%26aulast%3DZidek%26aufirst%3DW.%26aulast%3DJankowski%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520the%2520vasoconstriction-inhibiting%2520factor%2520%2528VIF%2529%252C%2520a%2520potent%2520endogenous%2520cofactor%2520of%2520angiotensin%2520II%2520acting%2520on%2520the%2520angiotensin%2520II%2520type%25202%2520receptor%26jtitle%3DCirculation%26date%3D2015%26volume%3D131%26spage%3D1426%26epage%3D1434%26doi%3D10.1161%2FCIRCULATIONAHA.114.013168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span> <span> </span><span class="NLM_article-title">Nonpeptide AT2R agonists</span>. <i>Med. Chem. Reviews</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.29200/acsmedchemrev-v51.ch5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.29200%2Facsmedchemrev-v51.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=69-82&author=M.+Larhedauthor=M.+Hallbergauthor=A.+Hallberg&title=Nonpeptide+AT2R+agonists&doi=10.29200%2Facsmedchemrev-v51.ch5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.29200%2Facsmedchemrev-v51.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.29200%252Facsmedchemrev-v51.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DLarhed%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DNonpeptide%2520AT2R%2520agonists%26jtitle%3DMed.%2520Chem.%2520Reviews%26date%3D2016%26volume%3D51%26spage%3D69%26epage%3D82%26doi%3D10.29200%2Facsmedchemrev-v51.ch5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speth, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span> <span> </span><span class="NLM_article-title">Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanin-6-angiotensin II</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(90)91993-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2F0006-291X%2890%2991993-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=2194459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK3cXkslWrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=1990&pages=997-1006&author=R.+C.+Spethauthor=K.+H.+Kim&title=Discrimination+of+two+angiotensin+II+receptor+subtypes+with+a+selective+agonist+analogue+of+angiotensin+II%2C+p-aminophenylalanin-6-angiotensin+II&doi=10.1016%2F0006-291X%2890%2991993-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discrimination of two angiotensin II receptor subtypes with a selective agonist analog of angiotensin II, p-aminophenylalanine6 angiotensin II</span></div><div class="casAuthors">Speth, Robert C.; Kim, Kwan Hee</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">997-1006</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Angiotensin II receptor binding sites in rat liver and PC12 cells differ in their affinities for a nonpeptidic antagonist, DuP 753, and p-aminophenylalanine6-angiotensin II.  In liver, which primarily contains the sulfhydryl reducing agent-inhibited type of angiotensin II receptor, referred to as the AIIα subtype, DuP 753 displays an IC50 of 55 nM, while p-aminophenylalanine6-angiotensin II displays an IC50 of 8-9 μM.  In PC12 cells, which primarily contain the angiotensin II receptor type whose binding affinity is enhanced by sulfhydryl reducing agents (AIIβ), DuP 753 displays an IC50 in excess of 100μM, while p-aminophenylalanine6-angiotensin II displays an IC50 of 12 nM.  p-Aminophenylalanine6-angiotensin II binding affinity in liver is decreased in the presence of guanosine 5'-O-(3-thiotriphosphate) (GTP-γS), suggesting that this analog is an agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxbmhrET9RlbVg90H21EOLACvtfcHk0lhoQjpZ-MRf6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkslWrtr0%253D&md5=c9ad030ac52823051ae64f2658870f88</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2890%2991993-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252890%252991993-3%26sid%3Dliteratum%253Aachs%26aulast%3DSpeth%26aufirst%3DR.%2BC.%26aulast%3DKim%26aufirst%3DK.%2BH.%26atitle%3DDiscrimination%2520of%2520two%2520angiotensin%2520II%2520receptor%2520subtypes%2520with%2520a%2520selective%2520agonist%2520analogue%2520of%2520angiotensin%2520II%252C%2520p-aminophenylalanin-6-angiotensin%2520II%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1990%26volume%3D169%26spage%3D997%26epage%3D1006%26doi%3D10.1016%2F0006-291X%2890%2991993-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johannesson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdélyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frändberg, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span> <span> </span><span class="NLM_article-title">AT<sub>2</sub>-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">6009</span>– <span class="NLM_lpage">6019</span>, <span class="refDoi"> DOI: 10.1021/jm049651m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049651m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1WjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6009-6019&author=P.+Johannessonauthor=M.+Erd%C3%A9lyiauthor=G.+Lindebergauthor=P.+A.+Fr%C3%A4ndbergauthor=F.+Nybergauthor=A.+Karl%C3%A9nauthor=A.+Hallberg&title=AT2-selective+angiotensin+II+analogues+containing+tyrosine-functionalized+5%2C5-bicyclic+thiazabicycloalkane+dipeptide+mimetics&doi=10.1021%2Fjm049651m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">AT2-Selective Angiotensin II Analogues Containing Tyrosine-Functionalized 5,5-Bicyclic Thiazabicycloalkane Dipeptide Mimetics</span></div><div class="casAuthors">Johannesson, Petra; Erdelyi, Mate; Lindeberg, Gunnar; Fraendberg, Per-Anders; Nyberg, Fred; Karlen, Anders; Hallberg, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6009-6019</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper reports the synthesis of two angiotensin II analogs with tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics replacing the Tyr4-Ile5 residues.  The prepn. of these analogs relies on the synthesis and incorporation of an α,α-disubstituted chimeric amino acid deriv. I and on-resin bicyclization to a cysteine residue.  The synthesized analogs both displayed high angiotensin AT2/AT1 receptor binding preferences and had AT2 receptor affinities in the same low nanomolar range as angiotensin II itself.  Conformational anal., using exptl. constraints derived from NMR studies, indicated that the Tyr4 and His6 residues in one of the angiotensin II analogs were in close proximity to each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokD2-nXABi67Vg90H21EOLACvtfcHk0lhoQjpZ-MRf6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1WjsLs%253D&md5=c59524ab47daa4b1ea7fd14bca82e217</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm049651m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049651m%26sid%3Dliteratum%253Aachs%26aulast%3DJohannesson%26aufirst%3DP.%26aulast%3DErd%25C3%25A9lyi%26aufirst%3DM.%26aulast%3DLindeberg%26aufirst%3DG.%26aulast%3DFr%25C3%25A4ndberg%26aufirst%3DP.%2BA.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DAT2-selective%2520angiotensin%2520II%2520analogues%2520containing%2520tyrosine-functionalized%25205%252C5-bicyclic%2520thiazabicycloalkane%2520dipeptide%2520mimetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6009%26epage%3D6019%26doi%3D10.1021%2Fjm049651m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del
Borgo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosnyak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spizzo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlmutter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span> <span> </span><span class="NLM_article-title">Beta-Pro<sup>7</sup> Ang III is a novel highly selective angiotensin AT2R agonist, which acts as a vasodepressor agent via the AT2 receptor in conscious SHR</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1042/CS20150077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1042%2FCS20150077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26186568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OmurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2015&pages=505-513&author=M.+P.+Del%0ABorgoauthor=Y.+Wangauthor=S.+Bosnyakauthor=M.+Khanauthor=P.+Waltersauthor=I.+Spizzoauthor=P.+Perlmutterauthor=L.+Hilliardauthor=K.+Dentonauthor=M.+I.+Aguilarauthor=R.+Widdopauthor=E.+S.+Jones&title=Beta-Pro7+Ang+III+is+a+novel+highly+selective+angiotensin+AT2R+agonist%2C+which+acts+as+a+vasodepressor+agent+via+the+AT2+receptor+in+conscious+SHR&doi=10.1042%2FCS20150077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">β-Pro7 Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats</span></div><div class="casAuthors">Del Borgo, Mark; Wang, Yan; Bosnyak, Sanja; Khan, Morimer; Walters, Pia; Spizzo, Iresha; Perlmutter, Patrick; Hilliard, Lucinda; Denton, Kate; Aguilar, Marie-Isabel; Widdop, Robert E.; Jones, Emma S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">505-513</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">We have previously shown that individual β-amino acid substitution in angiotensin (Ang) II reduced Ang II type 1 receptor (AT1R) but not Ang II type 2 receptor (AT2R)-binding and that the heptapeptide Ang III exhibited greater AT2R:AT1R selectivity than Ang II.  Therefore, we hypothesized that β-amino-acid-substituted Ang III peptide analogs would yield highly selective AT2R ligands, which we have tested in binding and functional vascular assays.  In competition binding expts. using either AT1R- or AT2R-transfected human embryonic kidney (HEK)-293 cells, novel β-substituted Ang III analogs lacked appreciable AT1R affinity, whereas most compds. could fully displace 125I-Sar1Ile8 Ang II from AT2R.  The rank order of affinity at AT2R was CGP42112 > Ang III > β-Pro7 Ang III = Ang II > β-Tyr4 Ang III ≥ PD123319 >> β-Phe8 Ang III >> β Arg2 Ang III = β-Val3 Ang III >> β-Ile5 Ang III.  The novel analog β-Pro7 Ang III was the most selective AT2R ligand tested, which was >20 000-fold more selective for AT2R than AT1R.  IC50 values at AT2R from binding studies correlated with max. vasorelaxation in mouse aortic rings.  Given that β-Pro7 Ang III was an AT2R agonist, we compared β-Pro7 Ang III and native Ang III for their ability to reduce blood pressure in sep. groups of conscious spontaneously hypertensive rats.  Whereas Ang III alone increased mean arterial pressure (MAP), β-Pro7 Ang III had no effect.  During low-level AT1R blockade, both Ang III and β-Pro7 Ang III, but not Ang II, lowered MAP (by ∼30 mmHg) at equimolar infusions (150 pmol/kg/min for 4 h) and these depressor effects were abolished by the co-administration of the AT2R antagonist PD123319.  Thus, β-Pro7 Ang III has remarkable AT2R selectivity detd. in binding and functional studies and will be a valuable research tool for insight into AT2R function and for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp253Q4ZRqqMrVg90H21EOLACvtfcHk0ljhyf2VxUs5QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OmurfK&md5=5ebc6245b4d4c80de80a11ee57603de0</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1042%2FCS20150077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20150077%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BBorgo%26aufirst%3DM.%2BP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBosnyak%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DWalters%26aufirst%3DP.%26aulast%3DSpizzo%26aufirst%3DI.%26aulast%3DPerlmutter%26aufirst%3DP.%26aulast%3DHilliard%26aufirst%3DL.%26aulast%3DDenton%26aufirst%3DK.%26aulast%3DAguilar%26aufirst%3DM.%2BI.%26aulast%3DWiddop%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DE.%2BS.%26atitle%3DBeta-Pro7%2520Ang%2520III%2520is%2520a%2520novel%2520highly%2520selective%2520angiotensin%2520AT2R%2520agonist%252C%2520which%2520acts%2520as%2520a%2520vasodepressor%2520agent%2520via%2520the%2520AT2%2520receptor%2520in%2520conscious%2520SHR%26jtitle%3DClin.%2520Sci.%26date%3D2015%26volume%3D129%26spage%3D505%26epage%3D513%26doi%3D10.1042%2FCS20150077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohinata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span> <span> </span><span class="NLM_article-title">The pharmacological effects of novokinin; a designed peptide agonist of the angiotensin AT2 receptor</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3009</span>– <span class="NLM_lpage">3012</span>, <span class="refDoi"> DOI: 10.2174/1381612811319170006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2174%2F1381612811319170006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23176213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFKhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3009-3012&author=M.+Yoshikawaauthor=K.+Ohinataauthor=Y.+Yamada&title=The+pharmacological+effects+of+novokinin%3B+a+designed+peptide+agonist+of+the+angiotensin+AT2+receptor&doi=10.2174%2F1381612811319170006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacological effects of novokinin; a designed peptide agonist of the angiotensin AT2 receptor</span></div><div class="casAuthors">Yoshikawa, Masaaki; Ohinata, Kousaku; Yamada, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3009-3012</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Novokinin (RPLKPW) was designed based on ovokinin (FRADHPFL), a vasorelaxing peptide derived from ovalbumin.  Novokinin relaxed a mesenteric artery isolated from the spontaneously hypertensive rat (SHR) at 10-5 M, and reduced SHR blood pressure at a dose of 0.1 mg/kg (po.) emulsified in 30% egg yolk.  Novokinin exhibited an affinity for the AT2 receptor (Ki = 7 × 10-6M), and its antihypertensive and vasorelaxing activities were blocked by PD123319, an AT2 receptor antagonist.  The hypotensive effect of novokinin in normotensive mice was not obsd. in the AT2 receptor-knockout mice.  Its antihypertensive and vasorelaxing activities in SHR were also blocked by CAY-10441, an antagonist of the IP receptor for prostaglandin I2 (PGI2) suggesting that these activities are mediated by the AT2 receptor, followed by the prostaglandin I2-IP receptor pathway.  Novokinin suppressed food intake after icv. or po. administration in mice.  The anorexigenic activity was not obsd. in the AT2 receptor-knockout mice, but was obsd. in the AT1 receptor-knockout mice.  The anorexigenic activities of novokinin and angiotensin II were blocked by PD123319, and ONO-AE3-208, an antagonist of the EP4 receptor suggesting that the anorexigenic activities of the AT2 agonists are mediated by the PGE2-EP4 receptor pathway downstream of the AT2 receptor.  Novokinin given icv. in mice antagonized the antinociceptive effect of morphine.  The antiopiod activites of novokinin and angiotensin II were are blocked by PD123319, and by ONO-AE3-240, an antagonist of the EP3 receptor, suggesting that the antiopioid activities of AT2 agonists is mediated by the PGE2-EP3 receptor downstream of the AT2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7wyfXfmyaErVg90H21EOLACvtfcHk0ljhyf2VxUs5QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFKhtLY%253D&md5=93cc7903618fa9f808519db7fe146381</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.2174%2F1381612811319170006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319170006%26sid%3Dliteratum%253Aachs%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DOhinata%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DY.%26atitle%3DThe%2520pharmacological%2520effects%2520of%2520novokinin%253B%2520a%2520designed%2520peptide%2520agonist%2520of%2520the%2520angiotensin%2520AT2%2520receptor%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D3009%26epage%3D3012%26doi%3D10.2174%2F1381612811319170006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Georgsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sköld, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogoll, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II pseudopeptides containing 1,3,5-trisubsituted benzene scaffolds with high AT<sub>2</sub> receptor affinity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6620</span>– <span class="NLM_lpage">6631</span>, <span class="refDoi"> DOI: 10.1021/jm050280z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050280z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVegt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6620-6631&author=J.+Georgssonauthor=C.+Sk%C3%B6ldauthor=B.+Plouffeauthor=G.+Lindebergauthor=M.+Botrosauthor=M.+Larhedauthor=F.+Nybergauthor=N.+Gallo-Payetauthor=A.+Gogollauthor=A.+Karl%C3%A9nauthor=A.+Hallberg&title=Angiotensin+II+pseudopeptides+containing+1%2C3%2C5-trisubsituted+benzene+scaffolds+with+high+AT2+receptor+affinity&doi=10.1021%2Fjm050280z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II Pseudopeptides Containing 1,3,5-Trisubstituted Benzene Scaffolds with High AT2 Receptor Affinity</span></div><div class="casAuthors">Georgsson, Jennie; Skoeld, Christian; Plouffe, Bianca; Lindeberg, Gunnar; Botros, Milad; Larhed, Mats; Nyberg, Fred; Gallo-Payet, Nicole; Gogoll, Adolf; Karlen, Anders; Hallberg, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6620-6631</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two 1,3,5-trisubstituted arom. scaffolds intended to serve as γ-turn mimetics have been synthesized and incorporated in five pseudopeptide analogs of angiotensin II (H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH), replacing Val-Tyr-Ile, Val-Tyr, or Tyr-Ile.  All the tested compds. exhibited nanomolar affinity for the AT2 receptor with the best compd., pseudopeptide I with Ki = 1.85 nM.  Four pseudopeptides were AT2 selective, while pseudopeptide II also exhibited good affinity for the AT1 receptor (Ki = 30.3 nM).  This pseudopeptide exerted full agonistic activity in an AT2 receptor induced neurite outgrowth assay but displayed no agonistic effect in an AT1 receptor functional assay.  Mol. modeling, using the program DISCOtech, showed that the high-affinity ligands could interact similarly with the AT2 receptor as other ligands with high affinity for this receptor.  A tentative agonist model is proposed for AT2 receptor activation by angiotensin II analogs.  The authors conclude that the 1,3,5-trisubstituted benzene rings can be conveniently prepd. and are suitable as γ-turn mimics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo_DtMVb43c7Vg90H21EOLACvtfcHk0ljhyf2VxUs5QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVegt7rI&md5=d0d04a9501ed77044d48783f69df4660</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm050280z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050280z%26sid%3Dliteratum%253Aachs%26aulast%3DGeorgsson%26aufirst%3DJ.%26aulast%3DSk%25C3%25B6ld%26aufirst%3DC.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DLindeberg%26aufirst%3DG.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DLarhed%26aufirst%3DM.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DGogoll%26aufirst%3DA.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DAngiotensin%2520II%2520pseudopeptides%2520containing%25201%252C3%252C5-trisubsituted%2520benzene%2520scaffolds%2520with%2520high%2520AT2%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6620%26epage%3D6631%26doi%3D10.1021%2Fjm050280z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Georgsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sköld, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT<sub>2</sub> receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1715</span>, <span class="refDoi"> DOI: 10.1021/jm0613469</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0613469" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislKrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1711-1715&author=J.+Georgssonauthor=C.+Sk%C3%B6ldauthor=M.+Botrosauthor=G.+Lindebergauthor=F.+Nybergauthor=A.+Karl%C3%A9nauthor=A.+Hallbergauthor=M.+Larhed&title=Synthesis+of+a+new+class+of+druglike+angiotensin+II+C-terminal+mimics+with+affinity+for+the+AT2+receptor&doi=10.1021%2Fjm0613469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT2 receptor</span></div><div class="casAuthors">Georgsson, Jennie; Skoeld, Christian; Botros, Milad; Lindeberg, Gunnar; Nyberg, Fred; Karlen, Anders; Hallberg, Anders; Larhed, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1711-1715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Four tripeptides corresponding to the C-terminal region of angiotensin II were synthesized.  One of these peptides (Ac-His-Pro-Ile) showed moderate binding affinity for the AT2 receptor.  Two arom. histidine-related scaffolds were synthesized and introduced in the tripeptides to give eight new peptidomimetic structures.  Three of the peptide-derived druglike mols. exhibited selective, nanomolar affinity for the AT2 receptor.  These ligands may become lead compds. in the future development of novel classes of selective AT2 receptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSWg7500LLF7Vg90H21EOLACvtfcHk0lgRmrm3YRoxiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislKrsr8%253D&md5=2caa1e026577b56f2342bd8bd5925fba</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fjm0613469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0613469%26sid%3Dliteratum%253Aachs%26aulast%3DGeorgsson%26aufirst%3DJ.%26aulast%3DSk%25C3%25B6ld%26aufirst%3DC.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DLindeberg%26aufirst%3DG.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DLarhed%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520a%2520new%2520class%2520of%2520druglike%2520angiotensin%2520II%2520C-terminal%2520mimics%2520with%2520affinity%2520for%2520the%2520AT2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1711%26epage%3D1715%26doi%3D10.1021%2Fjm0613469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Gasparo, M.</span></span> <span> </span><span class="NLM_article-title">Preliminary biochemical characterization of two angiotensin II receptor subtypes</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(89)92133-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2F0006-291X%2889%2992133-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=2775266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaL1MXlsVOnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=1989&pages=284-291&author=S.+Whitebreadauthor=M.+Meleauthor=B.+Kamberauthor=M.+de+Gasparo&title=Preliminary+biochemical+characterization+of+two+angiotensin+II+receptor+subtypes&doi=10.1016%2F0006-291X%2889%2992133-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary biochemical characterization of two angiotensin II receptor subtypes</span></div><div class="casAuthors">Whitebread, Steven; Mele, Michele; Kamber, Bruno; De Gasparo, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">284-91</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Two angiotensin II receptor subtypes (A and B) from rat and human tissues have been characterized using specific peptidic and nonpeptidic ligands with affinities differing by 1000-fold or more.  These subtypes are present in the adrenal glomerulosa of both species.  Human uterus contains only subtype A, whereas both subtypes are found in rat uterus.  Vascular smooth muscle cells in culture express only subtype B.  Dithiothreitol totally inhibits binding to subtype B, but enhances the affinity to subtype A.  There is a good correlation between the affinities of the selected agonists and antagonists for the two subtypes in the various tissues tested, which is a usual requirement for receptor classification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUpya3IHUYIbVg90H21EOLACvtfcHk0lgRmrm3YRoxiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlsVOnsLs%253D&md5=018f8ff198b49720f4880adc6ff2221f</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2889%2992133-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252889%252992133-5%26sid%3Dliteratum%253Aachs%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DMele%26aufirst%3DM.%26aulast%3DKamber%26aufirst%3DB.%26aulast%3Dde%2BGasparo%26aufirst%3DM.%26atitle%3DPreliminary%2520biochemical%2520characterization%2520of%2520two%2520angiotensin%2520II%2520receptor%2520subtypes%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1989%26volume%3D163%26spage%3D284%26epage%3D291%26doi%3D10.1016%2F0006-291X%2889%2992133-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brait, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugam, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobey, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo</span>. <i>Exp. Transl. Stroke Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.1186/2040-7378-4-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1186%2F2040-7378-4-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22920387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKltL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=16&author=S.+Leeauthor=V.+H.+Braitauthor=T.+V.+Arumugamauthor=M.+A.+Evansauthor=H.+A.+Kimauthor=R.+E.+Widdopauthor=G.+R.+Drummondauthor=C.+G.+Sobeyauthor=E.+S.+Jones&title=Neuroprotective+effect+of+an+angiotensin+receptor+type+2+agonist+following+cerebral+ischemia+in+vitro+and+in+vivo&doi=10.1186%2F2040-7378-4-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo</span></div><div class="casAuthors">Lee, Seyoung; Brait, Vanessa H.; Arumugam, Thiruma V.; Evans, Megan A.; Kim, Hyun Ah; Widdop, Robert E.; Drummond, Grant R.; Sobey, Christopher G.; Jones, Emma S.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & Translational Stroke Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16</span>CODEN:
                <span class="NLM_cas:coden">ETSMCZ</span>;
        ISSN:<span class="NLM_cas:issn">2040-7378</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Intracerebral administration of the angiotensin II type 2 receptor (AT2R) agonist, CGP42112, is neuroprotective in a rat model of ischemic stroke.  To explore further its possible cellular target(s) and therapeutic utility, we firstly examd. whether CGP42112 may exert direct protective effects on primary neurons following glucose deprivation in vitro.  Secondly, we tested whether CGP42112 is effective when administered systemically in a mouse model of cerebral ischemia.  Methods: Primary cortical neurons were cultured from E17 C57Bl6 mouse embryos for 9 d, exposed to glucose deprivation for 24 h alone or with drug treatments and percent cell survival assessed using trypan blue exclusion.  Ischemic stroke was induced in adult male C57Bl6 mice by middle cerebral artery occlusion for 30 min, followed by reperfusion for 23.5 h.  Neurol. assessment was performed and then mice were euthanized and infarct and edema vol. were analyzed.  Results: During glucose deprivation, CGP42112 (1 × 10-8 M and 1 × 10-7 M) reduced cell death by ∼30%, an effect that was prevented by the AT2R antagonist, PD123319 (1 × 10-6 M).  Neuroprotection by CGP42112 was lost at a higher concn. (1 × 10-6 M) but was unmasked by co-application with the AT1R antagonist, candesartan (1 × 10-7 M).  By contrast, Compd. 21 (1 × 10-8 M to 1 × 10-6 M), a second AT2R agonist, had no effect on neuronal survival.  Mice treated with CGP42112 (1 mg/kg i.p.) after cerebral ischemia had improved functional outcomes over vehicle-treated mice as well as reduced total and cortical infarct vols.  Conclusions: These results indicate that CGP42112 can directly protect neurons from ischemia-like injury in vitro via activation of AT2Rs, an effect opposed by AT1R activation at high concns.  Furthermore, systemic administration of CGP42112 can reduce functional deficits and infarct vol. following cerebral ischemia in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXflrPTMoM37Vg90H21EOLACvtfcHk0lgRmrm3YRoxiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKltL3L&md5=5bcc47a7f146d896a63ad87cf1745e6b</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1186%2F2040-7378-4-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2040-7378-4-16%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DBrait%26aufirst%3DV.%2BH.%26aulast%3DArumugam%26aufirst%3DT.%2BV.%26aulast%3DEvans%26aufirst%3DM.%2BA.%26aulast%3DKim%26aufirst%3DH.%2BA.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DDrummond%26aufirst%3DG.%2BR.%26aulast%3DSobey%26aufirst%3DC.%2BG.%26aulast%3DJones%26aufirst%3DE.%2BS.%26atitle%3DNeuroprotective%2520effect%2520of%2520an%2520angiotensin%2520receptor%2520type%25202%2520agonist%2520following%2520cerebral%2520ischemia%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DExp.%2520Transl.%2520Stroke%2520Med.%26date%3D2012%26volume%3D4%26spage%3D16%26doi%3D10.1186%2F2040-7378-4-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umschweif, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liraz-Zaltsman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabashov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrovich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trembovler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shohami, E.</span></span> <span> </span><span class="NLM_article-title">Angiotensin receptor type 2 activation induces neuroprotection and neurogenesis after traumatic brain injury</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1007/s13311-014-0286-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs13311-014-0286-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24957202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOjtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=665-678&author=G.+Umschweifauthor=S.+Liraz-Zaltsmanauthor=D.+Shabashovauthor=A.+Alexandrovichauthor=V.+Trembovlerauthor=M.+Horowitzauthor=E.+Shohami&title=Angiotensin+receptor+type+2+activation+induces+neuroprotection+and+neurogenesis+after+traumatic+brain+injury&doi=10.1007%2Fs13311-014-0286-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin Receptor Type 2 Activation Induces Neuroprotection and Neurogenesis After Traumatic Brain Injury</span></div><div class="casAuthors">Umschweif, Gali; Liraz-Zaltsman, Sigal; Shabashov, Dalia; Alexandrovich, Alexander; Trembovler, Victoria; Horowitz, Michal; Shohami, Esther</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">665-678</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Angiotensin II receptor type 2 (AT2) agonists have been shown to limit brain ischemic insult and to improve its outcome.  The activation of AT2 was also linked to induced neuronal proliferation and differentiation in vitro.  In this study, we examd. the therapeutic potential of AT2 activation following traumatic brain injury (TBI) in mice, a brain pathol. that displays ischemia-like secondary damages.  The AT2 agonist CGP42112A was continuously infused immediately after closed head injury (CHI) for 3 days.  We have followed the functional recovery of the injured mice for 35 days post-CHI, and evaluated cognitive function, lesion vol., mol. signaling, and neurogenesis at different time points after the impact.  We found dose-dependent improvement in functional recovery and cognitive performance after CGP42112A treatment that was accompanied by reduced lesion vol. and induced neurogenesis in the neurogenic niches of the brain and also in the injury region.  At the cellular/mol. level, CGP42112A induced early activation of neuroprotective kinases protein kinase B (Akt) and extracellular-regulated kinases 1/2 (ERK1/2), and the neurotrophins nerve growth factor and brain-derived neurotrophic factor; all were blocked by treatment with the AT2 antagonist PD123319.  Our results suggest that AT2 activation after TBI promotes neuroprotection and neurogenesis, and may be a novel approach for the development of new drugs to treat victims of TBI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlqvL6wZPIgbVg90H21EOLACvtfcHk0lgBWCmpUofyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOjtbvI&md5=c153337ab9f77b3da39f52d683e7288e</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2Fs13311-014-0286-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-014-0286-x%26sid%3Dliteratum%253Aachs%26aulast%3DUmschweif%26aufirst%3DG.%26aulast%3DLiraz-Zaltsman%26aufirst%3DS.%26aulast%3DShabashov%26aufirst%3DD.%26aulast%3DAlexandrovich%26aufirst%3DA.%26aulast%3DTrembovler%26aufirst%3DV.%26aulast%3DHorowitz%26aufirst%3DM.%26aulast%3DShohami%26aufirst%3DE.%26atitle%3DAngiotensin%2520receptor%2520type%25202%2520activation%2520induces%2520neuroprotection%2520and%2520neurogenesis%2520after%2520traumatic%2520brain%2520injury%26jtitle%3DNeurotherapeutics%26date%3D2014%26volume%3D11%26spage%3D665%26epage%3D678%26doi%3D10.1007%2Fs13311-014-0286-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toedebusch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belenchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulakat, L.</span></span> <span> </span><span class="NLM_article-title">Cell-specific protective signaling induced by the novel AT2R-agonist NP-6A4 on human endothelial and smooth muscle cells</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">928</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffphar.2018.00928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30186168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFyltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=928&author=R.+Toedebuschauthor=A.+Belenchiaauthor=L.+Pulakat&title=Cell-specific+protective+signaling+induced+by+the+novel+AT2R-agonist+NP-6A4+on+human+endothelial+and+smooth+muscle+cells&doi=10.3389%2Ffphar.2018.00928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-specific protective signaling induced by the novel AT2R-agonist NP-6A4 on human endothelial and smooth muscle cells</span></div><div class="casAuthors">Toedebusch, Ryan; Belenchia, Anthony; Pulakat, Lakshmi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">928/1-928/14</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Cardiovascular disease incidence continues to rise and new treatment paradigms are warranted.  We reported previously that activation of Angiotensin II receptor (encoded by the X-linked Agtr2 gene) by a new peptide agonist, NP-6A4, was more effective in protecting mouse cardiomyocyte HL-1 cells and human coronary artery vascular smooth muscle cells (hCAVSMCs) from acute nutrient deficiency than other drugs tested.  To elucidate further the protective effects of NP-6A4 in human cells, we studied the effects of NP-6A4 treatment on functions of human coronary artery endothelial cells (hCAECs), and hCAVSMCs.  In hCAVSMCs, NP-6A4 (1 μM) increased Agtr2 mRNA (sixfold, p < 0.05) after 12-h exposure, whereas in hCAECs, significant increase in Agtr2 mRNA (hCAECs: eightfold) was obsd. after prolonged exposure.  Interestingly, NP- 6A4 treatment (1 μM, 12 h) increased AT2R protein levels in all human cells tested.  Pre-treatment with AT2R-antagonist PD123319 (20 μM) and anti-AT2R siRNA (1 μM) suppressed this effect.  Thus, NP-6A4 activates a pos. feedback loop for AT2R expression and signaling in hCAVSMCs and hCAECs.  NP-6A4 (1-20 μM) increased cell index (CI) of hCAVSMCs as detd. by real time cell analyzer (RTCA), indicating that high concns. of NP-6A4 were not cytotoxic for hCAVSMCs, rather promoting better cell attachment and growth.  Seahorse Extracellular Flux Assay revealed that NP- 6A4 (1 μM) treatment for 7 days increased whole cell-based mitochondrial parameters of hCAVSMCs, specifically maximal respiration (p < 0.05), spare respiratory capacity (p < 0.05) and ATP prodn. (p < 0.05).  NP-6A4 (1 μM; 7 days) also suppressed Reactive Oxygen Species (ROS) in hCAVSMCs.  Exposure to Doxorubicin (DOXO) (1 μM) increased ROS in hCAVSMCs and this effect was suppressed by NP-6A4 (1 μM).  In hCAECs grown in complete medium, NP-6A4 (1 μM) and Ang II (1 μM) exerted similar changes in CI.  Addnl., NP-6A4 (5 μM: 12 h) increased expression of eNOS (sixfold, p < 0.05) and generation of nitric oxide (1.3-fold, p < 0.05) in hCAECs and pre-treatment with PD123319 (20 μM) suppressed this effect partially (65%).  Finally, NP-6A4 decreased phosphorylation of Jun-N-terminal kinase, implicated in apoptosis of ECs in atherosclerotic sites.  Taken together, NP-6A4, through its ability to increase AT2R expression and signaling, exerts different cell-specific protective effects in human VSMCs and ECs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphyApOE4IiILVg90H21EOLACvtfcHk0lgBWCmpUofyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFyltbg%253D&md5=4702699a8659833cb37c9b1dab18f507</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00928%26sid%3Dliteratum%253Aachs%26aulast%3DToedebusch%26aufirst%3DR.%26aulast%3DBelenchia%26aufirst%3DA.%26aulast%3DPulakat%26aufirst%3DL.%26atitle%3DCell-specific%2520protective%2520signaling%2520induced%2520by%2520the%2520novel%2520AT2R-agonist%2520NP-6A4%2520on%2520human%2520endothelial%2520and%2520smooth%2520muscle%2520cells%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D928%26doi%3D10.3389%2Ffphar.2018.00928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dimmeler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rippmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiland, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haendeler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiher, A. M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">970</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1161/01.RES.81.6.970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.RES.81.6.970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9400377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFWrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1997&pages=970-976&author=S.+Dimmelerauthor=V.+Rippmannauthor=U.+Weilandauthor=J.+Haendelerauthor=A.+M.+Zeiher&title=Angiotensin+II+induces+apoptosis+of+human+endothelial+cells.+Protective+effect+of+nitric+oxide&doi=10.1161%2F01.RES.81.6.970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II induces apoptosis of human endothelial cells: protective effect of nitric oxide</span></div><div class="casAuthors">Dimmeler, Stefanie; Rippmann, Volker; Weiland, Ulrike; Haendeler, Judith; Zeiher, Andreas M.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">970-976</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">American Heart Association</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II) importantly contributes to the pathobiol. of atherosclerosis.  Since endothelial injury is a key event early in the pathogenesis of atherosclerosis, the authors tested the hypothesis that Ang II may injure endothelial cells by activation of cellular suicide pathways leading to apoptosis.  Human umbilical venous endothelial cells (HUVECs) were incubated with increasing doses of Ang II for 18 h.  Apoptosis of HUVECs was measured by ELISA specific for histone-assocd. DNA fragments and confirmed by DNA laddering and nuclear staining.  Ang II dose-dependently induced apoptosis of HUVECs.  Simultaneous blockade of both the AT1 and AT2 receptor prevented Ang II-induced apoptosis, whereas each individual receptor blocker alone was not effective.  Selective agonistic stimulation of the AT2 receptor also dose-dependently induced apoptosis.  Ang II-mediated as well as selective AT2 receptor stimulation-mediated apoptosis was assocd. with the activation of caspase-3, a central down-stream effector of the caspase cascade executing the cell death program.  Specific inhibition of caspase-3 activity abrogated Ang II-induced apoptosis.  In addn., the NO donors sodium nitroprusside and S-nitrosopenicillamine completely inhibited Ang II-induced apoptosis and eliminated caspase-3 activity.  Thus, Ang II induces apoptosis of HUVECs via activation of the caspase cascade, the central downstream effector arm executing the cell death program.  NO completely abrogated Ang II-induced apoptosis by interfering with the activation of the caspase cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH2dhA5oFOMLVg90H21EOLACvtfcHk0lgBWCmpUofyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFWrtbc%253D&md5=8d0ff36eb9743ffcbecd29303f8fdb70</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1161%2F01.RES.81.6.970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.81.6.970%26sid%3Dliteratum%253Aachs%26aulast%3DDimmeler%26aufirst%3DS.%26aulast%3DRippmann%26aufirst%3DV.%26aulast%3DWeiland%26aufirst%3DU.%26aulast%3DHaendeler%26aufirst%3DJ.%26aulast%3DZeiher%26aufirst%3DA.%2BM.%26atitle%3DAngiotensin%2520II%2520induces%2520apoptosis%2520of%2520human%2520endothelial%2520cells.%2520Protective%2520effect%2520of%2520nitric%2520oxide%26jtitle%3DCirc.%2520Res.%26date%3D1997%26volume%3D81%26spage%3D970%26epage%3D976%26doi%3D10.1161%2F01.RES.81.6.970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanif, K.</span></span> <span> </span><span class="NLM_article-title">AT2R activation prevents microglia pro-inflammatory activation in a NOX-dependent manner: inhibition of PKC activation and p47<sup>phox</sup> phosphorylation by PP2A</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3005</span>– <span class="NLM_lpage">3023</span>, <span class="refDoi"> DOI: 10.1007/s12035-018-1272-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs12035-018-1272-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30076526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGjsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2019&pages=3005-3023&author=S.+A.+Bhatauthor=A.+Soodauthor=R.+Shuklaauthor=K.+Hanif&title=AT2R+activation+prevents+microglia+pro-inflammatory+activation+in+a+NOX-dependent+manner%3A+inhibition+of+PKC+activation+and+p47phox+phosphorylation+by+PP2A&doi=10.1007%2Fs12035-018-1272-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">AT2R Activation Prevents Microglia Pro-inflammatory Activation in a NOX-Dependent Manner: Inhibition of PKC Activation and p47phox Phosphorylation by PP2A</span></div><div class="casAuthors">Bhat, Shahnawaz Ali; Sood, Anika; Shukla, Rakesh; Hanif, Kashif</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">3005-3023</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Microglia-induced reactive oxygen species (ROS) prodn. and inflammation play an imperative role in neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease (PD).  It has been established that angiotensin II type-2 receptor (AT2R) activation is neuroprotective in central nervous system diseases like stroke and AD.  However, the involvement of AT2R in NADPH oxidase (NOX)-mediated microglia activation is still elusive.  Therefore, the present study investigated the role of AT2R in angiotensin II (Ang II) or Phorbol 12-myristate 13-acetate (PMA)-induced microglia activation in BV2 cells, primary microglia, p47phox knockout (p47KO) microglia, and in vivo.  Treatment of microglia with Ang II or PMA induced a significant ROS generation and promoted pro-inflammatory microglia in a NOX-dependent manner.  In contrast, AT2R activation by CGP42112A (CGP) inhibited NOX activation, ROS prodn., and pro-inflammatory microglia activation, while promoting the immunoregulatory microglia.  This inhibitory effect of AT2R on NOX and pro-inflammatory activation was attenuated by AT2R antagonist, PD123319.  Essentially, NOX inhibition (by DPI) or scavenging cellular ROS (by NAC) or p47KO microglia were immune to Ang II- or PMA-induced pro-inflammatory microglia activation.  Mechanistically, AT2R, via activation of protein phosphatase-2A (PP2A), prevented the Ang II- or PMA-induced protein kinase C (PKC) activation and phosphorylation of p47phox, an effect that was reversed by the addn. of PP2A inhibitor, Okadaic acid (OA).  Importantly, PKC inhibitor, Rottlerin, inhibited the Ang II- or PMA-induced p47phox phosphorylation and ROS generation to the similar extent as AT2R activation.  In addn., AT2R activation or p47KO prevented ROS prodn., pro-inflammatory microglial activation, and sickness behavior in mice model of neuroinflammation.  Therefore, the present findings suggested that AT2R, via PP2A-mediated inhibition of PKC, prevents the NOX activation, ROS generation, and subsequent pro-inflammatory activation of microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrJgTy8po9LVg90H21EOLACvtfcHk0lhUdEqDGcYNnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGjsb3F&md5=cadf6f4ee801ca95b275e3aaf442ca0e</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1007%2Fs12035-018-1272-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-018-1272-9%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DS.%2BA.%26aulast%3DSood%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DR.%26aulast%3DHanif%26aufirst%3DK.%26atitle%3DAT2R%2520activation%2520prevents%2520microglia%2520pro-inflammatory%2520activation%2520in%2520a%2520NOX-dependent%2520manner%253A%2520inhibition%2520of%2520PKC%2520activation%2520and%2520p47phox%2520phosphorylation%2520by%2520PP2A%26jtitle%3DMol.%2520Neurobiol.%26date%3D2019%26volume%3D56%26spage%3D3005%26epage%3D3023%26doi%3D10.1007%2Fs12035-018-1272-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X. F.</span></span> <span> </span><span class="NLM_article-title">Brain endogenous angiotensin II receptor type 2 (AT2-R) protects against DOCA/salt-induced hypertension in female rats</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">47</span>, <span class="refDoi"> DOI: 10.1186/s12974-015-0261-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1186%2Fs12974-015-0261-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25885968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjls1egsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=47&author=S.+Y.+Daiauthor=W.+Pengauthor=Y.+P.+Zhangauthor=J.+D.+Liauthor=Y.+Shenauthor=X.+F.+Sun&title=Brain+endogenous+angiotensin+II+receptor+type+2+%28AT2-R%29+protects+against+DOCA%2Fsalt-induced+hypertension+in+female+rats&doi=10.1186%2Fs12974-015-0261-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Brain endogenous angiotensin II receptor type 2 (AT2-R) protects against DOCA/salt-induced hypertension in female rats</span></div><div class="casAuthors">Dai Shu-Yan; Shen Ying; Sun Xiao-Fei; Peng Wei; Zhang Yu-Ping; Li Jian-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroinflammation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recent studies demonstrate that there are sex differences in the expression of angiotensin receptor type 2 (AT2-R) in the kidney and that AT2-R plays an enhanced role in regulating blood pressure (BP) in females.  Also, brain AT2-R activation has been reported to negatively modulate BP and sympathetic outflow.  The present study investigated whether the central blockade of endogenous AT2-R augments deoxycorticosterone acetate (DOCA)/salt-induced hypertension in both male and female rats.  METHODS:  All rats were subcutaneously infused with DOCA combined with 1% NaCl solution as the sole drinking fluid.  BP and heart rate (HR) were recorded by telemetric transmitters.  To determine the effect of central AT2-R on DOCA/salt-induced hypertension, male and female rats were intracerebroventricularly (icv) infused with AT2-R antagonist, PD123,319, during DOCA/salt treatment.  Subsequently, the paraventricular nucleus (PVN) of the hypothalamus, a key cardiovascular regulatory region of the brain, was analyzed by quantitative real-time PCR and Western blot.  RESULTS:  DOCA/salt treatment elicited a greater increase in BP in male rats than that in females.  Icv infusions of the AT2-R antagonist significantly augmented DOCA/salt pressor effects in females.  However, this same treatment had no enhanced effect on DOCA/salt-induced increase in the BP in males.  Real-time PCR and Western blot analysis of the female brain revealed that DOCA/salt treatment enhanced the mRNA and protein expression for both antihypertensive components including AT2-R, angiotensin-converting enzyme (ACE)-2, and interleukin (IL)-10 and hypertensive components including angiotensin receptor type 1 (AT1-R), ACE-1, tumor necrosis factor (TNF)-α, and IL-1β, but decreased mRNA expression of renin in the PVN.  The central blockade of AT2-R reversed the changes in mRNA and protein expressions of ACE-2, IL-10, and renin, further increased the expressions of TNF-α and IL-1β, and kept higher the expressions of AT1-R, ACE-1, and AT2-R.  CONCLUSIONS:  These results indicate that endogenous AT2-R activation in the brain plays an important protective role in the development of DOCA/salt-induced hypertension in females, but not in males.  The protective effect of AT2-R in females involves regulating the expression of brain renin-angiotensin system components and proinflammatory cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6oVgkPGP0IvxQvRxYU81tfW6udTcc2eYfLLFKbx4C4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjls1egsQ%253D%253D&md5=b1e12db3c1f16a93d8baa61a5572ec03</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1186%2Fs12974-015-0261-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-015-0261-4%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DS.%2BY.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%2BP.%26aulast%3DLi%26aufirst%3DJ.%2BD.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DX.%2BF.%26atitle%3DBrain%2520endogenous%2520angiotensin%2520II%2520receptor%2520type%25202%2520%2528AT2-R%2529%2520protects%2520against%2520DOCA%252Fsalt-induced%2520hypertension%2520in%2520female%2520rats%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2015%26volume%3D12%26spage%3D47%26doi%3D10.1186%2Fs12974-015-0261-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyse, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muralidharan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, T.</span></span> <span> </span><span class="NLM_article-title">A small molecule angiotensin II type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia</span>. <i>Pain Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1557</span>– <span class="NLM_lpage">1568</span>, <span class="refDoi"> DOI: 10.1111/pme.12157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2Fpme.12157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23742186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC3sjgtl2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1557-1568&author=M.+T.+Smithauthor=T.+M.+Woodruffauthor=B.+D.+Wyseauthor=A.+Muralidharanauthor=T.+Walther&title=A+small+molecule+angiotensin+II+type+2+receptor+%28AT2R%29+antagonist+produces+analgesia+in+a+rat+model+of+neuropathic+pain+by+inhibition+of+p38+mitogen-activated+protein+kinase+%28MAPK%29+and+p44%2Fp42+MAPK+activation+in+the+dorsal+root+ganglia&doi=10.1111%2Fpme.12157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule angiotensin II type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia</span></div><div class="casAuthors">Smith Maree T; Woodruff Trent M; Wyse Bruce D; Muralidharan Arjun; Walther Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pain medicine (Malden, Mass.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1557-68</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  There is an unmet clinical need for novel analgesics for neuropathic pain.  This study was designed to elucidate the mechanism through which EMA300, a small molecule antagonist of the angiotensin II type 2 receptor (AT2R) with >1,000-fold selectivity over the angiotensin II type 1 receptor, produces analgesia in a rodent model of neuropathic pain.  DESIGN AND METHODS:  Groups of AT2R knockout, hemizygotes, and wild-type mice with a chronic constriction injury (CCI) of the sciatic nerve received single intraperitoneal (i.p.) bolus doses of EMA300 (100 or 300 mg/kg), and analgesic efficacy was assessed.  Groups of control, sham-operated, and CCI rats were euthanized and perfusion fixed.  Lumbar dorsal root ganglia (DRGs) were removed for investigation of the mechanism through which EMA300 alleviates neuropathic pain.  RESULTS:  EMA300 analgesia was abolished in AT2R knockout CCI mice with intermediate responses in the hemizygotes, affirming the AT2R as the target mediating EMA300 analgesia.  In CCI rats, DRG immunofluorescence (IF) levels for angiotensin II, the main endogenous ligand of the AT2R, were increased ∼1.5-2.0-fold (P < 0.05) cf. sham-controls.  Mean DRG IF levels for activated p38 (pp38) and activated p44/p42 (pp44/pp42) MAPK were also increased ∼1.5-2.0-fold (P < 0.05) cf. sham-controls.  At the time of peak EMA300 analgesia in CCI rats, mean DRG levels of pp38 MAPK and pp44/pp42 MAPK (but not angiotensin II) were reduced to match the respective levels in sham-controls.  CONCLUSION:  Augmented angiotensin II/AT2R signaling in the DRGs of CCI rats is attenuated by EMA300 to block p38 MAPK and p44/p42 MAPK activation, a mechanism with clinical validity for alleviating neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXnivkNFx8x--MdeMhXAHkfW6udTcc2eYfLLFKbx4C4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjgtl2hsA%253D%253D&md5=58e8198bfaf990ad99b1b887abd88611</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1111%2Fpme.12157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpme.12157%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BT.%26aulast%3DWoodruff%26aufirst%3DT.%2BM.%26aulast%3DWyse%26aufirst%3DB.%2BD.%26aulast%3DMuralidharan%26aufirst%3DA.%26aulast%3DWalther%26aufirst%3DT.%26atitle%3DA%2520small%2520molecule%2520angiotensin%2520II%2520type%25202%2520receptor%2520%2528AT2R%2529%2520antagonist%2520produces%2520analgesia%2520in%2520a%2520rat%2520model%2520of%2520neuropathic%2520pain%2520by%2520inhibition%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520%2528MAPK%2529%2520and%2520p44%252Fp42%2520MAPK%2520activation%2520in%2520the%2520dorsal%2520root%2520ganglia%26jtitle%3DPain%2520Med.%26date%3D2013%26volume%3D14%26spage%3D1557%26epage%3D1568%26doi%3D10.1111%2Fpme.12157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyse, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, S. R.</span></span> <span> </span><span class="NLM_article-title">Small molecule angiotensin II type 2 receptor (AT2 R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats</span>. <i>Pain Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1111/pme.12063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2Fpme.12063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23489258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC3svmtVKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=692-705&author=M.+T.+Smithauthor=B.+D.+Wyseauthor=S.+R.+Edwards&title=Small+molecule+angiotensin+II+type+2+receptor+%28AT2+R%29+antagonists+as+novel+analgesics+for+neuropathic+pain%3A+comparative+pharmacokinetics%2C+radioligand+binding%2C+and+efficacy+in+rats&doi=10.1111%2Fpme.12063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats</span></div><div class="casAuthors">Smith Maree T; Wyse Bruce D; Edwards Stephen R</div><div class="citationInfo"><span class="NLM_cas:title">Pain medicine (Malden, Mass.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">692-705</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Neuropathic pain is an area of unmet clinical need.  The objective of this study was to define the pharmacokinetics, oral bioavailability, and efficacy in rats of small molecule antagonists of the angiotensin II type 2 receptor (AT2R) for the relief of neuropathic pain.  DESIGN AND METHODS:  Adult male Sprague-Dawley (SD) rats received single intravenous (1-10 mg/kg) or oral (5-10 mg/kg) bolus doses of EMA200, EMA300, EMA400 or EMA401 (S-enantiomer of EMA400).  Blood samples were collected immediately pre-dose and at specified times over a 12- to 24-hour post-dosing period.  Liquid chromatography tandem mass spectrometry was used to measure plasma drug concentrations.  Efficacy was assessed in adult male SD rats with a unilateral chronic constriction injury (CCI) of the sciatic nerve.  RESULTS:  After intravenous administration in rats, mean (±standard error of the mean) plasma clearance for EMA200, EMA300, EMA400, and EMA401 was 9.3, 6.1, 0.7, and 1.1 L/hour/kg, respectively.  After oral dosing, the dose-normalized systemic exposures of EMA400 and EMA401 were 20- to 30-fold and 50- to 60-fold higher than that for EMA300 and EMA200, respectively.  The oral bioavailability of EMA400 and EMA401 was similar at ∼30%, whereas it was only 5.9% and 7.1% for EMA200 and EMA300, respectively.  In CCI rats, single intraperitoneal bolus doses of EMA200, EMA300, and EMA400 evoked dose-dependent pain relief.  The pain relief potency rank order in CCI rats was EMA400 > EMA300 > EMA200 in agreement with the dose-normalized systemic exposure rank order in SD rats.  CONCLUSION:  The small molecule AT2R antagonist, EMA401, is in clinical development as a novel analgesic for the relief of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjI5YuvrZVpNts4TFFB11gfW6udTcc2eby2EWWSQwgkbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svmtVKisg%253D%253D&md5=5a5aecc9c63f4a49d650978d90603471</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1111%2Fpme.12063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpme.12063%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BT.%26aulast%3DWyse%26aufirst%3DB.%2BD.%26aulast%3DEdwards%26aufirst%3DS.%2BR.%26atitle%3DSmall%2520molecule%2520angiotensin%2520II%2520type%25202%2520receptor%2520%2528AT2%2520R%2529%2520antagonists%2520as%2520novel%2520analgesics%2520for%2520neuropathic%2520pain%253A%2520comparative%2520pharmacokinetics%252C%2520radioligand%2520binding%252C%2520and%2520efficacy%2520in%2520rats%26jtitle%3DPain%2520Med.%26date%3D2013%26volume%3D14%26spage%3D692%26epage%3D705%26doi%3D10.1111%2Fpme.12063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. S.</span></span> <span> </span><span class="NLM_article-title">Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">S33</span>– <span class="NLM_lpage">S41</span>, <span class="refDoi"> DOI: 10.1097/j.pain.0000000000000369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2Fj.pain.0000000000000369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26785154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Cltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=S33-S41&author=M.+T.+Smithauthor=P.+Anandauthor=A.+S.+Rice&title=Selective+small+molecule+angiotensin+II+type+2+receptor+antagonists+for+neuropathic+pain%3A+preclinical+and+clinical+studies&doi=10.1097%2Fj.pain.0000000000000369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies</span></div><div class="casAuthors">Smith, Maree T.; Anand, Praveen; Rice, Andrew S. C.</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">Suppl1</span>),
    <span class="NLM_cas:pages">S33-S41</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Neuropathic pain affects up to 10% of the general population, but drug treatments recommended for the treatment of neuropathic pain are assocd. with modest efficacy and/or produce dose-limiting side effects.  Hence, neuropathic pain is an unmet medical need.  In the past 2 decades, research on the pathobiol. of neuropathic pain has revealed many novel pain targets for use in analgesic drug discovery programs.  However, these efforts have been largely unsuccessful as mols. that showed promising pain relief in rodent models of neuropathic pain generally failed to produce analgesia in early phase clin. trials in patients with neuropathic pain.  One notable exception is the angiotensin II type 2 (AT2) receptor that has clin. validity on the basis of a successful double-blind, randomized, placebo-controlled, clin. trial of EMA401, a highly selective, orally active, peripherally restricted AT2 receptor antagonist in patients with postherpetic neuralgia.  In this study, we review research to date on target validation, efficacy, and mode of action of small mol. AT2 receptor antagonists in rodent models of peripheral neuropathic pain and in cultured human sensory neurons, the preclin. pharmacokinetics of these compds., and the outcome of the above clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6HyCVNeBH3rVg90H21EOLACvtfcHk0lg1JJcBTmRMZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Cltrw%253D&md5=a86d4155baffaafb2cdb1788493ce5ca</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1097%2Fj.pain.0000000000000369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fj.pain.0000000000000369%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BT.%26aulast%3DAnand%26aufirst%3DP.%26aulast%3DRice%26aufirst%3DA.%2BS.%26atitle%3DSelective%2520small%2520molecule%2520angiotensin%2520II%2520type%25202%2520receptor%2520antagonists%2520for%2520neuropathic%2520pain%253A%2520preclinical%2520and%2520clinical%2520studies%26jtitle%3DPain%26date%3D2016%26volume%3D157%26spage%3DS33%26epage%3DS41%26doi%3D10.1097%2Fj.pain.0000000000000369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keppel Hesselink, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatman, M. E.</span></span> <span> </span><span class="NLM_article-title">EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.2147/JPR.S128520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2147%2FJPR.S128520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28255254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC1czitlyhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=439-443&author=J.+M.+Keppel+Hesselinkauthor=M.+E.+Schatman&title=EMA401%3A+an+old+antagonist+of+the+AT2R+for+a+new+indication+in+neuropathic+pain&doi=10.2147%2FJPR.S128520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain</span></div><div class="casAuthors">Keppel Hesselink Jan M; Schatman Michael E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pain research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">439-443</span>
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    </div><div class="casAbstract">EMA401 is an old molecule, synthesized by Parke-Davis in the last century and characterized at that time as an AT2R antagonist.  Professor Maree Smith and her group from the University of Queensland (Australia) patented the drug and many related derivatives and other compounds with high affinity for the AT2R for the indication neuropathic pain in 2004, an example of drug repositioning.  After some years of university work, the Australian biotech company Spinifex Pharmaceuticals took over further research and development and characterized the S-enantiomer, code name EMA401, and related compounds in a variety of animal models for neuropathic and cancer pain.  EMA401 was selected as the lead compound, based on high selectivity for the AT2R and good oral bioavailability (33%).  EMA401, however, was only administered once in a chronic neuropathic pain model, and no data have been published in other pain models, or during steady state, although such data were available for the racemate EMA400 and some related compounds (EMA200, EMA400).  A pilot phase IIa study demonstrated the efficacy and safety of the drug taken twice daily as two capsules of 50 mg (400 mg/day).  In 2015, Novartis took over the clinical development.  Two phase IIb studies designed by Spinifex Pharmaceuticals were put on hold, probably because Novartis wanted to improve the clinical design or collect additional preclinical data.  Further data are eagerly awaited, especially since EMA401 is first-in-class in neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTQ2J8oScirIqdXsLcGTEUfW6udTcc2eby2EWWSQwgkbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czitlyhsA%253D%253D&md5=43664175cb490bced798d012aac8b2d4</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.2147%2FJPR.S128520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S128520%26sid%3Dliteratum%253Aachs%26aulast%3DKeppel%2BHesselink%26aufirst%3DJ.%2BM.%26aulast%3DSchatman%26aufirst%3DM.%2BE.%26atitle%3DEMA401%253A%2520an%2520old%2520antagonist%2520of%2520the%2520AT2R%2520for%2520a%2520new%2520indication%2520in%2520neuropathic%2520pain%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2017%26volume%3D10%26spage%3D439%26epage%3D443%26doi%3D10.2147%2FJPR.S128520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magnani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charalampos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magafa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordopatis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosnyak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerothanassis, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span> <span> </span><span class="NLM_article-title">Electronic sculpting of ligand-GPCR subtype selectivity: the case of angiotensin II</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1420</span>– <span class="NLM_lpage">1425</span>, <span class="refDoi"> DOI: 10.1021/cb500063y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500063y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFCgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1420-1425&author=F.+Magnaniauthor=G.+Charalamposauthor=T.+Pappasauthor=V.+Crookauthor=V.+Magafaauthor=P.+Cordopatisauthor=S.+Ishiguroauthor=N.+Ohtaauthor=J.+Selentauthor=S.+Bosnyakauthor=E.+S.+Jonesauthor=I.+P.+Gerothanassisauthor=M.+Tamuraauthor=R.+E.+Widdopauthor=A.+G.+Tzakos&title=Electronic+sculpting+of+ligand-GPCR+subtype+selectivity%3A+the+case+of+angiotensin+II&doi=10.1021%2Fcb500063y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Electronic Sculpting of Ligand-GPCR Subtype Selectivity: The Case of Angiotensin II</span></div><div class="casAuthors">Magnani, Francesca; Pappas, Charalampos G.; Crook, Tim; Magafa, Vassiliki; Cordopatis, Paul; Ishiguro, Susumu; Ohta, Naomi; Selent, Jana; Bosnyak, Sanja; Jones, Emma S.; Gerothanassis, Ioannis P.; Tamura, Masaaki; Widdop, Robert E.; Tzakos, Andreas G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1420-1425</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GPCR subtypes possess distinct functional and pharmacol. profiles, and thus development of subtype-selective ligands has immense therapeutic potential.  This is esp. the case for the angiotensin receptor subtypes AT1R and AT2R, where a functional neg. control has been described and AT2R activation highlighted as an important cancer drug target.  We describe a strategy to fine-tune ligand selectivity for the AT2R/AT1R subtypes through electronic control of ligand arom.-prolyl interactions.  Through this strategy an AT2R high affinity (Ki = 3 nM) agonist analog that exerted 18,000-fold higher selectivity for AT2R vs. AT1R was obtained.  We show that this compd. is a neg. regulator of AT1R signaling since it is able to inhibit MCF-7 breast carcinoma cellular proliferation in the low nanomolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiXuq9nm13uLVg90H21EOLACvtfcHk0ljTP7JPXfHbag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFCgtL4%253D&md5=027fe2a11bccf1d87d640f1084c09948</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fcb500063y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500063y%26sid%3Dliteratum%253Aachs%26aulast%3DMagnani%26aufirst%3DF.%26aulast%3DCharalampos%26aufirst%3DG.%26aulast%3DPappas%26aufirst%3DT.%26aulast%3DCrook%26aufirst%3DV.%26aulast%3DMagafa%26aufirst%3DV.%26aulast%3DCordopatis%26aufirst%3DP.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DN.%26aulast%3DSelent%26aufirst%3DJ.%26aulast%3DBosnyak%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DE.%2BS.%26aulast%3DGerothanassis%26aufirst%3DI.%2BP.%26aulast%3DTamura%26aufirst%3DM.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26atitle%3DElectronic%2520sculpting%2520of%2520ligand-GPCR%2520subtype%2520selectivity%253A%2520the%2520case%2520of%2520angiotensin%2520II%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1420%26epage%3D1425%26doi%3D10.1021%2Fcb500063y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eldahshan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishrat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayed, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alwhaibi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouda, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ergul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, S. C.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study</span>. <i>Am. J. Physiol., Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">H1192</span>– <span class="NLM_lpage">H1201</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00446.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajpheart.00446.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30822121" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2019&pages=H1192-H1201&author=W.+Eldahshanauthor=T.+Ishratauthor=B.+Pillaiauthor=M.+A.+Sayedauthor=A.+Alwhaibiauthor=A.+Y.+Foudaauthor=A.+Ergulauthor=S.+C.+Fagan&title=Angiotensin+II+type+2+receptor+stimulation+with+compound+21+improves+neurological+function+after+stroke+in+female+rats%3A+a+pilot+study&doi=10.1152%2Fajpheart.00446.2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00446.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00446.2018%26sid%3Dliteratum%253Aachs%26aulast%3DEldahshan%26aufirst%3DW.%26aulast%3DIshrat%26aufirst%3DT.%26aulast%3DPillai%26aufirst%3DB.%26aulast%3DSayed%26aufirst%3DM.%2BA.%26aulast%3DAlwhaibi%26aufirst%3DA.%26aulast%3DFouda%26aufirst%3DA.%2BY.%26aulast%3DErgul%26aufirst%3DA.%26aulast%3DFagan%26aufirst%3DS.%2BC.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor%2520stimulation%2520with%2520compound%252021%2520improves%2520neurological%2520function%2520after%2520stroke%2520in%2520female%2520rats%253A%2520a%2520pilot%2520study%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Heart%2520Circ.%2520Physiol.%26date%3D2019%26volume%3D316%26spage%3DH1192%26epage%3DH1201%26doi%3D10.1152%2Fajpheart.00446.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickle, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halabi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kloet, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samineni, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gereau, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohapatra, D. P.</span></span> <span> </span><span class="NLM_article-title">Macrophage angiotensin type 2 receptor triggers neuropathic pain</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E8057</span>– <span class="NLM_lpage">E8066</span>, <span class="refDoi"> DOI: 10.1073/pnas.1721815115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1073%2Fpnas.1721815115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30082378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCitLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E8057-E8066&author=A.+J.+Shepherdauthor=A.+D.+Mickleauthor=J.+P.+Goldenauthor=M.+R.+Mackauthor=C.+M.+Halabiauthor=A.+D.+de+Kloetauthor=V.+K.+Samineniauthor=B.+S.+Kimauthor=E.+G.+Krauseauthor=R.+W.+Gereauauthor=D.+P.+Mohapatra&title=Macrophage+angiotensin+type+2+receptor+triggers+neuropathic+pain&doi=10.1073%2Fpnas.1721815115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage angiotensin II type 2 receptor triggers neuropathic pain</span></div><div class="casAuthors">Shepherd, Andrew J.; Mickle, Aaron D.; Golden, Judith P.; Mack, Madison R.; Halabi, Carmen M.; de Kloet, Annette D.; Samineni, Vijay K.; Kim, Brian S.; Krause, Eric G.; Gereau, Robert W. IV; Mohapatra, Durga P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">E8057-E8066</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Peripheral nerve damage initiates a complex series of structural and cellular processes that culminate in chronic neuropathic pain.  The recent success of a type 2 angiotensin II (Ang II) receptor (AT2R) antagonist in a phase II clin. trial for the treatment of postherpetic neuralgia suggests angiotensin signaling is involved in neuropathic pain.  However, transcriptome anal. indicates a lack of AT2R gene (Agtr2) expression in human and rodent sensory ganglia, raising questions regarding the tissue/cell target underlying the analgesic effect of AT2R antagonism.  We show that selective antagonism of AT2R attenuates neuropathic but not inflammatory mech. and cold pain hypersensitivity behaviors in mice.  Agtr2-expressing macrophages constitute the predominant immune cells that infiltrate the site of nerve injury.  Interestingly, neuropathic mech. and cold pain hypersensitivity can be attenuated by chemogenetic depletion of peripheral macrophages and AT2R-null hematopoietic cell transplantation.  Our study identifies AT2R on peripheral macrophages as a crit. trigger for pain sensitization at the site of nerve injury, and therefore proposes a translatable peripheral mechanism underlying chronic neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHHGnThUpEILVg90H21EOLACvtfcHk0ljTP7JPXfHbag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCitLfO&md5=cdb381f5ca5b5f8703fae815ac249477</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1721815115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1721815115%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DA.%2BJ.%26aulast%3DMickle%26aufirst%3DA.%2BD.%26aulast%3DGolden%26aufirst%3DJ.%2BP.%26aulast%3DMack%26aufirst%3DM.%2BR.%26aulast%3DHalabi%26aufirst%3DC.%2BM.%26aulast%3Dde%2BKloet%26aufirst%3DA.%2BD.%26aulast%3DSamineni%26aufirst%3DV.%2BK.%26aulast%3DKim%26aufirst%3DB.%2BS.%26aulast%3DKrause%26aufirst%3DE.%2BG.%26aulast%3DGereau%26aufirst%3DR.%2BW.%26aulast%3DMohapatra%26aufirst%3DD.%2BP.%26atitle%3DMacrophage%2520angiotensin%2520type%25202%2520receptor%2520triggers%2520neuropathic%2520pain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE8057%26epage%3DE8066%26doi%3D10.1073%2Fpnas.1721815115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copits, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickle, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadunganattil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haroutounian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadinada, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kloet, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valtcheva, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIlvried, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usachev, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gereau, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohapatra, D. P.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II triggers peripheral macrophage-to-sensory neuron redox crosstalk to elicit pain</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">7032</span>– <span class="NLM_lpage">7057</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.3542-17.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1523%2FJNEUROSCI.3542-17.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29976627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKrtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=7032-7057&author=A.+J.+Shepherdauthor=B.+A.+Copitsauthor=A.+D.+Mickleauthor=P.+Karlssonauthor=S.+Kadunganattilauthor=S.+Haroutounianauthor=S.+M.+Tadinadaauthor=A.+D.+de+Kloetauthor=M.+V.+Valtchevaauthor=L.+A.+McIlvriedauthor=T.+D.+Sheahanauthor=S.+Jainauthor=P.+R.+Rayauthor=Y.+M.+Usachevauthor=G.+Dussorauthor=E.+G.+Krauseauthor=T.+J.+Priceauthor=R.+G.+Gereauauthor=D.+P.+Mohapatra&title=Angiotensin+II+triggers+peripheral+macrophage-to-sensory+neuron+redox+crosstalk+to+elicit+pain&doi=10.1523%2FJNEUROSCI.3542-17.2018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II triggers peripheral macrophage-to-sensory neuron redox crosstalk to elicit pain</span></div><div class="casAuthors">Shepherd, X. Andrew J.; Copits, Bryan A.; Mickle, Aaron D.; Karlsson, Pall; Kadunganattil, Suraj; Haroutounian, Simon; Tadinada, Satya M.; de Kloet, Annette D.; Valtcheva, Manouela V.; McIlvried, Lisa A.; Sheahan, Tayler D.; Jain, Sanjay; Ray, Pradipta R.; Usachev, Yuriy M.; Dussor, Gregory; Krause, Eric G.; Price, Theodore J.; Gereau, Robert W., IV; Mohapatra, Durga P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">7032-7057</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">1529-2401</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Injury, inflammation, and nerve damage initiate a wide variety of cellular and mol. processes that culminate in hyperexcitation of sensory nerves, which underlies chronic inflammatory and neuropathic pain.  Using behavioral read outs of pain hypersensitivity induced by angiotensin II (Ang II) injection into mouse hindpaws, our study shows that activation of the type 2 Ang II receptor (AT2R) and the cell-damage-sensing ion channel TRPA1 are required for peripheral mech. pain sensitization induced by Ang II in male and female mice.  However, we show that AT2R is not expressed in mouse and human dorsal root ganglia (DRG) sensory neurons.  Instead, expression/activation of AT2R on peripheral/skin macrophages (M [H9021] s) constitutes a crit. trigger of mouse and human DRG sensory neuron excitation.  Ang II-induced peripheral mech. pain hypersensitivity can be attenuated by chemogenetic depletion of peripheral M [H9021] s.  Furthermore, AT2R activation in M [H9021] s triggers prodn. of reactive oxygen/nitrogen species, which trans -activate TRPA1 on mouse and human DRG sensory neurons via cysteine modification of the channel.  Our study thus identifies a translatable immune cell-to-sensory neuron signaling crosstalk underlying peripheral nociceptor sensitization.  This form of cell-to-cell signaling represents a crit. peripheral mechanism for chronic pain and thus identifies multiple druggable analgesic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov8sQ--O9vv7Vg90H21EOLACvtfcHk0lgVwxjxoEkNHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKrtb7M&md5=c9928e4c1b69c7ad7f07e48488fe0533</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3542-17.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3542-17.2018%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DA.%2BJ.%26aulast%3DCopits%26aufirst%3DB.%2BA.%26aulast%3DMickle%26aufirst%3DA.%2BD.%26aulast%3DKarlsson%26aufirst%3DP.%26aulast%3DKadunganattil%26aufirst%3DS.%26aulast%3DHaroutounian%26aufirst%3DS.%26aulast%3DTadinada%26aufirst%3DS.%2BM.%26aulast%3Dde%2BKloet%26aufirst%3DA.%2BD.%26aulast%3DValtcheva%26aufirst%3DM.%2BV.%26aulast%3DMcIlvried%26aufirst%3DL.%2BA.%26aulast%3DSheahan%26aufirst%3DT.%2BD.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DP.%2BR.%26aulast%3DUsachev%26aufirst%3DY.%2BM.%26aulast%3DDussor%26aufirst%3DG.%26aulast%3DKrause%26aufirst%3DE.%2BG.%26aulast%3DPrice%26aufirst%3DT.%2BJ.%26aulast%3DGereau%26aufirst%3DR.%2BG.%26aulast%3DMohapatra%26aufirst%3DD.%2BP.%26atitle%3DAngiotensin%2520II%2520triggers%2520peripheral%2520macrophage-to-sensory%2520neuron%2520redox%2520crosstalk%2520to%2520elicit%2520pain%26jtitle%3DJ.%2520Neurosci.%26date%3D2018%26volume%3D38%26spage%3D7032%26epage%3D7057%26doi%3D10.1523%2FJNEUROSCI.3542-17.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danser, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span> <span> </span><span class="NLM_article-title">The angiotensin II type 2 receptor for pain control</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1504</span>– <span class="NLM_lpage">1506</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2014.05.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.cell.2014.05.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24949962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVCisrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2014&pages=1504-1506&author=A.+H.+Danserauthor=P.+Anand&title=The+angiotensin+II+type+2+receptor+for+pain+control&doi=10.1016%2Fj.cell.2014.05.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">The angiotensin II type 2 receptor for pain control</span></div><div class="casAuthors">Danser, A. H. Jan; Anand, Praveen</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1504-1506</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  All well-known deleterious effects of angiotensin (Ang) II, including vasoconstriction, inflammation, water and salt retention, and vascular remodeling, are mediated via its type 1 (AT1) receptor.  This explains why AT1 receptor blockers (ARBs) and inhibitors of Ang II synthesis, such as ACE inhibitors and renin inhibitors, are beneficial for cardiovascular disease.  Yet, Ang II has a second receptor, the Ang II type 2 (AT2) receptor, the function of which, even after over 20 years of research, remains largely unknown.  In this issue, Marion et al. provide a new chapter to the AT2 receptor story.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUvsZKUtFkvrVg90H21EOLACvtfcHk0lgVwxjxoEkNHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVCisrbJ&md5=2b1ffcd039fae4b8fed26dbe94349ad9</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.05.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.05.030%26sid%3Dliteratum%253Aachs%26aulast%3DDanser%26aufirst%3DA.%2BH.%26aulast%3DAnand%26aufirst%3DP.%26atitle%3DThe%2520angiotensin%2520II%2520type%25202%2520receptor%2520for%2520pain%2520control%26jtitle%3DCell%26date%3D2014%26volume%3D157%26spage%3D1504%26epage%3D1506%26doi%3D10.1016%2Fj.cell.2014.05.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworkin, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCloud, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desem, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raff, M.</span></span> <span> </span><span class="NLM_article-title">EMA401–003 study group. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 2 clinical trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">1637</span>– <span class="NLM_lpage">1647</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(13)62337-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0140-6736%2813%2962337-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24507377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2gtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2014&pages=1637-1647&author=A.+S.+C.+Riceauthor=R.+H.+Dworkinauthor=T.+D.+McCarthyauthor=P.+Anandauthor=C.+Bountraauthor=P.+I.+McCloudauthor=J.+Hillauthor=G.+Cutterauthor=G.+Kitsonauthor=N.+Desemauthor=M.+Raff&title=EMA401%E2%80%93003+study+group.+EMA401%2C+an+orally+administered+highly+selective+angiotensin+II+type+2+receptor+antagonist%2C+as+a+novel+treatment+for+postherpetic+neuralgia%3A+a+randomized%2C+double-blind%2C+placebo-controlled+phase+2+clinical+trial&doi=10.1016%2FS0140-6736%2813%2962337-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial</span></div><div class="casAuthors">Rice, Andrew S. C.; Dworkin, Robert H.; McCarthy, Tom D.; Anand, Praveen; Bountra, Chas; McCloud, Philip I.; Hill, Julie; Cutter, Gary; Kitson, Geoff; Desem, Nuket; Raff, Milton</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">9929</span>),
    <span class="NLM_cas:pages">1637-1647</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Existing treatments for postherpetic neuralgia, and for neuropathic pain in general, are limited by modest efficacy and unfavorable side-effects.  The angiotensin II type 2 receptor (AT2R) is a new target for neuropathic pain.  EMA401, a highly selective AT2R antagonist, is under development as a novel neuropathic pain therapeutic agent.  We assessed the therapeutic potential of EMA401 in patients with postherpetic neuralgia.  In this multicentre, placebo-controlled, double-blind, randomised, phase 2 clin. trial, we enrolled patients (aged 22-89 years) with postherpetic neuralgia of at least 6 mo' duration from 29 centers across six countries.  We randomly allocated 183 participants to receive either oral EMA401 (100 mg twice daily) or placebo for 28 days.  Randomisation was done according to a centralized randomization schedule, blocked by study site, which was generated by an independent, unmasked statistician.  Patients and staff at each site were masked to treatment assignment.  We assessed the efficacy, safety, and pharmacokinetics of EMA401.  The primary efficacy endpoint was change in mean pain intensity between baseline and the last week of dosing (days 22-28), measured on an 11-point numerical rating scale.  The primary efficacy anal. was intention to treat.  This trial is registered with the Australian New Zealand Clin. Trials Registry, no. ACTRN12611000822987.92 patients were assigned to EMA401 and 91 were assigned to placebo.  The patients given EMA401 reported significantly less pain compared with baseline values in the final week of treatment than did those given placebo (mean redns. in pain scores -2·29 [SD 1·75] vs -1·60 [1·66]; difference of adjusted least square means -0·69 [SE 0·25]; 95% CI -1·19 to -0·20; p=0·0066).  No serious adverse events related to EMA401 occurred.  Overall, 32 patients reported 56 treatment-emergent adverse events in the EMA401 group compared with 45 such events reported by 29 patients given placebo.  EMA401 (100 mg twice daily) provides superior relief of postherpetic neuralgia compared with placebo at the end of 28 days of treatment.  EMA401 was well tolerated by patients.Spinifex Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYXDSBTzLOH7Vg90H21EOLACvtfcHk0lhT7XOCLhDCmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2gtr8%253D&md5=375e5101e14bff60644e783745038238</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2962337-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252962337-5%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DA.%2BS.%2BC.%26aulast%3DDworkin%26aufirst%3DR.%2BH.%26aulast%3DMcCarthy%26aufirst%3DT.%2BD.%26aulast%3DAnand%26aufirst%3DP.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DMcCloud%26aufirst%3DP.%2BI.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DCutter%26aufirst%3DG.%26aulast%3DKitson%26aufirst%3DG.%26aulast%3DDesem%26aufirst%3DN.%26aulast%3DRaff%26aufirst%3DM.%26atitle%3DEMA401%25E2%2580%2593003%2520study%2520group.%2520EMA401%252C%2520an%2520orally%2520administered%2520highly%2520selective%2520angiotensin%2520II%2520type%25202%2520receptor%2520antagonist%252C%2520as%2520a%2520novel%2520treatment%2520for%2520postherpetic%2520neuralgia%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25202%2520clinical%2520trial%26jtitle%3DLancet%26date%3D2014%26volume%3D383%26spage%3D1637%26epage%3D1647%26doi%3D10.1016%2FS0140-6736%2813%2962337-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basbaum, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bautista, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julius, D.</span></span> <span> </span><span class="NLM_article-title">Cellular and molecular mechanisms of pain</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.cell.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19837031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFWht7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2009&pages=267-284&author=A.+I.+Basbaumauthor=D.+M.+Bautistaauthor=G.+Scherrerauthor=D.+Julius&title=Cellular+and+molecular+mechanisms+of+pain&doi=10.1016%2Fj.cell.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular and molecular mechanisms of pain</span></div><div class="casAuthors">Basbaum, Allan I.; Bautista, Diana M.; Scherrer, Gregory; Julius, David</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-284</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The nervous system detects and interprets a wide range of thermal and mech. stimuli, as well as environmental and endogenous chem. irritants.  When intense, these stimuli generate acute pain, and in the setting of persistent injury, both peripheral and central nervous system components of the pain transmission pathway exhibit tremendous plasticity, enhancing pain signals and producing hypersensitivity.  When plasticity facilitates protective reflexes, it can be beneficial, but when the changes persist, a chronic pain condition may result.  Genetic, electrophysiol., and pharmacol. studies are elucidating the mol. mechanisms that underlie detection, coding, and modulation of noxious stimuli that generate pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdNLc2p-hLJLVg90H21EOLACvtfcHk0lhT7XOCLhDCmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFWht7zI&md5=afa43d19ea22a39b27952a2962df504b</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DBasbaum%26aufirst%3DA.%2BI.%26aulast%3DBautista%26aufirst%3DD.%2BM.%26aulast%3DScherrer%26aufirst%3DG.%26aulast%3DJulius%26aufirst%3DD.%26atitle%3DCellular%2520and%2520molecular%2520mechanisms%2520of%2520pain%26jtitle%3DCell%26date%3D2009%26volume%3D139%26spage%3D267%26epage%3D284%26doi%3D10.1016%2Fj.cell.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Premer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamondin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speth, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownfield, M. S.</span></span> <span> </span><span class="NLM_article-title">Immunohistochemical localization of AT1a, AT1b, and AT2 angiotensin II receptor subtypes in the rat adrenal, pituitary, and brain with a perspective commentary</span>. <i>Int. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">175428</span>, <span class="refDoi"> DOI: 10.1155/2013/175428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1155%2F2013%2F175428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23573410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC3srktVSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=175428&author=C.+Premerauthor=C.+Lamondinauthor=A.+Mitzeyauthor=R.+C.+Spethauthor=M.+S.+Brownfield&title=Immunohistochemical+localization+of+AT1a%2C+AT1b%2C+and+AT2+angiotensin+II+receptor+subtypes+in+the+rat+adrenal%2C+pituitary%2C+and+brain+with+a+perspective+commentary&doi=10.1155%2F2013%2F175428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical Localization of AT1a, AT1b, and AT2 Angiotensin II Receptor Subtypes in the Rat Adrenal, Pituitary, and Brain with a Perspective Commentary</span></div><div class="casAuthors">Premer Courtney; Lamondin Courtney; Mitzey Ann; Speth Robert C; Brownfield Mark S</div><div class="citationInfo"><span class="NLM_cas:title">International journal of hypertension</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2013</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175428</span>
        ISSN:<span class="NLM_cas:issn">2090-0384</span>.
    </div><div class="casAbstract">Angiotensin II increases blood pressure and stimulates thirst and sodium appetite in the brain.  It also stimulates secretion of aldosterone from the adrenal zona glomerulosa and epinephrine from the adrenal medulla.  The rat has 3 subtypes of angiotensin II receptors: AT1a, AT1b, and AT2. mRNAs for all three subtypes occur in the adrenal and brain.  To immunohistochemically differentiate these receptor subtypes, rabbits were immunized with C-terminal fragments of these subtypes to generate receptor subtype-specific antibodies.  Immunofluorescence revealed AT1a and AT2 receptors in adrenal zona glomerulosa and medulla.  AT1b immunofluorescence was present in the zona glomerulosa, but not the medulla.  Ultrastructural immunogold labeling for the AT1a receptor in glomerulosa and medullary cells localized it to plasma membrane, endocytic vesicles, multivesicular bodies, and the nucleus.  AT1b and AT2, but not AT1a, immunofluorescence was observed in the anterior pituitary.  Stellate cells were AT1b positive while ovoid cells were AT2 positive.  In the brain, neurons were AT1a, AT1b, and AT2 positive, but glia was only AT1b positive.  Highest levels of AT1a, AT1b, and AT2 receptor immunofluorescence were in the subfornical organ, median eminence, area postrema, paraventricular nucleus, and solitary tract nucleus.  These studies complement those employing different techniques to characterize Ang II receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQv2qX-67QscdK0qsdY6Nc1fW6udTcc2eY3_vmpaLkVZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srktVSrug%253D%253D&md5=d0948e1ad56dad1869060baf8b6ff144</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1155%2F2013%2F175428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F175428%26sid%3Dliteratum%253Aachs%26aulast%3DPremer%26aufirst%3DC.%26aulast%3DLamondin%26aufirst%3DC.%26aulast%3DMitzey%26aufirst%3DA.%26aulast%3DSpeth%26aufirst%3DR.%2BC.%26aulast%3DBrownfield%26aufirst%3DM.%2BS.%26atitle%3DImmunohistochemical%2520localization%2520of%2520AT1a%252C%2520AT1b%252C%2520and%2520AT2%2520angiotensin%2520II%2520receptor%2520subtypes%2520in%2520the%2520rat%2520adrenal%252C%2520pituitary%252C%2520and%2520brain%2520with%2520a%2520perspective%2520commentary%26jtitle%3DInt.%2520J.%2520Hypertens.%26date%3D2013%26volume%3D2013%26spage%3D175428%26doi%3D10.1155%2F2013%2F175428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenkei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palkovits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvol, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Cortes, C.</span></span> <span> </span><span class="NLM_article-title">Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review</span>. <i>Front. Neuroendocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1006/frne.1997.0155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1006%2Ffrne.1997.0155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9344632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1KlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1997&pages=383-439&author=Z.+Lenkeiauthor=M.+Palkovitsauthor=P.+Corvolauthor=C.+Llorens-Cortes&title=Expression+of+angiotensin+type-1+%28AT1%29+and+type-2+%28AT2%29+receptor+mRNAs+in+the+adult+rat+brain%3A+a+functional+neuroanatomical+review&doi=10.1006%2Ffrne.1997.0155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review</span></div><div class="casAuthors">Lenkei, Z.; Palkovits, M.; Corvol, P.; Llorens-Cortes, C.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Neuroendocrinology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-439</span>CODEN:
                <span class="NLM_cas:coden">FNEDA7</span>;
        ISSN:<span class="NLM_cas:issn">0091-3022</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A review, with 242 refs.  The discovery that all components of the renin-angiotensin system (RAS) are present in the central nervous system led investigators to postulate the existence of a local brain RAS.  Supporting this, angiotensin immunoreactive neurons have been visualized in the brain.  Two major pathways were described: a forebrain pathway which connects circumventricular organs to the median preoptic nucleus, paraventricular nucleus, and supraoptic nucleus, and a second pathway connecting the hypothalamus to the medulla oblongata.  Blood-brain barrier deficient circumventricular organs are rich in angiotensin II receptors.  By activating these receptors, circulating angiotensin II may act on central cardiovascular centers via angiotensinergic neurons, providing a link between peripheral and central angiotensin II systems.  Among the effector peptides of the brain RAS, angiotensin II and angiotensin III have the same affinity for the two pharmacol. well-defined receptors: type 1 (AT1) and type 2 (AT2).  When injected in the brain, these peptides increase blood pressure, water intake, and anterior and posterior pituitary hormone release and may modify memory and learning.  The cloning of AT1 and AT2 receptor cDNAs has revealed that these receptors belong to the seven transmembrane domain receptor family.  In rodents, two AT1 receptor subtypes, AT1A and AT1B, have been isolated.  Using specific riboprobes for in situ hybridization histochem., recent studies mapped the distribution of AT1A, AT1B, and AT2 receptor mRNAs in the adult rat and found a predominant expression of AT1A and AT2 mRNA in the brain and of AT1B in the pituitary.  Very limited overlap was found between the brain expression of AT1A and AT2 mRNAs.  In several functional entities of the brain, such as the preoptic region, the hypothalamus, the olivocerebellary system, and the brainstem baroreflex arc, the colocalization or receptor mRNA, binding sites, and angiotensin immunoreactive nerve terminals suggests local synthesis and expression of angiotensin II receptors.  In other areas, such as the bed nucleus of the stria terminalis, the median eminence, or certain parts of the nucleus of the solitary tract, angiotensin II receptors are likely of extrinsic origin.  The neuronal expression of AT1A and AT2 receptors was demonstrated in the subfornical organ, the hypothalamus, and the lateral septum.  By using double label in situ hybridization, AT1A receptor expression was localized in corticotropin releasing hormone but not in vasopressin contg. neurons in the hypothalamus.  The information is discussed together with functional data concerning the role of brain angiotensins, in an attempt to provide a better understanding of the physiol. and functional roles of each receptor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptQjkL-PAEvrVg90H21EOLACvtfcHk0liLbPRCirqmcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1KlsL4%253D&md5=33a1e18fb02c66ea3096072fbd051471</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1006%2Ffrne.1997.0155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Ffrne.1997.0155%26sid%3Dliteratum%253Aachs%26aulast%3DLenkei%26aufirst%3DZ.%26aulast%3DPalkovits%26aufirst%3DM.%26aulast%3DCorvol%26aufirst%3DP.%26aulast%3DLlorens-Cortes%26aufirst%3DC.%26atitle%3DExpression%2520of%2520angiotensin%2520type-1%2520%2528AT1%2529%2520and%2520type-2%2520%2528AT2%2529%2520receptor%2520mRNAs%2520in%2520the%2520adult%2520rat%2520brain%253A%2520a%2520functional%2520neuroanatomical%2520review%26jtitle%3DFront.%2520Neuroendocrinol.%26date%3D1997%26volume%3D18%26spage%3D383%26epage%3D439%26doi%3D10.1006%2Ffrne.1997.0155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">The AT2 receptor-a matter of love and hate</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2005.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.peptides.2005.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=16042980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVCqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=1401-1409&author=U.+M.+Steckelingsauthor=E.+Kaschinaauthor=T.+Unger&title=The+AT2+receptor-a+matter+of+love+and+hate&doi=10.1016%2Fj.peptides.2005.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">The AT2 receptor-A matter of love and hate</span></div><div class="casAuthors">Steckelings, U. M.; Kaschina, E.; Unger, Th.</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1401-1409</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  In 1989, the development of specific angiotensin receptor antagonists which distinguish between two angiotensin receptor subtypes (AT1 and AT2) led to a breakthrough in angiotensin research.  It turned out, that the AT1 receptor was almost entirely responsible for the "classical" actions of angiotensin II related to the regulation of blood pressure as well as vol. and electrolyte balance.  However, actions and signal transduction mechanisms coupled to the AT2 receptor remained enigmatic for a long time.  The present review summarizes the current knowledge of AT2 receptor distribution, signaling and function with an emphasis on growth/anti-growth, differentiation and the regeneration of neuronal tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouASpis89iJrVg90H21EOLACvtfcHk0liLbPRCirqmcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVCqsr8%253D&md5=d42e2460209f2ad65b52d64fcdcd88e1</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2005.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2005.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DKaschina%26aufirst%3DE.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DThe%2520AT2%2520receptor-a%2520matter%2520of%2520love%2520and%2520hate%26jtitle%3DPeptides%26date%3D2005%26volume%3D26%26spage%3D1401%26epage%3D1409%26doi%3D10.1016%2Fj.peptides.2005.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakugi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takiuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennessy, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogihara, T.</span></span> <span> </span><span class="NLM_article-title">Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages</span>. <i>J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1097/00004872-199917040-00012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2F00004872-199917040-00012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10404956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1MXktFGgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=537-545&author=A.+Okamuraauthor=H.+Rakugiauthor=M.+Ohishiauthor=Y.+Yanagitaniauthor=S.+Takiuchiauthor=K.+Moriguchiauthor=P.+A.+Fennessyauthor=J.+Higakiauthor=T.+Ogihara&title=Upregulation+of+renin-angiotensin+system+during+differentiation+of+monocytes+to+macrophages&doi=10.1097%2F00004872-199917040-00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages</span></div><div class="casAuthors">Okamura, Atsunori; Rakugi, Hiromi; Ohishi, Mitsuru; Yanagitani, Yoshihiro; Takiuchi, Shin; Moriguchi, Koichi; Fennessy, Paul A.; Higaki, Jitsuo; Ogihara, Toshio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">537-545</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The authors have demonstrated that accumulated macrophages in human coronary arteries strongly express angiotensin converting enzyme in accordance with the development of atheromatous plaques.  However, there are few reports on the regulation of the renin-angiotensin system in macrophages and in monocytes as their source.  Studies were carried out to examine whether the renin-angiotensin system is upregulated during the differentiation of monocytes to macrophages, and whether it is further regulated by angiotensin II and cytokines.  The authors used a human leukemia cell line, THP-1, for monocytes.  Differentiated THP-1, induced by adding phorbol 12-myristate 13-acetate for 24 h, were used as macrophages.  Expression of mRNA of the renin-angiotensin system components was measured by quant. reverse-transcriptase polymerase chain reaction.  Angiotensin converting enzyme activity and subtype-specific angiotensin-binding sites of cultured cells, and angiotensin II prodn. in the culture medium were measured.  Macrophages expressed all components of the renin-angiotensin system except chymase.  Cellular angiotensin converting enzyme activity and angiotensin II in the medium were increased 3.2- and 4.5-fold during differentiation, resp.  Expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors was increased 6.2- and 6.4-fold during differentiation, and was sustained for 7 days.  Incubation with angiotensin II for 24 h caused downregulation of both AT1 and AT2 receptor mRNA, but the expression levels were still more than threefold higher compared with monocytes.  The d. of binding sites of AT1 and AT2 receptors in macrophages was 0.26 and 0.15 fmol/106 cells, resp.  The renin-angiotensin system is markedly activated during monocyte/macrophage differentiation, and may participate in the development of atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoujtwTll1qFLVg90H21EOLACvtfcHk0liLbPRCirqmcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktFGgsrw%253D&md5=9f9d3f5bc04aeedec5f4151af81c2e61</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1097%2F00004872-199917040-00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004872-199917040-00012%26sid%3Dliteratum%253Aachs%26aulast%3DOkamura%26aufirst%3DA.%26aulast%3DRakugi%26aufirst%3DH.%26aulast%3DOhishi%26aufirst%3DM.%26aulast%3DYanagitani%26aufirst%3DY.%26aulast%3DTakiuchi%26aufirst%3DS.%26aulast%3DMoriguchi%26aufirst%3DK.%26aulast%3DFennessy%26aufirst%3DP.%2BA.%26aulast%3DHigaki%26aufirst%3DJ.%26aulast%3DOgihara%26aufirst%3DT.%26atitle%3DUpregulation%2520of%2520renin-angiotensin%2520system%2520during%2520differentiation%2520of%2520monocytes%2520to%2520macrophages%26jtitle%3DJ.%2520Hypertens.%26date%3D1999%26volume%3D17%26spage%3D537%26epage%3D545%26doi%3D10.1097%2F00004872-199917040-00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saavedra, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imboden, H.</span></span> <span> </span><span class="NLM_article-title">Intraneuronal angiotensinergic system in rat and human dorsal root ganglia</span>. <i>Regul. Pept.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.regpep.2010.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.regpep.2010.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=20346377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVGis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2010&pages=90-98&author=J.+Patilauthor=A.+Schwabauthor=J.+Nussbergerauthor=T.+Schaffnerauthor=J.+M.+Saavedraauthor=H.+Imboden&title=Intraneuronal+angiotensinergic+system+in+rat+and+human+dorsal+root+ganglia&doi=10.1016%2Fj.regpep.2010.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Intraneuronal angiotensinergic system in rat and human dorsal root ganglia</span></div><div class="casAuthors">Patil, Jaspal; Schwab, Alexander; Nussberger, Juerg; Schaffner, Thomas; Saavedra, Juan M.; Imboden, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">90-98</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To elucidate the local formation of angiotensin II (Ang II) in the neurons of sensory dorsal root ganglia (DRG), we studied the expression of angiotensinogen (Ang-N)-, renin-, angiotensin converting enzyme (ACE)- and cathepsin D-mRNA, and the presence of protein renin, Ang II, Substance P and calcitonin gene-related peptide (CGRP) in the rat and human thoracic DRG.  Quant. real time PCR (qRT-PCR) studies revealed that rat DRG expressed substantial amts. of Ang-N- and ACE mRNA, while renin mRNA as well as the protein renin were untraceable.  Cathepsin D-mRNA and cathepsin D-protein were detected in the rat DRG indicating the possibility of existence of pathways alternative to renin for Ang I formation.  Angiotensin peptides were successfully detected with high performance liq. chromatog. and RIA in human DRG exts.  In situ hybridization in rat DRG confirmed addnl. expression of Ang-N mRNA in the cytoplasm of numerous neurons.  Intracellular Ang II staining could be shown in no. of neurons and their processes in both the rat and human DRG.  Interestingly we obsd. neuronal processes with angiotensinergic synapses en passant, colocalized with synaptophysin, within the DRG.  In the DRG, we also identified by qRT-PCR, expression of Ang II receptor AT1A and AT2-mRNA while AT1B-mRNA was not traceable.  In some neurons Substance P and CGRP were found colocalized with Ang II.  The intracellular localization and colocalization of Ang II with Substance P and CGRP in the DRG neurons may indicate a participation and function of Ang II in the regulation of nociception.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEJctxQ9syXrVg90H21EOLACvtfcHk0liLbPRCirqmcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVGis7c%253D&md5=5e18118744b3faff40a65205e73c963b</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.regpep.2010.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.regpep.2010.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DJ.%26aulast%3DSchwab%26aufirst%3DA.%26aulast%3DNussberger%26aufirst%3DJ.%26aulast%3DSchaffner%26aufirst%3DT.%26aulast%3DSaavedra%26aufirst%3DJ.%2BM.%26aulast%3DImboden%26aufirst%3DH.%26atitle%3DIntraneuronal%2520angiotensinergic%2520system%2520in%2520rat%2520and%2520human%2520dorsal%2520root%2520ganglia%26jtitle%3DRegul.%2520Pept.%26date%3D2010%26volume%3D162%26spage%3D90%26epage%3D98%26doi%3D10.1016%2Fj.regpep.2010.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sumners, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span> <span> </span><span class="NLM_article-title">Protective arms of the renin-angiotensin-system in neurological disease</span>. <i>Clin. Exp. Pharmacol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.1111/1440-1681.12137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2F1440-1681.12137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23735163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOisbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2013&pages=580-588&author=C.+Sumnersauthor=M.+Horiuchiauthor=R.+E.+Widdopauthor=C.+McCarthyauthor=T.+Ungerauthor=U.+M.+Steckelings&title=Protective+arms+of+the+renin-angiotensin-system+in+neurological+disease&doi=10.1111%2F1440-1681.12137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Protective arms of the renin-angiotensin-system in neurological disease</span></div><div class="casAuthors">Sumners, Colin; Horiuchi, Masatsugu; Widdop, Robert E.; McCarthy, Claudia; Unger, Thomas; Steckelings, Ulrike M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Pharmacology and Physiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">580-588</span>CODEN:
                <span class="NLM_cas:coden">CEXPB9</span>;
        ISSN:<span class="NLM_cas:issn">0305-1870</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Summary : In recent years it has been firmly established that apart from the classic renin-angiotensin system (RAS) comprising angiotensin (Ang) II, angiotensin converting enzyme (ACE; responsible for AngII generation) and the angiotensin AT1 receptor (AT1R), there also exist protective arms of the RAS that comprise the angiotensin AT2 receptor (AT2R), Ang-(1-7), ACE2 (mainly responsible for Ang-(1-7) synthesis) and Mas, the receptor for Ang-(1-7).  Stimulation of AT2R promotes neuronal differentiation, neurite outgrowth and axonal regeneration, which results in an acceleration of repair and improved functional outcome after injury of peripheral nerves or the spinal cord.  Stimulation of AT2R and the receptor Mas has been shown to reduce infarct size and ameliorate neurol. deficits in various animal models of stroke.  The underlying mechanisms of action are comprised of activation of direct neurotrophic, anti-inflammatory and anti-oxidant pathways, as well as the augmentation of cerebral blood flow.  Cognitive function is improved by AT2R stimulation due, at least in part, to increased cerebral blood flow.  There is indirect evidence that Ang-(1-7) could also play a role in protection against cognitive decline, but studies confirming this have not yet been published.  In view of the data reviewed in this article, it can be assumed that the protective arms of the RAS are putative targets in the treatment of neurol. diseases, which involve tissue damage or cognitive impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1LaAKH24a2bVg90H21EOLACvtfcHk0lhTE8gKSyML2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOisbnK&md5=ebf627d31dd8f3e53f8a72d7286499c0</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1111%2F1440-1681.12137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1440-1681.12137%26sid%3Dliteratum%253Aachs%26aulast%3DSumners%26aufirst%3DC.%26aulast%3DHoriuchi%26aufirst%3DM.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26atitle%3DProtective%2520arms%2520of%2520the%2520renin-angiotensin-system%2520in%2520neurological%2520disease%26jtitle%3DClin.%2520Exp.%2520Pharmacol.%2520Physiol.%26date%3D2013%26volume%3D40%26spage%3D580%26epage%3D588%26doi%3D10.1111%2F1440-1681.12137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhave, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasier, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxford, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gereau, R. W.</span></span> <span> </span><span class="NLM_article-title">cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1016/S0896-6273(02)00802-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0896-6273%2802%2900802-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12194871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2002&pages=721-731&author=G.+Bhaveauthor=W.+Zhuauthor=H.+Wangauthor=D.+J.+Brasierauthor=G.+S.+Oxfordauthor=R.+W.+Gereau&title=cAMP-dependent+protein+kinase+regulates+desensitization+of+the+capsaicin+receptor+%28VR1%29+by+direct+phosphorylation&doi=10.1016%2FS0896-6273%2802%2900802-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation</span></div><div class="casAuthors">Bhave, Gautam; Zhu, Weiguo; Wang, Haibin; Brasier, D. J.; Oxford, Gerry S.; Gereau, Robert W., IV</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">721-731</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The capsaicin receptor, VR1 (also known as TRPV1), is a ligand-gated ion channel expressed on nociceptive sensory neurons that responds to noxious thermal and chem. stimuli.  Capsaicin responses in sensory neurons exhibit robust potentiation by cAMP-dependent protein kinase (PKA).  In this study, we demonstrate that PKA reduces VR1 desensitization and directly phosphorylates VR1.  In vitro phosphorylation, phosphopeptide mapping, and protein sequencing of VR1 cytoplasmic domains delineate several candidate PKA phosphorylation sites.  Electrophysiol. anal. of phosphorylation site mutants clearly pinpoints Ser116 as the residue responsible for PKA-dependent modulation of VR1.  Given the significant roles of VR1 and PKA in inflammatory pain hypersensitivity, VR1 phosphorylation at Ser116 by PKA may represent an important mol. mechanism involved in the regulation of VR1 function after tissue injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhqIokbTh0OLVg90H21EOLACvtfcHk0lhTE8gKSyML2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSlsbg%253D&md5=1cd1eb78b48c2405da537ebd6f3439dc</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2802%2900802-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252802%252900802-4%26sid%3Dliteratum%253Aachs%26aulast%3DBhave%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBrasier%26aufirst%3DD.%2BJ.%26aulast%3DOxford%26aufirst%3DG.%2BS.%26aulast%3DGereau%26aufirst%3DR.%2BW.%26atitle%3DcAMP-dependent%2520protein%2520kinase%2520regulates%2520desensitization%2520of%2520the%2520capsaicin%2520receptor%2520%2528VR1%2529%2520by%2520direct%2520phosphorylation%26jtitle%3DNeuron%26date%3D2002%26volume%3D35%26spage%3D721%26epage%3D731%26doi%3D10.1016%2FS0896-6273%2802%2900802-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rompe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namsolleck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funke-Kaiser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">The past, present and future of angiotensin II type 2 receptor stimulation</span>. <i>JRAAS</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1177/1470320309347791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1177%2F1470320309347791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Wjsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=67-73&author=U.+M.+Steckelingsauthor=F.+Rompeauthor=E.+Kaschinaauthor=P.+Namsolleckauthor=A.+Grzesiakauthor=H.+Funke-Kaiserauthor=M.+Baderauthor=T.+Unger&title=The+past%2C+present+and+future+of+angiotensin+II+type+2+receptor+stimulation&doi=10.1177%2F1470320309347791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">The past, present and future of angiotensin II type 2 receptor stimulation</span></div><div class="casAuthors">Steckelings, U. Muscha; Grzesiak, Aleksandra; Funke-Kaiser, Heiko; Bader, Michael; Unger, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">JRAAS</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-73</span>CODEN:
                <span class="NLM_cas:coden">JRAAAG</span>;
        ISSN:<span class="NLM_cas:issn">1470-3203</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Studying the angiotensin type 2 receptor (AT2) has been problematic in the past because a pharmacol. tool for direct, specific in vitro and in vivo stimulation of the receptor has been lacking.  Consequently, current knowledge about AT2 receptor signalling and function had to be obtained by indirect approaches, like studying animals or cells with genetically altered AT2 receptor expression levels, inhibitory expts. using specific AT2 receptor antagonists, stimulation with angiotensin II under concomitant angiotensin II type 1 receptor blockade or stimulation with the peptide agonist CGP42112A, which has addnl. AT2 receptor antagonistic properties.  The recently developed non-peptide AT2 receptor agonist Compd. 21 now, for the first time, allows direct, selective and specific AT2 receptor stimulation in vitro and in vivo.  This new tool will certainly revolutionize AT2 receptor research, enable many new insights into AT2 receptor function and may also have the potential to become a future medical drug.  This article reviews milestone findings about AT2 receptor functional properties obtained by 'conventional' exptl. approaches within the last 20 years.  Moreover, it provides an overview of the first results obtained by direct AT2 receptor stimulation with Compd. 21, comprising effects on alk. secretion, neurite outgrowth, blood pressure and post-infarct cardiac function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFJF54VlxTEbVg90H21EOLACvtfcHk0lhTE8gKSyML2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Wjsr3K&md5=1a2d4f1ef689d38085d8e4f0f73a951b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1177%2F1470320309347791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1470320309347791%26sid%3Dliteratum%253Aachs%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DRompe%26aufirst%3DF.%26aulast%3DKaschina%26aufirst%3DE.%26aulast%3DNamsolleck%26aufirst%3DP.%26aulast%3DGrzesiak%26aufirst%3DA.%26aulast%3DFunke-Kaiser%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DM.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DThe%2520past%252C%2520present%2520and%2520future%2520of%2520angiotensin%2520II%2520type%25202%2520receptor%2520stimulation%26jtitle%3DJRAAS%26date%3D2010%26volume%3D11%26spage%3D67%26epage%3D73%26doi%3D10.1177%2F1470320309347791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaway, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e95762</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0095762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1371%2Fjournal.pone.0095762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24752645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=C.+A.+McCarthyauthor=A.+Vinhauthor=A.+A.+Millerauthor=A.+Hallbergauthor=M.+Altermanauthor=J.+K.+Callawayauthor=R.+E.+Widdop&title=Direct+angiotensin+AT2+receptor+stimulation+using+a+novel+AT2+receptor+agonist%2C+compound+21%2C+evokes+neuroprotection+in+conscious+hypertensive+rats&doi=10.1371%2Fjournal.pone.0095762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats</span></div><div class="casAuthors">McCarthy, Claudia A.; Vinh, Antony; Miller, Alyson A.; Hallberg, Anders; Alterman, Mathias; Callaway, Jennifer K.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e95762/1-e95762/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was examd. in a conscious model of stroke to verify a class effect of AT2R agonists as neuroprotective agents.  Methods and Results: Spontaneously hypertensive rats (SHR) were pre-treated for 5 days prior to stroke with C21 alone or in combination with the AT2R antagonist PD123319.  In a sep. series of expts. C21 was administered in a series of 4 doses commencing 6 h after stroke.  A focal reperfusion model of ischemia was induced in conscious SHR by administering endothelin-1 to the middle cerebral artery (MCA).  Motor coordination was assessed at 1 and 3 days after stroke and post mortem analyses of infarct vols., microglia activation and neuronal survival were performed at 72 h post MCA occlusion.  When given prior to stroke, C21 dose dependently decreased infarct vol., which is consistent with the behavioral findings illustrating an improvement in motor deficit.  During the pre-treatment protocol C21 was shown to enhance microglia activation, which are likely to be evoking protection by releasing brain derived neurotrophic factor.  When drug administration was delayed until 6 h after stroke, C21 still reduced brain injury.  Conclusion: These results indicate that centrally administered C21 confers neuroprotection against stroke damage.  This benefit is likely to involve various mechanisms, including microglial activation of endogenous repair and enhanced cerebroperfusion.  Thus, we have confirmed the neuroprotective effect of AT2R stimulation using a nonpeptide compd. which highlights the clin. potential of the AT2R agonists for future development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLJ8khaoxR6LVg90H21EOLACvtfcHk0li4RILo4T_qvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtbzI&md5=bcc1f9fdc33490c63c07afbe8b0f8543</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0095762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0095762%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DC.%2BA.%26aulast%3DVinh%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DA.%2BA.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26aulast%3DCallaway%26aufirst%3DJ.%2BK.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DDirect%2520angiotensin%2520AT2%2520receptor%2520stimulation%2520using%2520a%2520novel%2520AT2%2520receptor%2520agonist%252C%2520compound%252021%252C%2520evokes%2520neuroprotection%2520in%2520conscious%2520hypertensive%2520rats%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0095762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fouda, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhandapani, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ergul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, S. C.</span></span> <span> </span><span class="NLM_article-title">Role of interleukin-10 in the neuroprotective effect of the angiotensin type 2 receptor agonist, compound 21, after ischemia/reperfusion injury</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>799</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2017.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.ejphar.2017.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28192099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=799&publication_year=2017&pages=128-134&author=A.+Y.+Foudaauthor=B.+Pillaiauthor=K.+M.+Dhandapaniauthor=A.+Ergulauthor=S.+C.+Fagan&title=Role+of+interleukin-10+in+the+neuroprotective+effect+of+the+angiotensin+type+2+receptor+agonist%2C+compound+21%2C+after+ischemia%2Freperfusion+injury&doi=10.1016%2Fj.ejphar.2017.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury</span></div><div class="casAuthors">Fouda, Abdelrahman Y.; Pillai, Bindu; Dhandapani, Krishnan M.; Ergul, Adviye; Fagan, Susan C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">799</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">128-134</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We and others have shown that the angiotensin type 2 (AT2) receptor agonist, compd. 21 (C21), provides neuroprotection and enhances recovery in rodent stroke models yet the mechanism involved is not known.  Moreover, C21 treatment is assocd. with an anti-inflammatory response.  Here we tested the hypothesis that C21 mediates neuroprotection by upregulating the neuroprotective and anti-inflammatory cytokine, interleukin (IL)-10.  Wistar rats were subjected to 3 h-middle cerebral artery suture occlusion and treated at reperfusion with C21 (0.03 mg/kg)±IL-10 neutralizing antibody (0.1 mg/kg) both given i.p.  Infarct size, behavioral outcomes, and mol. anal. were performed at 24 h post-injury.  Primary rat neurons were used to test the direct neuroprotective effect of C21 in vitro.  C21 treatment reduced infarct size, improved functional outcome and decreased the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-α) in the ischemic hemisphere compared to saline.  Anti-IL-10 co-treatment blocked the C21-induced redn. in infarct size and inflammation, and the improvement in behavioral outcome.  In vitro, C21 treatment increased neuron survival and reduced cell apoptosis after oxygen glucose deprivation (OGD) and OGD/reoxygenation.  These effects were mediated through AT2R stimulation.  C21 provides direct neuroprotection as well as indirect protection through IL-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6amaaEuFlxrVg90H21EOLACvtfcHk0li4RILo4T_qvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrt74%253D&md5=7c8c881619ba5fdc3cf256f623b5dfcb</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DFouda%26aufirst%3DA.%2BY.%26aulast%3DPillai%26aufirst%3DB.%26aulast%3DDhandapani%26aufirst%3DK.%2BM.%26aulast%3DErgul%26aufirst%3DA.%26aulast%3DFagan%26aufirst%3DS.%2BC.%26atitle%3DRole%2520of%2520interleukin-10%2520in%2520the%2520neuroprotective%2520effect%2520of%2520the%2520angiotensin%2520type%25202%2520receptor%2520agonist%252C%2520compound%252021%252C%2520after%2520ischemia%252Freperfusion%2520injury%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D799%26spage%3D128%26epage%3D134%26doi%3D10.1016%2Fj.ejphar.2017.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chow, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koulis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jandeleit-Dahm, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, T. J.</span></span> <span> </span><span class="NLM_article-title">The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1778</span>– <span class="NLM_lpage">1790</span>, <span class="refDoi"> DOI: 10.1007/s00125-016-3977-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs00125-016-3977-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=27168137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVGlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1778-1790&author=B.+S.+Chowauthor=C.+Koulisauthor=P.+Krishnaswamyauthor=U.+M.+Steckelingsauthor=T.+Ungerauthor=M.+E.+Cooperauthor=K.+A.+Jandeleit-Dahmauthor=T.+J.+Allen&title=The+angiotensin+II+type+2+receptor+agonist+Compound+21+is+protective+in+experimental+diabetes-associated+atherosclerosis&doi=10.1007%2Fs00125-016-3977-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis</span></div><div class="casAuthors">Chow, Bryna S. M.; Koulis, Christine; Krishnaswamy, Pooja; Steckelings, Ulrike M.; Unger, Thomas; Cooper, Mark E.; Jandeleit-Dahm, Karin A.; Allen, Terri J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1778-1790</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aims/hypothesis: Angiotensin II is well-recognized to be a key mediator in driving the pathol. events of diabetes-assocd. atherosclerosis via signalling through its angiotensin II type 1 receptor (AT1R) subtype.  However, its actions via the angiotensin II type 2 receptor (AT2R) subtype are still poorly understood.  This study is the first to investigate the role of the novel selective AT2R agonist, Compd. 21 (C21) in an exptl. model of diabetes-assocd. atherosclerosis (DAA).  Methods: Streptozotocin-induced diabetic Apoe-knockout mice were treated with vehicle (0.1 mol/l citrate buffer), C21 (1 mg/kg per day), candesartan cilexetil (4 mg/kg per day) or C21 + candesartan cilexetil over a 20 wk period.  In vitro models of DAA using human aortic endothelial cells and monocyte cultures treated with C21 were also performed.  At the end of the expts., assessment of plaque content and markers of oxidative stress, inflammation and fibrosis were conducted.  Results: C21 treatment significantly attenuated aortic plaque deposition in a mouse model of DAA in vivo, in assocn. with a decreased infiltration of macrophages and mediators of inflammation, oxidative stress and fibrosis.  On the other hand, combination therapy with C21 and candesartan (AT1R antagonist) appeared to have a limited additive effect in attenuating the pathol. of DAA when compared with either treatment alone.  Similarly, C21 was found to confer profound anti-atherosclerotic actions at the in vitro level, particularly in the setting of hyperglycemia.  Strikingly, these atheroprotective actions of C21 were completely blocked by the AT2R antagonist PD123319.  Conclusions/interpretation: Taken together, these findings provide novel mechanistic and potential therapeutic insights into C21 as a monotherapy agent against DAA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1DPyHx9XOP7Vg90H21EOLACvtfcHk0liHlv5LEAVA_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVGlu7Y%253D&md5=1489ad105903161b2451223d2a9e04df</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1007%2Fs00125-016-3977-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-016-3977-5%26sid%3Dliteratum%253Aachs%26aulast%3DChow%26aufirst%3DB.%2BS.%26aulast%3DKoulis%26aufirst%3DC.%26aulast%3DKrishnaswamy%26aufirst%3DP.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DCooper%26aufirst%3DM.%2BE.%26aulast%3DJandeleit-Dahm%26aufirst%3DK.%2BA.%26aulast%3DAllen%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520angiotensin%2520II%2520type%25202%2520receptor%2520agonist%2520Compound%252021%2520is%2520protective%2520in%2520experimental%2520diabetes-associated%2520atherosclerosis%26jtitle%3DDiabetologia%26date%3D2016%26volume%3D59%26spage%3D1778%26epage%3D1790%26doi%3D10.1007%2Fs00125-016-3977-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaikwad, A. B.</span></span> <span> </span><span class="NLM_article-title">Compound 21 and telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase mediated apoptosis</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.04.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bbrc.2017.04.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28456626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFCrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2017&pages=827-833&author=A.+Pandeyauthor=A.+B.+Gaikwad&title=Compound+21+and+telmisartan+combination+mitigates+type+2+diabetic+nephropathy+through+amelioration+of+caspase+mediated+apoptosis&doi=10.1016%2Fj.bbrc.2017.04.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Compound 21 and Telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase mediated apoptosis</span></div><div class="casAuthors">Pandey, Anuradha; Gaikwad, Anil Bhanudas</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">827-833</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The current study aimed to understand the role of novel, highly selective, orally active, non-peptide Angiotensin II type 2 receptor (AT2R) agonist, Compd. 21 and its potential additive effect with Telmisartan on apoptosis and underlying posttranslational modifications in a non-genetic murine model for type 2 diabetic nephropathy (T2DN).  An exptl. model for T2DN was developed by administering low dose Streptozotocin in high fat diet fed male Wistar rats, followed by their treatment with Telmisartan, C21 or their combination.  Our results demonstrated that C21 and Telmisartan combination attenuated metabolic and renal dysfunction, renal morphol. and micro-architectural aberrations and hemodynamic disturbances in type 2 diabetic rats.  The anti-apoptotic and anti-inflammatory effects of Telmisartan were significantly accentuated by C21 indicated by expression of apoptotic markers (Parp1, Caspase 8, Caspase 7, cleaved PARP and cleaved Caspase 3) and NF-κB mediated inflammatory mols. like interleukin 6, tumor necrosis factor alpha; monocyte chemoattractant protein 1 and vascular cell adhesion mol. 1.  C21 was found to improve Telmisartan mediated reversal of histone H3 acetylation at lysine 14 and 27 and expression of histone acetyl transferase, p300/CBP-assocd. factor also known to regulate NF-κB activity and DNA damage response.  C21 in combination with Telmisartan markedly mitigates caspase mediated apoptosis and NF-κB signalling in T2D kidney, which could be partially attributed to its influence on PCAF mediated histone H3 acetylation.  Hence further research should be done to develop this combination to treat T2DN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAgvco_Clg97Vg90H21EOLACvtfcHk0liHlv5LEAVA_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFCrsLk%253D&md5=bb4276bbf9f65cceaec65dfddbc451af</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.04.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.04.134%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DGaikwad%26aufirst%3DA.%2BB.%26atitle%3DCompound%252021%2520and%2520telmisartan%2520combination%2520mitigates%2520type%25202%2520diabetic%2520nephropathy%2520through%2520amelioration%2520of%2520caspase%2520mediated%2520apoptosis%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D487%26spage%3D827%26epage%3D833%26doi%3D10.1016%2Fj.bbrc.2017.04.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaikwad, A. B.</span></span> <span> </span><span class="NLM_article-title">AT2 receptor agonist Compound 21: a silver lining for diabetic nephropathy</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>815</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2017.09.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.ejphar.2017.09.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28943106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFKisrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=815&publication_year=2017&pages=251-257&author=A.+Pandeyauthor=A.+B.+Gaikwad&title=AT2+receptor+agonist+Compound+21%3A+a+silver+lining+for+diabetic+nephropathy&doi=10.1016%2Fj.ejphar.2017.09.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">AT2 receptor agonist Compound 21: A silver lining for diabetic nephropathy</span></div><div class="casAuthors">Pandey, Anuradha; Gaikwad, Anil Bhanudas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">815</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">251-257</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The currently available therapies for diabetic nephropathy, one of the leading causes of renal failure globally are based on inhibition of renin angiotensin system.  However, recently, the focus has shifted towards activation of its protective arm rather than the inhibition of deteriorative axis, using specific agonists.  Compd. 21 (C21), a novel non-peptide angiotensin II type 2 receptor (AT2) agonist, recently granted orphan drug status for the treatment of a rare disease, idiopathic pulmonary fibrosis has also shown a potent anti-inflammatory, anti-fibrotic, antioxidant and anti-apoptotic potential in various diseases including heart failure, myocardial infarction, chronic inflammatory diseases, and neurol. diseases such as ischemic stroke.  A pool of evidences suggest that C21, either alone or in combination with angiotensin receptor blockers could be extremely beneficial in the treatment of diabetic nephropathy, a chronic inflammatory condition sharing its pathogenesis with aforementioned diseases.  The review analyses the new therapeutic tool, C21, its mechanisms of action for renoprotection in diabetic nephropathy, and its future perspectives and thereby provides an insight into the potential application of C21 as a novel therapeutic tool in the eradication of diabetic nephropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLdkV-2Hu-kLVg90H21EOLACvtfcHk0liHlv5LEAVA_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFKisrjN&md5=000e24b04cf14864bd441289f3d96fed</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.09.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.09.036%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DGaikwad%26aufirst%3DA.%2BB.%26atitle%3DAT2%2520receptor%2520agonist%2520Compound%252021%253A%2520a%2520silver%2520lining%2520for%2520diabetic%2520nephropathy%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D815%26spage%3D251%26epage%3D257%26doi%3D10.1016%2Fj.ejphar.2017.09.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucker, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span> <span> </span><span class="NLM_article-title">Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure</span>. <i>Am. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1093/ajh/hpu044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1093%2Fajh%2Fhpu044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24687998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFSis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=1248-1256&author=J.+Gaoauthor=I.+H.+Zuckerauthor=L.+Gao&title=Activation+of+central+angiotensin+type+2+receptors+by+compound+21+improves+arterial+baroreflex+sensitivity+in+rats+with+heart+failure&doi=10.1093%2Fajh%2Fhpu044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure</span></div><div class="casAuthors">Gao, Juan; Zucker, Irving H.; Gao, Lie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hypertension</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1248-1256</span>CODEN:
                <span class="NLM_cas:coden">AJHYE6</span>;
        ISSN:<span class="NLM_cas:issn">0895-7061</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background In a previous study we demonstrated that central administration of compd. 21 (C21), a nonpeptide AT2R agonist, inhibited sympathetic tone in normal rats.  In this study, we hypothesized that C21 exerts a similar effect in rats with coronary ligation-induced heart failure (HF).  Methods C21 was intracerebroventricularly infused for 7 days by osmotic minipump.  Blood pressure (BP) and heart rate (HR) were recorded by radiotelemetry in the conscious state to measure spontaneous arterial baroreflex sensitivity.  Urine was collected for measurement of norepinephrine excretion.  On the last day of C21 treatment, renal sympathetic nerve activity, BP, and HR were directly recorded under anesthesia, and the induced arterial baroreflex sensitivity was evaluated.  Protein expressions of neuronal nitric oxide synthase (nNOS) and angiotensin II type 1 receptor (AT1R) in the subfornical organ, paraventricular nucleus, rostral ventrolateral medulla, and nucleus tractus solitarius were detd. by Western blot anal.  Results C21-treated HF rats displayed significantly less norepinephrine excretion (2,385.6 ± 121.1 vs. 3,677.3 ± 147.6 ng/24 h; P < 0.05) and lower renal sympathetic nerve activity (50.2 ± 1.9% of max vs. 70.9 ± 8.2% of max; P < 0.05) than vehicle-treated HF rats.  C21-treated rats also exhibited improved spontaneous arterial baroreflex sensitivity and induced arterial baroreflex sensitivity.  Bolus intracerebroventricular injection of angiotensin II-evoked pressor and sympatho-excitatory responses were attenuated in the C21-treated HF rats, which displayed upregulated nNOS and downregulated AT1R expression in the subfornical organ, paraventricular nucleus, and rostral ventrolateral medulla.  Conclusions Activation of central angiotensin II type 2 receptor AT2R by C21 suppresses sympathetic outflow in rats with HF by improving baroreflex sensitivity and may provide important benefit in the HF syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCGIVRwSniWbVg90H21EOLACvtfcHk0lh-H3nlQ2il9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFSis7c%253D&md5=405cfac4511f5fabb05b15b88df67326</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1093%2Fajh%2Fhpu044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fajh%252Fhpu044%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DZucker%26aufirst%3DI.%2BH.%26aulast%3DGao%26aufirst%3DL.%26atitle%3DActivation%2520of%2520central%2520angiotensin%2520type%25202%2520receptors%2520by%2520compound%252021%2520improves%2520arterial%2520baroreflex%2520sensitivity%2520in%2520rats%2520with%2520heart%2520failure%26jtitle%3DAm.%2520J.%2520Hypertens.%26date%3D2014%26volume%3D27%26spage%3D1248%26epage%3D1256%26doi%3D10.1093%2Fajh%2Fhpu044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foryst-Ludwig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rompe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemnitz, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namsolleck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöpe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hucko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paetsch, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnackenburg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlöf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor stimulation. A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">2523</span>– <span class="NLM_lpage">2532</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.108.784868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FCIRCULATIONAHA.108.784868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19029468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVerur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2008&pages=2523-2532&author=E.+Kaschinaauthor=A.+Grzesiakauthor=J.+Liauthor=A.+Foryst-Ludwigauthor=M.+Timmauthor=F.+Rompeauthor=M.+Sommerfeldauthor=U.+R.+Kemnitzauthor=C.+Curatoauthor=P.+Namsolleckauthor=C.+Tsch%C3%B6peauthor=A.+Hallbergauthor=M.+Altermanauthor=T.+Huckoauthor=I.+Paetschauthor=T.+Dietrichauthor=B.+Schnackenburgauthor=K.+Grafauthor=B.+Dahl%C3%B6fauthor=U.+Kintscherauthor=T.+Ungerauthor=U.+M.+Steckelings&title=Angiotensin+II+type+2+receptor+stimulation.+A+novel+option+of+therapeutic+interference+with+the+renin-angiotensin+system+in+myocardial+infarction%3F&doi=10.1161%2FCIRCULATIONAHA.108.784868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II Type 2 Receptor Stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?</span></div><div class="casAuthors">Kaschina, Elena; Grzesiak, Aleksandra; Li, Jun; Foryst-Ludwig, Anna; Timm, Melanie; Rompe, Franziska; Sommerfeld, Manuela; Kemnitz, U. Rudolf; Curato, Caterina; Namsolleck, Pawel; Tschoepe, Carsten; Hallberg, Anders; Alterman, Mathias; Hucko, Thomas; Paetsch, Ingo; Dietrich, Thore; Schnackenburg, Bernhard; Graf, Kristof; Dahloef, Bjoern; Kintscher, Ulrich; Unger, Thomas; Steckelings, U. Muscha</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2523-2532</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: This study is the first to examine the effect of direct angiotensin II type 2 (AT2) receptor stimulation on postinfarct cardiac function with the use of the novel nonpeptide AT2 receptor agonist compd. 21 (C21).  Methods and Results: Myocardial infarction (MI) was induced in Wistar rats by permanent ligation of the left coronary artery.  Treatment with C21 (0.01, 0.03, 0.3 mg/kg per day IP) was started 24 h after MI and was continued until euthanasia (7 days after MI).  Infarct size was assessed by magnetic resonance imaging, and hemodynamic measurements were performed via transthoracic Doppler echocardiog. and intracardiac Millar catheter.  Cardiac tissues were analyzed for inflammation and apoptosis markers with immunoblotting and real-time reverse transcription polymerase chain reaction.  C21 significantly improved systolic and diastolic ventricular function.  Scar size was smallest in the C21-treated rats.  In regard to underlying mechanisms, C21 diminished MI-induced Fas-ligand and caspase-3 expression in the peri-infarct zone, indicating an antiapoptotic effect.  Phosphorylation of the p44/42 and p38 mitogen-activated protein kinases, both involved in the regulation of cell survival, was strongly reduced after MI but almost completely rescued by C21 treatment.  Furthermore, C21 decreased MI-induced serum monocyte chemoattractant protein-1 and myeloperoxidase as well as cardiac interleukin-6, interleukin-1β, and interleukin-2 expression, suggesting an antiinflammatory effect.  Conclusions: Direct AT2 receptor stimulation may be a novel therapeutic approach to improve post-MI systolic and diastolic function by antiapoptotic and antiinflammatory mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjl087BWN2T7Vg90H21EOLACvtfcHk0lh-H3nlQ2il9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVerur3E&md5=533faa85059b7d67036abf7a338015e0</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.108.784868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.108.784868%26sid%3Dliteratum%253Aachs%26aulast%3DKaschina%26aufirst%3DE.%26aulast%3DGrzesiak%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DForyst-Ludwig%26aufirst%3DA.%26aulast%3DTimm%26aufirst%3DM.%26aulast%3DRompe%26aufirst%3DF.%26aulast%3DSommerfeld%26aufirst%3DM.%26aulast%3DKemnitz%26aufirst%3DU.%2BR.%26aulast%3DCurato%26aufirst%3DC.%26aulast%3DNamsolleck%26aufirst%3DP.%26aulast%3DTsch%25C3%25B6pe%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26aulast%3DHucko%26aufirst%3DT.%26aulast%3DPaetsch%26aufirst%3DI.%26aulast%3DDietrich%26aufirst%3DT.%26aulast%3DSchnackenburg%26aufirst%3DB.%26aulast%3DGraf%26aufirst%3DK.%26aulast%3DDahl%25C3%25B6f%26aufirst%3DB.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor%2520stimulation.%2520A%2520novel%2520option%2520of%2520therapeutic%2520interference%2520with%2520the%2520renin-angiotensin%2520system%2520in%2520myocardial%2520infarction%253F%26jtitle%3DCirculation%26date%3D2008%26volume%3D118%26spage%3D2523%26epage%3D2532%26doi%3D10.1161%2FCIRCULATIONAHA.108.784868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosnyak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welungoda, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span> <span> </span><span class="NLM_article-title">Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00575.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2Fj.1476-5381.2009.00575.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=20128808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlChsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2010&pages=709-716&author=S.+Bosnyakauthor=I.+K.+Welungodaauthor=A.+Hallbergauthor=M.+Altermanauthor=R.+E.+Widdopauthor=E.+S.+Jones&title=Stimulation+of+angiotensin+AT2+receptors+by+the+non-peptide+agonist%2C+Compound+21%2C+evokes+vasodepressor+effects+in+conscious+spontaneously+hypertensive+rats&doi=10.1111%2Fj.1476-5381.2009.00575.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats</span></div><div class="casAuthors">Bosnyak, S.; Welungoda, I. K.; Hallberg, A.; Alterman, M.; Widdop, R. E.; Jones, E. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">709-716</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Angiotensin type 2 receptor (AT2 receptor) stimulation evokes vasodilator effects in vitro and in vivo that oppose the vasoconstrictor effects of angiotensin type 1 receptors (AT1 receptors).  Recently, a novel non-peptide AT2 receptor agonist, Compd. 21, was described, which exhibited high AT2 receptor selectivity.  Functional cardiovascular effects of the drug candidate Compd. 21 were assessed, using mouse isolated aorta and rat mesenteric arteries in vitro and in conscious spontaneously hypertensive rats (SHR).  Compd. 21 evoked dose-dependent vasorelaxations in aortic and mesenteric vessels, abolished by the AT2 receptor antagonist, PD123319.  In vivo, Compd. 21 administered alone, at doses ranging from 50 to 1000 ng/kg-1/min-1 over 4 h did not decrease blood pressure in conscious normotensive Wistar-Kyoto rats or SHR.  However, when given in combination with the AT1 receptor antagonist, candesartan, Compd. 21 (300 ng/kg-1/min-1) lowered blood pressure in SHR only.  Further anal. in sep. groups of conscious SHR revealed that, at a sixfold lower dose, Compd. 21 (50 ng/kg-1/min-1) still evoked a significant depressor response in adult SHR (∼30 mmHg) when combined with different doses of candesartan (0.01 or 0.1 mg/kg-1).  Moreover, the Compd. 21-evoked depressor effect was abolished when co-infused (50 μg/kg-1/min-1 for 2 h) with the AT2 receptor antagonist PD123319.  Collectively, our results indicate that acute administration of Compd. 21 evoked blood pressure redns. via AT2 receptor stimulation.  Thus Compd. 21 can be considered an excellent drug candidate for further study of AT2 receptor function in cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXNBgMew3RELVg90H21EOLACvtfcHk0ljcH_n-hcENiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlChsr0%253D&md5=069e16cdad1181028613321d5975c9f4</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00575.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00575.x%26sid%3Dliteratum%253Aachs%26aulast%3DBosnyak%26aufirst%3DS.%26aulast%3DWelungoda%26aufirst%3DI.%2BK.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DJones%26aufirst%3DE.%2BS.%26atitle%3DStimulation%2520of%2520angiotensin%2520AT2%2520receptors%2520by%2520the%2520non-peptide%2520agonist%252C%2520Compound%252021%252C%2520evokes%2520vasodepressor%2520effects%2520in%2520conscious%2520spontaneously%2520hypertensive%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D159%26spage%3D709%26epage%3D716%26doi%3D10.1111%2Fj.1476-5381.2009.00575.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennion, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumners, C.</span></span> <span> </span><span class="NLM_article-title">Neuroprotection via AT<sub>2</sub> receptor agonists in ischemic stroke</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1042/CS20171549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1042%2FCS20171549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29802210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOqs7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=1055-1067&author=D.+M.+Bennionauthor=U.+M.+Steckelingsauthor=C.+Sumners&title=Neuroprotection+via+AT2+receptor+agonists+in+ischemic+stroke&doi=10.1042%2FCS20171549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotection via AT2 receptor agonists in ischemic stroke</span></div><div class="casAuthors">Bennion, Douglas M.; Steckelings, U. Muscha; Sumners, Colin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1055-1067</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Stroke is a devastating disease that afflicts millions of people each year worldwide.  Ischemic stroke, which accounts for 88% of cases, occurs when blood supply to the brain is decreased, often because of thromboembolism or atherosclerotic occlusion.  This deprives the brain of oxygen and nutrients, causing immediate, irreversible necrosis within the core of the ischemic area, but more delayed and potentially reversible neuronal damage in the surrounding brain tissue, the penumbra.  The only currently approved therapies for ischemic stroke, the thrombolytic agent recombinant tissue plasminogen activator (rtPA) and the endovascular clot retrieval/destruction processes, are aimed at restoring blood flow to the infarcted area, but are only available for a minority of patients and are not able in most cases to completely restore neurol. deficits.  Consequently, there remains a need for agents that will protect neurons against death following ischemic stroke.  Here, we evaluate angiotensin II (Ang II) type 2 (AT2) receptor agonists as a possible therapeutic target for this disease.  We first provide an overview of stroke epidemiol., pathophysiol., and currently approved therapies.  We next review the large amt. of preclin. evidence, accumulated over the past decade and a half, which indicates that AT2 receptor agonists exert significant neuroprotective effects in various animal models, and discuss the potential mechanisms involved.  Finally, after discussing the challenges of delivering blood-brain barrier (BBB) impermeable AT2 receptor agonists to the infarcted areas of the brain, we summarize the evidence for and against the development of these agents as a promising therapeutic strategy for ischemic stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVCXzpo1iC-rVg90H21EOLACvtfcHk0ljcH_n-hcENiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOqs7jP&md5=d1aa44f115be87046f9a777fff382ec3</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1042%2FCS20171549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20171549%26sid%3Dliteratum%253Aachs%26aulast%3DBennion%26aufirst%3DD.%2BM.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DSumners%26aufirst%3DC.%26atitle%3DNeuroprotection%2520via%2520AT2%2520receptor%2520agonists%2520in%2520ischemic%2520stroke%26jtitle%3DClin.%2520Sci.%26date%3D2018%26volume%3D132%26spage%3D1055%26epage%3D1067%26doi%3D10.1042%2FCS20171549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaway, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1482</span>– <span class="NLM_lpage">1489</span>, <span class="refDoi"> DOI: 10.1161/STROKEAHA.108.531509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FSTROKEAHA.108.531509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19246705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsVOntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2009&pages=1482-1489&author=C.+A.+McCarthyauthor=A.+Vinhauthor=J.+K.+Callawayauthor=R.+E.+Widdop&title=Angiotensin+AT2+receptor+stimulation+causes+neuroprotection+in+a+conscious+rat+model+of+stroke&doi=10.1161%2FSTROKEAHA.108.531509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin AT2 Receptor Stimulation Causes Neuroprotection in a Conscious Rat Model of Stroke</span></div><div class="casAuthors">McCarthy, Claudia A.; Vinh, Antony; Callaway, Jennifer K.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1482-1489</span>CODEN:
                <span class="NLM_cas:coden">SJCCA7</span>;
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background and Purpose: The angiotensin II type 2 receptor (AT2R) is implicated to be neuroprotective in stroke, although this premise has not been directly tested.  Therefore, we have examd. the neuroprotective effect of AT2R stimulation after intracerebroventricular administration of AT2R agonist CGP42112 in a conscious rat model of stroke.  Methods: Spontaneously hypertensive rats were treated with either CGP42112 (0.1 to 10 ng/kg/min intracerebroventricularly) alone or in combination with the AT2R antagonist PD123319 (36 ng/kg/min intracerebroventricularly) beginning 5 days before stroke induction.  A focal reperfusion model of stroke was induced in conscious spontaneously hypertensive rats by administering endothelin-1 to the middle cerebral artery through a surgically implanted cannula.  Behavioral tests were used to assess the severity of neurol. deficit as a result of the ischemic event.  Cortical and striatal infarct vols. were measured 72 h poststroke.  Results- Blood pressure was unaffected by treatments.  CGP42112 dose-dependently reduced cortical infarct vol. poststroke, and PD123319 abolished the neuroprotective effect of CGP42112.  PD123319 had no effect on infarct vol. alone.  These results were consistent with the behavioral findings, indicating that CGP42112 reduced motor deficit on the ledged beam test at 72 h poststroke and immunohistochem. analyses showing that CGP42112 increased neuronal survival and minimized the loss of AT2R expression in the infarcted region.  Conclusion: Based on infarct, behavioral, and immunohistochem. data, these results indicate that centrally administered CGP42112 exhibits a neuroprotective effect, which was independent of blood pressure.  Thus, for the first time, we have shown that central AT2R stimulation is neuroprotective in a conscious rat model of stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNMckW8OZAuLVg90H21EOLACvtfcHk0ljcH_n-hcENiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsVOntb0%253D&md5=57945540f901ebadea58e0fa374a29f3</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1161%2FSTROKEAHA.108.531509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FSTROKEAHA.108.531509%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DC.%2BA.%26aulast%3DVinh%26aufirst%3DA.%26aulast%3DCallaway%26aufirst%3DJ.%2BK.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DAngiotensin%2520AT2%2520receptor%2520stimulation%2520causes%2520neuroprotection%2520in%2520a%2520conscious%2520rat%2520model%2520of%2520stroke%26jtitle%3DStroke%26date%3D2009%26volume%3D40%26spage%3D1482%26epage%3D1489%26doi%3D10.1161%2FSTROKEAHA.108.531509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danyel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span> <span> </span><span class="NLM_article-title">Impact of AT2-receptor stimulation on vascular biology, kidney function, and blood pressure</span>. <i>Integr. Blood Pressure Control</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.2147/IBPC.S34425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2147%2FIBPC.S34425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24379697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvVGrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=153-161&author=L.+A.+Danyelauthor=P.+Schmerlerauthor=L.+Paulisauthor=T.+Ungerauthor=U.+M.+Steckelings&title=Impact+of+AT2-receptor+stimulation+on+vascular+biology%2C+kidney+function%2C+and+blood+pressure&doi=10.2147%2FIBPC.S34425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of AT2-receptor stimulation on vascular biology, kidney function and blood pressure</span></div><div class="casAuthors">Danyel, Leon A.; Schmerler, Patrick; Paulis, Ludovit; Unger, Thomas; Steckelings, U. Muscha</div><div class="citationInfo"><span class="NLM_cas:title">Integrated Blood Pressure Control</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-161, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">IBPCB9</span>;
        ISSN:<span class="NLM_cas:issn">1178-7104</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The angiotensin type 2 receptor (AT2R) and the receptor MAS are receptors within the renin-angiotensin system, which mediate tissue-protective actions such as anti-inflammation, antifibrosis and antiapoptosis.  In recent years, several programs have been launched in order to develop drugs that act as agonists on the AT2R or MAS to take therapeutic advantage of the protective and regenerative properties of these receptors.  This review article will focus on recent data obtained in preclin. animal and on vitro models with new AT2R-agonistic mols. (Compd. 21 and β-amino acid substituted angiotensin II) and with relevance for blood pressure (BP) regulation or hypertensive end-organ damage.  These data will include studies on vasodilation/vasoconstriction in isolated resistance arteries ex vivo, studies on kidney function, studies on vascular remodeling, and studies that measured the net effect of AT2R stimulation on BP in vivo.  Current data indicate that although AT2R stimulation causes vasodilation ex vivo and promotes natriuresis, it does not alter BP levels in vivo acutely - at least as long as there is no addnl. low-dose blockade of AT1R.  However, AT2R stimulation alone is able to attenuate hypertension-induced vascular remodeling and reduce arterial stiffening, which in more chronic settings and together with the natriuretic effect may result in modest lowering of BP.  We conclude from these preclin. data that AT2R agonists are not suitable for antihypertensive monotherapy, but that this new future drug class may be beneficial in combination with established antihypertensives for the treatment of hypertension with improved protection from end-organ damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot9RFOyx7x2rVg90H21EOLACvtfcHk0lipkvHyzWgP_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvVGrtbw%253D&md5=3ae15e261423252f5c7e173afea27f0c</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.2147%2FIBPC.S34425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIBPC.S34425%26sid%3Dliteratum%253Aachs%26aulast%3DDanyel%26aufirst%3DL.%2BA.%26aulast%3DSchmerler%26aufirst%3DP.%26aulast%3DPaulis%26aufirst%3DL.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26atitle%3DImpact%2520of%2520AT2-receptor%2520stimulation%2520on%2520vascular%2520biology%252C%2520kidney%2520function%252C%2520and%2520blood%2520pressure%26jtitle%3DIntegr.%2520Blood%2520Pressure%2520Control%26date%3D2013%26volume%3D6%26spage%3D153%26epage%3D161%26doi%3D10.2147%2FIBPC.S34425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibowitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rautureau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffrin, E. L.</span></span> <span> </span><span class="NLM_article-title">Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.111.180158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.111.180158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22184324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVeluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2012&pages=291-299&author=A.+Rehmanauthor=A.+Leibowitzauthor=N.+Yamamotoauthor=Y.+Rautureauauthor=P.+Paradisauthor=E.+L.+Schiffrin&title=Angiotensin+type+2+receptor+agonist+compound+21+reduces+vascular+injury+and+myocardial+fibrosis+in+stroke-prone+spontaneously+hypertensive+rats&doi=10.1161%2FHYPERTENSIONAHA.111.180158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats</span></div><div class="casAuthors">Rehman, Asia; Leibowitz, Avshalom; Yamamoto, Naoki; Rautureau, Yohann; Paradis, Pierre; Schiffrin, Ernesto L.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">291-299</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">-Angiotensin type 2 receptor-mediated effects of angiotensin II appear to counteract many of the effects mediated via the angiotensin type 1 receptor.  Compd. 21 (C21), a selective angiotensin type 2 receptor agonist, has demonstrated beneficial effects on cardiac function after myocardial infarction in rodents.  We hypothesized that C21 alone or in combination with an angiotensin type 1 receptor antagonist would blunt the development of hypertension and vascular damage in stroke-prone spontaneously hypertensive rats.  Six-week-old stroke-prone spontaneously hypertensive rats received C21 (1 mg/kg per day), the angiotensin type 1 receptor antagonist losartan (10 mg/kg per day), C21 plus losartan, or vehicle PO for 6 wk.  Systolic blood pressure was lower in losartan and C21-losartan combination groups (P<0.001).  Endothelium-dependent relaxation was enhanced (P<0.001) in the C21-losartan combination group at lower acetylcholine concns.  C21 or C21-losartan combination reduced vascular stiffness, aortic medial and myocardial interstitial collagen content, and aortic fibronectin (P<0.05).  C21 and losartan decreased the expression of 2 genes assocd. with cardiac hypertrophy, myosin heavy chain-β (myh7) by 30 to 50%, and α-skeletal muscle actin by 30% to 35% (P<0.05).  C21-losartan combination caused an addnl. 40% redn. in myh7 compared with C21 (P<0.01).  Aortic superoxide generation was reduced equally by the 3 treatments (P<0.001).  Monocyte/macrophage infiltration in the aorta and kidney (P<0.001) and T-lymphocyte infiltration in the renal cortex (P<0.05) were lowered similarly by the 3 treatments.  These data suggest that C21 alone or in combination with losartan may improve endothelial function and vascular compn. and mechanics by reducing oxidative stress, collagen content, fibronectin, and inflammatory cell infiltration in stroke-prone spontaneously hypertensive rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob-8rmJBw_47Vg90H21EOLACvtfcHk0lipkvHyzWgP_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVeluw%253D%253D&md5=131d4b435a6ad8e6e7c33618df03a3c2</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.111.180158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.111.180158%26sid%3Dliteratum%253Aachs%26aulast%3DRehman%26aufirst%3DA.%26aulast%3DLeibowitz%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DRautureau%26aufirst%3DY.%26aulast%3DParadis%26aufirst%3DP.%26aulast%3DSchiffrin%26aufirst%3DE.%2BL.%26atitle%3DAngiotensin%2520type%25202%2520receptor%2520agonist%2520compound%252021%2520reduces%2520vascular%2520injury%2520and%2520myocardial%2520fibrosis%2520in%2520stroke-prone%2520spontaneously%2520hypertensive%2520rats%26jtitle%3DHypertension%26date%3D2012%26volume%3D59%26spage%3D291%26epage%3D299%26doi%3D10.1161%2FHYPERTENSIONAHA.111.180158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thöne-Reineke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkovska, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlöf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span> <span> </span><span class="NLM_article-title">Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e60</span>– <span class="NLM_lpage">e67</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.113.02522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.113.02522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24379181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXit1yrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2014&pages=e60-e67&author=D.+Lauerauthor=S.+Slavicauthor=M.+Sommerfeldauthor=C.+Th%C3%B6ne-Reinekeauthor=Y.+Sharkovskaauthor=A.+Hallbergauthor=B.+Dahl%C3%B6fauthor=U.+Kintscherauthor=T.+Ungerauthor=U.+M.+Steckelingsauthor=E.+Kaschina&title=Angiotensin+type+2+receptor+stimulation+ameliorates+left+ventricular+fibrosis+and+dysfunction+via+regulation+of+tissue+inhibitor+of+matrix+metalloproteinase+1%2Fmatrix+metalloproteinase+9+axis+and+transforming+growth+factor+%CE%B21+in+the+rat+heart&doi=10.1161%2FHYPERTENSIONAHA.113.02522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase 1/Matrix Metalloproteinase 9 Axis and Transforming Growth Factor β1 in the Rat Heart</span></div><div class="casAuthors">Lauer, Dilyara; Slavic, Svetlana; Sommerfeld, Manuela; Thoene-Reineke, Christa; Sharkovska, Yuliya; Hallberg, Anders; Dahloef, Bjorn; Kintscher, Ulrich; Unger, Thomas; Steckelings, Ulrike Muscha; Kaschina, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e60-e67</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Left ventricular (LV) remodeling is the main reason for the development of progressive cardiac dysfunction after myocardial infarction (MI).  This study investigated whether stimulation of the angiotensin type 2 receptor is able to ameliorate post-MI cardiac remodeling and what the underlying mechanisms may be.  MI was induced in Wistar rats by permanent ligation of the left coronary artery.  Treatment with the angiotensin type 2 receptor agonist compd. 21 ( 0.03 mg/kg) was started 6 h post-MI and continued for 6 wk.  Hemodynamic parameters were measured by echocardiog. and intracardiac catheter.  Effects on proteolysis were studied in heart tissue and primary cardiac fibroblasts.  Compd. 21 significantly improved systolic and diastolic functions, resulting in improved ejection fraction (71.2±4.7% vs. 53.4±7.0%; P<0.001), fractional shortening (P<0.05), LV internal dimension in systole (P<0.05), LV end-diastolic pressure (16.9±1.2 vs. 22.1±1.4 mm Hg; P<0.05), ratio of early (E) to late (A) ventricular filling velocities, and max. and min. rate of LV pressure rise (P<0.05).  Compd. 21 improved arterial stiffness parameters and reduced collagen content in peri-infarct myocardium.  Tissue inhibitor of matrix metalloproteinase 1 was strongly upregulated, whereas matrix metalloproteinases 2 and 9 and transforming growth factor β1 were diminished in LV of treated animals.  In cardiac fibroblasts, compd. 21 initially induced tissue inhibitor of matrix metalloproteinase 1 expression followed by attenuated matrix metalloproteinase 9 and transforming growth factor β1 secretion.  In conclusion, angiotensin type 2 receptor stimulation improves cardiac function and prevents cardiac remodeling in the late stage after MI, suggesting that angiotensin type 2 receptor agonists may be considered a future pharmacol. approach for the improvement of post-MI cardiac dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDbLTec17DHLVg90H21EOLACvtfcHk0lipkvHyzWgP_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXit1yrs7s%253D&md5=578fcae9d335242824a1a40c8d5bf399</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.113.02522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.113.02522%26sid%3Dliteratum%253Aachs%26aulast%3DLauer%26aufirst%3DD.%26aulast%3DSlavic%26aufirst%3DS.%26aulast%3DSommerfeld%26aufirst%3DM.%26aulast%3DTh%25C3%25B6ne-Reineke%26aufirst%3DC.%26aulast%3DSharkovska%26aufirst%3DY.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DDahl%25C3%25B6f%26aufirst%3DB.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DKaschina%26aufirst%3DE.%26atitle%3DAngiotensin%2520type%25202%2520receptor%2520stimulation%2520ameliorates%2520left%2520ventricular%2520fibrosis%2520and%2520dysfunction%2520via%2520regulation%2520of%2520tissue%2520inhibitor%2520of%2520matrix%2520metalloproteinase%25201%252Fmatrix%2520metalloproteinase%25209%2520axis%2520and%2520transforming%2520growth%2520factor%2520%25CE%25B21%2520in%2520the%2520rat%2520heart%26jtitle%3DHypertension%26date%3D2014%26volume%3D63%26spage%3De60%26epage%3De67%26doi%3D10.1161%2FHYPERTENSIONAHA.113.02522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namsolleck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span> <span> </span><span class="NLM_article-title">AT<sub>2</sub>R (angiotensin AT2 receptor) agonist, compound 21, prevents abdominal aortic aneurysm progression in the rat</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">e20</span>– <span class="NLM_lpage">e29</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.118.11168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.118.11168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29987108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVKisLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2018&pages=e20-e29&author=C.+Langeauthor=M.+Sommerfeldauthor=P.+Namsolleckauthor=U.+Kintscherauthor=T.+Ungerauthor=E.+Kaschina&title=AT2R+%28angiotensin+AT2+receptor%29+agonist%2C+compound+21%2C+prevents+abdominal+aortic+aneurysm+progression+in+the+rat&doi=10.1161%2FHYPERTENSIONAHA.118.11168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">AT2R (Angiotensin AT2 Receptor) Agonist, Compound 21, Prevents Abdominal Aortic Aneurysm Progression in the Rat</span></div><div class="casAuthors">Lange, Christoph; Sommerfeld, Manuela; Namsolleck, Pawel; Kintscher, Ulrich; Unger, Thomas; Kaschina, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e20-e29</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The effects of the selective AT2R (angiotensin AT2 receptor) agonist, Compd. 21 (C21), on abdominal aortic aneurysm formation were investigated in normotensive Wistar rats.  Abdominal aortic aneurysm was induced by perfusion of isolated aortic segments with elastase.  Treatment with C21 (0.03 mg/kg daily) was started after operation and continued for 14 days.  Sham-operated animals and vehicle-treated animals after aneurysm induction served as controls.  Aortic diam., aortic wall distensibility, and pulse propagation velocity were measured via ultrasound.  Hemodynamic parameters, aortic tissue protein expression, and serum cytokines were analyzed.  On day 14 post aneurysm induction, aortic diam. of vehicle-treated animals was increased 1.6-fold compared with sham-operated rats (2.65±0.05 vs. 1.70±0.06 mm; P<0.0001).  C21 decreased aortic diam. in comparison to vehicle (1.9±0.06 vs. 2.65±0.05; P<0.0001).  Infrarenal blood velocity and aortic distensibility were reduced, whereas aortic wall stiffness was increased post aneurysm induction.  These alterations were significantly ameliorated by treatment with C21 while blood pressure and cardiac contractility remained unchanged.  Protein expression of IL-1β (interleukin-1β), NFκB (nuclear factor κB), MMP9 (matrix metalloproteinase 9), TGF-β1 (transforming growth factor-β1), and MLKL (mixed lineage kinase domain-like) in the aorta was significantly (P<0.05) down-regulated in the C21 group compared with vehicle.  Serum concn. of TGF-β1 was decreased by C21 in comparison to vehicle (P<0.01).  AT2R stimulation with C21 prevented extracellular matrix degrdn., maintained vascular integrity of the aorta and prevented abdominal aortic aneurysm progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB3zA4di23NLVg90H21EOLACvtfcHk0ljRL60HUwHaPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVKisLzP&md5=65a09de5da5eeb8716ace6423886b863</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.118.11168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.118.11168%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DC.%26aulast%3DSommerfeld%26aufirst%3DM.%26aulast%3DNamsolleck%26aufirst%3DP.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKaschina%26aufirst%3DE.%26atitle%3DAT2R%2520%2528angiotensin%2520AT2%2520receptor%2529%2520agonist%252C%2520compound%252021%252C%2520prevents%2520abdominal%2520aortic%2520aneurysm%2520progression%2520in%2520the%2520rat%26jtitle%3DHypertension%26date%3D2018%26volume%3D72%26spage%3De20%26epage%3De29%26doi%3D10.1161%2FHYPERTENSIONAHA.118.11168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Borgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirmiz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">Anti-fibrotic potential of AT<sub>2</sub> receptor agonists</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">564</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffphar.2017.00564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28912715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=564&author=Y.+Wangauthor=M.+Del+Borgoauthor=H.+W.+Leeauthor=D.+Baraldiauthor=B.+Hirmizauthor=T.+A.+Gaspariauthor=K.+M.+Dentonauthor=M.+I.+Aguilarauthor=C.+S.+Samuelauthor=R.+E.+Widdop&title=Anti-fibrotic+potential+of+AT2+receptor+agonists&doi=10.3389%2Ffphar.2017.00564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-fibrotic potential of AT2 receptor agonists</span></div><div class="casAuthors">Wang, Yan; Del Borgo, Mark; Lee, Huey W.; Baraldi, Dhaniel; Hirmiz, Baydaa; Gaspari, Tracey A.; Denton, Kate M.; Aguilar, Marie-Isabel; Samuel, Chrishan S.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">564/1-564/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">There are a no. of therapeutic targets to treat organ fibrosis that are under investigation in preclin. models.  There is increasing evidence that stimulation of the angiotensin II type 2 receptor (AT2R) is a novel anti-fibrotic strategy and we have reviewed the published in vivo preclin. data relating to the effects of compd. 21 (C21), which is the only nonpeptide AT2R agonist that is currently available for use in chronic preclin. studies.  In particular, the differential influence of AT2R on extracellular matrix status in various preclin. fibrotic models is discussed.  Collectively, these studies demonstrate that pharmacol. AT2R stimulation using C21 decreases organ fibrosis, which has been most studied in the setting of cardiovascular and renal disease.  In addn., AT2R-mediated anti-inflammatory effects may contribute to the beneficial AT2R-mediated anti-fibrotic effects seen in preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXQrEmlGvVi7Vg90H21EOLACvtfcHk0ljRL60HUwHaPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsrfP&md5=616e2c23a2a6d046dd5bb0cd2c3733ed</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00564%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDel%2BBorgo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DBaraldi%26aufirst%3DD.%26aulast%3DHirmiz%26aufirst%3DB.%26aulast%3DGaspari%26aufirst%3DT.%2BA.%26aulast%3DDenton%26aufirst%3DK.%2BM.%26aulast%3DAguilar%26aufirst%3DM.%2BI.%26aulast%3DSamuel%26aufirst%3DC.%2BS.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DAnti-fibrotic%2520potential%2520of%2520AT2%2520receptor%2520agonists%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D564%26doi%3D10.3389%2Ffphar.2017.00564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koulis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, B. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKelvey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thallas-Bonke, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jandeleit-Dahm, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, T. J.</span></span> <span> </span><span class="NLM_article-title">AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1073</span>– <span class="NLM_lpage">1081</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.115.05204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.115.05204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25776077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFGgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=1073-1081&author=C.+Koulisauthor=B.+S.+M.+Chowauthor=M.+McKelveyauthor=U.+M.+Steckelingsauthor=T.+Ungerauthor=V.+Thallas-Bonkeauthor=M.+C.+Thomasauthor=M.+E.+Cooperauthor=K.+A.+Jandeleit-Dahmauthor=T.+J.+Allen&title=AT2R+agonist%2C+compound+21%2C+is+reno-protective+against+type+1+diabetic+nephropathy&doi=10.1161%2FHYPERTENSIONAHA.115.05204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">AT2R Agonist, Compound 21, Is Reno-Protective Against Type 1 Diabetic Nephropathy</span></div><div class="casAuthors">Koulis, Christine; Chow, Bryna S. M.; McKelvey, Maria; Steckelings, Ulrike M.; Unger, Thomas; Thallas-Bonke, Vicki; Thomas, Merlin C.; Cooper, Mark E.; Jandeleit-Dahm, Karin A.; Allen, Terri J.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1073-1081</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The hemodynamic and nonhemodynamic effects of angiotensin II on diabetic complications are considered to be primarily mediated by the angiotensin II type 1 receptor subtype.  However, its biol. and functional effect mediated through the angiotensin II type 2 receptor subtype is still unclear.  Activation of the angiotensin II type 2 receptors has been postulated to oppose angiotensin II type 1 receptor-mediated actions and thus attenuate fibrosis.  This study aimed to elucidate the reno-protective role of the novel selective angiotensin II type 2 receptor agonist, Compd. 21, in an exptl. model of type 1 diabetic nephropathy.  Compd. 21 treatment significantly attenuated diabetes mellitus-induced elevated levels of cystatin C, albuminuria, mesangial expansion, and glomerulosclerosis in diabetic mice.  Moreover, Compd. 21 markedly inhibited the expression of various proteins implicated in oxidative stress, inflammation, and fibrosis, in assocn. with decreased extracellular matrix prodn.  These findings demonstrate that monotherapy of Compd. 21 is protective against the progression of exptl. diabetic nephropathy by inhibiting renal oxidative stress, inflammation, and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPzvc-jfzhbrVg90H21EOLACvtfcHk0lj8L8mxqTlsTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFGgtLg%253D&md5=825aa6adcf583a062af2b65d529697b3</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.115.05204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.115.05204%26sid%3Dliteratum%253Aachs%26aulast%3DKoulis%26aufirst%3DC.%26aulast%3DChow%26aufirst%3DB.%2BS.%2BM.%26aulast%3DMcKelvey%26aufirst%3DM.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DThallas-Bonke%26aufirst%3DV.%26aulast%3DThomas%26aufirst%3DM.%2BC.%26aulast%3DCooper%26aufirst%3DM.%2BE.%26aulast%3DJandeleit-Dahm%26aufirst%3DK.%2BA.%26aulast%3DAllen%26aufirst%3DT.%2BJ.%26atitle%3DAT2R%2520agonist%252C%2520compound%252021%252C%2520is%2520reno-protective%2520against%2520type%25201%2520diabetic%2520nephropathy%26jtitle%3DHypertension%26date%3D2015%26volume%3D65%26spage%3D1073%26epage%3D1081%26doi%3D10.1161%2FHYPERTENSIONAHA.115.05204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, T.</span></span> <span> </span><span class="NLM_article-title">Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1038/ki.2013.193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fki.2013.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23823602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWqtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=931-939&author=Q.+Aliauthor=Y.+Wuauthor=T.+Hussain&title=Chronic+AT2+receptor+activation+increases+renal+ACE2+activity%2C+attenuates+AT1+receptor+function+and+blood+pressure+in+obese+Zucker+rats&doi=10.1038%2Fki.2013.193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats</span></div><div class="casAuthors">Ali, Quaisar; Wu, Yonnie; Hussain, Tahir</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">931-939</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Abnormal regulation of the renin angiotensin system such as enhanced renal AT1R function and reduced ACE2 activity contributes to obesity-related hypertension.  Here, we tested whether long-term AT2R activation affects renal function in obesity using lean and obese Zucker rats treated with the AT2R agonist CGP42112A for 2 wk.  This caused blood pressure to decrease by 13 mm Hg, which was assocd. with increased urinary sodium excretion in the obese rats.  Cortical ACE2 expression and activity, the Mas receptor (MasR), and its ligand angiotensin-(1-7) were all increased in CGP-treated obese compared with control rats.  Candesartan-induced natriuresis, a measure of AT1R function, was reduced but cortical AT1R expression and angiotensin II levels were similar in CGP-treated obese compared with control rats.  Renin and AT2R expression in obese rats was not affected by CGP treatment.  In HK-2 cells in vitro, CGP treatment caused increased ACE2 activity and MasR levels but decreased AT1R levels and renin activity.  Thus, long-term AT2R activation shifts the opposing arms of renin angiotensin system and contributes to natriuresis and blood pressure redn. in obese animals.  Our study highlights the importance of AT2R as a target for treating obesity-related hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCEhKVv6TAxLVg90H21EOLACvtfcHk0lj8L8mxqTlsTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWqtrrF&md5=5ac9ffedccefc2d0278c45d53740252d</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1038%2Fki.2013.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2013.193%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHussain%26aufirst%3DT.%26atitle%3DChronic%2520AT2%2520receptor%2520activation%2520increases%2520renal%2520ACE2%2520activity%252C%2520attenuates%2520AT1%2520receptor%2520function%2520and%2520blood%2520pressure%2520in%2520obese%2520Zucker%2520rats%26jtitle%3DKidney%2520Int.%26date%3D2013%26volume%3D84%26spage%3D931%26epage%3D939%26doi%3D10.1038%2Fki.2013.193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quiroga, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pffeifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toblli, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giani, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominici, F. P.</span></span> <span> </span><span class="NLM_article-title">Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice</span>. <i>Physiol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e13824</span> <span class="refDoi"> DOI: 10.14814/phy2.13824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.14814%2Fphy2.13824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30156060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2mtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&author=D.+T.+Quirogaauthor=M.+C.+Mu%C3%B1ozauthor=C.+Gilauthor=M.+Pffeiferauthor=J.+E.+Toblliauthor=U.+M.+Steckelingsauthor=J.+F.+Gianiauthor=F.+P.+Dominici&title=Chronic+administration+of+the+angiotensin+type+2+receptor+agonist+C21+improves+insulin+sensitivity+in+C57BL%2F6+mice&doi=10.14814%2Fphy2.13824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice.</span></div><div class="casAuthors">Quiroga, Diego Tomas; Munoz, Marina C.; Gil, Carolina; Pffeifer, Marlies; Toblli, Jorge E.; Steckelings, Ulrike M.; Giani, Jorge F.; Dominici, Fernando P.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">e13824/1-e13824/13</span>CODEN:
                <span class="NLM_cas:coden">PRHEJ2</span>;
        ISSN:<span class="NLM_cas:issn">2051-817X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The renin-angiotensin system modulates insulin action.  Angiotensin type 1 receptor exerts a deleterious effect, whereas the angiotensin type 2 receptor (AT2R) appears to have beneficial effects providing protection against insulin resistance and type 2 diabetes.  To further explore the role of the AT2R on insulin action and glucose homeostasis, in this study we administered C57Bl/6 mice with the synthetic agonist of the AT2R C21 for 12 wk (1 mg/kg per day; i.p.).  Vehicle-treated animals were used as control.  Metabolic parameters, glucose, and insulin tolerance, in vivo insulin signaling in main insulin-target tissues as well as adipose tissue levels of adiponectin, and TNF-α were assessed.  C21-treated animals displayed decreased glycemia together with unaltered insulinemia, increased insulin sensitivity, and increased glucose tolerance compared to nontreated controls.  This was accompanied by a significant decrease in adipocytes size in epididymal adipose tissue and significant increases in both adiponectin and UCP-1 expression in this tissue.  C21-treated mice showed an increase in both basal Akt and ERK1/2 phosphorylation levels in the liver, and increased insulin-stimulated Akt activation in adipose tissue.  This pos. modulation of insulin action induced by C21 appeared not to involve the insulin receptor.  In C21-treated mice, adipose tissue and skeletal muscle became unresponsive to insulin in terms of ERK1/2 phosphorylation levels.  Present data show that chronic pharmacol. activation of AT2R with C21 increases insulin sensitivity in mice and indicate that the AT2R has a physiol. role in the conservation of insulin action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofW80EhzU4xbVg90H21EOLACvtfcHk0lj8L8mxqTlsTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2mtrfO&md5=f4902bf81535cfdb766d2e6a286c9292</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.14814%2Fphy2.13824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14814%252Fphy2.13824%26sid%3Dliteratum%253Aachs%26aulast%3DQuiroga%26aufirst%3DD.%2BT.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%2BC.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DPffeifer%26aufirst%3DM.%26aulast%3DToblli%26aufirst%3DJ.%2BE.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DGiani%26aufirst%3DJ.%2BF.%26aulast%3DDominici%26aufirst%3DF.%2BP.%26atitle%3DChronic%2520administration%2520of%2520the%2520angiotensin%2520type%25202%2520receptor%2520agonist%2520C21%2520improves%2520insulin%2520sensitivity%2520in%2520C57BL%252F6%2520mice%26jtitle%3DPhysiol.%2520Rep.%26date%3D2018%26volume%3D6%26doi%3D10.14814%2Fphy2.13824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guimond, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span> <span> </span><span class="NLM_article-title">The angiotensin II type 2 receptor in brain functions: an update</span>. <i>Int. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">351758</span>, <span class="refDoi"> DOI: 10.1155/2012/351758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1155%2F2012%2F351758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23320146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC3s3psFOruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=351758&author=M.+O.+Guimondauthor=N.+Gallo-Payet&title=The+angiotensin+II+type+2+receptor+in+brain+functions%3A+an+update&doi=10.1155%2F2012%2F351758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">The Angiotensin II Type 2 Receptor in Brain Functions: An Update</span></div><div class="casAuthors">Guimond Marie-Odile; Gallo-Payet Nicole</div><div class="citationInfo"><span class="NLM_cas:title">International journal of hypertension</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">351758</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Angiotensin II (Ang II) is the main active product of the renin-angiotensin system (RAS), mediating its action via two major receptors, namely, the Ang II type 1 (AT(1)) receptor and the type 2 (AT(2)) receptor.  Recent results also implicate several other members of the renin-angiotensin system in various aspects of brain functions.  The first aim of this paper is to summarize the current state of knowledge regarding the properties and signaling of the AT(2) receptor, its expression in the brain, and its well-established effects.  Secondly, we will highlight the potential role of the AT(2) receptor in cognitive function, neurological disorders and in the regulation of appetite and the possible link with development of metabolic disorders.  The potential utility of novel nonpeptide selective AT(2) receptor ligands in clarifying potential roles of this receptor in physiology will also be discussed.  If confirmed, these new pharmacological tools should help to improve impaired cognitive performance, not only through its action on brain microcirculation and inflammation, but also through more specific effects on neurons.  However, the overall physiological relevance of the AT(2) receptor in the brain must also consider the Ang IV/AT(4) receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuZ1E7KO21PSCEBeYuoi7AfW6udTcc2eYfJARmm5BUPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3psFOruw%253D%253D&md5=5e280982ffbcae0314948bcb98e32a2b</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1155%2F2012%2F351758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F351758%26sid%3Dliteratum%253Aachs%26aulast%3DGuimond%26aufirst%3DM.%2BO.%26aulast%3DGallo-Payet%26aufirst%3DN.%26atitle%3DThe%2520angiotensin%2520II%2520type%25202%2520receptor%2520in%2520brain%2520functions%253A%2520an%2520update%26jtitle%3DInt.%2520J.%2520Hypertens.%26date%3D2012%26volume%3D2012%26spage%3D351758%26doi%3D10.1155%2F2012%2F351758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdonk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abd-Alla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batenburg, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Bogaerdt, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veghel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roks, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danser, A. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Esch, J. H. M.</span></span> <span> </span><span class="NLM_article-title">Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.112.196022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.112.196022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22802221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1SitbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=722-729&author=K.+Verdonkauthor=M.+Durikauthor=N.+Abd-Allaauthor=W.+M.+Batenburgauthor=A.+J.+van+den+Bogaerdtauthor=R.+van+Veghelauthor=A.+J.+M.+Roksauthor=A.+H.+J.+Danserauthor=J.+H.+M.+van+Esch&title=Compound+21+induces+vasorelaxation+via+an+endothelium-+and+angiotensin+II+type+2+receptor-independent+mechanism&doi=10.1161%2FHYPERTENSIONAHA.112.196022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Compound 21 Induces Vasorelaxation via an Endothelium- and Angiotensin II Type 2 Receptor-Independent Mechanism</span></div><div class="casAuthors">Verdonk, Koen; Durik, Matej; Abd-Alla, Nalina; Batenburg, Wendy W.; van den Bogaerdt, Antoon J.; van Veghel, Richard; Roks, Anton J. M.; Danser, A. H. Jan; van Esch, Joep H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">722-729</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Angiotensin II type 2 (AT2) receptor stimulation has been linked to vasodilation.  Yet, AT2 receptor-independent hypertension and hypotension (or no effect on blood pressure) have been obsd. in vivo after application of the AT2 receptor agonist compd. 21 (C21).  We, therefore, studied its effects in vitro, using prepns. known to display AT2 receptor-mediated responses.  Hearts of Wistar rats, spontaneously hypertensive rats (SHRs), C57Bl/6 mice, and AT2 receptor knockout mice were perfused according to Langendorff.  Mesenteric and iliac arteries of these animals, as well as coronary microarteries from human donor hearts, were mounted in Mulvany myographs.  In the coronary vascular bed of Wistar rats, C57Bl/6 mice, and AT2 receptor knockout mice, C21 induced constriction followed by dilation.  SHR hearts displayed enhanced constriction and no dilation.  Irbesartan (angiotensin II type 1 receptor blocker) abolished the constriction and enhanced or (in SHRs) reintroduced dilation, and PD123319 (AT2 receptor blocker) did not block the latter.  C21 relaxed preconstricted vessels of all species, and this did not depend on angiotensin II receptors, the endothelium, or the NO-guanylyl cyclase-cGMP pathway.  C21 constricted SHR iliac arteries but none of the other vessels, and irbesartan prevented this.  C21 shifted the concn.-response curves to U46619 (thromboxane A2 analog) and phenylephrine (α-adrenoceptor agonist) but not ionomycine (calcium ionophore) to the right.  In conclusion, C21 did not cause AT2 receptor-mediated vasodilation.  Yet, it did induce vasodilation by blocking calcium transport into the cell and constriction via angiotensin II type 1 receptor stimulation.  The latter effect is enhanced in SHRs.  These data may explain the varying effects of C21 on blood pressure in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP_wXzTtIEJLVg90H21EOLACvtfcHk0ljXPBEvDn7wDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1SitbbO&md5=62d45012a16c1a77d0c29cb5f92aa1e1</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.112.196022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.112.196022%26sid%3Dliteratum%253Aachs%26aulast%3DVerdonk%26aufirst%3DK.%26aulast%3DDurik%26aufirst%3DM.%26aulast%3DAbd-Alla%26aufirst%3DN.%26aulast%3DBatenburg%26aufirst%3DW.%2BM.%26aulast%3Dvan%2Bden%2BBogaerdt%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BVeghel%26aufirst%3DR.%26aulast%3DRoks%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DDanser%26aufirst%3DA.%2BH.%2BJ.%26aulast%3Dvan%2BEsch%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DCompound%252021%2520induces%2520vasorelaxation%2520via%2520an%2520endothelium-%2520and%2520angiotensin%2520II%2520type%25202%2520receptor-independent%2520mechanism%26jtitle%3DHypertension%26date%3D2012%26volume%3D60%26spage%3D722%26epage%3D729%26doi%3D10.1161%2FHYPERTENSIONAHA.112.196022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumners, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule AT2 receptor agonists</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1002/med.21449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fmed.21449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28609561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2ntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=602-624&author=M.+Hallbergauthor=C.+Sumnersauthor=U.+M.+Steckelingsauthor=A.+Hallberg&title=Small-molecule+AT2+receptor+agonists&doi=10.1002%2Fmed.21449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule AT2 receptor agonists</span></div><div class="casAuthors">Hallberg, Mathias; Sumners, Colin; Steckelings, U. Muscha; Hallberg, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">602-624</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the first selective, small-mol. ATR receptor (AT2R) agonist compd. 21 (C21) (8) that is now extensively studied in a large variety of in vitro and in vivo models is described.  The sulfonylcarbamate deriv. 8, encompassing a phenylthiofen scaffold is the drug-like agonist with the highest affinity for the AT2R reported to date (Ki = 0.4 nM).  Structure-activity relationships (SAR), regarding different biaryl scaffolds and functional groups attached to these scaffolds and with a particular focus on the impact of various para substituents displacing the methylene imidazole group of 8, are discussed.  Furthermore, the consequences of migration of the methylene imidazole group and presumed structural requirements for ligands that are aimed as AT2R agonists (e.g. 8) or AT2R antagonists (e.g. 9), resp., are briefly addressed.  A summary of the pharmacol. actions of C21 (8) is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJdPNSkTXtH7Vg90H21EOLACvtfcHk0ljXPBEvDn7wDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2ntrg%253D&md5=ab5b0cbb445d896af83e4e525a05cab2</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1002%2Fmed.21449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21449%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DSumners%26aufirst%3DC.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DSmall-molecule%2520AT2%2520receptor%2520agonists%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D602%26epage%3D624%26doi%3D10.1002%2Fmed.21449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">Selective angiotensin II AT<sub>2</sub> receptor agonists: arylbenzylimidazole structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">7160</span>– <span class="NLM_lpage">7168</span>, <span class="refDoi"> DOI: 10.1021/jm0606185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0606185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOmtLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7160-7168&author=X.+Wuauthor=Y.+Wanauthor=A.+K.+Mahalingamauthor=B.+Plouffeauthor=M.+Botrosauthor=A.+Karl%C3%A9nauthor=M.+Hallbergauthor=N.+Gallo-Payetauthor=M.+Alterman&title=Selective+angiotensin+II+AT2+receptor+agonists%3A+arylbenzylimidazole+structure-activity+relationships&doi=10.1021%2Fjm0606185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Angiotensin II AT2 Receptor Agonists: Arylbenzylimidazole Structure-Activity Relationships</span></div><div class="casAuthors">Wu, Xiongyu; Wan, Yiqian; Mahalingam, A. K.; Murugaiah, A. M. S.; Plouffe, Bianca; Botros, Milad; Karlen, Anders; Hallberg, Mathias; Gallo-Payet, Nicole; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7160-7168</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structural alterations in the 2- and 5-positions of the first drug-like selective angiotensin II AT2 receptor agonist I have been performed.  The imidazole ring system was proven to be a strong determinant for the AT2 selectivity, and with few exceptions all variations gave good AT2 receptor affinities and with retained high AT2/AT1 selectivities.  On the contrary to the findings with AT1 receptor agonists, the impact of structural modifications in the 5-position of the AT2 selective compds. were less pronounced regarding activation of the AT2 receptor.  The butyloxyphenyl (56) and the propylthienyl (50) derivs. were found to exert a high agonistic effect as deduced from their capacity to induce neurite elongation in neuronal cells, as does angiotensin II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf4sAB0bMOUbVg90H21EOLACvtfcHk0lg7pDTGq5l7gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOmtLbE&md5=ad6b1ffa071f77461cf222546f6a84e2</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fjm0606185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0606185%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DMahalingam%26aufirst%3DA.%2BK.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DSelective%2520angiotensin%2520II%2520AT2%2520receptor%2520agonists%253A%2520arylbenzylimidazole%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7160%26epage%3D7168%26doi%3D10.1021%2Fjm0606185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugaiah, A. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">Selective angiotensin II AT2 receptor agonists devoid of the imidazole ring system</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">7166</span>– <span class="NLM_lpage">7183</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.07.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bmc.2007.07.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=17825570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFWiur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=7166-7183&author=A.+M.+S.+Murugaiahauthor=C.+Wallinderauthor=A.+K.+Mahalingamauthor=X.+Wuauthor=Y.+Wanauthor=B.+Plouffeauthor=M.+Botrosauthor=A.+Karl%C3%A9nauthor=M.+Hallbergauthor=N.+Gallo-Payetauthor=M.+Alterman&title=Selective+angiotensin+II+AT2+receptor+agonists+devoid+of+the+imidazole+ring+system&doi=10.1016%2Fj.bmc.2007.07.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Selective angiotensin II AT2 receptor agonists devoid of the imidazole ring system</span></div><div class="casAuthors">Murugaiah, A. M. S.; Wallinder, Chalotta; Mahalingam, A. K.; Wu, Xiongyu; Wan, Yiqian; Plouffe, Bianca; Botros, Milad; Karlen, Anders; Hallberg, Mathias; Gallo-Payet, Nicole; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7166-7183</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A versatile parallel synthetic method to obtain three series of noncyclic analogs of the first drug-like selective angiotensin II AT2 receptor agonist (1) has been developed.  In analogy with the transformation of losartan to valsartan it was demonstrated that a noncyclic moiety could be employed as an imidazole replacement to obtain AT2 selective compds.  In all the three series, AT2 receptor ligands with affinities in the lower nanomolar range were found.  None of the analogs exhibited any affinity for the AT1 receptor.  Four compds., (I, II, III, IV) were examd. in a neurite outgrowth cell assay.  All four compds. were found to exert a high agonistic effect as deduced from their capacity to induce neurite elongation in neuronal cells, as does angiotensin II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodM62cLXvKH7Vg90H21EOLACvtfcHk0lg7pDTGq5l7gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFWiur3N&md5=a6442c26d78f0c47a0aeeef727adb589</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.07.026%26sid%3Dliteratum%253Aachs%26aulast%3DMurugaiah%26aufirst%3DA.%2BM.%2BS.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DMahalingam%26aufirst%3DA.%2BK.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DSelective%2520angiotensin%2520II%2520AT2%2520receptor%2520agonists%2520devoid%2520of%2520the%2520imidazole%2520ring%2520system%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D7166%26epage%3D7183%26doi%3D10.1016%2Fj.bmc.2007.07.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenström, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimond, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudry, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">Selective angiotensin II AT<sub>2</sub> receptor agonists: benzamide structure–activity relationships</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6841</span>– <span class="NLM_lpage">6849</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.05.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bmc.2008.05.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=18599297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVKqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=6841-6849&author=C.+Wallinderauthor=M.+Botrosauthor=U.+Rosenstr%C3%B6mauthor=M.+O.+Guimondauthor=H.+Beaudryauthor=F.+Nybergauthor=N.+Gallo-Payetauthor=A.+Hallbergauthor=M.+Alterman&title=Selective+angiotensin+II+AT2+receptor+agonists%3A+benzamide+structure%E2%80%93activity+relationships&doi=10.1016%2Fj.bmc.2008.05.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships</span></div><div class="casAuthors">Wallinder, Charlotta; Botros, Milad; Rosenstroem, Ulrika; Guimond, Marie-Odile; Beaudry, Helene; Nyberg, Fred; Gallo-Payet, Nicole; Hallberg, Anders; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6841-6849</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the investigation of the structure-activity relationship of nonpeptide AT2 receptor agonists, a series of substituted benzamide analogs of the selective nonpeptide AT2 receptor agonist M024 have been synthesized.  In a second series, the biphenyl scaffold was compared to the thienylphenyl scaffold and the impact of the iso-Bu substituent and its position on AT1/AT2 receptor selectivity was also investigated.  Both series included several compds. with high affinity and selectivity for the AT2 receptor.  Three of the compds. were also proven to function as agonists at the AT2 receptor, as deduced from a neurite outgrowth assay, conducted in NG108-15 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpVnwTEEumorVg90H21EOLACvtfcHk0lg7pDTGq5l7gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVKqsb0%253D&md5=52015aa6eb2a1c96c0a78b106b6b6e2a</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.05.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.05.066%26sid%3Dliteratum%253Aachs%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DRosenstr%25C3%25B6m%26aufirst%3DU.%26aulast%3DGuimond%26aufirst%3DM.%2BO.%26aulast%3DBeaudry%26aufirst%3DH.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DSelective%2520angiotensin%2520II%2520AT2%2520receptor%2520agonists%253A%2520benzamide%2520structure%25E2%2580%2593activity%2520relationships%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D6841%26epage%3D6849%26doi%3D10.1016%2Fj.bmc.2008.05.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugaiah, A. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">Selective angiotensin II AT<sub>2</sub> receptor agonists with reduced CYP 450 inhibition</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4570</span>– <span class="NLM_lpage">4590</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.03.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bmc.2010.03.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=20493713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntV2qsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4570-4590&author=A.+K.+Mahalingamauthor=Y.+Wanauthor=A.+M.+S.+Murugaiahauthor=C.+Wallinderauthor=X.+Wuauthor=B.+Plouffeauthor=M.+Botrosauthor=F.+Nybergauthor=A.+Hallbergauthor=N.+Gallo-Payetauthor=M.+Alterman&title=Selective+angiotensin+II+AT2+receptor+agonists+with+reduced+CYP+450+inhibition&doi=10.1016%2Fj.bmc.2010.03.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Selective angiotensin II AT2 receptor agonists with reduced CYP 450 inhibition</span></div><div class="casAuthors">Mahalingam, A. K.; Wan, Yiqian; Murugaiah, A. M. S.; Wallinder, Charlotta; Wu, Xiongyu; Plouffe, Bianca; Botros, Milad; Nyberg, Fred; Hallberg, Anders; Gallo-Payet, Nicole; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4570-4590</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Structural alterations to the benzylic position of the first drug-like selective angiotensin II AT2 receptor agonist (1) have been performed, with the emphasis to reduce the CYP 450 inhibitory property of the initial structure.  The imidazole moiety, responsible for the CYP 450 inhibitory effect in 1, was replaced with various heterocycles.  In addn., the modes of attachment of the heterocycles, i.e., carbon vs. nitrogen attachment, and introduction of carbonyl functionalities to the benzylic position have been evaluated.  In all the three series, AT2 receptor ligands with affinity in the lower nanomolar range were identified.  None of the analogs, regardless of the substituents, exhibited any affinity for the AT1 receptor.  Compds. with substantially reduced inhibition of the CYP 450 enzymes were obtained.  Among them the compd. 60 was found to induce neurite elongation in NG 108-15 cells and served as potent AT2 selective agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Z6ZPAY8DaLVg90H21EOLACvtfcHk0lhrSVNbXyEUnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntV2qsrc%253D&md5=80cfa58d9d0e5950a1c6c9408a81c153</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.03.064%26sid%3Dliteratum%253Aachs%26aulast%3DMahalingam%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DMurugaiah%26aufirst%3DA.%2BM.%2BS.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DSelective%2520angiotensin%2520II%2520AT2%2520receptor%2520agonists%2520with%2520reduced%2520CYP%2520450%2520inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4570%26epage%3D4590%26doi%3D10.1016%2Fj.bmc.2010.03.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugaiah, A. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sköld, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimond, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">From the first selective non-peptide AT<sub>2</sub> receptor agonist to structurally related antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2278</span>, <span class="refDoi"> DOI: 10.1021/jm2015099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2015099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2265-2278&author=A.+M.+S.+Murugaiahauthor=X.+Wuauthor=C.+Wallinderauthor=A.+K.+Mahalingamauthor=Y.+Wanauthor=C.+Sk%C3%B6ldauthor=M.+Botrosauthor=M.+O.+Guimondauthor=A.+Joshiauthor=F.+Nybergauthor=N.+Gallo-Payetauthor=A.+Hallbergauthor=M.+Alterman&title=From+the+first+selective+non-peptide+AT2+receptor+agonist+to+structurally+related+antagonists&doi=10.1021%2Fjm2015099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">From the First Selective Non-Peptide AT2 Receptor Agonist to Structurally Related Antagonists</span></div><div class="casAuthors">Murugaiah, A. M. S.; Wu, Xiongyu; Wallinder, Charlotta; Mahalingam, A. K.; Wan, Yiqian; Skoeld, Christian; Botros, Milad; Guimond, Marie-Odile; Joshi, Advait; Nyberg, Fred; Gallo-Payet, Nicole; Hallberg, Anders; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2265-2278</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A para substitution pattern of the Ph ring is a characteristic feature of the first reported selective AT2 receptor agonist M024/C21 (1) and all the nonpeptidic AT2 receptor agonists described so far.  Two series of compds. structurally related to 1 but with a meta substitution pattern have now been synthesized and biol. evaluated for their affinity to the AT1 and AT2 receptors.  A high AT2/AT1 receptor selectivity was obtained with all 41 compds. synthesized, and the majority exhibited Ki ranging from 2 to 100 nM.  Five compds. were evaluated for their functional activity at the AT2 receptor, applying a neurite outgrowth assay in NG108-15 cells.  Notably, four of the five compds., with representatives from both series, acted as potent AT2 receptor antagonists.  These compds. were found to be considerably more effective than PD 123,319, the std. AT2 receptor antagonist used in most labs.  No AT2 receptor antagonists were previously reported among the derivs. with a para substitution pattern.  Hence, by a minor modification of the agonist 1 it could be transformed into the antagonist, compd. 38.  These compds. should serve as valuable tools in the assessment of the role of the AT2 receptor in more complex physiol. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPhSjJ131hU7Vg90H21EOLACvtfcHk0lhrSVNbXyEUnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFGqsQ%253D%253D&md5=dbc405b40e113ba09195cc6be72e1400</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Fjm2015099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2015099%26sid%3Dliteratum%253Aachs%26aulast%3DMurugaiah%26aufirst%3DA.%2BM.%2BS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DMahalingam%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DSk%25C3%25B6ld%26aufirst%3DC.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DGuimond%26aufirst%3DM.%2BO.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DFrom%2520the%2520first%2520selective%2520non-peptide%2520AT2%2520receptor%2520agonist%2520to%2520structurally%2520related%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2265%26epage%3D2278%26doi%3D10.1021%2Fjm2015099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guimond, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span> <span> </span><span class="NLM_article-title">Comparative functional properties of two structurally similar selective nonpeptide drug-like ligands for the angiotensin II type-2 (AT<sub>2</sub>) receptor. Effects on neurite outgrowth in NG108–15 cells</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>699</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.11.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.ejphar.2012.11.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23211679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlaqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=699&publication_year=2013&pages=160-171&author=M.+O.+Guimondauthor=C.+Wallinderauthor=M.+Altermanauthor=A.+Hallbergauthor=N.+Gallo-Payet&title=Comparative+functional+properties+of+two+structurally+similar+selective+nonpeptide+drug-like+ligands+for+the+angiotensin+II+type-2+%28AT2%29+receptor.+Effects+on+neurite+outgrowth+in+NG108%E2%80%9315+cells&doi=10.1016%2Fj.ejphar.2012.11.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative functional properties of two structurally similar selective nonpeptide drug-like ligands for the angiotensin II type-2 (AT2) receptor. Effects on neurite outgrowth in NG108-15 cells</span></div><div class="casAuthors">Guimond, Marie-Odile; Wallinder, Charlotta; Alterman, Mathias; Hallberg, Anders; Gallo-Payet, Nicole</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">699</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">160-171</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There is increasing evidence that angiotensin II (Ang II), through binding to the type 2 (AT2) receptor may have beneficial effects in various physiol. and pathol. situations.  However, specific action presumably mediated by the angiotensin AT2 receptor has been hampered by the absence of appropriate selective ligands.  The aim of this study was to compare the biol. properties of two related and selective drug-like nonpeptide AT2 ligands, namely an agonist called M024 (also known as Compd. 21) and a new ligand, presumably an antagonist, C38/M132, (originally called C38).  Properties of the compds. were investigated in NG108-15 cells expressing angiotensin AT2 receptor and known to develop neurite outgrowth upon Ang II stimulation.  NG108-15 cells stimulated for three days with C21/M024 (0.1 or 100 nM) exhibited the same neurite outgrowth as cells stimulated with Ang II (100 nM) while co-incubation of Ang II or C21/M024 with C38/M132 (10 or 100 nM) inhibited their effects, similarly to the angiotensin AT2 receptor antagonist, PD123319 (10 μM).  As Ang II, C21/M024 induced a Rap1-dependent activation of p42/p44mapk whereas preincubation of cells with C38/M132 inhibited p42/p44mapk and Rap1 activation induced by Ang II.  Three-day treatment with C21/M024 or Ang II decreased cell no. in culture, an effect that was rescued by preincubation with C38/M132.  Taken together, these results indicate that the nonpeptide ligand C21/M024 is a potent angiotensin AT2 receptor agonist while C38/M132 acts as an antagonist.  These selective nonpeptide angiotensin AT2 ligands may represent unique and long-awaited tools for the pursuit of in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppSbhxynZSXrVg90H21EOLACvtfcHk0liHsXJLw0Bxkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlaqtrs%253D&md5=4654d2d54485809d948577c0390c0a74</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.11.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.11.032%26sid%3Dliteratum%253Aachs%26aulast%3DGuimond%26aufirst%3DM.%2BO.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DAlterman%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DGallo-Payet%26aufirst%3DN.%26atitle%3DComparative%2520functional%2520properties%2520of%2520two%2520structurally%2520similar%2520selective%2520nonpeptide%2520drug-like%2520ligands%2520for%2520the%2520angiotensin%2520II%2520type-2%2520%2528AT2%2529%2520receptor.%2520Effects%2520on%2520neurite%2520outgrowth%2520in%2520NG108%25E2%2580%259315%2520cells%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D699%26spage%3D160%26epage%3D171%26doi%3D10.1016%2Fj.ejphar.2012.11.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sallander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åqvist, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutiérrez-de-Terán, H.</span></span> <span> </span><span class="NLM_article-title">Structural determinants of subtype selectivity and functional activity of angiotensin II receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1359</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bmcl.2015.10.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26810314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1CisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1355-1359&author=J.+Sallanderauthor=C.+Wallinderauthor=A.+Hallbergauthor=J.+%C3%85qvistauthor=H.+Guti%C3%A9rrez-de-Ter%C3%A1n&title=Structural+determinants+of+subtype+selectivity+and+functional+activity+of+angiotensin+II+receptors&doi=10.1016%2Fj.bmcl.2015.10.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of subtype selectivity and functional activity of angiotensin II receptors</span></div><div class="casAuthors">Sallander, Jessica; Wallinder, Charlotta; Hallberg, Anders; Aaqvist, Johan; Gutierrez-de-Teran, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1355-1359</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Agonists of the angiotensin II receptor type 2 (AT2), a G-protein coupled receptor, promote tissue protective effects in cardiovascular and renal diseases, while antagonists reduce neuropathic pain.  We here report detailed mol. models that explain the AT2 receptor selectivity of our recent series of non-peptide ligands.  In addn., minor structural changes of these ligands that provoke different functional activity are rationalized at a mol. level, and related to the selectivity for the different receptor conformations.  These findings should pave the way to structure based drug discovery of AT2 receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrChP5GGPcsOrVg90H21EOLACvtfcHk0liHsXJLw0Bxkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1CisL8%253D&md5=c4e6634a5abebc5529ea69de5498bded</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.084%26sid%3Dliteratum%253Aachs%26aulast%3DSallander%26aufirst%3DJ.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3D%25C3%2585qvist%26aufirst%3DJ.%26aulast%3DGuti%25C3%25A9rrez-de-Ter%25C3%25A1n%26aufirst%3DH.%26atitle%3DStructural%2520determinants%2520of%2520subtype%2520selectivity%2520and%2520functional%2520activity%2520of%2520angiotensin%2520II%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1355%26epage%3D1359%26doi%3D10.1016%2Fj.bmcl.2015.10.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isaksson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backlund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åqvist, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez de Teran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gising, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span> <span> </span><span class="NLM_article-title">A series of analogues to the AT<sub>2</sub>R prototype antagonist C38 allow fine tuning of the previously reported antagonist binding mode</span>. <i>ChemistryOpen</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1002/open.201800282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fopen.201800282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30697513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=114-125&author=R.+Isakssonauthor=J.+Lindmanauthor=J.+Wannbergauthor=J.+Sallanderauthor=M.+Backlundauthor=D.+Baraldiauthor=R.+Widdopauthor=M.+Hallbergauthor=J.+%C3%85qvistauthor=H.+Gutierrez+de+Teranauthor=J.+Gisingauthor=M.+Larhed&title=A+series+of+analogues+to+the+AT2R+prototype+antagonist+C38+allow+fine+tuning+of+the+previously+reported+antagonist+binding+mode&doi=10.1002%2Fopen.201800282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">A Series of Analogues to the AT2R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode</span></div><div class="casAuthors">Isaksson, Rebecka; Lindman, Jens; Wannberg, Johan; Sallander, Jessica; Backlund, Maria; Baraldi, Dhaniel; Widdop, Robert; Hallberg, Mathias; Aaqvist, Johan; Gutierrez de Teran, Hugo; Gising, Johan; Larhed, Mats</div><div class="citationInfo"><span class="NLM_cas:title">ChemistryOpen</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-125</span>CODEN:
                <span class="NLM_cas:coden">CHOPCK</span>;
        ISSN:<span class="NLM_cas:issn">2191-1363</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We here report on our continued studies of ligands binding to the promising drug target angiotensin II type 2 receptor (AT2R).  Two series of compds. were synthesized and investigated.  The first series explored the effects of adding small substituents to the Ph ring of the known selective nonpeptide AT2R antagonist C38, generating small but significant shifts in AT2R affinity.  One compd. in the first series was equipotent to C38 and showed similar kinetic soly., and stability in both human and mouse liver microsomes.  The second series was comprised of new bicyclic derivs., amongst which one ligand exhibited a five-fold improved affinity to AT2R as compared to C38.  The majority of the compds. in the second series, including the most potent ligand, were inferior to C38 with regard to stability in both human and mouse microsomes.  In contrast to our previously reported findings, ligands with shorter carbamate alkyl chains only demonstrated slightly improved stability in microsomes.  Based on data presented herein, a more adequate, tentative model of the binding modes of ligand analogs to the prototype AT2R antagonist C38 is proposed, as deduced from docking redefined by mol. dynamic simulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSax4q9NnPGbVg90H21EOLACvtfcHk0liHsXJLw0Bxkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCnu70%253D&md5=59ec8cea9c18b86233d9785f54976f8f</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1002%2Fopen.201800282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fopen.201800282%26sid%3Dliteratum%253Aachs%26aulast%3DIsaksson%26aufirst%3DR.%26aulast%3DLindman%26aufirst%3DJ.%26aulast%3DWannberg%26aufirst%3DJ.%26aulast%3DSallander%26aufirst%3DJ.%26aulast%3DBacklund%26aufirst%3DM.%26aulast%3DBaraldi%26aufirst%3DD.%26aulast%3DWiddop%26aufirst%3DR.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3D%25C3%2585qvist%26aufirst%3DJ.%26aulast%3DGutierrez%2Bde%2BTeran%26aufirst%3DH.%26aulast%3DGising%26aufirst%3DJ.%26aulast%3DLarhed%26aufirst%3DM.%26atitle%3DA%2520series%2520of%2520analogues%2520to%2520the%2520AT2R%2520prototype%2520antagonist%2520C38%2520allow%2520fine%2520tuning%2520of%2520the%2520previously%2520reported%2520antagonist%2520binding%2520mode%26jtitle%3DChemistryOpen%26date%3D2019%26volume%3D8%26spage%3D114%26epage%3D125%26doi%3D10.1002%2Fopen.201800282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaksson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremberg, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backlund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sävmarker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span> <span> </span><span class="NLM_article-title">A convenient transesterification method for synthesis of AT2 receptor ligands with improved stability in human liver microsomes</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.11.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bmcl.2017.11.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29279275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVejtL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=519-522&author=J.+Wannbergauthor=R.+Isakssonauthor=U.+Brembergauthor=M.+Backlundauthor=J.+S%C3%A4vmarkerauthor=M.+Hallbergauthor=M.+Larhed&title=A+convenient+transesterification+method+for+synthesis+of+AT2+receptor+ligands+with+improved+stability+in+human+liver+microsomes&doi=10.1016%2Fj.bmcl.2017.11.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient transesterification method for synthesis of AT2 receptor ligands with improved stability in human liver microsomes</span></div><div class="casAuthors">Wannberg, Johan; Isaksson, Rebecka; Bremberg, Ulf; Backlund, Maria; Saevmarker, Jonas; Hallberg, Mathias; Larhed, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">519-522</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of AT2R ligands were synthesized applying a quick, simple, and safe transesterification-type reaction whereby the sulfonyl carbamate alkyl tail of the selective AT2R antagonist C38 was varied.  Furthermore, a limited no. of compds. where acyl sulfonamides and sulfonyl ureas served as carboxylic acid bioisosteres were synthesized and evaluated.  By reducing the size of the alkyl chain of the sulfonyl carbamates, ligands Me ((3-(3-((1H-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2-yl)sulfonyl)carbamate and Et ((3-(3-((1H-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2-yl)sulfonyl)carbamate 2,2,2-trifluoroacetate were identified with significantly improved in vitro metabolic stability in both human and mouse liver microsomes as compared to C38 while retaining the AT2R binding affinity and AT2R/AT1R selectivity.  Eight of the compds. synthesized exhibit an improved stability in human microsomes as compared to C38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSozr1rZ8LU7Vg90H21EOLACvtfcHk0limwSekN4v_3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVejtL7P&md5=c16d5d848e3d2298e592b5da75cb5738</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.11.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.11.042%26sid%3Dliteratum%253Aachs%26aulast%3DWannberg%26aufirst%3DJ.%26aulast%3DIsaksson%26aufirst%3DR.%26aulast%3DBremberg%26aufirst%3DU.%26aulast%3DBacklund%26aufirst%3DM.%26aulast%3DS%25C3%25A4vmarker%26aufirst%3DJ.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DLarhed%26aufirst%3DM.%26atitle%3DA%2520convenient%2520transesterification%2520method%2520for%2520synthesis%2520of%2520AT2%2520receptor%2520ligands%2520with%2520improved%2520stability%2520in%2520human%2520liver%2520microsomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D519%26epage%3D522%26doi%3D10.1016%2Fj.bmcl.2017.11.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosnyak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1042/CS20110036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1042%2FCS20110036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=21542804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntlSjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=297-303&author=S.+Bosnyakauthor=E.+S.+Jonesauthor=A.+Christopoulosauthor=M.+I.+Aguilarauthor=W.+G.+Thomasauthor=R.+E.+Widdop&title=Relative+affinity+of+angiotensin+peptides+and+novel+ligands+at+AT1+and+AT2+receptors&doi=10.1042%2FCS20110036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors</span></div><div class="casAuthors">Bosnyak, Sanja; Jones, Emma S.; Christopoulos, Arthur; Aguilar, Marie-Isabel; Thomas, Walter G.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7/8</span>),
    <span class="NLM_cas:pages">297-303</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">0143-5221</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">AT1R (angiotensin type 1 receptor) and AT2R (angiotensin type 2 receptor) are well known to be involved in the complex cardiovascular actions of AngII (angiotensin II).  However, shorter peptide fragments of AngII are thought to have biol. activity in their own right and elicit effects that oppose those mediated by AngII.  In the present study, we have used HEK (human embryonic kidney)-293 cells stably transfected with either AT1R or AT2R to perform a systematic anal. of binding affinities of all the major angiotensin peptides.  Addnl., we tested the novel AT2R agonist Compd. 21, as well as the MasR (Mas receptor) agonist and antagonist AVE0991 and A-779 resp., for their ability to bind to AT1R or AT2R.  Candesartan, CGP42214 and PD123319 were used as ref. compds.  Binding studies using 125I-[Sar1Ile8]AngII on the AT1R-transfected HEK-293 cells revealed only AngII, AngIII [angiotensin III; angiotensin-(2-8)] and candesartan to have high affinity for AT1R.  In the AT2R-transfected HEK-293 cells, competition for 125I-[Sar1Ile8]AngII binding was obsd. for all ligands except candesartan, AVE0991 and A-779, the latter two compds. having negligible affinity at either AT1R or AT2R.  The rank order of affinity of ligands at AT2R was CGP42112>AngII≥AngIII>Compd. 21≥PD123319»AngIV [angiotensin IV; angiotensin-(3-8)]>Ang-(1-7) [angiotensin-(1-7)].  Of note, although AngIV and Ang-(1-7) exhibited only modest affinity at AT2R compared with AngII, these two angiotensin peptides, together with AngIII, had substantial AT2R selectivity over AT1R.  Collectively, our results suggest that shorter angiotensin peptides can act as endogenous ligands at AT2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPONK0yiaKCrVg90H21EOLACvtfcHk0limwSekN4v_3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntlSjsbk%253D&md5=b8e8a22de54c7e39995afecdb18d329c</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1042%2FCS20110036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20110036%26sid%3Dliteratum%253Aachs%26aulast%3DBosnyak%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DE.%2BS.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DAguilar%26aufirst%3DM.%2BI.%26aulast%3DThomas%26aufirst%3DW.%2BG.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DRelative%2520affinity%2520of%2520angiotensin%2520peptides%2520and%2520novel%2520ligands%2520at%2520AT1%2520and%2520AT2%2520receptors%26jtitle%3DClin.%2520Sci.%26date%3D2011%26volume%3D121%26spage%3D297%26epage%3D303%26doi%3D10.1042%2FCS20110036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Targeted gamma-secretase inhibition of Notch signaling activation in acute renal injury</span>. <i>Am. J. Physiol., Renal Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">F736</span>– <span class="NLM_lpage">F746</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.00414.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajprenal.00414.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28971991" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2018&pages=F736-F746&author=J.+C.+Wyssauthor=R.+Kumarauthor=J.+Mikulicauthor=M.+Schneiderauthor=J.+D.+Aebiauthor=L.+Juillerat-Jeanneretauthor=D.+Golshayan&title=Targeted+gamma-secretase+inhibition+of+Notch+signaling+activation+in+acute+renal+injury&doi=10.1152%2Fajprenal.00414.2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00414.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00414.2016%26sid%3Dliteratum%253Aachs%26aulast%3DWyss%26aufirst%3DJ.%2BC.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DMikulic%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DAebi%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DTargeted%2520gamma-secretase%2520inhibition%2520of%2520Notch%2520signaling%2520activation%2520in%2520acute%2520renal%2520injury%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Renal%2520Physiol.%26date%3D2018%26volume%3D314%26spage%3DF736%26epage%3DF746%26doi%3D10.1152%2Fajprenal.00414.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yanghui Guo, Xiangui Huang, Weiwei Liao, Lichen Meng, Daiwang Xu, Cheng Ye, Lei Chen, <span class="NLM_string-name hlFld-ContribAuthor">Taishan Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of Highly Potent and Selective AT2R Antagonists to Relieve Peripheral Neuropathic Pain. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2021,</strong> <em>6 </em>
                                    (23)
                                     , 15412-15420. <a href="https://doi.org/10.1021/acsomega.1c01866" title="DOI URL">https://doi.org/10.1021/acsomega.1c01866</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.1c01866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.1c01866%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252BHighly%252BPotent%252Band%252BSelective%252BAT2R%252BAntagonists%252Bto%252BRelieve%252BPeripheral%252BNeuropathic%252BPain%26aulast%3DGuo%26aufirst%3DYanghui%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08042021%26date%3D10052021%26date%3D28052021%26volume%3D6%26issue%3D23%26spage%3D15412%26epage%3D15420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Samuel Obeng, Takato Hiranita, Francisco León, Lance R. McMahon, <span class="NLM_string-name hlFld-ContribAuthor">Christopher R. McCurdy</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6523-6548. <a href="https://doi.org/10.1021/acs.jmedchem.1c00028" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00028%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BApproaches%25252C%252BDrug%252BCandidates%25252C%252Band%252BTargets%252Bin%252BPain%252BDrug%252BDiscovery%26aulast%3DObeng%26aufirst%3DSamuel%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D07012021%26date%3D06052021%26volume%3D64%26issue%3D10%26spage%3D6523%26epage%3D6548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dirk  Tourwé</span>, <span class="hlFld-ContribAuthor ">Antonis D.  Tsiailanis</span>, <span class="hlFld-ContribAuthor ">Nikolaos  Parisis</span>, <span class="hlFld-ContribAuthor ">Baydaa  Hirmiz</span>, <span class="hlFld-ContribAuthor ">Mark  Del Borgo</span>, <span class="hlFld-ContribAuthor ">Marie-Isabel  Aguilar</span>, <span class="hlFld-ContribAuthor ">Olivier  Van der Poorten</span>, <span class="hlFld-ContribAuthor ">Steven  Ballet</span>, <span class="hlFld-ContribAuthor ">Robert E.  Widdop</span>, <span class="hlFld-ContribAuthor ">Andreas G.  Tzakos</span>. </span><span class="cited-content_cbyCitation_article-title">Using conformational constraints at position 6 of Angiotensin II to generate compounds with enhanced AT2R selectivity and proteolytic stability. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>43 </em>, 128086. <a href="https://doi.org/10.1016/j.bmcl.2021.128086" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128086%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DUsing%252Bconformational%252Bconstraints%252Bat%252Bposition%252B6%252Bof%252BAngiotensin%252BII%252Bto%252Bgenerate%252Bcompounds%252Bwith%252Benhanced%252BAT2R%252Bselectivity%252Band%252Bproteolytic%252Bstability%26aulast%3DTourw%25C3%25A9%26aufirst%3DDirk%26date%3D2021%26volume%3D43%26spage%3D128086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arina  Ranjit</span>, <span class="hlFld-ContribAuthor ">Sana  Khajehpour</span>, <span class="hlFld-ContribAuthor ">Ali  Aghazadeh-Habashi</span>. </span><span class="cited-content_cbyCitation_article-title">Update on Angiotensin II Subtype 2 Receptor: Focus on Peptide and Nonpeptide Agonists. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmacology</span><span> <strong>2021,</strong> <em>99 </em>
                                    (6)
                                     , 469-487. <a href="https://doi.org/10.1124/molpharm.121.000236" title="DOI URL">https://doi.org/10.1124/molpharm.121.000236</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/molpharm.121.000236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fmolpharm.121.000236%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmacology%26atitle%3DUpdate%252Bon%252BAngiotensin%252BII%252BSubtype%252B2%252BReceptor%25253A%252BFocus%252Bon%252BPeptide%252Band%252BNonpeptide%252BAgonists%26aulast%3DRanjit%26aufirst%3DArina%26date%3D2021%26date%3D2021%26volume%3D99%26issue%3D6%26spage%3D469%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brendin  Flinn</span>, <span class="hlFld-ContribAuthor ">Nicholas  Royce</span>, <span class="hlFld-ContribAuthor ">Todd  Gress</span>, <span class="hlFld-ContribAuthor ">Nepal  Chowdhury</span>, <span class="hlFld-ContribAuthor ">Nalini  Santanam</span>. </span><span class="cited-content_cbyCitation_article-title">Dual role for angiotensin‐converting enzyme 2 in Severe Acute Respiratory Syndrome Coronavirus 2 infection and cardiac fat. </span><span class="cited-content_cbyCitation_journal-name">Obesity Reviews</span><span> <strong>2021,</strong> <em>22 </em>
                                    (5)
                                     <a href="https://doi.org/10.1111/obr.13225" title="DOI URL">https://doi.org/10.1111/obr.13225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/obr.13225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fobr.13225%26sid%3Dliteratum%253Aachs%26jtitle%3DObesity%2520Reviews%26atitle%3DDual%252Brole%252Bfor%252Bangiotensin%2525E2%252580%252590converting%252Benzyme%252B2%252Bin%252BSevere%252BAcute%252BRespiratory%252BSyndrome%252BCoronavirus%252B2%252Binfection%252Band%252Bcardiac%252Bfat%26aulast%3DFlinn%26aufirst%3DBrendin%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fan  Chen</span>, <span class="hlFld-ContribAuthor ">Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Jicheng  Hu</span>, <span class="hlFld-ContribAuthor ">Xinlu  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Chai</span>, <span class="hlFld-ContribAuthor ">Di  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Preoperative angiotensin II type 2 receptor is a predictor for developing chronic post-surgical pain after total knee arthroplasty surgery. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2021,</strong> <em>7 </em>, 119654. <a href="https://doi.org/10.1016/j.lfs.2021.119654" title="DOI URL">https://doi.org/10.1016/j.lfs.2021.119654</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2021.119654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2021.119654%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DPreoperative%252Bangiotensin%252BII%252Btype%252B2%252Breceptor%252Bis%252Ba%252Bpredictor%252Bfor%252Bdeveloping%252Bchronic%252Bpost-surgical%252Bpain%252Bafter%252Btotal%252Bknee%252Barthroplasty%252Bsurgery%26aulast%3DChen%26aufirst%3DFan%26date%3D2021%26volume%3D7%26spage%3D119654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Johan  Wannberg</span>, <span class="hlFld-ContribAuthor ">Johan  Gising</span>, <span class="hlFld-ContribAuthor ">Jens  Lindman</span>, <span class="hlFld-ContribAuthor ">Jessica  Salander</span>, <span class="hlFld-ContribAuthor ">Hugo  Gutiérrez-de-Terán</span>, <span class="hlFld-ContribAuthor ">Hanin  Ablahad</span>, <span class="hlFld-ContribAuthor ">Selin  Hamid</span>, <span class="hlFld-ContribAuthor ">Alfhild  Grönbladh</span>, <span class="hlFld-ContribAuthor ">Iresha  Spizzo</span>, <span class="hlFld-ContribAuthor ">Tracey A.  Gaspari</span>, <span class="hlFld-ContribAuthor ">Robert E.  Widdop</span>, <span class="hlFld-ContribAuthor ">Anders  Hallberg</span>, <span class="hlFld-ContribAuthor ">Maria  Backlund</span>, <span class="hlFld-ContribAuthor ">Anna  Leśniak</span>, <span class="hlFld-ContribAuthor ">Mathias  Hallberg</span>, <span class="hlFld-ContribAuthor ">Mats  Larhed</span>. </span><span class="cited-content_cbyCitation_article-title">N-(Methyloxycarbonyl)thiophene sulfonamides as high affinity AT2 receptor ligands. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>29 </em>, 115859. <a href="https://doi.org/10.1016/j.bmc.2020.115859" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115859</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115859%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DN-%252528Methyloxycarbonyl%252529thiophene%252Bsulfonamides%252Bas%252Bhigh%252Baffinity%252BAT2%252Breceptor%252Bligands%26aulast%3DWannberg%26aufirst%3DJohan%26date%3D2021%26volume%3D29%26spage%3D115859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Stein</span>, <span class="hlFld-ContribAuthor ">Lauren M.  Young</span>. </span><span class="cited-content_cbyCitation_article-title">From ACE2 to COVID-19: A multiorgan endothelial disease. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Infectious Diseases</span><span> <strong>2020,</strong> <em>100 </em>, 425-430. <a href="https://doi.org/10.1016/j.ijid.2020.08.083" title="DOI URL">https://doi.org/10.1016/j.ijid.2020.08.083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijid.2020.08.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijid.2020.08.083%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Infectious%2520Diseases%26atitle%3DFrom%252BACE2%252Bto%252BCOVID-19%25253A%252BA%252Bmultiorgan%252Bendothelial%252Bdisease%26aulast%3DStein%26aufirst%3DRichard%2BA.%26date%3D2020%26volume%3D100%26spage%3D425%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvana  Vasile</span>, <span class="hlFld-ContribAuthor ">Anders  Hallberg</span>, <span class="hlFld-ContribAuthor ">Jessica  Sallander</span>, <span class="hlFld-ContribAuthor ">Mathias  Hallberg</span>, <span class="hlFld-ContribAuthor ">Johan  Åqvist</span>, <span class="hlFld-ContribAuthor ">Hugo  Gutiérrez-de-Terán</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2020,</strong> <em>10 </em>
                                    (4)
                                     , 649. <a href="https://doi.org/10.3390/biom10040649" title="DOI URL">https://doi.org/10.3390/biom10040649</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom10040649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom10040649%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DEvolution%252Bof%252BAngiotensin%252BPeptides%252Band%252BPeptidomimetics%252Bas%252BAngiotensin%252BII%252BReceptor%252BType%252B2%252B%252528AT2%252529%252BReceptor%252BAgonists%26aulast%3DVasile%26aufirst%3DSilvana%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D4%26spage%3D649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Damiano  D’Ardes</span>, <span class="hlFld-ContribAuthor ">Andrea  Boccatonda</span>, <span class="hlFld-ContribAuthor ">Ilaria  Rossi</span>, <span class="hlFld-ContribAuthor ">Maria Teresa  Guagnano</span>, <span class="hlFld-ContribAuthor ">Francesca  Santilli</span>, <span class="hlFld-ContribAuthor ">Francesco  Cipollone</span>, <span class="hlFld-ContribAuthor ">Marco  Bucci</span>. </span><span class="cited-content_cbyCitation_article-title">COVID-19 and RAS: Unravelling an Unclear Relationship. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (8)
                                     , 3003. <a href="https://doi.org/10.3390/ijms21083003" title="DOI URL">https://doi.org/10.3390/ijms21083003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21083003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21083003%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DCOVID-19%252Band%252BRAS%25253A%252BUnravelling%252Ban%252BUnclear%252BRelationship%26aulast%3DD%25E2%2580%2599Ardes%26aufirst%3DDamiano%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D8%26spage%3D3003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Extended RAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Renin inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Some examples of ACE inhibitors in clinical use.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. APA and APN inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. IRAP, ACE2, and MasR modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. AT<sub>1</sub>R and AT<sub>2</sub>R cellular signaling and effects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. AT<sub>1</sub>R agonists and antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Consequences of modulating the Ang II production pathways in the classical RAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Some examples of AT<sub>2</sub>R agonists and antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structural modifications of <b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. From a nonspecific AT<sub>1</sub>R/AT<sub>2</sub>R agonist to a selective AT<sub>2</sub>R agonist to a selective AT<sub>2</sub>R antagonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/medium/jm9b01780_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Therapeutic interest of AT<sub>2</sub>R modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01780/20200306/images/large/jm9b01780_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01780&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i19">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33232" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33232" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 160 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurley, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirotsou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffman, T. M.</span></span> <span> </span><span class="NLM_article-title">Classical renin-angiotensin in kidney physiology</span>. <i>Compr. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1201</span>– <span class="NLM_lpage">1228</span>, <span class="refDoi"> DOI: 10.1002/cphy.c130040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fcphy.c130040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24944035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC2cfjvFygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1201-1228&author=M.+A.+Sparksauthor=S.+D.+Crowleyauthor=S.+B.+Gurleyauthor=M.+Mirotsouauthor=T.+M.+Coffman&title=Classical+renin-angiotensin+in+kidney+physiology&doi=10.1002%2Fcphy.c130040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Classical Renin-Angiotensin system in kidney physiology</span></div><div class="casAuthors">Sparks Matthew A; Crowley Steven D; Gurley Susan B; Mirotsou Maria; Coffman Thomas M</div><div class="citationInfo"><span class="NLM_cas:title">Comprehensive Physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1201-28</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The renin-angiotensin system has powerful effects in control of the blood pressure and sodium homeostasis.  These actions are coordinated through integrated actions in the kidney, cardiovascular system and the central nervous system.  Along with its impact on blood pressure, the renin-angiotensin system also influences a range of processes from inflammation and immune responses to longevity.  Here, we review the actions of the "classical" renin-angiotensin system, whereby the substrate protein angiotensinogen is processed in a two-step reaction by renin and angiotensin converting enzyme, resulting in the sequential generation of angiotensin I and angiotensin II, the major biologically active renin-angiotensin system peptide, which exerts its actions via type 1 and type 2 angiotensin receptors.  In recent years, several new enzymes, peptides, and receptors related to the renin-angiotensin system have been identified, manifesting a complexity that was previously unappreciated.  While the functions of these alternative pathways will be reviewed elsewhere in this journal, our focus here is on the physiological role of components of the "classical" renin-angiotensin system, with an emphasis on new developments and modern concepts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShV0-YwFOzpBwLZxei1HN8fW6udTcc2eY8MAOPXyOELbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfjvFygtw%253D%253D&md5=4a7268d31366074c46226401b0d8ecc4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fcphy.c130040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcphy.c130040%26sid%3Dliteratum%253Aachs%26aulast%3DSparks%26aufirst%3DM.%2BA.%26aulast%3DCrowley%26aufirst%3DS.%2BD.%26aulast%3DGurley%26aufirst%3DS.%2BB.%26aulast%3DMirotsou%26aufirst%3DM.%26aulast%3DCoffman%26aufirst%3DT.%2BM.%26atitle%3DClassical%2520renin-angiotensin%2520in%2520kidney%2520physiology%26jtitle%3DCompr.%2520Physiol.%26date%3D2014%26volume%3D4%26spage%3D1201%26epage%3D1228%26doi%3D10.1002%2Fcphy.c130040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Mello, W. C.</span></span> <span> </span><span class="NLM_article-title">Is an intracellular renin-angiotensin system involved in control of cell communication in heart?</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1097/00005344-199404000-00018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2F00005344-199404000-00018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=7516016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2cXitlOjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1994&pages=640-646&author=W.+C.+De%0AMello&title=Is+an+intracellular+renin-angiotensin+system+involved+in+control+of+cell+communication+in+heart%3F&doi=10.1097%2F00005344-199404000-00018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Is an intracellular renin-angiotensin system involved in control of cell communication in heart?</span></div><div class="casAuthors">De Mello, Walmor C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">640-6</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    </div><div class="casAbstract">The possible influence of an intracellular renin-angiotensin system (RAS) on control of cell communication in heart muscle was investigated in cell pairs isolated from adult rats.  Junctional conductance (gj) was measured with 2 sepd. voltage-clamp circuits.  Intracellular dialysis of angiotensin I (AI 10-8M) caused a decrease in gj of 76% (SE) in 7 min.  The effect of AI appears to be due mainly to its conversion to AII because enalaprilat (10-9M) dialyzed into the cell caused an appreciable redn. in the effect of AI.  AII (10-8M) alone caused a decrease in gj of 60% in 45 s.  The effect of AII on gj was suppressed by previous inhibition of protein kinase C (PKC), but enalaprilat could not alter the effect of the peptide.  Apparently, synthesis of AII inside cardiac myocytes plays an important role in modulation of gj and consequently on propagation of the elec. impulse in heart.  The effect of AII on gj was blocked by DuP 753 (10-9M) administered intracellularly, whereas [Sar1Val5Ala8]AII also caused a slight decrease (1.97%) in gj.  Apparently, an intracellular receptor is involved in the effect of the peptide on gj.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLRkecRWDulbVg90H21EOLACvtfcHk0lhnv76nh7L2rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlOjsL8%253D&md5=af3da8836140a7f7d855105ff19759ea</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1097%2F00005344-199404000-00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199404000-00018%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BMello%26aufirst%3DW.%2BC.%26atitle%3DIs%2520an%2520intracellular%2520renin-angiotensin%2520system%2520involved%2520in%2520control%2520of%2520cell%2520communication%2520in%2520heart%253F%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1994%26volume%3D23%26spage%3D640%26epage%3D646%26doi%3D10.1097%2F00005344-199404000-00018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filipeanu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henning, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zeeuw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelemans, A.</span></span> <span> </span><span class="NLM_article-title">Intracellular angiotensin II and cell growth of vascular smooth muscle cells</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1596</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0703984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fsj.bjp.0703984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11264254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVahsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2001&pages=1590-1596&author=C.+M.+Filipeanuauthor=R.+H.+Henningauthor=D.+de+Zeeuwauthor=A.+Nelemans&title=Intracellular+angiotensin+II+and+cell+growth+of+vascular+smooth+muscle+cells&doi=10.1038%2Fsj.bjp.0703984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular angiotensin II and cell growth of vascular smooth muscle cells</span></div><div class="casAuthors">Filipeanu, Catalin M.; Henning, Robert H.; De Zeeuw, Dick; Nelemans, Adriaan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1590-1596</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors recently demonstrated that intracellular application of Angiotensin II (Angiotensin IIintr) induces rat aorta contraction independent of plasma membrane Angiotensin II receptors.  In this study the authors investigated the effects of Angiotensin IIintr on cell growth in A7r5 smooth muscle cells.  DNA-synthesis was increased dose-dependently by liposomes filled with Angiotensin II as measured by [3H]-thymidine incorporation at high (EC50=27±6 pM) and low (EC50=14±5 nM) affinity binding sites with increases in Emax of 58±4 and 37±4% above quiescent cells, resp.  Cell growth was corroborated by an increase in cell no.  Extracellular Angiotensin II (10 pM-10 μM) did not modify [3H]-thymidine incorporation.  Growth effects of Angiotensin IIintr mediated via high affinity sites were inhibited by liposomes filled with 1 μM of the non-peptidergic antagonists losartan (AT1-receptor) or PD123319 (AT2-receptor) or with the peptidergic agonist CGP42112A (AT2-receptor).  Emax values were decreased to 30±3, 29±4 and 4±2%, resp., without changes in EC50.  The Angiotensin IIintr effect via low affinity sites was only antagonized by CGP42112A (Emax=11±3%), while losartan and PD123319 increased Emax to 69±4%.  Intracellular applications were ineffective in the absence of Angiotensin IIintr.  Neither intracellular nor extracellular Angiotensin I (1 μM) were effective.  The Angiotensin IIintr induced growth response was blocked by selective inhibition of phosphatidylinositol 3-kinase (PI-3K) by wortmannin (1 μM) and of the mitogen-activated protein kinase (MAPK/ERK) pathway by PD98059 (1 μM) to 61±14 and 4±8% of control, resp.  These data demonstrate that Angiotensin IIintr induces cell growth through atypical AT-receptors via a PI-3K and MAPK/ERK -sensitive pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3QZwKuHmCHLVg90H21EOLACvtfcHk0lhnv76nh7L2rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVahsbw%253D&md5=68092180d26771ac89e02304830209c1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703984%26sid%3Dliteratum%253Aachs%26aulast%3DFilipeanu%26aufirst%3DC.%2BM.%26aulast%3DHenning%26aufirst%3DR.%2BH.%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DNelemans%26aufirst%3DA.%26atitle%3DIntracellular%2520angiotensin%2520II%2520and%2520cell%2520growth%2520of%2520vascular%2520smooth%2520muscle%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D132%26spage%3D1590%26epage%3D1596%26doi%3D10.1038%2Fsj.bjp.0703984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Re, R.</span></span> <span> </span><span class="NLM_article-title">Intracellular renin-angiotensin system: the tip of the intracrine physiology iceberg</span>. <i>Am. J. Physiol., Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">H905</span>– <span class="NLM_lpage">H906</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00552.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajpheart.00552.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=17526648" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2007&pages=H905-H906&author=R.+Re&title=Intracellular+renin-angiotensin+system%3A+the+tip+of+the+intracrine+physiology+iceberg&doi=10.1152%2Fajpheart.00552.2007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00552.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00552.2007%26sid%3Dliteratum%253Aachs%26aulast%3DRe%26aufirst%3DR.%26atitle%3DIntracellular%2520renin-angiotensin%2520system%253A%2520the%2520tip%2520of%2520the%2520intracrine%2520physiology%2520iceberg%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Heart%2520Circ.%2520Physiol.%26date%3D2007%26volume%3D293%26spage%3DH905%26epage%3DH906%26doi%3D10.1152%2Fajpheart.00552.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paz
Ocaranza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riquelme, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalil, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandero, S.</span></span> <span> </span><span class="NLM_article-title">Counter-regulatory renin–angiotensin system in cardiovascular disease</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1038/s41569-019-0244-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fs41569-019-0244-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=31427727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BB3MvpsVKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=116-129&author=M.+Paz%0AOcaranzaauthor=J.+A.+Riquelmeauthor=L.+Garc%C3%ADaauthor=J.+E.+Jalilauthor=M.+Chiongauthor=R.+A.+S.+Santosauthor=S.+Lavandero&title=Counter-regulatory+renin%E2%80%93angiotensin+system+in+cardiovascular+disease&doi=10.1038%2Fs41569-019-0244-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Counter-regulatory renin-angiotensin system in cardiovascular disease</span></div><div class="casAuthors">Paz Ocaranza Maria; Jalil Jorge E; Riquelme Jaime A; Garcia Lorena; Chiong Mario; Lavandero Sergio; Santos Robson A S; Lavandero Sergio; Lavandero Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Cardiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The renin-angiotensin system is an important component of the cardiovascular system.  Mounting evidence suggests that the metabolic products of angiotensin I and II - initially thought to be biologically inactive - have key roles in cardiovascular physiology and pathophysiology.  This non-canonical axis of the renin-angiotensin system consists of angiotensin 1-7, angiotensin 1-9, angiotensin-converting enzyme 2, the type 2 angiotensin II receptor (AT2R), the proto-oncogene Mas receptor and the Mas-related G protein-coupled receptor member D.  Each of these components has been shown to counteract the effects of the classical renin-angiotensin system.  This counter-regulatory renin-angiotensin system has a central role in the pathogenesis and development of various cardiovascular diseases and, therefore, represents a potential therapeutic target.  In this Review, we provide the latest insights into the complexity and interplay of the components of the non-canonical renin-angiotensin system, and discuss the function and therapeutic potential of targeting this system to treat cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3XOEtE4JzWbrIbt-tGZmxfW6udTcc2eYyG_uZ9ZFRXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvpsVKktg%253D%253D&md5=03e0ead60a2c6139e470b69b364f1338</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fs41569-019-0244-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41569-019-0244-8%26sid%3Dliteratum%253Aachs%26aulast%3DPaz%2BOcaranza%26aufirst%3DM.%26aulast%3DRiquelme%26aufirst%3DJ.%2BA.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DL.%26aulast%3DJalil%26aufirst%3DJ.%2BE.%26aulast%3DChiong%26aufirst%3DM.%26aulast%3DSantos%26aufirst%3DR.%2BA.%2BS.%26aulast%3DLavandero%26aufirst%3DS.%26atitle%3DCounter-regulatory%2520renin%25E2%2580%2593angiotensin%2520system%2520in%2520cardiovascular%2520disease%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2020%26volume%3D17%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fs41569-019-0244-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2014.59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fnrcardio.2014.59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24776703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslGitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=413-426&author=F.+Jiangauthor=J.+Yangauthor=Y.+Zhangauthor=M.+Dongauthor=S.+Wangauthor=Q.+Zhangauthor=F.+F.+Liuauthor=K.+Zhangauthor=C.+Zhang&title=Angiotensin-converting+enzyme+2+and+angiotensin+1%E2%80%937%3A+novel+therapeutic+targets&doi=10.1038%2Fnrcardio.2014.59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets</span></div><div class="casAuthors">Jiang, Fan; Yang, Jianmin; Zhang, Yongtao; Dong, Mei; Wang, Shuangxi; Zhang, Qunye; Liu, Fang Fang; Zhang, Kai; Zhang, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">413-426</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The renin-angiotensin system (RAS) has pivotal roles in the regulation of normal physiol. and the pathogenesis of cardiovascular disease.  Angiotensin-converting enzyme (ACE) 2, and its product angiotensin 1-7, are thought to have counteracting effects against the adverse actions of other, better known and understood, members of the RAS.  The physiol. and pathol. importance of ACE2 and angiotensin 1-7 in the cardiovascular system are not completely understood, but numerous exptl. studies have indicated that these components have protective effects in the heart and blood vessels.  Here, we provide an overview on the basic properties of ACE2 and angiotensin 1-7 and a summary of the evidence from exptl. and clin. studies of various pathol. conditions, such as hypertension, atherosclerosis, myocardial remodelling, heart failure, ischemic stroke, and diabetes mellitus.  ACE2-mediated catabolism of angiotensin II is likely to have a major role in cardiovascular protection, whereas the relevant functions and signalling mechanisms of actions induced by angiotensin 1-7 have not been conclusively detd.  The ACE2-angiotensin 1-7 pathway, however, might provide a useful therapeutic target for the treatment of cardiovascular disease, esp. in patients with overactive RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraCy0GZ3yFW7Vg90H21EOLACvtfcHk0ljlcd5rixv1cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslGitLs%253D&md5=07d420f3ada328a490033348ac01b7ac</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2014.59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2014.59%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DF.%2BF.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DAngiotensin-converting%2520enzyme%25202%2520and%2520angiotensin%25201%25E2%2580%25937%253A%2520novel%2520therapeutic%2520targets%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2014%26volume%3D11%26spage%3D413%26epage%3D426%26doi%3D10.1038%2Fnrcardio.2014.59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickremesekera, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itinteang, T.</span></span> <span> </span><span class="NLM_article-title">Renin-angiotensin system and cancer: a review</span>. <i>Integr. Cancer Sci. Therap.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">231</span>, <span class="refDoi"> DOI: 10.15761/ICST.1000231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.15761%2FICST.1000231" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=231&author=M.+J.+Munroauthor=A.+C.+Wickremesekeraauthor=P.+F.+Davisauthor=R.+Marshauthor=S.+T.+Tanauthor=T.+Itinteang&title=Renin-angiotensin+system+and+cancer%3A+a+review&doi=10.15761%2FICST.1000231"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.15761%2FICST.1000231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15761%252FICST.1000231%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DM.%2BJ.%26aulast%3DWickremesekera%26aufirst%3DA.%2BC.%26aulast%3DDavis%26aufirst%3DP.%2BF.%26aulast%3DMarsh%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DS.%2BT.%26aulast%3DItinteang%26aufirst%3DT.%26atitle%3DRenin-angiotensin%2520system%2520and%2520cancer%253A%2520a%2520review%26jtitle%3DIntegr.%2520Cancer%2520Sci.%2520Therap.%26date%3D2017%26volume%3D4%26spage%3D231%26doi%3D10.15761%2FICST.1000231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKinley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albiston, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathai, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S. Y.</span></span> <span> </span><span class="NLM_article-title">The brain renin-angiotensin system: location and physiological roles</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">901</span>– <span class="NLM_lpage">918</span>, <span class="refDoi"> DOI: 10.1016/S1357-2725(02)00306-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS1357-2725%2802%2900306-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12676175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFShu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2003&pages=901-918&author=M.+J.+McKinleyauthor=A.+L.+Albistonauthor=A.+M.+Allenauthor=M.+L.+Mathaiauthor=C.+N.+Mayauthor=R.+M.+McAllenauthor=B.+J.+Oldfieldauthor=F.+A.+Mendelsohnauthor=S.+Y.+Chai&title=The+brain+renin-angiotensin+system%3A+location+and+physiological+roles&doi=10.1016%2FS1357-2725%2802%2900306-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The brain renin-angiotensin system: location and physiological roles</span></div><div class="casAuthors">McKinley, M. J.; Albiston, A. L.; Allen, A. M.; Mathai, M. L.; May, C. N.; McAllen, R. M.; Oldfield, B. J.; Mendelsohn, F. A. O.; Chai, S. Y.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">901-918</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiotensinogen, the precursor mol. for angiotensins I, II and III, and the enzymes renin, angiotensin-converting enzyme (ACE), and aminopeptidases A and N may all be synthesized within the brain.  Angiotensin (Ang) AT1, AT2 and AT4 receptors are also plentiful in the brain.  AT1 receptors are found in several brain regions, such as the hypothalamic paraventricular and supraoptic nuclei, the lamina terminalis, lateral parabrachial nucleus, ventrolateral medulla and nucleus of the solitary tract (NTS), which are known to have roles in the regulation of the cardiovascular system and/or body fluid and electrolyte balance.  Immunohistochem. and neuropharmacol. studies suggest that angiotensinergic neural pathways utilize Ang II and/or Ang III as a neurotransmitter or neuromodulator in the aforementioned brain regions.  Angiotensinogen is synthesized predominantly in astrocytes, but the processes by which Ang II is generated or incorporated in neurons for utilization as a neurotransmitter is unknown.  Centrally administered AT1 receptor antagonists or angiotensinogen antisense oligonucleotides inhibit sympathetic activity and reduce arterial blood pressure in certain physiol. or pathophysiol. conditions, as well as disrupting water drinking and sodium appetite, vasopressin secretion, sodium excretion, renin release and thermoregulation.  The AT4 receptor is identical to insulin-regulated aminopeptidase (IRAP) and plays a role in memory mechanisms.  In conclusion, angiotensinergic neural pathways and angiotensin peptides are important in neural function and may have important homeostatic roles, particularly related to cardiovascular function, osmoregulation and thermoregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA4nXg_hNM-LVg90H21EOLACvtfcHk0liDHgAu3lgDAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFShu7o%253D&md5=2fb9f3ee2d618990f6703c347e833e2a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS1357-2725%2802%2900306-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-2725%252802%252900306-0%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinley%26aufirst%3DM.%2BJ.%26aulast%3DAlbiston%26aufirst%3DA.%2BL.%26aulast%3DAllen%26aufirst%3DA.%2BM.%26aulast%3DMathai%26aufirst%3DM.%2BL.%26aulast%3DMay%26aufirst%3DC.%2BN.%26aulast%3DMcAllen%26aufirst%3DR.%2BM.%26aulast%3DOldfield%26aufirst%3DB.%2BJ.%26aulast%3DMendelsohn%26aufirst%3DF.%2BA.%26aulast%3DChai%26aufirst%3DS.%2BY.%26atitle%3DThe%2520brain%2520renin-angiotensin%2520system%253A%2520location%2520and%2520physiological%2520roles%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2003%26volume%3D35%26spage%3D901%26epage%3D918%26doi%3D10.1016%2FS1357-2725%2802%2900306-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohlender, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imboden, H.</span></span> <span> </span><span class="NLM_article-title">Angiotensinergic neurotransmission in the peripheral autonomic nervous system</span>. <i>Front. Biosci., Landmark Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2419</span>– <span class="NLM_lpage">2432</span>, <span class="refDoi"> DOI: 10.2741/4062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2741%2F4062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22652789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSksbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=2419-2432&author=J.+Bohlenderauthor=H.+Imboden&title=Angiotensinergic+neurotransmission+in+the+peripheral+autonomic+nervous+system&doi=10.2741%2F4062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensinergic neurotransmission in the peripheral autonomic nervous system</span></div><div class="casAuthors">Bohlender, Jurgen; Imboden, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience, Landmark Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2419-2432, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Angiotensin (Ang) II has for long been identified as a neuropeptide located within neurons and pathways of the central nervous system involved in the control of thirst and cardio-vascular homeostasis.  The presence of Ang II in ganglionic neurons of celiac, dorsal root and trigeminal ganglia has only recently been described in humans and rats.  Ang II-contg. fibers were also found in the mesenteric artery and the heart together with intrinsic Ang II-contg. cardiac neurons.  Ganglionic neurons express angiotensinogen and co-localize it with Ang II.  Its intraneuronal prodn. as a neuropeptide appears to involve angiotensinogen processing enzymes other than renin.  Immunocytochem. and gene expression data suggest that neuronal Ang II acts as a neuromodulatory peptide and co-transmitter in the peripheral autonomic and also sensory nervous system.  Neuronal Ang II probably competes with humoral Ang II for effector cell activtation.  Its functional role, however, still remains to be detd.  Angiotensinergic neurotransmission in the autonomic nervous system is a potential new target for therapeutic interventions in many common diseases such as essential hypertension, heart failure and cardiac arrhythmia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvJWhOr8t8ArVg90H21EOLACvtfcHk0liDHgAu3lgDAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSksbrK&md5=03e5319967fe00ab3e5cc3c618ca2c1d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2741%2F4062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F4062%26sid%3Dliteratum%253Aachs%26aulast%3DBohlender%26aufirst%3DJ.%26aulast%3DImboden%26aufirst%3DH.%26atitle%3DAngiotensinergic%2520neurotransmission%2520in%2520the%2520peripheral%2520autonomic%2520nervous%2520system%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2012%26volume%3D17%26spage%3D2419%26epage%3D2432%26doi%3D10.2741%2F4062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Célérier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuis Bernasconi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maerki, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzer, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvol, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasc, J. M.</span></span> <span> </span><span class="NLM_article-title">Renin and angiotensinogen expression and function in growth and apoptosis of human glioblastoma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1068</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6601646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fsj.bjc.6601646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=14997208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhslWrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=1059-1068&author=L.+Juillerat-Jeanneretauthor=J.+C%C3%A9l%C3%A9rierauthor=C.+Chapuis+Bernasconiauthor=G.+Nguyenauthor=W.+Wostlauthor=H.+P.+Maerkiauthor=R.+C.+Janzerauthor=P.+Corvolauthor=J.+M.+Gasc&title=Renin+and+angiotensinogen+expression+and+function+in+growth+and+apoptosis+of+human+glioblastoma&doi=10.1038%2Fsj.bjc.6601646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma</span></div><div class="casAuthors">Juillerat-Jeanneret, L.; Celerier, J.; Chapuis Bernasconi, C.; Nguyen, G.; Wostl, W.; Maerki, H. P.; Janzer, R-C.; Corvol, P.; Gasc, J-M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1059-1068</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The expression and function in growth and apoptosis of the renin-angiotensin system (RAS) was evaluated in human glioblastoma.  Renin and angiotensinogen (AGT) mRNAs and proteins were found by in situ hybridization and immunohistochem. in glioblastoma cells.  Angiotensinogen was present in glioblastoma cystic fluids.  Thus, human glioblastoma cells produce renin and AGT and secrete AGT.  Human glioblastoma and glioblastoma cells expressed renin, AGT, renin receptor, AT2 and/or AT1 mRNAs and proteins detd. by RT-PCR and/or Western blotting, resp.  The function of the RAS in glioblastoma was studied using human glioblastoma cells in culture.  Angiotensinogen, des(Ang I)AGT, tetradecapeptide renin substrate (AGT1-14), Ang I, Ang II or Ang III, added to glioblastoma cells in culture, did not modulate their proliferation, survival or death.  Angiotensin-converting enzyme inhibitors did not diminish glioblastoma cell proliferation.  However, the addn. of selective synthetic renin inhibitors to glioblastoma cells decreased DNA synthesis and viable tumor cell no., and induced apoptosis.  This effect was not counterbalanced by concomitant addn. of Ang II.  In conclusion, the complete RAS is expressed by human glioblastomas and glioblastoma cells in culture.  Inhibition of renin in glioblastoma cells may be a potential approach to control glioblastoma cell proliferation and survival, and glioblastoma progression in combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEViTYIexQ4LVg90H21EOLACvtfcHk0liDHgAu3lgDAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhslWrsbo%253D&md5=39005a7561f49040844dfd5e82dbe151</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601646%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DC%25C3%25A9l%25C3%25A9rier%26aufirst%3DJ.%26aulast%3DChapuis%2BBernasconi%26aufirst%3DC.%26aulast%3DNguyen%26aufirst%3DG.%26aulast%3DWostl%26aufirst%3DW.%26aulast%3DMaerki%26aufirst%3DH.%2BP.%26aulast%3DJanzer%26aufirst%3DR.%2BC.%26aulast%3DCorvol%26aufirst%3DP.%26aulast%3DGasc%26aufirst%3DJ.%2BM.%26atitle%3DRenin%2520and%2520angiotensinogen%2520expression%2520and%2520function%2520in%2520growth%2520and%2520apoptosis%2520of%2520human%2520glioblastoma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2004%26volume%3D90%26spage%3D1059%26epage%3D1068%26doi%3D10.1038%2Fsj.bjc.6601646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staessen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richart, T.</span></span> <span> </span><span class="NLM_article-title">Oral renin inhibitors</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1456</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(06)69442-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0140-6736%2806%2969442-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=17055947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSntb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1449-1456&author=J.+A.+Staessenauthor=Y.+Liauthor=T.+Richart&title=Oral+renin+inhibitors&doi=10.1016%2FS0140-6736%2806%2969442-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Oral renin inhibitors</span></div><div class="casAuthors">Staessen, Jan A.; Li, Yan; Richart, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">9545</span>),
    <span class="NLM_cas:pages">1449-1456</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Use of drugs that inhibit the renin-angiotensin system is an effective way to intervene in the pathogenesis of cardiovascular and renal disorders.  The idea of blocking the renin system at its origin by inhibition of renin has existed for more than 30 years.  Renin inhibition suppresses the generation of the active peptide angiotensin II.  The first generation of orally active renin inhibitors were never used clin. because of low bioavailability and weak blood-pressure-lowering activity.  At present, aliskiren is the first non-peptide orally active renin inhibitor to progress to phase-III clin. trials.  It might become the first renin inhibitor with indications for the treatment of hypertension and cardiovascular and renal disorders.  Novel compds. with improved oral bioavailability, specificity, and efficacy are now in preclin. development.  This Review summarizes the development of oral renin inhibitors and their pharmacokinetic and pharmacodynamic properties, with a focus on aliskiren.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3x7KVdYm_4rVg90H21EOLACvtfcHk0lhEQ1No0s43jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSntb3M&md5=a6867b4cea28566aa719c8633257a983</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969442-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969442-7%26sid%3Dliteratum%253Aachs%26aulast%3DStaessen%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRichart%26aufirst%3DT.%26atitle%3DOral%2520renin%2520inhibitors%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1449%26epage%3D1456%26doi%3D10.1016%2FS0140-6736%2806%2969442-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, C. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.1998.tb03121.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fj.1875-9114.1998.tb03121.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9620109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1cXkt1KjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=588-599&author=C.+M.+White&title=Pharmacologic%2C+pharmacokinetic%2C+and+therapeutic+differences+among+ACE+inhibitors&doi=10.1002%2Fj.1875-9114.1998.tb03121.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors</span></div><div class="casAuthors">White, C. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">588-599</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Pharmacotherapy Publications</span>)
        </div><div class="casAbstract">A review with 84 refs.  Angiotensin-converting enzyme (ACE) inhibitors are a heterogeneous group of agents, and important pharmacol., pharmacokinetic, and therapeutic differences among them must be understood to obtain optimal therapy.  For patients with severe liver disease, lisinopril and captopril are not prodrugs (e.g., do not require hepatic activation), and lisinopril has almost solely renal elimination.  Enalaprilat, the i.v. formulation of enalapril, is the only i.v. available ACE inhibitor and can be given to patients with severe liver dysfunction as it is also not a prodrug.  Fosinopril is the only drug with compensatory dual routes of elimination, and it does not require dosage adjustment in patients with reduced renal function, as other ACE inhibitors do.  Captopril and moexipril have potential drug-food interactions and are the only agents that should be spaced from meals.  The ACE inhibitors also differ in their dialyzability, half-life, lipophilicity, trough:peak ratios, approved indications, and therapeutic information available for many indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF-b_6jQNBqbVg90H21EOLACvtfcHk0lhEQ1No0s43jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt1KjtLs%253D&md5=4a57f9ba8f2dc75886fb07e69ed899de</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.1998.tb03121.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.1998.tb03121.x%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DC.%2BM.%26atitle%3DPharmacologic%252C%2520pharmacokinetic%252C%2520and%2520therapeutic%2520differences%2520among%2520ACE%2520inhibitors%26jtitle%3DPharmacotherapy%26date%3D1998%26volume%3D18%26spage%3D588%26epage%3D599%26doi%3D10.1002%2Fj.1875-9114.1998.tb03121.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaten, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monte, A. A.</span></span> <span> </span><span class="NLM_article-title">The pharmacogenomic and metabolomic predictors of ACE inhibitor and angiotensin II receptor blocker effectiveness and safety</span>. <i>Cardiovasc. Drugs Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1007/s10557-017-6733-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs10557-017-6733-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28741243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WqsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=471-482&author=H.+K.+Flatenauthor=A.+A.+Monte&title=The+pharmacogenomic+and+metabolomic+predictors+of+ACE+inhibitor+and+angiotensin+II+receptor+blocker+effectiveness+and+safety&doi=10.1007%2Fs10557-017-6733-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety</span></div><div class="casAuthors">Flaten, Hania K.; Monte, Andrew A.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drugs and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-482</span>CODEN:
                <span class="NLM_cas:coden">CDTHET</span>;
        ISSN:<span class="NLM_cas:issn">0920-3206</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Hypertension (HTN) is the most common chronic disease in the USA.  Hypertensive patients frequently require repeat primary care visits to find an effective drug or drug combination to control their disease.  Currently, patients are prescribed drugs for HTN based on race, age, and comorbidities and although the current guidelines are reasonable starting points for prescribing, 50% of hypertensive patients still fail to achieve target blood pressures.  Despite numerous strategies to improve compliance, drug effectiveness, and optimization of initial drug choice, effectiveness has remained largely unchanged over the past two decades.  Therefore, it is important to pursue alternative strategies to more effectively treat patients and to decrease medical costs.  Addnl. precision medicine work is needed to identify factors assocd. with effectiveness of commonly used antihypertensive medications.  The objective of this manuscript is to present a comprehensive review of the pharmacogenomic and metabolomic factors assocd. with ACEI and ARB effectiveness and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHCu01oUJnWLVg90H21EOLACvtfcHk0lhEQ1No0s43jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WqsL3I&md5=e8ea9afebdf21a9950a8162b3225dea7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10557-017-6733-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10557-017-6733-2%26sid%3Dliteratum%253Aachs%26aulast%3DFlaten%26aufirst%3DH.%2BK.%26aulast%3DMonte%26aufirst%3DA.%2BA.%26atitle%3DThe%2520pharmacogenomic%2520and%2520metabolomic%2520predictors%2520of%2520ACE%2520inhibitor%2520and%2520angiotensin%2520II%2520receptor%2520blocker%2520effectiveness%2520and%2520safety%26jtitle%3DCardiovasc.%2520Drugs%2520Ther.%26date%3D2017%26volume%3D31%26spage%3D471%26epage%3D482%26doi%3D10.1007%2Fs10557-017-6733-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, J. H.</span></span> <span> </span><span class="NLM_article-title">Angiotensin converting enzyme inhibitor</span>. <i>Am. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1093/ajh/3.4.331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1093%2Fajh%2F3.4.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=2189445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK3cXkslSntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1990&pages=331-337&author=J.+H.+Bauer&title=Angiotensin+converting+enzyme+inhibitor&doi=10.1093%2Fajh%2F3.4.331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-converting enzyme inhibitors</span></div><div class="casAuthors">Bauer, John H.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hypertension</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">331-7</span>CODEN:
                <span class="NLM_cas:coden">AJHYE6</span>;
        ISSN:<span class="NLM_cas:issn">0895-7061</span>.
    </div><div class="casAbstract">A review, with 133 refs., of the use of the title drugs, in hypertension.  Mechanisms of action, general pharmacol., renal effects, side effects, and efficacy are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGzlB_5FlRgrVg90H21EOLACvtfcHk0lhEQ1No0s43jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkslSntr0%253D&md5=4e3a7ab9b3999abfca751cb674803997</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fajh%2F3.4.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fajh%252F3.4.331%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DJ.%2BH.%26atitle%3DAngiotensin%2520converting%2520enzyme%2520inhibitor%26jtitle%3DAm.%2520J.%2520Hypertens.%26date%3D1990%26volume%3D3%26spage%3D331%26epage%3D337%26doi%3D10.1093%2Fajh%2F3.4.331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarco, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endlich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter-Katalinić, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weide, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavenstädt, H.</span></span> <span> </span><span class="NLM_article-title">Downregulation of the antioxidant protein peroxiredoxin 2 contributes to angiotensin II-mediated podocyte apoptosis</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">969</span>, <span class="refDoi"> DOI: 10.1038/ki.2011.250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fki.2011.250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=21814176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaiurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=959-969&author=H.+H.+Hsuauthor=S.+Hoffmannauthor=G.+S.+DiMarcoauthor=N.+Endlichauthor=J.+Peter-Katalini%C4%87author=T.+Weideauthor=H.+Pavenst%C3%A4dt&title=Downregulation+of+the+antioxidant+protein+peroxiredoxin+2+contributes+to+angiotensin+II-mediated+podocyte+apoptosis&doi=10.1038%2Fki.2011.250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Downregulation of the antioxidant protein peroxiredoxin 2 contributes to angiotensin II-mediated podocyte apoptosis</span></div><div class="casAuthors">Hsu, Hsiang-Hao; Hoffmann, Sigrid; Di Marco, Giovana S.; Endlich, Nicole; Peter-Katalinic, Jasna; Weide, Thomas; Pavenstaedt, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">959-969</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Podocytes have a significant role in establishing selective permeability of the glomerular filtration barrier.  Sustained renin-angiotensin-aldosterone system activation is crucial to the pathogenesis of podocyte injury, but the mechanisms by which angiotensin II modulates podocyte survival due to physiol. or injurious stimuli remain unclear.  Here, we used proteomic anal. to find new mediators of angiotensin II-induced podocyte injury.  Antioxidant protein peroxiredoxin 2 expression was decreased in cultured podocytes stimulated with angiotensin II.  Peroxiredoxin 2 was found to be expressed in podocytes in vivo, and its expression was decreased in the glomeruli of rats transgenic for angiotensin II type 1 receptors in a podocyte-specific manner, or in rats infused with angiotensin II.  Downregulation of peroxiredoxin 2 in podocytes resulted in increased reactive oxygen species release, protein overoxidn., and inhibition of the Akt pathway.  Both treatment with angiotensin II and downregulation of peroxiredoxin 2 expression led to apoptosis of podocytes.  Thus, peroxiredoxin 2 is an important modulator of angiotensin II-induced podocyte injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhhBhn7s4kPLVg90H21EOLACvtfcHk0ljb0plQpeecKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaiurzJ&md5=c0c97123a42c3f206098108d6b05375b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fki.2011.250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2011.250%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DHoffmann%26aufirst%3DS.%26aulast%3DDiMarco%26aufirst%3DG.%2BS.%26aulast%3DEndlich%26aufirst%3DN.%26aulast%3DPeter-Katalini%25C4%2587%26aufirst%3DJ.%26aulast%3DWeide%26aufirst%3DT.%26aulast%3DPavenst%25C3%25A4dt%26aufirst%3DH.%26atitle%3DDownregulation%2520of%2520the%2520antioxidant%2520protein%2520peroxiredoxin%25202%2520contributes%2520to%2520angiotensin%2520II-mediated%2520podocyte%2520apoptosis%26jtitle%3DKidney%2520Int.%26date%3D2011%26volume%3D80%26spage%3D959%26epage%3D969%26doi%3D10.1038%2Fki.2011.250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grobe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elased, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cool, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M.</span></span> <span> </span><span class="NLM_article-title">Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney</span>. <i>Am. J. Physiol., Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>302</i></span>,  <span class="NLM_fpage">E1016</span>– <span class="NLM_lpage">E1024</span>, <span class="refDoi"> DOI: 10.1152/ajpendo.00515.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajpendo.00515.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22318946" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2012&pages=E1016-E1024&author=N.+Grobeauthor=K.+M.+Elasedauthor=D.+R.+Coolauthor=M.+Morris&title=Mass+spectrometry+for+the+molecular+imaging+of+angiotensin+metabolism+in+kidney&doi=10.1152%2Fajpendo.00515.2011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1152%2Fajpendo.00515.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpendo.00515.2011%26sid%3Dliteratum%253Aachs%26aulast%3DGrobe%26aufirst%3DN.%26aulast%3DElased%26aufirst%3DK.%2BM.%26aulast%3DCool%26aufirst%3DD.%2BR.%26aulast%3DMorris%26aufirst%3DM.%26atitle%3DMass%2520spectrometry%2520for%2520the%2520molecular%2520imaging%2520of%2520angiotensin%2520metabolism%2520in%2520kidney%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Endocrinol.%2520Metab.%26date%3D2012%26volume%3D302%26spage%3DE1016%26epage%3DE1024%26doi%3D10.1152%2Fajpendo.00515.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, J. D.</span></span> <span> </span><span class="NLM_article-title">Targeted γ-secretase inhibition to control the Notch pathway in renal diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8097</span>– <span class="NLM_lpage">8109</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8097-8109&author=L.+Juillerat-Jeanneretauthor=A.+Flohrauthor=M.+Schneiderauthor=I.+Walterauthor=J.+C.+Wyssauthor=R.+Kumarauthor=D.+Golshayanauthor=J.+D.+Aebi&title=Targeted+%CE%B3-secretase+inhibition+to+control+the+Notch+pathway+in+renal+diseases&doi=10.1021%2Facs.jmedchem.5b00912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted γ-Secretase Inhibition To Control the Notch Pathway in Renal Diseases</span></div><div class="casAuthors">Juillerat-Jeanneret, Lucienne; Flohr, Alexander; Schneider, Manfred; Walter, Isabelle; Wyss, Jean-Christophe; Kumar, Rajesh; Golshayan, Dela; Aebi, Johannes D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8097-8109</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Notch is a membrane inserted protein activated by the membrane-inserted γ-secretase proteolytic complex.  The Notch pathway is a potential therapeutic target for the treatment of renal diseases but also controls the function of other cells, requiring cell-targeting of Notch antagonists.  Toward selective targeting, we have developed the γ-secretase inhibitor-based prodrugs 13a and 15a as substrates for γ-glutamyltranspeptidase (γ-GT) and/or γ-glutamylcyclotransferase (γ-GCT) as well as aminopeptidase A (APA), which are overexpressed in renal diseases, and have evaluated them in exptl. in vitro and in vivo models.  In nondiseased mice, the cleavage product from Ac-γ-Glu-γ-secretase inhibitor prodrug 13a (γ-GT-targeting and γ-GCT-targeting) but not from Ac-α-Glu-γ-secretase inhibitor prodrug 15a (APA-targeting) accumulated in kidneys when compared to blood and liver.  Potential nephroprotective effects of the γ-secretase inhibitor targeted prodrugs were investigated in vivo in a mouse model of acute kidney injury, demonstrating that the expression of Notch1 and cleaved Notch1 could be selectively down-regulated upon treatment with the Ac-γ-Glu-γ-secretase-inhibitor 13a.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpJIYcUrrK37Vg90H21EOLACvtfcHk0ljb0plQpeecKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7rN&md5=a2084cbd458203f5b0c061aae1c51cb3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00912%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DFlohr%26aufirst%3DA.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DWalter%26aufirst%3DI.%26aulast%3DWyss%26aufirst%3DJ.%2BC.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DGolshayan%26aufirst%3DD.%26aulast%3DAebi%26aufirst%3DJ.%2BD.%26atitle%3DTargeted%2520%25CE%25B3-secretase%2520inhibition%2520to%2520control%2520the%2520Notch%2520pathway%2520in%2520renal%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8097%26epage%3D8109%26doi%3D10.1021%2Facs.jmedchem.5b00912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">David-Basei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournié-Zaluski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span> <span> </span><span class="NLM_article-title">Aminopeptidase A inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1517/13543776.11.3.431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1517%2F13543776.11.3.431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslSis74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=431-444&author=C.+David-Baseiauthor=M.+C.+Fourni%C3%A9-Zaluskiauthor=B.+P.+Roques&title=Aminopeptidase+A+inhibitors&doi=10.1517%2F13543776.11.3.431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Aminopeptidase A inhibitors</span></div><div class="casAuthors">David-Basei, Christelle; Fournie-Zaluski, Marie-Claude; Roques, Bernard P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">431-444</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">Potent and specific aminopeptidase A (APA; glutamylaminopeptidase, EC 3.4.11.7) inhibitors could be useful as powerful tools in the study of the physiol. involvement of this enzyme in the metab. of various peptides.  Thus, using newly designed selective APA inhibitors, APA has been shown to participate in the metab. of cholecystokinin and to be responsible for the conversion of angiotensin II (Ang II), a peripheral vasoconstrictor peptide, into Ang III, which has been recently shown to induce an increase in blood pressure and in vasopressin release in rat brain.  Moreover, APA was shown to be overexpressed in several types of malignant tumors, probably by inducing the formation of as yet unidentified cell proliferating active peptide(s).  This review with 57 refs. highlights advances in the structure and functions of APA and in the design of very potent and selective inhibitors of this zinc metallopeptidase.  These compds. could have interesting applications in the treatment of essential hypertension and their usefulness in cancer chemotherapy warrants further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-WYMYLLXElLVg90H21EOLACvtfcHk0ljb0plQpeecKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslSis74%253D&md5=2776e6e05e45075a78b800c04d097189</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F13543776.11.3.431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.11.3.431%26sid%3Dliteratum%253Aachs%26aulast%3DDavid-Basei%26aufirst%3DC.%26aulast%3DFourni%25C3%25A9-Zaluski%26aufirst%3DM.%2BC.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26atitle%3DAminopeptidase%2520A%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2001%26volume%3D11%26spage%3D431%26epage%3D444%26doi%3D10.1517%2F13543776.11.3.431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournie-Zaluski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvol, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Cortes, C.</span></span> <span> </span><span class="NLM_article-title">Aminopeptidase A inhibitors as potential central antihypertensive agents</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">13415</span>– <span class="NLM_lpage">13420</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.23.13415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1073%2Fpnas.96.23.13415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10557335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1MXns1Gmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=13415-13420&author=A.+Reauxauthor=M.+C.+Fournie-Zaluskiauthor=C.+Davidauthor=S.+Ziniauthor=B.+P.+Roquesauthor=P.+Corvolauthor=C.+Llorens-Cortes&title=Aminopeptidase+A+inhibitors+as+potential+central+antihypertensive+agents&doi=10.1073%2Fpnas.96.23.13415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Aminopeptidase A inhibitors as potential central antihypertensive agents</span></div><div class="casAuthors">Reaux, Annabelle; Fournie-Zaluski, Marie Claude; David, Christelle; Zini, Sylvie; Roques, Bernard P.; Corvol, Pierre; Llorens-Cortes, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">13415-13420</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Overactivity of the brain renin-angiotensin system (RAS) has been implicated in the development and maintenance of hypertension in several exptl. models, such as spontaneously hypertensive rats and transgenic mice expressing both human renin and human angiotensinogen transgenes.  We recently reported that, in the murine brain, angiotensin II (AngII) is converted to angiotensin III (AngIII) by aminopeptidase A (APA), whereas AngIII is inactivated by aminopeptidase N (APN).  If injected into cerebral ventricles (ICV), AngII and AngIII cause similar pressor responses.  Because AngII is metabolized in vivo into AngIII, the exact nature of the active peptide is not precisely detd.  Here we report that, in rats, ICV injection of the selective APA inhibitor EC33 [(S)-3-amino-4-mercaptobutyl sulfonic acid] blocked the pressor response of exogenous AngII, suggesting that the conversion of AngII to AngIII is required to increase blood pressure (BP).  Furthermore, ICV injection, but not i.v. injection, of EC33 alone caused a dose-dependent decrease in BP by blocking the formation of brain but not systemic AngIII.  This is corroborated by the fact that the selective APN inhibitor, PC18 (2-amino-4-methylsulfonyl butane thiol), administered alone via the ICV route, increases BP.  This pressor response was blocked by prior treatment with the angiotensin type 1 (AT1) receptor antagonist, losartan, showing that blocking the action of APN on AngIII metab. leads to an increase in endogenous AngIII levels, resulting in BP increase, through interaction with AT1 receptors.  These data demonstrate that AngIII is a major effector peptide of the brain RAS, exerting tonic stimulatory control over BP.  Thus, APA, the enzyme responsible for the formation of brain AngIII, represents a potential central therapeutic target that justifies the development of APA inhibitors as central antihypertensive agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLqu7dS3hsm7Vg90H21EOLACvtfcHk0lh54MS5dPAc8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1Gmtbo%253D&md5=61de1e121e2db47d7174203dbaa42b78</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.23.13415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.23.13415%26sid%3Dliteratum%253Aachs%26aulast%3DReaux%26aufirst%3DA.%26aulast%3DFournie-Zaluski%26aufirst%3DM.%2BC.%26aulast%3DDavid%26aufirst%3DC.%26aulast%3DZini%26aufirst%3DS.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26aulast%3DCorvol%26aufirst%3DP.%26aulast%3DLlorens-Cortes%26aufirst%3DC.%26atitle%3DAminopeptidase%2520A%2520inhibitors%2520as%2520potential%2520central%2520antihypertensive%2520agents%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D13415%26epage%3D13420%26doi%3D10.1073%2Fpnas.96.23.13415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Padia, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournie-Zaluski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R.</span></span> <span> </span><span class="NLM_article-title">Conversion of renal angiotensin II to angiotensin III is critical for AT<sub>2</sub> receptor–mediated natriuresis in rats</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">460</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.107.103242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.107.103242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=18158338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1KrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=460-465&author=S.+H.+Padiaauthor=B.+A.+Kempauthor=N.+L.+Howellauthor=M.+C.+Fournie-Zaluskiauthor=B.+P.+Roquesauthor=R.+Carey&title=Conversion+of+renal+angiotensin+II+to+angiotensin+III+is+critical+for+AT2+receptor%E2%80%93mediated+natriuresis+in+rats&doi=10.1161%2FHYPERTENSIONAHA.107.103242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Conversion of Renal Angiotensin II to Angiotensin III Is Critical for AT2 Receptor-Mediated Natriuresis In Rats</span></div><div class="casAuthors">Padia, Shetal H.; Kemp, Brandon A.; Howell, Nancy L.; Fournie-Zaluski, Marie-Claude; Roques, Bernard P.; Carey, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2, Pt. 2</span>),
    <span class="NLM_cas:pages">460-465</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">In the kidney, angiotensin II (Ang II) is metabolized to angiotensin III (Ang III) by aminopeptidase A (APA).  In turn, Ang III is metabolized to angiotensin IV by aminopeptidase N (APN).  Renal interstitial (RI) infusion of Ang III, but not Ang II, results in angiotensin type-2 receptor (AT2R)-mediated natriuresis.  This response is augmented by coinfusion of PC-18, a specific inhibitor of APN.  The present study addresses the hypotheses that Ang II conversion to Ang III is crit. for the natriuretic response.  Sprague-Dawley rats received systemic angiotensin type-1 receptor (AT1R) blockade with candesartan (CAND; 0.01 mg/kg/min) for 24 h before and during the expt.  After a control period, rats received either RI infusion of Ang II or Ang II + PC-18.  The contralateral kidney received a RI infusion of vehicle in all rats.  Mean arterial pressure (MAP) was monitored, and urinary sodium excretion rate (UNaV) was calcd. sep. from exptl. and control kidneys for each period.  In contrast to Ang II-infused kidneys, UNaV from Ang II + PC-18-infused kidneys increased from a baseline of 0.03 ± 0.01 to 0.09 ± 0.02 μmol/min (P < 0.05).  MAP was unchanged by either infusion.  RI addn. of PD-123319, an AT2R antagonist, inhibited the natriuretic response.  Furthermore, RI addn. of EC-33, a selective APA inhibitor, abolished the natriuretic response to Ang II + PC-18.  These data demonstrate that RI addn. of PC-18 to Ang II enables natriuresis mediated by the AT2R, and that conversion of Ang II to Ang III is crit. for this response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPlVJK5sD7R7Vg90H21EOLACvtfcHk0lh54MS5dPAc8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1KrsQ%253D%253D&md5=ee931985a31c6e2ca26d1afc8a496b42</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.107.103242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.107.103242%26sid%3Dliteratum%253Aachs%26aulast%3DPadia%26aufirst%3DS.%2BH.%26aulast%3DKemp%26aufirst%3DB.%2BA.%26aulast%3DHowell%26aufirst%3DN.%2BL.%26aulast%3DFournie-Zaluski%26aufirst%3DM.%2BC.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26aulast%3DCarey%26aufirst%3DR.%26atitle%3DConversion%2520of%2520renal%2520angiotensin%2520II%2520to%2520angiotensin%2520III%2520is%2520critical%2520for%2520AT2%2520receptor%25E2%2580%2593mediated%2520natriuresis%2520in%2520rats%26jtitle%3DHypertension%26date%3D2008%26volume%3D51%26spage%3D460%26epage%3D465%26doi%3D10.1161%2FHYPERTENSIONAHA.107.103242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donoghue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baronas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godbout, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosselin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagliano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaseelan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitbart, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, S.</span></span> <span> </span><span class="NLM_article-title">A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">e1</span>– <span class="NLM_lpage">e9</span>, <span class="refDoi"> DOI: 10.1161/01.RES.87.5.e1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.RES.87.5.e1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10969042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2000&pages=e1-e9&author=M.+Donoghueauthor=F.+Hsiehauthor=E.+Baronasauthor=K.+Godboutauthor=M.+Gosselinauthor=N.+Staglianoauthor=M.+Donovanauthor=B.+Woolfauthor=K.+Robisonauthor=R.+Jeyaseelanauthor=R.+E.+Breitbartauthor=S.+Acton&title=A+novel+angiotensin-converting+enzyme-related+carboxypeptidase+%28ACE2%29+converts+angiotensin+I+to+angiotensin+1%E2%80%939&doi=10.1161%2F01.RES.87.5.e1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9</span></div><div class="casAuthors">Donoghue, Mary; Hsieh, Frank; Baronas, Elizabeth; Godbout, Kevin; Gosselin, Michael; Stagliano, Nancy; Donovan, Michael; Woolf, Betty; Robison, Keith; Jeyaseelan, Raju; Breitbart, Roger E.; Acton, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e1-e9</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">ACE2, the first known human homolog of angiotensin-converting enzyme (ACE), was identified from 5' sequencing of a human heart failure ventricle cDNA library.  ACE2 has an apparent signal peptide, a single metalloprotease active site, and a transmembrane domain.  The metalloprotease catalytic domains of ACE2 and ACE are 42% identical, and comparison of the genomic structures indicates that the two genes arose through duplication.  In contrast to the more ubiquitous ACE, ACE2 transcripts are found only in heart, kidney, and testis of 23 human tissues examd.  Immunohistochem. shows ACE2 protein predominantly in the endothelium of coronary and intrarenal vessels and in renal tubular epithelium.  Active ACE2 enzyme is secreted from transfected cells by cleavage N-terminal to the transmembrane domain.  Recombinant ACE2 hydrolyzes the carboxy terminal leucine from angiotensin I to generate angiotensin 1-9, which is converted to smaller angiotensin peptides by ACE in vitro and by cardiomyocytes in culture.  ACE2 can also cleave des-Arg bradykinin and neurotensin but not bradykinin or 15 other vasoactive and hormonal peptides tested.  ACE2 is not inhibited by lisinopril or captopril.  The organ- and cell-specific expression of ACE2 and its unique cleavage of key vasoactive peptides suggest an essential role for ACE2 in the local renin-angiotensin system of the heart and kidney.  The full text of this article is available at http://www.circresaha.org.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd1c3AtR1RlLVg90H21EOLACvtfcHk0lh54MS5dPAc8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslOisr8%253D&md5=094beb0d23cddb94676e14559946a790</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1161%2F01.RES.87.5.e1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.87.5.e1%26sid%3Dliteratum%253Aachs%26aulast%3DDonoghue%26aufirst%3DM.%26aulast%3DHsieh%26aufirst%3DF.%26aulast%3DBaronas%26aufirst%3DE.%26aulast%3DGodbout%26aufirst%3DK.%26aulast%3DGosselin%26aufirst%3DM.%26aulast%3DStagliano%26aufirst%3DN.%26aulast%3DDonovan%26aufirst%3DM.%26aulast%3DWoolf%26aufirst%3DB.%26aulast%3DRobison%26aufirst%3DK.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DBreitbart%26aufirst%3DR.%2BE.%26aulast%3DActon%26aufirst%3DS.%26atitle%3DA%2520novel%2520angiotensin-converting%2520enzyme-related%2520carboxypeptidase%2520%2528ACE2%2529%2520converts%2520angiotensin%2520I%2520to%2520angiotensin%25201%25E2%2580%25939%26jtitle%3DCirc.%2520Res.%26date%3D2000%26volume%3D87%26spage%3De1%26epage%3De9%26doi%3D10.1161%2F01.RES.87.5.e1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanga, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sävmarker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åqvist, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutiérrez-de-Terán, H.</span></span> <span> </span><span class="NLM_article-title">Structural basis of inhibition of human insulin-regulated aminopeptidase (IRAP) by aryl sulfonamides</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">4509</span>– <span class="NLM_lpage">4521</span>, <span class="refDoi"> DOI: 10.1021/acsomega.8b00595</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.8b00595" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFOgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=4509-4521&author=S.+R.+Vangaauthor=J.+S%C3%A4vmarkerauthor=L.+Ngauthor=M.+Larhedauthor=M.+Hallbergauthor=J.+%C3%85qvistauthor=A.+Hallbergauthor=S.+Y.+Chaiauthor=H.+Guti%C3%A9rrez-de-Ter%C3%A1n&title=Structural+basis+of+inhibition+of+human+insulin-regulated+aminopeptidase+%28IRAP%29+by+aryl+sulfonamides&doi=10.1021%2Facsomega.8b00595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides</span></div><div class="casAuthors">Vanga, Sudarsana Reddy; Saevmarker, Jonas; Ng, Leelee; Larhed, Mats; Hallberg, Mathias; Aaqvist, Johan; Hallberg, Anders; Chai, Siew Yeen; Gutierrez-de-Teran, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">4509-4521</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The insulin-regulated aminopeptidase (IRAP) is a membrane-bound zinc metallopeptidase with many important regulatory functions.  It has been demonstrated that inhibition of IRAP by angiotensin IV (Ang IV) and other peptides, as well as more druglike inhibitors, improves cognition in several rodent models.  The authors recently reported a series of aryl sulfonamides as small-mol. IRAP inhibitors and a promising scaffold for pharmacol. intervention.  The authors have now expanded with a no. of derivs., report their stability in liver microsomes, and characterize the activity of the whole series in a new assay performed on recombinant human IRAP.  Several compds., such as the new fluorinated deriv. I, present submicromolar affinity and high metabolic stability.  Starting from the two binding modes previously proposed for the sulfonamide scaffold, the authors systematically performed mol. dynamics simulations and binding affinity estn. with the linear interaction energy method for the full compd. series.  The significant agreement with exptl. affinities suggests one of the binding modes, which was further confirmed by the excellent correlation for binding affinity differences between the selected pair of compds. obtained by rigorous free energy perturbation calcns.  The new exptl. data and the computationally derived structure-activity relationship of the sulfonamide series provide valuable information for further lead optimization of novel IRAP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmyxsMeum5hLVg90H21EOLACvtfcHk0lhI7XNOOEzWUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFOgsrY%253D&md5=6efee8267a1ed6f5a7f535a5beeb8dad</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsomega.8b00595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.8b00595%26sid%3Dliteratum%253Aachs%26aulast%3DVanga%26aufirst%3DS.%2BR.%26aulast%3DS%25C3%25A4vmarker%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DL.%26aulast%3DLarhed%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3D%25C3%2585qvist%26aufirst%3DJ.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DChai%26aufirst%3DS.%2BY.%26aulast%3DGuti%25C3%25A9rrez-de-Ter%25C3%25A1n%26aufirst%3DH.%26atitle%3DStructural%2520basis%2520of%2520inhibition%2520of%2520human%2520insulin-regulated%2520aminopeptidase%2520%2528IRAP%2529%2520by%2520aryl%2520sulfonamides%26jtitle%3DACS%2520Omega%26date%3D2018%26volume%3D3%26spage%3D4509%26epage%3D4521%26doi%3D10.1021%2Facsomega.8b00595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keidar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamliel-Lazarovich, A.</span></span> <span> </span><span class="NLM_article-title">ACE2 of the heart: from angiotensin I to angiotensin (1–7)</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/j.cardiores.2006.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.cardiores.2006.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=17049503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=463-469&author=S.+Keidarauthor=M.+Kaplanauthor=A.+Gamliel-Lazarovich&title=ACE2+of+the+heart%3A+from+angiotensin+I+to+angiotensin+%281%E2%80%937%29&doi=10.1016%2Fj.cardiores.2006.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">ACE2 of the heart: From angiotensin I to angiotensin (1-7)</span></div><div class="casAuthors">Keidar, Shlomo; Kaplan, Marielle; Gamliel-Lazarovich, Aviva</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Angiotensin II (Ang II), a bioactive peptide of the renin-angiotensin system (RAAS), plays an important role in the development of cardiovascular diseases (CVD).  Pharmacol. inhibition of angiotensin-converting enzyme (ACE), the Ang II forming enzyme, or specific blockade of Ang II binding to angiotensin type 1 receptor (AT1R) through which it exerts its deleterious effects, were shown to provide some protection against progression of CVD.  The ACE-Ang II-AT1R axis has been challenged over the last few years with RAAS components able to counterbalance the effects of the main axis.  The ACE homolog ACE2 efficiently hydrolyzes Ang II to form Ang (1-7), a peptide that exerts actions opposite to those of Ang II.  In contrast to the Ang II axis, the role of the ACE2-Ang (1-7) axis in cardiac function is largely obscure.  Ang (1-7) is present in the viable myocardium, and its formation depends on Ang II as a substrate.  The expression of this peptide is assocd. with cardiac remodeling: it is lost in the infarcted area and significantly increased in the border area.  Low doses of Ang (1-7) improve cardiac output and antagonize Ang II-induced vasoconstriction.  The type of Ang (1-7) biol. activity is tissue specific and dose dependent.  These findings point to a possible protective role for Ang (1-7) in abating the Ang II-induced actions.  The elevated expression of Ang (1-7) in failing heart tissue paralleled the expression of its forming enzyme, ACE2.  Several observations and exptl. evidence suggest a beneficial role for ACE2 in cardiovascular function.  Elevated ACE2 expression at the initial stage of several pathologies which decline with progression of disease might indicate a protective role for ACE2.  Genetic manipulation of ACE2 expression, either targeted disruption or overexpression, point to the possible significance of this enzyme in cardiac function.  Based on the above, a therapeutic approach that will amplify the ACE2-Ang (1-7) axis could provide further protection against the development of CVD.  It turns out that the merits of currently used drugs - ACE inhibitors, AT1R blockers and mineralocorticoid receptor blockers (MRB) - lay beyond their direct effects on suppression of the ACE-Ang II-AT1R axis as they also increase cardiac ACE2 and Ang (1-7) significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJej3xhxIFg7Vg90H21EOLACvtfcHk0lhI7XNOOEzWUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVSqsg%253D%253D&md5=a24c864385617f5ebb6c284936a98820</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2006.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2006.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DKeidar%26aufirst%3DS.%26aulast%3DKaplan%26aufirst%3DM.%26aulast%3DGamliel-Lazarovich%26aufirst%3DA.%26atitle%3DACE2%2520of%2520the%2520heart%253A%2520from%2520angiotensin%2520I%2520to%2520angiotensin%2520%25281%25E2%2580%25937%2529%26jtitle%3DCardiovasc.%2520Res.%26date%3D2007%26volume%3D73%26spage%3D463%26epage%3D469%26doi%3D10.1016%2Fj.cardiores.2006.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burghi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echeverría, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiroga, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monczor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominici, F. P.</span></span> <span> </span><span class="NLM_article-title">Participation of Gα<sub>i</sub>-adenylate cyclase and ERK1/2 in Mas receptor signaling pathways</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">146</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffphar.2019.00146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30853914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlagtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=146&author=V.+Burghiauthor=E.+B.+Echeverr%C3%ADaauthor=M.+H.+Sosaauthor=D.+T.+Quirogaauthor=M.+C.+Mu%C3%B1ozauthor=C.+Davioauthor=F.+Monczorauthor=N.+C.+Fern%C3%A1ndezauthor=F.+P.+Dominici&title=Participation+of+G%CE%B1i-adenylate+cyclase+and+ERK1%2F2+in+Mas+receptor+signaling+pathways&doi=10.3389%2Ffphar.2019.00146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Participation of Gαi-adenylate cyclase and ERK1/2 in mas receptor signaling pathways</span></div><div class="casAuthors">Burghi, Valeria; Echeverria, Emiliana B.; Sosa, Maximo H.; Quiroga, Diego T.; Munoz, Marina C.; Davio, Carlos; Monczor, Federico; Fernandez†, Natalia C.; Dominici, Fernando P.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">146</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The MasR receptor (MasR) is an orphan G protein-coupled receptor proposed as a candidate for mediating the angiotensin (Ang)-converting enzyme 2-Ang-(1-7) protective axis of renin-angiotensin system.  This receptor has been suggested to participate in several physiol. processes including cardio- and reno-protection and regulation of the central nervous system function.  Although the knowledge of the signaling mechanisms assocd. with MasR is essential for therapeutic purposes, these are still poorly understood.  Accordingly, in the current study we aimed to characterize the signaling pathways triggered by the MasR.  To do that, we measured cAMP and Ca2+ levels in both na.ovrddot.ive and MasR transfected cells in basal conditions and upon incubation with putative MasR ligands.  Besides, we evaluated activation of ERK1/2 by Ang-(1-7) in MasR transfected cells.  Results indicated the existence of a high degree of MasR constitutive activity toward cAMP modulation.  This effect was not mediated by the PDZ-binding motif of the MasR but by receptor coupling to Gαi-adenylyl cyclase signaling pathway.  Incubation of MasR transfected cells with Ang-(1-7) or the synthetic ligand AVE 0991 amplified MasR neg. modulation of cAMP levels.  On the other hand, we provided evidence for lack of MasR-assocd. modulation of Ca2+ levels by Ang-(1-7).  Finally, it was detd. that the MasR attenuated Ang-(1-7)-induced ERK1/2 phosphorylation mediated by AT1R.  We provided further characterization of MasR signaling mechanisms regarding its constitutive activity and response to putative ligands.  This information could prove useful to better describe MasR physiol. role and development of therapeutic agents that could modulate its action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQBooqdyJTabVg90H21EOLACvtfcHk0liEqooK0R-pkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlagtrnN&md5=74d3eba4de3a588d5000e2221075dbf2</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00146%26sid%3Dliteratum%253Aachs%26aulast%3DBurghi%26aufirst%3DV.%26aulast%3DEcheverr%25C3%25ADa%26aufirst%3DE.%2BB.%26aulast%3DSosa%26aufirst%3DM.%2BH.%26aulast%3DQuiroga%26aufirst%3DD.%2BT.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%2BC.%26aulast%3DDavio%26aufirst%3DC.%26aulast%3DMonczor%26aufirst%3DF.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DN.%2BC.%26aulast%3DDominici%26aufirst%3DF.%2BP.%26atitle%3DParticipation%2520of%2520G%25CE%25B1i-adenylate%2520cyclase%2520and%2520ERK1%252F2%2520in%2520Mas%2520receptor%2520signaling%2520pathways%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D146%26doi%3D10.3389%2Ffphar.2019.00146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, T.</span></span> <span> </span><span class="NLM_article-title">Dimerization of AT<sub>2</sub> and Mas receptors in control of blood pressure</span>. <i>Curr. Hypertens. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.1007/s11906-018-0845-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs11906-018-0845-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29717388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC1MjovVyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=41&author=S.+Patelauthor=T.+Hussain&title=Dimerization+of+AT2+and+Mas+receptors+in+control+of+blood+pressure&doi=10.1007%2Fs11906-018-0845-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Dimerization of AT2 and Mas Receptors in Control of Blood Pressure</span></div><div class="casAuthors">Patel Sanket; Hussain Tahir</div><div class="citationInfo"><span class="NLM_cas:title">Current hypertension reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Angiotensin type 2 receptor (AT2R) and receptor Mas (MasR) are part of the "protective arm" of the renin angiotensin system.  Gene and pharmacological manipulation studies reveal that AT2R and MasR are involved in natriuretic, vasodilatory, and anti-inflammatory responses and in lowering blood pressure in various animal models under normal and pathological conditions such as salt-sensitive hypertension, obesity, and diabetes.  The scope of this review is to discuss co-localization and heterodimerization as potential molecular mechanisms of AT2R- and MasR-mediated functions including antihypertensive activities.  RECENT FINDINGS:  Accumulating evidences show that AT2R and MasR are co-localized, make a heterodimer, and are functionally interdependent in producing their physiological responses.  Moreover, ang-(1-7) preferably may be an AT1R-biased agonist while acting as a MasR agonist.  The physical interactions of AT2R and MasR appear to be an important mechanism by which these receptors are involved in blood pressure regulation and antihypertensive activity.  Whether heteromers of these receptors influence affinity or efficacy of endogenous or synthetic agonists remains a question to be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKJWY6AT4bBqcY7HFp97qMfW6udTcc2eYHY3YawZyUPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjovVyqtQ%253D%253D&md5=6aee7c9c20816e913a50db999b688d5b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs11906-018-0845-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11906-018-0845-3%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DHussain%26aufirst%3DT.%26atitle%3DDimerization%2520of%2520AT2%2520and%2520Mas%2520receptors%2520in%2520control%2520of%2520blood%2520pressure%26jtitle%3DCurr.%2520Hypertens.%2520Rep.%26date%3D2018%26volume%3D20%26spage%3D41%26doi%3D10.1007%2Fs11906-018-0845-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Ferrer, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heringer-Walther, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gembardt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheiss, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, T.</span></span> <span> </span><span class="NLM_article-title">G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1806</span>– <span class="NLM_lpage">1812</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000160867.23556.7D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.CIR.0000160867.23556.7D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=15809376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFelur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2005&pages=1806-1812&author=E.+Kostenisauthor=G.+Milliganauthor=A.+Christopoulosauthor=C.+F.+Sanchez-Ferrerauthor=S.+Heringer-Waltherauthor=P.+M.+Sextonauthor=F.+Gembardtauthor=E.+Kellettauthor=L.+Martiniauthor=P.+Vanderheydenauthor=H.+P.+Schultheissauthor=T.+Walther&title=G-protein-coupled+receptor+Mas+is+a+physiological+antagonist+of+the+angiotensin+II+type+1+receptor&doi=10.1161%2F01.CIR.0000160867.23556.7D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">G-Protein-Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor</span></div><div class="casAuthors">Kostenis, Evi; Milligan, Graeme; Christopoulos, Arthur; Sanchez-Ferrer, Carlos F.; Heringer-Walther, Silvia; Sexton, Patrick M.; Gembardt, Florian; Kellett, Elaine; Martini, Lene; Vanderheyden, Patrick; Schultheiss, Heinz-Peter; Walther, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1806-1813</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background- We previously identified the G-protein-coupled receptor Mas, encoded by the Mas proto-oncogene, as an endogenous receptor for the heptapeptide angiotensin-(1-7); however, the receptor is also suggested to be involved in actions of angiotensin II.  We therefore tested whether this could be mediated indirectly through an interaction with the angiotensin II type 1 receptor, AT1.  Methods and Results- In transfected mammalian cells, Mas was not activated by angiotensin II; however, AT1 receptor-mediated, angiotensin II-induced prodn. of inositol phosphates and mobilization of intracellular Ca2+ was diminished by 50% after coexpression of Mas, despite a concomitant increase in angiotensin II binding capacity.  Mas and the AT1 receptor formed a constitutive hetero-oligomeric complex that was unaffected by the presence of agonists or antagonists of the 2 receptors.  In vivo, Mas acts as an antagonist of the AT1 receptor; mice lacking the Mas gene show enhanced angiotensin II-mediated vasoconstriction in mesenteric microvessels.  Conclusions- These results demonstrate that Mas can hetero-oligomerize with the AT1 receptor and by so doing inhibit the actions of angiotensin II.  This is a novel demonstration that a G-protein-coupled receptor acts as a physiol. antagonist of a previously characterized receptor.  Consequently, the AT1-Mas complex could be of great importance as a target for pharmacol. intervention in cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhYEOYRiMOrrVg90H21EOLACvtfcHk0liEqooK0R-pkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFelur4%253D&md5=bede82574eb0570dd9127280e2d1cdcd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000160867.23556.7D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000160867.23556.7D%26sid%3Dliteratum%253Aachs%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DMilligan%26aufirst%3DG.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSanchez-Ferrer%26aufirst%3DC.%2BF.%26aulast%3DHeringer-Walther%26aufirst%3DS.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DGembardt%26aufirst%3DF.%26aulast%3DKellett%26aufirst%3DE.%26aulast%3DMartini%26aufirst%3DL.%26aulast%3DVanderheyden%26aufirst%3DP.%26aulast%3DSchultheiss%26aufirst%3DH.%2BP.%26aulast%3DWalther%26aufirst%3DT.%26atitle%3DG-protein-coupled%2520receptor%2520Mas%2520is%2520a%2520physiological%2520antagonist%2520of%2520the%2520angiotensin%2520II%2520type%25201%2520receptor%26jtitle%3DCirculation%26date%3D2005%26volume%3D111%26spage%3D1806%26epage%3D1812%26doi%3D10.1161%2F01.CIR.0000160867.23556.7D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leonhardt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villela, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teichmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Münter, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namsolleck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alenina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multhaup, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schülein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span> <span> </span><span class="NLM_article-title">Evidence for heterodimerization and functional interaction of the angiotensin type 2 receptor and the receptor MAS</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.116.08814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.116.08814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28461604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlyis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=1128-1135&author=J.+Leonhardtauthor=D.+C.+Villelaauthor=A.+Teichmannauthor=L.+M.+M%C3%BCnterauthor=M.+C.+Mayerauthor=M.+Mardahlauthor=S.+Kirschauthor=P.+Namsolleckauthor=K.+Luchtauthor=V.+Benzauthor=N.+Aleninaauthor=N.+Daniellauthor=M.+Horiuchiauthor=M.+Iwaiauthor=G.+Multhaupauthor=R.+Sch%C3%BCleinauthor=M.+Baderauthor=R.+A.+Santosauthor=T.+Ungerauthor=U.+M.+Steckelings&title=Evidence+for+heterodimerization+and+functional+interaction+of+the+angiotensin+type+2+receptor+and+the+receptor+MAS&doi=10.1161%2FHYPERTENSIONAHA.116.08814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for Heterodimerization and Functional Interaction of the Angiotensin Type 2 Receptor and the Receptor MAS</span></div><div class="casAuthors">Leonhardt, Julia; Villela, Daniel C.; Teichmann, Anke; Muenter, Lisa-Marie; Mayer, Magnus C.; Mardahl, Maibritt; Kirsch, Sebastian; Namsolleck, Pawel; Lucht, Kristin; Benz, Verena; Alenina, Natalia; Daniell, Nicholas; Horiuchi, Masatsugu; Iwai, Masaru; Multhaup, Gerhard; Schuelein, Ralf; Bader, Michael; Santos, Robson A.; Unger, Thomas; Steckelings, Ulrike Muscha</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1128-1135</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The angiotensin type 2 receptor (AT2R) and the receptor MAS are receptors of the protective arm of the renin-angiotensin system.  They mediate strikingly similar actions.  Moreover, in various studies, AT2R antagonists blocked the effects of MAS agonists and vice versa.  Such cross-inhibition may indicate heterodimerization of these receptors.  Therefore, this study investigated the mol. and functional interplay between MAS and the AT2R.  Mol. interactions were assessed by fluorescence resonance energy transfer and by cross correlation spectroscopy in human embryonic kidney-293 cells transfected with vectors encoding fluorophore-tagged MAS or AT2R.  Functional interaction of AT2R and MAS was studied in astrocytes with CX3C chemokine receptor-1 mRNA expression as readout.  Coexpression of fluorophore-tagged AT2R and MAS resulted in a fluorescence resonance energy transfer efficiency of 10.8 ± 0.8%, indicating that AT2R and MAS are capable to form heterodimers.  Heterodimerization was verified by competition expts. using untagged AT2R and MAS.  Specificity of dimerization of AT2R and MAS was supported by lack of dimerization with the transient receptor potential cation channel, subfamily C-member 6.  Dimerization of the AT2R was abolished when it was mutated at cysteine residue 35.  AT2R and MAS stimulation with the resp. agonists, Compd. 21 or angiotensin-(1-7), significantly induced CX3C chemokine receptor-1 mRNA expression.  Effects of each agonist were blocked by an AT2R antagonist (PD123319) and also by a MAS antagonist (A-779).  Knockout of a single of these receptors made astrocytes unresponsive for both agonists.  Our results suggest that MAS and the AT2R form heterodimers and that-at least in astrocytes-both receptors functionally depend on each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokeH4MMXUihbVg90H21EOLACvtfcHk0liQ829r5ikCoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlyis7Y%253D&md5=699eafec991f0245f80c741b6736a62a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.116.08814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.116.08814%26sid%3Dliteratum%253Aachs%26aulast%3DLeonhardt%26aufirst%3DJ.%26aulast%3DVillela%26aufirst%3DD.%2BC.%26aulast%3DTeichmann%26aufirst%3DA.%26aulast%3DM%25C3%25BCnter%26aufirst%3DL.%2BM.%26aulast%3DMayer%26aufirst%3DM.%2BC.%26aulast%3DMardahl%26aufirst%3DM.%26aulast%3DKirsch%26aufirst%3DS.%26aulast%3DNamsolleck%26aufirst%3DP.%26aulast%3DLucht%26aufirst%3DK.%26aulast%3DBenz%26aufirst%3DV.%26aulast%3DAlenina%26aufirst%3DN.%26aulast%3DDaniell%26aufirst%3DN.%26aulast%3DHoriuchi%26aufirst%3DM.%26aulast%3DIwai%26aufirst%3DM.%26aulast%3DMulthaup%26aufirst%3DG.%26aulast%3DSch%25C3%25BClein%26aufirst%3DR.%26aulast%3DBader%26aufirst%3DM.%26aulast%3DSantos%26aufirst%3DR.%2BA.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26atitle%3DEvidence%2520for%2520heterodimerization%2520and%2520functional%2520interaction%2520of%2520the%2520angiotensin%2520type%25202%2520receptor%2520and%2520the%2520receptor%2520MAS%26jtitle%3DHypertension%26date%3D2017%26volume%3D69%26spage%3D1128%26epage%3D1135%26doi%3D10.1161%2FHYPERTENSIONAHA.116.08814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anand, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yiangou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korchev, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons</span>. <i>Eur. J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1026</span>, <span class="refDoi"> DOI: 10.1002/j.1532-2149.2012.00269.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fj.1532-2149.2012.00269.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23255326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKhsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1012-1026&author=U.+Anandauthor=P.+Facerauthor=Y.+Yiangouauthor=M.+Sinisiauthor=M.+Foxauthor=T.+McCarthyauthor=C.+Bountraauthor=Y.+E.+Korchevauthor=P.+Anand&title=Angiotensin+II+type+2+receptor+%28AT2+R%29+localization+and+antagonist-mediated+inhibition+of+capsaicin+responses+and+neurite+outgrowth+in+human+and+rat+sensory+neurons&doi=10.1002%2Fj.1532-2149.2012.00269.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons</span></div><div class="casAuthors">Anand, U.; Facer, P.; Yiangou, Y.; Sinisi, M.; Fox, M.; McCarthy, T.; Bountra, C.; Korchev, Y. E.; Anand, P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pain (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1012-1026</span>CODEN:
                <span class="NLM_cas:coden">EJPAFJ</span>;
        ISSN:<span class="NLM_cas:issn">1090-3801</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : The angiotensin II (AngII) receptor subtype 2 (AT2R) is expressed in sensory neurons and may play a role in nociception and neuronal regeneration.  Methods : We used immunostaining with characterized antibodies to study the localization of AT2R in cultured human and rat dorsal root ganglion (DRG) neurons and a range of human tissues.  The effects of AngII and AT2R antagonist EMA401 on capsaicin responses in cultured human and rat (DRG) neurons were measured with calcium imaging, on neurite length and d. with Gap43 immunostaining, and on cyclic adenosine monophosphate (cAMP) expression using immunofluorescence.  Results : AT2R expression was localized in small-/medium-sized cultured neurons of human and rat DRG.  Treatment with the AT2R antagonist EMA401 resulted in dose-related functional inhibition of capsaicin responses (IC50=10nmol/L), which was reversed by 8-bromo-cAMP, and reduced neurite length and d.; AngII treatment significantly enhanced capsaicin responses, cAMP levels and neurite outgrowth.  The AT1R antagonist losartan had no effect on capsaicin responses.  AT2R was localized in sensory neurons of human DRG, and nerve fibers in peripheral nerves, skin, urinary bladder and bowel.  A majority sub-population (60%) of small-/medium-diam. neuronal cells were immunopos. in both control post-mortem and avulsion-injured human DRG; some very small neurons appeared to be intensely immunoreactive, with TRPV1 co-localization.  While AT2R levels were reduced in human limb peripheral nerve segments proximal to injury, they were preserved in painful neuromas.  Conclusions : AT2R antagonists could be particularly useful in the treatment of chronic pain and hypersensitivity assocd. with abnormal nerve sprouting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXE7j5pUExILVg90H21EOLACvtfcHk0liQ829r5ikCoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKhsrnF&md5=9550c73afcb055fb9144251b1f7d1872</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fj.1532-2149.2012.00269.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1532-2149.2012.00269.x%26sid%3Dliteratum%253Aachs%26aulast%3DAnand%26aufirst%3DU.%26aulast%3DFacer%26aufirst%3DP.%26aulast%3DYiangou%26aufirst%3DY.%26aulast%3DSinisi%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DM.%26aulast%3DMcCarthy%26aufirst%3DT.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DKorchev%26aufirst%3DY.%2BE.%26aulast%3DAnand%26aufirst%3DP.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor%2520%2528AT2%2520R%2529%2520localization%2520and%2520antagonist-mediated%2520inhibition%2520of%2520capsaicin%2520responses%2520and%2520neurite%2520outgrowth%2520in%2520human%2520and%2520rat%2520sensory%2520neurons%26jtitle%3DEur.%2520J.%2520Pain%26date%3D2013%26volume%3D17%26spage%3D1012%26epage%3D1026%26doi%3D10.1002%2Fj.1532-2149.2012.00269.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Gasparo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catt, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">International union of pharmacology. XXIII. The angiotensin II receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10977869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2000&pages=415-472&author=M.+de%0AGasparoauthor=K.+J.+Cattauthor=T.+Inagamiauthor=J.+W.+Wrightauthor=T.+Unger&title=International+union+of+pharmacology.+XXIII.+The+angiotensin+II+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">International union of pharmacology. XXIII. The angiotensin II receptors</span></div><div class="casAuthors">De Gasparo, M.; Catt, K. J.; Inagami, T.; Wright, J. W.; Unger, Th.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">415-472</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review with 741 refs.  The cardiovascular and other actions of angiotensin II (Ang II) are mediated by AT1 and AT2 receptors, which are seven transmembrane glycoproteins with 30% sequence similarity.  Most species express a single autosomal AT1 gene, but two related AT1A and AT1B receptor genes are expressed in rodents.  AT1 receptors are predominantly coupled to Gq/11, and signal through phospholipases A, C, D, inositol phosphates, calcium channels, and a variety of serine/threonine and tyrosine kinases.  Many AT1-induced growth responses are mediated by transactivation of growth factor receptors.  The receptor binding sites for agonist and nonpeptide antagonist ligands have been defined.  The latter compds. are as effective as angiotensin converting enzyme inhibitors in cardiovascular diseases but are better tolerated.  The AT2 receptor is expressed at high d. during fetal development.  It is much less abundant in adult tissues and is up-regulated in pathol. conditions.  Its signaling pathways include serine and tyrosine phosphatases, phospholipase A2, nitric oxide, and cyclic guanosine monophosphate.  The AT2 receptor counteracts several of the growth responses initiated by the AT1 and growth factor receptors.  The AT4 receptor specifically binds Ang IV (Ang 3-8), and is located in brain and kidney.  Its signaling mechanisms are unknown, but it influences local blood flow and is assocd. with cognitive processes and sensory and motor functions.  Although AT1 receptors mediate most of the known actions of Ang II, the AT2 receptor contributes to the regulation of blood pressure and renal function.  The development of specific nonpeptide receptor antagonists has led to major advances in the physiol., pharmacol., and therapy of the renin-angiotensin system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSSYESfE8nPrVg90H21EOLACvtfcHk0liQ829r5ikCoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbk%253D&md5=6abc5466d51de53202ecf1fd9ba3c186</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BGasparo%26aufirst%3DM.%26aulast%3DCatt%26aufirst%3DK.%2BJ.%26aulast%3DInagami%26aufirst%3DT.%26aulast%3DWright%26aufirst%3DJ.%2BW.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DInternational%2520union%2520of%2520pharmacology.%2520XXIII.%2520The%2520angiotensin%2520II%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2000%26volume%3D52%26spage%3D415%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirupula, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, P.</span></span> <span> </span><span class="NLM_article-title">International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1124/pr.114.010454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1124%2Fpr.114.010454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26315714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWhsr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=754-819&author=S.+S.+Karnikauthor=H.+Unalauthor=J.+R.+Kempauthor=K.+C.+Tirupulaauthor=W.+Thomasauthor=S.+Eguchiauthor=P.+Vanderheyden&title=International+Union+of+Basic+and+Clinical+Pharmacology.+XCIX.+Angiotensin+receptors%3A+interpreters+of+pathophysiological+angiotensinergic+stimuli&doi=10.1124%2Fpr.114.010454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">International union of basic and clinical pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli</span></div><div class="casAuthors">Karnik, Sadashiva S.; Unal, Hamiyet; Kemp, Jacqueline R.; Tirupula, Kalyan C.; Eguchi, Satoru; Vanderheyden, Patrick M. L.; Thomas, Walter G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">754-820</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The renin angiotensin system (RAS) produced hormone peptides regulate many vital body functions.  Dysfunctional signaling by receptors for RAS peptides leads to pathol. states.  Nearly half of humanity today would likely benefit from modern drugs targeting these receptors.  The receptors for RAS peptides consist of three G-protein-coupled receptors- the angiotensin II type 1 receptor (AT1 receptor), the angiotensin II type 2 receptor (AT2 receptor), the MAS receptor-and a type II trans-membrane zinc protein- the candidate angiotensin IV receptor (AngIV binding site).  The prorenin receptor is a relatively new contender for consideration, but is not included here because the role of prorenin receptor as an independent endocrine mediator is presently unclear.  The full spectrum of biol. characteristics of these receptors is still evolving, but there is evidence establishing unique roles of each receptor in cardiovascular, hemodynamic, neurol., renal, and endothelial functions, as well as in cell proliferation, survival,matrix-cell interaction, and inflammation.  Therapeutic agents targeted to these receptors are either in active use in clin. intervention of major common diseases or under evaluation for repurposing in many other disorders.  Broad-spectrum influence these receptors produce in complex pathophysiol. context in our body highlights their role as precise interpreters of distinctive angiotensinergic peptide cues.  This review article summarizes findings published in the last 15 years on the structure, pharmacol., signaling, physiol., and disease states related to angiotensin receptors.  We also discuss the challenges the pharmacologist presently faces in formally accepting newer members as established angiotensin receptors and emphasize necessary future developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhBn_d6p-zR7Vg90H21EOLACvtfcHk0ljks-PYYXXklw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWhsr%252FI&md5=0ec13e7282e81d8fb02cdc505592fbc0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.010454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.010454%26sid%3Dliteratum%253Aachs%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26aulast%3DUnal%26aufirst%3DH.%26aulast%3DKemp%26aufirst%3DJ.%2BR.%26aulast%3DTirupula%26aufirst%3DK.%2BC.%26aulast%3DThomas%26aufirst%3DW.%26aulast%3DEguchi%26aufirst%3DS.%26aulast%3DVanderheyden%26aufirst%3DP.%26atitle%3DInternational%2520Union%2520of%2520Basic%2520and%2520Clinical%2520Pharmacology.%2520XCIX.%2520Angiotensin%2520receptors%253A%2520interpreters%2520of%2520pathophysiological%2520angiotensinergic%2520stimuli%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D754%26epage%3D819%26doi%3D10.1124%2Fpr.114.010454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhanachandra
Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span> <span> </span><span class="NLM_article-title">Angiotensin receptors: structure, function, signaling and clinical applications</span>. <i>J. Cell Signal.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.4172/2576-1471.1000111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.4172%2F2576-1471.1000111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=111&author=K.+Dhanachandra%0ASinghauthor=S.+S.+Karnik&title=Angiotensin+receptors%3A+structure%2C+function%2C+signaling+and+clinical+applications&doi=10.4172%2F2576-1471.1000111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4172%2F2576-1471.1000111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2576-1471.1000111%26sid%3Dliteratum%253Aachs%26aulast%3DDhanachandra%2BSingh%26aufirst%3DK.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26atitle%3DAngiotensin%2520receptors%253A%2520structure%252C%2520function%252C%2520signaling%2520and%2520clinical%2520applications%26jtitle%3DJ.%2520Cell%2520Signal.%26date%3D2017%26volume%3D1%26spage%3D111%26doi%3D10.4172%2F2576-1471.1000111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vinturache, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, F. G.</span></span> <span> </span><span class="NLM_article-title">Renal effects of angiotensin II in the newborn period: role of type 1 and type 2 receptors</span>. <i>BMC Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/s12899-016-0022-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1186%2Fs12899-016-0022-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=27090941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtV2rsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=3&author=A.+E.+Vinturacheauthor=F.+G.+Smith&title=Renal+effects+of+angiotensin+II+in+the+newborn+period%3A+role+of+type+1+and+type+2+receptors&doi=10.1186%2Fs12899-016-0022-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Renal effects of angiotensin II in the newborn period: role of type 1 and type 2 receptors</span></div><div class="casAuthors">Vinturache, Angela E.; Smith, Francine G.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Physiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3/1-3/10</span>CODEN:
                <span class="NLM_cas:coden">BPMHCV</span>;
        ISSN:<span class="NLM_cas:issn">1472-6793</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Evidence suggests a crit. role for the renin-angiotensin system in regulating renal function during postnatal development.  Methods: The renal effects of the selective antagonist to AT1R, ZD 7155 and to AT2R, PD 1233319 were evaluated in two groups of conscious chronically instrumented lambs aged ∼ one week (N = 8) and ∼ six weeks (N = 10).  Two expts. were carried out in each animal and consisted of the assessment of renal variables including glomerular and tubular function, for 30 min before (Control) and 60 min after infusion of ZD 7155 and PD 123319, resp.  Results: ZD 7155 infusion was assocd. with a significant decrease in glomerular filtration rate and filtration fraction at one but not six weeks; urinary flow rate decreased significantly in older animals, whereas sodium excretion and free water clearance were not altered.  There was an age-dependent effect on potassium handling along the nephron, potassium excretion decreasing after ZD 7155 infusion in younger but not in older lambs.  PD 123319 had no significant effects on glomerular filtration rate and tubular function in either age group.  Conclusions: These results provide evidence to support an important role for AT1Rs in mediating the renal effects of angiotensin II during postnatal maturation in conscious developing animals.  In contrast to a role for AT2Rs later in life, there appears to be no role for AT2Rs in influencing the renal effects of Angiotensin II in the postnatal period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq82BkTygQ1n7Vg90H21EOLACvtfcHk0ljks-PYYXXklw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtV2rsbk%253D&md5=2e395b6d6e43ee6075315b938af34c50</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1186%2Fs12899-016-0022-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12899-016-0022-3%26sid%3Dliteratum%253Aachs%26aulast%3DVinturache%26aufirst%3DA.%2BE.%26aulast%3DSmith%26aufirst%3DF.%2BG.%26atitle%3DRenal%2520effects%2520of%2520angiotensin%2520II%2520in%2520the%2520newborn%2520period%253A%2520role%2520of%2520type%25201%2520and%2520type%25202%2520receptors%26jtitle%3DBMC%2520Physiol.%26date%3D2016%26volume%3D16%26spage%3D3%26doi%3D10.1186%2Fs12899-016-0022-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span> <span> </span><span class="NLM_article-title">Developmental expression patterns for angiotensin receptors in mouse skin and brain</span>. <i>JRAAS</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1177/1470320312467557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1177%2F1470320312467557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=139-149&author=L.+Yuauthor=C.+Shaoauthor=L.+Gao&title=Developmental+expression+patterns+for+angiotensin+receptors+in+mouse+skin+and+brain&doi=10.1177%2F1470320312467557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Developmental expression patterns for angiotensin receptors in mouse skin and brain</span></div><div class="casAuthors">Yu, Li; Shao, Chunhong; Gao, Lie</div><div class="citationInfo"><span class="NLM_cas:title">JRAAS</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-149, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JRAAAG</span>;
        ISSN:<span class="NLM_cas:issn">1470-3203</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Two G-protein-coupled receptors, angiotensin type 1 receptor (AT1R) and type 2 receptor (AT2R), mediate the majority of angiotensin II (Ang II) effects.  It has long been believed that the AT2R is reduced to extremely low levels in adulthood but is abundantly expressed in the fetus.  However, recent data from rats and mice do not support this notion.  Employing Western blot anal., we found a gradual increase in AT2R protein expression from fetal life to adulthood in brain, heart, lung, liver, and kidney.  The reason for the discrepancy between our observations and the conventional concept is unknown.  Evidence supporting a regression of the AT2R during maturation is derived largely from autoradiog. signals that were confined to the outline of fetal rats, implying that the previously reported high AT2R expression in the fetus might be valid only for skin.  We therefore hypothesized that the ontogeny of angiotensin receptors in skin is opposite that in other organs.  In the current expt., we employed Western blot anal. to compare AT2R and AT1R protein expressions in skin with that in the brainstem of fetal and adult mice.  Fetal brainstem expressed lower AT2R and higher AT1R protein compared to adult brainstem (AT2R/GAPDH: 0.08 ± 0.2 in fetus vs 7.6 ± 0.9 in adult, p < 0.05; AT1R/GAPDH: 5.9 ± 0.8 in fetus vs 0.7 ± 0.3 in adult, p < 0.05).  In contrast, fetal skin expresses higher AT2R and lower AT1R protein compared to adult skin (AT2R/GAPDH: 0.95 ± 0.4 in fetus vs 0.04 ± 0.2 in adult, p < 0.05; AT1R/GAPDH: 0.6 ± 0.2 in fetus vs 2.1 ± 0.5 in adult, p < 0.05).  This expression profile was also confirmed by immunofluorescence.  Using real-time RT-PCR, we could not detect any significant differences in mRNA of these two receptors in brainstem between fetal and adult mice.  However, we found a higher AT2R mRNA and lower AT1R mRNA in the fetal skin compared to adult skin.  The above results confirm our hypothesis that skin displays an expression profile of angiotensin receptors opposite that of other organs during development, suggesting that the currently held view concerning AT2R maturation is suitable only for skin.  In other organs and tissues, adults express higher AT2R protein than does the fetus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP8lMRg1Fgx7Vg90H21EOLACvtfcHk0ljks-PYYXXklw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWgu77F&md5=331eee1b6fe64ee8bf447b7036993db4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1177%2F1470320312467557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1470320312467557%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DL.%26aulast%3DShao%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DL.%26atitle%3DDevelopmental%2520expression%2520patterns%2520for%2520angiotensin%2520receptors%2520in%2520mouse%2520skin%2520and%2520brain%26jtitle%3DJRAAS%26date%3D2014%26volume%3D15%26spage%3D139%26epage%3D149%26doi%3D10.1177%2F1470320312467557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quitterer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AbdAlla, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of pathologic GPCR aggregation</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">9</span>, <span class="refDoi"> DOI: 10.3389/fmed.2019.00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffmed.2019.00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BB3cfjtFynsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=9&author=U.+Quittererauthor=S.+AbdAlla&title=Discovery+of+pathologic+GPCR+aggregation&doi=10.3389%2Ffmed.2019.00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pathologic GPCR Aggregation</span></div><div class="casAuthors">Quitterer Ursula; AbdAlla Said; Quitterer Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9</span>
        ISSN:<span class="NLM_cas:issn">2296-858X</span>.
    </div><div class="casAbstract">The family of G-protein-coupled receptors (GPCRs) is one of the most important drug targets.  Mechanisms underlying GPCR activation and signaling are therefore of great pharmacologic interest.  It was long thought that GPCRs exist and function as monomers.  This feature was considered to distinguish GPCRs from other membrane receptors such as receptor tyrosine kinases or cytokine receptors, which signal from dimeric receptor complexes.  But during the last two decades it was increasingly recognized that GPCRs can undergo aggregation to form dimers and higher order oligomers, resulting in homomeric and/or heteromeric protein complexes with different stoichiometries.  Moreover, this protein complex formation could modify GPCR signaling and function.  We contributed to this paradigm shift in GPCR pharmacology by the discovery of the first pathologic GPCR aggregation, which is the protein complex formation between the angiotensin II AT1 receptor and the bradykinin B2 receptor.  Increased AT1-B2 heteromerization accounts for the angiotensin II hypersensitivity of pregnant women with preeclampsia hypertension.  Since the discovery of AT1-B2, other pathologic GPCR aggregates were found, which contribute to atherosclerosis, neurodegeneration and Alzheimer's disease.  As a result of our findings, pathologic GPCR aggregation appears as an independent and disease-specific process, which is increasingly considered as a novel target for pharmacologic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-TR1YbDmoryA3UY9EwTNrfW6udTcc2eYoYF4WH_SU3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfjtFynsA%253D%253D&md5=7bc88e11ff82a30b54e9e55e33607374</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2019.00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2019.00009%26sid%3Dliteratum%253Aachs%26aulast%3DQuitterer%26aufirst%3DU.%26aulast%3DAbdAlla%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520pathologic%2520GPCR%2520aggregation%26jtitle%3DFront.%2520Med.%26date%3D2019%26volume%3D6%26spage%3D9%26doi%3D10.3389%2Ffmed.2019.00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zatsepin, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weierstall, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawaya, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messerschmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yefanov, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirupula, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnoyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span> <span> </span><span class="NLM_article-title">Structure of the angiotensin receptor revealed by serial femtosecond crystallography</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">833</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2015.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.cell.2015.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25913193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFKjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2015&pages=833-844&author=H.+Zhangauthor=H.+Unalauthor=C.+Gatiauthor=G.+W.+Hanauthor=W.+Liuauthor=N.+A.+Zatsepinauthor=D.+Jamesauthor=D.+Wangauthor=G.+Nelsonauthor=U.+Weierstallauthor=M.+R.+Sawayaauthor=Q.+Xuauthor=M.+Messerschmidtauthor=G.+J.+Williamsauthor=S.+Boutetauthor=O.+M.+Yefanovauthor=T.+A.+Whiteauthor=C.+Wangauthor=A.+Ishchenkoauthor=K.+C.+Tirupulaauthor=R.+Desnoyerauthor=J.+Coeauthor=C.+Conradauthor=P.+Frommeauthor=R.+C.+Stevensauthor=V.+Katritchauthor=S.+S.+Karnikauthor=V.+Cherezov&title=Structure+of+the+angiotensin+receptor+revealed+by+serial+femtosecond+crystallography&doi=10.1016%2Fj.cell.2015.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography</span></div><div class="casAuthors">Zhang, Haitao; Unal, Hamiyet; Gati, Cornelius; Han, Gye Won; Liu, Wei; Zatsepin, Nadia A.; James, Daniel; Wang, Dingjie; Nelson, Garrett; Weierstall, Uwe; Sawaya, Michael R.; Xu, Qingping; Messerschmidt, Marc; Williams, Garth J.; Boutet, Sebastien; Yefanov, Oleksandr M.; White, Thomas A.; Wang, Chong; Ishchenko, Andrii; Tirupula, Kalyan C.; Desnoyer, Russell; Coe, Jesse; Conrad, Chelsie E.; Fromme, Petra; Stevens, Raymond C.; Katritch, Vsevolod; Karnik, Sadashiva S.; Cherezov, Vadim</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">833-844</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Angiotensin II type 1 receptor (AT1R) is a G protein-coupled receptor that serves as a primary regulator for blood pressure maintenance.  Although several anti-hypertensive drugs have been developed as AT1R blockers (ARBs), the structural basis for AT1R ligand-binding and regulation has remained elusive, mostly due to the difficulties of growing high-quality crystals for structure detn. using synchrotron radiation.  By applying the recently developed method of serial femtosecond crystallog. at an X-ray free-electron laser, we successfully detd. the room-temp. crystal structure of the human AT1R in complex with its selective antagonist ZD 7155 at 2.9-Å resoln.  The AT1R-ZD 7155 complex structure revealed key structural features of AT1R and crit. interactions for ZD7155 binding.  Docking simulations of the clin. used ARBs into the AT1R structure further elucidated both the common and distinct binding modes for these anti-hypertensive drugs.  Our results thereby provide fundamental insights into AT1R structure-function relationship and structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9DHOZJVeyA7Vg90H21EOLACvtfcHk0lgXd9tN77RxgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFKjsLw%253D&md5=ac870c42fb32992de4398f5da440af15</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DUnal%26aufirst%3DH.%26aulast%3DGati%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZatsepin%26aufirst%3DN.%2BA.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DNelson%26aufirst%3DG.%26aulast%3DWeierstall%26aufirst%3DU.%26aulast%3DSawaya%26aufirst%3DM.%2BR.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMesserschmidt%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DG.%2BJ.%26aulast%3DBoutet%26aufirst%3DS.%26aulast%3DYefanov%26aufirst%3DO.%2BM.%26aulast%3DWhite%26aufirst%3DT.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DIshchenko%26aufirst%3DA.%26aulast%3DTirupula%26aufirst%3DK.%2BC.%26aulast%3DDesnoyer%26aufirst%3DR.%26aulast%3DCoe%26aufirst%3DJ.%26aulast%3DConrad%26aufirst%3DC.%26aulast%3DFromme%26aufirst%3DP.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26aulast%3DCherezov%26aufirst%3DV.%26atitle%3DStructure%2520of%2520the%2520angiotensin%2520receptor%2520revealed%2520by%2520serial%2520femtosecond%2520crystallography%26jtitle%3DCell%26date%3D2015%26volume%3D161%26spage%3D833%26epage%3D844%26doi%3D10.1016%2Fj.cell.2015.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnoyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structural basis for ligand recognition and functional selectivity at angiotensin receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">29127</span>– <span class="NLM_lpage">29139</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.689000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1074%2Fjbc.M115.689000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26420482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGku77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=29127-29139&author=H.+Zhangauthor=H.+Unalauthor=R.+Desnoyerauthor=G.+W.+Hanauthor=N.+Patelauthor=V.+Katritchauthor=S.+S.+Karnikauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structural+basis+for+ligand+recognition+and+functional+selectivity+at+angiotensin+receptor&doi=10.1074%2Fjbc.M115.689000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor</span></div><div class="casAuthors">Zhang, Haitao; Unal, Hamiyet; Desnoyer, Russell; Han, Gye Won; Patel, Nilkanth; Katritch, Vsevolod; Karnik, Sadashiva S.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">29127-29139</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Angiotensin II type 1 receptor (AT1R) is the primary blood pressure regulator.  AT1R blockers (ARBs) have been widely used in clin. settings as anti-hypertensive drugs and share a similar chem. scaffold, although even minor variations can lead to distinct therapeutic efficacies toward cardiovascular etiologies.  The structural basis for AT1R modulation by different peptide and non-peptide ligands has remained elusive.  Here, we report the crystal structure of the human AT1R in complex with an inverse agonist olmesartan (BenicarTM), a highly potent anti-hypertensive drug.  Olmesartan is anchored to the receptor primarily by the residues Tyr-351.39, Trp-842.60, and Arg-167ECL2, similar to the antagonist ZD 7155, corroborating a common binding mode of different ARBs.  Using docking simulations and site-directed mutagenesis, we identified specific interactions between AT1R and different ARBs, including olmesartan derivs. with inverse agonist, neutral antagonist, or agonist activities.  We further obsd. that the mutation N1113.35A in the putative sodium-binding site affects binding of the endogenous peptide agonist angiotensin II but not the β-arrestin-biased peptide TRV 120027.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIxvG2W4XcgLVg90H21EOLACvtfcHk0lgXd9tN77RxgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGku77P&md5=a7f4963798b4eeb805064460d01ef33e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.689000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.689000%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DUnal%26aufirst%3DH.%26aulast%3DDesnoyer%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructural%2520basis%2520for%2520ligand%2520recognition%2520and%2520functional%2520selectivity%2520at%2520angiotensin%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D29127%26epage%3D29139%26doi%3D10.1074%2Fjbc.M115.689000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kellici, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavromoustakos, T.</span></span> <span> </span><span class="NLM_article-title">Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3868</span>– <span class="NLM_lpage">3897</span>, <span class="refDoi"> DOI: 10.3390/molecules20033868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3390%2Fmolecules20033868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25738535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksFegtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=3868-3897&author=T.+F.+Kelliciauthor=A.+G.+Tzakosauthor=T.+Mavromoustakos&title=Rational+drug+design+and+synthesis+of+molecules+targeting+the+angiotensin+II+type+1+and+type+2+receptors&doi=10.3390%2Fmolecules20033868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 Receptors</span></div><div class="casAuthors">Kellici, Tahsin F.; Tzakos, Andreas G.; Mavromoustakos, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">3868-3897</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The angiotensin II (Ang II) type 1 and type 2 receptors (AT1R and AT2R) orchestrate an array of biol. processes that regulate human health.  Aberrant function of these receptors triggers pathophysiol. responses that can ultimately lead to death.  Therefore, it is important to design and synthesize compds. that affect beneficially these two receptors.  Cardiovascular disease, which is attributed to the overactivation of the vasoactive peptide hormone Ang II, can now be treated with com. AT1R antagonists.  Herein, recent achievements in rational drug design and synthesis of mols. acting on the two AT receptors are reviewed.  Quant. structure activity relationships (QSAR) and mol. modeling on the two receptors aim to assist the search for new active compds.  As AT1R and AT2R are GPCRs and drug action is localized in the transmembrane region the role of membrane bilayers is exploited.  The future perspectives in this field are outlined.  Tremendous progress in the field is expected if the two receptors are crystd., as this will assist the structure based screening of the chem. space and lead to new potent therapeutic agents in cardiovascular and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoote0qZSQyH7Vg90H21EOLACvtfcHk0ljoqShOwydSdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksFegtL4%253D&md5=b09be77448fa09ff43eb37baa7009cb2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3390%2Fmolecules20033868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules20033868%26sid%3Dliteratum%253Aachs%26aulast%3DKellici%26aufirst%3DT.%2BF.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26aulast%3DMavromoustakos%26aufirst%3DT.%26atitle%3DRational%2520drug%2520design%2520and%2520synthesis%2520of%2520molecules%2520targeting%2520the%2520angiotensin%2520II%2520type%25201%2520and%2520type%25202%2520receptors%26jtitle%3DMolecules%26date%3D2015%26volume%3D20%26spage%3D3868%26epage%3D3897%26doi%3D10.3390%2Fmolecules20033868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudry, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botoros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fändriks, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of the first selective nonpeptide AT<sub>2</sub> receptor agonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">5995</span>– <span class="NLM_lpage">6008</span>, <span class="refDoi"> DOI: 10.1021/jm049715t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049715t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1WjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=5995-6008&author=Y.+Wanauthor=C.+Wallinderauthor=B.+Plouffeauthor=H.+Beaudryauthor=A.+K.+Mahalingamauthor=X.+Wuauthor=B.+Johanssonauthor=M.+Holmauthor=M.+Botorosauthor=A.+Karl%C3%A9nauthor=A.+Petterssonauthor=F.+Nybergauthor=L.+F%C3%A4ndriksauthor=N.+Gallo-Payetauthor=A.+Hallbergauthor=M.+Alterman&title=Design%2C+synthesis%2C+and+biological+evaluation+of+the+first+selective+nonpeptide+AT2+receptor+agonist&doi=10.1021%2Fjm049715t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT2 Receptor Agonist</span></div><div class="casAuthors">Wan, Yiqian; Wallinder, Charlotta; Plouffe, Bianca; Beaudry, Helene; Mahalingam, A. K.; Wu, Xiongyu; Johansson, Berndt; Holm, Mathias; Botoros, Milad; Karlen, Anders; Pettersson, Anders; Nyberg, Fred; Faendriks, Lars; Gallo-Payet, Nicole; Hallberg, Anders; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5995-6008</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first druglike selective angiotensin II AT2 receptor agonist (21) with a Ki value of 0.4 nM for the AT2 receptor and a Ki >10 μM for the AT1 receptor is reported.  Compd. 21, with a bioavailability of 20-30% after oral administration and a half-life estd. to 4 h in rat, induces outgrowth of neurite cells, stimulates p42/p44mapk, enhances in vivo duodenal alk. secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats.  Thus, the peptidomimetic 21 (I) exerts a similar biol. response as the endogenous peptide angiotensin II after selective activation of the AT2 receptor.  Compd. 21, derived from the prototype nonselective AT1/AT2 receptor agonist L-162,313 will serve as a valuable research tool, enabling studies of the function of the AT2 receptor in more detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryZC-ZeMQYarVg90H21EOLACvtfcHk0ljoqShOwydSdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1WjsLg%253D&md5=cf2ffe7214ce8912d3dd51035c65a50a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm049715t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049715t%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DY.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DBeaudry%26aufirst%3DH.%26aulast%3DMahalingam%26aufirst%3DA.%2BK.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJohansson%26aufirst%3DB.%26aulast%3DHolm%26aufirst%3DM.%26aulast%3DBotoros%26aufirst%3DM.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DPettersson%26aufirst%3DA.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DF%25C3%25A4ndriks%26aufirst%3DL.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520the%2520first%2520selective%2520nonpeptide%2520AT2%2520receptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D5995%26epage%3D6008%26doi%3D10.1021%2Fjm049715t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diop-Frimpong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span> <span> </span><span class="NLM_article-title">Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">2909</span>– <span class="NLM_lpage">2914</span>, <span class="refDoi"> DOI: 10.1073/pnas.1018892108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1073%2Fpnas.1018892108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=21282607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitl2lsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=2909-2914&author=B.+Diop-Frimpongauthor=V.+P.+Chauhanauthor=S.+Kraneauthor=Y.+Boucherauthor=R.+K.+Jain&title=Losartan+inhibits+collagen+I+synthesis+and+improves+the+distribution+and+efficacy+of+nanotherapeutics+in+tumors&doi=10.1073%2Fpnas.1018892108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors</span></div><div class="casAuthors">Diop-Frimpong, Benjamin; Chauhan, Vikash P.; Krane, Stephen; Boucher, Yves; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2909-2914, S2909/1-S2909/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The dense collagen network in tumors significantly reduces the penetration and efficacy of nanotherapeutics.  We tested whether losartan - a clin. approved angiotensin II receptor antagonist with noted antifibrotic activity - can enhance the penetration and efficacy of nanomedicine.  We found that losartan inhibited collagen I prodn. by carcinoma-assocd. fibroblasts isolated from breast cancer biopsies.  Addnl., it led to a dose-dependent redn. in stromal collagen in desmoplastic models of human breast pancreatic, and skin tumors in mice.  Furthermore, losartan improved the distribution and therapeutic efficacy of intratumorally injected oncolytic herpes simplex viruses.  Finally, it also enhanced the efficacy of i.v. injected pegylated liposomal doxorubicin (Doxil).  Thus, losartan has the potential to enhance the efficacy of nanotherapeutics in patients with desmoplastic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHM20w3PNOLVg90H21EOLACvtfcHk0ljoqShOwydSdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitl2lsb8%253D&md5=20046ce2bab341bff6d8b5514df8327e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1018892108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1018892108%26sid%3Dliteratum%253Aachs%26aulast%3DDiop-Frimpong%26aufirst%3DB.%26aulast%3DChauhan%26aufirst%3DV.%2BP.%26aulast%3DKrane%26aufirst%3DS.%26aulast%3DBoucher%26aufirst%3DY.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DLosartan%2520inhibits%2520collagen%2520I%2520synthesis%2520and%2520improves%2520the%2520distribution%2520and%2520efficacy%2520of%2520nanotherapeutics%2520in%2520tumors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D2909%26epage%3D2914%26doi%3D10.1073%2Fpnas.1018892108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondaca-Ruff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riquelme, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiroga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norambuena-Soto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanhueza-Olivares, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villar-Fincheira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Díaz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancino-Arenas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiong, M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II-regulated autophagy is required for vascular smooth muscle cell hypertrophy</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1553</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffphar.2018.01553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30804791" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1553&author=D.+Mondaca-Ruffauthor=J.+A.+Riquelmeauthor=C.+Quirogaauthor=I.+Norambuena-Sotoauthor=F.+Sanhueza-Olivaresauthor=P.+Villar-Fincheiraauthor=T.+Hern%C3%A1ndez-D%C3%ADazauthor=N.+Cancino-Arenasauthor=A.+San+Martinauthor=L.+Garc%C3%ADaauthor=S.+Lavanderoauthor=M.+Chiong&title=Angiotensin+II-regulated+autophagy+is+required+for+vascular+smooth+muscle+cell+hypertrophy&doi=10.3389%2Ffphar.2018.01553"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01553%26sid%3Dliteratum%253Aachs%26aulast%3DMondaca-Ruff%26aufirst%3DD.%26aulast%3DRiquelme%26aufirst%3DJ.%2BA.%26aulast%3DQuiroga%26aufirst%3DC.%26aulast%3DNorambuena-Soto%26aufirst%3DI.%26aulast%3DSanhueza-Olivares%26aufirst%3DF.%26aulast%3DVillar-Fincheira%26aufirst%3DP.%26aulast%3DHern%25C3%25A1ndez-D%25C3%25ADaz%26aufirst%3DT.%26aulast%3DCancino-Arenas%26aufirst%3DN.%26aulast%3DSan%2BMartin%26aufirst%3DA.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DL.%26aulast%3DLavandero%26aufirst%3DS.%26aulast%3DChiong%26aufirst%3DM.%26atitle%3DAngiotensin%2520II-regulated%2520autophagy%2520is%2520required%2520for%2520vascular%2520smooth%2520muscle%2520cell%2520hypertrophy%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D9%26spage%3D1553%26doi%3D10.3389%2Ffphar.2018.01553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKallip, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">6043</span>– <span class="NLM_lpage">6054</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S95333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2147%2FDDDT.S95333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26648693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1Sjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=6043-6054&author=X.+F.+Pangauthor=L.+H.+Zhangauthor=F.+Baiauthor=N.+P.+Wangauthor=R.+E.+Garnerauthor=R.+J.+McKallipauthor=Z.+Q.+Zhao&title=Attenuation+of+myocardial+fibrosis+with+curcumin+is+mediated+by+modulating+expression+of+angiotensin+II+AT1%2FAT2+receptors+and+ACE2+in+rats&doi=10.2147%2FDDDT.S95333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats</span></div><div class="casAuthors">Pang, Xue-Fen; Zhang, Li-Hui; Bai, Feng; Wang, Ning-Ping; Garner, Ron E.; McKallip, Robert J.; Zhao, Zhi-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6043-6054</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Curcumin is known to improve cardiac function by balancing degrdn. and synthesis of collagens after myocardial infarction.  This study tested the hypothesis that inhibition of myocardial fibrosis by curcumin is assocd. with modulating expression of angiotensin II (Ang II) receptors and angiotensin-converting enzyme 2 (ACE2).  Male Sprague Dawley rats were subjected to Ang II infusion (500 ng/kg/min) using osmotic minipumps for 2 and 4 wk, resp., and curcumin (150 mg/kg/day) was fed by gastric gavage during Ang II infusion.  Compared to the animals with Ang II infusion, curcumin significantly decreased the mean arterial blood pressure during the course of the observation.  The protein level of the Ang II type 1 (AT1) receptor was reduced, and the Ang II type 2 (AT2) receptor was up-regulated, evidenced by an increased ratio of the AT2 receptor over the AT1 receptor in the curcumin group (1.2±0.02%) vs in the Ang II group (0.7±0.03%, P<0.05).  These changes were coincident with less locally expressed AT1 receptor and enhanced AT2 receptor in the intracardiac vessels and intermyocardium.  Along with these modulations, curcumin significantly decreased the populations of macrophages and alpha smooth muscle actin-expressing myofibroblasts, which were accompanied by reduced expression of transforming growth factor beta 1 and phosphorylated-Smad2/3.  Collagen I synthesis was inhibited, and tissue fibrosis was attenuated, as demonstrated by less extensive collagen-rich fibrosis.  Furthermore, curcumin increased protein level of ACE2 and enhanced its expression in the intermyocardium relative to the Ang II group.  These results suggest that curcumin could be considered as an add-on therapeutic agent in the treatment of fibrosis-derived heart failure patient who is intolerant of ACE inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhKyEygGyjVLVg90H21EOLACvtfcHk0liEmGy9IqVl7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1Sjtr4%253D&md5=87d58358354203eb8ebb40422a86fb5f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S95333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S95333%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DX.%2BF.%26aulast%3DZhang%26aufirst%3DL.%2BH.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DN.%2BP.%26aulast%3DGarner%26aufirst%3DR.%2BE.%26aulast%3DMcKallip%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DZ.%2BQ.%26atitle%3DAttenuation%2520of%2520myocardial%2520fibrosis%2520with%2520curcumin%2520is%2520mediated%2520by%2520modulating%2520expression%2520of%2520angiotensin%2520II%2520AT1%252FAT2%2520receptors%2520and%2520ACE2%2520in%2520rats%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D6043%26epage%3D6054%26doi%3D10.2147%2FDDDT.S95333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzau, V. J.</span></span> <span> </span><span class="NLM_article-title">Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">24539</span>– <span class="NLM_lpage">24542</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=8227010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2cXisVahtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=24539-24542&author=M.+Mukoyamaauthor=M.+Nakajimaauthor=M.+Horiuchiauthor=H.+Sasamuraauthor=R.+E.+Prattauthor=V.+J.+Dzau&title=Expression+cloning+of+type+2+angiotensin+II+receptor+reveals+a+unique+class+of+seven-transmembrane+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors</span></div><div class="casAuthors">Mukoyama, Masashi; Nakajima, Masatoshi; Horiuchi, Masatsugu; Sasamura, Hiroyuki; Pratt, Richard E.; Dzau, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">24539-42</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Angiotensin II acts on at least two distinct receptor subtypes (AT1 and AT2).  Most known effects of angiotensin II in adult tissues are attributable to the AT1 receptor.  The function of AT2 receptor is undefined, but its abundant expressions in fetal tissues, immature brain, skin wound, and atretic ovarian follicles suggest a role in growth and development.  Previous studies suggested that AT2 receptor may not be G protein-coupled.  Here, from a rat fetus expression library, the authors cloned a cDNA encoding a unique 363-amino acid protein with pharmacol. specificity, tissue distribution, and developmental pattern of the AT2 receptor.  It is 34% identical in sequence to the AT1 receptor, sharing a seven-transmembrane domain topol.  A review of prior data on other receptors suggests that this receptor may belong to a unique class of seven-transmembrane receptors (including somatostatin SSTR1, dopamine D3, and frizzled protein Fz) for which G protein coupling has not been demonstrated.  All members of this class exhibit fetal and developmental and/or neuronal-specific expression.  A conserved motif in the third intracellular loop, distinguishing this class from "classical" G protein-coupled receptors, may mediate novel intracellular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS1rHYpNLNBLVg90H21EOLACvtfcHk0liEmGy9IqVl7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXisVahtw%253D%253D&md5=05318096e5998d5da30e0b7f42d221ca</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMukoyama%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DHoriuchi%26aufirst%3DM.%26aulast%3DSasamura%26aufirst%3DH.%26aulast%3DPratt%26aufirst%3DR.%2BE.%26aulast%3DDzau%26aufirst%3DV.%2BJ.%26atitle%3DExpression%2520cloning%2520of%2520type%25202%2520angiotensin%2520II%2520receptor%2520reveals%2520a%2520unique%2520class%2520of%2520seven-transmembrane%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D24539%26epage%3D24542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kambayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamakubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagami, T.</span></span> <span> </span><span class="NLM_article-title">Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">24543</span>– <span class="NLM_lpage">24546</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=8227011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2cXitlOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=24543-24546&author=Y.+Kambayashiauthor=S.+Bardhanauthor=K.+Takahashiauthor=S.+Tsuzukiauthor=H.+Inuiauthor=T.+Hamakuboauthor=T.+Inagami&title=Molecular+cloning+of+a+novel+angiotensin+II+receptor+isoform+involved+in+phosphotyrosine+phosphatase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition</span></div><div class="casAuthors">Kambayashi, Yoshikazu; Bardhan, Smriti; Takahashi, Kyoko; Tsuzuki, Satoshi; Inui, Hiroshi; Hamakubo, Takao; Inagami, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">24543-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">There are two major isoforms of the angiotensin II receptor, type 1 (AT1) and type 2 (AT2).  AT2 is distinguished from AT1 with respect to its ligand selectivity, its insensitivity to non-hydrolyzable GTP analogs, and its as yet unidentified biol. functions.  In the present study the authors have expression-cloned AT2 cDNA from a cDNA library of a rat pheochromocytoma cell line (PC12w).  Rat AT2 cDNA encodes a 363-amino acid protein that has seven transmembrane domains.  AT1 is the closest in homol. to AT2 but with only a 32% identity of amino acid sequence.  Stably expressed in COS-7 cells, the receptor showed selective binding to AT2-specific ligands PD 123319 and CGP 42112A but not to the AT1-specific ligand, losartan.  Northern blot anal. revealed that the mRNA of rat AT2 was expressed not only in PC12w cells but also in the adrenal glands and in the inferior olive of the brain, both of which are known to contain AT2 type binding sites.  The expressed AT2 receptor mediated angiotensin II-induced inhibition of protein tyrosine phosphatase, an action that was dependent on a pertussis toxin-sensitive G-protein-coupled mechanism in COS-7 cells.  The AT2-specific ligand CGP42112A was an agonist rather than antagonist in the inhibition of phosphotyrosine phosphatase.  AT2 did not cause a decrease in cGMP in PC12w or COS-7 cells expressing AT2 stably.  The results indicate that the AT2 receptor is structurally and functionally different from AT1 and suggest novel functional roles of the renin-angiotensin system in cross-talk with phosphotyrosine signaling by modulating protein phosphotyrosine levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz2Bf_VYyqKrVg90H21EOLACvtfcHk0lgjVn6olQO_QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlOhsQ%253D%253D&md5=978c3de28dc0233e85fa46ab37c07075</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKambayashi%26aufirst%3DY.%26aulast%3DBardhan%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DTsuzuki%26aufirst%3DS.%26aulast%3DInui%26aufirst%3DH.%26aulast%3DHamakubo%26aufirst%3DT.%26aulast%3DInagami%26aufirst%3DT.%26atitle%3DMolecular%2520cloning%2520of%2520a%2520novel%2520angiotensin%2520II%2520receptor%2520isoform%2520involved%2520in%2520phosphotyrosine%2520phosphatase%2520inhibition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D24543%26epage%3D24546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vervoort, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beachem, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Mollerat, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuPont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. K.</span></span> <span> </span><span class="NLM_article-title">AGTR2 mutations in X-linked mental retardation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">2401</span>– <span class="NLM_lpage">2403</span>, <span class="refDoi"> DOI: 10.1126/science.1072191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1126%2Fscience.1072191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12089445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38XltFWksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=2401-2403&author=V.+S.+Vervoortauthor=M.+A.+Beachemauthor=P.+S.+Edwardsauthor=S.+Laddauthor=K.+E.+Millerauthor=X.+de+Molleratauthor=K.+Clarksonauthor=B.+DuPontauthor=C.+E.+Schwartzauthor=R.+E.+Stevensonauthor=E.+Boydauthor=A.+K.+Srivastava&title=AGTR2+mutations+in+X-linked+mental+retardation&doi=10.1126%2Fscience.1072191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">AGTR2 mutations in X-linked mental retardation</span></div><div class="casAuthors">Vervoort, Virginie S.; Beachem, Michael A.; Edwards, Penny S.; Ladd, Sydney; Miller, Karin E.; de Mollerat, Xavier; Clarkson, Katie; DuPont, Barbara; Schwartz, Charles E.; Stevenson, Roger E.; Boyd, Ellen; Srivastava, Anand K.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5577</span>),
    <span class="NLM_cas:pages">2401-2403</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Two angiotensin II (Ang II)-specific receptors, AGTR1 and AGTR2, are expressed in the mammalian brain.  Ang II actions on blood pressure regulation, water electrolyte balance, and hormone secretion are primarily mediated by AGTR1.  The function of AGTR2 remains unclear.  Here, the authors show that expression of the AGTR2 gene was absent in a female patient with mental retardation (MR) who had a balanced X;7 chromosomal translocation.  Addnl., 8 of 590 unrelated male patients with MR were found to have sequence changes in the AGTR2 gene, including one frameshift and three missense mutations.  These findings indicate a role for AGTR2 in brain development and cognitive function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX_YkE6B52SrVg90H21EOLACvtfcHk0lgjVn6olQO_QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltFWksrg%253D&md5=23bfdc50f2369cc5efeb3becd5058856</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1126%2Fscience.1072191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1072191%26sid%3Dliteratum%253Aachs%26aulast%3DVervoort%26aufirst%3DV.%2BS.%26aulast%3DBeachem%26aufirst%3DM.%2BA.%26aulast%3DEdwards%26aufirst%3DP.%2BS.%26aulast%3DLadd%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DK.%2BE.%26aulast%3Dde%2BMollerat%26aufirst%3DX.%26aulast%3DClarkson%26aufirst%3DK.%26aulast%3DDuPont%26aufirst%3DB.%26aulast%3DSchwartz%26aufirst%3DC.%2BE.%26aulast%3DStevenson%26aufirst%3DR.%2BE.%26aulast%3DBoyd%26aufirst%3DE.%26aulast%3DSrivastava%26aufirst%3DA.%2BK.%26atitle%3DAGTR2%2520mutations%2520in%2520X-linked%2520mental%2520retardation%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D2401%26epage%3D2403%26doi%3D10.1126%2Fscience.1072191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bienvenu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Esch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraine, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryns, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ropers, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beldjord, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yntema, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chelly, J.</span></span> <span> </span><span class="NLM_article-title">Rare polymorphic variants of the AGTR2 gene in boys with non-specific mental retardation</span>. <i>J. Med. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1136/jmg.40.5.357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1136%2Fjmg.40.5.357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12746399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1Gksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2003&pages=357-359&author=T.+Bienvenuauthor=K.+Poirierauthor=H.+Van+Eschauthor=B.+Hamelauthor=C.+Moraineauthor=J.+P.+Frynsauthor=H.+H.+Ropersauthor=C.+Beldjordauthor=H.+G.+Yntemaauthor=J.+Chelly&title=Rare+polymorphic+variants+of+the+AGTR2+gene+in+boys+with+non-specific+mental+retardation&doi=10.1136%2Fjmg.40.5.357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Rare polymorphic variants of the AGTR2 gene in boys with non-specific mental retardation</span></div><div class="casAuthors">Bienvenu, T.; Poirier, K.; Van Esch, H.; Hamel, B.; Moraine, C.; Fryns, J. P.; Ropers, H. H.; Beldjord, C.; Yntema, H. G.; Chelly, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">357-359</span>CODEN:
                <span class="NLM_cas:coden">JMDGAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-2593</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Mutation anal. of the angiotensin II specific receptor (AGTR2) gene was performed in 15 large families with mental retardation-linked to Xq24, in a panel of 101 clin. well characterized small families with at least two boys affected with MR, and in 244 sporadic cases of non-specific MR.  Denaturing high pressure liq. chromatog. anal. of the entire coding region detected no deleterious mutations in the 360 patients.  A novel C117F amino acid substitution was identified as a non-pathogenic rare genetic variant.  Results suggest that AGTR2 is rarely involved in non-specific MR but could be involved in more specific forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofGtYu1SFuRbVg90H21EOLACvtfcHk0lgjVn6olQO_QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1Gksb4%253D&md5=83658f4d64d62665a48885390cc50523</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1136%2Fjmg.40.5.357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjmg.40.5.357%26sid%3Dliteratum%253Aachs%26aulast%3DBienvenu%26aufirst%3DT.%26aulast%3DPoirier%26aufirst%3DK.%26aulast%3DVan%2BEsch%26aufirst%3DH.%26aulast%3DHamel%26aufirst%3DB.%26aulast%3DMoraine%26aufirst%3DC.%26aulast%3DFryns%26aufirst%3DJ.%2BP.%26aulast%3DRopers%26aufirst%3DH.%2BH.%26aulast%3DBeldjord%26aufirst%3DC.%26aulast%3DYntema%26aufirst%3DH.%2BG.%26aulast%3DChelly%26aufirst%3DJ.%26atitle%3DRare%2520polymorphic%2520variants%2520of%2520the%2520AGTR2%2520gene%2520in%2520boys%2520with%2520non-specific%2520mental%2520retardation%26jtitle%3DJ.%2520Med.%2520Genet.%26date%3D2003%26volume%3D40%26spage%3D357%26epage%3D359%26doi%3D10.1136%2Fjmg.40.5.357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pescucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meloni, I.</span></span> <span> </span><span class="NLM_article-title">Non-syndronic X-linked mental retardation from a molecular to a clinical point of view</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1002/jcp.20296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fjcp.20296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=15690397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2005&pages=8-20&author=A.+Renieriauthor=C.+Pescucciauthor=I.+Longoauthor=F.+Arianiauthor=F.+Mariauthor=I.+Meloni&title=Non-syndronic+X-linked+mental+retardation+from+a+molecular+to+a+clinical+point+of+view&doi=10.1002%2Fjcp.20296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Non-syndromic X-linked mental retardation: From a molecular to a clinical point of view</span></div><div class="casAuthors">Renieri, A.; Pescucci, C.; Longo, I.; Ariani, F.; Mari, F.; Meloni, I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-20</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">This review focuses on the 19 identified genes involved in X-linked "non-syndromic" mental retardation (MR) and defines the signaling pathways in which they are involved, focusing on emerging common mechanisms.  The majority of proteins are involved in three distinct pathways:.  (1) Rho GTPases pathway modulating neuronal differentiation and synaptic plasticity;.  (2) Rab GTPases pathway regulating synaptic vesicle cycling;.  (3) Gene expression regulation.  The function of four proteins (ACSL4, AT2, SLC6A8, and SAP102) could not be reconciled to a common pathway.  From a clin. point of view, the review discusses whether some common dysmorphic features can be identified even in non-syndromic MR patients and whether it is correct to maintain the distinction between "non-syndromic" and "syndromic" MR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0rBVhNgR64rVg90H21EOLACvtfcHk0lgtdPA-IBtl6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr8%253D&md5=81ec0ffa6bf7c0bd10bf19cc766ec045</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fjcp.20296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.20296%26sid%3Dliteratum%253Aachs%26aulast%3DRenieri%26aufirst%3DA.%26aulast%3DPescucci%26aufirst%3DC.%26aulast%3DLongo%26aufirst%3DI.%26aulast%3DAriani%26aufirst%3DF.%26aulast%3DMari%26aufirst%3DF.%26aulast%3DMeloni%26aufirst%3DI.%26atitle%3DNon-syndronic%2520X-linked%2520mental%2520retardation%2520from%2520a%2520molecular%2520to%2520a%2520clinical%2520point%2520of%2520view%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2005%26volume%3D204%26spage%3D8%26epage%3D20%26doi%3D10.1002%2Fjcp.20296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmieder, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regitz-Zagrosek, V.</span></span> <span> </span><span class="NLM_article-title">Effect of the angiotensin II type 2-receptor gene (11675 G/A) on left ventricular structure in humans</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/S0735-1097(00)01063-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0735-1097%2800%2901063-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11153734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVKjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=175-182&author=R.+E.+Schmiederauthor=J.+Erdmannauthor=C.+Dellesauthor=J.+Jacobiauthor=E.+Fleckauthor=K.+Hilgersauthor=V.+Regitz-Zagrosek&title=Effect+of+the+angiotensin+II+type+2-receptor+gene+%2811675+G%2FA%29+on+left+ventricular+structure+in+humans&doi=10.1016%2FS0735-1097%2800%2901063-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans</span></div><div class="casAuthors">Schmieder, Roland E.; Erdmann, Jeanette; Delles, Christian; Jacobi, Johannes; Fleck, Eckart; Hilgers, Karl; Regitz-Zagrosek, Vera</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-182</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The authors' study goal was to analyze whether gene variants of angiotensin II type 2-receptor (AT2-R) modulate the effects of angiotensin II on the left ventricle (LV).  Exptl. data suggest that angiotensin II modifies ventricular growth responses via angiotensin II type 1-receptors (AT1-R) and AT2-R.  In 120 white, young male subjects with normal or mildly elevated blood pressure, the authors assessed plasma angiotensin II and aldosterone concns. (RIA), 24-h urinary sodium excretion, 24-h ambulatory blood pressure and LV structure (two-dimensional guided M-mode echocardiog.).  The intronic + 1675 G/A polymorphism of the X-chromosomal located AT2-R gene was investigated by single-strand conformational polymorphism anal. and DNA-sequencing.  Hypertensive subjects with the A-allele had a greater LV posterior (11.0 vs. 9 mm), septal (11.8 vs. 10.1 mm) and relative wall thickness (0.44 vs. 39) as well as LV mass index (138 vs. 120 g/M2) than those with the G-allele.  Confounding factors (i.e., body mass index and surface area, plasma angiotensin II, sodium excretion, systolic and diastolic ambulatory blood pressure) were similar between the two genotypes.  In normotensive subjects, relative wall thickness (0.36 vs. 35) and LV mass index (115 vs. 112 g/M2) were nearly identical across the two genotypes, with similar confounding variables.  The authors' data indicate that the X-chromosomal located + 1675 G/A-polymorphism of the AT2-R gene is assocd. with LV structure in young male humans with early structural changes of the heart due to arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAtSvQmwEReLVg90H21EOLACvtfcHk0lgtdPA-IBtl6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVKjuw%253D%253D&md5=55e09808707bb8d354b14573d3dabc08</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0735-1097%2800%2901063-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0735-1097%252800%252901063-9%26sid%3Dliteratum%253Aachs%26aulast%3DSchmieder%26aufirst%3DR.%2BE.%26aulast%3DErdmann%26aufirst%3DJ.%26aulast%3DDelles%26aufirst%3DC.%26aulast%3DJacobi%26aufirst%3DJ.%26aulast%3DFleck%26aufirst%3DE.%26aulast%3DHilgers%26aufirst%3DK.%26aulast%3DRegitz-Zagrosek%26aufirst%3DV.%26atitle%3DEffect%2520of%2520the%2520angiotensin%2520II%2520type%25202-receptor%2520gene%2520%252811675%2520G%252FA%2529%2520on%2520left%2520ventricular%2520structure%2520in%2520humans%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2001%26volume%3D37%26spage%3D175%26epage%3D182%26doi%3D10.1016%2FS0735-1097%2800%2901063-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titze, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreutz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgers, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaich, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmieder, R. E.</span></span> <span> </span><span class="NLM_article-title">High sodium intake modulates left ventricular mass in patients with Gexpression of + 1675 G/A angiotensin receptor type 2 gene</span>. <i>J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1627</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1097/HJH.0b013e3281cd40f5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2FHJH.0b013e3281cd40f5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=17620959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVCrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1627-1632&author=C.+Ottauthor=S.+I.+Titzeauthor=T.+K.+Schwarzauthor=R.+Kreutzauthor=K.+F.+Hilgersauthor=B.+M.+Schmidtauthor=M.+P.+Schlaichauthor=R.+E.+Schmieder&title=High+sodium+intake+modulates+left+ventricular+mass+in+patients+with+Gexpression+of+%2B+1675+G%2FA+angiotensin+receptor+type+2+gene&doi=10.1097%2FHJH.0b013e3281cd40f5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene</span></div><div class="casAuthors">Ott, Christian; Titze, Stephanie I.; Schwarz, Thomas K.; Kreutz, Reinhold; Hilgers, Karl F.; Schmidt, Bernhard M. W.; Schlaich, Markus P.; Schmieder, Roland E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1627-1632</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">In patients with hypertension left ventricular hypertrophy (LVH) is assocd. with genetic variations of the angiotensin type 2 receptor (AT2R).  Hypertension and LVH are often aggravated by salt intake.  The authors' objective was to assess the relationship between AT2R gene variation and salt intake and their impact on left ventricular mass (LVM).  In 205 subjects with normal or mildly elevated blood pressure, the authors assessed sodium intake and left ventricular structure and function by echocardiog.  Intronic +1675 G/A polymorphism of the AT2R gene was investigated.  A-allele carriers had a greater LVM (P = 0.049) than G-allele carriers.  Independent of diet, septal wall thickness was higher in A-allele carriers (P = 0.001).  Fractional fiber shortening was greater in A-allele carriers (P = 0.034), and the velocity of circumferential fiber shortening tended to be greater in A-allele carriers (P = 0.057).  When the 2 groups were stratified according to their salt intake, only G-allele carriers displayed a modulating effect of salt intake on LVM.  Covariance anal. revealed that there was a trend towards a modulating effect of salt intake on LVM, even after taking blood pressure into account (P = 0.054).  The authors' data clearly support the notion that LVM is influenced by AT2R polymorphisms.  Furthermore, G-allele carriers in particular appear to be susceptible to a modifying effect of increased salt intake on LVM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt5lFcNbqXirVg90H21EOLACvtfcHk0lggfvOtc_p_3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVCrs7s%253D&md5=53ead8878c84f4958f7d47c38285615e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1097%2FHJH.0b013e3281cd40f5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHJH.0b013e3281cd40f5%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DC.%26aulast%3DTitze%26aufirst%3DS.%2BI.%26aulast%3DSchwarz%26aufirst%3DT.%2BK.%26aulast%3DKreutz%26aufirst%3DR.%26aulast%3DHilgers%26aufirst%3DK.%2BF.%26aulast%3DSchmidt%26aufirst%3DB.%2BM.%26aulast%3DSchlaich%26aufirst%3DM.%2BP.%26aulast%3DSchmieder%26aufirst%3DR.%2BE.%26atitle%3DHigh%2520sodium%2520intake%2520modulates%2520left%2520ventricular%2520mass%2520in%2520patients%2520with%2520Gexpression%2520of%2520%252B%25201675%2520G%252FA%2520angiotensin%2520receptor%2520type%25202%2520gene%26jtitle%3DJ.%2520Hypertens.%26date%3D2007%26volume%3D25%26spage%3D1627%26epage%3D1632%26doi%3D10.1097%2FHJH.0b013e3281cd40f5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hohenfellner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunley, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schloemer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerkes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zepp, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kon, V.</span></span> <span> </span><span class="NLM_article-title">Angiotensin type 2 receptor is important in the normal development of the ureter</span>. <i>Pediatr. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1007/s004670050589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs004670050589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10353402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADyaK1M3nvFynsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=187-191&author=K.+Hohenfellnerauthor=T.+E.+Hunleyauthor=C.+Schloemerauthor=W.+Brennerauthor=E.+Yerkesauthor=F.+Zeppauthor=J.+W.+Brockauthor=V.+Kon&title=Angiotensin+type+2+receptor+is+important+in+the+normal+development+of+the+ureter&doi=10.1007%2Fs004670050589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin type 2 receptor is important in the normal development of the ureter</span></div><div class="casAuthors">Hohenfellner K; Hunley T E; Schloemer C; Brenner W; Yerkes E; Zepp F; Brock J W 3rd; Kon V</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric nephrology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-91</span>
        ISSN:<span class="NLM_cas:issn">0931-041X</span>.
    </div><div class="casAbstract">In humans, the actions of angiotensin II are transduced through the AT1 and AT2 receptors which have recently been implicated in renal organogenesis.  Polymorphisms in the human angiotensin II receptor genes have been linked to cardiovascular and nephrological disorders.  In this study we evaluated 35 patients with either primary obstructive megaureter or posterior urethral valves.  Each was genotyped for the A1166 AT1 polymorphism and the recently described A-1332G AT2 transition.  The incidence of these genetic variants was also evaluated in normal controls without any ultrasonographic urological abnormalities.  Similar to our previous findings in congenital urological abnormalities, the AT1 receptor genotype distribution did not differ between patients with either primary obstructive megaureter or posterior urethral valves versus controls.  In contrast, compared with normal controls, there was a dramatic increase in the occurrence of the AT2 A-1332G transition in patients with primary obstructive megaureter (75.0% vs. 41.9% in controls, P<0.025).  In patients with posterior urethral valves, there was no difference in the occurrence of the transition versus controls (36.9%, P=NS).  Thus, there is no correlation between the AT1 receptor gene polymorphism and urological abnormalities.  However there is an increased incidence in the AT2 genetic variant in patients with primary obstructive megaureter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4E-NO8velOynGiHuhFGv8fW6udTcc2eaT1lryCd9xuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3nvFynsA%253D%253D&md5=ff24b491e6dbcd1c1ec0578142fcdcb9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs004670050589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs004670050589%26sid%3Dliteratum%253Aachs%26aulast%3DHohenfellner%26aufirst%3DK.%26aulast%3DHunley%26aufirst%3DT.%2BE.%26aulast%3DSchloemer%26aufirst%3DC.%26aulast%3DBrenner%26aufirst%3DW.%26aulast%3DYerkes%26aufirst%3DE.%26aulast%3DZepp%26aufirst%3DF.%26aulast%3DBrock%26aufirst%3DJ.%2BW.%26aulast%3DKon%26aufirst%3DV.%26atitle%3DAngiotensin%2520type%25202%2520receptor%2520is%2520important%2520in%2520the%2520normal%2520development%2520of%2520the%2520ureter%26jtitle%3DPediatr.%2520Nephrol.%26date%3D1999%26volume%3D13%26spage%3D187%26epage%3D191%26doi%3D10.1007%2Fs004670050589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speth, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grove, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saylor, D.</span></span> <span> </span><span class="NLM_article-title">Sulfhydril reducing agents distinguish two subtypes of angiotensin II receptors in the rat brain</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>548</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(91)91098-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2F0006-8993%2891%2991098-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1868325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK3MXks1Gntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=548&publication_year=1991&pages=1-8&author=R.+C.+Spethauthor=B.+P.+Roweauthor=K.+L.+Groveauthor=M.+R.+Carterauthor=D.+Saylor&title=Sulfhydril+reducing+agents+distinguish+two+subtypes+of+angiotensin+II+receptors+in+the+rat+brain&doi=10.1016%2F0006-8993%2891%2991098-L"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfhydryl reducing agents distinguish two subtypes of angiotensin II receptors in the rat brain</span></div><div class="casAuthors">Speth, Robert C.; Rowe, Brian P.; Grove, Kevin L.; Carter, Michelle R.; Saylor, David</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">548</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">Two angiotensin II receptor subtypes were distinguished in the rat brain using in vitro receptor autoradiog. based on the differential effects of sulfhydryl reducing agents on 125I-sarcosine1, isoleucine8 angiotensin II binding in various brain nuclei.  At several nuclei, e.g. the hypothalamus, circumventricular organs, and the dorsal medulla, 125I-sarcosine1, isoleucine8 angiotensin II binding was strongly inhibited by 30 mM β-mercaptoethanol or 5 mM dithiothreitol, whereas at other nuclei, e.g. the lateral septum, colliculi, locus ceruleus, and medial amygdala, sulfhydryl reducing agents had either little effect on radioligand binding or enhanced the binding.  The distribution of the sulfhydryl reducing agent inactivated subtype corresponds exactly with the distribution of DuP 743 sensitive (designated as AIIα) 125I-sarcosine1, isoleucine8 angiotensin II binding sites.  The subtype not inhibited by sulfhydryl reducing agents corresponds with the DuP 753 insensitive (designated as AIIβ) sites in the brain.  The sulfhydryl reducing agent effect on brain angiotensin II receptor subtypes is similar to that seen in angiotensin II receptor subtypes in peripheral tissues.  These observations indicate that many previous studies of brain angiotensin II receptor binding that included 5 mM dithiothreitol in the assay medium overlooked the sulfhydryl reducing agent inactivated (AIIα) receptor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpghcvSM9y_L7Vg90H21EOLACvtfcHk0lgy3-PK1s7u4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXks1Gntbs%253D&md5=f581b397bbb7e43658529f9362b4da3c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2891%2991098-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252891%252991098-L%26sid%3Dliteratum%253Aachs%26aulast%3DSpeth%26aufirst%3DR.%2BC.%26aulast%3DRowe%26aufirst%3DB.%2BP.%26aulast%3DGrove%26aufirst%3DK.%2BL.%26aulast%3DCarter%26aufirst%3DM.%2BR.%26aulast%3DSaylor%26aufirst%3DD.%26atitle%3DSulfhydril%2520reducing%2520agents%2520distinguish%2520two%2520subtypes%2520of%2520angiotensin%2520II%2520receptors%2520in%2520the%2520rat%2520brain%26jtitle%3DBrain%2520Res.%26date%3D1991%26volume%3D548%26spage%3D1%26epage%3D8%26doi%3D10.1016%2F0006-8993%2891%2991098-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span> <span> </span><span class="NLM_article-title">Reversible inactivation of AT(2) angiotensin II receptor from cysteine-disulfide bond exchange</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>484</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(00)02141-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0014-5793%2800%2902141-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11068047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVamuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=484&publication_year=2000&pages=133-138&author=Y.+H.+Fengauthor=Y.+Saadauthor=S.+S.+Karnik&title=Reversible+inactivation+of+AT%282%29+angiotensin+II+receptor+from+cysteine-disulfide+bond+exchange&doi=10.1016%2FS0014-5793%2800%2902141-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible inactivation of AT2 angiotensin II receptor from cysteine-disulfide bond exchange</span></div><div class="casAuthors">Feng, Y.-H.; Saad, Y.; Karnik, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">484</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-138</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Dithiothreitol (DTT) treatment of angiotensin II (Ang II) type 2 (AT2) receptor potentiates ligand binding, but the underlying mechanism is not known.  Two disulfide bonds proposed in the extracellular domain were examd. in this report.  Based on the anal. of ligand affinity of cysteine (Cys, C) to alanine (Ala, A) substitution mutants, we provide evidence that Cys35-Cys290 and Cys117-Cys195 disulfide bonds are formed in the wild-type AT2 receptor.  Disruption of the highly conserved Cys117-Cys195 disulfide bond linking the second and third extracellular segments leads to inactivation of the receptor.  The Cys35-Cys290 bond is highly sensitive to DTT.  Its breakage results in an increased binding affinity for both Ang II and the AT2 receptor-specific antagonist PD123319.  Surprisingly, in the single Cys mutants, C35A and C290A, a labile population of receptors is produced which can be re-folded to high-affinity state by DTT treatment.  These results suggest that the free -SH group of Cys35 or Cys290 competes with the disulfide bond formation between Cys117 and Cys195.  This Cys-disulfide bond exchange results in prodn. of the inactive population of the mutant receptors through formation of a non-native disulfide bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVLBM8_Lm1LrVg90H21EOLACvtfcHk0lgy3-PK1s7u4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVamuro%253D&md5=40c807c66eb03ea9d6eb4f87f1ea922f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2800%2902141-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252800%252902141-4%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%2BH.%26aulast%3DSaad%26aufirst%3DY.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26atitle%3DReversible%2520inactivation%2520of%2520AT%25282%2529%2520angiotensin%2520II%2520receptor%2520from%2520cysteine-disulfide%2520bond%2520exchange%26jtitle%3DFEBS%2520Lett.%26date%3D2000%26volume%3D484%26spage%3D133%26epage%3D138%26doi%3D10.1016%2FS0014-5793%2800%2902141-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holleran, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillargeon, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavigne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leduc, R.</span></span> <span> </span><span class="NLM_article-title">Interplay between intracellular loop 1 and helix VIII of the angiotensin II type 2 receptor controls its activation</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bcp.2019.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=31348898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWmurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=330-338&author=A.+Connollyauthor=B.+J.+Holleranauthor=E.+Simardauthor=J.-P.+Baillargeonauthor=P.+Lavigneauthor=R.+Leduc&title=Interplay+between+intracellular+loop+1+and+helix+VIII+of+the+angiotensin+II+type+2+receptor+controls+its+activation&doi=10.1016%2Fj.bcp.2019.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Interplay between intracellular loop 1 and helix VIII of the angiotensin II type 2 receptor controls its activation</span></div><div class="casAuthors">Connolly, Alexandre; Holleran, Brian J.; Simard, Elie; Baillargeon, Jean-Patrice; Lavigne, Pierre; Leduc, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">330-338</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The signaling mechanisms of the angiotensin II type 2 receptor (AT2R), a heptahelical receptor, have not yet been clearly and completely defined.  In the present contribution, we set out to identify the mol. determinants involved in AT2R activation.  Although AT2R has not been shown to engage Gq/11, G12, Gi2, and β-arrestin (βarr) pathways as does the AT1R upon angiotensin II (AngII) stimulation, the atypical positioning of helix VIII in the recently published AT2R structure may play a role in the receptor's capacity to couple to downstream effectors.  In the AT2R structure, helix VIII points inwards and towards intracellular loop 3 (ICL3) to form tertiary interactions with transmembrane domain 6 (TM6), possibly impeding access to signaling effectors.  On the other hand, in most class A GPCRs, helix VIII is found to be engaged in tertiary interactions with ICL1 and away from the effector binding site.  Upon closer examn. of the AT2R structure, we found that the residues contained within intracellular loop 1 (ICL1) may be involved in driving this unusual conformation of helix VIII.  To explore this hypothesis, we designed a series of AT1R/AT2R receptor chimeras to validate the roles of ICL1 and helix VIII in AT2R signaling.  Substituting the AT1R ICL1 into AT2R led to a mutant receptor that coupled to Gi2.  The substitution of the helix VIII and C-terminal domains of AT2R into the AT1R backbone led to a mutant receptor that retained AT1R-like signaling properties.  These results suggest that the C-terminal portion of AT2R is compatible with canonical GPCR signaling and that ICL1 of AT2R is involved in repositioning helix VIII, which impedes engagement of classical GPCR effectors such as G proteins or βarrs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcgci_00VRNrVg90H21EOLACvtfcHk0lgy3-PK1s7u4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWmurnO&md5=767016b28eeeef5bb755dcedfb3a4940</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DA.%26aulast%3DHolleran%26aufirst%3DB.%2BJ.%26aulast%3DSimard%26aufirst%3DE.%26aulast%3DBaillargeon%26aufirst%3DJ.-P.%26aulast%3DLavigne%26aufirst%3DP.%26aulast%3DLeduc%26aufirst%3DR.%26atitle%3DInterplay%2520between%2520intracellular%2520loop%25201%2520and%2520helix%2520VIII%2520of%2520the%2520angiotensin%2520II%2520type%25202%2520receptor%2520controls%2520its%2520activation%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2019%26volume%3D168%26spage%3D330%26epage%3D338%26doi%3D10.1016%2Fj.bcp.2019.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiroishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamakubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusano-Arai, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, S.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">570</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0079-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fs41594-018-0079-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29967536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=570-576&author=H.+Asadaauthor=S.+Horitaauthor=K.+Hirataauthor=M.+Shiroishiauthor=Y.+Shiimuraauthor=H.+Iwanariauthor=T.+Hamakuboauthor=T.+Shimamuraauthor=N.+Nomuraauthor=O.+Kusano-Araiauthor=T.+Uemuraauthor=C.+Sunoauthor=T.+Kobayashiauthor=S.+Iwata&title=Crystal+structure+of+the+human+angiotensin+II+type+2+receptor+bound+to+an+angiotensin+II+analog&doi=10.1038%2Fs41594-018-0079-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog</span></div><div class="casAuthors">Asada, Hidetsugu; Horita, Shoichiro; Hirata, Kunio; Shiroishi, Mitsunori; Shiimura, Yuki; Iwanari, Hiroko; Hamakubo, Takao; Shimamura, Tatsuro; Nomura, Norimichi; Kusano-Arai, Osamu; Uemura, Tomoko; Suno, Chiyo; Kobayashi, Takuya; Iwata, So</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">570-576</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Angiotensin II (AngII) plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngII and the G-protein-coupled receptors (GPCRs) AngII type 1 receptor (AT1R) and AngII type 2 receptor (AT2R).  We have solved the crystal structure of human AT2R binding the peptide ligand [Sar1, Ile8]AngII and its specific antibody at 3.2-Å resoln. [Sar1, Ile8]AngII interacts with both the 'core' binding domain, where the small-mol. ligands of AT1R and AT2R bind, and the 'extended' binding domain, which is equiv. to the allosteric modulator binding site of muscarinic acetylcholine receptor.  We generated an antibody fragment to stabilize the extended binding domain that functions as a pos. allosteric modulator.  We also identified a signature pos. charged cluster, which is conserved among peptide-binding receptors, to locate C termini at the bottom of the binding pocket.  The reported results should help with designing ligands for angiotensin receptors and possibly to other peptide GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYfv71Hv599bVg90H21EOLACvtfcHk0lj9-X9soYqdSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7fM&md5=27fefcc3b51c9cb881e7b47a4e0064c2</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0079-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0079-8%26sid%3Dliteratum%253Aachs%26aulast%3DAsada%26aufirst%3DH.%26aulast%3DHorita%26aufirst%3DS.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DShiroishi%26aufirst%3DM.%26aulast%3DShiimura%26aufirst%3DY.%26aulast%3DIwanari%26aufirst%3DH.%26aulast%3DHamakubo%26aufirst%3DT.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DKusano-Arai%26aufirst%3DO.%26aulast%3DUemura%26aufirst%3DT.%26aulast%3DSuno%26aufirst%3DC.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DIwata%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520angiotensin%2520II%2520type%25202%2520receptor%2520bound%2520to%2520an%2520angiotensin%2520II%2520analog%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D570%26epage%3D576%26doi%3D10.1038%2Fs41594-018-0079-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batyuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadybekov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamlynny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenstein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstikova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weierstall, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babaoglu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Calvo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span> <span> </span><span class="NLM_article-title">Structural basis for selectivity and diversity in angiotensin II receptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>544</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1038/nature22035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fnature22035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28379944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVKhs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=544&publication_year=2017&pages=327-332&author=H.+Zhangauthor=G.+W.+Hanauthor=A.+Batyukauthor=A.+Ishchenkoauthor=K.+L.+Whiteauthor=N.+Patelauthor=A.+Sadybekovauthor=B.+Zamlynnyauthor=M.+T.+Ruddauthor=K.+Hollensteinauthor=A.+Tolstikovaauthor=T.+A.+Whiteauthor=M.+S.+Hunterauthor=U.+Weierstallauthor=W.+Liuauthor=K.+Babaogluauthor=E.+L.+Mooreauthor=R.+D.+Katzauthor=J.+M.+Shipmanauthor=M.+Garcia-Calvoauthor=S.+Sharmaauthor=P.+Shethauthor=S.+M.+Soissonauthor=R.+C.+Stevensauthor=V.+Katritchauthor=V.+Cherezov&title=Structural+basis+for+selectivity+and+diversity+in+angiotensin+II+receptors&doi=10.1038%2Fnature22035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for selectivity and diversity in angiotensin II receptors</span></div><div class="casAuthors">Zhang, Haitao; Han, Gye Won; Batyuk, Alexander; Ishchenko, Andrii; White, Kate L.; Patel, Nilkanth; Sadybekov, Anastasiia; Zamlynny, Beata; Rudd, Michael T.; Hollenstein, Kaspar; Tolstikova, Alexandra; White, Thomas A.; Hunter, Mark S.; Weierstall, Uwe; Liu, Wei; Babaoglu, Kerim; Moore, Eric L.; Katz, Ryan D.; Shipman, Jennifer M.; Garcia-Calvo, Margarita; Sharma, Sujata; Sheth, Payal; Soisson, Stephen M.; Stevens, Raymond C.; Katritch, Vsevolod; Cherezov, Vadim</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">544</span>
        (<span class="NLM_cas:issue">7650</span>),
    <span class="NLM_cas:pages">327-332</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The angiotensin II receptors AT1R and AT2R serve as key components of the renin-angiotensin-aldosterone system.  AT1R has a central role in the regulation of blood pressure, but the function of AT2R is unclear and it has a variety of reported effects.  To identify the mechanisms that underlie the differences in function and ligand selectivity between these receptors, here the authors report crystal structures of human AT2R bound to an AT2R-selective ligand and to an AT1R/AT2R dual ligand, capturing the receptor in an active-like conformation.  Unexpectedly, helix VIII was found in a non-canonical position, stabilizing the active-like state, but at the same time preventing the recruitment of G proteins or β-arrestins, in agreement with the lack of signaling responses in std. cellular assays.  Structure-activity relationship, docking and mutagenesis studies revealed the crucial interactions for ligand binding and selectivity.  The authors' results thus provide insights into the structural basis of the distinct functions of the angiotensin receptors, and may guide the design of new selective ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonEzSnnYnMorVg90H21EOLACvtfcHk0lj9-X9soYqdSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVKhs7c%253D&md5=4473fb24c39c800b2126b1303c02afec</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnature22035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22035%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DBatyuk%26aufirst%3DA.%26aulast%3DIshchenko%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DSadybekov%26aufirst%3DA.%26aulast%3DZamlynny%26aufirst%3DB.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DHollenstein%26aufirst%3DK.%26aulast%3DTolstikova%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DT.%2BA.%26aulast%3DHunter%26aufirst%3DM.%2BS.%26aulast%3DWeierstall%26aufirst%3DU.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBabaoglu%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DE.%2BL.%26aulast%3DKatz%26aufirst%3DR.%2BD.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DGarcia-Calvo%26aufirst%3DM.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSheth%26aufirst%3DP.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DCherezov%26aufirst%3DV.%26atitle%3DStructural%2520basis%2520for%2520selectivity%2520and%2520diversity%2520in%2520angiotensin%2520II%2520receptors%26jtitle%3DNature%26date%3D2017%26volume%3D544%26spage%3D327%26epage%3D332%26doi%3D10.1038%2Fnature22035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guimond, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span> <span> </span><span class="NLM_article-title">Saralasin and sarile are AT2 receptor agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1132</span>, <span class="refDoi"> DOI: 10.1021/ml500278g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500278g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlynu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1129-1132&author=M.+O.+Guimondauthor=M.+Hallbergauthor=N.+Gallo-Payetauthor=C.+Wallinder&title=Saralasin+and+sarile+are+AT2+receptor+agonists&doi=10.1021%2Fml500278g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Saralasin and Sarile Are AT2 Receptor Agonists</span></div><div class="casAuthors">Guimond, Marie-Odile; Hallberg, Mathias; Gallo-Payet, Nicole; Wallinder, Charlotta</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1129-1132</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Saralasin and sarile, extensively studied over the past 40 years as angiotensin II (Ang II) receptor blockers, induce neurite outgrowth in a NG108-15 cell assay to a similar extent as the endogenous Ang II.  In their undifferentiated state, these cells express mainly the AT2 receptor.  The neurite outgrowth was inhibited by preincubation with the AT2 receptor selective antagonist PD 123,319, which suggests that the obsd. outgrowth was mediated by the AT2 receptor.  Neither saralasin nor sarile reduced the neurite outgrowth induced by Ang II proving that the two octapeptides do not act as antagonists at the AT2 receptor and may be considered as AT2 receptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Y9fqgIPsgLVg90H21EOLACvtfcHk0lgaMUqn2k9NiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlynu7rE&md5=2417e096b8cb64f4dfe0e2aaf7c13755</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fml500278g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500278g%26sid%3Dliteratum%253Aachs%26aulast%3DGuimond%26aufirst%3DM.%2BO.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DWallinder%26aufirst%3DC.%26atitle%3DSaralasin%2520and%2520sarile%2520are%2520AT2%2520receptor%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1129%26epage%3D1132%26doi%3D10.1021%2Fml500278g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition</span>. <i>J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1097/00004872-199917030-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2F00004872-199917030-00013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10100078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1MXjsVOgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=397-404&author=S.+Miuraauthor=S.+S.+Karnik&title=Angiotensin+II+type+1+and+type+2+receptors+bind+angiotensin+II+through+different+types+of+epitope+recognition&doi=10.1097%2F00004872-199917030-00013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition</span></div><div class="casAuthors">Miura, Shin-Ichiro; Karnik, Sadashiva S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-404</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This study was designed to demonstrate that the principle of mol. recognition underlying high-affinity binding of angiotensin II to the type 2 (AT2) receptor is distinct from that of the type 1 (AT1) receptor.  In general, the same functional pharmacophores in hormones are used to bind and activate different subtypes of cell surface receptors.  However, the binding of angiotensin II to the AT2 receptor is distinct from that of the AT1 receptor.  To systematically evaluate the effect of modification of angiotensin II side chains on binding to both the receptors, several analogs of angiotensin II were synthesized.  Rat AT1 or AT2 receptors expressed in COS1 cell membranes were used to det. the affinity of analogs using radioligand competition binding expts. under equil. conditions.  Modifications of all angiotensin II side chains affected binding to the AT2 receptor to nearly similar extents.  In contrast, binding to the AT1 receptor was significantly affected by modifications at side chain positions 2, 4, 6 and 7.  In accordance with previous observations that Tyr4- or Phe8-modified angiotensin II analogs antagonized vasoconstriction mediated exclusively by the AT1 receptor, binding to the AT1 receptor was significantly dependent on Tyr4 or Phe8 of angiotensin II, whereas binding to the AT2 receptor was not.  Rather surprisingly, the affinity profile of several angiotensin II analogs towards the AT2 receptor was similar to the measured affinity of the constitutively active N111G mutant AT1 receptor.  These results suggest that the AT2-receptor pharmacophore is very distinct from that of the AT1 receptor.  The AT1 receptor is in a constrained conformation and is activated only when bound to angiotensin II.  In contrast, the AT2 receptor is relaxed in that no single interaction is crit. for binding, like the N111G mutant AT1 receptor, which is constitutively active.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHKqce7-EWg7Vg90H21EOLACvtfcHk0lgaMUqn2k9NiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsVOgsbg%253D&md5=dbbe4d8e9ed840e8df09703519408e9d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1097%2F00004872-199917030-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004872-199917030-00013%26sid%3Dliteratum%253Aachs%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26atitle%3DAngiotensin%2520II%2520type%25201%2520and%2520type%25202%2520receptors%2520bind%2520angiotensin%2520II%2520through%2520different%2520types%2520of%2520epitope%2520recognition%26jtitle%3DJ.%2520Hypertens.%26date%3D1999%26volume%3D17%26spage%3D397%26epage%3D404%26doi%3D10.1097%2F00004872-199917030-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span> <span> </span><span class="NLM_article-title">Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane helix-2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">24299</span>– <span class="NLM_lpage">24305</span>, <span class="refDoi"> DOI: 10.1074/jbc.M202743200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1074%2Fjbc.M202743200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11983705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlOhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=24299-24305&author=S.+Miuraauthor=S.+S.+Karnik&title=Constitutive+activation+of+angiotensin+II+type+1+receptor+alters+the+orientation+of+transmembrane+helix-2&doi=10.1074%2Fjbc.M202743200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane helix-2</span></div><div class="casAuthors">Miura, Shin-Ichiro; Karnik, Sadashiva S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">24299-24305</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A key step in transmembrane (TM) signal transduction by G-protein-coupled receptors (GPCRs) is the ligand-induced conformational change of the receptor, which triggers the activation of a guanine nucleotide-binding protein.  GPCRs contain a seven-TM helical structure essential for signal transduction in response to a large variety of sensory and hormonal signals.  Primary structure comparison of GPCRs has shown that the second TM helix contains a highly conserved Asp residue, which is crit. for agonist activation in these receptors.  How conformational changes in TM2 relate to signal transduction by a GPCR is not known, because activation-induced conformational changes in TM2 helix have not been measured.  Here we use modification of reporter cysteines to measure water accessibility at specific residues in TM2 of the type 1 receptor for the octapeptide hormone angiotensin II.  Activation-dependent changes in the accessibility of Cys76 on TM2 were measured in constitutively activated mutants.  These changes were directly correlated with measurement of function, establishing the link between phys. changes in TM2 and function.  Accessibility changes were measured at several consecutive residues on TM2, which suggest that TM2 undergoes a transmembrane movement in response to activation.  This is the first report of in situ measurement of TM2 movement in a GPCR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr88wlFJzPET7Vg90H21EOLACvtfcHk0ljDR0-5oqp1ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlOhsL4%253D&md5=aaf855e11ac5bfb5c0cf993a1c7b8ade</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M202743200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M202743200%26sid%3Dliteratum%253Aachs%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26atitle%3DConstitutive%2520activation%2520of%2520angiotensin%2520II%2520type%25201%2520receptor%2520alters%2520the%2520orientation%2520of%2520transmembrane%2520helix-2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D24299%26epage%3D24305%26doi%3D10.1074%2Fjbc.M202743200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span> <span> </span><span class="NLM_article-title">Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4026</span>– <span class="NLM_lpage">4035</span>, <span class="refDoi"> DOI: 10.1093/emboj/19.15.4026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1093%2Femboj%2F19.15.4026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10921883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVKqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=4026-4035&author=S.+Miuraauthor=S.+S.+Karnik&title=Ligand-independent+signals+from+angiotensin+II+type+2+receptor+induce+apoptosis&doi=10.1093%2Femboj%2F19.15.4026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis</span></div><div class="casAuthors">Miura, Shin-Ichiro; Karnik, Sadashiva S.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4026-4035</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Conventional models of ligand-receptor regulation predict that agonists enhance the tone of signals generated by the receptor in the absence of ligand.  Contrary to this paradigm, stimulation of the type 2 (AT2) receptor by angiotensin II (Ang II) is not required for induction of apoptosis but the level of receptor protein expression is crit.  The authors compared Ang II-dependent and -independent AT2 receptor signals involved in regulating apoptosis of cultured fibroblasts, epithelial cells and vascular smooth muscle cells.  The authors found that induction of apoptosis-blocked by pharmacol. inhibition of p38 mitogen-activated protein kinase and caspase 3-is a constitutive function of the AT2 receptor.  Biochem. and genetic studies suggest that the level of AT2 receptor expression is crit. for physiol. ontogenesis and its expression is restricted postnatally, coinciding with cessation of developmental apoptosis.  Re-expression of the AT2 receptor in remodeling tissues in the adult is linked to control of tissue growth and regeneration.  Therefore, the authors propose that overexpression of the AT2 receptor itself is a signal for apoptosis that does not require the renin-angiotensin system hormone Ang II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5kbZxTVjwUrVg90H21EOLACvtfcHk0ljDR0-5oqp1ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVKqu78%253D&md5=c3c1c2305ef3084e3ec04f548094a381</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.15.4026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.15.4026%26sid%3Dliteratum%253Aachs%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26atitle%3DLigand-independent%2520signals%2520from%2520angiotensin%2520II%2520type%25202%2520receptor%2520induce%2520apoptosis%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D4026%26epage%3D4035%26doi%3D10.1093%2Femboj%2F19.15.4026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharov, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nass, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbah, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, O. A.</span></span> <span> </span><span class="NLM_article-title">Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1926</span>– <span class="NLM_lpage">1935</span>, <span class="refDoi"> DOI: 10.1172/JCI119360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1172%2FJCI119360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9109437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2sXisF2qu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1997&pages=1926-1935&author=Y.+H.+Liuauthor=X.+P.+Yangauthor=V.+G.+Sharovauthor=O.+Nassauthor=H.+N.+Sabbahauthor=E.+Petersonauthor=O.+A.+Carretero&title=Effects+of+angiotensin-converting+enzyme+inhibitors+and+angiotensin+II+type+1+receptor+antagonists+in+rats+with+heart+failure.+Role+of+kinins+and+angiotensin+II+type+2+receptors&doi=10.1172%2FJCI119360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors</span></div><div class="casAuthors">Liu, Yun-He; Yang, Xiao-Ping; Sharov, Victor G.; Nass, Omar; Sabbah, Hani N.; Peterson, Edward; Carretero, Oscar A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1926-1935</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Angiotensin-converting enzyme inhibitors (ACEi) improve cardiac function and remodeling and prolong survival in patients with heart failure (HF).  Blockade of the renin-angiotensin system (RAS) with an angiotensin II type 1 receptor antagonist (AT1-ant) may have a similar beneficial effect.  In addn. to inhibition of the RAS, ACEi may also act by inhibiting kinin destruction, whereas AT1-ant may block the RAS at the level of the AT1 receptor and activate the angiotensin II type 2 (AT2) receptor.  Using a model of HF induced by myocardial infarction (MI) in rats, we studied the role of kinins in the cardioprotective effect of ACEi.  We also investigated whether an AT1-ant has a similar effect and whether these effects are partly due to activation of the AT2 receptor.  Two months after MI, rats were treated for 2 mo with: (a) vehicle; (b) the ACEi ramipril, with and without the B2 receptor antagonist icatibant (B2-ant); or (c) an AT1-ant with and without an AT2-antagonist (AT2-ant) or B2-ant.  Vehicle-treated rats had a significant increase in left ventricular end-diastolic (LVEDV) and end-systolic vol. (LVESV) as well as interstitial collagen deposition and cardiomyocyte size, whereas ejection fraction was decreased.  Left ventricular remodeling and cardiac function were improved by the ACEi and AT1-ant.  The B2-ant blocked most of the cardioprotective effect of the ACEi, whereas the effect of the AT1-ant was blocked by the AT2-ant.  The decreases in LVEDV and LVESV caused by the AT1-ant were also partially blocked by the B2-ant.  We concluded that (a) in HF both ACEi and AT1-ant have a cardioprotective effect, which could be due to either a direct action on the heart or secondary to altered hemodynamics, or both; and (b) the effect of the ACEi is mediated in part by kinins, whereas that of the AT1-ant is triggered by activation of the AT2 receptor and is also mediated in part by kinins.  We speculate that in HF, blockade of AT1 receptors increases both renin and angiotensins; these angiotensins stimulate the AT2 receptor, which in turn may play an important role in the therapeutic effect of the AT1-ant via kinins and other autacoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkxavfJUkJrrVg90H21EOLACvtfcHk0ljDR0-5oqp1ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisF2qu7g%253D&md5=81f7f7fad69b2467e6c1a751b5fbab91</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1172%2FJCI119360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI119360%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BH.%26aulast%3DYang%26aufirst%3DX.%2BP.%26aulast%3DSharov%26aufirst%3DV.%2BG.%26aulast%3DNass%26aufirst%3DO.%26aulast%3DSabbah%26aufirst%3DH.%2BN.%26aulast%3DPeterson%26aufirst%3DE.%26aulast%3DCarretero%26aufirst%3DO.%2BA.%26atitle%3DEffects%2520of%2520angiotensin-converting%2520enzyme%2520inhibitors%2520and%2520angiotensin%2520II%2520type%25201%2520receptor%2520antagonists%2520in%2520rats%2520with%2520heart%2520failure.%2520Role%2520of%2520kinins%2520and%2520angiotensin%2520II%2520type%25202%2520receptors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1997%26volume%3D99%26spage%3D1926%26epage%3D1935%26doi%3D10.1172%2FJCI119360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gohlke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pees, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.31.1.349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.HYP.31.1.349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9453327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1cXptF2ntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1998&pages=349-355&author=P.+Gohlkeauthor=C.+Peesauthor=T.+Unger&title=AT2+receptor+stimulation+increases+aortic+cyclic+GMP+in+SHRSP+by+a+kinin-dependent+mechanism&doi=10.1161%2F01.HYP.31.1.349"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism</span></div><div class="casAuthors">Gohlke, Peter; Pees, Christiane; Unger, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1, Pt. 2</span>),
    <span class="NLM_cas:pages">349-355</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">In the present study we tested the hypothesis whether an angiotensin AT2 receptor-mediated stimulation of the bradykinin (BK)/nitric oxide (NO) system can account for the effects of AT1 receptor antagonism on aortic cGMP described previously in SHRSP.  Adult SHRSP were treated for 4 h with angiotensin II (ANG II) (30 ng/kg per min i.v.) or vehicle (0.9% NaCl i.v.).  Animals were pretreated with vehicle, losartan (100 mg/kg p.o.), PD 123319 (30 mg/kg i.v.), losartan plus PD 123319, icatibant (500 μg/kg i.v.), NG-nitro-L-arginine Me ester (L-NAME; 1 mg/kg i.v.), or minoxidil (3 mg/kg i.v.).  Mean arterial blood pressure (MAP) was continuously monitored over the 4-h exptl. period, and plasma ANG II and aortic cGMP were measured by RIA at the end of the study.  ANG II infusion over 4 h raised MAP by about 20 mm Hg.  Losartan alone or losartan plus ANG II as well as minoxidil plus ANG II markedly reduced blood pressure when compared to vehicle-treated or ANG II-treated animals, resp.  Plasma levels of ANG II were increased 2-fold by ANG II infusion alone or by ANG II in combination with icatibant, L-NAME, or minoxidil.  The increase in plasma ANG II levels was even more pronounced after losartan treatment.  Aortic cGMP content was significantly increased by ANG II, losartan, losartan plus ANG II, and minoxidil plus ANG II by 60%, 45%, 68%, and 52%, resp.  The effects of ANG II and of losartan plus ANG II on aortic cGMP content were both blocked by cotreatment with the AT2 receptor antagonist PD 123319.  Icatibant and L-NAME abolished the effects of ANG II on aortic cGMP.  Our results demonstrate the following: (1) ANG II increases aortic cGMP by an AT2 receptor-mediated action because the effect could be prevented by an AT2 receptor antagonist; (2) the effect of ANG II was not secondary to blood pressure increase because it remained under redn. of MAP with minoxidil; (3) losartan increased aortic cGMP most likely by increasing plasma ANG II levels with a subsequent stimulation of AT2 receptor; and (4) the effects of AT2 receptor stimulation are mediated by BK and, subsequently, NO because they were abolished by B2 receptor blockade as well as by NO synthase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-f9ZtGY8CmbVg90H21EOLACvtfcHk0lj4j1f0i0b11w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXptF2ntA%253D%253D&md5=dfcbb507c01312b422657d202fd54071</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.31.1.349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.31.1.349%26sid%3Dliteratum%253Aachs%26aulast%3DGohlke%26aufirst%3DP.%26aulast%3DPees%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DAT2%2520receptor%2520stimulation%2520increases%2520aortic%2520cyclic%2520GMP%2520in%2520SHRSP%2520by%2520a%2520kinin-dependent%2520mechanism%26jtitle%3DHypertension%26date%3D1998%26volume%3D31%26spage%3D349%26epage%3D355%26doi%3D10.1161%2F01.HYP.31.1.349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fushiki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, K.</span></span> <span> </span><span class="NLM_article-title">Contrasting effects of angiotensin type 1 and 2 receptors on nitric oxide release under pressure</span>. <i>Hypertens. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1291/hypres.25.779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1291%2Fhypres.25.779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12452333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlSltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2002&pages=779-786&author=S.+Haradaauthor=T.+Nakataauthor=A.+Oguniauthor=H.+Kidoauthor=T.+Hattaauthor=R.+Fukuyamaauthor=S.+Fushikiauthor=S.+Sasakiauthor=K.+Takeda&title=Contrasting+effects+of+angiotensin+type+1+and+2+receptors+on+nitric+oxide+release+under+pressure&doi=10.1291%2Fhypres.25.779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Contrasting effects of angiotensin type 1 and 2 receptors on nitric oxide release under pressure</span></div><div class="casAuthors">Harada, Sanae; Nakata, Tetsuo; Oguni, Atsuhiko; Kido, Hidenori; Hatta, Tsuguru; Fukuyama, Ryuichi; Fushiki, Shinji; Sasaki, Susumu; Takeda, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">HRESE4</span>;
        ISSN:<span class="NLM_cas:issn">0916-9636</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Hypertension</span>)
        </div><div class="casAbstract">This study was designed to test the hypothesis that increased pressure itself could cause endothelial dysfunction and lead to decreased nitric oxide (NO) release, partly through effects on the tissue renin angiotensin system in hypertension.  Cultured endothelial cells (ECs) isolated from the aortas of WKY rats were continuously exposed to a pressure of 150 mmHg in a CO2 incubator for 72 h using a pressure system, and the NOx (NO2 and NO3) and angiotensin II (Ang II) concns. in the supernatant were measured.  An Ang II type 1 receptor (AT1R) antagonist (losartan) and an Ang II type 2 receptor (AT2R) antagonist (PD 123319) were added to the medium.  The expression of AT1R and AT2R mRNAs was also examd.  Pressure loading significantly decreased the NO release from ECs.  Concomitant administration of losartan restored NO release to the level before the application of pressure.  This effect of losartan was blocked by simultaneous administration of PD 123319, bradykinin type 2 receptor antagonist, and NO synthase inhibitor.  The Ang II concn. was increased by pressure and was further increased by losartan.  The gene expression of AT1R was not changed by pressure, but AT2R mRNA was increased almost 2-fold.  These results indicate that high pressure itself attenuates NO release from ECs, and that losartan improves NO release by activating the bradykinin system via AT2R stimulation.  In addn., the increase of AT2R gene expression in ECs during exposure to pressure may compensate for the redn. of NO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrncBdSbx7Y7LVg90H21EOLACvtfcHk0lj4j1f0i0b11w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlSltb4%253D&md5=14d5437ff95524855095e6097e76ae53</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1291%2Fhypres.25.779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1291%252Fhypres.25.779%26sid%3Dliteratum%253Aachs%26aulast%3DHarada%26aufirst%3DS.%26aulast%3DNakata%26aufirst%3DT.%26aulast%3DOguni%26aufirst%3DA.%26aulast%3DKido%26aufirst%3DH.%26aulast%3DHatta%26aufirst%3DT.%26aulast%3DFukuyama%26aufirst%3DR.%26aulast%3DFushiki%26aufirst%3DS.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DTakeda%26aufirst%3DK.%26atitle%3DContrasting%2520effects%2520of%2520angiotensin%2520type%25201%2520and%25202%2520receptors%2520on%2520nitric%2520oxide%2520release%2520under%2520pressure%26jtitle%3DHypertens.%2520Res.%26date%3D2002%26volume%3D25%26spage%3D779%26epage%3D786%26doi%3D10.1291%2Fhypres.25.779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Batenburg, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrelds, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, C.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kats, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danser, A. H. J.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor-mediated vasodilatation in human coronary microarteries</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2296</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000128696.12245.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.CIR.0000128696.12245.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=15117835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslOru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2004&pages=2296-2301&author=W.+W.+Batenburgauthor=I.+M.+Garreldsauthor=C.C.+Bernasconiauthor=L.+Juillerat-Jeanneretauthor=J.+P.+van+Katsauthor=P.+R.+Saxenaauthor=A.+H.+J.+Danser&title=Angiotensin+II+type+2+receptor-mediated+vasodilatation+in+human+coronary+microarteries&doi=10.1161%2F01.CIR.0000128696.12245.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II Type 2 Receptor-Mediated Vasodilation in Human Coronary Microarteries</span></div><div class="casAuthors">Batenburg, Wendy W.; Garrelds, Ingrid M.; Bernasconi, Catherine Chapuis; Juillerat-Jeanneret, Lucienne; Van Kats, Jorge P.; Saxena, Pramod R.; Danser, A. H. Jan</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2296-2301</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background- Angiotensin (Ang) II type 2 (AT2) receptor stimulation results in coronary vasodilation in the rat heart.  In contrast, AT2 receptor-mediated vasodilation could not be obsd. in large human coronary arteries.  We studied Ang II-induced vasodilation of human coronary microarteries (HCMAs).  Methods and Results- HCMAs (diam., 160 to 500 μm) were obtained from 49 heart valve donors (age, 3 to 65 yr).  Ang II constricted HCMAs, mounted in Mulvany myographs, in a concn.-dependent manner (pEC50, 8.6; maximal effect [Emax], 79% of the contraction to 100 mmol/L K+).  The Ang II type 1 receptor antagonist irbesartan prevented this vasoconstriction, whereas the AT2 receptor antagonist PD 123319 increased Emax to 97%.  The increase in Emax was larger in older donors (correlation ΔEmax vs. age, r=0.47).  The PD 123319-induced potentiation was not obsd. in the presence of the NO synthase inhibitor L-NAME, the bradykinin type 2 (B2) receptor antagonist Hoe 140, or after removal of the endothelium.  Ang II relaxed U 46619-preconstricted HCMAs in the presence of irbesartan by maximally 49%, and PD 123319 prevented this relaxation.  Finally, radioligand binding studies and reverse transcription-polymerase chain reaction confirmed the expression of AT2 receptors in HCMAs.  Conclusions- AT2 receptor-mediated vasodilation in the human heart appears to be limited to coronary microarteries and is mediated by B2 receptors and NO.  Most likely, AT2 receptors are located on endothelial cells, and their contribution increases with age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRYo8y3N9J27Vg90H21EOLACvtfcHk0lj4j1f0i0b11w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslOru7c%253D&md5=0dcd1f98b6c7fac4e516f64585ce81e6</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000128696.12245.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000128696.12245.57%26sid%3Dliteratum%253Aachs%26aulast%3DBatenburg%26aufirst%3DW.%2BW.%26aulast%3DGarrelds%26aufirst%3DI.%2BM.%26aulast%3DBernasconi%26aufirst%3DC.C.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3Dvan%2BKats%26aufirst%3DJ.%2BP.%26aulast%3DSaxena%26aufirst%3DP.%2BR.%26aulast%3DDanser%26aufirst%3DA.%2BH.%2BJ.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor-mediated%2520vasodilatation%2520in%2520human%2520coronary%2520microarteries%26jtitle%3DCirculation%26date%3D2004%26volume%3D109%26spage%3D2296%26epage%3D2301%26doi%3D10.1161%2F01.CIR.0000128696.12245.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozono, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siragy, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R. M.</span></span> <span> </span><span class="NLM_article-title">Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.32.1.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.HYP.32.1.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9674641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVOlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1998&pages=78-83&author=Z.+Q.+Wangauthor=A.+F.+Mooreauthor=R.+Ozonoauthor=H.+M.+Siragyauthor=R.+M.+Carey&title=Immunolocalization+of+subtype+2+angiotensin+II+%28AT2%29+receptor+protein+in+rat+heart&doi=10.1161%2F01.HYP.32.1.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart</span></div><div class="casAuthors">Wang, Zhi-Qin; Moore, Allan F.; Ozono, Ryoji; Siragy, Helmy M.; Carey, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-83</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The expression and localization of AT2 receptor protein in the rat heart was investigated using an antipeptide polyclonal antibody against the native rat AT2 receptor by light microscopic immunocytochem. and Western blot anal.  In frozen tissue sections, pos. immunostaining was obsd. in the myocardium and coronary vessels throughout the ventricle and atrium of neonatal and young rat hearts.  Coronary vessels of the neonatal heart were more intensely stained compared with the surrounding myocardium.  Pos. immunoreactivity in the coronary vessels of young rats was localized to vascular endothelium but not in the smooth muscle cells.  Preadsorption controls were all neg.  Western blot anal. showed that the AT2 receptor protein (≈44 kDa) was detectable from the AT2 receptor-transfected COS-7 cells and neonatal rat cardiac myocytes but not from fibroblasts or young rat aortic smooth muscle cells.  The neonatal rat heart expressed significantly more AT2 receptors than young rat heart.  These data provide the 1st direct evidence for the expression and localization of AT2 receptor protein in the rat heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosaV_hcPuYkLVg90H21EOLACvtfcHk0lg4cpes2_RaTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVOlu7Y%253D&md5=48345b749af4413818bd427760967838</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.32.1.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.32.1.78%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%2BQ.%26aulast%3DMoore%26aufirst%3DA.%2BF.%26aulast%3DOzono%26aufirst%3DR.%26aulast%3DSiragy%26aufirst%3DH.%2BM.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26atitle%3DImmunolocalization%2520of%2520subtype%25202%2520angiotensin%2520II%2520%2528AT2%2529%2520receptor%2520protein%2520in%2520rat%2520heart%26jtitle%3DHypertension%26date%3D1998%26volume%3D32%26spage%3D78%26epage%3D83%26doi%3D10.1161%2F01.HYP.32.1.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, A. W.</span></span> <span> </span><span class="NLM_article-title">Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">F437</span>– <span class="NLM_lpage">F446</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.1999.277.3.F437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajprenal.1999.277.3.F437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10484527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1MXmt1Gisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1999&pages=F437-F446&author=N.+Miyataauthor=F.+Parkauthor=X.+F.+Liauthor=A.+W.+Cowley&title=Distribution+of+angiotensin+AT1+and+AT2+receptor+subtypes+in+the+rat+kidney&doi=10.1152%2Fajprenal.1999.277.3.F437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney</span></div><div class="casAuthors">Miyata, Noriyuki; Park, Frank; Li, Xiao Feng; Cowley, Allen W., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">3, Pt. 2</span>),
    <span class="NLM_cas:pages">F437-F446</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">ANG II contributes importantly to the regulation of renal vascular resistance, glomerular filtration, and tubular epithelial transport, yet there remains a paucity of information regarding the localization of the ANG II type 1 and 2 (AT1 and AT2) receptors within the rat kidney particularly within the vasculature.  The present study was designed to localize the transcriptional and translational site(s) of AT1 and AT2 receptor (AT1R and AT2R, resp.) expression within the rat kidney.  Using immunohistochem., the authors detected the AT1R translational sites throughout the kidney, with the strongest labeling found in the vasculature of the renal cortex and the proximal tubules of the outer medulla.  The AT2R protein expression was found throughout the rat kidney, although there was little to no expression found in the glomerulus and medullary thick ascending limbs of Henle (TAL).  Gene-specific primers were then designed to distinguish between the receptor subtypes within microdissected renal tubular and vascular segments using RT-PCR.  AT1AR, AT1BR, and AT2R mRNA were found within the renal vasculature (afferent arterioles, arcuate artery, and outer medullary descending vasa recta).  The mRNA for both the AT1R isoforms was also detected in the glomeruli and the renal tubules (proximal tubules, TAL, and collecting ducts); however, no AT2R mRNA was detected within the glomerulus and was inconsistently found within the medullary TAL (MTAL).  Taken together, these data show that mRNA for the AT1R subtypes was located in all of the renal tubular and vascular segments.  Evidence for AT2R mRNA was also found in all but two of the vascular and tubular segments, the MTAL, and the glomeruli.  These results are consistent with the whole tissue immunohistochem. localized receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6N5uZmO-x2LVg90H21EOLACvtfcHk0lg4cpes2_RaTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt1Gisb0%253D&md5=cf3b91f9d223a835f927d86697124493</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.1999.277.3.F437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.1999.277.3.F437%26sid%3Dliteratum%253Aachs%26aulast%3DMiyata%26aufirst%3DN.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DX.%2BF.%26aulast%3DCowley%26aufirst%3DA.%2BW.%26atitle%3DDistribution%2520of%2520angiotensin%2520AT1%2520and%2520AT2%2520receptor%2520subtypes%2520in%2520the%2520rat%2520kidney%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1999%26volume%3D277%26spage%3DF437%26epage%3DF446%26doi%3D10.1152%2Fajprenal.1999.277.3.F437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span> <span> </span><span class="NLM_article-title">Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion</span>. <i>J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1075</span>– <span class="NLM_lpage">1081</span>, <span class="refDoi"> DOI: 10.1097/00004872-200106000-00012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2F00004872-200106000-00012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11403356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlSqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=1075-1081&author=F.+Bonnetauthor=M.+E.+Cooperauthor=R.+M.+Careyauthor=D.+Casleyauthor=Z.+Cao&title=Vascular+expression+of+angiotensin+type+2+receptor+in+the+adult+rat%3A+influence+of+angiotensin+II+infusion&doi=10.1097%2F00004872-200106000-00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion</span></div><div class="casAuthors">Bonnet, Fabrice; Cooper, Mark E.; Carey, Robert M.; Casley, David; Cao, Zemin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1075-1081</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The aim of this study was to investigate the relative role of the angiotensin type 1 (AT1) and type 2 (AT2) receptors in mediating angiotensin II-induced regulation of AT2 receptor in mesenteric artery.  Sprague-Dawley rats were infused with either angiotensin II or vehicle for 14 days at a dose of 58.3 ng/min.  Ang II-infused rats were allocated to receive either an AT1 antagonist, valsartan at a dose of 30 mg/kg per day or the AT2 receptor antagonist PD123319 at a dose of 830 ng/min.  Gene and protein expression of the AT2 receptor in the mesenteric vasculature was assessed by quant. reverse transcriptase polymerase chain reaction, immunohistochem. and by in vitro autoradiog. with a specific radioligand, 125I-CGP 42112B.  The AT2 receptor mRNA and protein were detected in the mesenteric artery from adult rats.  Both nuclear emulsion and immunohistochem. staining showed expression of the AT2 receptor in the adventitial and medial layers.  Compared to control rats, angiotensin II infusion was assocd. with a significant increase in the AT2 receptor expression.  Valsartan treatment significantly reduced AT2 receptor gene expression, with no significant effect of PD123319 on this parameter.  This study confirms that the presence of the AT2 receptor in mesenteric arteries in adult rats, shows an up-regulation of the AT2 receptor following angiotensin II infusion and suggests a role for the AT1 receptor in this regulation.  In view of the recently demonstrated effects of the AT2 receptor, these findings may be relevant to the role of the AT2 receptor in the pathophysiol. of vascular remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9d57rNnrFLVg90H21EOLACvtfcHk0lg4cpes2_RaTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlSqs7c%253D&md5=61acfa50273553f0a1eb53624693b00b</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1097%2F00004872-200106000-00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004872-200106000-00012%26sid%3Dliteratum%253Aachs%26aulast%3DBonnet%26aufirst%3DF.%26aulast%3DCooper%26aufirst%3DM.%2BE.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26aulast%3DCasley%26aufirst%3DD.%26aulast%3DCao%26aufirst%3DZ.%26atitle%3DVascular%2520expression%2520of%2520angiotensin%2520type%25202%2520receptor%2520in%2520the%2520adult%2520rat%253A%2520influence%2520of%2520angiotensin%2520II%2520infusion%26jtitle%3DJ.%2520Hypertens.%26date%3D2001%26volume%3D19%26spage%3D1075%26epage%3D1081%26doi%3D10.1097%2F00004872-200106000-00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nahmod, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raiden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamone, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamberale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Calotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahmod, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geffner, J. R.</span></span> <span> </span><span class="NLM_article-title">Control of dendritic cell differentiation by angiotensin II</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1096/fj.02-0755fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1096%2Ffj.02-0755fje" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12514109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFaquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=491-493&author=K.+A.+Nahmodauthor=M.+E.+Vermeulenauthor=S.+Raidenauthor=G.+A.+Salamoneauthor=R.+Gamberaleauthor=P.+Fernandez-Calottiauthor=A.+Alvarezauthor=V.+Nahmodauthor=M.+Giordanoauthor=J.+R.+Geffner&title=Control+of+dendritic+cell+differentiation+by+angiotensin+II&doi=10.1096%2Ffj.02-0755fje"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Control of dendritic cell differentiation by angiotensin II</span></div><div class="casAuthors">Nahmod, Karen A.; Vermeulen, Monica E.; Radien, Silvina; Salamone, Gabriela; Gamberale, Romina; Fernandez-Calotti, Paula; Alvarez, Azucena; Nahmod, Victor; Giordano, Mirta; Geffner, Jorge R.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">491-493, 10.1096/fj.02-0755fje</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Here the authors analyze the role of the angiotensinergic system in the differentiation of dendritic cells (DC).  The authors found that human monocytes produce angiotensin II (AII) and express AT1 and AT2 receptors for AII.  DC differentiated from human monocytes in the presence of AT1 receptor antagonists losartan or candesartan show very low levels of CD1a expression and poor endocytic and allostimulatory activities.  By contrast, DC differentiation in the presence of either the AT2 receptor antagonist PD 123319 or exogenous AII results in the development of nonadherent cells with CD1a expression and endocytic and allostimulatory activities higher than control DC.  Similar contrasting effects were obsd. in mouse DC obtained from bone marrow cultures supplemented with granulocyte-monocyte colony-stimulating factor.  DC differentiated in the presence of the AT1 receptor antagonist losartan express lower levels of CD11c, CD40, and Ia and display a lower ability to endocyte horseradish peroxidase (HRP) and to induce antibody responses in vivo, compared with controls.  By contrast, DC differentiation in the presence of either the AT2 receptor antagonist PD 123319 or exogenous AII results in cells with high levels of CD11c, CD40, and Ia, as well as high ability to endocyte HRP and to induce antibody responses in vivo.  The authors' results support the notion that the differentiation of DC is regulated by AII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyQ116_bflLVg90H21EOLACvtfcHk0lgPSxvszmrQnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFaquro%253D&md5=8fd0d8cfbadb117e39b12eca80724c4c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1096%2Ffj.02-0755fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.02-0755fje%26sid%3Dliteratum%253Aachs%26aulast%3DNahmod%26aufirst%3DK.%2BA.%26aulast%3DVermeulen%26aufirst%3DM.%2BE.%26aulast%3DRaiden%26aufirst%3DS.%26aulast%3DSalamone%26aufirst%3DG.%2BA.%26aulast%3DGamberale%26aufirst%3DR.%26aulast%3DFernandez-Calotti%26aufirst%3DP.%26aulast%3DAlvarez%26aufirst%3DA.%26aulast%3DNahmod%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DM.%26aulast%3DGeffner%26aufirst%3DJ.%2BR.%26atitle%3DControl%2520of%2520dendritic%2520cell%2520differentiation%2520by%2520angiotensin%2520II%26jtitle%3DFASEB%2520J.%26date%3D2003%26volume%3D17%26spage%3D491%26epage%3D493%26doi%3D10.1096%2Ffj.02-0755fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altarche-Xifró, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miteva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imboden, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Identification of noncytotoxic and IL-10–producing CD8<sup>+</sup>AT2R<sup>+</sup> T cell population in response to ischemic heart injury</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">6286</span>– <span class="NLM_lpage">6293</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0903681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.4049%2Fjimmunol.0903681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=20935205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlOhsbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2010&pages=6286-6293&author=C.+Curatoauthor=S.+Slavicauthor=J.+Dongauthor=A.+Skorskaauthor=W.+Altarche-Xifr%C3%B3author=K.+Mitevaauthor=E.+Kaschinaauthor=A.+Thielauthor=H.+Imbodenauthor=J.+Wangauthor=U.+Steckelingsauthor=G.+Steinhoffauthor=T.+Ungerauthor=J.+Li&title=Identification+of+noncytotoxic+and+IL-10%E2%80%93producing+CD8%2BAT2R%2B+T+cell+population+in+response+to+ischemic+heart+injury&doi=10.4049%2Fjimmunol.0903681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Noncytotoxic and IL-10-Producing CD8+AT2R+ T Cell Population in Response to Ischemic Heart Injury</span></div><div class="casAuthors">Curato, Caterina; Slavic, Svetlana; Dong, Jun; Skorska, Anna; Altarche-Xifro, Wassim; Miteva, Kapka; Kaschina, Elena; Thiel, Andreas; Imboden, Hans; Wang, Jianan; Steckelings, Ulrike; Steinhoff, Gustav; Unger, Thomas; Li, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6286-6293</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Emerging evidence suggests a cardioprotective role of the angiotensin AT2R, albeit the underlying cellular mechanisms are not well understood.  We aimed in this article to elucidate a potential role of cardiac angiotensin AT2R in regulating cellular immune response to ischemic heart injury.  Seven days after myocardial infarction in rats, double-immunofluorescence staining showed that AT2R was detected in a fraction of CD8+ T cells infiltrating in the peri-infarct myocardium.  We developed a method that allowed the isolation of myocardial infiltrating CD8+AT2R+ T cells using modified MACS, and further characterization and purifn. with flow cytometry.  Although the CD8+AT2R- T cells exhibited potent cytotoxicity to both adult and fetal cardiomyocytes (CMs), the CD8+AT2R+ T cells were noncytotoxic to these CMs.  The CD8+AT2R+ T cells were characterized by upregulated IL-10 and downregulated IL-2 and INF-γ expression when compared with CD8+AT2R- T cells.  We further showed that IL-10 gene expression was enhanced in CD8+ T cells on in vitro AT2R stimulation.  Importantly, in vivo AT2R activation engendered an increment of CD8+AT2R+ T cells and IL-10 prodn. in the ischemic myocardium.  In addn., intramyocardial transplantation of CD8+AT2R+ T cells (vs. CD8+AT2R-) led to reduced ischemic heart injury.  Moreover, the CD8+AT2R+ T cell population was also demonstrated in human peripheral blood.  Thus, we have defined the cardioprotective CD8+AT2R+ T cell population, which increases during ischemic heart injury and contributes to maintaining CM viability and providing IL-10, hence revealing an AT2R-mediated cellular mechanism in modulating adaptive immune response in the heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdJEWH0cF9s7Vg90H21EOLACvtfcHk0lgPSxvszmrQnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlOhsbnE&md5=76935cde3daf859a59a36d50e7c86131</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0903681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0903681%26sid%3Dliteratum%253Aachs%26aulast%3DCurato%26aufirst%3DC.%26aulast%3DSlavic%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DSkorska%26aufirst%3DA.%26aulast%3DAltarche-Xifr%25C3%25B3%26aufirst%3DW.%26aulast%3DMiteva%26aufirst%3DK.%26aulast%3DKaschina%26aufirst%3DE.%26aulast%3DThiel%26aufirst%3DA.%26aulast%3DImboden%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSteckelings%26aufirst%3DU.%26aulast%3DSteinhoff%26aufirst%3DG.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520noncytotoxic%2520and%2520IL-10%25E2%2580%2593producing%2520CD8%252BAT2R%252B%2520T%2520cell%2520population%2520in%2520response%2520to%2520ischemic%2520heart%2520injury%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D185%26spage%3D6286%26epage%3D6293%26doi%3D10.4049%2Fjimmunol.0903681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathinasabapathy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espejo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oswalt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raizada, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumners, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katovich, M. J.</span></span> <span> </span><span class="NLM_article-title">Selective activation of angiotensin AT<sub>2</sub> receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">2219</span>– <span class="NLM_lpage">2231</span>, <span class="refDoi"> DOI: 10.1111/bph.13044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2Fbph.13044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25522140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVentrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=2219-2231&author=E.+Bruceauthor=V.+Shenoyauthor=A.+Rathinasabapathyauthor=A.+Espejoauthor=A.+Horowitzauthor=A.+Oswaltauthor=J.+Francisauthor=A.+Nairauthor=T.+Ungerauthor=M.+K.+Raizadaauthor=U.+M.+Steckelingsauthor=C.+Sumnersauthor=M.+J.+Katovich&title=Selective+activation+of+angiotensin+AT2+receptors+attenuates+progression+of+pulmonary+hypertension+and+inhibits+cardiopulmonary+fibrosis&doi=10.1111%2Fbph.13044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis</span></div><div class="casAuthors">Bruce, E.; Shenoy, V.; Rathinasabapathy, A.; Espejo, A.; Horowitz, A.; Oswalt, A.; Francis, J.; Nair, A.; Unger, T.; Raizada, M. K.; Steckelings, U. M.; Sumners, C.; Katovich, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2219-2231</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Pulmonary hypertension (PH) is a devastating disease characterized by increased pulmonary arterial pressure, which progressively leads to right-heart failure and death.  A dys-regulated renin angiotensin system (RAS) has been implicated in the development and progression of PH.  However, the role of the angiotensin AT2 receptor in PH has not been fully elucidated.  We have taken advantage of a recently identified non-peptide AT2 receptor agonist, Compd. 21 (C21), to investigate its effects on the well-established monocrotaline (MCT) rat model of PH.  Exptl. Approach : A single s.c. injection of MCT (50 mg·kg-1) was used to induce PH in 8-wk-old male Sprague Dawley rats.  After 2 wk of MCT administration, a subset of animals began receiving either 0.03 mg·kg-1 C21, 3 mg·kg-1 PD-123319 or 0.5 mg·kg-1 A779 for an addnl. 2 wk, after which right ventricular haemodynamic parameters were measured and tissues were collected for gene expression and histol. analyses.  Key Results : Initiation of C21 treatment significantly attenuated much of the pathophysiol. assocd. with MCT-induced PH.  Most notably, C21 reversed pulmonary fibrosis and prevented right ventricular fibrosis.  These beneficial effects were assocd. with improvement in right heart function, decreased pulmonary vessel wall thickness, reduced pro-inflammatory cytokines and favorable modulation of the lung RAS.  Conversely, co-administration of the AT2 receptor antagonist, PD-123319, or the Mas antagonist, A779, abolished the protective actions of C21.  Conclusions and Implications : Taken together, our results suggest that the AT2 receptor agonist, C21, may hold promise for patients with PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJWqeNKOlr-7Vg90H21EOLACvtfcHk0ljGDqtXb6eVLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVentrbN&md5=18540b3c5040756c43d8fb60a5dcf35f</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1111%2Fbph.13044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13044%26sid%3Dliteratum%253Aachs%26aulast%3DBruce%26aufirst%3DE.%26aulast%3DShenoy%26aufirst%3DV.%26aulast%3DRathinasabapathy%26aufirst%3DA.%26aulast%3DEspejo%26aufirst%3DA.%26aulast%3DHorowitz%26aufirst%3DA.%26aulast%3DOswalt%26aufirst%3DA.%26aulast%3DFrancis%26aufirst%3DJ.%26aulast%3DNair%26aufirst%3DA.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DRaizada%26aufirst%3DM.%2BK.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DSumners%26aufirst%3DC.%26aulast%3DKatovich%26aufirst%3DM.%2BJ.%26atitle%3DSelective%2520activation%2520of%2520angiotensin%2520AT2%2520receptors%2520attenuates%2520progression%2520of%2520pulmonary%2520hypertension%2520and%2520inhibits%2520cardiopulmonary%2520fibrosis%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D2219%26epage%3D2231%26doi%3D10.1111%2Fbph.13044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namsolleck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlöf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">Non-peptide AT2-receptor agonists</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2010.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.coph.2010.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=21167778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFymsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=187-192&author=U.+M.+Steckelingsauthor=M.+Larhedauthor=A.+Hallbergauthor=R.+E.+Widdopauthor=E.+S.+Jonesauthor=C.+Wallinderauthor=P.+Namsolleckauthor=B.+Dahl%C3%B6fauthor=T.+Unger&title=Non-peptide+AT2-receptor+agonists&doi=10.1016%2Fj.coph.2010.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Non-peptide AT2-receptor agonists</span></div><div class="casAuthors">Steckelings, U. Muscha; Larhed, Mats; Hallberg, Anders; Widdop, Robert E.; Jones, Emma S.; Wallinder, Charlotta; Namsolleck, Pawel; Dahloef, Bjoern; Unger, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-192</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The renin-angiotensin-system harbours two main receptor subtypes binding angiotensin II which are the AT1-receptor and the AT2-receptor.  While the AT1-receptor has been a drug target in cardiovascular disease for many years, the AT2-receptor was only a subject of academic interest.  This has changed with the design and synthesis of a first non-peptide, orally active AT2-receptor agonist, compd. 21 (C21).  First data using C21 revealed tissue protective effects and functional improvement after myocardial infarction and in hypertension-induced end organ damage, notably in a blood-pressure independent way.  In all of these models, AT2-receptor mediated anti-inflammation seemed an important underlying mechanism.  C21 is awaited to enter a phase I clin. study in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI57AJFDrpYLVg90H21EOLACvtfcHk0ljGDqtXb6eVLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFymsLg%253D&md5=6134dd4d3aa5e97993939bd4cf4d7bc7</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2010.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2010.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DLarhed%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DJones%26aufirst%3DE.%2BS.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DNamsolleck%26aufirst%3DP.%26aulast%3DDahl%25C3%25B6f%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DNon-peptide%2520AT2-receptor%2520agonists%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D187%26epage%3D192%26doi%3D10.1016%2Fj.coph.2010.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moudgil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musat-Marcu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jugdutt, B. I.</span></span> <span> </span><span class="NLM_article-title">Increased AT(2)R protein expression but not increased apoptosis during cardioprotection induced by AT(1)R blockade</span>. <i>Can. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12420045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt12htLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=1107-1116&author=R.+Moudgilauthor=S.+Musat-Marcuauthor=Y.+Xuauthor=D.+Kumarauthor=B.+I.+Jugdutt&title=Increased+AT%282%29R+protein+expression+but+not+increased+apoptosis+during+cardioprotection+induced+by+AT%281%29R+blockade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade</span></div><div class="casAuthors">Moudgil, Rohit; Musat-Marcu, Sorin; Xu, Yi; Kumar, Dinender; Jugdutt, Bodh I.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Cardiology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1107-1116</span>CODEN:
                <span class="NLM_cas:coden">CJCAEX</span>;
        ISSN:<span class="NLM_cas:issn">0828-282X</span>.
    
            (<span class="NLM_cas:orgname">Pulsus Group</span>)
        </div><div class="casAbstract">The angiotensin II type 2 receptor (AT2R) is considered to be antigrowth and to mediate apoptosis in several cell types.  Whether AT2R upregulation, assocd. with angiotensin II type 1 receptor (AT1R) blockade and cardioprotection after ischemia-reperfusion (IR), might not result in increased cardiomyocyte (CM) apoptosis has not been documented.  To det. whether increased AT2R protein expression, during AT1R blockade after acute IR, is assocd. with no increase in CM apoptosis.  The recovery of left ventricular (LV) mech. function after acute IR (30 min of ischemia, 40 min of reperfusion) was measured in isolated Langendorff rat hearts following pretreatment with the AT1R antagonist candesartan (CN) (CN 10 nmol/L) for 40 min before ischemia.  The authors established with an initial dose-response curve using escalating concns. of CN that 10 nmol/L abrogated vasoconstriction induced by angiotensin II (0.1 μmol/L).  AT1R and AT2R protein expression (Western immunoblot), CM apoptosis (terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick end-labeling assay and nuclear morphol.) and apoptotic markers (Bax, Bcl-2, caspase-3, p53) were assessed in LV tissue.  Compared with IR controls, CN improved peak systolic pressure, LV developed pressure and pos. dp/dt, and increased AT2R (not AT1R) protein, but did not change the level of apoptosis or the expression of Bax, Bcl-2, caspase-3 or p53.  CN also increased AT2R protein after ischemia alone but did not change CM apoptosis or expression of the markers.  Increased AT2R protein expression during AT1R blockade after IR in the isolated Langendorff rat heart is assocd. with cardioprotection but no increase in CM apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpip-YLtsjh_7Vg90H21EOLACvtfcHk0ljGDqtXb6eVLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt12htLk%253D&md5=38719fd04fb61e48fdf44122aa8491d7</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoudgil%26aufirst%3DR.%26aulast%3DMusat-Marcu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DJugdutt%26aufirst%3DB.%2BI.%26atitle%3DIncreased%2520AT%25282%2529R%2520protein%2520expression%2520but%2520not%2520increased%2520apoptosis%2520during%2520cardioprotection%2520induced%2520by%2520AT%25281%2529R%2520blockade%26jtitle%3DCan.%2520J.%2520Cardiol.%26date%3D2002%26volume%3D18%26spage%3D1107%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulakat, L.</span></span> <span> </span><span class="NLM_article-title">Identification of the region of AT2 receptor needed for inhibition of the AT1 receptor-mediated inositol 1,4,5-triphosphate generation</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(02)03713-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0014-5793%2802%2903713-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12482596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlCqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2002&pages=379-386&author=V.+Kumarauthor=D.+Knowleauthor=N.+Gaviniauthor=L.+Pulakat&title=Identification+of+the+region+of+AT2+receptor+needed+for+inhibition+of+the+AT1+receptor-mediated+inositol+1%2C4%2C5-triphosphate+generation&doi=10.1016%2FS0014-5793%2802%2903713-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the region of AT2 receptor needed for inhibition of the AT1 receptor-mediated inositol 1,4,5-triphosphate generation</span></div><div class="casAuthors">Kumar, Vikas; Knowle, Dieter; Gavini, Narasaiah; Pulakat, Lakshmidevi</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">379-386</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Increase in the intracellular inositol triphosphate (IP3) levels in Xenopus oocytes in response to expression and activation of rat angiotensin II (Ang II) receptor AT1 was inhibited by co-expression of rat AT2 receptor.  To identify which region of the AT2 was involved in this inhibition, ability of three AT2 mutants to abolish this inhibition was analyzed.  Deletion of the C-terminus of the AT2 did not abolish this inhibition.  Replacing Ile249 in the third intracellular loop (3rd ICL) of the AT2 with proline, corresponding amino acid in the AT1, in the mutant M6, resulted in slightly reduced affinity to [125I]Ang II (Kd=0.259 nM), however, did not abolish the inhibition.  In contrast, replacing eight more amino acids in the 3rd ICL of the AT2 (at positions 241-244, 250-251 and 255-256) with that of the AT1 in the mutant M8, not only increased the affinity of the AT2 receptor to [125I]Ang II (Kd=0.038 nM) but also abolished AT2-mediated inhibition.  Interestingly, activation of the M8 by Ang II binding also resulted in increase in the intracellular IP3 levels in oocytes.  These results imply that the region of the 3rd ICL of AT2 spanning amino acids 241-256 is sufficient for the AT2-mediated inhibition of AT1-stimulated IP3 generation.  Moreover, these nine mutations are also sufficient to render the AT2 with the ability to activate phospholipase C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwjQTZUkVyq7Vg90H21EOLACvtfcHk0li_Oi3JuxzSqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlCqtbw%253D&md5=12beb8c7c58fa1058ad4e04f87b6ea8d</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2802%2903713-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252802%252903713-4%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DKnowle%26aufirst%3DD.%26aulast%3DGavini%26aufirst%3DN.%26aulast%3DPulakat%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520the%2520region%2520of%2520AT2%2520receptor%2520needed%2520for%2520inhibition%2520of%2520the%2520AT1%2520receptor-mediated%2520inositol%25201%252C4%252C5-triphosphate%2520generation%26jtitle%3DFEBS%2520Lett.%26date%3D2002%26volume%3D532%26spage%3D379%26epage%3D386%26doi%3D10.1016%2FS0014-5793%2802%2903713-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shesely, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhaleb, N.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-P.</span></span> <span> </span><span class="NLM_article-title">Effects of cardiac overexpression of the angiotensin II type 2 receptor on remodeling and dysfunction in mice post-myocardial infarction</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.114.03247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.114.03247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24732892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Kqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2014&pages=1251-1259&author=J.+Xuauthor=Y.+Sunauthor=O.+A.+Carreteroauthor=L.+Zhuauthor=P.+Hardingauthor=E.+G.+Sheselyauthor=X.+Daiauthor=N.-E.+Rhalebauthor=E.+Petersonauthor=X.-P.+Yang&title=Effects+of+cardiac+overexpression+of+the+angiotensin+II+type+2+receptor+on+remodeling+and+dysfunction+in+mice+post-myocardial+infarction&doi=10.1161%2FHYPERTENSIONAHA.114.03247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Cardiac Overexpression of the Angiotensin II Type 2 Receptor on Remodeling and Dysfunction in Mice Post-Myocardial Infarction</span></div><div class="casAuthors">Xu, Jiang; Sun, Ying; Carretero, Oscar A.; Zhu, Liping; Harding, Pamela; Shesely, Edward G.; Dai, Xiangguo; Rhaleb, Nour-Eddine; Peterson, Edward; Yang, Xiao-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1251-1259</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The activation of angiotensin II type 2 receptor (AT2R) has been considered cardioprotective.  However, there are controversial findings regarding the role of overexpressing AT2R in the heart.  Using transgenic mice with different levels of AT2R gene overexpression in the heart (1, 4, or 9 copies of the AT2R transgene: Tg, Tg, or Tg), we studied the effect of AT2R overexpression on left ventricular remodeling and dysfunction post-myocardial infarction (MI).  Tg, Tg, Tg, and their wild-type littermates were divided into (1) sham MI, (2) MI plus vehicle, and (3) MI plus AT2R antagonist.  Treatments were started 4 wk after MI and continued for 8 wk.  AT2R protein and mRNA expression in the heart was significantly increased in transgenic mice, and the increase pos. correlated with copies of the transgene.  AT1R protein and mRNA expression remained unchanged in Tg and Tg but slightly increased in Tg mice.  Systolic blood pressure and cardiac phenotypes did not differ among strains under basal conditions.  MI caused myocardial hypertrophy, interstitial fibrosis, ventricular dilatation, and dysfunction assocd. with increased protein expression of Nox2 and transforming growth factor β1.  These pathol. responses were diminished in Tg and Tg mice.  Moreover, the protective effects of AT2R were abolished by AT2R antagonist and also absent in Tg mice.  We thus conclude that whether overexpression of AT2R is beneficial or detrimental to the heart is largely dependent on expression levels and possibly via regulations of Nox2 and transforming growth factor β1 signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7ORJ7CYzkebVg90H21EOLACvtfcHk0li_Oi3JuxzSqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Kqs74%253D&md5=f7522d78a65fb30ca9e65f8aa9d0d29b</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.114.03247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.114.03247%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DCarretero%26aufirst%3DO.%2BA.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DHarding%26aufirst%3DP.%26aulast%3DShesely%26aufirst%3DE.%2BG.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DRhaleb%26aufirst%3DN.-E.%26aulast%3DPeterson%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DX.-P.%26atitle%3DEffects%2520of%2520cardiac%2520overexpression%2520of%2520the%2520angiotensin%2520II%2520type%25202%2520receptor%2520on%2520remodeling%2520and%2520dysfunction%2520in%2520mice%2520post-myocardial%2520infarction%26jtitle%3DHypertension%26date%3D2014%26volume%3D63%26spage%3D1251%26epage%3D1259%26doi%3D10.1161%2FHYPERTENSIONAHA.114.03247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannan, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, T. A.</span></span> <span> </span><span class="NLM_article-title">Angiotensin AT2 receptors: cardiovascular: hope or hype?</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">824</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0705448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fsj.bjp.0705448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=14530223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1eksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2003&pages=809-824&author=R.+E.+Widdopauthor=E.+S.+Jonesauthor=R.+E.+Hannanauthor=T.+A.+Gaspari&title=Angiotensin+AT2+receptors%3A+cardiovascular%3A+hope+or+hype%3F&doi=10.1038%2Fsj.bjp.0705448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin AT2 receptors: Cardiovascular hope or hype?</span></div><div class="casAuthors">Widdop, Robert E.; Jones, Emma S.; Hannan, Ruth E.; Gaspari, Tracey A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">809-824</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review is given on the pharmacol. and pathophysiol. role of angiotensin AT2 receptors.  The authors describe anatomical distribution, signaling pathways, angiotensin AT2 receptor-mediated relaxation/vasodilatation, structural effects mediated by angiotensin AT2 receptors, and the role of angiotensin AT2 receptors in cardiovascular action of angiotensin AT1 receptor blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAh_C4WE_cbLVg90H21EOLACvtfcHk0livqosrucsobA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1eksrw%253D&md5=0ceb805540aaf7d91a17d45cbfae41e9</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705448%26sid%3Dliteratum%253Aachs%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DJones%26aufirst%3DE.%2BS.%26aulast%3DHannan%26aufirst%3DR.%2BE.%26aulast%3DGaspari%26aufirst%3DT.%2BA.%26atitle%3DAngiotensin%2520AT2%2520receptors%253A%2520cardiovascular%253A%2520hope%2520or%2520hype%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D140%26spage%3D809%26epage%3D824%26doi%3D10.1038%2Fsj.bjp.0705448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">AT2 receptors: functional relevance in cardiovascular disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2008.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.pharmthera.2008.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=18804122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2008&pages=292-316&author=E.+S.+Jonesauthor=A.+Vinhauthor=C.+A.+McCarthyauthor=T.+A.+Gaspariauthor=R.+E.+Widdop&title=AT2+receptors%3A+functional+relevance+in+cardiovascular+disease&doi=10.1016%2Fj.pharmthera.2008.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">AT2 receptors: Functional relevance in cardiovascular disease</span></div><div class="casAuthors">Jones, Emma S.; Vinh, Antony; McCarthy, Claudia A.; Gaspari, Tracey A.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-316</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The renin angiotensin system (RAS) is intricately involved in normal cardiovascular homeostasis.  Excessive stimulation by the octapeptide angiotensin II contributes to a range of cardiovascular pathologies and diseases via angiotensin type 1 receptor (AT1R) activation.  On the other hand, the angiotensin type 2 receptor (AT2R) is thought to counter-regulate AT1R function.  In this review, we describe the enhanced expression and function of AT2R in various cardiovascular disease settings.  In addn., we illustrate that the RAS consists of a family of angiotensin peptides that exert cardiovascular effects that are often distinct from those of Ang II.  During cardiovascular disease, there is likely to be an increased functional importance of AT2R, stimulated by Ang II, or even shorter angiotensin peptide fragments, to limit AT1R-mediated overactivity and cardiovascular pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1mCsfGWYR07Vg90H21EOLACvtfcHk0livqosrucsobA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsL7N&md5=5ba08b8428ce0bad39a8f3df3eea768d</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2008.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2008.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DE.%2BS.%26aulast%3DVinh%26aufirst%3DA.%26aulast%3DMcCarthy%26aufirst%3DC.%2BA.%26aulast%3DGaspari%26aufirst%3DT.%2BA.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DAT2%2520receptors%253A%2520functional%2520relevance%2520in%2520cardiovascular%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2008%26volume%3D120%26spage%3D292%26epage%3D316%26doi%3D10.1016%2Fj.pharmthera.2008.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">The regenerative potential of angiotensin AT2 receptor in cardiac repair</span>. <i>Can. J. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1139/y11-108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1139%2Fy11-108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22364522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlCktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2012&pages=287-293&author=M.+Ludwigauthor=G.+Steinhoffauthor=J.+Li&title=The+regenerative+potential+of+angiotensin+AT2+receptor+in+cardiac+repair&doi=10.1139%2Fy11-108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">The regenerative potential of angiotensin AT2 receptor in cardiac repair</span></div><div class="casAuthors">Ludwig, Marion; Steinhoff, Gustav; Li, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-293</span>CODEN:
                <span class="NLM_cas:coden">CJPPA3</span>;
        ISSN:<span class="NLM_cas:issn">0008-4212</span>.
    
            (<span class="NLM_cas:orgname">Canadian Science Publishing</span>)
        </div><div class="casAbstract">A review.  Angiotensin II, the main effector peptide of the renin-angiotensin system, interferes with cardiac remodeling and repair through its receptors, including AT1 and AT2 receptor (R).  The functional relevance of the previously neglected AT2R is currently intensively studied.  Pharmacol. therapies with AT1R blockers have improved outcomes in patients with ischemic heart injury, probably involving an indirect stimulation of AT2R.  Previous exptl. studies have clearly shown a protective action of AT2R in tissue repair and regeneration.  We have recently identified the c-kit+AT2R+ progenitor cell population in rat heart and bone marrow, which increases after induction of myocardial infarction.  Further exptl. evidence demonstrates that AT2R mediates cardiac homing and repair process of the c-kit+ progenitor cells.  AT2R stimulation through AT1R blockers or directly by AT2R agonist or both in combination may potentially offer the translational options to improve the regenerative potentials of stem/progenitor cells derived from patients with cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorRPtiDwP_4LVg90H21EOLACvtfcHk0livqosrucsobA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlCktr0%253D&md5=0b35422e2c3b6826477b590a34b2524b</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1139%2Fy11-108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fy11-108%26sid%3Dliteratum%253Aachs%26aulast%3DLudwig%26aufirst%3DM.%26aulast%3DSteinhoff%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DThe%2520regenerative%2520potential%2520of%2520angiotensin%2520AT2%2520receptor%2520in%2520cardiac%2520repair%26jtitle%3DCan.%2520J.%2520Physiol.%2520Pharmacol.%26date%3D2012%26volume%3D90%26spage%3D287%26epage%3D293%26doi%3D10.1139%2Fy11-108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saku, K.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2009.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bbrc.2009.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19896468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFSi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2010&pages=85-90&author=S.+Miuraauthor=Y.+Matsuoauthor=Y.+Kiyaauthor=S.+S.+Karnikauthor=K.+Saku&title=Molecular+mechanisms+of+the+antagonistic+action+between+AT1+and+AT2+receptors&doi=10.1016%2Fj.bbrc.2009.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors</span></div><div class="casAuthors">Miura, Shin-ichiro; Matsuo, Yoshino; Kiya, Yoshihiro; Karnik, Sadashiva S.; Saku, Keijiro</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-90</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Although angiotensin II (Ang II) binds to Ang II type 1 (AT1) and type 2 (AT2) receptors, AT1 and AT2 receptors have antagonistic actions with regard to cell signaling.  The mol. mechanisms that underlie this antagonism are not well understood.  We examd. AT1 and AT2 receptor-induced signal cross-talk in the cytoplasm and the importance of the hetero-dimerization of AT1 receptor with AT2 receptor on the cell surface.  AT1 and AT2 receptors showed antagonistic effects toward inositol phosphate prodn.  AT1 receptors mainly formed homo-dimers, rather than hetero-dimers with AT2 receptor, on the cell surface as detd. by immunopptn., and subsequently induced cell signals.  AT2 receptor mainly formed homo-dimers, rather than hetero-dimers with AT1 receptor, on the cell surface.  The expression levels of homo-dimerized AT1 receptor or AT2 receptor on the cell surface did not change after treatment with Ang II, the AT1 receptor antagonist telmisartan or the AT2 receptor antagonist PD 123319.  Finally, AT1 and AT2 receptor-induced signals antagonized phospholipase C-β3 phosphorylation.  In conclusion, Ang II-induced AT1 receptor signals may be mainly blocked by AT2 receptor signals through their neg. cross-talk in the cytoplasm rather than by the hetero-dimerization of both receptors on the cell surface.  The proper balance of the expression levels of AT1 and AT2 receptors might be crit. for the antagonistic action between these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMnbObAVyCn7Vg90H21EOLACvtfcHk0lj7IOpQ3tAhjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFSi&md5=ec8dea407037f02e6ad86c8dae4bee50</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2009.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2009.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DMatsuo%26aufirst%3DY.%26aulast%3DKiya%26aufirst%3DY.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26aulast%3DSaku%26aufirst%3DK.%26atitle%3DMolecular%2520mechanisms%2520of%2520the%2520antagonistic%2520action%2520between%2520AT1%2520and%2520AT2%2520receptors%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2010%26volume%3D391%26spage%3D85%26epage%3D90%26doi%3D10.1016%2Fj.bbrc.2009.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benessiano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrion, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duriez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poitevin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, J. L.</span></span> <span> </span><span class="NLM_article-title">Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1172/JCI118807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1172%2FJCI118807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=8755652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK28XksFCltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1996&pages=418-425&author=B.+I.+Levyauthor=J.+Benessianoauthor=D.+Henrionauthor=L.+Caputoauthor=C.+Heymesauthor=M.+Duriezauthor=P.+Poitevinauthor=J.+L.+Samuel&title=Chronic+blockade+of+AT2-subtype+receptors+prevents+the+effect+of+angiotensin+II+on+the+rat+vascular+structure&doi=10.1172%2FJCI118807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure</span></div><div class="casAuthors">Levy, Bernard I.; Benessiano, Joelle; Henrion, Daniel; Caputo, Lidia; Heymes, Christophe; Duriez, Micheline; Poitevin, Pierre; Samuel, Jane Lise</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-425</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II) is both a vasoactive and a potent growth-promoting factor for vascular smooth muscle cells.  Little is known about the in vivo contribution of AT1 and AT2 receptor activation to the biol. action of Ang II.  Therefore, we investigated the effect of AT1 or AT2 subtype receptor chronic blockade by losartan or PD 123319 on the vascular hypertrophy in rats with Ang II-induced hypertension.  Normotensive rats received for 3 wk s.c. infusions of Ang II (120 ng/kg per min), or Ang II + PD 123319 (30 mg/kg per d), or Ang II + losartan (10 mg/kg per d) or PD 123319 alone, and were compared with control animals.  In normotensive animals, chronic blockade of AT2 receptors did not affect the plasma level of angiotensin II and the vascular reactivity to angiotensin II mediated by the AT1 receptor.  Chronic blockade of AT1 in rats receiving Ang II resulted in normal arterial pressure, but it induced significant aortic hypertrophy and fibrosis.  Chronic blockade of AT2 receptors in Ang II-induced hypertensive rats had no effect on arterial pressure, but antagonized the effect of Ang II on arterial hypertrophy and fibrosis, suggesting that in vivo vasotrophic effects of Ang II are at least partially mediated via AT2 subtype receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm9-du4uXMvrVg90H21EOLACvtfcHk0lj7IOpQ3tAhjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFCltr4%253D&md5=a94ce425856b8a0d71e222cd19349787</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1172%2FJCI118807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI118807%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DB.%2BI.%26aulast%3DBenessiano%26aufirst%3DJ.%26aulast%3DHenrion%26aufirst%3DD.%26aulast%3DCaputo%26aufirst%3DL.%26aulast%3DHeymes%26aufirst%3DC.%26aulast%3DDuriez%26aufirst%3DM.%26aulast%3DPoitevin%26aufirst%3DP.%26aulast%3DSamuel%26aufirst%3DJ.%2BL.%26atitle%3DChronic%2520blockade%2520of%2520AT2-subtype%2520receptors%2520prevents%2520the%2520effect%2520of%2520angiotensin%2520II%2520on%2520the%2520rat%2520vascular%2520structure%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1996%26volume%3D98%26spage%3D418%26epage%3D425%26doi%3D10.1172%2FJCI118807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benndorf, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch-Hoffmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwedhelm, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cieslar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Haupt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Schwesinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaiss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmchen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehmke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böger, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, U. O.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1038/ki.2009.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fki.2009.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19212419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlt1Sltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2009&pages=1039-1049&author=R.+A.+Benndorfauthor=C.+Krebsauthor=B.+Hirsch-Hoffmannauthor=E.+Schwedhelmauthor=G.+Cieslarauthor=R.+Schmidt-Hauptauthor=O.+M.+Steinmetzauthor=C.+Meyer-Schwesingerauthor=F.+Thaissauthor=M.+Haddadauthor=S.+Fehrauthor=A.+Heilmannauthor=U.+Helmchenauthor=L.+Heinauthor=H.+Ehmkeauthor=R.+A.+Stahlauthor=R.+H.+B%C3%B6gerauthor=U.+O.+Wenzel&title=Angiotensin+II+type+2+receptor+deficiency+aggravates+renal+injury+and+reduces+survival+in+chronic+kidney+disease+in+mice&doi=10.1038%2Fki.2009.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice</span></div><div class="casAuthors">Benndorf, Ralf A.; Krebs, Christian; Hirsch-Hoffmann, Birgit; Schwedhelm, Edzard; Cieslar, Gabriele; Schmidt-Haupt, Robin; Steinmetz, Oliver M.; Meyer-Schwesinger, Catherine; Thaiss, Friedrich; Haddad, Munif; Fehr, Susanne; Heilmann, Andreas; Helmchen, Udo; Hein, Lutz; Ehmke, Heimo; Stahl, Rolf A.; Boeger, Rainer H.; Wenzel, Ulrich O.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1039-1049</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II) activates at least two receptors, AT1 and AT2, with the majority of its effects-such as vasoconstriction, inflammation, and matrix deposition-mediated by the AT1 receptor.  It is thought that the AT2 receptor counteracts these processes; however, recent studies have found proinflammatory and hypertrophic effects of this receptor subtype.  To identify the physiol. roles of the AT2 receptor in chronic kidney disease, we performed renal ablation in AT2 receptor knockout and wild-type mice.  Renal injury caused a greater impairment of renal function, glomerular injury, albuminuria, and mortality in the knockout mice than in the wild-type mice.  There was increased fibronectin expression and inflammation in the knockout mice, as shown by augmented monocyte/macrophage infiltration and higher chemokine monocyte chemotactic protein-1 (MCP-1) and RANTES expression in the remnant kidney.  The higher mortality and renal morbidity of the knockout mice was not due to differences in systemic blood pressure, glomerular vol., AT1 receptor, renin, or endothelial nitric oxide synthase expression.  Whether activation of the AT2 receptor will have therapeutic benefit in chronic kidney disease will require further study.  Kidney International (2009) 75, 1039-1049; doi:10.1038/ki.2009.2; published online 11 Feb. 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOjqjoqy37FLVg90H21EOLACvtfcHk0lj7IOpQ3tAhjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlt1Sltbc%253D&md5=94b41c37e45555d4c11f8748f1a02d66</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fki.2009.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2009.2%26sid%3Dliteratum%253Aachs%26aulast%3DBenndorf%26aufirst%3DR.%2BA.%26aulast%3DKrebs%26aufirst%3DC.%26aulast%3DHirsch-Hoffmann%26aufirst%3DB.%26aulast%3DSchwedhelm%26aufirst%3DE.%26aulast%3DCieslar%26aufirst%3DG.%26aulast%3DSchmidt-Haupt%26aufirst%3DR.%26aulast%3DSteinmetz%26aufirst%3DO.%2BM.%26aulast%3DMeyer-Schwesinger%26aufirst%3DC.%26aulast%3DThaiss%26aufirst%3DF.%26aulast%3DHaddad%26aufirst%3DM.%26aulast%3DFehr%26aufirst%3DS.%26aulast%3DHeilmann%26aufirst%3DA.%26aulast%3DHelmchen%26aufirst%3DU.%26aulast%3DHein%26aufirst%3DL.%26aulast%3DEhmke%26aufirst%3DH.%26aulast%3DStahl%26aufirst%3DR.%2BA.%26aulast%3DB%25C3%25B6ger%26aufirst%3DR.%2BH.%26aulast%3DWenzel%26aufirst%3DU.%2BO.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor%2520deficiency%2520aggravates%2520renal%2520injury%2520and%2520reduces%2520survival%2520in%2520chronic%2520kidney%2520disease%2520in%2520mice%26jtitle%3DKidney%2520Int.%26date%3D2009%26volume%3D75%26spage%3D1039%26epage%3D1049%26doi%3D10.1038%2Fki.2009.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padia, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R. M.</span></span> <span> </span><span class="NLM_article-title">AT2 receptor activation induces natriuresis and lowers blood pressure</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.115.304110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FCIRCRESAHA.115.304110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24903104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOlt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2014&pages=388-399&author=B.+A.+Kempauthor=N.+L.+Howellauthor=J.+J.+Gildeaauthor=S.+R.+Kellerauthor=S.+H.+Padiaauthor=R.+M.+Carey&title=AT2+receptor+activation+induces+natriuresis+and+lowers+blood+pressure&doi=10.1161%2FCIRCRESAHA.115.304110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">AT2 Receptor Activation Induces Natriuresis and Lowers Blood Pressure</span></div><div class="casAuthors">Kemp, Brandon A.; Howell, Nancy L.; Gildea, John J.; Keller, Susanna R.; Padia, Shetal H.; Carey, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">388-399</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: Compd. 21 (C-21) is a highly selective nonpeptide AT2 receptor (AT2R) agonist.  Objective: To test the hypothesis that renal proximal tubule AT2Rs induce natriuresis and lower blood pressure in Sprague-Dawley rats and mice.  Methods and results: In rats, AT2R activation with i.v. C-21 increased urinary sodium excretion by 10-fold (P<0.0001); this natriuresis was abolished by direct renal interstitial infusion of specific AT2R antagonist PD-123319.  C-21 increased fractional excretion of Na (P<0.05) and lithium (P<0.01) without altering renal hemodynamic function.  AT2R activation increased renal proximal tubule cell apical membrane AT2R protein (P<0.001) without changing total AT2R expression and internalized/inactivated Na-H exchanger-3 and Na/KATPase.  C-21-induced natriuresis was accompanied by an increase in renal interstitial cGMP (P<0.01); C-21-induced increases in urinary sodium excretion and renal interstitial cGMP were abolished by renal interstitial nitric oxide synthase inhibitor L-N-nitroarginine Me ester or bradykinin B2 receptor antagonist icatibant.  Renal AT2R activation with C-21 prevented Na retention and lowered blood pressure in the angiotensin II infusion model of exptl. hypertension.  Conclusions: AT2R activation initiates its translocation to the renal proximal tubule cell apical membrane and the internalization of Na-H exchanger-3 and Na/KATPase, inducing natriuresis in a bradykinin-nitric oxide-cGMP-dependent manner.  Intrarenal AT2R activation prevents Na retention and lowers blood pressure in angiotensin II-dependent hypertension.  AT2R activation holds promise as a renal proximal tubule natriuretic/diuretic target for the treatment of fluid-retaining states and hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhMcuc8Fsbo7Vg90H21EOLACvtfcHk0lhKOFxblzZmhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOlt77L&md5=eff0d06d331c7afa584ce27e8900edfb</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.115.304110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.115.304110%26sid%3Dliteratum%253Aachs%26aulast%3DKemp%26aufirst%3DB.%2BA.%26aulast%3DHowell%26aufirst%3DN.%2BL.%26aulast%3DGildea%26aufirst%3DJ.%2BJ.%26aulast%3DKeller%26aufirst%3DS.%2BR.%26aulast%3DPadia%26aufirst%3DS.%2BH.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26atitle%3DAT2%2520receptor%2520activation%2520induces%2520natriuresis%2520and%2520lowers%2520blood%2520pressure%26jtitle%3DCirc.%2520Res.%26date%3D2014%26volume%3D115%26spage%3D388%26epage%3D399%26doi%3D10.1161%2FCIRCRESAHA.115.304110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jose, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor inhibits expression and function of insulin receptor in rat renal proximal tubule cells</span>. <i>J. Am. Soc. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1016/j.jash.2017.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.jash.2017.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29289466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFyktb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=135-145&author=Y.+Yangauthor=C.+Chenauthor=C.+Fuauthor=Z.+Xuauthor=C.+Lanauthor=Y.+Zengauthor=Z.+Chenauthor=P.+A.+Joseauthor=Y.+Zhangauthor=C.+Zeng&title=Angiotensin+II+type+2+receptor+inhibits+expression+and+function+of+insulin+receptor+in+rat+renal+proximal+tubule+cells&doi=10.1016%2Fj.jash.2017.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II type 2 receptor inhibits expression and function of insulin receptor in rat renal proximal tubule cells</span></div><div class="casAuthors">Yang, Yang; Chen, Caiyu; Fu, Chunjiang; Xu, Zaicheng; Lan, Cong; Zeng, Yongchun; Chen, Zhi; Jose, Pedro A.; Zhang, Ye; Zeng, Chunyu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Hypertension</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-145</span>CODEN:
                <span class="NLM_cas:coden">JASHCA</span>;
        ISSN:<span class="NLM_cas:issn">1878-7436</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Both renin-angiotensin systems and insulin participate in kidney-involved blood pressure regulation.  Activation of angiotensin II type 2 receptor (AT2R) decreases sodium reabsorption in renal proximal tubule (RPT) cells, whereas insulin produces the opposite effect.  We presume that AT2R has an inhibitory effect on insulin receptor expression in RPT cells, which may affect renal sodium transport and therefore be of physiol. or pathol. significance.  Our present study found that activation of AT2R inhibited insulin receptor expression in a concn. and time-dependent manner in RPT cells from Wistar-Kyoto (WKY) rats.  In the presence of a protein kinase C (PKC) inhibitor (PKC inhibitor peptide 19-31, 10-6 mol/L) or a phosphatidylinositol 3 kinase inhibitor (wortmannin, 10-6 mol/L), the inhibitory effect of AT2R on insulin receptor was blocked, indicating that both PKC and phosphatidylinositol 3 kinase were involved in the signaling pathway.  There was a linkage between AT2R and insulin receptor which was detd. by both laser confocal microscopy and coimmunopptn.  However, the effect of AT2R activation on insulin receptor expression was different in RPT cells from spontaneously hypertensive rats (SHRs).  Being contrary to the effect in WKY RPT cells, AT2R stimulation increased insulin receptor in SHR RPT cells.  Insulin (10-7 mol/L, 15 min) enhanced Na+-K+-ATPase activity in both WKY and SHR RPT cells.  Pretreatment with CGP42112 decreased the stimulatory effect of insulin on Na+-K+-ATPase activity in WKY RPT cells, whereas pretreatment with CGP42112 increased it in SHR RPT cells.  It is suggested that activation of AT2R inhibits insulin receptor expression and function in RPT cells.  The lost inhibitory effect of AT2R on insulin receptor expression may contribute to the pathophysiol. of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxuYrFY-ZAILVg90H21EOLACvtfcHk0lhKOFxblzZmhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFyktb7P&md5=1143c43065e9b8513c774babfbe22c03</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.jash.2017.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jash.2017.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DFu%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLan%26aufirst%3DC.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJose%26aufirst%3DP.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DC.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor%2520inhibits%2520expression%2520and%2520function%2520of%2520insulin%2520receptor%2520in%2520rat%2520renal%2520proximal%2520tubule%2520cells%26jtitle%3DJ.%2520Am.%2520Soc.%2520Hypertens.%26date%3D2018%26volume%3D12%26spage%3D135%26epage%3D145%26doi%3D10.1016%2Fj.jash.2017.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renziehausen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Nigro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lattanzio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega-Rioja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Carranco, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harwood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szlosarek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proby, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, T.</span></span> <span> </span><span class="NLM_article-title">The Renin Angiotensin System (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2320</span>– <span class="NLM_lpage">2336</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0563-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fs41388-018-0563-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30478450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSqsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=2320-2336&author=A.+Renziehausenauthor=H.+Wangauthor=B.+Raoauthor=L.+Weirauthor=C.+Lo+Nigroauthor=L.+Lattanzioauthor=M.+Merlanoauthor=A.+Vega-Riojaauthor=M.+C.+Fernandez-Carrancoauthor=N.+Hajjiauthor=R.+Matinauthor=C.+Harwoodauthor=S.+Liauthor=V.+R.+Simauthor=K.+O%E2%80%99Neillauthor=A.+Evansauthor=A.+Thompsonauthor=P.+Szlosarekauthor=C.+Flemingauthor=J.+Stebbingauthor=C.+Probyauthor=A.+G.+Tzakosauthor=N.+Syedauthor=T.+Crook&title=The+Renin+Angiotensin+System+%28RAS%29+mediates+bifunctional+growth+regulation+in+melanoma+and+is+a+novel+target+for+therapeutic+intervention&doi=10.1038%2Fs41388-018-0563-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention</span></div><div class="casAuthors">Renziehausen, Alexander; Wang, Hexiao; Rao, Bhavya; Weir, Lynda; Nigro, Cristiana Lo; Lattanzio, Laura; Merlano, Marco; Vega-Rioja, Antonio; del Carmen Fernandez-Carranco, Maria; Hajji, Nabil; Matin, Rubeta; Harwood, Catherine; Li, Su; Sim, Van Ren; O'Neill, Kevin; Evans, Alan; Thompson, Alastair; Szlosarek, Peter; Fleming, Colin; Stebbing, Justin; Proby, Charlotte; Tzakos, Andreas G.; Syed, Nelofer; Crook, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2320-2336</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Despite emergence of new systemic therapies, metastatic melanoma remains a challenging and often fatal form of skin cancer.  The renin-angiotensin system (RAS) is a major physiol. regulatory pathway controlling salt-water equil., intravascular vol. and blood pressure.  Biol. effects of the RAS are mediated by the vasoactive hormone angiotensin II (AngII) via two receptor subtypes, AT1R (encoded by AGTR1) and AT2R (encoded by AGTR2).  We report decreasing expression and increasing CpG island methylation of AGTR1 in metastatic vs. primary melanoma and detection in serum of methylated genomic DNA from the AGTR1 CpG island in metastatic melanoma implying that AGTR1 encodes a tumor suppressor function in melanoma.  Consistent with this hypothesis, antagonism of AT1R using losartan or shRNA-mediated knockdown in melanoma cell lines expressing AGTR1 resulted in acquisition of the ability to proliferate in serum-free conditions.  Conversely, ectopic expression of AGTR1 in cell lines lacking endogenous expression inhibits proliferation irresp. of the presence of AngII implying a ligand-independent suppressor function for AT1R.  Treatment of melanoma cell lines expressing endogenous AT2R with either AngII or the AT2R-selective agonist Y6AII induces proliferation in serum-free conditions whereas the AT2R-specific antagonists PD123319 and EMA401 inhibit melanoma growth and angiogenesis and potentiate inhibitors of BRAF and MEK in cells with BRAF V600 mutations.  Our results demonstrate that the RAS has both oncogenic and tumor suppressor functions in melanoma.  Pharmacol. inhibition of AT2R may provide therapeutic opportunities in melanomas expressing this receptor and AGTR1 CpG island methylation in serum may serve as a novel biomarker of metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocfJXsr7oKIbVg90H21EOLACvtfcHk0lgucKYjiV0Kuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSqsbnK&md5=923bbfd8618a30af04c25ba8cb7d82b8</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0563-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0563-y%26sid%3Dliteratum%253Aachs%26aulast%3DRenziehausen%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRao%26aufirst%3DB.%26aulast%3DWeir%26aufirst%3DL.%26aulast%3DLo%2BNigro%26aufirst%3DC.%26aulast%3DLattanzio%26aufirst%3DL.%26aulast%3DMerlano%26aufirst%3DM.%26aulast%3DVega-Rioja%26aufirst%3DA.%26aulast%3DFernandez-Carranco%26aufirst%3DM.%2BC.%26aulast%3DHajji%26aufirst%3DN.%26aulast%3DMatin%26aufirst%3DR.%26aulast%3DHarwood%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DSim%26aufirst%3DV.%2BR.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DK.%26aulast%3DEvans%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DSzlosarek%26aufirst%3DP.%26aulast%3DFleming%26aufirst%3DC.%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DProby%26aufirst%3DC.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26aulast%3DSyed%26aufirst%3DN.%26aulast%3DCrook%26aufirst%3DT.%26atitle%3DThe%2520Renin%2520Angiotensin%2520System%2520%2528RAS%2529%2520mediates%2520bifunctional%2520growth%2520regulation%2520in%2520melanoma%2520and%2520is%2520a%2520novel%2520target%2520for%2520therapeutic%2520intervention%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D2320%26epage%3D2336%26doi%3D10.1038%2Fs41388-018-0563-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mary, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Differential effects of the mitochondria-active tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) and its peptidase-targeted prodrugs in experimental acute kidney injury</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1209</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.01209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffphar.2019.01209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=31780923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BB3MfksFaltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1209&author=J.+C.+Wyssauthor=R.+Kumarauthor=J.+Mikulicauthor=M.+Schneiderauthor=J.+L.+Maryauthor=J.+D.+Aebiauthor=L.+Juillerat-Jeanneretauthor=D.+Golshayan&title=Differential+effects+of+the+mitochondria-active+tetrapeptide+SS-31+%28D-Arg-dimethylTyr-Lys-Phe-NH2%29+and+its+peptidase-targeted+prodrugs+in+experimental+acute+kidney+injury&doi=10.3389%2Ffphar.2019.01209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Effects of the Mitochondria-Active Tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) and Its Peptidase-Targeted Prodrugs in Experimental Acute Kidney Injury</span></div><div class="casAuthors">Wyss Jean-Christophe; Kumar Rajesh; Mikulic Josip; Juillerat-Jeanneret Lucienne; Golshayan Dela; Schneider Manfred; Mary Jean-Luc; Aebi Johannes D; Juillerat-Jeanneret Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1209</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">The mitochondria-active tetrapeptide SS-31 can control oxidative tissue damage in kidney diseases.  To investigate other potential beneficial nephroprotective effects of SS-31, in vivo murine models of acute tubular injury and glomerular damage were developed.  Reduction of acute kidney injury was demonstrated in mice treated with SS-31.  The expression of mRNAs involved in acute inflammatory and oxidative stress responses in the diseased kidneys confirmed that SS-31 could regulate these pathways in our in vivo models.  Furthermore, ex vivo histoenzymography of mouse kidneys showed that aminopeptidase A (APA), the enzyme involved in the processing of angiotensin (Ang) II to Ang III, was induced in the diseased kidneys, and its activity was inhibited by SS-31.  As the renin-angiotensin system (RAS) is a main regulator of kidney functions, the modulation of Ang receptors (ATR) and APA by SS-31 was further investigated using mRNAs extracted from diseased kidneys.  Following acute tubular and/or glomerular damage, the expression of the AT1R mRNA was upregulated, which could be selectively downregulated upon SS-31 administration to the animals.  At the same time, SS-31 was able to increase the expression of the AT2R, which may contribute to limit renal damage.  Consequently, SS-31-based prodrugs were developed as substrates and/or inhibitors for APA and were screened using cells expressing high levels of APA, showing its selective regulation by α-Glu-SS-31.  Thus, a link between SS-31 and the RAS opens new therapeutic implications for SS-31 in kidney diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsJPizEcy1hAHqQV89nF-2fW6udTcc2eZg9pKINaaryLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfksFaltg%253D%253D&md5=017f0a2adfc05b8937ff5e1a9817d76b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01209%26sid%3Dliteratum%253Aachs%26aulast%3DWyss%26aufirst%3DJ.%2BC.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DMikulic%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DMary%26aufirst%3DJ.%2BL.%26aulast%3DAebi%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DDifferential%2520effects%2520of%2520the%2520mitochondria-active%2520tetrapeptide%2520SS-31%2520%2528D-Arg-dimethylTyr-Lys-Phe-NH2%2529%2520and%2520its%2520peptidase-targeted%2520prodrugs%2520in%2520experimental%2520acute%2520kidney%2520injury%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1209%26doi%3D10.3389%2Ffphar.2019.01209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abadir, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucker, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedarko, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walston, J. D.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of a functional mitochondrial angiotensin system</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">14849</span>– <span class="NLM_lpage">14854</span>, <span class="refDoi"> DOI: 10.1073/pnas.1101507108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1073%2Fpnas.1101507108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=21852574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFyktLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=14849-14854&author=P.+M.+Abadirauthor=D.+B.+Fosterauthor=M.+Crowauthor=C.+A.+Cookeauthor=J.+J.+Ruckerauthor=A.+Jainauthor=B.+J.+Smithauthor=T.+N.+Burksauthor=R.+D.+Cohnauthor=N.+S.+Fedarkoauthor=R.+M.+Careyauthor=B.+O%E2%80%99Rourkeauthor=J.+D.+Walston&title=Identification+and+characterization+of+a+functional+mitochondrial+angiotensin+system&doi=10.1073%2Fpnas.1101507108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization if a functional mitochondrial angiotensin system</span></div><div class="casAuthors">Abadir, Peter M.; Foster, D. Brian; Crow, Michael; Cooke, Carol A.; Rucker, Jasma J.; Jain, Alka; Smith, Barbara J.; Burks, Tyesha N.; Cohn, Ronald D.; Fedarko, Neal S.; Carey, Robert M.; O'Rourke, Brian; Walston, Jeremy D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">14849-14854, S14849/1-S14849/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The renin-angiotensin (Ang) system regulates multiple physiol. functions through Ang II type 1 and type 2 receptors.  Prior studies suggest an intracellular pool of Ang II that may be released in an autocrine manner upon stretch to activate surface membrane Ang receptors.  Alternatively, an intracellular renin-Ang system has been proposed, with a primary focus on nuclear Ang receptors.  A mitochondrial Ang system has not been previously described.  Here we report that functional Ang II type 2 receptors are present on mitochondrial inner membranes and are colocalized with endogenous Ang.  We demonstrate that activation of the mitochondrial Ang system is coupled to mitochondrial nitric oxide prodn. and can modulate respiration.  In addn., we present evidence of age-related changes in mitochondrial Ang receptor expression, i.e., increased mitochondrial Ang II type 1 receptor and decreased type 2 receptor d. that is reversed by chronic treatment with the Ang II type 1 receptor blocker losartan.  The presence of a functional Ang system in human mitochondria provides a foundation for understanding, the interaction between mitochondria and chronic disease states and reveals potential therapeutic targets for optimizing mitochondrial function and decreasing chronic disease burden with aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbLv-W_FnS0bVg90H21EOLACvtfcHk0lgGZa-Uz2ZRAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFyktLfJ&md5=de6176eab577214fab3c06b6b0149acd</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1101507108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1101507108%26sid%3Dliteratum%253Aachs%26aulast%3DAbadir%26aufirst%3DP.%2BM.%26aulast%3DFoster%26aufirst%3DD.%2BB.%26aulast%3DCrow%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DC.%2BA.%26aulast%3DRucker%26aufirst%3DJ.%2BJ.%26aulast%3DJain%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DBurks%26aufirst%3DT.%2BN.%26aulast%3DCohn%26aufirst%3DR.%2BD.%26aulast%3DFedarko%26aufirst%3DN.%2BS.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DB.%26aulast%3DWalston%26aufirst%3DJ.%2BD.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520a%2520functional%2520mitochondrial%2520angiotensin%2520system%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D14849%26epage%3D14854%26doi%3D10.1073%2Fpnas.1101507108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escobales, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javadov, S.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial angiotensin receptors and cardioprotective pathways</span>. <i>Am. J. Physiol., Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">H1426</span>– <span class="NLM_lpage">H1438</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00772.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajpheart.00772.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30978131" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2019&pages=H1426-H1438&author=N.+Escobalesauthor=R.+E.+Nu%C3%B1ezauthor=S.+Javadov&title=Mitochondrial+angiotensin+receptors+and+cardioprotective+pathways&doi=10.1152%2Fajpheart.00772.2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00772.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00772.2018%26sid%3Dliteratum%253Aachs%26aulast%3DEscobales%26aufirst%3DN.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DR.%2BE.%26aulast%3DJavadov%26aufirst%3DS.%26atitle%3DMitochondrial%2520angiotensin%2520receptors%2520and%2520cardioprotective%2520pathways%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Heart%2520Circ.%2520Physiol.%26date%3D2019%26volume%3D316%26spage%3DH1426%26epage%3DH1438%26doi%3D10.1152%2Fajpheart.00772.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micakovic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papagiannarou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzay, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramovic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sticht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawroth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammes, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alenina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gröne, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, S. C.</span></span> <span> </span><span class="NLM_article-title">The angiotensin II type 2 receptors protect renal tubule mitochondria in early stages of diabetes mellitus</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1016/j.kint.2018.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.kint.2018.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30190172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1eku7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2018&pages=937-950&author=T.+Micakovicauthor=S.+Papagiannarouauthor=E.+Clarkauthor=Y.+Kuzayauthor=K.+Abramovicauthor=J.+Petersauthor=C.+Stichtauthor=N.+Volkauthor=T.+Flemingauthor=P.+Nawrothauthor=H.+P.+Hammesauthor=N.+Aleninaauthor=H.+J.+Gr%C3%B6neauthor=S.+C.+Hoffmann&title=The+angiotensin+II+type+2+receptors+protect+renal+tubule+mitochondria+in+early+stages+of+diabetes+mellitus&doi=10.1016%2Fj.kint.2018.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The angiotensin II type 2 receptors protect renal tubule mitochondria in early stages of diabetes mellitus</span></div><div class="casAuthors">Micakovic, Tamara; Papagiannarou, Stamatia; Clark, Euan; Kuzay, Yalcin; Abramovic, Katarina; Peters, Joerg; Sticht, Carsten; Volk, Nadine; Fleming, Thomas; Nawroth, Peter; Hammes, Hans-Peter; Alenina, Natalia; Groene, Hermann-Josef; Hoffmann, Sigrid Christa</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">937-950</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Diabetic nephropathy correlates more closely to defective mitochondria and increased oxidative stress in the kidney than to hyperglycemia.  A key driving factor of diabetic nephropathy is angiotensin II acting via the G-protein-coupled cell membrane type 1 receptor.  The present study aimed to investigate the role of the angiotensin II type 2 receptor (AT2R) at the early stages of diabetic nephropathy.  Using receptor binding studies and immunohistochem. we found that the mitochondria in renal tubules contain high-affinity AT2Rs.  Increased renal mitochondrial AT2R d. by transgenic overexpression was assocd. with reduced superoxide prodn. of isolated mitochondria from non-diabetic rats.  Streptozotocin-induced diabetes (28 days) caused a drop in the ATP/oxygen ratio and an increase in the superoxide prodn. of isolated renal mitochondria from wild-type diabetic rats.  This correlated with changes in the renal expression profile and increased tubular epithelial cell proliferation.  AT2R overexpression in tubular epithelial cells inhibited all diabetes-induced renal changes including a drop in mitochondrial bioenergetics efficiency, a rise in mitochondrial superoxide prodn., metabolic reprogramming, and increased proliferation.  Thus, AT2Rs translocate to mitochondria and can contribute to reno-protective effects at early stages of diabetes.  Hence, targeted AT2R overexpression in renal cells may open new avenues to develop novel types of drugs preventing diabetic nephropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKqUgcGZoHm7Vg90H21EOLACvtfcHk0lhcAyjaocAGuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1eku7jM&md5=afd0172f5344a7d5ac07218eb13ffff9</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.kint.2018.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.kint.2018.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DMicakovic%26aufirst%3DT.%26aulast%3DPapagiannarou%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DE.%26aulast%3DKuzay%26aufirst%3DY.%26aulast%3DAbramovic%26aufirst%3DK.%26aulast%3DPeters%26aufirst%3DJ.%26aulast%3DSticht%26aufirst%3DC.%26aulast%3DVolk%26aufirst%3DN.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DNawroth%26aufirst%3DP.%26aulast%3DHammes%26aufirst%3DH.%2BP.%26aulast%3DAlenina%26aufirst%3DN.%26aulast%3DGr%25C3%25B6ne%26aufirst%3DH.%2BJ.%26aulast%3DHoffmann%26aufirst%3DS.%2BC.%26atitle%3DThe%2520angiotensin%2520II%2520type%25202%2520receptors%2520protect%2520renal%2520tubule%2520mitochondria%2520in%2520early%2520stages%2520of%2520diabetes%2520mellitus%26jtitle%3DKidney%2520Int.%26date%3D2018%26volume%3D94%26spage%3D937%26epage%3D950%26doi%3D10.1016%2Fj.kint.2018.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Te
Riet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Esch, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roks, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Meiracker, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danser, A. H.</span></span> <span> </span><span class="NLM_article-title">Hypertension: renin-angiotensin-aldosterone system alterations</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">975</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.116.303587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FCIRCRESAHA.116.303587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25767283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktlSisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2015&pages=960-975&author=L.+Te%0ARietauthor=J.+H.+van+Eschauthor=A.+J.+Roksauthor=A.+H.+van+den+Meirackerauthor=A.+H.+Danser&title=Hypertension%3A+renin-angiotensin-aldosterone+system+alterations&doi=10.1161%2FCIRCRESAHA.116.303587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Hypertension: Renin-Angiotensin-Aldosterone System Alterations</span></div><div class="casAuthors">te Riet, Luuk; van Esch, Joep H. M.; Roks, Anton J. M.; van den Meiracker, Anton H.; Danser, A. H. Jan</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">960-975</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Blockers of the renin-angiotensin-aldosterone system (RAAS), i.e., renin inhibitors, angiotensin (Ang)-converting enzyme (ACE) inhibitors, Ang II type 1 receptor antagonists, and mineralocorticoid receptor antagonists, are a cornerstone in the treatment of hypertension.  How exactly they exert their effect, in particular in patients with low circulating RAAS activity, also taking into consideration the so-called Ang II/aldosterone escape that often occurs after initial blockade, is still incompletely understood.  Multiple studies have tried to find parameters that predict the response to RAAS blockade, allowing a personalized treatment approach.  Consequently, the question should now be answered on what basis (eg, sex, ethnicity, age, salt intake, baseline renin, ACE or aldosterone, and genetic variance) a RAAS blocker can be chosen to treat an individual patient.  Are all blockers equal Does optimal blockade imply max. RAAS blockade, for example, by combining ≥2 RAAS blockers or by simply increasing the dose of 1 blocker Exciting recent investigations reveal a range of unanticipated extrarenal effects of aldosterone, as well as a detailed insight in the genetic causes of primary aldosteronism, and mineralocorticoid receptor blockers have now become an important treatment option for resistant hypertension.  Finally, apart from the deleterious ACE-Ang II-Ang II type 1 receptor arm, animal studies support the existence of protective aminopeptidase A-Ang III-Ang II type 2 receptor and ACE2-Ang-(1 to 7)-Mas receptor arms, paving the way for multiple new treatment options.  This review provides an update about all these aspects, critically discussing the many controversies and allowing the reader to obtain a full understanding of what we currently know about RAAS alterations in hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlvyUVPG2x27Vg90H21EOLACvtfcHk0lhcAyjaocAGuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktlSisLc%253D&md5=40292de9f623880fc37fc2a6d82a4e4d</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.116.303587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.116.303587%26sid%3Dliteratum%253Aachs%26aulast%3DTe%2BRiet%26aufirst%3DL.%26aulast%3Dvan%2BEsch%26aufirst%3DJ.%2BH.%26aulast%3DRoks%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2Bden%2BMeiracker%26aufirst%3DA.%2BH.%26aulast%3DDanser%26aufirst%3DA.%2BH.%26atitle%3DHypertension%253A%2520renin-angiotensin-aldosterone%2520system%2520alterations%26jtitle%3DCirc.%2520Res.%26date%3D2015%26volume%3D116%26spage%3D960%26epage%3D975%26doi%3D10.1161%2FCIRCRESAHA.116.303587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akishita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakami, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzau, V. J.</span></span> <span> </span><span class="NLM_article-title">Inflammation influences vascular remodeling through AT2 receptor expression and signaling</span>. <i>Physiol. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1152/physiolgenomics.2000.2.1.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fphysiolgenomics.2000.2.1.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11015577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltFGktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=13-20&author=M.+Akishitaauthor=M.+Horiuchiauthor=H.+Yamadaauthor=L.+Zhangauthor=G.+Shirakamiauthor=K.+Tamuraauthor=Y.+Ouchiauthor=V.+J.+Dzau&title=Inflammation+influences+vascular+remodeling+through+AT2+receptor+expression+and+signaling&doi=10.1152%2Fphysiolgenomics.2000.2.1.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation influences vascular remodeling through AT2 receptor expression and signaling</span></div><div class="casAuthors">Akishita, Masahiro; Horiuchi, Masatsugu; Yamada, Hiroyuki; Zhang, Lunan; Shirakami, Gotaro; Tamura, Rouichi; Ouchi, Yasuyoshi; Dzau, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Genomics [online computer file]</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-20</span>CODEN:
                <span class="NLM_cas:coden">PHGEFP</span>;
        ISSN:<span class="NLM_cas:issn">1094-8341</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">The AT2 receptor, which exerts growth inhibitory effects in cell culture, is present scantily in the adult vasculature but is reexpressed after vascular injury.  To examine the in vivo role of this receptor in vascular diseases, we developed a mouse model of vascular remodeling and compared the responses in wild-type (Agtr2+) and AT2 receptor knockout (Agtr2-) mice.  Polyethylene cuff placement on the femoral artery led to the vascular expression of cytokines, the transcriptional factor interferon regulatory factor-1 (IRF-1), and both the AT1 and AT2 receptors.  Although the expressions of IRF-1 and AT1 receptor were induced to comparable levels in both the Agtr2+ and Agtr2- mice, the neointimal lesion size and the smooth muscle cell proliferation were twice greater in the Agtr2- than in the Agtr2+ mouse.  Correlated with this difference, AT2 receptor expression was induced predominantly in the smooth muscle cells of Agtr2+ mouse.  These results demonstrate that the AT2 receptor plays an important role in nonocclusive inflammatory injury by mediating the effects of inflammation on vascular smooth muscle growth inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwqFpQOpyqbbVg90H21EOLACvtfcHk0lid1JWJlONouA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltFGktbo%253D&md5=6a6845a2d9c3f5ede256150a891757f9</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1152%2Fphysiolgenomics.2000.2.1.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysiolgenomics.2000.2.1.13%26sid%3Dliteratum%253Aachs%26aulast%3DAkishita%26aufirst%3DM.%26aulast%3DHoriuchi%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShirakami%26aufirst%3DG.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DOuchi%26aufirst%3DY.%26aulast%3DDzau%26aufirst%3DV.%2BJ.%26atitle%3DInflammation%2520influences%2520vascular%2520remodeling%2520through%2520AT2%2520receptor%2520expression%2520and%2520signaling%26jtitle%3DPhysiol.%2520Genomics%26date%3D2000%26volume%3D2%26spage%3D13%26epage%3D20%26doi%3D10.1152%2Fphysiolgenomics.2000.2.1.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortnagl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blume, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirnagl, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1096/fj.04-2960fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1096%2Ffj.04-2960fje" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=15665034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFaks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=617-619&author=J.+Liauthor=J.+Culmanauthor=H.+Hortnaglauthor=Y.+Zhaoauthor=N.+Gerovaauthor=M.+Timmauthor=A.+Blumeauthor=K.+Zimmermannauthor=K.+Seidelauthor=U.+Dirnaglauthor=T.+Unger&title=Angiotensin+AT2+receptor+protects+against+cerebral+ischemia-induced+neuronal+injury&doi=10.1096%2Ffj.04-2960fje"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury</span></div><div class="casAuthors">Li, Jun; Culman, Juraj; Hoertnagl, Heide; Zhao, Yi; Gerova, Nadezhda; Timm, Melanie; Blume, Annegret; Zimmermann, Mathias; Seidel, Kerstin; Dirnagl, Ulrich; Unger, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">617-619, 10.1096/fj.04-2960fje</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Several lines of clin. and exptl. evidence suggest an important role of the renin-angiotensin system in ischemic brain injury although the cellular regulation of the angiotensin AT1 and AT2 receptors and their potential relevance in this condition have not yet been clearly defined.  We first assessed the regulation of brain AT1 and AT2 receptors in response to transient unilateral medial cerebral artery occlusion in rats by real-time RT-PCR, Western blot, and immunofluorescence labeling.  AT2 receptors in the peri-infarct zone were significantly upregulated 2 days after transient focal cerebral ischemia.  Increased AT2 receptors, which were abundantly distributed in a large no. of brain regions adjacent to the infarct area including cerebral frontal cortex, piriform cortex, striatum, and hippocampus, were exclusively expressed in neurons.  By contrast, AT1 receptors, which remained unaltered, were mainly expressed in astrocytes.  In neurons of ischemic striatum, increased AT2 receptors were assocd. with intense neurite outgrowth.  Blockade of central AT2 receptors with PD123177 abolished the neuroprotective effects of central AT1 receptor blockade with irbesartan on infarct size and neurol. outcome.  In primary cortical neurons, stimulation of AT2 receptors supported neuronal survival and neurite outgrowth.  Our data indicate that cerebral AT2 receptors exert neuroprotective actions in response to ischemia-induced neuronal injury, possibly by supporting neuronal survival and neurite outgrowth in peri-ischemic brain areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcchA7MJUAE7Vg90H21EOLACvtfcHk0lid1JWJlONouA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFaks7o%253D&md5=0f6b46627af09be20244e0f4c409e4fb</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1096%2Ffj.04-2960fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.04-2960fje%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCulman%26aufirst%3DJ.%26aulast%3DHortnagl%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGerova%26aufirst%3DN.%26aulast%3DTimm%26aufirst%3DM.%26aulast%3DBlume%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DSeidel%26aufirst%3DK.%26aulast%3DDirnagl%26aufirst%3DU.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DAngiotensin%2520AT2%2520receptor%2520protects%2520against%2520cerebral%2520ischemia-induced%2520neuronal%2520injury%26jtitle%3DFASEB%2520J.%26date%3D2005%26volume%3D19%26spage%3D617%26epage%3D619%26doi%3D10.1096%2Ffj.04-2960fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altarche-Xifro, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imboden, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Cardiac c-kitCAT2C cell population is increased in response to ischemic injury and supports cardiomyocyte performance</span>. <i>Stem Cells</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2488</span>– <span class="NLM_lpage">2497</span>, <span class="refDoi"> DOI: 10.1002/stem.171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fstem.171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19591228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFenur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=2488-2497&author=W.+Altarche-Xifroauthor=C.+Curatoauthor=E.+Kaschinaauthor=A.+Grzesiakauthor=S.+Slavicauthor=J.+Dongauthor=K.+Kappertauthor=M.+Steckelingsauthor=H.+Imbodenauthor=T.+Ungerauthor=J.+Li&title=Cardiac+c-kitCAT2C+cell+population+is+increased+in+response+to+ischemic+injury+and+supports+cardiomyocyte+performance&doi=10.1002%2Fstem.171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac c-kit+AT2+ cell population is increased in response to ischemic injury and supports cardiomyocyte performance</span></div><div class="casAuthors">Altarche-Xifro, Wassim; Curato, Caterina; Kaschina, Elena; Grzesiak, Aleksandra; Slavic, Svetlana; Dong, Jun; Kappert, Kai; Steckelings, Muscha; Imboden, Hans; Unger, Thomas; Li, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells (Durham, NC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2488-2497</span>CODEN:
                <span class="NLM_cas:coden">STCEEJ</span>;
        ISSN:<span class="NLM_cas:issn">1066-5099</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">The expression pattern of angiotensin AT2 receptors with predominance during fetal life and upregulation under pathol. conditions during tissue injury/repair process suggests that AT2 receptors may exert an important action in injury/repair adaptive mechanisms.  Less is known about AT2 receptors in acute ischemia-induced cardiac injury.  We aimed here to elucidate the role of AT2 receptors after acute myocardial infarction.  Double immunofluorescence staining showed that cardiac AT2 receptors were mainly detected in clusters of small c-kit+ cells accumulating in peri-infarct zone and c-kit+AT2+ cells increased in response to acute cardiac injury.  Further, we isolated cardiac c-kit+AT2+ cell population by modified magnetic activated cell sorting and fluorescence activated cell sorting.  These cardiac c-kit+AT2+ cells, represented ∼0.19% of total cardiac cells in infarcted heart, were characterized by upregulated transcription factors implicated in cardiogenic differentiation (Gata-4, Notch-2, Nkx-2.5) and genes required for self-renewal (Tbx-3, c-Myc, Akt).  When adult cardiomyocytes and cardiac c-kit+AT2+ cells isolated from infarcted rat hearts were cocultured, AT2 receptor stimulation in vitro inhibited apoptosis of these cocultured cardiomyocytes.  Moreover, in vivo AT2 receptor stimulation led to an increased c-kit+AT2+ cell population in the infarcted myocardium and reduced apoptosis of cardiomyocytes in rats with acute myocardial infarction.  These data suggest that cardiac c-kit+AT2+ cell population exists and increases after acute ischemic injury.  AT2 receptor activation supports performance of cardiomyocytes, thus contributing to cardioprotection via cardiac c-kit+AT2+ cell population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKQ78A4B4itbVg90H21EOLACvtfcHk0lgDq-x4lwO_0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFenur%252FI&md5=56bda5978285a7f7c05187e01f373b17</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1002%2Fstem.171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fstem.171%26sid%3Dliteratum%253Aachs%26aulast%3DAltarche-Xifro%26aufirst%3DW.%26aulast%3DCurato%26aufirst%3DC.%26aulast%3DKaschina%26aufirst%3DE.%26aulast%3DGrzesiak%26aufirst%3DA.%26aulast%3DSlavic%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DKappert%26aufirst%3DK.%26aulast%3DSteckelings%26aufirst%3DM.%26aulast%3DImboden%26aufirst%3DH.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DCardiac%2520c-kitCAT2C%2520cell%2520population%2520is%2520increased%2520in%2520response%2520to%2520ischemic%2520injury%2520and%2520supports%2520cardiomyocyte%2520performance%26jtitle%3DStem%2520Cells%26date%3D2009%26volume%3D27%26spage%3D2488%26epage%3D2497%26doi%3D10.1002%2Fstem.171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Edavarone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3019</span>– <span class="NLM_lpage">3033</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S144807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2147%2FDDDT.S144807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29081650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSkt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=3019-3033&author=W.+W.+Zhangauthor=F.+Baiauthor=J.+Wangauthor=R.+H.+Zhengauthor=L.+W.+Yangauthor=E.+A.+Jamesauthor=Z.+Q.+Zhao&title=Edavarone+inhibits+pressure+overload-induced+cardiac+fibrosis+and+dysfunction+by+reducing+expression+of+angiotensin+II+AT1+receptor&doi=10.2147%2FDDDT.S144807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor</span></div><div class="casAuthors">Zhang, Wei-Wei; Bai, Feng; Wang, Jin; Zheng, Rong-Hua; Yang, Li-Wang; James, Erskine A.; Zhao, Zhi-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3019-3033</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II) is known to be involved in the progression of ventricular dysfunction and heart failure by eliciting cardiac fibrosis.  The purpose of this study was to demonstrate whether treatment with an antioxidant compd., edaravone, reduces cardiac fibrosis and improves ventricular function by inhibiting Ang II AT1 receptor.  The study was conducted in a rat model of transverse aortic constriction (TAC).  In control, rats were subjected to 8 wk of TAC.  In treated rats, edaravone (10 mg/kg/day) or Ang II AT1 receptor blocker, telmisartan (10 mg/kg/day) was administered by i.p. injection or gastric gavage, resp., during TAC.  Relative to the animals with TAC, edaravone reduced myocardial malonaldehyde level and increased superoxide dismutase activity.  Protein level of the AT1 receptor was reduced and the AT2 receptor was upregulated, as evidenced by the reduced ratio of AT1 over AT2 receptor (0.57±0.2 vs 3.16±0.39, p<0.05) and less locally expressed AT1 receptor in the myocardium.  Furthermore, the protein level of angiotensin converting enzyme 2 was upregulated.  In coincidence with these changes, edaravone significantly decreased the populations of macrophages and myofibroblasts in the myocardium, which were accompanied by reduced levels of transforming growth factor beta 1 and Smad2/3.  Collagen I synthesis was inhibited and collagen-rich fibrosis was attenuated.  Relative to the TAC group, cardiac systolic function was preserved, as shown by increased left ventricular systolic pressure (204±51 vs 110±19 mmHg, p<0.05) and ejection fraction (82%±3% vs 60%±5%, p<0.05).  Treatment with telmisartan provided a comparable level of protection as compared with edaravone in all the parameters measured.  Taken together, edaravone treatment ameliorates cardiac fibrosis and improves left ventricular function in the pressure overload rat model, potentially via suppressing the AT1 receptor-mediated signaling pathways.  These data indicate that edaravone might be selected in combination with other existing drugs in preventing progression of cardiac dysfunction in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdgiWC1QUkDLVg90H21EOLACvtfcHk0lgDq-x4lwO_0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSkt7nE&md5=b869850a0f306239e13dcc3ae3991cb9</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S144807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S144807%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%2BW.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DR.%2BH.%26aulast%3DYang%26aufirst%3DL.%2BW.%26aulast%3DJames%26aufirst%3DE.%2BA.%26aulast%3DZhao%26aufirst%3DZ.%2BQ.%26atitle%3DEdavarone%2520inhibits%2520pressure%2520overload-induced%2520cardiac%2520fibrosis%2520and%2520dysfunction%2520by%2520reducing%2520expression%2520of%2520angiotensin%2520II%2520AT1%2520receptor%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D3019%26epage%3D3033%26doi%3D10.2147%2FDDDT.S144807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">AbdAlla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lother, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Tawab, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quitterer, U.</span></span> <span> </span><span class="NLM_article-title">The angiotensin II AT2 receptor is an AT1 receptor antagonist</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">39721</span>– <span class="NLM_lpage">39726</span>, <span class="refDoi"> DOI: 10.1074/jbc.M105253200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1074%2Fjbc.M105253200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=11507095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotFGit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=39721-39726&author=S.+AbdAllaauthor=H.+Lotherauthor=A.+M.+Abdel-Tawabauthor=U.+Quitterer&title=The+angiotensin+II+AT2+receptor+is+an+AT1+receptor+antagonist&doi=10.1074%2Fjbc.M105253200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The angiotensin II AT2 receptor is an AT1 receptor antagonist</span></div><div class="casAuthors">AbdAlla, Said; Lother, Heinz; Abdel-Tawab, Ahmed M.; Quitterer, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">39721-39726</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The vasopressor angiotensin II activates AT1 and AT2 receptors.  Most of the known in vivo effects of angiotensin II are mediated by AT1 receptors while the biol. functions of AT2 receptors are less clear.  We report here that the AT2 receptor binds directly to the AT1 receptor and thereby antagonizes the function of the AT1 receptor.  The AT1-specific antagonism of the AT2 receptor was independent of AT2 receptor activation and signaling, and it was effective on different cells and on human myometrial biopsies with AT1/AT2 receptor expression.  Thus, the AT2 receptor is the first identified example of a G-protein-coupled receptor which acts as a receptor-specific antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKCbYkE9odorVg90H21EOLACvtfcHk0lg73Rmo9WYWow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotFGit7s%253D&md5=e08a9974752dbf40ddecd2b993265f16</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M105253200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M105253200%26sid%3Dliteratum%253Aachs%26aulast%3DAbdAlla%26aufirst%3DS.%26aulast%3DLother%26aufirst%3DH.%26aulast%3DAbdel-Tawab%26aufirst%3DA.%2BM.%26aulast%3DQuitterer%26aufirst%3DU.%26atitle%3DThe%2520angiotensin%2520II%2520AT2%2520receptor%2520is%2520an%2520AT1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D39721%26epage%3D39726%26doi%3D10.1074%2Fjbc.M105253200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gildea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jose, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, R. A.</span></span> <span> </span><span class="NLM_article-title">The dopamine D<sub>1</sub> receptor and angiotensin II Type-2 receptor are required for inhibition of sodium transport through a protein phosphatase 2A pathway</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1258</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.119.12705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.119.12705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=31030607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlegtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2019&pages=1258-1265&author=J.+J.+Gildeaauthor=P.+Xuauthor=B.+A.+Kempauthor=R.+M.+Careyauthor=P.+A.+Joseauthor=R.+A.+Felder&title=The+dopamine+D1+receptor+and+angiotensin+II+Type-2+receptor+are+required+for+inhibition+of+sodium+transport+through+a+protein+phosphatase+2A+pathway&doi=10.1161%2FHYPERTENSIONAHA.119.12705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">The Dopamine D1 Receptor and Angiotensin II Type-2 Receptor are Required for Inhibition of Sodium Transport Through a Protein Phosphatase 2A Pathway</span></div><div class="casAuthors">Gildea, John J.; Xu, Peng; Kemp, Brandon A.; Carey, Robert M.; Jose, Pedro A.; Felder, Robin A.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1258-1265</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Activation of the renal D1R (dopamine D1-like receptor) or AT2R (angiotensin II type-2 receptor), individually or both, simultaneously, is necessary in the normal regulation of renal sodium (Na) transport and blood pressure.  However, little is known regarding the precise mechanism of this interaction.  Pharmacol. stimulation, membrane biotinylation, and cell surface immunofluorescence were used to study the effect of the D1R/AT2R interaction in human renal proximal tubule cells.  D1R activation of GαS stimulates AC (adenylyl cyclase) and induces apical plasma membrane recruitment of AT2Rs.  We now show for the first time the reciprocal reaction, AT2R stimulation with Ang III (angiotensin III) leads to the apical plasma membrane recruitment of the D1R.  The cell-permeable second messenger analogs of cAMP (8-Br-cAMP) or cGMP (8-Br-cGMP) induce translocation of both D1R and AT2R to the plasma membrane.  Inhibition of PKA (protein kinase A) with Rp-cAMPS and PKG (protein kinase G) with Rp-8-CPT-cGMPS blocks D1R and AT2R recruitment, resp., indicating that both PKA and PKG are necessary for D1R and AT2R trafficking.  Both 8-Br-cAMP and 8-Br-cGMP activate PP2A (protein phosphatase 2A), which is necessary for both plasma membrane recruitment of D1R and AT2R and the inhibition of sodium hydrogen exchanger 3-dependent Na transport.  These studies provide insights into the D1R/AT2R transregulation mechanisms that play a crucial role in maintaining Na and ultimately blood pressure homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp9ShHdQD2_7Vg90H21EOLACvtfcHk0lg73Rmo9WYWow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlegtLk%253D&md5=25ffaf7075ce2446d67d4447958224ed</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.119.12705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.119.12705%26sid%3Dliteratum%253Aachs%26aulast%3DGildea%26aufirst%3DJ.%2BJ.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DKemp%26aufirst%3DB.%2BA.%26aulast%3DCarey%26aufirst%3DR.%2BM.%26aulast%3DJose%26aufirst%3DP.%2BA.%26aulast%3DFelder%26aufirst%3DR.%2BA.%26atitle%3DThe%2520dopamine%2520D1%2520receptor%2520and%2520angiotensin%2520II%2520Type-2%2520receptor%2520are%2520required%2520for%2520inhibition%2520of%2520sodium%2520transport%2520through%2520a%2520protein%2520phosphatase%25202A%2520pathway%26jtitle%3DHypertension%26date%3D2019%26volume%3D73%26spage%3D1258%26epage%3D1265%26doi%3D10.1161%2FHYPERTENSIONAHA.119.12705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenström, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sköld, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and AT<sub>2</sub> receptor-binding properties of angiotensin II analogues</span>. <i>J. Pept. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.2004.00184.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2Fj.1399-3011.2004.00184.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=15485557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BD2crmt1yqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=194-201&author=U.+Rosenstr%C3%B6mauthor=C.+Sk%C3%B6ldauthor=G.+Lindebergauthor=M.+Botrosauthor=F.+Nybergauthor=A.+Hallbergauthor=A.+Karl%C3%A9n&title=Synthesis+and+AT2+receptor-binding+properties+of+angiotensin+II+analogues&doi=10.1111%2Fj.1399-3011.2004.00184.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and AT2 receptor-binding properties of angiotensin II analogues</span></div><div class="casAuthors">Rosenstrom U; Skold C; Lindeberg G; Botros M; Nyberg F; Hallberg A; Karlen A</div><div class="citationInfo"><span class="NLM_cas:title">The journal of peptide research : official journal of the American Peptide Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">194-201</span>
        ISSN:<span class="NLM_cas:issn">1397-002X</span>.
    </div><div class="casAbstract">The present study investigates the importance of the amino acid side chains in the octapeptide angiotensin II (Ang II) for binding to the AT2 receptor.  A Gly scan was performed where each amino acid in Ang II was substituted one-by-one with glycine.  The resulting set of peptides was tested for affinity to the AT2 receptor (porcine myometrial membranes).  For a comparison, the peptides were also tested for affinity to the AT1 receptor (rat liver membranes).  Only the substitution of Arg2 reduced affinity to the AT2 receptor considerably (92-fold when compared with Ang II).  For the other Gly-substituted analogues the affinity to the AT2 receptor was only moderately affected.  To further investigate the role of the Arg2 side chain for receptor binding, we synthesized some N-terminally modified Ang II analogues.  According to these studies a positive charge in the N-terminal end of angiotensin III [Ang II (2-8)] is not required for high AT2 receptor affinity but seems to be more important in Ang II.  With respect to the AT1 receptor, [Gly2]Ang II and [Gly8]Ang II lacked binding affinity (Ki > 10 microM).  Replacement of the Val3 or Ile5 residues with Gly produced only a slight decrease in affinity.  Interestingly, substitution of Tyr4 or His6, which are known to be very important for AT1 receptor binding, resulted in only 48 and 14 times reduction in affinity, respectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTL9YyCCETfREH3Rlp_k91zfW6udTcc2ebZclgl0C0Xzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crmt1yqug%253D%253D&md5=2f9c1144fd6316505092015d81c61fc2</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.2004.00184.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.2004.00184.x%26sid%3Dliteratum%253Aachs%26aulast%3DRosenstr%25C3%25B6m%26aufirst%3DU.%26aulast%3DSk%25C3%25B6ld%26aufirst%3DC.%26aulast%3DLindeberg%26aufirst%3DG.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520AT2%2520receptor-binding%2520properties%2520of%2520angiotensin%2520II%2520analogues%26jtitle%3DJ.%2520Pept.%2520Res.%26date%3D2004%26volume%3D64%26spage%3D194%26epage%3D201%26doi%3D10.1111%2Fj.1399-3011.2004.00184.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sävmarker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span> <span> </span><span class="NLM_article-title">Angiotensin peptides as AT2 receptor agonists</span>. <i>Curr. Protein Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.2174/1389203718666170203150344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2174%2F1389203718666170203150344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28164758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVShtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=809-818&author=M.+Hallbergauthor=J.+S%C3%A4vmarkerauthor=A.+Hallberg&title=Angiotensin+peptides+as+AT2+receptor+agonists&doi=10.2174%2F1389203718666170203150344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin Peptides as AT2 Receptor Agonists</span></div><div class="casAuthors">Hallberg, Mathias; Saevmarker, Jonas; Hallberg, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Current Protein and Peptide Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">809-818</span>CODEN:
                <span class="NLM_cas:coden">CPPSCM</span>;
        ISSN:<span class="NLM_cas:issn">1389-2037</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In 2004, the first nonpeptide selective angiotensin II type 2 receptor (AT2R) agonist was reported.  This nonpeptide (C21), which, exerts anti-inflammatory and antifibrotic actions in vivo, has been extensively explored and is currently in clin. trials.  Subsequently, a large no. of related drug-like AT2R agonists have been disclosed.  Reviews that summarize known structure-activity relationships (SAR) of nonpeptide AT2R agonists have recently appeared in the literature; however, very few reviews discuss the role of angiotensin peptides as AT2R agonists.  Furthermore, to date, there have been no reports focusing on the medicinal chem. perspective of peptide AT2R agonists.  In the present review, reports on linear and conformationally constrained Ang II analogs, with a focus on AT2R selective ligands that are proven to act as agonists at the AT2 receptor are summarized.  The impact of truncations and macrocyclizations of Ang II analogs and of incorporation of scaffolds that mimic secondary structures into Ang II related peptides is highlighted.  A survey of the efforts to transform the nonselective octapeptide Ang II to more drug-like selective AT2R agonists is presented.  The relationship between the structures of the AT2R agonists and their affinity to the AT2R is briefly discussed and common pharmacophore elements of AT2R selective Ang II peptide analogs and selective nonpeptide AT2R agonists are compared.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr860hLK9E6sLVg90H21EOLACvtfcHk0lgSjF4QVH6KMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVShtrjP&md5=f6b91646608c02bbbe32d593c30755fb</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.2174%2F1389203718666170203150344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389203718666170203150344%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DS%25C3%25A4vmarker%26aufirst%3DJ.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DAngiotensin%2520peptides%2520as%2520AT2%2520receptor%2520agonists%26jtitle%3DCurr.%2520Protein%2520Pept.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D809%26epage%3D818%26doi%3D10.2174%2F1389203718666170203150344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asare, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liehn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raya-Bermudez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda-Martos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Castañeda, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinze, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zidek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowski, J.</span></span> <span> </span><span class="NLM_article-title">Identification of the vasoconstriction-inhibiting factor (VIF), a potent endogenous cofactor of angiotensin II acting on the angiotensin II type 2 receptor</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1426</span>– <span class="NLM_lpage">1434</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.114.013168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FCIRCULATIONAHA.114.013168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25810338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFSgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2015&pages=1426-1434&author=S.+Salemauthor=V.+Jankowskiauthor=Y.+Asareauthor=E.+Liehnauthor=P.+Welkerauthor=A.+Raya-Bermudezauthor=C.+Pineda-Martosauthor=M.+Rodriguezauthor=J.+R.+Mu%C3%B1oz-Casta%C3%B1edaauthor=H.+Bruckauthor=N.+Marxauthor=F.+B.+Machadoauthor=M.+Staudtauthor=G.+Heinzeauthor=W.+Zidekauthor=J.+Jankowski&title=Identification+of+the+vasoconstriction-inhibiting+factor+%28VIF%29%2C+a+potent+endogenous+cofactor+of+angiotensin+II+acting+on+the+angiotensin+II+type+2+receptor&doi=10.1161%2FCIRCULATIONAHA.114.013168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the Vasoconstriction-Inhibiting Factor (VIF), a Potent Endogenous Cofactor of Angiotensin II Acting on the Angiotensin II Type 2 Receptor</span></div><div class="casAuthors">Salem, Silvia; Jankowski, Vera; Asare, Yaw; Liehn, Elisa; Welker, Pia; Raya-Bermudez, Ana; Pineda-Martos, Carmen; Rodriguez, Mariano; Munoz-Castaneda, Juan Rafael; Bruck, Heike; Marx, Nikolaus; Machado, Fernanda B.; Staudt, Mareike; Heinze, Georg; Zidek, Walter; Jankowski, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1426-1434</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND-: The renin-angiotensin system and esp. the angiotensin peptides play a central role in blood pressure regulation.  Here, we hypothesize that an as-yet unknown peptide is involved in the action of angiotensin II modulating the vasoregulatory effects as a cofactor.  METHODS AND RESULTS-: The peptide with vasodilatory properties was isolated from adrenal glands chromatog.  The effects of this peptide were evaluated in vitro and in vivo, and the receptor affinity was analyzed.  The plasma concn. in humans was quantified in patients with chronic kidney disease, patients with heart failure, and healthy control subjects.  The amino acid sequence of the peptide from bovine adrenal glands was HSSYEDELSEVL EKPNDQAE PKEVTEEVSSKDAAE, which is a degrdn. product of chromogranin A.  The sequence of the peptide isolated from human plasma was HSGFEDELSEVLENQSSQAELKEAVEEPSSKDVME.  Both peptides diminished significantly the vasoconstrictive effect of angiotensin II in vitro.  Therefore, we named the peptide vasoconstriction-inhibiting factor (VIF).  The vasoregulatory effects of VIF are mediated by the angiotensin II type 2 receptor.  VIF impairs angiotensin II-induced phosphorylation of the p38 mitogen-activated protein kinase pathway but not of extracellular-regulated kinase 1/2.  The vasodilatory effects were confirmed in vivo.  The plasma concn. was significantly increased in renal patients and patients with heart failure.  CONCLUSIONS-: VIF is a vasoregulatory peptide that modulates the vasoconstrictive effects of angiotensin II by acting on the angiotensin II type 2 receptor.  It is likely that the increase in VIF may serve as a counterregulatory effect to defend against hypertension.  The identification of this target may help us to understand the pathophysiol. of renal and heart failure and may form a basis for the development of new strategies for the prevention and treatment of cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBu2Pwyj6Oo7Vg90H21EOLACvtfcHk0lgZ20FTf6Uy2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFSgtLg%253D&md5=a05ad402a8bbe135c3a2522f0980e35a</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.114.013168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.114.013168%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DS.%26aulast%3DJankowski%26aufirst%3DV.%26aulast%3DAsare%26aufirst%3DY.%26aulast%3DLiehn%26aufirst%3DE.%26aulast%3DWelker%26aufirst%3DP.%26aulast%3DRaya-Bermudez%26aufirst%3DA.%26aulast%3DPineda-Martos%26aufirst%3DC.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DMu%25C3%25B1oz-Casta%25C3%25B1eda%26aufirst%3DJ.%2BR.%26aulast%3DBruck%26aufirst%3DH.%26aulast%3DMarx%26aufirst%3DN.%26aulast%3DMachado%26aufirst%3DF.%2BB.%26aulast%3DStaudt%26aufirst%3DM.%26aulast%3DHeinze%26aufirst%3DG.%26aulast%3DZidek%26aufirst%3DW.%26aulast%3DJankowski%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520the%2520vasoconstriction-inhibiting%2520factor%2520%2528VIF%2529%252C%2520a%2520potent%2520endogenous%2520cofactor%2520of%2520angiotensin%2520II%2520acting%2520on%2520the%2520angiotensin%2520II%2520type%25202%2520receptor%26jtitle%3DCirculation%26date%3D2015%26volume%3D131%26spage%3D1426%26epage%3D1434%26doi%3D10.1161%2FCIRCULATIONAHA.114.013168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span> <span> </span><span class="NLM_article-title">Nonpeptide AT2R agonists</span>. <i>Med. Chem. Reviews</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.29200/acsmedchemrev-v51.ch5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.29200%2Facsmedchemrev-v51.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=69-82&author=M.+Larhedauthor=M.+Hallbergauthor=A.+Hallberg&title=Nonpeptide+AT2R+agonists&doi=10.29200%2Facsmedchemrev-v51.ch5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.29200%2Facsmedchemrev-v51.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.29200%252Facsmedchemrev-v51.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DLarhed%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DNonpeptide%2520AT2R%2520agonists%26jtitle%3DMed.%2520Chem.%2520Reviews%26date%3D2016%26volume%3D51%26spage%3D69%26epage%3D82%26doi%3D10.29200%2Facsmedchemrev-v51.ch5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speth, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span> <span> </span><span class="NLM_article-title">Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanin-6-angiotensin II</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(90)91993-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2F0006-291X%2890%2991993-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=2194459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK3cXkslWrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=1990&pages=997-1006&author=R.+C.+Spethauthor=K.+H.+Kim&title=Discrimination+of+two+angiotensin+II+receptor+subtypes+with+a+selective+agonist+analogue+of+angiotensin+II%2C+p-aminophenylalanin-6-angiotensin+II&doi=10.1016%2F0006-291X%2890%2991993-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discrimination of two angiotensin II receptor subtypes with a selective agonist analog of angiotensin II, p-aminophenylalanine6 angiotensin II</span></div><div class="casAuthors">Speth, Robert C.; Kim, Kwan Hee</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">997-1006</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Angiotensin II receptor binding sites in rat liver and PC12 cells differ in their affinities for a nonpeptidic antagonist, DuP 753, and p-aminophenylalanine6-angiotensin II.  In liver, which primarily contains the sulfhydryl reducing agent-inhibited type of angiotensin II receptor, referred to as the AIIα subtype, DuP 753 displays an IC50 of 55 nM, while p-aminophenylalanine6-angiotensin II displays an IC50 of 8-9 μM.  In PC12 cells, which primarily contain the angiotensin II receptor type whose binding affinity is enhanced by sulfhydryl reducing agents (AIIβ), DuP 753 displays an IC50 in excess of 100μM, while p-aminophenylalanine6-angiotensin II displays an IC50 of 12 nM.  p-Aminophenylalanine6-angiotensin II binding affinity in liver is decreased in the presence of guanosine 5'-O-(3-thiotriphosphate) (GTP-γS), suggesting that this analog is an agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxbmhrET9RlbVg90H21EOLACvtfcHk0lgZ20FTf6Uy2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkslWrtr0%253D&md5=c9ad030ac52823051ae64f2658870f88</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2890%2991993-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252890%252991993-3%26sid%3Dliteratum%253Aachs%26aulast%3DSpeth%26aufirst%3DR.%2BC.%26aulast%3DKim%26aufirst%3DK.%2BH.%26atitle%3DDiscrimination%2520of%2520two%2520angiotensin%2520II%2520receptor%2520subtypes%2520with%2520a%2520selective%2520agonist%2520analogue%2520of%2520angiotensin%2520II%252C%2520p-aminophenylalanin-6-angiotensin%2520II%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1990%26volume%3D169%26spage%3D997%26epage%3D1006%26doi%3D10.1016%2F0006-291X%2890%2991993-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johannesson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdélyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frändberg, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span> <span> </span><span class="NLM_article-title">AT<sub>2</sub>-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">6009</span>– <span class="NLM_lpage">6019</span>, <span class="refDoi"> DOI: 10.1021/jm049651m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049651m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1WjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6009-6019&author=P.+Johannessonauthor=M.+Erd%C3%A9lyiauthor=G.+Lindebergauthor=P.+A.+Fr%C3%A4ndbergauthor=F.+Nybergauthor=A.+Karl%C3%A9nauthor=A.+Hallberg&title=AT2-selective+angiotensin+II+analogues+containing+tyrosine-functionalized+5%2C5-bicyclic+thiazabicycloalkane+dipeptide+mimetics&doi=10.1021%2Fjm049651m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">AT2-Selective Angiotensin II Analogues Containing Tyrosine-Functionalized 5,5-Bicyclic Thiazabicycloalkane Dipeptide Mimetics</span></div><div class="casAuthors">Johannesson, Petra; Erdelyi, Mate; Lindeberg, Gunnar; Fraendberg, Per-Anders; Nyberg, Fred; Karlen, Anders; Hallberg, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6009-6019</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper reports the synthesis of two angiotensin II analogs with tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics replacing the Tyr4-Ile5 residues.  The prepn. of these analogs relies on the synthesis and incorporation of an α,α-disubstituted chimeric amino acid deriv. I and on-resin bicyclization to a cysteine residue.  The synthesized analogs both displayed high angiotensin AT2/AT1 receptor binding preferences and had AT2 receptor affinities in the same low nanomolar range as angiotensin II itself.  Conformational anal., using exptl. constraints derived from NMR studies, indicated that the Tyr4 and His6 residues in one of the angiotensin II analogs were in close proximity to each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokD2-nXABi67Vg90H21EOLACvtfcHk0lhRrSQ8ATozAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1WjsLs%253D&md5=c59524ab47daa4b1ea7fd14bca82e217</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm049651m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049651m%26sid%3Dliteratum%253Aachs%26aulast%3DJohannesson%26aufirst%3DP.%26aulast%3DErd%25C3%25A9lyi%26aufirst%3DM.%26aulast%3DLindeberg%26aufirst%3DG.%26aulast%3DFr%25C3%25A4ndberg%26aufirst%3DP.%2BA.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DAT2-selective%2520angiotensin%2520II%2520analogues%2520containing%2520tyrosine-functionalized%25205%252C5-bicyclic%2520thiazabicycloalkane%2520dipeptide%2520mimetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6009%26epage%3D6019%26doi%3D10.1021%2Fjm049651m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del
Borgo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosnyak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spizzo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlmutter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span> <span> </span><span class="NLM_article-title">Beta-Pro<sup>7</sup> Ang III is a novel highly selective angiotensin AT2R agonist, which acts as a vasodepressor agent via the AT2 receptor in conscious SHR</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1042/CS20150077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1042%2FCS20150077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26186568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OmurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2015&pages=505-513&author=M.+P.+Del%0ABorgoauthor=Y.+Wangauthor=S.+Bosnyakauthor=M.+Khanauthor=P.+Waltersauthor=I.+Spizzoauthor=P.+Perlmutterauthor=L.+Hilliardauthor=K.+Dentonauthor=M.+I.+Aguilarauthor=R.+Widdopauthor=E.+S.+Jones&title=Beta-Pro7+Ang+III+is+a+novel+highly+selective+angiotensin+AT2R+agonist%2C+which+acts+as+a+vasodepressor+agent+via+the+AT2+receptor+in+conscious+SHR&doi=10.1042%2FCS20150077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">β-Pro7 Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats</span></div><div class="casAuthors">Del Borgo, Mark; Wang, Yan; Bosnyak, Sanja; Khan, Morimer; Walters, Pia; Spizzo, Iresha; Perlmutter, Patrick; Hilliard, Lucinda; Denton, Kate; Aguilar, Marie-Isabel; Widdop, Robert E.; Jones, Emma S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">505-513</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">We have previously shown that individual β-amino acid substitution in angiotensin (Ang) II reduced Ang II type 1 receptor (AT1R) but not Ang II type 2 receptor (AT2R)-binding and that the heptapeptide Ang III exhibited greater AT2R:AT1R selectivity than Ang II.  Therefore, we hypothesized that β-amino-acid-substituted Ang III peptide analogs would yield highly selective AT2R ligands, which we have tested in binding and functional vascular assays.  In competition binding expts. using either AT1R- or AT2R-transfected human embryonic kidney (HEK)-293 cells, novel β-substituted Ang III analogs lacked appreciable AT1R affinity, whereas most compds. could fully displace 125I-Sar1Ile8 Ang II from AT2R.  The rank order of affinity at AT2R was CGP42112 > Ang III > β-Pro7 Ang III = Ang II > β-Tyr4 Ang III ≥ PD123319 >> β-Phe8 Ang III >> β Arg2 Ang III = β-Val3 Ang III >> β-Ile5 Ang III.  The novel analog β-Pro7 Ang III was the most selective AT2R ligand tested, which was >20 000-fold more selective for AT2R than AT1R.  IC50 values at AT2R from binding studies correlated with max. vasorelaxation in mouse aortic rings.  Given that β-Pro7 Ang III was an AT2R agonist, we compared β-Pro7 Ang III and native Ang III for their ability to reduce blood pressure in sep. groups of conscious spontaneously hypertensive rats.  Whereas Ang III alone increased mean arterial pressure (MAP), β-Pro7 Ang III had no effect.  During low-level AT1R blockade, both Ang III and β-Pro7 Ang III, but not Ang II, lowered MAP (by ∼30 mmHg) at equimolar infusions (150 pmol/kg/min for 4 h) and these depressor effects were abolished by the co-administration of the AT2R antagonist PD123319.  Thus, β-Pro7 Ang III has remarkable AT2R selectivity detd. in binding and functional studies and will be a valuable research tool for insight into AT2R function and for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp253Q4ZRqqMrVg90H21EOLACvtfcHk0lhRrSQ8ATozAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OmurfK&md5=5ebc6245b4d4c80de80a11ee57603de0</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1042%2FCS20150077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20150077%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BBorgo%26aufirst%3DM.%2BP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBosnyak%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DWalters%26aufirst%3DP.%26aulast%3DSpizzo%26aufirst%3DI.%26aulast%3DPerlmutter%26aufirst%3DP.%26aulast%3DHilliard%26aufirst%3DL.%26aulast%3DDenton%26aufirst%3DK.%26aulast%3DAguilar%26aufirst%3DM.%2BI.%26aulast%3DWiddop%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DE.%2BS.%26atitle%3DBeta-Pro7%2520Ang%2520III%2520is%2520a%2520novel%2520highly%2520selective%2520angiotensin%2520AT2R%2520agonist%252C%2520which%2520acts%2520as%2520a%2520vasodepressor%2520agent%2520via%2520the%2520AT2%2520receptor%2520in%2520conscious%2520SHR%26jtitle%3DClin.%2520Sci.%26date%3D2015%26volume%3D129%26spage%3D505%26epage%3D513%26doi%3D10.1042%2FCS20150077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohinata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span> <span> </span><span class="NLM_article-title">The pharmacological effects of novokinin; a designed peptide agonist of the angiotensin AT2 receptor</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3009</span>– <span class="NLM_lpage">3012</span>, <span class="refDoi"> DOI: 10.2174/1381612811319170006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2174%2F1381612811319170006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23176213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFKhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3009-3012&author=M.+Yoshikawaauthor=K.+Ohinataauthor=Y.+Yamada&title=The+pharmacological+effects+of+novokinin%3B+a+designed+peptide+agonist+of+the+angiotensin+AT2+receptor&doi=10.2174%2F1381612811319170006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacological effects of novokinin; a designed peptide agonist of the angiotensin AT2 receptor</span></div><div class="casAuthors">Yoshikawa, Masaaki; Ohinata, Kousaku; Yamada, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3009-3012</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Novokinin (RPLKPW) was designed based on ovokinin (FRADHPFL), a vasorelaxing peptide derived from ovalbumin.  Novokinin relaxed a mesenteric artery isolated from the spontaneously hypertensive rat (SHR) at 10-5 M, and reduced SHR blood pressure at a dose of 0.1 mg/kg (po.) emulsified in 30% egg yolk.  Novokinin exhibited an affinity for the AT2 receptor (Ki = 7 × 10-6M), and its antihypertensive and vasorelaxing activities were blocked by PD123319, an AT2 receptor antagonist.  The hypotensive effect of novokinin in normotensive mice was not obsd. in the AT2 receptor-knockout mice.  Its antihypertensive and vasorelaxing activities in SHR were also blocked by CAY-10441, an antagonist of the IP receptor for prostaglandin I2 (PGI2) suggesting that these activities are mediated by the AT2 receptor, followed by the prostaglandin I2-IP receptor pathway.  Novokinin suppressed food intake after icv. or po. administration in mice.  The anorexigenic activity was not obsd. in the AT2 receptor-knockout mice, but was obsd. in the AT1 receptor-knockout mice.  The anorexigenic activities of novokinin and angiotensin II were blocked by PD123319, and ONO-AE3-208, an antagonist of the EP4 receptor suggesting that the anorexigenic activities of the AT2 agonists are mediated by the PGE2-EP4 receptor pathway downstream of the AT2 receptor.  Novokinin given icv. in mice antagonized the antinociceptive effect of morphine.  The antiopiod activites of novokinin and angiotensin II were are blocked by PD123319, and by ONO-AE3-240, an antagonist of the EP3 receptor, suggesting that the antiopioid activities of AT2 agonists is mediated by the PGE2-EP3 receptor downstream of the AT2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7wyfXfmyaErVg90H21EOLACvtfcHk0lhXO0d6CPBjjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFKhtLY%253D&md5=93cc7903618fa9f808519db7fe146381</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.2174%2F1381612811319170006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319170006%26sid%3Dliteratum%253Aachs%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DOhinata%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DY.%26atitle%3DThe%2520pharmacological%2520effects%2520of%2520novokinin%253B%2520a%2520designed%2520peptide%2520agonist%2520of%2520the%2520angiotensin%2520AT2%2520receptor%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D3009%26epage%3D3012%26doi%3D10.2174%2F1381612811319170006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Georgsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sköld, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogoll, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II pseudopeptides containing 1,3,5-trisubsituted benzene scaffolds with high AT<sub>2</sub> receptor affinity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6620</span>– <span class="NLM_lpage">6631</span>, <span class="refDoi"> DOI: 10.1021/jm050280z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050280z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVegt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6620-6631&author=J.+Georgssonauthor=C.+Sk%C3%B6ldauthor=B.+Plouffeauthor=G.+Lindebergauthor=M.+Botrosauthor=M.+Larhedauthor=F.+Nybergauthor=N.+Gallo-Payetauthor=A.+Gogollauthor=A.+Karl%C3%A9nauthor=A.+Hallberg&title=Angiotensin+II+pseudopeptides+containing+1%2C3%2C5-trisubsituted+benzene+scaffolds+with+high+AT2+receptor+affinity&doi=10.1021%2Fjm050280z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II Pseudopeptides Containing 1,3,5-Trisubstituted Benzene Scaffolds with High AT2 Receptor Affinity</span></div><div class="casAuthors">Georgsson, Jennie; Skoeld, Christian; Plouffe, Bianca; Lindeberg, Gunnar; Botros, Milad; Larhed, Mats; Nyberg, Fred; Gallo-Payet, Nicole; Gogoll, Adolf; Karlen, Anders; Hallberg, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6620-6631</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two 1,3,5-trisubstituted arom. scaffolds intended to serve as γ-turn mimetics have been synthesized and incorporated in five pseudopeptide analogs of angiotensin II (H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH), replacing Val-Tyr-Ile, Val-Tyr, or Tyr-Ile.  All the tested compds. exhibited nanomolar affinity for the AT2 receptor with the best compd., pseudopeptide I with Ki = 1.85 nM.  Four pseudopeptides were AT2 selective, while pseudopeptide II also exhibited good affinity for the AT1 receptor (Ki = 30.3 nM).  This pseudopeptide exerted full agonistic activity in an AT2 receptor induced neurite outgrowth assay but displayed no agonistic effect in an AT1 receptor functional assay.  Mol. modeling, using the program DISCOtech, showed that the high-affinity ligands could interact similarly with the AT2 receptor as other ligands with high affinity for this receptor.  A tentative agonist model is proposed for AT2 receptor activation by angiotensin II analogs.  The authors conclude that the 1,3,5-trisubstituted benzene rings can be conveniently prepd. and are suitable as γ-turn mimics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo_DtMVb43c7Vg90H21EOLACvtfcHk0lhXO0d6CPBjjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVegt7rI&md5=d0d04a9501ed77044d48783f69df4660</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm050280z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050280z%26sid%3Dliteratum%253Aachs%26aulast%3DGeorgsson%26aufirst%3DJ.%26aulast%3DSk%25C3%25B6ld%26aufirst%3DC.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DLindeberg%26aufirst%3DG.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DLarhed%26aufirst%3DM.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DGogoll%26aufirst%3DA.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DAngiotensin%2520II%2520pseudopeptides%2520containing%25201%252C3%252C5-trisubsituted%2520benzene%2520scaffolds%2520with%2520high%2520AT2%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6620%26epage%3D6631%26doi%3D10.1021%2Fjm050280z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Georgsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sköld, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT<sub>2</sub> receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1715</span>, <span class="refDoi"> DOI: 10.1021/jm0613469</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0613469" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislKrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1711-1715&author=J.+Georgssonauthor=C.+Sk%C3%B6ldauthor=M.+Botrosauthor=G.+Lindebergauthor=F.+Nybergauthor=A.+Karl%C3%A9nauthor=A.+Hallbergauthor=M.+Larhed&title=Synthesis+of+a+new+class+of+druglike+angiotensin+II+C-terminal+mimics+with+affinity+for+the+AT2+receptor&doi=10.1021%2Fjm0613469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT2 receptor</span></div><div class="casAuthors">Georgsson, Jennie; Skoeld, Christian; Botros, Milad; Lindeberg, Gunnar; Nyberg, Fred; Karlen, Anders; Hallberg, Anders; Larhed, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1711-1715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Four tripeptides corresponding to the C-terminal region of angiotensin II were synthesized.  One of these peptides (Ac-His-Pro-Ile) showed moderate binding affinity for the AT2 receptor.  Two arom. histidine-related scaffolds were synthesized and introduced in the tripeptides to give eight new peptidomimetic structures.  Three of the peptide-derived druglike mols. exhibited selective, nanomolar affinity for the AT2 receptor.  These ligands may become lead compds. in the future development of novel classes of selective AT2 receptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSWg7500LLF7Vg90H21EOLACvtfcHk0lgj5OpbdYXuQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislKrsr8%253D&md5=2caa1e026577b56f2342bd8bd5925fba</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fjm0613469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0613469%26sid%3Dliteratum%253Aachs%26aulast%3DGeorgsson%26aufirst%3DJ.%26aulast%3DSk%25C3%25B6ld%26aufirst%3DC.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DLindeberg%26aufirst%3DG.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DLarhed%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520a%2520new%2520class%2520of%2520druglike%2520angiotensin%2520II%2520C-terminal%2520mimics%2520with%2520affinity%2520for%2520the%2520AT2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1711%26epage%3D1715%26doi%3D10.1021%2Fjm0613469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Gasparo, M.</span></span> <span> </span><span class="NLM_article-title">Preliminary biochemical characterization of two angiotensin II receptor subtypes</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(89)92133-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2F0006-291X%2889%2992133-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=2775266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaL1MXlsVOnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=1989&pages=284-291&author=S.+Whitebreadauthor=M.+Meleauthor=B.+Kamberauthor=M.+de+Gasparo&title=Preliminary+biochemical+characterization+of+two+angiotensin+II+receptor+subtypes&doi=10.1016%2F0006-291X%2889%2992133-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary biochemical characterization of two angiotensin II receptor subtypes</span></div><div class="casAuthors">Whitebread, Steven; Mele, Michele; Kamber, Bruno; De Gasparo, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">284-91</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Two angiotensin II receptor subtypes (A and B) from rat and human tissues have been characterized using specific peptidic and nonpeptidic ligands with affinities differing by 1000-fold or more.  These subtypes are present in the adrenal glomerulosa of both species.  Human uterus contains only subtype A, whereas both subtypes are found in rat uterus.  Vascular smooth muscle cells in culture express only subtype B.  Dithiothreitol totally inhibits binding to subtype B, but enhances the affinity to subtype A.  There is a good correlation between the affinities of the selected agonists and antagonists for the two subtypes in the various tissues tested, which is a usual requirement for receptor classification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUpya3IHUYIbVg90H21EOLACvtfcHk0lgj5OpbdYXuQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlsVOnsLs%253D&md5=018f8ff198b49720f4880adc6ff2221f</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2889%2992133-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252889%252992133-5%26sid%3Dliteratum%253Aachs%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DMele%26aufirst%3DM.%26aulast%3DKamber%26aufirst%3DB.%26aulast%3Dde%2BGasparo%26aufirst%3DM.%26atitle%3DPreliminary%2520biochemical%2520characterization%2520of%2520two%2520angiotensin%2520II%2520receptor%2520subtypes%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1989%26volume%3D163%26spage%3D284%26epage%3D291%26doi%3D10.1016%2F0006-291X%2889%2992133-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brait, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugam, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobey, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo</span>. <i>Exp. Transl. Stroke Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.1186/2040-7378-4-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1186%2F2040-7378-4-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22920387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKltL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=16&author=S.+Leeauthor=V.+H.+Braitauthor=T.+V.+Arumugamauthor=M.+A.+Evansauthor=H.+A.+Kimauthor=R.+E.+Widdopauthor=G.+R.+Drummondauthor=C.+G.+Sobeyauthor=E.+S.+Jones&title=Neuroprotective+effect+of+an+angiotensin+receptor+type+2+agonist+following+cerebral+ischemia+in+vitro+and+in+vivo&doi=10.1186%2F2040-7378-4-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo</span></div><div class="casAuthors">Lee, Seyoung; Brait, Vanessa H.; Arumugam, Thiruma V.; Evans, Megan A.; Kim, Hyun Ah; Widdop, Robert E.; Drummond, Grant R.; Sobey, Christopher G.; Jones, Emma S.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & Translational Stroke Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16</span>CODEN:
                <span class="NLM_cas:coden">ETSMCZ</span>;
        ISSN:<span class="NLM_cas:issn">2040-7378</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Intracerebral administration of the angiotensin II type 2 receptor (AT2R) agonist, CGP42112, is neuroprotective in a rat model of ischemic stroke.  To explore further its possible cellular target(s) and therapeutic utility, we firstly examd. whether CGP42112 may exert direct protective effects on primary neurons following glucose deprivation in vitro.  Secondly, we tested whether CGP42112 is effective when administered systemically in a mouse model of cerebral ischemia.  Methods: Primary cortical neurons were cultured from E17 C57Bl6 mouse embryos for 9 d, exposed to glucose deprivation for 24 h alone or with drug treatments and percent cell survival assessed using trypan blue exclusion.  Ischemic stroke was induced in adult male C57Bl6 mice by middle cerebral artery occlusion for 30 min, followed by reperfusion for 23.5 h.  Neurol. assessment was performed and then mice were euthanized and infarct and edema vol. were analyzed.  Results: During glucose deprivation, CGP42112 (1 × 10-8 M and 1 × 10-7 M) reduced cell death by ∼30%, an effect that was prevented by the AT2R antagonist, PD123319 (1 × 10-6 M).  Neuroprotection by CGP42112 was lost at a higher concn. (1 × 10-6 M) but was unmasked by co-application with the AT1R antagonist, candesartan (1 × 10-7 M).  By contrast, Compd. 21 (1 × 10-8 M to 1 × 10-6 M), a second AT2R agonist, had no effect on neuronal survival.  Mice treated with CGP42112 (1 mg/kg i.p.) after cerebral ischemia had improved functional outcomes over vehicle-treated mice as well as reduced total and cortical infarct vols.  Conclusions: These results indicate that CGP42112 can directly protect neurons from ischemia-like injury in vitro via activation of AT2Rs, an effect opposed by AT1R activation at high concns.  Furthermore, systemic administration of CGP42112 can reduce functional deficits and infarct vol. following cerebral ischemia in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXflrPTMoM37Vg90H21EOLACvtfcHk0lg59lPTmuDSgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKltL3L&md5=5bcc47a7f146d896a63ad87cf1745e6b</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1186%2F2040-7378-4-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2040-7378-4-16%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DBrait%26aufirst%3DV.%2BH.%26aulast%3DArumugam%26aufirst%3DT.%2BV.%26aulast%3DEvans%26aufirst%3DM.%2BA.%26aulast%3DKim%26aufirst%3DH.%2BA.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DDrummond%26aufirst%3DG.%2BR.%26aulast%3DSobey%26aufirst%3DC.%2BG.%26aulast%3DJones%26aufirst%3DE.%2BS.%26atitle%3DNeuroprotective%2520effect%2520of%2520an%2520angiotensin%2520receptor%2520type%25202%2520agonist%2520following%2520cerebral%2520ischemia%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DExp.%2520Transl.%2520Stroke%2520Med.%26date%3D2012%26volume%3D4%26spage%3D16%26doi%3D10.1186%2F2040-7378-4-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umschweif, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liraz-Zaltsman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabashov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrovich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trembovler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shohami, E.</span></span> <span> </span><span class="NLM_article-title">Angiotensin receptor type 2 activation induces neuroprotection and neurogenesis after traumatic brain injury</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1007/s13311-014-0286-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs13311-014-0286-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24957202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOjtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=665-678&author=G.+Umschweifauthor=S.+Liraz-Zaltsmanauthor=D.+Shabashovauthor=A.+Alexandrovichauthor=V.+Trembovlerauthor=M.+Horowitzauthor=E.+Shohami&title=Angiotensin+receptor+type+2+activation+induces+neuroprotection+and+neurogenesis+after+traumatic+brain+injury&doi=10.1007%2Fs13311-014-0286-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin Receptor Type 2 Activation Induces Neuroprotection and Neurogenesis After Traumatic Brain Injury</span></div><div class="casAuthors">Umschweif, Gali; Liraz-Zaltsman, Sigal; Shabashov, Dalia; Alexandrovich, Alexander; Trembovler, Victoria; Horowitz, Michal; Shohami, Esther</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">665-678</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Angiotensin II receptor type 2 (AT2) agonists have been shown to limit brain ischemic insult and to improve its outcome.  The activation of AT2 was also linked to induced neuronal proliferation and differentiation in vitro.  In this study, we examd. the therapeutic potential of AT2 activation following traumatic brain injury (TBI) in mice, a brain pathol. that displays ischemia-like secondary damages.  The AT2 agonist CGP42112A was continuously infused immediately after closed head injury (CHI) for 3 days.  We have followed the functional recovery of the injured mice for 35 days post-CHI, and evaluated cognitive function, lesion vol., mol. signaling, and neurogenesis at different time points after the impact.  We found dose-dependent improvement in functional recovery and cognitive performance after CGP42112A treatment that was accompanied by reduced lesion vol. and induced neurogenesis in the neurogenic niches of the brain and also in the injury region.  At the cellular/mol. level, CGP42112A induced early activation of neuroprotective kinases protein kinase B (Akt) and extracellular-regulated kinases 1/2 (ERK1/2), and the neurotrophins nerve growth factor and brain-derived neurotrophic factor; all were blocked by treatment with the AT2 antagonist PD123319.  Our results suggest that AT2 activation after TBI promotes neuroprotection and neurogenesis, and may be a novel approach for the development of new drugs to treat victims of TBI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlqvL6wZPIgbVg90H21EOLACvtfcHk0lg59lPTmuDSgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOjtbvI&md5=c153337ab9f77b3da39f52d683e7288e</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2Fs13311-014-0286-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-014-0286-x%26sid%3Dliteratum%253Aachs%26aulast%3DUmschweif%26aufirst%3DG.%26aulast%3DLiraz-Zaltsman%26aufirst%3DS.%26aulast%3DShabashov%26aufirst%3DD.%26aulast%3DAlexandrovich%26aufirst%3DA.%26aulast%3DTrembovler%26aufirst%3DV.%26aulast%3DHorowitz%26aufirst%3DM.%26aulast%3DShohami%26aufirst%3DE.%26atitle%3DAngiotensin%2520receptor%2520type%25202%2520activation%2520induces%2520neuroprotection%2520and%2520neurogenesis%2520after%2520traumatic%2520brain%2520injury%26jtitle%3DNeurotherapeutics%26date%3D2014%26volume%3D11%26spage%3D665%26epage%3D678%26doi%3D10.1007%2Fs13311-014-0286-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toedebusch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belenchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulakat, L.</span></span> <span> </span><span class="NLM_article-title">Cell-specific protective signaling induced by the novel AT2R-agonist NP-6A4 on human endothelial and smooth muscle cells</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">928</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffphar.2018.00928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30186168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFyltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=928&author=R.+Toedebuschauthor=A.+Belenchiaauthor=L.+Pulakat&title=Cell-specific+protective+signaling+induced+by+the+novel+AT2R-agonist+NP-6A4+on+human+endothelial+and+smooth+muscle+cells&doi=10.3389%2Ffphar.2018.00928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-specific protective signaling induced by the novel AT2R-agonist NP-6A4 on human endothelial and smooth muscle cells</span></div><div class="casAuthors">Toedebusch, Ryan; Belenchia, Anthony; Pulakat, Lakshmi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">928/1-928/14</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Cardiovascular disease incidence continues to rise and new treatment paradigms are warranted.  We reported previously that activation of Angiotensin II receptor (encoded by the X-linked Agtr2 gene) by a new peptide agonist, NP-6A4, was more effective in protecting mouse cardiomyocyte HL-1 cells and human coronary artery vascular smooth muscle cells (hCAVSMCs) from acute nutrient deficiency than other drugs tested.  To elucidate further the protective effects of NP-6A4 in human cells, we studied the effects of NP-6A4 treatment on functions of human coronary artery endothelial cells (hCAECs), and hCAVSMCs.  In hCAVSMCs, NP-6A4 (1 μM) increased Agtr2 mRNA (sixfold, p < 0.05) after 12-h exposure, whereas in hCAECs, significant increase in Agtr2 mRNA (hCAECs: eightfold) was obsd. after prolonged exposure.  Interestingly, NP- 6A4 treatment (1 μM, 12 h) increased AT2R protein levels in all human cells tested.  Pre-treatment with AT2R-antagonist PD123319 (20 μM) and anti-AT2R siRNA (1 μM) suppressed this effect.  Thus, NP-6A4 activates a pos. feedback loop for AT2R expression and signaling in hCAVSMCs and hCAECs.  NP-6A4 (1-20 μM) increased cell index (CI) of hCAVSMCs as detd. by real time cell analyzer (RTCA), indicating that high concns. of NP-6A4 were not cytotoxic for hCAVSMCs, rather promoting better cell attachment and growth.  Seahorse Extracellular Flux Assay revealed that NP- 6A4 (1 μM) treatment for 7 days increased whole cell-based mitochondrial parameters of hCAVSMCs, specifically maximal respiration (p < 0.05), spare respiratory capacity (p < 0.05) and ATP prodn. (p < 0.05).  NP-6A4 (1 μM; 7 days) also suppressed Reactive Oxygen Species (ROS) in hCAVSMCs.  Exposure to Doxorubicin (DOXO) (1 μM) increased ROS in hCAVSMCs and this effect was suppressed by NP-6A4 (1 μM).  In hCAECs grown in complete medium, NP-6A4 (1 μM) and Ang II (1 μM) exerted similar changes in CI.  Addnl., NP-6A4 (5 μM: 12 h) increased expression of eNOS (sixfold, p < 0.05) and generation of nitric oxide (1.3-fold, p < 0.05) in hCAECs and pre-treatment with PD123319 (20 μM) suppressed this effect partially (65%).  Finally, NP-6A4 decreased phosphorylation of Jun-N-terminal kinase, implicated in apoptosis of ECs in atherosclerotic sites.  Taken together, NP-6A4, through its ability to increase AT2R expression and signaling, exerts different cell-specific protective effects in human VSMCs and ECs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphyApOE4IiILVg90H21EOLACvtfcHk0lj0G1txB2HLlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFyltbg%253D&md5=4702699a8659833cb37c9b1dab18f507</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00928%26sid%3Dliteratum%253Aachs%26aulast%3DToedebusch%26aufirst%3DR.%26aulast%3DBelenchia%26aufirst%3DA.%26aulast%3DPulakat%26aufirst%3DL.%26atitle%3DCell-specific%2520protective%2520signaling%2520induced%2520by%2520the%2520novel%2520AT2R-agonist%2520NP-6A4%2520on%2520human%2520endothelial%2520and%2520smooth%2520muscle%2520cells%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D928%26doi%3D10.3389%2Ffphar.2018.00928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dimmeler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rippmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiland, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haendeler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiher, A. M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">970</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1161/01.RES.81.6.970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2F01.RES.81.6.970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9400377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFWrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1997&pages=970-976&author=S.+Dimmelerauthor=V.+Rippmannauthor=U.+Weilandauthor=J.+Haendelerauthor=A.+M.+Zeiher&title=Angiotensin+II+induces+apoptosis+of+human+endothelial+cells.+Protective+effect+of+nitric+oxide&doi=10.1161%2F01.RES.81.6.970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II induces apoptosis of human endothelial cells: protective effect of nitric oxide</span></div><div class="casAuthors">Dimmeler, Stefanie; Rippmann, Volker; Weiland, Ulrike; Haendeler, Judith; Zeiher, Andreas M.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">970-976</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">American Heart Association</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II) importantly contributes to the pathobiol. of atherosclerosis.  Since endothelial injury is a key event early in the pathogenesis of atherosclerosis, the authors tested the hypothesis that Ang II may injure endothelial cells by activation of cellular suicide pathways leading to apoptosis.  Human umbilical venous endothelial cells (HUVECs) were incubated with increasing doses of Ang II for 18 h.  Apoptosis of HUVECs was measured by ELISA specific for histone-assocd. DNA fragments and confirmed by DNA laddering and nuclear staining.  Ang II dose-dependently induced apoptosis of HUVECs.  Simultaneous blockade of both the AT1 and AT2 receptor prevented Ang II-induced apoptosis, whereas each individual receptor blocker alone was not effective.  Selective agonistic stimulation of the AT2 receptor also dose-dependently induced apoptosis.  Ang II-mediated as well as selective AT2 receptor stimulation-mediated apoptosis was assocd. with the activation of caspase-3, a central down-stream effector of the caspase cascade executing the cell death program.  Specific inhibition of caspase-3 activity abrogated Ang II-induced apoptosis.  In addn., the NO donors sodium nitroprusside and S-nitrosopenicillamine completely inhibited Ang II-induced apoptosis and eliminated caspase-3 activity.  Thus, Ang II induces apoptosis of HUVECs via activation of the caspase cascade, the central downstream effector arm executing the cell death program.  NO completely abrogated Ang II-induced apoptosis by interfering with the activation of the caspase cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH2dhA5oFOMLVg90H21EOLACvtfcHk0lj0G1txB2HLlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFWrtbc%253D&md5=8d0ff36eb9743ffcbecd29303f8fdb70</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1161%2F01.RES.81.6.970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.81.6.970%26sid%3Dliteratum%253Aachs%26aulast%3DDimmeler%26aufirst%3DS.%26aulast%3DRippmann%26aufirst%3DV.%26aulast%3DWeiland%26aufirst%3DU.%26aulast%3DHaendeler%26aufirst%3DJ.%26aulast%3DZeiher%26aufirst%3DA.%2BM.%26atitle%3DAngiotensin%2520II%2520induces%2520apoptosis%2520of%2520human%2520endothelial%2520cells.%2520Protective%2520effect%2520of%2520nitric%2520oxide%26jtitle%3DCirc.%2520Res.%26date%3D1997%26volume%3D81%26spage%3D970%26epage%3D976%26doi%3D10.1161%2F01.RES.81.6.970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanif, K.</span></span> <span> </span><span class="NLM_article-title">AT2R activation prevents microglia pro-inflammatory activation in a NOX-dependent manner: inhibition of PKC activation and p47<sup>phox</sup> phosphorylation by PP2A</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3005</span>– <span class="NLM_lpage">3023</span>, <span class="refDoi"> DOI: 10.1007/s12035-018-1272-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs12035-018-1272-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30076526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGjsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2019&pages=3005-3023&author=S.+A.+Bhatauthor=A.+Soodauthor=R.+Shuklaauthor=K.+Hanif&title=AT2R+activation+prevents+microglia+pro-inflammatory+activation+in+a+NOX-dependent+manner%3A+inhibition+of+PKC+activation+and+p47phox+phosphorylation+by+PP2A&doi=10.1007%2Fs12035-018-1272-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">AT2R Activation Prevents Microglia Pro-inflammatory Activation in a NOX-Dependent Manner: Inhibition of PKC Activation and p47phox Phosphorylation by PP2A</span></div><div class="casAuthors">Bhat, Shahnawaz Ali; Sood, Anika; Shukla, Rakesh; Hanif, Kashif</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">3005-3023</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Microglia-induced reactive oxygen species (ROS) prodn. and inflammation play an imperative role in neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease (PD).  It has been established that angiotensin II type-2 receptor (AT2R) activation is neuroprotective in central nervous system diseases like stroke and AD.  However, the involvement of AT2R in NADPH oxidase (NOX)-mediated microglia activation is still elusive.  Therefore, the present study investigated the role of AT2R in angiotensin II (Ang II) or Phorbol 12-myristate 13-acetate (PMA)-induced microglia activation in BV2 cells, primary microglia, p47phox knockout (p47KO) microglia, and in vivo.  Treatment of microglia with Ang II or PMA induced a significant ROS generation and promoted pro-inflammatory microglia in a NOX-dependent manner.  In contrast, AT2R activation by CGP42112A (CGP) inhibited NOX activation, ROS prodn., and pro-inflammatory microglia activation, while promoting the immunoregulatory microglia.  This inhibitory effect of AT2R on NOX and pro-inflammatory activation was attenuated by AT2R antagonist, PD123319.  Essentially, NOX inhibition (by DPI) or scavenging cellular ROS (by NAC) or p47KO microglia were immune to Ang II- or PMA-induced pro-inflammatory microglia activation.  Mechanistically, AT2R, via activation of protein phosphatase-2A (PP2A), prevented the Ang II- or PMA-induced protein kinase C (PKC) activation and phosphorylation of p47phox, an effect that was reversed by the addn. of PP2A inhibitor, Okadaic acid (OA).  Importantly, PKC inhibitor, Rottlerin, inhibited the Ang II- or PMA-induced p47phox phosphorylation and ROS generation to the similar extent as AT2R activation.  In addn., AT2R activation or p47KO prevented ROS prodn., pro-inflammatory microglial activation, and sickness behavior in mice model of neuroinflammation.  Therefore, the present findings suggested that AT2R, via PP2A-mediated inhibition of PKC, prevents the NOX activation, ROS generation, and subsequent pro-inflammatory activation of microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrJgTy8po9LVg90H21EOLACvtfcHk0lgtBgtDE9ZOug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGjsb3F&md5=cadf6f4ee801ca95b275e3aaf442ca0e</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1007%2Fs12035-018-1272-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-018-1272-9%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DS.%2BA.%26aulast%3DSood%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DR.%26aulast%3DHanif%26aufirst%3DK.%26atitle%3DAT2R%2520activation%2520prevents%2520microglia%2520pro-inflammatory%2520activation%2520in%2520a%2520NOX-dependent%2520manner%253A%2520inhibition%2520of%2520PKC%2520activation%2520and%2520p47phox%2520phosphorylation%2520by%2520PP2A%26jtitle%3DMol.%2520Neurobiol.%26date%3D2019%26volume%3D56%26spage%3D3005%26epage%3D3023%26doi%3D10.1007%2Fs12035-018-1272-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X. F.</span></span> <span> </span><span class="NLM_article-title">Brain endogenous angiotensin II receptor type 2 (AT2-R) protects against DOCA/salt-induced hypertension in female rats</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">47</span>, <span class="refDoi"> DOI: 10.1186/s12974-015-0261-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1186%2Fs12974-015-0261-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25885968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjls1egsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=47&author=S.+Y.+Daiauthor=W.+Pengauthor=Y.+P.+Zhangauthor=J.+D.+Liauthor=Y.+Shenauthor=X.+F.+Sun&title=Brain+endogenous+angiotensin+II+receptor+type+2+%28AT2-R%29+protects+against+DOCA%2Fsalt-induced+hypertension+in+female+rats&doi=10.1186%2Fs12974-015-0261-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Brain endogenous angiotensin II receptor type 2 (AT2-R) protects against DOCA/salt-induced hypertension in female rats</span></div><div class="casAuthors">Dai Shu-Yan; Shen Ying; Sun Xiao-Fei; Peng Wei; Zhang Yu-Ping; Li Jian-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroinflammation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recent studies demonstrate that there are sex differences in the expression of angiotensin receptor type 2 (AT2-R) in the kidney and that AT2-R plays an enhanced role in regulating blood pressure (BP) in females.  Also, brain AT2-R activation has been reported to negatively modulate BP and sympathetic outflow.  The present study investigated whether the central blockade of endogenous AT2-R augments deoxycorticosterone acetate (DOCA)/salt-induced hypertension in both male and female rats.  METHODS:  All rats were subcutaneously infused with DOCA combined with 1% NaCl solution as the sole drinking fluid.  BP and heart rate (HR) were recorded by telemetric transmitters.  To determine the effect of central AT2-R on DOCA/salt-induced hypertension, male and female rats were intracerebroventricularly (icv) infused with AT2-R antagonist, PD123,319, during DOCA/salt treatment.  Subsequently, the paraventricular nucleus (PVN) of the hypothalamus, a key cardiovascular regulatory region of the brain, was analyzed by quantitative real-time PCR and Western blot.  RESULTS:  DOCA/salt treatment elicited a greater increase in BP in male rats than that in females.  Icv infusions of the AT2-R antagonist significantly augmented DOCA/salt pressor effects in females.  However, this same treatment had no enhanced effect on DOCA/salt-induced increase in the BP in males.  Real-time PCR and Western blot analysis of the female brain revealed that DOCA/salt treatment enhanced the mRNA and protein expression for both antihypertensive components including AT2-R, angiotensin-converting enzyme (ACE)-2, and interleukin (IL)-10 and hypertensive components including angiotensin receptor type 1 (AT1-R), ACE-1, tumor necrosis factor (TNF)-α, and IL-1β, but decreased mRNA expression of renin in the PVN.  The central blockade of AT2-R reversed the changes in mRNA and protein expressions of ACE-2, IL-10, and renin, further increased the expressions of TNF-α and IL-1β, and kept higher the expressions of AT1-R, ACE-1, and AT2-R.  CONCLUSIONS:  These results indicate that endogenous AT2-R activation in the brain plays an important protective role in the development of DOCA/salt-induced hypertension in females, but not in males.  The protective effect of AT2-R in females involves regulating the expression of brain renin-angiotensin system components and proinflammatory cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6oVgkPGP0IvxQvRxYU81tfW6udTcc2ebHs6JogIG71bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjls1egsQ%253D%253D&md5=b1e12db3c1f16a93d8baa61a5572ec03</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1186%2Fs12974-015-0261-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-015-0261-4%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DS.%2BY.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%2BP.%26aulast%3DLi%26aufirst%3DJ.%2BD.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DX.%2BF.%26atitle%3DBrain%2520endogenous%2520angiotensin%2520II%2520receptor%2520type%25202%2520%2528AT2-R%2529%2520protects%2520against%2520DOCA%252Fsalt-induced%2520hypertension%2520in%2520female%2520rats%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2015%26volume%3D12%26spage%3D47%26doi%3D10.1186%2Fs12974-015-0261-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyse, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muralidharan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, T.</span></span> <span> </span><span class="NLM_article-title">A small molecule angiotensin II type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia</span>. <i>Pain Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1557</span>– <span class="NLM_lpage">1568</span>, <span class="refDoi"> DOI: 10.1111/pme.12157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2Fpme.12157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23742186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC3sjgtl2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1557-1568&author=M.+T.+Smithauthor=T.+M.+Woodruffauthor=B.+D.+Wyseauthor=A.+Muralidharanauthor=T.+Walther&title=A+small+molecule+angiotensin+II+type+2+receptor+%28AT2R%29+antagonist+produces+analgesia+in+a+rat+model+of+neuropathic+pain+by+inhibition+of+p38+mitogen-activated+protein+kinase+%28MAPK%29+and+p44%2Fp42+MAPK+activation+in+the+dorsal+root+ganglia&doi=10.1111%2Fpme.12157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule angiotensin II type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia</span></div><div class="casAuthors">Smith Maree T; Woodruff Trent M; Wyse Bruce D; Muralidharan Arjun; Walther Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pain medicine (Malden, Mass.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1557-68</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  There is an unmet clinical need for novel analgesics for neuropathic pain.  This study was designed to elucidate the mechanism through which EMA300, a small molecule antagonist of the angiotensin II type 2 receptor (AT2R) with >1,000-fold selectivity over the angiotensin II type 1 receptor, produces analgesia in a rodent model of neuropathic pain.  DESIGN AND METHODS:  Groups of AT2R knockout, hemizygotes, and wild-type mice with a chronic constriction injury (CCI) of the sciatic nerve received single intraperitoneal (i.p.) bolus doses of EMA300 (100 or 300 mg/kg), and analgesic efficacy was assessed.  Groups of control, sham-operated, and CCI rats were euthanized and perfusion fixed.  Lumbar dorsal root ganglia (DRGs) were removed for investigation of the mechanism through which EMA300 alleviates neuropathic pain.  RESULTS:  EMA300 analgesia was abolished in AT2R knockout CCI mice with intermediate responses in the hemizygotes, affirming the AT2R as the target mediating EMA300 analgesia.  In CCI rats, DRG immunofluorescence (IF) levels for angiotensin II, the main endogenous ligand of the AT2R, were increased ∼1.5-2.0-fold (P < 0.05) cf. sham-controls.  Mean DRG IF levels for activated p38 (pp38) and activated p44/p42 (pp44/pp42) MAPK were also increased ∼1.5-2.0-fold (P < 0.05) cf. sham-controls.  At the time of peak EMA300 analgesia in CCI rats, mean DRG levels of pp38 MAPK and pp44/pp42 MAPK (but not angiotensin II) were reduced to match the respective levels in sham-controls.  CONCLUSION:  Augmented angiotensin II/AT2R signaling in the DRGs of CCI rats is attenuated by EMA300 to block p38 MAPK and p44/p42 MAPK activation, a mechanism with clinical validity for alleviating neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXnivkNFx8x--MdeMhXAHkfW6udTcc2eZTpGWC_uklB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjgtl2hsA%253D%253D&md5=58e8198bfaf990ad99b1b887abd88611</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1111%2Fpme.12157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpme.12157%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BT.%26aulast%3DWoodruff%26aufirst%3DT.%2BM.%26aulast%3DWyse%26aufirst%3DB.%2BD.%26aulast%3DMuralidharan%26aufirst%3DA.%26aulast%3DWalther%26aufirst%3DT.%26atitle%3DA%2520small%2520molecule%2520angiotensin%2520II%2520type%25202%2520receptor%2520%2528AT2R%2529%2520antagonist%2520produces%2520analgesia%2520in%2520a%2520rat%2520model%2520of%2520neuropathic%2520pain%2520by%2520inhibition%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520%2528MAPK%2529%2520and%2520p44%252Fp42%2520MAPK%2520activation%2520in%2520the%2520dorsal%2520root%2520ganglia%26jtitle%3DPain%2520Med.%26date%3D2013%26volume%3D14%26spage%3D1557%26epage%3D1568%26doi%3D10.1111%2Fpme.12157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyse, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, S. R.</span></span> <span> </span><span class="NLM_article-title">Small molecule angiotensin II type 2 receptor (AT2 R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats</span>. <i>Pain Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1111/pme.12063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2Fpme.12063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23489258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC3svmtVKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=692-705&author=M.+T.+Smithauthor=B.+D.+Wyseauthor=S.+R.+Edwards&title=Small+molecule+angiotensin+II+type+2+receptor+%28AT2+R%29+antagonists+as+novel+analgesics+for+neuropathic+pain%3A+comparative+pharmacokinetics%2C+radioligand+binding%2C+and+efficacy+in+rats&doi=10.1111%2Fpme.12063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats</span></div><div class="casAuthors">Smith Maree T; Wyse Bruce D; Edwards Stephen R</div><div class="citationInfo"><span class="NLM_cas:title">Pain medicine (Malden, Mass.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">692-705</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Neuropathic pain is an area of unmet clinical need.  The objective of this study was to define the pharmacokinetics, oral bioavailability, and efficacy in rats of small molecule antagonists of the angiotensin II type 2 receptor (AT2R) for the relief of neuropathic pain.  DESIGN AND METHODS:  Adult male Sprague-Dawley (SD) rats received single intravenous (1-10 mg/kg) or oral (5-10 mg/kg) bolus doses of EMA200, EMA300, EMA400 or EMA401 (S-enantiomer of EMA400).  Blood samples were collected immediately pre-dose and at specified times over a 12- to 24-hour post-dosing period.  Liquid chromatography tandem mass spectrometry was used to measure plasma drug concentrations.  Efficacy was assessed in adult male SD rats with a unilateral chronic constriction injury (CCI) of the sciatic nerve.  RESULTS:  After intravenous administration in rats, mean (±standard error of the mean) plasma clearance for EMA200, EMA300, EMA400, and EMA401 was 9.3, 6.1, 0.7, and 1.1 L/hour/kg, respectively.  After oral dosing, the dose-normalized systemic exposures of EMA400 and EMA401 were 20- to 30-fold and 50- to 60-fold higher than that for EMA300 and EMA200, respectively.  The oral bioavailability of EMA400 and EMA401 was similar at ∼30%, whereas it was only 5.9% and 7.1% for EMA200 and EMA300, respectively.  In CCI rats, single intraperitoneal bolus doses of EMA200, EMA300, and EMA400 evoked dose-dependent pain relief.  The pain relief potency rank order in CCI rats was EMA400 > EMA300 > EMA200 in agreement with the dose-normalized systemic exposure rank order in SD rats.  CONCLUSION:  The small molecule AT2R antagonist, EMA401, is in clinical development as a novel analgesic for the relief of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjI5YuvrZVpNts4TFFB11gfW6udTcc2eYYaIueNWIPGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svmtVKisg%253D%253D&md5=5a5aecc9c63f4a49d650978d90603471</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1111%2Fpme.12063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpme.12063%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BT.%26aulast%3DWyse%26aufirst%3DB.%2BD.%26aulast%3DEdwards%26aufirst%3DS.%2BR.%26atitle%3DSmall%2520molecule%2520angiotensin%2520II%2520type%25202%2520receptor%2520%2528AT2%2520R%2529%2520antagonists%2520as%2520novel%2520analgesics%2520for%2520neuropathic%2520pain%253A%2520comparative%2520pharmacokinetics%252C%2520radioligand%2520binding%252C%2520and%2520efficacy%2520in%2520rats%26jtitle%3DPain%2520Med.%26date%3D2013%26volume%3D14%26spage%3D692%26epage%3D705%26doi%3D10.1111%2Fpme.12063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. S.</span></span> <span> </span><span class="NLM_article-title">Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">S33</span>– <span class="NLM_lpage">S41</span>, <span class="refDoi"> DOI: 10.1097/j.pain.0000000000000369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2Fj.pain.0000000000000369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26785154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Cltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=S33-S41&author=M.+T.+Smithauthor=P.+Anandauthor=A.+S.+Rice&title=Selective+small+molecule+angiotensin+II+type+2+receptor+antagonists+for+neuropathic+pain%3A+preclinical+and+clinical+studies&doi=10.1097%2Fj.pain.0000000000000369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies</span></div><div class="casAuthors">Smith, Maree T.; Anand, Praveen; Rice, Andrew S. C.</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">Suppl1</span>),
    <span class="NLM_cas:pages">S33-S41</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Neuropathic pain affects up to 10% of the general population, but drug treatments recommended for the treatment of neuropathic pain are assocd. with modest efficacy and/or produce dose-limiting side effects.  Hence, neuropathic pain is an unmet medical need.  In the past 2 decades, research on the pathobiol. of neuropathic pain has revealed many novel pain targets for use in analgesic drug discovery programs.  However, these efforts have been largely unsuccessful as mols. that showed promising pain relief in rodent models of neuropathic pain generally failed to produce analgesia in early phase clin. trials in patients with neuropathic pain.  One notable exception is the angiotensin II type 2 (AT2) receptor that has clin. validity on the basis of a successful double-blind, randomized, placebo-controlled, clin. trial of EMA401, a highly selective, orally active, peripherally restricted AT2 receptor antagonist in patients with postherpetic neuralgia.  In this study, we review research to date on target validation, efficacy, and mode of action of small mol. AT2 receptor antagonists in rodent models of peripheral neuropathic pain and in cultured human sensory neurons, the preclin. pharmacokinetics of these compds., and the outcome of the above clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6HyCVNeBH3rVg90H21EOLACvtfcHk0ljLPXaYHhBtoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Cltrw%253D&md5=a86d4155baffaafb2cdb1788493ce5ca</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1097%2Fj.pain.0000000000000369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fj.pain.0000000000000369%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BT.%26aulast%3DAnand%26aufirst%3DP.%26aulast%3DRice%26aufirst%3DA.%2BS.%26atitle%3DSelective%2520small%2520molecule%2520angiotensin%2520II%2520type%25202%2520receptor%2520antagonists%2520for%2520neuropathic%2520pain%253A%2520preclinical%2520and%2520clinical%2520studies%26jtitle%3DPain%26date%3D2016%26volume%3D157%26spage%3DS33%26epage%3DS41%26doi%3D10.1097%2Fj.pain.0000000000000369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keppel Hesselink, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatman, M. E.</span></span> <span> </span><span class="NLM_article-title">EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.2147/JPR.S128520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2147%2FJPR.S128520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28255254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC1czitlyhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=439-443&author=J.+M.+Keppel+Hesselinkauthor=M.+E.+Schatman&title=EMA401%3A+an+old+antagonist+of+the+AT2R+for+a+new+indication+in+neuropathic+pain&doi=10.2147%2FJPR.S128520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain</span></div><div class="casAuthors">Keppel Hesselink Jan M; Schatman Michael E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pain research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">439-443</span>
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    </div><div class="casAbstract">EMA401 is an old molecule, synthesized by Parke-Davis in the last century and characterized at that time as an AT2R antagonist.  Professor Maree Smith and her group from the University of Queensland (Australia) patented the drug and many related derivatives and other compounds with high affinity for the AT2R for the indication neuropathic pain in 2004, an example of drug repositioning.  After some years of university work, the Australian biotech company Spinifex Pharmaceuticals took over further research and development and characterized the S-enantiomer, code name EMA401, and related compounds in a variety of animal models for neuropathic and cancer pain.  EMA401 was selected as the lead compound, based on high selectivity for the AT2R and good oral bioavailability (33%).  EMA401, however, was only administered once in a chronic neuropathic pain model, and no data have been published in other pain models, or during steady state, although such data were available for the racemate EMA400 and some related compounds (EMA200, EMA400).  A pilot phase IIa study demonstrated the efficacy and safety of the drug taken twice daily as two capsules of 50 mg (400 mg/day).  In 2015, Novartis took over the clinical development.  Two phase IIb studies designed by Spinifex Pharmaceuticals were put on hold, probably because Novartis wanted to improve the clinical design or collect additional preclinical data.  Further data are eagerly awaited, especially since EMA401 is first-in-class in neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTQ2J8oScirIqdXsLcGTEUfW6udTcc2eYYaIueNWIPGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czitlyhsA%253D%253D&md5=43664175cb490bced798d012aac8b2d4</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.2147%2FJPR.S128520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S128520%26sid%3Dliteratum%253Aachs%26aulast%3DKeppel%2BHesselink%26aufirst%3DJ.%2BM.%26aulast%3DSchatman%26aufirst%3DM.%2BE.%26atitle%3DEMA401%253A%2520an%2520old%2520antagonist%2520of%2520the%2520AT2R%2520for%2520a%2520new%2520indication%2520in%2520neuropathic%2520pain%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2017%26volume%3D10%26spage%3D439%26epage%3D443%26doi%3D10.2147%2FJPR.S128520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magnani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charalampos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magafa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordopatis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosnyak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerothanassis, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span> <span> </span><span class="NLM_article-title">Electronic sculpting of ligand-GPCR subtype selectivity: the case of angiotensin II</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1420</span>– <span class="NLM_lpage">1425</span>, <span class="refDoi"> DOI: 10.1021/cb500063y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500063y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFCgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1420-1425&author=F.+Magnaniauthor=G.+Charalamposauthor=T.+Pappasauthor=V.+Crookauthor=V.+Magafaauthor=P.+Cordopatisauthor=S.+Ishiguroauthor=N.+Ohtaauthor=J.+Selentauthor=S.+Bosnyakauthor=E.+S.+Jonesauthor=I.+P.+Gerothanassisauthor=M.+Tamuraauthor=R.+E.+Widdopauthor=A.+G.+Tzakos&title=Electronic+sculpting+of+ligand-GPCR+subtype+selectivity%3A+the+case+of+angiotensin+II&doi=10.1021%2Fcb500063y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Electronic Sculpting of Ligand-GPCR Subtype Selectivity: The Case of Angiotensin II</span></div><div class="casAuthors">Magnani, Francesca; Pappas, Charalampos G.; Crook, Tim; Magafa, Vassiliki; Cordopatis, Paul; Ishiguro, Susumu; Ohta, Naomi; Selent, Jana; Bosnyak, Sanja; Jones, Emma S.; Gerothanassis, Ioannis P.; Tamura, Masaaki; Widdop, Robert E.; Tzakos, Andreas G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1420-1425</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GPCR subtypes possess distinct functional and pharmacol. profiles, and thus development of subtype-selective ligands has immense therapeutic potential.  This is esp. the case for the angiotensin receptor subtypes AT1R and AT2R, where a functional neg. control has been described and AT2R activation highlighted as an important cancer drug target.  We describe a strategy to fine-tune ligand selectivity for the AT2R/AT1R subtypes through electronic control of ligand arom.-prolyl interactions.  Through this strategy an AT2R high affinity (Ki = 3 nM) agonist analog that exerted 18,000-fold higher selectivity for AT2R vs. AT1R was obtained.  We show that this compd. is a neg. regulator of AT1R signaling since it is able to inhibit MCF-7 breast carcinoma cellular proliferation in the low nanomolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiXuq9nm13uLVg90H21EOLACvtfcHk0liXfuzUNcC5mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFCgtL4%253D&md5=027fe2a11bccf1d87d640f1084c09948</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fcb500063y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500063y%26sid%3Dliteratum%253Aachs%26aulast%3DMagnani%26aufirst%3DF.%26aulast%3DCharalampos%26aufirst%3DG.%26aulast%3DPappas%26aufirst%3DT.%26aulast%3DCrook%26aufirst%3DV.%26aulast%3DMagafa%26aufirst%3DV.%26aulast%3DCordopatis%26aufirst%3DP.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DN.%26aulast%3DSelent%26aufirst%3DJ.%26aulast%3DBosnyak%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DE.%2BS.%26aulast%3DGerothanassis%26aufirst%3DI.%2BP.%26aulast%3DTamura%26aufirst%3DM.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26atitle%3DElectronic%2520sculpting%2520of%2520ligand-GPCR%2520subtype%2520selectivity%253A%2520the%2520case%2520of%2520angiotensin%2520II%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1420%26epage%3D1425%26doi%3D10.1021%2Fcb500063y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eldahshan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishrat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayed, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alwhaibi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouda, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ergul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, S. C.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study</span>. <i>Am. J. Physiol., Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">H1192</span>– <span class="NLM_lpage">H1201</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00446.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajpheart.00446.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30822121" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2019&pages=H1192-H1201&author=W.+Eldahshanauthor=T.+Ishratauthor=B.+Pillaiauthor=M.+A.+Sayedauthor=A.+Alwhaibiauthor=A.+Y.+Foudaauthor=A.+Ergulauthor=S.+C.+Fagan&title=Angiotensin+II+type+2+receptor+stimulation+with+compound+21+improves+neurological+function+after+stroke+in+female+rats%3A+a+pilot+study&doi=10.1152%2Fajpheart.00446.2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00446.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00446.2018%26sid%3Dliteratum%253Aachs%26aulast%3DEldahshan%26aufirst%3DW.%26aulast%3DIshrat%26aufirst%3DT.%26aulast%3DPillai%26aufirst%3DB.%26aulast%3DSayed%26aufirst%3DM.%2BA.%26aulast%3DAlwhaibi%26aufirst%3DA.%26aulast%3DFouda%26aufirst%3DA.%2BY.%26aulast%3DErgul%26aufirst%3DA.%26aulast%3DFagan%26aufirst%3DS.%2BC.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor%2520stimulation%2520with%2520compound%252021%2520improves%2520neurological%2520function%2520after%2520stroke%2520in%2520female%2520rats%253A%2520a%2520pilot%2520study%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Heart%2520Circ.%2520Physiol.%26date%3D2019%26volume%3D316%26spage%3DH1192%26epage%3DH1201%26doi%3D10.1152%2Fajpheart.00446.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickle, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halabi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kloet, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samineni, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gereau, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohapatra, D. P.</span></span> <span> </span><span class="NLM_article-title">Macrophage angiotensin type 2 receptor triggers neuropathic pain</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E8057</span>– <span class="NLM_lpage">E8066</span>, <span class="refDoi"> DOI: 10.1073/pnas.1721815115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1073%2Fpnas.1721815115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30082378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCitLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E8057-E8066&author=A.+J.+Shepherdauthor=A.+D.+Mickleauthor=J.+P.+Goldenauthor=M.+R.+Mackauthor=C.+M.+Halabiauthor=A.+D.+de+Kloetauthor=V.+K.+Samineniauthor=B.+S.+Kimauthor=E.+G.+Krauseauthor=R.+W.+Gereauauthor=D.+P.+Mohapatra&title=Macrophage+angiotensin+type+2+receptor+triggers+neuropathic+pain&doi=10.1073%2Fpnas.1721815115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage angiotensin II type 2 receptor triggers neuropathic pain</span></div><div class="casAuthors">Shepherd, Andrew J.; Mickle, Aaron D.; Golden, Judith P.; Mack, Madison R.; Halabi, Carmen M.; de Kloet, Annette D.; Samineni, Vijay K.; Kim, Brian S.; Krause, Eric G.; Gereau, Robert W. IV; Mohapatra, Durga P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">E8057-E8066</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Peripheral nerve damage initiates a complex series of structural and cellular processes that culminate in chronic neuropathic pain.  The recent success of a type 2 angiotensin II (Ang II) receptor (AT2R) antagonist in a phase II clin. trial for the treatment of postherpetic neuralgia suggests angiotensin signaling is involved in neuropathic pain.  However, transcriptome anal. indicates a lack of AT2R gene (Agtr2) expression in human and rodent sensory ganglia, raising questions regarding the tissue/cell target underlying the analgesic effect of AT2R antagonism.  We show that selective antagonism of AT2R attenuates neuropathic but not inflammatory mech. and cold pain hypersensitivity behaviors in mice.  Agtr2-expressing macrophages constitute the predominant immune cells that infiltrate the site of nerve injury.  Interestingly, neuropathic mech. and cold pain hypersensitivity can be attenuated by chemogenetic depletion of peripheral macrophages and AT2R-null hematopoietic cell transplantation.  Our study identifies AT2R on peripheral macrophages as a crit. trigger for pain sensitization at the site of nerve injury, and therefore proposes a translatable peripheral mechanism underlying chronic neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHHGnThUpEILVg90H21EOLACvtfcHk0lh-euWdrEsBPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCitLfO&md5=cdb381f5ca5b5f8703fae815ac249477</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1721815115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1721815115%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DA.%2BJ.%26aulast%3DMickle%26aufirst%3DA.%2BD.%26aulast%3DGolden%26aufirst%3DJ.%2BP.%26aulast%3DMack%26aufirst%3DM.%2BR.%26aulast%3DHalabi%26aufirst%3DC.%2BM.%26aulast%3Dde%2BKloet%26aufirst%3DA.%2BD.%26aulast%3DSamineni%26aufirst%3DV.%2BK.%26aulast%3DKim%26aufirst%3DB.%2BS.%26aulast%3DKrause%26aufirst%3DE.%2BG.%26aulast%3DGereau%26aufirst%3DR.%2BW.%26aulast%3DMohapatra%26aufirst%3DD.%2BP.%26atitle%3DMacrophage%2520angiotensin%2520type%25202%2520receptor%2520triggers%2520neuropathic%2520pain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE8057%26epage%3DE8066%26doi%3D10.1073%2Fpnas.1721815115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copits, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickle, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadunganattil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haroutounian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadinada, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kloet, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valtcheva, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIlvried, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usachev, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gereau, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohapatra, D. P.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II triggers peripheral macrophage-to-sensory neuron redox crosstalk to elicit pain</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">7032</span>– <span class="NLM_lpage">7057</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.3542-17.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1523%2FJNEUROSCI.3542-17.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29976627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKrtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=7032-7057&author=A.+J.+Shepherdauthor=B.+A.+Copitsauthor=A.+D.+Mickleauthor=P.+Karlssonauthor=S.+Kadunganattilauthor=S.+Haroutounianauthor=S.+M.+Tadinadaauthor=A.+D.+de+Kloetauthor=M.+V.+Valtchevaauthor=L.+A.+McIlvriedauthor=T.+D.+Sheahanauthor=S.+Jainauthor=P.+R.+Rayauthor=Y.+M.+Usachevauthor=G.+Dussorauthor=E.+G.+Krauseauthor=T.+J.+Priceauthor=R.+G.+Gereauauthor=D.+P.+Mohapatra&title=Angiotensin+II+triggers+peripheral+macrophage-to-sensory+neuron+redox+crosstalk+to+elicit+pain&doi=10.1523%2FJNEUROSCI.3542-17.2018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II triggers peripheral macrophage-to-sensory neuron redox crosstalk to elicit pain</span></div><div class="casAuthors">Shepherd, X. Andrew J.; Copits, Bryan A.; Mickle, Aaron D.; Karlsson, Pall; Kadunganattil, Suraj; Haroutounian, Simon; Tadinada, Satya M.; de Kloet, Annette D.; Valtcheva, Manouela V.; McIlvried, Lisa A.; Sheahan, Tayler D.; Jain, Sanjay; Ray, Pradipta R.; Usachev, Yuriy M.; Dussor, Gregory; Krause, Eric G.; Price, Theodore J.; Gereau, Robert W., IV; Mohapatra, Durga P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">7032-7057</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">1529-2401</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Injury, inflammation, and nerve damage initiate a wide variety of cellular and mol. processes that culminate in hyperexcitation of sensory nerves, which underlies chronic inflammatory and neuropathic pain.  Using behavioral read outs of pain hypersensitivity induced by angiotensin II (Ang II) injection into mouse hindpaws, our study shows that activation of the type 2 Ang II receptor (AT2R) and the cell-damage-sensing ion channel TRPA1 are required for peripheral mech. pain sensitization induced by Ang II in male and female mice.  However, we show that AT2R is not expressed in mouse and human dorsal root ganglia (DRG) sensory neurons.  Instead, expression/activation of AT2R on peripheral/skin macrophages (M [H9021] s) constitutes a crit. trigger of mouse and human DRG sensory neuron excitation.  Ang II-induced peripheral mech. pain hypersensitivity can be attenuated by chemogenetic depletion of peripheral M [H9021] s.  Furthermore, AT2R activation in M [H9021] s triggers prodn. of reactive oxygen/nitrogen species, which trans -activate TRPA1 on mouse and human DRG sensory neurons via cysteine modification of the channel.  Our study thus identifies a translatable immune cell-to-sensory neuron signaling crosstalk underlying peripheral nociceptor sensitization.  This form of cell-to-cell signaling represents a crit. peripheral mechanism for chronic pain and thus identifies multiple druggable analgesic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov8sQ--O9vv7Vg90H21EOLACvtfcHk0lhUJQXNPb-a0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKrtb7M&md5=c9928e4c1b69c7ad7f07e48488fe0533</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3542-17.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3542-17.2018%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DA.%2BJ.%26aulast%3DCopits%26aufirst%3DB.%2BA.%26aulast%3DMickle%26aufirst%3DA.%2BD.%26aulast%3DKarlsson%26aufirst%3DP.%26aulast%3DKadunganattil%26aufirst%3DS.%26aulast%3DHaroutounian%26aufirst%3DS.%26aulast%3DTadinada%26aufirst%3DS.%2BM.%26aulast%3Dde%2BKloet%26aufirst%3DA.%2BD.%26aulast%3DValtcheva%26aufirst%3DM.%2BV.%26aulast%3DMcIlvried%26aufirst%3DL.%2BA.%26aulast%3DSheahan%26aufirst%3DT.%2BD.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DP.%2BR.%26aulast%3DUsachev%26aufirst%3DY.%2BM.%26aulast%3DDussor%26aufirst%3DG.%26aulast%3DKrause%26aufirst%3DE.%2BG.%26aulast%3DPrice%26aufirst%3DT.%2BJ.%26aulast%3DGereau%26aufirst%3DR.%2BG.%26aulast%3DMohapatra%26aufirst%3DD.%2BP.%26atitle%3DAngiotensin%2520II%2520triggers%2520peripheral%2520macrophage-to-sensory%2520neuron%2520redox%2520crosstalk%2520to%2520elicit%2520pain%26jtitle%3DJ.%2520Neurosci.%26date%3D2018%26volume%3D38%26spage%3D7032%26epage%3D7057%26doi%3D10.1523%2FJNEUROSCI.3542-17.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danser, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span> <span> </span><span class="NLM_article-title">The angiotensin II type 2 receptor for pain control</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1504</span>– <span class="NLM_lpage">1506</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2014.05.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.cell.2014.05.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24949962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVCisrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2014&pages=1504-1506&author=A.+H.+Danserauthor=P.+Anand&title=The+angiotensin+II+type+2+receptor+for+pain+control&doi=10.1016%2Fj.cell.2014.05.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">The angiotensin II type 2 receptor for pain control</span></div><div class="casAuthors">Danser, A. H. Jan; Anand, Praveen</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1504-1506</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  All well-known deleterious effects of angiotensin (Ang) II, including vasoconstriction, inflammation, water and salt retention, and vascular remodeling, are mediated via its type 1 (AT1) receptor.  This explains why AT1 receptor blockers (ARBs) and inhibitors of Ang II synthesis, such as ACE inhibitors and renin inhibitors, are beneficial for cardiovascular disease.  Yet, Ang II has a second receptor, the Ang II type 2 (AT2) receptor, the function of which, even after over 20 years of research, remains largely unknown.  In this issue, Marion et al. provide a new chapter to the AT2 receptor story.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUvsZKUtFkvrVg90H21EOLACvtfcHk0lhUJQXNPb-a0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVCisrbJ&md5=2b1ffcd039fae4b8fed26dbe94349ad9</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.05.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.05.030%26sid%3Dliteratum%253Aachs%26aulast%3DDanser%26aufirst%3DA.%2BH.%26aulast%3DAnand%26aufirst%3DP.%26atitle%3DThe%2520angiotensin%2520II%2520type%25202%2520receptor%2520for%2520pain%2520control%26jtitle%3DCell%26date%3D2014%26volume%3D157%26spage%3D1504%26epage%3D1506%26doi%3D10.1016%2Fj.cell.2014.05.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworkin, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCloud, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desem, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raff, M.</span></span> <span> </span><span class="NLM_article-title">EMA401–003 study group. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 2 clinical trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">1637</span>– <span class="NLM_lpage">1647</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(13)62337-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0140-6736%2813%2962337-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24507377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2gtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2014&pages=1637-1647&author=A.+S.+C.+Riceauthor=R.+H.+Dworkinauthor=T.+D.+McCarthyauthor=P.+Anandauthor=C.+Bountraauthor=P.+I.+McCloudauthor=J.+Hillauthor=G.+Cutterauthor=G.+Kitsonauthor=N.+Desemauthor=M.+Raff&title=EMA401%E2%80%93003+study+group.+EMA401%2C+an+orally+administered+highly+selective+angiotensin+II+type+2+receptor+antagonist%2C+as+a+novel+treatment+for+postherpetic+neuralgia%3A+a+randomized%2C+double-blind%2C+placebo-controlled+phase+2+clinical+trial&doi=10.1016%2FS0140-6736%2813%2962337-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial</span></div><div class="casAuthors">Rice, Andrew S. C.; Dworkin, Robert H.; McCarthy, Tom D.; Anand, Praveen; Bountra, Chas; McCloud, Philip I.; Hill, Julie; Cutter, Gary; Kitson, Geoff; Desem, Nuket; Raff, Milton</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">9929</span>),
    <span class="NLM_cas:pages">1637-1647</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Existing treatments for postherpetic neuralgia, and for neuropathic pain in general, are limited by modest efficacy and unfavorable side-effects.  The angiotensin II type 2 receptor (AT2R) is a new target for neuropathic pain.  EMA401, a highly selective AT2R antagonist, is under development as a novel neuropathic pain therapeutic agent.  We assessed the therapeutic potential of EMA401 in patients with postherpetic neuralgia.  In this multicentre, placebo-controlled, double-blind, randomised, phase 2 clin. trial, we enrolled patients (aged 22-89 years) with postherpetic neuralgia of at least 6 mo' duration from 29 centers across six countries.  We randomly allocated 183 participants to receive either oral EMA401 (100 mg twice daily) or placebo for 28 days.  Randomisation was done according to a centralized randomization schedule, blocked by study site, which was generated by an independent, unmasked statistician.  Patients and staff at each site were masked to treatment assignment.  We assessed the efficacy, safety, and pharmacokinetics of EMA401.  The primary efficacy endpoint was change in mean pain intensity between baseline and the last week of dosing (days 22-28), measured on an 11-point numerical rating scale.  The primary efficacy anal. was intention to treat.  This trial is registered with the Australian New Zealand Clin. Trials Registry, no. ACTRN12611000822987.92 patients were assigned to EMA401 and 91 were assigned to placebo.  The patients given EMA401 reported significantly less pain compared with baseline values in the final week of treatment than did those given placebo (mean redns. in pain scores -2·29 [SD 1·75] vs -1·60 [1·66]; difference of adjusted least square means -0·69 [SE 0·25]; 95% CI -1·19 to -0·20; p=0·0066).  No serious adverse events related to EMA401 occurred.  Overall, 32 patients reported 56 treatment-emergent adverse events in the EMA401 group compared with 45 such events reported by 29 patients given placebo.  EMA401 (100 mg twice daily) provides superior relief of postherpetic neuralgia compared with placebo at the end of 28 days of treatment.  EMA401 was well tolerated by patients.Spinifex Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYXDSBTzLOH7Vg90H21EOLACvtfcHk0lg18uv8cuCvJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2gtr8%253D&md5=375e5101e14bff60644e783745038238</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2962337-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252962337-5%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DA.%2BS.%2BC.%26aulast%3DDworkin%26aufirst%3DR.%2BH.%26aulast%3DMcCarthy%26aufirst%3DT.%2BD.%26aulast%3DAnand%26aufirst%3DP.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DMcCloud%26aufirst%3DP.%2BI.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DCutter%26aufirst%3DG.%26aulast%3DKitson%26aufirst%3DG.%26aulast%3DDesem%26aufirst%3DN.%26aulast%3DRaff%26aufirst%3DM.%26atitle%3DEMA401%25E2%2580%2593003%2520study%2520group.%2520EMA401%252C%2520an%2520orally%2520administered%2520highly%2520selective%2520angiotensin%2520II%2520type%25202%2520receptor%2520antagonist%252C%2520as%2520a%2520novel%2520treatment%2520for%2520postherpetic%2520neuralgia%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25202%2520clinical%2520trial%26jtitle%3DLancet%26date%3D2014%26volume%3D383%26spage%3D1637%26epage%3D1647%26doi%3D10.1016%2FS0140-6736%2813%2962337-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basbaum, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bautista, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julius, D.</span></span> <span> </span><span class="NLM_article-title">Cellular and molecular mechanisms of pain</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.cell.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19837031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFWht7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2009&pages=267-284&author=A.+I.+Basbaumauthor=D.+M.+Bautistaauthor=G.+Scherrerauthor=D.+Julius&title=Cellular+and+molecular+mechanisms+of+pain&doi=10.1016%2Fj.cell.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular and molecular mechanisms of pain</span></div><div class="casAuthors">Basbaum, Allan I.; Bautista, Diana M.; Scherrer, Gregory; Julius, David</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-284</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The nervous system detects and interprets a wide range of thermal and mech. stimuli, as well as environmental and endogenous chem. irritants.  When intense, these stimuli generate acute pain, and in the setting of persistent injury, both peripheral and central nervous system components of the pain transmission pathway exhibit tremendous plasticity, enhancing pain signals and producing hypersensitivity.  When plasticity facilitates protective reflexes, it can be beneficial, but when the changes persist, a chronic pain condition may result.  Genetic, electrophysiol., and pharmacol. studies are elucidating the mol. mechanisms that underlie detection, coding, and modulation of noxious stimuli that generate pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdNLc2p-hLJLVg90H21EOLACvtfcHk0lg18uv8cuCvJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFWht7zI&md5=afa43d19ea22a39b27952a2962df504b</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DBasbaum%26aufirst%3DA.%2BI.%26aulast%3DBautista%26aufirst%3DD.%2BM.%26aulast%3DScherrer%26aufirst%3DG.%26aulast%3DJulius%26aufirst%3DD.%26atitle%3DCellular%2520and%2520molecular%2520mechanisms%2520of%2520pain%26jtitle%3DCell%26date%3D2009%26volume%3D139%26spage%3D267%26epage%3D284%26doi%3D10.1016%2Fj.cell.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Premer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamondin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speth, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownfield, M. S.</span></span> <span> </span><span class="NLM_article-title">Immunohistochemical localization of AT1a, AT1b, and AT2 angiotensin II receptor subtypes in the rat adrenal, pituitary, and brain with a perspective commentary</span>. <i>Int. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">175428</span>, <span class="refDoi"> DOI: 10.1155/2013/175428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1155%2F2013%2F175428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23573410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC3srktVSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=175428&author=C.+Premerauthor=C.+Lamondinauthor=A.+Mitzeyauthor=R.+C.+Spethauthor=M.+S.+Brownfield&title=Immunohistochemical+localization+of+AT1a%2C+AT1b%2C+and+AT2+angiotensin+II+receptor+subtypes+in+the+rat+adrenal%2C+pituitary%2C+and+brain+with+a+perspective+commentary&doi=10.1155%2F2013%2F175428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical Localization of AT1a, AT1b, and AT2 Angiotensin II Receptor Subtypes in the Rat Adrenal, Pituitary, and Brain with a Perspective Commentary</span></div><div class="casAuthors">Premer Courtney; Lamondin Courtney; Mitzey Ann; Speth Robert C; Brownfield Mark S</div><div class="citationInfo"><span class="NLM_cas:title">International journal of hypertension</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2013</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175428</span>
        ISSN:<span class="NLM_cas:issn">2090-0384</span>.
    </div><div class="casAbstract">Angiotensin II increases blood pressure and stimulates thirst and sodium appetite in the brain.  It also stimulates secretion of aldosterone from the adrenal zona glomerulosa and epinephrine from the adrenal medulla.  The rat has 3 subtypes of angiotensin II receptors: AT1a, AT1b, and AT2. mRNAs for all three subtypes occur in the adrenal and brain.  To immunohistochemically differentiate these receptor subtypes, rabbits were immunized with C-terminal fragments of these subtypes to generate receptor subtype-specific antibodies.  Immunofluorescence revealed AT1a and AT2 receptors in adrenal zona glomerulosa and medulla.  AT1b immunofluorescence was present in the zona glomerulosa, but not the medulla.  Ultrastructural immunogold labeling for the AT1a receptor in glomerulosa and medullary cells localized it to plasma membrane, endocytic vesicles, multivesicular bodies, and the nucleus.  AT1b and AT2, but not AT1a, immunofluorescence was observed in the anterior pituitary.  Stellate cells were AT1b positive while ovoid cells were AT2 positive.  In the brain, neurons were AT1a, AT1b, and AT2 positive, but glia was only AT1b positive.  Highest levels of AT1a, AT1b, and AT2 receptor immunofluorescence were in the subfornical organ, median eminence, area postrema, paraventricular nucleus, and solitary tract nucleus.  These studies complement those employing different techniques to characterize Ang II receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQv2qX-67QscdK0qsdY6Nc1fW6udTcc2eavafFPpPgMArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srktVSrug%253D%253D&md5=d0948e1ad56dad1869060baf8b6ff144</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1155%2F2013%2F175428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F175428%26sid%3Dliteratum%253Aachs%26aulast%3DPremer%26aufirst%3DC.%26aulast%3DLamondin%26aufirst%3DC.%26aulast%3DMitzey%26aufirst%3DA.%26aulast%3DSpeth%26aufirst%3DR.%2BC.%26aulast%3DBrownfield%26aufirst%3DM.%2BS.%26atitle%3DImmunohistochemical%2520localization%2520of%2520AT1a%252C%2520AT1b%252C%2520and%2520AT2%2520angiotensin%2520II%2520receptor%2520subtypes%2520in%2520the%2520rat%2520adrenal%252C%2520pituitary%252C%2520and%2520brain%2520with%2520a%2520perspective%2520commentary%26jtitle%3DInt.%2520J.%2520Hypertens.%26date%3D2013%26volume%3D2013%26spage%3D175428%26doi%3D10.1155%2F2013%2F175428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenkei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palkovits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvol, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Cortes, C.</span></span> <span> </span><span class="NLM_article-title">Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review</span>. <i>Front. Neuroendocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1006/frne.1997.0155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1006%2Ffrne.1997.0155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=9344632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1KlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1997&pages=383-439&author=Z.+Lenkeiauthor=M.+Palkovitsauthor=P.+Corvolauthor=C.+Llorens-Cortes&title=Expression+of+angiotensin+type-1+%28AT1%29+and+type-2+%28AT2%29+receptor+mRNAs+in+the+adult+rat+brain%3A+a+functional+neuroanatomical+review&doi=10.1006%2Ffrne.1997.0155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review</span></div><div class="casAuthors">Lenkei, Z.; Palkovits, M.; Corvol, P.; Llorens-Cortes, C.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Neuroendocrinology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-439</span>CODEN:
                <span class="NLM_cas:coden">FNEDA7</span>;
        ISSN:<span class="NLM_cas:issn">0091-3022</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A review, with 242 refs.  The discovery that all components of the renin-angiotensin system (RAS) are present in the central nervous system led investigators to postulate the existence of a local brain RAS.  Supporting this, angiotensin immunoreactive neurons have been visualized in the brain.  Two major pathways were described: a forebrain pathway which connects circumventricular organs to the median preoptic nucleus, paraventricular nucleus, and supraoptic nucleus, and a second pathway connecting the hypothalamus to the medulla oblongata.  Blood-brain barrier deficient circumventricular organs are rich in angiotensin II receptors.  By activating these receptors, circulating angiotensin II may act on central cardiovascular centers via angiotensinergic neurons, providing a link between peripheral and central angiotensin II systems.  Among the effector peptides of the brain RAS, angiotensin II and angiotensin III have the same affinity for the two pharmacol. well-defined receptors: type 1 (AT1) and type 2 (AT2).  When injected in the brain, these peptides increase blood pressure, water intake, and anterior and posterior pituitary hormone release and may modify memory and learning.  The cloning of AT1 and AT2 receptor cDNAs has revealed that these receptors belong to the seven transmembrane domain receptor family.  In rodents, two AT1 receptor subtypes, AT1A and AT1B, have been isolated.  Using specific riboprobes for in situ hybridization histochem., recent studies mapped the distribution of AT1A, AT1B, and AT2 receptor mRNAs in the adult rat and found a predominant expression of AT1A and AT2 mRNA in the brain and of AT1B in the pituitary.  Very limited overlap was found between the brain expression of AT1A and AT2 mRNAs.  In several functional entities of the brain, such as the preoptic region, the hypothalamus, the olivocerebellary system, and the brainstem baroreflex arc, the colocalization or receptor mRNA, binding sites, and angiotensin immunoreactive nerve terminals suggests local synthesis and expression of angiotensin II receptors.  In other areas, such as the bed nucleus of the stria terminalis, the median eminence, or certain parts of the nucleus of the solitary tract, angiotensin II receptors are likely of extrinsic origin.  The neuronal expression of AT1A and AT2 receptors was demonstrated in the subfornical organ, the hypothalamus, and the lateral septum.  By using double label in situ hybridization, AT1A receptor expression was localized in corticotropin releasing hormone but not in vasopressin contg. neurons in the hypothalamus.  The information is discussed together with functional data concerning the role of brain angiotensins, in an attempt to provide a better understanding of the physiol. and functional roles of each receptor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptQjkL-PAEvrVg90H21EOLACvtfcHk0ljL2T105ikK7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1KlsL4%253D&md5=33a1e18fb02c66ea3096072fbd051471</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1006%2Ffrne.1997.0155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Ffrne.1997.0155%26sid%3Dliteratum%253Aachs%26aulast%3DLenkei%26aufirst%3DZ.%26aulast%3DPalkovits%26aufirst%3DM.%26aulast%3DCorvol%26aufirst%3DP.%26aulast%3DLlorens-Cortes%26aufirst%3DC.%26atitle%3DExpression%2520of%2520angiotensin%2520type-1%2520%2528AT1%2529%2520and%2520type-2%2520%2528AT2%2529%2520receptor%2520mRNAs%2520in%2520the%2520adult%2520rat%2520brain%253A%2520a%2520functional%2520neuroanatomical%2520review%26jtitle%3DFront.%2520Neuroendocrinol.%26date%3D1997%26volume%3D18%26spage%3D383%26epage%3D439%26doi%3D10.1006%2Ffrne.1997.0155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">The AT2 receptor-a matter of love and hate</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2005.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.peptides.2005.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=16042980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVCqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=1401-1409&author=U.+M.+Steckelingsauthor=E.+Kaschinaauthor=T.+Unger&title=The+AT2+receptor-a+matter+of+love+and+hate&doi=10.1016%2Fj.peptides.2005.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">The AT2 receptor-A matter of love and hate</span></div><div class="casAuthors">Steckelings, U. M.; Kaschina, E.; Unger, Th.</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1401-1409</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  In 1989, the development of specific angiotensin receptor antagonists which distinguish between two angiotensin receptor subtypes (AT1 and AT2) led to a breakthrough in angiotensin research.  It turned out, that the AT1 receptor was almost entirely responsible for the "classical" actions of angiotensin II related to the regulation of blood pressure as well as vol. and electrolyte balance.  However, actions and signal transduction mechanisms coupled to the AT2 receptor remained enigmatic for a long time.  The present review summarizes the current knowledge of AT2 receptor distribution, signaling and function with an emphasis on growth/anti-growth, differentiation and the regeneration of neuronal tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouASpis89iJrVg90H21EOLACvtfcHk0lhgQntQPL-CJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVCqsr8%253D&md5=d42e2460209f2ad65b52d64fcdcd88e1</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2005.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2005.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DKaschina%26aufirst%3DE.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DThe%2520AT2%2520receptor-a%2520matter%2520of%2520love%2520and%2520hate%26jtitle%3DPeptides%26date%3D2005%26volume%3D26%26spage%3D1401%26epage%3D1409%26doi%3D10.1016%2Fj.peptides.2005.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakugi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takiuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennessy, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogihara, T.</span></span> <span> </span><span class="NLM_article-title">Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages</span>. <i>J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1097/00004872-199917040-00012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1097%2F00004872-199917040-00012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10404956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADyaK1MXktFGgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=537-545&author=A.+Okamuraauthor=H.+Rakugiauthor=M.+Ohishiauthor=Y.+Yanagitaniauthor=S.+Takiuchiauthor=K.+Moriguchiauthor=P.+A.+Fennessyauthor=J.+Higakiauthor=T.+Ogihara&title=Upregulation+of+renin-angiotensin+system+during+differentiation+of+monocytes+to+macrophages&doi=10.1097%2F00004872-199917040-00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages</span></div><div class="casAuthors">Okamura, Atsunori; Rakugi, Hiromi; Ohishi, Mitsuru; Yanagitani, Yoshihiro; Takiuchi, Shin; Moriguchi, Koichi; Fennessy, Paul A.; Higaki, Jitsuo; Ogihara, Toshio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">537-545</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The authors have demonstrated that accumulated macrophages in human coronary arteries strongly express angiotensin converting enzyme in accordance with the development of atheromatous plaques.  However, there are few reports on the regulation of the renin-angiotensin system in macrophages and in monocytes as their source.  Studies were carried out to examine whether the renin-angiotensin system is upregulated during the differentiation of monocytes to macrophages, and whether it is further regulated by angiotensin II and cytokines.  The authors used a human leukemia cell line, THP-1, for monocytes.  Differentiated THP-1, induced by adding phorbol 12-myristate 13-acetate for 24 h, were used as macrophages.  Expression of mRNA of the renin-angiotensin system components was measured by quant. reverse-transcriptase polymerase chain reaction.  Angiotensin converting enzyme activity and subtype-specific angiotensin-binding sites of cultured cells, and angiotensin II prodn. in the culture medium were measured.  Macrophages expressed all components of the renin-angiotensin system except chymase.  Cellular angiotensin converting enzyme activity and angiotensin II in the medium were increased 3.2- and 4.5-fold during differentiation, resp.  Expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors was increased 6.2- and 6.4-fold during differentiation, and was sustained for 7 days.  Incubation with angiotensin II for 24 h caused downregulation of both AT1 and AT2 receptor mRNA, but the expression levels were still more than threefold higher compared with monocytes.  The d. of binding sites of AT1 and AT2 receptors in macrophages was 0.26 and 0.15 fmol/106 cells, resp.  The renin-angiotensin system is markedly activated during monocyte/macrophage differentiation, and may participate in the development of atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoujtwTll1qFLVg90H21EOLACvtfcHk0lhgQntQPL-CJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktFGgsrw%253D&md5=9f9d3f5bc04aeedec5f4151af81c2e61</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1097%2F00004872-199917040-00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004872-199917040-00012%26sid%3Dliteratum%253Aachs%26aulast%3DOkamura%26aufirst%3DA.%26aulast%3DRakugi%26aufirst%3DH.%26aulast%3DOhishi%26aufirst%3DM.%26aulast%3DYanagitani%26aufirst%3DY.%26aulast%3DTakiuchi%26aufirst%3DS.%26aulast%3DMoriguchi%26aufirst%3DK.%26aulast%3DFennessy%26aufirst%3DP.%2BA.%26aulast%3DHigaki%26aufirst%3DJ.%26aulast%3DOgihara%26aufirst%3DT.%26atitle%3DUpregulation%2520of%2520renin-angiotensin%2520system%2520during%2520differentiation%2520of%2520monocytes%2520to%2520macrophages%26jtitle%3DJ.%2520Hypertens.%26date%3D1999%26volume%3D17%26spage%3D537%26epage%3D545%26doi%3D10.1097%2F00004872-199917040-00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saavedra, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imboden, H.</span></span> <span> </span><span class="NLM_article-title">Intraneuronal angiotensinergic system in rat and human dorsal root ganglia</span>. <i>Regul. Pept.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.regpep.2010.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.regpep.2010.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=20346377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVGis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2010&pages=90-98&author=J.+Patilauthor=A.+Schwabauthor=J.+Nussbergerauthor=T.+Schaffnerauthor=J.+M.+Saavedraauthor=H.+Imboden&title=Intraneuronal+angiotensinergic+system+in+rat+and+human+dorsal+root+ganglia&doi=10.1016%2Fj.regpep.2010.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Intraneuronal angiotensinergic system in rat and human dorsal root ganglia</span></div><div class="casAuthors">Patil, Jaspal; Schwab, Alexander; Nussberger, Juerg; Schaffner, Thomas; Saavedra, Juan M.; Imboden, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">90-98</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To elucidate the local formation of angiotensin II (Ang II) in the neurons of sensory dorsal root ganglia (DRG), we studied the expression of angiotensinogen (Ang-N)-, renin-, angiotensin converting enzyme (ACE)- and cathepsin D-mRNA, and the presence of protein renin, Ang II, Substance P and calcitonin gene-related peptide (CGRP) in the rat and human thoracic DRG.  Quant. real time PCR (qRT-PCR) studies revealed that rat DRG expressed substantial amts. of Ang-N- and ACE mRNA, while renin mRNA as well as the protein renin were untraceable.  Cathepsin D-mRNA and cathepsin D-protein were detected in the rat DRG indicating the possibility of existence of pathways alternative to renin for Ang I formation.  Angiotensin peptides were successfully detected with high performance liq. chromatog. and RIA in human DRG exts.  In situ hybridization in rat DRG confirmed addnl. expression of Ang-N mRNA in the cytoplasm of numerous neurons.  Intracellular Ang II staining could be shown in no. of neurons and their processes in both the rat and human DRG.  Interestingly we obsd. neuronal processes with angiotensinergic synapses en passant, colocalized with synaptophysin, within the DRG.  In the DRG, we also identified by qRT-PCR, expression of Ang II receptor AT1A and AT2-mRNA while AT1B-mRNA was not traceable.  In some neurons Substance P and CGRP were found colocalized with Ang II.  The intracellular localization and colocalization of Ang II with Substance P and CGRP in the DRG neurons may indicate a participation and function of Ang II in the regulation of nociception.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEJctxQ9syXrVg90H21EOLACvtfcHk0ljL67X3TWIicw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVGis7c%253D&md5=5e18118744b3faff40a65205e73c963b</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.regpep.2010.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.regpep.2010.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DJ.%26aulast%3DSchwab%26aufirst%3DA.%26aulast%3DNussberger%26aufirst%3DJ.%26aulast%3DSchaffner%26aufirst%3DT.%26aulast%3DSaavedra%26aufirst%3DJ.%2BM.%26aulast%3DImboden%26aufirst%3DH.%26atitle%3DIntraneuronal%2520angiotensinergic%2520system%2520in%2520rat%2520and%2520human%2520dorsal%2520root%2520ganglia%26jtitle%3DRegul.%2520Pept.%26date%3D2010%26volume%3D162%26spage%3D90%26epage%3D98%26doi%3D10.1016%2Fj.regpep.2010.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sumners, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span> <span> </span><span class="NLM_article-title">Protective arms of the renin-angiotensin-system in neurological disease</span>. <i>Clin. Exp. Pharmacol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.1111/1440-1681.12137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2F1440-1681.12137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23735163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOisbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2013&pages=580-588&author=C.+Sumnersauthor=M.+Horiuchiauthor=R.+E.+Widdopauthor=C.+McCarthyauthor=T.+Ungerauthor=U.+M.+Steckelings&title=Protective+arms+of+the+renin-angiotensin-system+in+neurological+disease&doi=10.1111%2F1440-1681.12137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Protective arms of the renin-angiotensin-system in neurological disease</span></div><div class="casAuthors">Sumners, Colin; Horiuchi, Masatsugu; Widdop, Robert E.; McCarthy, Claudia; Unger, Thomas; Steckelings, Ulrike M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Pharmacology and Physiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">580-588</span>CODEN:
                <span class="NLM_cas:coden">CEXPB9</span>;
        ISSN:<span class="NLM_cas:issn">0305-1870</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Summary : In recent years it has been firmly established that apart from the classic renin-angiotensin system (RAS) comprising angiotensin (Ang) II, angiotensin converting enzyme (ACE; responsible for AngII generation) and the angiotensin AT1 receptor (AT1R), there also exist protective arms of the RAS that comprise the angiotensin AT2 receptor (AT2R), Ang-(1-7), ACE2 (mainly responsible for Ang-(1-7) synthesis) and Mas, the receptor for Ang-(1-7).  Stimulation of AT2R promotes neuronal differentiation, neurite outgrowth and axonal regeneration, which results in an acceleration of repair and improved functional outcome after injury of peripheral nerves or the spinal cord.  Stimulation of AT2R and the receptor Mas has been shown to reduce infarct size and ameliorate neurol. deficits in various animal models of stroke.  The underlying mechanisms of action are comprised of activation of direct neurotrophic, anti-inflammatory and anti-oxidant pathways, as well as the augmentation of cerebral blood flow.  Cognitive function is improved by AT2R stimulation due, at least in part, to increased cerebral blood flow.  There is indirect evidence that Ang-(1-7) could also play a role in protection against cognitive decline, but studies confirming this have not yet been published.  In view of the data reviewed in this article, it can be assumed that the protective arms of the RAS are putative targets in the treatment of neurol. diseases, which involve tissue damage or cognitive impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1LaAKH24a2bVg90H21EOLACvtfcHk0ljL67X3TWIicw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOisbnK&md5=ebf627d31dd8f3e53f8a72d7286499c0</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1111%2F1440-1681.12137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1440-1681.12137%26sid%3Dliteratum%253Aachs%26aulast%3DSumners%26aufirst%3DC.%26aulast%3DHoriuchi%26aufirst%3DM.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26atitle%3DProtective%2520arms%2520of%2520the%2520renin-angiotensin-system%2520in%2520neurological%2520disease%26jtitle%3DClin.%2520Exp.%2520Pharmacol.%2520Physiol.%26date%3D2013%26volume%3D40%26spage%3D580%26epage%3D588%26doi%3D10.1111%2F1440-1681.12137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhave, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasier, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxford, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gereau, R. W.</span></span> <span> </span><span class="NLM_article-title">cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1016/S0896-6273(02)00802-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2FS0896-6273%2802%2900802-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=12194871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2002&pages=721-731&author=G.+Bhaveauthor=W.+Zhuauthor=H.+Wangauthor=D.+J.+Brasierauthor=G.+S.+Oxfordauthor=R.+W.+Gereau&title=cAMP-dependent+protein+kinase+regulates+desensitization+of+the+capsaicin+receptor+%28VR1%29+by+direct+phosphorylation&doi=10.1016%2FS0896-6273%2802%2900802-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation</span></div><div class="casAuthors">Bhave, Gautam; Zhu, Weiguo; Wang, Haibin; Brasier, D. J.; Oxford, Gerry S.; Gereau, Robert W., IV</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">721-731</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The capsaicin receptor, VR1 (also known as TRPV1), is a ligand-gated ion channel expressed on nociceptive sensory neurons that responds to noxious thermal and chem. stimuli.  Capsaicin responses in sensory neurons exhibit robust potentiation by cAMP-dependent protein kinase (PKA).  In this study, we demonstrate that PKA reduces VR1 desensitization and directly phosphorylates VR1.  In vitro phosphorylation, phosphopeptide mapping, and protein sequencing of VR1 cytoplasmic domains delineate several candidate PKA phosphorylation sites.  Electrophysiol. anal. of phosphorylation site mutants clearly pinpoints Ser116 as the residue responsible for PKA-dependent modulation of VR1.  Given the significant roles of VR1 and PKA in inflammatory pain hypersensitivity, VR1 phosphorylation at Ser116 by PKA may represent an important mol. mechanism involved in the regulation of VR1 function after tissue injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhqIokbTh0OLVg90H21EOLACvtfcHk0lg6eYDE2nmZPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSlsbg%253D&md5=1cd1eb78b48c2405da537ebd6f3439dc</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2802%2900802-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252802%252900802-4%26sid%3Dliteratum%253Aachs%26aulast%3DBhave%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBrasier%26aufirst%3DD.%2BJ.%26aulast%3DOxford%26aufirst%3DG.%2BS.%26aulast%3DGereau%26aufirst%3DR.%2BW.%26atitle%3DcAMP-dependent%2520protein%2520kinase%2520regulates%2520desensitization%2520of%2520the%2520capsaicin%2520receptor%2520%2528VR1%2529%2520by%2520direct%2520phosphorylation%26jtitle%3DNeuron%26date%3D2002%26volume%3D35%26spage%3D721%26epage%3D731%26doi%3D10.1016%2FS0896-6273%2802%2900802-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rompe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namsolleck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funke-Kaiser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span> <span> </span><span class="NLM_article-title">The past, present and future of angiotensin II type 2 receptor stimulation</span>. <i>JRAAS</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1177/1470320309347791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1177%2F1470320309347791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Wjsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=67-73&author=U.+M.+Steckelingsauthor=F.+Rompeauthor=E.+Kaschinaauthor=P.+Namsolleckauthor=A.+Grzesiakauthor=H.+Funke-Kaiserauthor=M.+Baderauthor=T.+Unger&title=The+past%2C+present+and+future+of+angiotensin+II+type+2+receptor+stimulation&doi=10.1177%2F1470320309347791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">The past, present and future of angiotensin II type 2 receptor stimulation</span></div><div class="casAuthors">Steckelings, U. Muscha; Grzesiak, Aleksandra; Funke-Kaiser, Heiko; Bader, Michael; Unger, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">JRAAS</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-73</span>CODEN:
                <span class="NLM_cas:coden">JRAAAG</span>;
        ISSN:<span class="NLM_cas:issn">1470-3203</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Studying the angiotensin type 2 receptor (AT2) has been problematic in the past because a pharmacol. tool for direct, specific in vitro and in vivo stimulation of the receptor has been lacking.  Consequently, current knowledge about AT2 receptor signalling and function had to be obtained by indirect approaches, like studying animals or cells with genetically altered AT2 receptor expression levels, inhibitory expts. using specific AT2 receptor antagonists, stimulation with angiotensin II under concomitant angiotensin II type 1 receptor blockade or stimulation with the peptide agonist CGP42112A, which has addnl. AT2 receptor antagonistic properties.  The recently developed non-peptide AT2 receptor agonist Compd. 21 now, for the first time, allows direct, selective and specific AT2 receptor stimulation in vitro and in vivo.  This new tool will certainly revolutionize AT2 receptor research, enable many new insights into AT2 receptor function and may also have the potential to become a future medical drug.  This article reviews milestone findings about AT2 receptor functional properties obtained by 'conventional' exptl. approaches within the last 20 years.  Moreover, it provides an overview of the first results obtained by direct AT2 receptor stimulation with Compd. 21, comprising effects on alk. secretion, neurite outgrowth, blood pressure and post-infarct cardiac function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFJF54VlxTEbVg90H21EOLACvtfcHk0lg6eYDE2nmZPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Wjsr3K&md5=1a2d4f1ef689d38085d8e4f0f73a951b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1177%2F1470320309347791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1470320309347791%26sid%3Dliteratum%253Aachs%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DRompe%26aufirst%3DF.%26aulast%3DKaschina%26aufirst%3DE.%26aulast%3DNamsolleck%26aufirst%3DP.%26aulast%3DGrzesiak%26aufirst%3DA.%26aulast%3DFunke-Kaiser%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DM.%26aulast%3DUnger%26aufirst%3DT.%26atitle%3DThe%2520past%252C%2520present%2520and%2520future%2520of%2520angiotensin%2520II%2520type%25202%2520receptor%2520stimulation%26jtitle%3DJRAAS%26date%3D2010%26volume%3D11%26spage%3D67%26epage%3D73%26doi%3D10.1177%2F1470320309347791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaway, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e95762</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0095762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1371%2Fjournal.pone.0095762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24752645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=C.+A.+McCarthyauthor=A.+Vinhauthor=A.+A.+Millerauthor=A.+Hallbergauthor=M.+Altermanauthor=J.+K.+Callawayauthor=R.+E.+Widdop&title=Direct+angiotensin+AT2+receptor+stimulation+using+a+novel+AT2+receptor+agonist%2C+compound+21%2C+evokes+neuroprotection+in+conscious+hypertensive+rats&doi=10.1371%2Fjournal.pone.0095762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats</span></div><div class="casAuthors">McCarthy, Claudia A.; Vinh, Antony; Miller, Alyson A.; Hallberg, Anders; Alterman, Mathias; Callaway, Jennifer K.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e95762/1-e95762/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was examd. in a conscious model of stroke to verify a class effect of AT2R agonists as neuroprotective agents.  Methods and Results: Spontaneously hypertensive rats (SHR) were pre-treated for 5 days prior to stroke with C21 alone or in combination with the AT2R antagonist PD123319.  In a sep. series of expts. C21 was administered in a series of 4 doses commencing 6 h after stroke.  A focal reperfusion model of ischemia was induced in conscious SHR by administering endothelin-1 to the middle cerebral artery (MCA).  Motor coordination was assessed at 1 and 3 days after stroke and post mortem analyses of infarct vols., microglia activation and neuronal survival were performed at 72 h post MCA occlusion.  When given prior to stroke, C21 dose dependently decreased infarct vol., which is consistent with the behavioral findings illustrating an improvement in motor deficit.  During the pre-treatment protocol C21 was shown to enhance microglia activation, which are likely to be evoking protection by releasing brain derived neurotrophic factor.  When drug administration was delayed until 6 h after stroke, C21 still reduced brain injury.  Conclusion: These results indicate that centrally administered C21 confers neuroprotection against stroke damage.  This benefit is likely to involve various mechanisms, including microglial activation of endogenous repair and enhanced cerebroperfusion.  Thus, we have confirmed the neuroprotective effect of AT2R stimulation using a nonpeptide compd. which highlights the clin. potential of the AT2R agonists for future development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLJ8khaoxR6LVg90H21EOLACvtfcHk0lhkV8iIYwuClQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtbzI&md5=bcc1f9fdc33490c63c07afbe8b0f8543</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0095762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0095762%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DC.%2BA.%26aulast%3DVinh%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DA.%2BA.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26aulast%3DCallaway%26aufirst%3DJ.%2BK.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DDirect%2520angiotensin%2520AT2%2520receptor%2520stimulation%2520using%2520a%2520novel%2520AT2%2520receptor%2520agonist%252C%2520compound%252021%252C%2520evokes%2520neuroprotection%2520in%2520conscious%2520hypertensive%2520rats%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0095762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fouda, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhandapani, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ergul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, S. C.</span></span> <span> </span><span class="NLM_article-title">Role of interleukin-10 in the neuroprotective effect of the angiotensin type 2 receptor agonist, compound 21, after ischemia/reperfusion injury</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>799</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2017.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.ejphar.2017.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28192099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=799&publication_year=2017&pages=128-134&author=A.+Y.+Foudaauthor=B.+Pillaiauthor=K.+M.+Dhandapaniauthor=A.+Ergulauthor=S.+C.+Fagan&title=Role+of+interleukin-10+in+the+neuroprotective+effect+of+the+angiotensin+type+2+receptor+agonist%2C+compound+21%2C+after+ischemia%2Freperfusion+injury&doi=10.1016%2Fj.ejphar.2017.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury</span></div><div class="casAuthors">Fouda, Abdelrahman Y.; Pillai, Bindu; Dhandapani, Krishnan M.; Ergul, Adviye; Fagan, Susan C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">799</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">128-134</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We and others have shown that the angiotensin type 2 (AT2) receptor agonist, compd. 21 (C21), provides neuroprotection and enhances recovery in rodent stroke models yet the mechanism involved is not known.  Moreover, C21 treatment is assocd. with an anti-inflammatory response.  Here we tested the hypothesis that C21 mediates neuroprotection by upregulating the neuroprotective and anti-inflammatory cytokine, interleukin (IL)-10.  Wistar rats were subjected to 3 h-middle cerebral artery suture occlusion and treated at reperfusion with C21 (0.03 mg/kg)±IL-10 neutralizing antibody (0.1 mg/kg) both given i.p.  Infarct size, behavioral outcomes, and mol. anal. were performed at 24 h post-injury.  Primary rat neurons were used to test the direct neuroprotective effect of C21 in vitro.  C21 treatment reduced infarct size, improved functional outcome and decreased the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-α) in the ischemic hemisphere compared to saline.  Anti-IL-10 co-treatment blocked the C21-induced redn. in infarct size and inflammation, and the improvement in behavioral outcome.  In vitro, C21 treatment increased neuron survival and reduced cell apoptosis after oxygen glucose deprivation (OGD) and OGD/reoxygenation.  These effects were mediated through AT2R stimulation.  C21 provides direct neuroprotection as well as indirect protection through IL-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6amaaEuFlxrVg90H21EOLACvtfcHk0lhkV8iIYwuClQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrt74%253D&md5=7c8c881619ba5fdc3cf256f623b5dfcb</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DFouda%26aufirst%3DA.%2BY.%26aulast%3DPillai%26aufirst%3DB.%26aulast%3DDhandapani%26aufirst%3DK.%2BM.%26aulast%3DErgul%26aufirst%3DA.%26aulast%3DFagan%26aufirst%3DS.%2BC.%26atitle%3DRole%2520of%2520interleukin-10%2520in%2520the%2520neuroprotective%2520effect%2520of%2520the%2520angiotensin%2520type%25202%2520receptor%2520agonist%252C%2520compound%252021%252C%2520after%2520ischemia%252Freperfusion%2520injury%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D799%26spage%3D128%26epage%3D134%26doi%3D10.1016%2Fj.ejphar.2017.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chow, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koulis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jandeleit-Dahm, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, T. J.</span></span> <span> </span><span class="NLM_article-title">The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1778</span>– <span class="NLM_lpage">1790</span>, <span class="refDoi"> DOI: 10.1007/s00125-016-3977-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1007%2Fs00125-016-3977-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=27168137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVGlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1778-1790&author=B.+S.+Chowauthor=C.+Koulisauthor=P.+Krishnaswamyauthor=U.+M.+Steckelingsauthor=T.+Ungerauthor=M.+E.+Cooperauthor=K.+A.+Jandeleit-Dahmauthor=T.+J.+Allen&title=The+angiotensin+II+type+2+receptor+agonist+Compound+21+is+protective+in+experimental+diabetes-associated+atherosclerosis&doi=10.1007%2Fs00125-016-3977-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis</span></div><div class="casAuthors">Chow, Bryna S. M.; Koulis, Christine; Krishnaswamy, Pooja; Steckelings, Ulrike M.; Unger, Thomas; Cooper, Mark E.; Jandeleit-Dahm, Karin A.; Allen, Terri J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1778-1790</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aims/hypothesis: Angiotensin II is well-recognized to be a key mediator in driving the pathol. events of diabetes-assocd. atherosclerosis via signalling through its angiotensin II type 1 receptor (AT1R) subtype.  However, its actions via the angiotensin II type 2 receptor (AT2R) subtype are still poorly understood.  This study is the first to investigate the role of the novel selective AT2R agonist, Compd. 21 (C21) in an exptl. model of diabetes-assocd. atherosclerosis (DAA).  Methods: Streptozotocin-induced diabetic Apoe-knockout mice were treated with vehicle (0.1 mol/l citrate buffer), C21 (1 mg/kg per day), candesartan cilexetil (4 mg/kg per day) or C21 + candesartan cilexetil over a 20 wk period.  In vitro models of DAA using human aortic endothelial cells and monocyte cultures treated with C21 were also performed.  At the end of the expts., assessment of plaque content and markers of oxidative stress, inflammation and fibrosis were conducted.  Results: C21 treatment significantly attenuated aortic plaque deposition in a mouse model of DAA in vivo, in assocn. with a decreased infiltration of macrophages and mediators of inflammation, oxidative stress and fibrosis.  On the other hand, combination therapy with C21 and candesartan (AT1R antagonist) appeared to have a limited additive effect in attenuating the pathol. of DAA when compared with either treatment alone.  Similarly, C21 was found to confer profound anti-atherosclerotic actions at the in vitro level, particularly in the setting of hyperglycemia.  Strikingly, these atheroprotective actions of C21 were completely blocked by the AT2R antagonist PD123319.  Conclusions/interpretation: Taken together, these findings provide novel mechanistic and potential therapeutic insights into C21 as a monotherapy agent against DAA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1DPyHx9XOP7Vg90H21EOLACvtfcHk0liT5yYNbmuRpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVGlu7Y%253D&md5=1489ad105903161b2451223d2a9e04df</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1007%2Fs00125-016-3977-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-016-3977-5%26sid%3Dliteratum%253Aachs%26aulast%3DChow%26aufirst%3DB.%2BS.%26aulast%3DKoulis%26aufirst%3DC.%26aulast%3DKrishnaswamy%26aufirst%3DP.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DCooper%26aufirst%3DM.%2BE.%26aulast%3DJandeleit-Dahm%26aufirst%3DK.%2BA.%26aulast%3DAllen%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520angiotensin%2520II%2520type%25202%2520receptor%2520agonist%2520Compound%252021%2520is%2520protective%2520in%2520experimental%2520diabetes-associated%2520atherosclerosis%26jtitle%3DDiabetologia%26date%3D2016%26volume%3D59%26spage%3D1778%26epage%3D1790%26doi%3D10.1007%2Fs00125-016-3977-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaikwad, A. B.</span></span> <span> </span><span class="NLM_article-title">Compound 21 and telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase mediated apoptosis</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.04.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bbrc.2017.04.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28456626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFCrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2017&pages=827-833&author=A.+Pandeyauthor=A.+B.+Gaikwad&title=Compound+21+and+telmisartan+combination+mitigates+type+2+diabetic+nephropathy+through+amelioration+of+caspase+mediated+apoptosis&doi=10.1016%2Fj.bbrc.2017.04.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Compound 21 and Telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase mediated apoptosis</span></div><div class="casAuthors">Pandey, Anuradha; Gaikwad, Anil Bhanudas</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">827-833</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The current study aimed to understand the role of novel, highly selective, orally active, non-peptide Angiotensin II type 2 receptor (AT2R) agonist, Compd. 21 and its potential additive effect with Telmisartan on apoptosis and underlying posttranslational modifications in a non-genetic murine model for type 2 diabetic nephropathy (T2DN).  An exptl. model for T2DN was developed by administering low dose Streptozotocin in high fat diet fed male Wistar rats, followed by their treatment with Telmisartan, C21 or their combination.  Our results demonstrated that C21 and Telmisartan combination attenuated metabolic and renal dysfunction, renal morphol. and micro-architectural aberrations and hemodynamic disturbances in type 2 diabetic rats.  The anti-apoptotic and anti-inflammatory effects of Telmisartan were significantly accentuated by C21 indicated by expression of apoptotic markers (Parp1, Caspase 8, Caspase 7, cleaved PARP and cleaved Caspase 3) and NF-κB mediated inflammatory mols. like interleukin 6, tumor necrosis factor alpha; monocyte chemoattractant protein 1 and vascular cell adhesion mol. 1.  C21 was found to improve Telmisartan mediated reversal of histone H3 acetylation at lysine 14 and 27 and expression of histone acetyl transferase, p300/CBP-assocd. factor also known to regulate NF-κB activity and DNA damage response.  C21 in combination with Telmisartan markedly mitigates caspase mediated apoptosis and NF-κB signalling in T2D kidney, which could be partially attributed to its influence on PCAF mediated histone H3 acetylation.  Hence further research should be done to develop this combination to treat T2DN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAgvco_Clg97Vg90H21EOLACvtfcHk0liT5yYNbmuRpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFCrsLk%253D&md5=bb4276bbf9f65cceaec65dfddbc451af</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.04.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.04.134%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DGaikwad%26aufirst%3DA.%2BB.%26atitle%3DCompound%252021%2520and%2520telmisartan%2520combination%2520mitigates%2520type%25202%2520diabetic%2520nephropathy%2520through%2520amelioration%2520of%2520caspase%2520mediated%2520apoptosis%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D487%26spage%3D827%26epage%3D833%26doi%3D10.1016%2Fj.bbrc.2017.04.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaikwad, A. B.</span></span> <span> </span><span class="NLM_article-title">AT2 receptor agonist Compound 21: a silver lining for diabetic nephropathy</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>815</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2017.09.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.ejphar.2017.09.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28943106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFKisrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=815&publication_year=2017&pages=251-257&author=A.+Pandeyauthor=A.+B.+Gaikwad&title=AT2+receptor+agonist+Compound+21%3A+a+silver+lining+for+diabetic+nephropathy&doi=10.1016%2Fj.ejphar.2017.09.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">AT2 receptor agonist Compound 21: A silver lining for diabetic nephropathy</span></div><div class="casAuthors">Pandey, Anuradha; Gaikwad, Anil Bhanudas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">815</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">251-257</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The currently available therapies for diabetic nephropathy, one of the leading causes of renal failure globally are based on inhibition of renin angiotensin system.  However, recently, the focus has shifted towards activation of its protective arm rather than the inhibition of deteriorative axis, using specific agonists.  Compd. 21 (C21), a novel non-peptide angiotensin II type 2 receptor (AT2) agonist, recently granted orphan drug status for the treatment of a rare disease, idiopathic pulmonary fibrosis has also shown a potent anti-inflammatory, anti-fibrotic, antioxidant and anti-apoptotic potential in various diseases including heart failure, myocardial infarction, chronic inflammatory diseases, and neurol. diseases such as ischemic stroke.  A pool of evidences suggest that C21, either alone or in combination with angiotensin receptor blockers could be extremely beneficial in the treatment of diabetic nephropathy, a chronic inflammatory condition sharing its pathogenesis with aforementioned diseases.  The review analyses the new therapeutic tool, C21, its mechanisms of action for renoprotection in diabetic nephropathy, and its future perspectives and thereby provides an insight into the potential application of C21 as a novel therapeutic tool in the eradication of diabetic nephropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLdkV-2Hu-kLVg90H21EOLACvtfcHk0liT5yYNbmuRpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFKisrjN&md5=000e24b04cf14864bd441289f3d96fed</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.09.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.09.036%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DGaikwad%26aufirst%3DA.%2BB.%26atitle%3DAT2%2520receptor%2520agonist%2520Compound%252021%253A%2520a%2520silver%2520lining%2520for%2520diabetic%2520nephropathy%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D815%26spage%3D251%26epage%3D257%26doi%3D10.1016%2Fj.ejphar.2017.09.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucker, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span> <span> </span><span class="NLM_article-title">Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure</span>. <i>Am. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1093/ajh/hpu044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1093%2Fajh%2Fhpu044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24687998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFSis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=1248-1256&author=J.+Gaoauthor=I.+H.+Zuckerauthor=L.+Gao&title=Activation+of+central+angiotensin+type+2+receptors+by+compound+21+improves+arterial+baroreflex+sensitivity+in+rats+with+heart+failure&doi=10.1093%2Fajh%2Fhpu044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure</span></div><div class="casAuthors">Gao, Juan; Zucker, Irving H.; Gao, Lie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hypertension</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1248-1256</span>CODEN:
                <span class="NLM_cas:coden">AJHYE6</span>;
        ISSN:<span class="NLM_cas:issn">0895-7061</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background In a previous study we demonstrated that central administration of compd. 21 (C21), a nonpeptide AT2R agonist, inhibited sympathetic tone in normal rats.  In this study, we hypothesized that C21 exerts a similar effect in rats with coronary ligation-induced heart failure (HF).  Methods C21 was intracerebroventricularly infused for 7 days by osmotic minipump.  Blood pressure (BP) and heart rate (HR) were recorded by radiotelemetry in the conscious state to measure spontaneous arterial baroreflex sensitivity.  Urine was collected for measurement of norepinephrine excretion.  On the last day of C21 treatment, renal sympathetic nerve activity, BP, and HR were directly recorded under anesthesia, and the induced arterial baroreflex sensitivity was evaluated.  Protein expressions of neuronal nitric oxide synthase (nNOS) and angiotensin II type 1 receptor (AT1R) in the subfornical organ, paraventricular nucleus, rostral ventrolateral medulla, and nucleus tractus solitarius were detd. by Western blot anal.  Results C21-treated HF rats displayed significantly less norepinephrine excretion (2,385.6 ± 121.1 vs. 3,677.3 ± 147.6 ng/24 h; P < 0.05) and lower renal sympathetic nerve activity (50.2 ± 1.9% of max vs. 70.9 ± 8.2% of max; P < 0.05) than vehicle-treated HF rats.  C21-treated rats also exhibited improved spontaneous arterial baroreflex sensitivity and induced arterial baroreflex sensitivity.  Bolus intracerebroventricular injection of angiotensin II-evoked pressor and sympatho-excitatory responses were attenuated in the C21-treated HF rats, which displayed upregulated nNOS and downregulated AT1R expression in the subfornical organ, paraventricular nucleus, and rostral ventrolateral medulla.  Conclusions Activation of central angiotensin II type 2 receptor AT2R by C21 suppresses sympathetic outflow in rats with HF by improving baroreflex sensitivity and may provide important benefit in the HF syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCGIVRwSniWbVg90H21EOLACvtfcHk0lgyQya7wEe6WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFSis7c%253D&md5=405cfac4511f5fabb05b15b88df67326</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1093%2Fajh%2Fhpu044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fajh%252Fhpu044%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DZucker%26aufirst%3DI.%2BH.%26aulast%3DGao%26aufirst%3DL.%26atitle%3DActivation%2520of%2520central%2520angiotensin%2520type%25202%2520receptors%2520by%2520compound%252021%2520improves%2520arterial%2520baroreflex%2520sensitivity%2520in%2520rats%2520with%2520heart%2520failure%26jtitle%3DAm.%2520J.%2520Hypertens.%26date%3D2014%26volume%3D27%26spage%3D1248%26epage%3D1256%26doi%3D10.1093%2Fajh%2Fhpu044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foryst-Ludwig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rompe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemnitz, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namsolleck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöpe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hucko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paetsch, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnackenburg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlöf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 2 receptor stimulation. A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">2523</span>– <span class="NLM_lpage">2532</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.108.784868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FCIRCULATIONAHA.108.784868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19029468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVerur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2008&pages=2523-2532&author=E.+Kaschinaauthor=A.+Grzesiakauthor=J.+Liauthor=A.+Foryst-Ludwigauthor=M.+Timmauthor=F.+Rompeauthor=M.+Sommerfeldauthor=U.+R.+Kemnitzauthor=C.+Curatoauthor=P.+Namsolleckauthor=C.+Tsch%C3%B6peauthor=A.+Hallbergauthor=M.+Altermanauthor=T.+Huckoauthor=I.+Paetschauthor=T.+Dietrichauthor=B.+Schnackenburgauthor=K.+Grafauthor=B.+Dahl%C3%B6fauthor=U.+Kintscherauthor=T.+Ungerauthor=U.+M.+Steckelings&title=Angiotensin+II+type+2+receptor+stimulation.+A+novel+option+of+therapeutic+interference+with+the+renin-angiotensin+system+in+myocardial+infarction%3F&doi=10.1161%2FCIRCULATIONAHA.108.784868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II Type 2 Receptor Stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?</span></div><div class="casAuthors">Kaschina, Elena; Grzesiak, Aleksandra; Li, Jun; Foryst-Ludwig, Anna; Timm, Melanie; Rompe, Franziska; Sommerfeld, Manuela; Kemnitz, U. Rudolf; Curato, Caterina; Namsolleck, Pawel; Tschoepe, Carsten; Hallberg, Anders; Alterman, Mathias; Hucko, Thomas; Paetsch, Ingo; Dietrich, Thore; Schnackenburg, Bernhard; Graf, Kristof; Dahloef, Bjoern; Kintscher, Ulrich; Unger, Thomas; Steckelings, U. Muscha</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2523-2532</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: This study is the first to examine the effect of direct angiotensin II type 2 (AT2) receptor stimulation on postinfarct cardiac function with the use of the novel nonpeptide AT2 receptor agonist compd. 21 (C21).  Methods and Results: Myocardial infarction (MI) was induced in Wistar rats by permanent ligation of the left coronary artery.  Treatment with C21 (0.01, 0.03, 0.3 mg/kg per day IP) was started 24 h after MI and was continued until euthanasia (7 days after MI).  Infarct size was assessed by magnetic resonance imaging, and hemodynamic measurements were performed via transthoracic Doppler echocardiog. and intracardiac Millar catheter.  Cardiac tissues were analyzed for inflammation and apoptosis markers with immunoblotting and real-time reverse transcription polymerase chain reaction.  C21 significantly improved systolic and diastolic ventricular function.  Scar size was smallest in the C21-treated rats.  In regard to underlying mechanisms, C21 diminished MI-induced Fas-ligand and caspase-3 expression in the peri-infarct zone, indicating an antiapoptotic effect.  Phosphorylation of the p44/42 and p38 mitogen-activated protein kinases, both involved in the regulation of cell survival, was strongly reduced after MI but almost completely rescued by C21 treatment.  Furthermore, C21 decreased MI-induced serum monocyte chemoattractant protein-1 and myeloperoxidase as well as cardiac interleukin-6, interleukin-1β, and interleukin-2 expression, suggesting an antiinflammatory effect.  Conclusions: Direct AT2 receptor stimulation may be a novel therapeutic approach to improve post-MI systolic and diastolic function by antiapoptotic and antiinflammatory mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjl087BWN2T7Vg90H21EOLACvtfcHk0li9I3RmwKfmKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVerur3E&md5=533faa85059b7d67036abf7a338015e0</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.108.784868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.108.784868%26sid%3Dliteratum%253Aachs%26aulast%3DKaschina%26aufirst%3DE.%26aulast%3DGrzesiak%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DForyst-Ludwig%26aufirst%3DA.%26aulast%3DTimm%26aufirst%3DM.%26aulast%3DRompe%26aufirst%3DF.%26aulast%3DSommerfeld%26aufirst%3DM.%26aulast%3DKemnitz%26aufirst%3DU.%2BR.%26aulast%3DCurato%26aufirst%3DC.%26aulast%3DNamsolleck%26aufirst%3DP.%26aulast%3DTsch%25C3%25B6pe%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26aulast%3DHucko%26aufirst%3DT.%26aulast%3DPaetsch%26aufirst%3DI.%26aulast%3DDietrich%26aufirst%3DT.%26aulast%3DSchnackenburg%26aufirst%3DB.%26aulast%3DGraf%26aufirst%3DK.%26aulast%3DDahl%25C3%25B6f%26aufirst%3DB.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26atitle%3DAngiotensin%2520II%2520type%25202%2520receptor%2520stimulation.%2520A%2520novel%2520option%2520of%2520therapeutic%2520interference%2520with%2520the%2520renin-angiotensin%2520system%2520in%2520myocardial%2520infarction%253F%26jtitle%3DCirculation%26date%3D2008%26volume%3D118%26spage%3D2523%26epage%3D2532%26doi%3D10.1161%2FCIRCULATIONAHA.108.784868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosnyak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welungoda, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span> <span> </span><span class="NLM_article-title">Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00575.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1111%2Fj.1476-5381.2009.00575.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=20128808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlChsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2010&pages=709-716&author=S.+Bosnyakauthor=I.+K.+Welungodaauthor=A.+Hallbergauthor=M.+Altermanauthor=R.+E.+Widdopauthor=E.+S.+Jones&title=Stimulation+of+angiotensin+AT2+receptors+by+the+non-peptide+agonist%2C+Compound+21%2C+evokes+vasodepressor+effects+in+conscious+spontaneously+hypertensive+rats&doi=10.1111%2Fj.1476-5381.2009.00575.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats</span></div><div class="casAuthors">Bosnyak, S.; Welungoda, I. K.; Hallberg, A.; Alterman, M.; Widdop, R. E.; Jones, E. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">709-716</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Angiotensin type 2 receptor (AT2 receptor) stimulation evokes vasodilator effects in vitro and in vivo that oppose the vasoconstrictor effects of angiotensin type 1 receptors (AT1 receptors).  Recently, a novel non-peptide AT2 receptor agonist, Compd. 21, was described, which exhibited high AT2 receptor selectivity.  Functional cardiovascular effects of the drug candidate Compd. 21 were assessed, using mouse isolated aorta and rat mesenteric arteries in vitro and in conscious spontaneously hypertensive rats (SHR).  Compd. 21 evoked dose-dependent vasorelaxations in aortic and mesenteric vessels, abolished by the AT2 receptor antagonist, PD123319.  In vivo, Compd. 21 administered alone, at doses ranging from 50 to 1000 ng/kg-1/min-1 over 4 h did not decrease blood pressure in conscious normotensive Wistar-Kyoto rats or SHR.  However, when given in combination with the AT1 receptor antagonist, candesartan, Compd. 21 (300 ng/kg-1/min-1) lowered blood pressure in SHR only.  Further anal. in sep. groups of conscious SHR revealed that, at a sixfold lower dose, Compd. 21 (50 ng/kg-1/min-1) still evoked a significant depressor response in adult SHR (∼30 mmHg) when combined with different doses of candesartan (0.01 or 0.1 mg/kg-1).  Moreover, the Compd. 21-evoked depressor effect was abolished when co-infused (50 μg/kg-1/min-1 for 2 h) with the AT2 receptor antagonist PD123319.  Collectively, our results indicate that acute administration of Compd. 21 evoked blood pressure redns. via AT2 receptor stimulation.  Thus Compd. 21 can be considered an excellent drug candidate for further study of AT2 receptor function in cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXNBgMew3RELVg90H21EOLACvtfcHk0li9I3RmwKfmKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlChsr0%253D&md5=069e16cdad1181028613321d5975c9f4</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00575.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00575.x%26sid%3Dliteratum%253Aachs%26aulast%3DBosnyak%26aufirst%3DS.%26aulast%3DWelungoda%26aufirst%3DI.%2BK.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DJones%26aufirst%3DE.%2BS.%26atitle%3DStimulation%2520of%2520angiotensin%2520AT2%2520receptors%2520by%2520the%2520non-peptide%2520agonist%252C%2520Compound%252021%252C%2520evokes%2520vasodepressor%2520effects%2520in%2520conscious%2520spontaneously%2520hypertensive%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D159%26spage%3D709%26epage%3D716%26doi%3D10.1111%2Fj.1476-5381.2009.00575.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennion, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumners, C.</span></span> <span> </span><span class="NLM_article-title">Neuroprotection via AT<sub>2</sub> receptor agonists in ischemic stroke</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1042/CS20171549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1042%2FCS20171549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29802210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOqs7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=1055-1067&author=D.+M.+Bennionauthor=U.+M.+Steckelingsauthor=C.+Sumners&title=Neuroprotection+via+AT2+receptor+agonists+in+ischemic+stroke&doi=10.1042%2FCS20171549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotection via AT2 receptor agonists in ischemic stroke</span></div><div class="casAuthors">Bennion, Douglas M.; Steckelings, U. Muscha; Sumners, Colin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1055-1067</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Stroke is a devastating disease that afflicts millions of people each year worldwide.  Ischemic stroke, which accounts for 88% of cases, occurs when blood supply to the brain is decreased, often because of thromboembolism or atherosclerotic occlusion.  This deprives the brain of oxygen and nutrients, causing immediate, irreversible necrosis within the core of the ischemic area, but more delayed and potentially reversible neuronal damage in the surrounding brain tissue, the penumbra.  The only currently approved therapies for ischemic stroke, the thrombolytic agent recombinant tissue plasminogen activator (rtPA) and the endovascular clot retrieval/destruction processes, are aimed at restoring blood flow to the infarcted area, but are only available for a minority of patients and are not able in most cases to completely restore neurol. deficits.  Consequently, there remains a need for agents that will protect neurons against death following ischemic stroke.  Here, we evaluate angiotensin II (Ang II) type 2 (AT2) receptor agonists as a possible therapeutic target for this disease.  We first provide an overview of stroke epidemiol., pathophysiol., and currently approved therapies.  We next review the large amt. of preclin. evidence, accumulated over the past decade and a half, which indicates that AT2 receptor agonists exert significant neuroprotective effects in various animal models, and discuss the potential mechanisms involved.  Finally, after discussing the challenges of delivering blood-brain barrier (BBB) impermeable AT2 receptor agonists to the infarcted areas of the brain, we summarize the evidence for and against the development of these agents as a promising therapeutic strategy for ischemic stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVCXzpo1iC-rVg90H21EOLACvtfcHk0liCK0Xz55hZlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOqs7jP&md5=d1aa44f115be87046f9a777fff382ec3</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1042%2FCS20171549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20171549%26sid%3Dliteratum%253Aachs%26aulast%3DBennion%26aufirst%3DD.%2BM.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DSumners%26aufirst%3DC.%26atitle%3DNeuroprotection%2520via%2520AT2%2520receptor%2520agonists%2520in%2520ischemic%2520stroke%26jtitle%3DClin.%2520Sci.%26date%3D2018%26volume%3D132%26spage%3D1055%26epage%3D1067%26doi%3D10.1042%2FCS20171549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaway, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1482</span>– <span class="NLM_lpage">1489</span>, <span class="refDoi"> DOI: 10.1161/STROKEAHA.108.531509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FSTROKEAHA.108.531509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=19246705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsVOntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2009&pages=1482-1489&author=C.+A.+McCarthyauthor=A.+Vinhauthor=J.+K.+Callawayauthor=R.+E.+Widdop&title=Angiotensin+AT2+receptor+stimulation+causes+neuroprotection+in+a+conscious+rat+model+of+stroke&doi=10.1161%2FSTROKEAHA.108.531509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin AT2 Receptor Stimulation Causes Neuroprotection in a Conscious Rat Model of Stroke</span></div><div class="casAuthors">McCarthy, Claudia A.; Vinh, Antony; Callaway, Jennifer K.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1482-1489</span>CODEN:
                <span class="NLM_cas:coden">SJCCA7</span>;
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background and Purpose: The angiotensin II type 2 receptor (AT2R) is implicated to be neuroprotective in stroke, although this premise has not been directly tested.  Therefore, we have examd. the neuroprotective effect of AT2R stimulation after intracerebroventricular administration of AT2R agonist CGP42112 in a conscious rat model of stroke.  Methods: Spontaneously hypertensive rats were treated with either CGP42112 (0.1 to 10 ng/kg/min intracerebroventricularly) alone or in combination with the AT2R antagonist PD123319 (36 ng/kg/min intracerebroventricularly) beginning 5 days before stroke induction.  A focal reperfusion model of stroke was induced in conscious spontaneously hypertensive rats by administering endothelin-1 to the middle cerebral artery through a surgically implanted cannula.  Behavioral tests were used to assess the severity of neurol. deficit as a result of the ischemic event.  Cortical and striatal infarct vols. were measured 72 h poststroke.  Results- Blood pressure was unaffected by treatments.  CGP42112 dose-dependently reduced cortical infarct vol. poststroke, and PD123319 abolished the neuroprotective effect of CGP42112.  PD123319 had no effect on infarct vol. alone.  These results were consistent with the behavioral findings, indicating that CGP42112 reduced motor deficit on the ledged beam test at 72 h poststroke and immunohistochem. analyses showing that CGP42112 increased neuronal survival and minimized the loss of AT2R expression in the infarcted region.  Conclusion: Based on infarct, behavioral, and immunohistochem. data, these results indicate that centrally administered CGP42112 exhibits a neuroprotective effect, which was independent of blood pressure.  Thus, for the first time, we have shown that central AT2R stimulation is neuroprotective in a conscious rat model of stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNMckW8OZAuLVg90H21EOLACvtfcHk0liCK0Xz55hZlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsVOntb0%253D&md5=57945540f901ebadea58e0fa374a29f3</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1161%2FSTROKEAHA.108.531509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FSTROKEAHA.108.531509%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DC.%2BA.%26aulast%3DVinh%26aufirst%3DA.%26aulast%3DCallaway%26aufirst%3DJ.%2BK.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DAngiotensin%2520AT2%2520receptor%2520stimulation%2520causes%2520neuroprotection%2520in%2520a%2520conscious%2520rat%2520model%2520of%2520stroke%26jtitle%3DStroke%26date%3D2009%26volume%3D40%26spage%3D1482%26epage%3D1489%26doi%3D10.1161%2FSTROKEAHA.108.531509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danyel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span> <span> </span><span class="NLM_article-title">Impact of AT2-receptor stimulation on vascular biology, kidney function, and blood pressure</span>. <i>Integr. Blood Pressure Control</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.2147/IBPC.S34425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.2147%2FIBPC.S34425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24379697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvVGrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=153-161&author=L.+A.+Danyelauthor=P.+Schmerlerauthor=L.+Paulisauthor=T.+Ungerauthor=U.+M.+Steckelings&title=Impact+of+AT2-receptor+stimulation+on+vascular+biology%2C+kidney+function%2C+and+blood+pressure&doi=10.2147%2FIBPC.S34425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of AT2-receptor stimulation on vascular biology, kidney function and blood pressure</span></div><div class="casAuthors">Danyel, Leon A.; Schmerler, Patrick; Paulis, Ludovit; Unger, Thomas; Steckelings, U. Muscha</div><div class="citationInfo"><span class="NLM_cas:title">Integrated Blood Pressure Control</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-161, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">IBPCB9</span>;
        ISSN:<span class="NLM_cas:issn">1178-7104</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The angiotensin type 2 receptor (AT2R) and the receptor MAS are receptors within the renin-angiotensin system, which mediate tissue-protective actions such as anti-inflammation, antifibrosis and antiapoptosis.  In recent years, several programs have been launched in order to develop drugs that act as agonists on the AT2R or MAS to take therapeutic advantage of the protective and regenerative properties of these receptors.  This review article will focus on recent data obtained in preclin. animal and on vitro models with new AT2R-agonistic mols. (Compd. 21 and β-amino acid substituted angiotensin II) and with relevance for blood pressure (BP) regulation or hypertensive end-organ damage.  These data will include studies on vasodilation/vasoconstriction in isolated resistance arteries ex vivo, studies on kidney function, studies on vascular remodeling, and studies that measured the net effect of AT2R stimulation on BP in vivo.  Current data indicate that although AT2R stimulation causes vasodilation ex vivo and promotes natriuresis, it does not alter BP levels in vivo acutely - at least as long as there is no addnl. low-dose blockade of AT1R.  However, AT2R stimulation alone is able to attenuate hypertension-induced vascular remodeling and reduce arterial stiffening, which in more chronic settings and together with the natriuretic effect may result in modest lowering of BP.  We conclude from these preclin. data that AT2R agonists are not suitable for antihypertensive monotherapy, but that this new future drug class may be beneficial in combination with established antihypertensives for the treatment of hypertension with improved protection from end-organ damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot9RFOyx7x2rVg90H21EOLACvtfcHk0ljl2q_vawFVvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvVGrtbw%253D&md5=3ae15e261423252f5c7e173afea27f0c</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.2147%2FIBPC.S34425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIBPC.S34425%26sid%3Dliteratum%253Aachs%26aulast%3DDanyel%26aufirst%3DL.%2BA.%26aulast%3DSchmerler%26aufirst%3DP.%26aulast%3DPaulis%26aufirst%3DL.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26atitle%3DImpact%2520of%2520AT2-receptor%2520stimulation%2520on%2520vascular%2520biology%252C%2520kidney%2520function%252C%2520and%2520blood%2520pressure%26jtitle%3DIntegr.%2520Blood%2520Pressure%2520Control%26date%3D2013%26volume%3D6%26spage%3D153%26epage%3D161%26doi%3D10.2147%2FIBPC.S34425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibowitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rautureau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffrin, E. L.</span></span> <span> </span><span class="NLM_article-title">Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.111.180158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.111.180158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22184324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVeluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2012&pages=291-299&author=A.+Rehmanauthor=A.+Leibowitzauthor=N.+Yamamotoauthor=Y.+Rautureauauthor=P.+Paradisauthor=E.+L.+Schiffrin&title=Angiotensin+type+2+receptor+agonist+compound+21+reduces+vascular+injury+and+myocardial+fibrosis+in+stroke-prone+spontaneously+hypertensive+rats&doi=10.1161%2FHYPERTENSIONAHA.111.180158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats</span></div><div class="casAuthors">Rehman, Asia; Leibowitz, Avshalom; Yamamoto, Naoki; Rautureau, Yohann; Paradis, Pierre; Schiffrin, Ernesto L.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">291-299</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">-Angiotensin type 2 receptor-mediated effects of angiotensin II appear to counteract many of the effects mediated via the angiotensin type 1 receptor.  Compd. 21 (C21), a selective angiotensin type 2 receptor agonist, has demonstrated beneficial effects on cardiac function after myocardial infarction in rodents.  We hypothesized that C21 alone or in combination with an angiotensin type 1 receptor antagonist would blunt the development of hypertension and vascular damage in stroke-prone spontaneously hypertensive rats.  Six-week-old stroke-prone spontaneously hypertensive rats received C21 (1 mg/kg per day), the angiotensin type 1 receptor antagonist losartan (10 mg/kg per day), C21 plus losartan, or vehicle PO for 6 wk.  Systolic blood pressure was lower in losartan and C21-losartan combination groups (P<0.001).  Endothelium-dependent relaxation was enhanced (P<0.001) in the C21-losartan combination group at lower acetylcholine concns.  C21 or C21-losartan combination reduced vascular stiffness, aortic medial and myocardial interstitial collagen content, and aortic fibronectin (P<0.05).  C21 and losartan decreased the expression of 2 genes assocd. with cardiac hypertrophy, myosin heavy chain-β (myh7) by 30 to 50%, and α-skeletal muscle actin by 30% to 35% (P<0.05).  C21-losartan combination caused an addnl. 40% redn. in myh7 compared with C21 (P<0.01).  Aortic superoxide generation was reduced equally by the 3 treatments (P<0.001).  Monocyte/macrophage infiltration in the aorta and kidney (P<0.001) and T-lymphocyte infiltration in the renal cortex (P<0.05) were lowered similarly by the 3 treatments.  These data suggest that C21 alone or in combination with losartan may improve endothelial function and vascular compn. and mechanics by reducing oxidative stress, collagen content, fibronectin, and inflammatory cell infiltration in stroke-prone spontaneously hypertensive rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob-8rmJBw_47Vg90H21EOLACvtfcHk0ljl2q_vawFVvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVeluw%253D%253D&md5=131d4b435a6ad8e6e7c33618df03a3c2</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.111.180158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.111.180158%26sid%3Dliteratum%253Aachs%26aulast%3DRehman%26aufirst%3DA.%26aulast%3DLeibowitz%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DRautureau%26aufirst%3DY.%26aulast%3DParadis%26aufirst%3DP.%26aulast%3DSchiffrin%26aufirst%3DE.%2BL.%26atitle%3DAngiotensin%2520type%25202%2520receptor%2520agonist%2520compound%252021%2520reduces%2520vascular%2520injury%2520and%2520myocardial%2520fibrosis%2520in%2520stroke-prone%2520spontaneously%2520hypertensive%2520rats%26jtitle%3DHypertension%26date%3D2012%26volume%3D59%26spage%3D291%26epage%3D299%26doi%3D10.1161%2FHYPERTENSIONAHA.111.180158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thöne-Reineke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkovska, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlöf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span> <span> </span><span class="NLM_article-title">Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e60</span>– <span class="NLM_lpage">e67</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.113.02522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.113.02522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=24379181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2cXit1yrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2014&pages=e60-e67&author=D.+Lauerauthor=S.+Slavicauthor=M.+Sommerfeldauthor=C.+Th%C3%B6ne-Reinekeauthor=Y.+Sharkovskaauthor=A.+Hallbergauthor=B.+Dahl%C3%B6fauthor=U.+Kintscherauthor=T.+Ungerauthor=U.+M.+Steckelingsauthor=E.+Kaschina&title=Angiotensin+type+2+receptor+stimulation+ameliorates+left+ventricular+fibrosis+and+dysfunction+via+regulation+of+tissue+inhibitor+of+matrix+metalloproteinase+1%2Fmatrix+metalloproteinase+9+axis+and+transforming+growth+factor+%CE%B21+in+the+rat+heart&doi=10.1161%2FHYPERTENSIONAHA.113.02522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase 1/Matrix Metalloproteinase 9 Axis and Transforming Growth Factor β1 in the Rat Heart</span></div><div class="casAuthors">Lauer, Dilyara; Slavic, Svetlana; Sommerfeld, Manuela; Thoene-Reineke, Christa; Sharkovska, Yuliya; Hallberg, Anders; Dahloef, Bjorn; Kintscher, Ulrich; Unger, Thomas; Steckelings, Ulrike Muscha; Kaschina, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e60-e67</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Left ventricular (LV) remodeling is the main reason for the development of progressive cardiac dysfunction after myocardial infarction (MI).  This study investigated whether stimulation of the angiotensin type 2 receptor is able to ameliorate post-MI cardiac remodeling and what the underlying mechanisms may be.  MI was induced in Wistar rats by permanent ligation of the left coronary artery.  Treatment with the angiotensin type 2 receptor agonist compd. 21 ( 0.03 mg/kg) was started 6 h post-MI and continued for 6 wk.  Hemodynamic parameters were measured by echocardiog. and intracardiac catheter.  Effects on proteolysis were studied in heart tissue and primary cardiac fibroblasts.  Compd. 21 significantly improved systolic and diastolic functions, resulting in improved ejection fraction (71.2±4.7% vs. 53.4±7.0%; P<0.001), fractional shortening (P<0.05), LV internal dimension in systole (P<0.05), LV end-diastolic pressure (16.9±1.2 vs. 22.1±1.4 mm Hg; P<0.05), ratio of early (E) to late (A) ventricular filling velocities, and max. and min. rate of LV pressure rise (P<0.05).  Compd. 21 improved arterial stiffness parameters and reduced collagen content in peri-infarct myocardium.  Tissue inhibitor of matrix metalloproteinase 1 was strongly upregulated, whereas matrix metalloproteinases 2 and 9 and transforming growth factor β1 were diminished in LV of treated animals.  In cardiac fibroblasts, compd. 21 initially induced tissue inhibitor of matrix metalloproteinase 1 expression followed by attenuated matrix metalloproteinase 9 and transforming growth factor β1 secretion.  In conclusion, angiotensin type 2 receptor stimulation improves cardiac function and prevents cardiac remodeling in the late stage after MI, suggesting that angiotensin type 2 receptor agonists may be considered a future pharmacol. approach for the improvement of post-MI cardiac dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDbLTec17DHLVg90H21EOLACvtfcHk0lgY9yXeqre02w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXit1yrs7s%253D&md5=578fcae9d335242824a1a40c8d5bf399</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.113.02522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.113.02522%26sid%3Dliteratum%253Aachs%26aulast%3DLauer%26aufirst%3DD.%26aulast%3DSlavic%26aufirst%3DS.%26aulast%3DSommerfeld%26aufirst%3DM.%26aulast%3DTh%25C3%25B6ne-Reineke%26aufirst%3DC.%26aulast%3DSharkovska%26aufirst%3DY.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DDahl%25C3%25B6f%26aufirst%3DB.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DKaschina%26aufirst%3DE.%26atitle%3DAngiotensin%2520type%25202%2520receptor%2520stimulation%2520ameliorates%2520left%2520ventricular%2520fibrosis%2520and%2520dysfunction%2520via%2520regulation%2520of%2520tissue%2520inhibitor%2520of%2520matrix%2520metalloproteinase%25201%252Fmatrix%2520metalloproteinase%25209%2520axis%2520and%2520transforming%2520growth%2520factor%2520%25CE%25B21%2520in%2520the%2520rat%2520heart%26jtitle%3DHypertension%26date%3D2014%26volume%3D63%26spage%3De60%26epage%3De67%26doi%3D10.1161%2FHYPERTENSIONAHA.113.02522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namsolleck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschina, E.</span></span> <span> </span><span class="NLM_article-title">AT<sub>2</sub>R (angiotensin AT2 receptor) agonist, compound 21, prevents abdominal aortic aneurysm progression in the rat</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">e20</span>– <span class="NLM_lpage">e29</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.118.11168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.118.11168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29987108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVKisLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2018&pages=e20-e29&author=C.+Langeauthor=M.+Sommerfeldauthor=P.+Namsolleckauthor=U.+Kintscherauthor=T.+Ungerauthor=E.+Kaschina&title=AT2R+%28angiotensin+AT2+receptor%29+agonist%2C+compound+21%2C+prevents+abdominal+aortic+aneurysm+progression+in+the+rat&doi=10.1161%2FHYPERTENSIONAHA.118.11168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">AT2R (Angiotensin AT2 Receptor) Agonist, Compound 21, Prevents Abdominal Aortic Aneurysm Progression in the Rat</span></div><div class="casAuthors">Lange, Christoph; Sommerfeld, Manuela; Namsolleck, Pawel; Kintscher, Ulrich; Unger, Thomas; Kaschina, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e20-e29</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The effects of the selective AT2R (angiotensin AT2 receptor) agonist, Compd. 21 (C21), on abdominal aortic aneurysm formation were investigated in normotensive Wistar rats.  Abdominal aortic aneurysm was induced by perfusion of isolated aortic segments with elastase.  Treatment with C21 (0.03 mg/kg daily) was started after operation and continued for 14 days.  Sham-operated animals and vehicle-treated animals after aneurysm induction served as controls.  Aortic diam., aortic wall distensibility, and pulse propagation velocity were measured via ultrasound.  Hemodynamic parameters, aortic tissue protein expression, and serum cytokines were analyzed.  On day 14 post aneurysm induction, aortic diam. of vehicle-treated animals was increased 1.6-fold compared with sham-operated rats (2.65±0.05 vs. 1.70±0.06 mm; P<0.0001).  C21 decreased aortic diam. in comparison to vehicle (1.9±0.06 vs. 2.65±0.05; P<0.0001).  Infrarenal blood velocity and aortic distensibility were reduced, whereas aortic wall stiffness was increased post aneurysm induction.  These alterations were significantly ameliorated by treatment with C21 while blood pressure and cardiac contractility remained unchanged.  Protein expression of IL-1β (interleukin-1β), NFκB (nuclear factor κB), MMP9 (matrix metalloproteinase 9), TGF-β1 (transforming growth factor-β1), and MLKL (mixed lineage kinase domain-like) in the aorta was significantly (P<0.05) down-regulated in the C21 group compared with vehicle.  Serum concn. of TGF-β1 was decreased by C21 in comparison to vehicle (P<0.01).  AT2R stimulation with C21 prevented extracellular matrix degrdn., maintained vascular integrity of the aorta and prevented abdominal aortic aneurysm progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB3zA4di23NLVg90H21EOLACvtfcHk0lgY9yXeqre02w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVKisLzP&md5=65a09de5da5eeb8716ace6423886b863</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.118.11168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.118.11168%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DC.%26aulast%3DSommerfeld%26aufirst%3DM.%26aulast%3DNamsolleck%26aufirst%3DP.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKaschina%26aufirst%3DE.%26atitle%3DAT2R%2520%2528angiotensin%2520AT2%2520receptor%2529%2520agonist%252C%2520compound%252021%252C%2520prevents%2520abdominal%2520aortic%2520aneurysm%2520progression%2520in%2520the%2520rat%26jtitle%3DHypertension%26date%3D2018%26volume%3D72%26spage%3De20%26epage%3De29%26doi%3D10.1161%2FHYPERTENSIONAHA.118.11168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Borgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirmiz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">Anti-fibrotic potential of AT<sub>2</sub> receptor agonists</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">564</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.3389%2Ffphar.2017.00564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28912715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=564&author=Y.+Wangauthor=M.+Del+Borgoauthor=H.+W.+Leeauthor=D.+Baraldiauthor=B.+Hirmizauthor=T.+A.+Gaspariauthor=K.+M.+Dentonauthor=M.+I.+Aguilarauthor=C.+S.+Samuelauthor=R.+E.+Widdop&title=Anti-fibrotic+potential+of+AT2+receptor+agonists&doi=10.3389%2Ffphar.2017.00564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-fibrotic potential of AT2 receptor agonists</span></div><div class="casAuthors">Wang, Yan; Del Borgo, Mark; Lee, Huey W.; Baraldi, Dhaniel; Hirmiz, Baydaa; Gaspari, Tracey A.; Denton, Kate M.; Aguilar, Marie-Isabel; Samuel, Chrishan S.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">564/1-564/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">There are a no. of therapeutic targets to treat organ fibrosis that are under investigation in preclin. models.  There is increasing evidence that stimulation of the angiotensin II type 2 receptor (AT2R) is a novel anti-fibrotic strategy and we have reviewed the published in vivo preclin. data relating to the effects of compd. 21 (C21), which is the only nonpeptide AT2R agonist that is currently available for use in chronic preclin. studies.  In particular, the differential influence of AT2R on extracellular matrix status in various preclin. fibrotic models is discussed.  Collectively, these studies demonstrate that pharmacol. AT2R stimulation using C21 decreases organ fibrosis, which has been most studied in the setting of cardiovascular and renal disease.  In addn., AT2R-mediated anti-inflammatory effects may contribute to the beneficial AT2R-mediated anti-fibrotic effects seen in preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXQrEmlGvVi7Vg90H21EOLACvtfcHk0lioAQVBdGNf8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsrfP&md5=616e2c23a2a6d046dd5bb0cd2c3733ed</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00564%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDel%2BBorgo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DBaraldi%26aufirst%3DD.%26aulast%3DHirmiz%26aufirst%3DB.%26aulast%3DGaspari%26aufirst%3DT.%2BA.%26aulast%3DDenton%26aufirst%3DK.%2BM.%26aulast%3DAguilar%26aufirst%3DM.%2BI.%26aulast%3DSamuel%26aufirst%3DC.%2BS.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DAnti-fibrotic%2520potential%2520of%2520AT2%2520receptor%2520agonists%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D564%26doi%3D10.3389%2Ffphar.2017.00564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koulis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, B. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKelvey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thallas-Bonke, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jandeleit-Dahm, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, T. J.</span></span> <span> </span><span class="NLM_article-title">AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1073</span>– <span class="NLM_lpage">1081</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.115.05204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.115.05204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=25776077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFGgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=1073-1081&author=C.+Koulisauthor=B.+S.+M.+Chowauthor=M.+McKelveyauthor=U.+M.+Steckelingsauthor=T.+Ungerauthor=V.+Thallas-Bonkeauthor=M.+C.+Thomasauthor=M.+E.+Cooperauthor=K.+A.+Jandeleit-Dahmauthor=T.+J.+Allen&title=AT2R+agonist%2C+compound+21%2C+is+reno-protective+against+type+1+diabetic+nephropathy&doi=10.1161%2FHYPERTENSIONAHA.115.05204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">AT2R Agonist, Compound 21, Is Reno-Protective Against Type 1 Diabetic Nephropathy</span></div><div class="casAuthors">Koulis, Christine; Chow, Bryna S. M.; McKelvey, Maria; Steckelings, Ulrike M.; Unger, Thomas; Thallas-Bonke, Vicki; Thomas, Merlin C.; Cooper, Mark E.; Jandeleit-Dahm, Karin A.; Allen, Terri J.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1073-1081</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The hemodynamic and nonhemodynamic effects of angiotensin II on diabetic complications are considered to be primarily mediated by the angiotensin II type 1 receptor subtype.  However, its biol. and functional effect mediated through the angiotensin II type 2 receptor subtype is still unclear.  Activation of the angiotensin II type 2 receptors has been postulated to oppose angiotensin II type 1 receptor-mediated actions and thus attenuate fibrosis.  This study aimed to elucidate the reno-protective role of the novel selective angiotensin II type 2 receptor agonist, Compd. 21, in an exptl. model of type 1 diabetic nephropathy.  Compd. 21 treatment significantly attenuated diabetes mellitus-induced elevated levels of cystatin C, albuminuria, mesangial expansion, and glomerulosclerosis in diabetic mice.  Moreover, Compd. 21 markedly inhibited the expression of various proteins implicated in oxidative stress, inflammation, and fibrosis, in assocn. with decreased extracellular matrix prodn.  These findings demonstrate that monotherapy of Compd. 21 is protective against the progression of exptl. diabetic nephropathy by inhibiting renal oxidative stress, inflammation, and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPzvc-jfzhbrVg90H21EOLACvtfcHk0lioAQVBdGNf8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFGgtLg%253D&md5=825aa6adcf583a062af2b65d529697b3</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.115.05204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.115.05204%26sid%3Dliteratum%253Aachs%26aulast%3DKoulis%26aufirst%3DC.%26aulast%3DChow%26aufirst%3DB.%2BS.%2BM.%26aulast%3DMcKelvey%26aufirst%3DM.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DThallas-Bonke%26aufirst%3DV.%26aulast%3DThomas%26aufirst%3DM.%2BC.%26aulast%3DCooper%26aufirst%3DM.%2BE.%26aulast%3DJandeleit-Dahm%26aufirst%3DK.%2BA.%26aulast%3DAllen%26aufirst%3DT.%2BJ.%26atitle%3DAT2R%2520agonist%252C%2520compound%252021%252C%2520is%2520reno-protective%2520against%2520type%25201%2520diabetic%2520nephropathy%26jtitle%3DHypertension%26date%3D2015%26volume%3D65%26spage%3D1073%26epage%3D1081%26doi%3D10.1161%2FHYPERTENSIONAHA.115.05204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, T.</span></span> <span> </span><span class="NLM_article-title">Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1038/ki.2013.193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1038%2Fki.2013.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23823602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWqtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=931-939&author=Q.+Aliauthor=Y.+Wuauthor=T.+Hussain&title=Chronic+AT2+receptor+activation+increases+renal+ACE2+activity%2C+attenuates+AT1+receptor+function+and+blood+pressure+in+obese+Zucker+rats&doi=10.1038%2Fki.2013.193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats</span></div><div class="casAuthors">Ali, Quaisar; Wu, Yonnie; Hussain, Tahir</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">931-939</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Abnormal regulation of the renin angiotensin system such as enhanced renal AT1R function and reduced ACE2 activity contributes to obesity-related hypertension.  Here, we tested whether long-term AT2R activation affects renal function in obesity using lean and obese Zucker rats treated with the AT2R agonist CGP42112A for 2 wk.  This caused blood pressure to decrease by 13 mm Hg, which was assocd. with increased urinary sodium excretion in the obese rats.  Cortical ACE2 expression and activity, the Mas receptor (MasR), and its ligand angiotensin-(1-7) were all increased in CGP-treated obese compared with control rats.  Candesartan-induced natriuresis, a measure of AT1R function, was reduced but cortical AT1R expression and angiotensin II levels were similar in CGP-treated obese compared with control rats.  Renin and AT2R expression in obese rats was not affected by CGP treatment.  In HK-2 cells in vitro, CGP treatment caused increased ACE2 activity and MasR levels but decreased AT1R levels and renin activity.  Thus, long-term AT2R activation shifts the opposing arms of renin angiotensin system and contributes to natriuresis and blood pressure redn. in obese animals.  Our study highlights the importance of AT2R as a target for treating obesity-related hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCEhKVv6TAxLVg90H21EOLACvtfcHk0ljlbqZKj76M8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWqtrrF&md5=5ac9ffedccefc2d0278c45d53740252d</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1038%2Fki.2013.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2013.193%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHussain%26aufirst%3DT.%26atitle%3DChronic%2520AT2%2520receptor%2520activation%2520increases%2520renal%2520ACE2%2520activity%252C%2520attenuates%2520AT1%2520receptor%2520function%2520and%2520blood%2520pressure%2520in%2520obese%2520Zucker%2520rats%26jtitle%3DKidney%2520Int.%26date%3D2013%26volume%3D84%26spage%3D931%26epage%3D939%26doi%3D10.1038%2Fki.2013.193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quiroga, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pffeifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toblli, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giani, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominici, F. P.</span></span> <span> </span><span class="NLM_article-title">Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice</span>. <i>Physiol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e13824</span> <span class="refDoi"> DOI: 10.14814/phy2.13824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.14814%2Fphy2.13824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30156060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2mtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&author=D.+T.+Quirogaauthor=M.+C.+Mu%C3%B1ozauthor=C.+Gilauthor=M.+Pffeiferauthor=J.+E.+Toblliauthor=U.+M.+Steckelingsauthor=J.+F.+Gianiauthor=F.+P.+Dominici&title=Chronic+administration+of+the+angiotensin+type+2+receptor+agonist+C21+improves+insulin+sensitivity+in+C57BL%2F6+mice&doi=10.14814%2Fphy2.13824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice.</span></div><div class="casAuthors">Quiroga, Diego Tomas; Munoz, Marina C.; Gil, Carolina; Pffeifer, Marlies; Toblli, Jorge E.; Steckelings, Ulrike M.; Giani, Jorge F.; Dominici, Fernando P.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">e13824/1-e13824/13</span>CODEN:
                <span class="NLM_cas:coden">PRHEJ2</span>;
        ISSN:<span class="NLM_cas:issn">2051-817X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The renin-angiotensin system modulates insulin action.  Angiotensin type 1 receptor exerts a deleterious effect, whereas the angiotensin type 2 receptor (AT2R) appears to have beneficial effects providing protection against insulin resistance and type 2 diabetes.  To further explore the role of the AT2R on insulin action and glucose homeostasis, in this study we administered C57Bl/6 mice with the synthetic agonist of the AT2R C21 for 12 wk (1 mg/kg per day; i.p.).  Vehicle-treated animals were used as control.  Metabolic parameters, glucose, and insulin tolerance, in vivo insulin signaling in main insulin-target tissues as well as adipose tissue levels of adiponectin, and TNF-α were assessed.  C21-treated animals displayed decreased glycemia together with unaltered insulinemia, increased insulin sensitivity, and increased glucose tolerance compared to nontreated controls.  This was accompanied by a significant decrease in adipocytes size in epididymal adipose tissue and significant increases in both adiponectin and UCP-1 expression in this tissue.  C21-treated mice showed an increase in both basal Akt and ERK1/2 phosphorylation levels in the liver, and increased insulin-stimulated Akt activation in adipose tissue.  This pos. modulation of insulin action induced by C21 appeared not to involve the insulin receptor.  In C21-treated mice, adipose tissue and skeletal muscle became unresponsive to insulin in terms of ERK1/2 phosphorylation levels.  Present data show that chronic pharmacol. activation of AT2R with C21 increases insulin sensitivity in mice and indicate that the AT2R has a physiol. role in the conservation of insulin action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofW80EhzU4xbVg90H21EOLACvtfcHk0ljlbqZKj76M8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2mtrfO&md5=f4902bf81535cfdb766d2e6a286c9292</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.14814%2Fphy2.13824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14814%252Fphy2.13824%26sid%3Dliteratum%253Aachs%26aulast%3DQuiroga%26aufirst%3DD.%2BT.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%2BC.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DPffeifer%26aufirst%3DM.%26aulast%3DToblli%26aufirst%3DJ.%2BE.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DGiani%26aufirst%3DJ.%2BF.%26aulast%3DDominici%26aufirst%3DF.%2BP.%26atitle%3DChronic%2520administration%2520of%2520the%2520angiotensin%2520type%25202%2520receptor%2520agonist%2520C21%2520improves%2520insulin%2520sensitivity%2520in%2520C57BL%252F6%2520mice%26jtitle%3DPhysiol.%2520Rep.%26date%3D2018%26volume%3D6%26doi%3D10.14814%2Fphy2.13824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guimond, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span> <span> </span><span class="NLM_article-title">The angiotensin II type 2 receptor in brain functions: an update</span>. <i>Int. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">351758</span>, <span class="refDoi"> DOI: 10.1155/2012/351758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1155%2F2012%2F351758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23320146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A280%3ADC%252BC3s3psFOruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=351758&author=M.+O.+Guimondauthor=N.+Gallo-Payet&title=The+angiotensin+II+type+2+receptor+in+brain+functions%3A+an+update&doi=10.1155%2F2012%2F351758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">The Angiotensin II Type 2 Receptor in Brain Functions: An Update</span></div><div class="casAuthors">Guimond Marie-Odile; Gallo-Payet Nicole</div><div class="citationInfo"><span class="NLM_cas:title">International journal of hypertension</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">351758</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Angiotensin II (Ang II) is the main active product of the renin-angiotensin system (RAS), mediating its action via two major receptors, namely, the Ang II type 1 (AT(1)) receptor and the type 2 (AT(2)) receptor.  Recent results also implicate several other members of the renin-angiotensin system in various aspects of brain functions.  The first aim of this paper is to summarize the current state of knowledge regarding the properties and signaling of the AT(2) receptor, its expression in the brain, and its well-established effects.  Secondly, we will highlight the potential role of the AT(2) receptor in cognitive function, neurological disorders and in the regulation of appetite and the possible link with development of metabolic disorders.  The potential utility of novel nonpeptide selective AT(2) receptor ligands in clarifying potential roles of this receptor in physiology will also be discussed.  If confirmed, these new pharmacological tools should help to improve impaired cognitive performance, not only through its action on brain microcirculation and inflammation, but also through more specific effects on neurons.  However, the overall physiological relevance of the AT(2) receptor in the brain must also consider the Ang IV/AT(4) receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuZ1E7KO21PSCEBeYuoi7AfW6udTcc2eZ2PQGgRY5FQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3psFOruw%253D%253D&md5=5e280982ffbcae0314948bcb98e32a2b</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1155%2F2012%2F351758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F351758%26sid%3Dliteratum%253Aachs%26aulast%3DGuimond%26aufirst%3DM.%2BO.%26aulast%3DGallo-Payet%26aufirst%3DN.%26atitle%3DThe%2520angiotensin%2520II%2520type%25202%2520receptor%2520in%2520brain%2520functions%253A%2520an%2520update%26jtitle%3DInt.%2520J.%2520Hypertens.%26date%3D2012%26volume%3D2012%26spage%3D351758%26doi%3D10.1155%2F2012%2F351758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdonk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abd-Alla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batenburg, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Bogaerdt, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veghel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roks, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danser, A. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Esch, J. H. M.</span></span> <span> </span><span class="NLM_article-title">Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.112.196022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1161%2FHYPERTENSIONAHA.112.196022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=22802221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1SitbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=722-729&author=K.+Verdonkauthor=M.+Durikauthor=N.+Abd-Allaauthor=W.+M.+Batenburgauthor=A.+J.+van+den+Bogaerdtauthor=R.+van+Veghelauthor=A.+J.+M.+Roksauthor=A.+H.+J.+Danserauthor=J.+H.+M.+van+Esch&title=Compound+21+induces+vasorelaxation+via+an+endothelium-+and+angiotensin+II+type+2+receptor-independent+mechanism&doi=10.1161%2FHYPERTENSIONAHA.112.196022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Compound 21 Induces Vasorelaxation via an Endothelium- and Angiotensin II Type 2 Receptor-Independent Mechanism</span></div><div class="casAuthors">Verdonk, Koen; Durik, Matej; Abd-Alla, Nalina; Batenburg, Wendy W.; van den Bogaerdt, Antoon J.; van Veghel, Richard; Roks, Anton J. M.; Danser, A. H. Jan; van Esch, Joep H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">722-729</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Angiotensin II type 2 (AT2) receptor stimulation has been linked to vasodilation.  Yet, AT2 receptor-independent hypertension and hypotension (or no effect on blood pressure) have been obsd. in vivo after application of the AT2 receptor agonist compd. 21 (C21).  We, therefore, studied its effects in vitro, using prepns. known to display AT2 receptor-mediated responses.  Hearts of Wistar rats, spontaneously hypertensive rats (SHRs), C57Bl/6 mice, and AT2 receptor knockout mice were perfused according to Langendorff.  Mesenteric and iliac arteries of these animals, as well as coronary microarteries from human donor hearts, were mounted in Mulvany myographs.  In the coronary vascular bed of Wistar rats, C57Bl/6 mice, and AT2 receptor knockout mice, C21 induced constriction followed by dilation.  SHR hearts displayed enhanced constriction and no dilation.  Irbesartan (angiotensin II type 1 receptor blocker) abolished the constriction and enhanced or (in SHRs) reintroduced dilation, and PD123319 (AT2 receptor blocker) did not block the latter.  C21 relaxed preconstricted vessels of all species, and this did not depend on angiotensin II receptors, the endothelium, or the NO-guanylyl cyclase-cGMP pathway.  C21 constricted SHR iliac arteries but none of the other vessels, and irbesartan prevented this.  C21 shifted the concn.-response curves to U46619 (thromboxane A2 analog) and phenylephrine (α-adrenoceptor agonist) but not ionomycine (calcium ionophore) to the right.  In conclusion, C21 did not cause AT2 receptor-mediated vasodilation.  Yet, it did induce vasodilation by blocking calcium transport into the cell and constriction via angiotensin II type 1 receptor stimulation.  The latter effect is enhanced in SHRs.  These data may explain the varying effects of C21 on blood pressure in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP_wXzTtIEJLVg90H21EOLACvtfcHk0lh5aJwExcbVGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1SitbbO&md5=62d45012a16c1a77d0c29cb5f92aa1e1</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.112.196022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.112.196022%26sid%3Dliteratum%253Aachs%26aulast%3DVerdonk%26aufirst%3DK.%26aulast%3DDurik%26aufirst%3DM.%26aulast%3DAbd-Alla%26aufirst%3DN.%26aulast%3DBatenburg%26aufirst%3DW.%2BM.%26aulast%3Dvan%2Bden%2BBogaerdt%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BVeghel%26aufirst%3DR.%26aulast%3DRoks%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DDanser%26aufirst%3DA.%2BH.%2BJ.%26aulast%3Dvan%2BEsch%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DCompound%252021%2520induces%2520vasorelaxation%2520via%2520an%2520endothelium-%2520and%2520angiotensin%2520II%2520type%25202%2520receptor-independent%2520mechanism%26jtitle%3DHypertension%26date%3D2012%26volume%3D60%26spage%3D722%26epage%3D729%26doi%3D10.1161%2FHYPERTENSIONAHA.112.196022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumners, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule AT2 receptor agonists</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1002/med.21449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fmed.21449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28609561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2ntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=602-624&author=M.+Hallbergauthor=C.+Sumnersauthor=U.+M.+Steckelingsauthor=A.+Hallberg&title=Small-molecule+AT2+receptor+agonists&doi=10.1002%2Fmed.21449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule AT2 receptor agonists</span></div><div class="casAuthors">Hallberg, Mathias; Sumners, Colin; Steckelings, U. Muscha; Hallberg, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">602-624</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the first selective, small-mol. ATR receptor (AT2R) agonist compd. 21 (C21) (8) that is now extensively studied in a large variety of in vitro and in vivo models is described.  The sulfonylcarbamate deriv. 8, encompassing a phenylthiofen scaffold is the drug-like agonist with the highest affinity for the AT2R reported to date (Ki = 0.4 nM).  Structure-activity relationships (SAR), regarding different biaryl scaffolds and functional groups attached to these scaffolds and with a particular focus on the impact of various para substituents displacing the methylene imidazole group of 8, are discussed.  Furthermore, the consequences of migration of the methylene imidazole group and presumed structural requirements for ligands that are aimed as AT2R agonists (e.g. 8) or AT2R antagonists (e.g. 9), resp., are briefly addressed.  A summary of the pharmacol. actions of C21 (8) is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJdPNSkTXtH7Vg90H21EOLACvtfcHk0liccuhwoBcdpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2ntrg%253D&md5=ab5b0cbb445d896af83e4e525a05cab2</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1002%2Fmed.21449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21449%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DSumners%26aufirst%3DC.%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DSmall-molecule%2520AT2%2520receptor%2520agonists%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D602%26epage%3D624%26doi%3D10.1002%2Fmed.21449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">Selective angiotensin II AT<sub>2</sub> receptor agonists: arylbenzylimidazole structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">7160</span>– <span class="NLM_lpage">7168</span>, <span class="refDoi"> DOI: 10.1021/jm0606185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0606185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOmtLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7160-7168&author=X.+Wuauthor=Y.+Wanauthor=A.+K.+Mahalingamauthor=B.+Plouffeauthor=M.+Botrosauthor=A.+Karl%C3%A9nauthor=M.+Hallbergauthor=N.+Gallo-Payetauthor=M.+Alterman&title=Selective+angiotensin+II+AT2+receptor+agonists%3A+arylbenzylimidazole+structure-activity+relationships&doi=10.1021%2Fjm0606185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Angiotensin II AT2 Receptor Agonists: Arylbenzylimidazole Structure-Activity Relationships</span></div><div class="casAuthors">Wu, Xiongyu; Wan, Yiqian; Mahalingam, A. K.; Murugaiah, A. M. S.; Plouffe, Bianca; Botros, Milad; Karlen, Anders; Hallberg, Mathias; Gallo-Payet, Nicole; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7160-7168</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structural alterations in the 2- and 5-positions of the first drug-like selective angiotensin II AT2 receptor agonist I have been performed.  The imidazole ring system was proven to be a strong determinant for the AT2 selectivity, and with few exceptions all variations gave good AT2 receptor affinities and with retained high AT2/AT1 selectivities.  On the contrary to the findings with AT1 receptor agonists, the impact of structural modifications in the 5-position of the AT2 selective compds. were less pronounced regarding activation of the AT2 receptor.  The butyloxyphenyl (56) and the propylthienyl (50) derivs. were found to exert a high agonistic effect as deduced from their capacity to induce neurite elongation in neuronal cells, as does angiotensin II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf4sAB0bMOUbVg90H21EOLACvtfcHk0liccuhwoBcdpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOmtLbE&md5=ad6b1ffa071f77461cf222546f6a84e2</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fjm0606185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0606185%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DMahalingam%26aufirst%3DA.%2BK.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DSelective%2520angiotensin%2520II%2520AT2%2520receptor%2520agonists%253A%2520arylbenzylimidazole%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7160%26epage%3D7168%26doi%3D10.1021%2Fjm0606185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugaiah, A. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">Selective angiotensin II AT2 receptor agonists devoid of the imidazole ring system</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">7166</span>– <span class="NLM_lpage">7183</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.07.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bmc.2007.07.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=17825570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFWiur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=7166-7183&author=A.+M.+S.+Murugaiahauthor=C.+Wallinderauthor=A.+K.+Mahalingamauthor=X.+Wuauthor=Y.+Wanauthor=B.+Plouffeauthor=M.+Botrosauthor=A.+Karl%C3%A9nauthor=M.+Hallbergauthor=N.+Gallo-Payetauthor=M.+Alterman&title=Selective+angiotensin+II+AT2+receptor+agonists+devoid+of+the+imidazole+ring+system&doi=10.1016%2Fj.bmc.2007.07.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Selective angiotensin II AT2 receptor agonists devoid of the imidazole ring system</span></div><div class="casAuthors">Murugaiah, A. M. S.; Wallinder, Chalotta; Mahalingam, A. K.; Wu, Xiongyu; Wan, Yiqian; Plouffe, Bianca; Botros, Milad; Karlen, Anders; Hallberg, Mathias; Gallo-Payet, Nicole; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7166-7183</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A versatile parallel synthetic method to obtain three series of noncyclic analogs of the first drug-like selective angiotensin II AT2 receptor agonist (1) has been developed.  In analogy with the transformation of losartan to valsartan it was demonstrated that a noncyclic moiety could be employed as an imidazole replacement to obtain AT2 selective compds.  In all the three series, AT2 receptor ligands with affinities in the lower nanomolar range were found.  None of the analogs exhibited any affinity for the AT1 receptor.  Four compds., (I, II, III, IV) were examd. in a neurite outgrowth cell assay.  All four compds. were found to exert a high agonistic effect as deduced from their capacity to induce neurite elongation in neuronal cells, as does angiotensin II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodM62cLXvKH7Vg90H21EOLACvtfcHk0liccuhwoBcdpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFWiur3N&md5=a6442c26d78f0c47a0aeeef727adb589</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.07.026%26sid%3Dliteratum%253Aachs%26aulast%3DMurugaiah%26aufirst%3DA.%2BM.%2BS.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DMahalingam%26aufirst%3DA.%2BK.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DKarl%25C3%25A9n%26aufirst%3DA.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DSelective%2520angiotensin%2520II%2520AT2%2520receptor%2520agonists%2520devoid%2520of%2520the%2520imidazole%2520ring%2520system%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D7166%26epage%3D7183%26doi%3D10.1016%2Fj.bmc.2007.07.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenström, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimond, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudry, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">Selective angiotensin II AT<sub>2</sub> receptor agonists: benzamide structure–activity relationships</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6841</span>– <span class="NLM_lpage">6849</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.05.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bmc.2008.05.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=18599297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVKqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=6841-6849&author=C.+Wallinderauthor=M.+Botrosauthor=U.+Rosenstr%C3%B6mauthor=M.+O.+Guimondauthor=H.+Beaudryauthor=F.+Nybergauthor=N.+Gallo-Payetauthor=A.+Hallbergauthor=M.+Alterman&title=Selective+angiotensin+II+AT2+receptor+agonists%3A+benzamide+structure%E2%80%93activity+relationships&doi=10.1016%2Fj.bmc.2008.05.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships</span></div><div class="casAuthors">Wallinder, Charlotta; Botros, Milad; Rosenstroem, Ulrika; Guimond, Marie-Odile; Beaudry, Helene; Nyberg, Fred; Gallo-Payet, Nicole; Hallberg, Anders; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6841-6849</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the investigation of the structure-activity relationship of nonpeptide AT2 receptor agonists, a series of substituted benzamide analogs of the selective nonpeptide AT2 receptor agonist M024 have been synthesized.  In a second series, the biphenyl scaffold was compared to the thienylphenyl scaffold and the impact of the iso-Bu substituent and its position on AT1/AT2 receptor selectivity was also investigated.  Both series included several compds. with high affinity and selectivity for the AT2 receptor.  Three of the compds. were also proven to function as agonists at the AT2 receptor, as deduced from a neurite outgrowth assay, conducted in NG108-15 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpVnwTEEumorVg90H21EOLACvtfcHk0lj3Mw3xbRii1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVKqsb0%253D&md5=52015aa6eb2a1c96c0a78b106b6b6e2a</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.05.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.05.066%26sid%3Dliteratum%253Aachs%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DRosenstr%25C3%25B6m%26aufirst%3DU.%26aulast%3DGuimond%26aufirst%3DM.%2BO.%26aulast%3DBeaudry%26aufirst%3DH.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DSelective%2520angiotensin%2520II%2520AT2%2520receptor%2520agonists%253A%2520benzamide%2520structure%25E2%2580%2593activity%2520relationships%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D6841%26epage%3D6849%26doi%3D10.1016%2Fj.bmc.2008.05.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugaiah, A. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">Selective angiotensin II AT<sub>2</sub> receptor agonists with reduced CYP 450 inhibition</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4570</span>– <span class="NLM_lpage">4590</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.03.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bmc.2010.03.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=20493713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntV2qsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4570-4590&author=A.+K.+Mahalingamauthor=Y.+Wanauthor=A.+M.+S.+Murugaiahauthor=C.+Wallinderauthor=X.+Wuauthor=B.+Plouffeauthor=M.+Botrosauthor=F.+Nybergauthor=A.+Hallbergauthor=N.+Gallo-Payetauthor=M.+Alterman&title=Selective+angiotensin+II+AT2+receptor+agonists+with+reduced+CYP+450+inhibition&doi=10.1016%2Fj.bmc.2010.03.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Selective angiotensin II AT2 receptor agonists with reduced CYP 450 inhibition</span></div><div class="casAuthors">Mahalingam, A. K.; Wan, Yiqian; Murugaiah, A. M. S.; Wallinder, Charlotta; Wu, Xiongyu; Plouffe, Bianca; Botros, Milad; Nyberg, Fred; Hallberg, Anders; Gallo-Payet, Nicole; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4570-4590</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Structural alterations to the benzylic position of the first drug-like selective angiotensin II AT2 receptor agonist (1) have been performed, with the emphasis to reduce the CYP 450 inhibitory property of the initial structure.  The imidazole moiety, responsible for the CYP 450 inhibitory effect in 1, was replaced with various heterocycles.  In addn., the modes of attachment of the heterocycles, i.e., carbon vs. nitrogen attachment, and introduction of carbonyl functionalities to the benzylic position have been evaluated.  In all the three series, AT2 receptor ligands with affinity in the lower nanomolar range were identified.  None of the analogs, regardless of the substituents, exhibited any affinity for the AT1 receptor.  Compds. with substantially reduced inhibition of the CYP 450 enzymes were obtained.  Among them the compd. 60 was found to induce neurite elongation in NG 108-15 cells and served as potent AT2 selective agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Z6ZPAY8DaLVg90H21EOLACvtfcHk0lj3Mw3xbRii1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntV2qsrc%253D&md5=80cfa58d9d0e5950a1c6c9408a81c153</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.03.064%26sid%3Dliteratum%253Aachs%26aulast%3DMahalingam%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DMurugaiah%26aufirst%3DA.%2BM.%2BS.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DSelective%2520angiotensin%2520II%2520AT2%2520receptor%2520agonists%2520with%2520reduced%2520CYP%2520450%2520inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4570%26epage%3D4590%26doi%3D10.1016%2Fj.bmc.2010.03.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugaiah, A. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sköld, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimond, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span> <span> </span><span class="NLM_article-title">From the first selective non-peptide AT<sub>2</sub> receptor agonist to structurally related antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2278</span>, <span class="refDoi"> DOI: 10.1021/jm2015099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2015099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2265-2278&author=A.+M.+S.+Murugaiahauthor=X.+Wuauthor=C.+Wallinderauthor=A.+K.+Mahalingamauthor=Y.+Wanauthor=C.+Sk%C3%B6ldauthor=M.+Botrosauthor=M.+O.+Guimondauthor=A.+Joshiauthor=F.+Nybergauthor=N.+Gallo-Payetauthor=A.+Hallbergauthor=M.+Alterman&title=From+the+first+selective+non-peptide+AT2+receptor+agonist+to+structurally+related+antagonists&doi=10.1021%2Fjm2015099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">From the First Selective Non-Peptide AT2 Receptor Agonist to Structurally Related Antagonists</span></div><div class="casAuthors">Murugaiah, A. M. S.; Wu, Xiongyu; Wallinder, Charlotta; Mahalingam, A. K.; Wan, Yiqian; Skoeld, Christian; Botros, Milad; Guimond, Marie-Odile; Joshi, Advait; Nyberg, Fred; Gallo-Payet, Nicole; Hallberg, Anders; Alterman, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2265-2278</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A para substitution pattern of the Ph ring is a characteristic feature of the first reported selective AT2 receptor agonist M024/C21 (1) and all the nonpeptidic AT2 receptor agonists described so far.  Two series of compds. structurally related to 1 but with a meta substitution pattern have now been synthesized and biol. evaluated for their affinity to the AT1 and AT2 receptors.  A high AT2/AT1 receptor selectivity was obtained with all 41 compds. synthesized, and the majority exhibited Ki ranging from 2 to 100 nM.  Five compds. were evaluated for their functional activity at the AT2 receptor, applying a neurite outgrowth assay in NG108-15 cells.  Notably, four of the five compds., with representatives from both series, acted as potent AT2 receptor antagonists.  These compds. were found to be considerably more effective than PD 123,319, the std. AT2 receptor antagonist used in most labs.  No AT2 receptor antagonists were previously reported among the derivs. with a para substitution pattern.  Hence, by a minor modification of the agonist 1 it could be transformed into the antagonist, compd. 38.  These compds. should serve as valuable tools in the assessment of the role of the AT2 receptor in more complex physiol. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPhSjJ131hU7Vg90H21EOLACvtfcHk0lge-oEaMlJfMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFGqsQ%253D%253D&md5=dbc405b40e113ba09195cc6be72e1400</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Fjm2015099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2015099%26sid%3Dliteratum%253Aachs%26aulast%3DMurugaiah%26aufirst%3DA.%2BM.%2BS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DMahalingam%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DSk%25C3%25B6ld%26aufirst%3DC.%26aulast%3DBotros%26aufirst%3DM.%26aulast%3DGuimond%26aufirst%3DM.%2BO.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DNyberg%26aufirst%3DF.%26aulast%3DGallo-Payet%26aufirst%3DN.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DAlterman%26aufirst%3DM.%26atitle%3DFrom%2520the%2520first%2520selective%2520non-peptide%2520AT2%2520receptor%2520agonist%2520to%2520structurally%2520related%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2265%26epage%3D2278%26doi%3D10.1021%2Fjm2015099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guimond, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alterman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo-Payet, N.</span></span> <span> </span><span class="NLM_article-title">Comparative functional properties of two structurally similar selective nonpeptide drug-like ligands for the angiotensin II type-2 (AT<sub>2</sub>) receptor. Effects on neurite outgrowth in NG108–15 cells</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>699</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.11.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.ejphar.2012.11.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=23211679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlaqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=699&publication_year=2013&pages=160-171&author=M.+O.+Guimondauthor=C.+Wallinderauthor=M.+Altermanauthor=A.+Hallbergauthor=N.+Gallo-Payet&title=Comparative+functional+properties+of+two+structurally+similar+selective+nonpeptide+drug-like+ligands+for+the+angiotensin+II+type-2+%28AT2%29+receptor.+Effects+on+neurite+outgrowth+in+NG108%E2%80%9315+cells&doi=10.1016%2Fj.ejphar.2012.11.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative functional properties of two structurally similar selective nonpeptide drug-like ligands for the angiotensin II type-2 (AT2) receptor. Effects on neurite outgrowth in NG108-15 cells</span></div><div class="casAuthors">Guimond, Marie-Odile; Wallinder, Charlotta; Alterman, Mathias; Hallberg, Anders; Gallo-Payet, Nicole</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">699</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">160-171</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There is increasing evidence that angiotensin II (Ang II), through binding to the type 2 (AT2) receptor may have beneficial effects in various physiol. and pathol. situations.  However, specific action presumably mediated by the angiotensin AT2 receptor has been hampered by the absence of appropriate selective ligands.  The aim of this study was to compare the biol. properties of two related and selective drug-like nonpeptide AT2 ligands, namely an agonist called M024 (also known as Compd. 21) and a new ligand, presumably an antagonist, C38/M132, (originally called C38).  Properties of the compds. were investigated in NG108-15 cells expressing angiotensin AT2 receptor and known to develop neurite outgrowth upon Ang II stimulation.  NG108-15 cells stimulated for three days with C21/M024 (0.1 or 100 nM) exhibited the same neurite outgrowth as cells stimulated with Ang II (100 nM) while co-incubation of Ang II or C21/M024 with C38/M132 (10 or 100 nM) inhibited their effects, similarly to the angiotensin AT2 receptor antagonist, PD123319 (10 μM).  As Ang II, C21/M024 induced a Rap1-dependent activation of p42/p44mapk whereas preincubation of cells with C38/M132 inhibited p42/p44mapk and Rap1 activation induced by Ang II.  Three-day treatment with C21/M024 or Ang II decreased cell no. in culture, an effect that was rescued by preincubation with C38/M132.  Taken together, these results indicate that the nonpeptide ligand C21/M024 is a potent angiotensin AT2 receptor agonist while C38/M132 acts as an antagonist.  These selective nonpeptide angiotensin AT2 ligands may represent unique and long-awaited tools for the pursuit of in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppSbhxynZSXrVg90H21EOLACvtfcHk0lge-oEaMlJfMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlaqtrs%253D&md5=4654d2d54485809d948577c0390c0a74</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.11.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.11.032%26sid%3Dliteratum%253Aachs%26aulast%3DGuimond%26aufirst%3DM.%2BO.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DAlterman%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3DGallo-Payet%26aufirst%3DN.%26atitle%3DComparative%2520functional%2520properties%2520of%2520two%2520structurally%2520similar%2520selective%2520nonpeptide%2520drug-like%2520ligands%2520for%2520the%2520angiotensin%2520II%2520type-2%2520%2528AT2%2529%2520receptor.%2520Effects%2520on%2520neurite%2520outgrowth%2520in%2520NG108%25E2%2580%259315%2520cells%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D699%26spage%3D160%26epage%3D171%26doi%3D10.1016%2Fj.ejphar.2012.11.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sallander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åqvist, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutiérrez-de-Terán, H.</span></span> <span> </span><span class="NLM_article-title">Structural determinants of subtype selectivity and functional activity of angiotensin II receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1359</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bmcl.2015.10.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=26810314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1CisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1355-1359&author=J.+Sallanderauthor=C.+Wallinderauthor=A.+Hallbergauthor=J.+%C3%85qvistauthor=H.+Guti%C3%A9rrez-de-Ter%C3%A1n&title=Structural+determinants+of+subtype+selectivity+and+functional+activity+of+angiotensin+II+receptors&doi=10.1016%2Fj.bmcl.2015.10.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of subtype selectivity and functional activity of angiotensin II receptors</span></div><div class="casAuthors">Sallander, Jessica; Wallinder, Charlotta; Hallberg, Anders; Aaqvist, Johan; Gutierrez-de-Teran, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1355-1359</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Agonists of the angiotensin II receptor type 2 (AT2), a G-protein coupled receptor, promote tissue protective effects in cardiovascular and renal diseases, while antagonists reduce neuropathic pain.  We here report detailed mol. models that explain the AT2 receptor selectivity of our recent series of non-peptide ligands.  In addn., minor structural changes of these ligands that provoke different functional activity are rationalized at a mol. level, and related to the selectivity for the different receptor conformations.  These findings should pave the way to structure based drug discovery of AT2 receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrChP5GGPcsOrVg90H21EOLACvtfcHk0lge-oEaMlJfMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1CisL8%253D&md5=c4e6634a5abebc5529ea69de5498bded</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.084%26sid%3Dliteratum%253Aachs%26aulast%3DSallander%26aufirst%3DJ.%26aulast%3DWallinder%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DA.%26aulast%3D%25C3%2585qvist%26aufirst%3DJ.%26aulast%3DGuti%25C3%25A9rrez-de-Ter%25C3%25A1n%26aufirst%3DH.%26atitle%3DStructural%2520determinants%2520of%2520subtype%2520selectivity%2520and%2520functional%2520activity%2520of%2520angiotensin%2520II%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1355%26epage%3D1359%26doi%3D10.1016%2Fj.bmcl.2015.10.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isaksson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backlund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åqvist, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez de Teran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gising, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span> <span> </span><span class="NLM_article-title">A series of analogues to the AT<sub>2</sub>R prototype antagonist C38 allow fine tuning of the previously reported antagonist binding mode</span>. <i>ChemistryOpen</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1002/open.201800282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1002%2Fopen.201800282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=30697513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=114-125&author=R.+Isakssonauthor=J.+Lindmanauthor=J.+Wannbergauthor=J.+Sallanderauthor=M.+Backlundauthor=D.+Baraldiauthor=R.+Widdopauthor=M.+Hallbergauthor=J.+%C3%85qvistauthor=H.+Gutierrez+de+Teranauthor=J.+Gisingauthor=M.+Larhed&title=A+series+of+analogues+to+the+AT2R+prototype+antagonist+C38+allow+fine+tuning+of+the+previously+reported+antagonist+binding+mode&doi=10.1002%2Fopen.201800282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">A Series of Analogues to the AT2R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode</span></div><div class="casAuthors">Isaksson, Rebecka; Lindman, Jens; Wannberg, Johan; Sallander, Jessica; Backlund, Maria; Baraldi, Dhaniel; Widdop, Robert; Hallberg, Mathias; Aaqvist, Johan; Gutierrez de Teran, Hugo; Gising, Johan; Larhed, Mats</div><div class="citationInfo"><span class="NLM_cas:title">ChemistryOpen</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-125</span>CODEN:
                <span class="NLM_cas:coden">CHOPCK</span>;
        ISSN:<span class="NLM_cas:issn">2191-1363</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We here report on our continued studies of ligands binding to the promising drug target angiotensin II type 2 receptor (AT2R).  Two series of compds. were synthesized and investigated.  The first series explored the effects of adding small substituents to the Ph ring of the known selective nonpeptide AT2R antagonist C38, generating small but significant shifts in AT2R affinity.  One compd. in the first series was equipotent to C38 and showed similar kinetic soly., and stability in both human and mouse liver microsomes.  The second series was comprised of new bicyclic derivs., amongst which one ligand exhibited a five-fold improved affinity to AT2R as compared to C38.  The majority of the compds. in the second series, including the most potent ligand, were inferior to C38 with regard to stability in both human and mouse microsomes.  In contrast to our previously reported findings, ligands with shorter carbamate alkyl chains only demonstrated slightly improved stability in microsomes.  Based on data presented herein, a more adequate, tentative model of the binding modes of ligand analogs to the prototype AT2R antagonist C38 is proposed, as deduced from docking redefined by mol. dynamic simulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSax4q9NnPGbVg90H21EOLACvtfcHk0ljY-8Kyt3-T3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCnu70%253D&md5=59ec8cea9c18b86233d9785f54976f8f</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1002%2Fopen.201800282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fopen.201800282%26sid%3Dliteratum%253Aachs%26aulast%3DIsaksson%26aufirst%3DR.%26aulast%3DLindman%26aufirst%3DJ.%26aulast%3DWannberg%26aufirst%3DJ.%26aulast%3DSallander%26aufirst%3DJ.%26aulast%3DBacklund%26aufirst%3DM.%26aulast%3DBaraldi%26aufirst%3DD.%26aulast%3DWiddop%26aufirst%3DR.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3D%25C3%2585qvist%26aufirst%3DJ.%26aulast%3DGutierrez%2Bde%2BTeran%26aufirst%3DH.%26aulast%3DGising%26aufirst%3DJ.%26aulast%3DLarhed%26aufirst%3DM.%26atitle%3DA%2520series%2520of%2520analogues%2520to%2520the%2520AT2R%2520prototype%2520antagonist%2520C38%2520allow%2520fine%2520tuning%2520of%2520the%2520previously%2520reported%2520antagonist%2520binding%2520mode%26jtitle%3DChemistryOpen%26date%3D2019%26volume%3D8%26spage%3D114%26epage%3D125%26doi%3D10.1002%2Fopen.201800282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaksson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremberg, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backlund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sävmarker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhed, M.</span></span> <span> </span><span class="NLM_article-title">A convenient transesterification method for synthesis of AT2 receptor ligands with improved stability in human liver microsomes</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.11.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1016%2Fj.bmcl.2017.11.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=29279275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVejtL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=519-522&author=J.+Wannbergauthor=R.+Isakssonauthor=U.+Brembergauthor=M.+Backlundauthor=J.+S%C3%A4vmarkerauthor=M.+Hallbergauthor=M.+Larhed&title=A+convenient+transesterification+method+for+synthesis+of+AT2+receptor+ligands+with+improved+stability+in+human+liver+microsomes&doi=10.1016%2Fj.bmcl.2017.11.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient transesterification method for synthesis of AT2 receptor ligands with improved stability in human liver microsomes</span></div><div class="casAuthors">Wannberg, Johan; Isaksson, Rebecka; Bremberg, Ulf; Backlund, Maria; Saevmarker, Jonas; Hallberg, Mathias; Larhed, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">519-522</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of AT2R ligands were synthesized applying a quick, simple, and safe transesterification-type reaction whereby the sulfonyl carbamate alkyl tail of the selective AT2R antagonist C38 was varied.  Furthermore, a limited no. of compds. where acyl sulfonamides and sulfonyl ureas served as carboxylic acid bioisosteres were synthesized and evaluated.  By reducing the size of the alkyl chain of the sulfonyl carbamates, ligands Me ((3-(3-((1H-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2-yl)sulfonyl)carbamate and Et ((3-(3-((1H-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2-yl)sulfonyl)carbamate 2,2,2-trifluoroacetate were identified with significantly improved in vitro metabolic stability in both human and mouse liver microsomes as compared to C38 while retaining the AT2R binding affinity and AT2R/AT1R selectivity.  Eight of the compds. synthesized exhibit an improved stability in human microsomes as compared to C38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSozr1rZ8LU7Vg90H21EOLACvtfcHk0ljY-8Kyt3-T3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVejtL7P&md5=c16d5d848e3d2298e592b5da75cb5738</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.11.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.11.042%26sid%3Dliteratum%253Aachs%26aulast%3DWannberg%26aufirst%3DJ.%26aulast%3DIsaksson%26aufirst%3DR.%26aulast%3DBremberg%26aufirst%3DU.%26aulast%3DBacklund%26aufirst%3DM.%26aulast%3DS%25C3%25A4vmarker%26aufirst%3DJ.%26aulast%3DHallberg%26aufirst%3DM.%26aulast%3DLarhed%26aufirst%3DM.%26atitle%3DA%2520convenient%2520transesterification%2520method%2520for%2520synthesis%2520of%2520AT2%2520receptor%2520ligands%2520with%2520improved%2520stability%2520in%2520human%2520liver%2520microsomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D519%26epage%3D522%26doi%3D10.1016%2Fj.bmcl.2017.11.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosnyak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1042/CS20110036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1042%2FCS20110036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=21542804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntlSjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=297-303&author=S.+Bosnyakauthor=E.+S.+Jonesauthor=A.+Christopoulosauthor=M.+I.+Aguilarauthor=W.+G.+Thomasauthor=R.+E.+Widdop&title=Relative+affinity+of+angiotensin+peptides+and+novel+ligands+at+AT1+and+AT2+receptors&doi=10.1042%2FCS20110036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors</span></div><div class="casAuthors">Bosnyak, Sanja; Jones, Emma S.; Christopoulos, Arthur; Aguilar, Marie-Isabel; Thomas, Walter G.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7/8</span>),
    <span class="NLM_cas:pages">297-303</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">0143-5221</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">AT1R (angiotensin type 1 receptor) and AT2R (angiotensin type 2 receptor) are well known to be involved in the complex cardiovascular actions of AngII (angiotensin II).  However, shorter peptide fragments of AngII are thought to have biol. activity in their own right and elicit effects that oppose those mediated by AngII.  In the present study, we have used HEK (human embryonic kidney)-293 cells stably transfected with either AT1R or AT2R to perform a systematic anal. of binding affinities of all the major angiotensin peptides.  Addnl., we tested the novel AT2R agonist Compd. 21, as well as the MasR (Mas receptor) agonist and antagonist AVE0991 and A-779 resp., for their ability to bind to AT1R or AT2R.  Candesartan, CGP42214 and PD123319 were used as ref. compds.  Binding studies using 125I-[Sar1Ile8]AngII on the AT1R-transfected HEK-293 cells revealed only AngII, AngIII [angiotensin III; angiotensin-(2-8)] and candesartan to have high affinity for AT1R.  In the AT2R-transfected HEK-293 cells, competition for 125I-[Sar1Ile8]AngII binding was obsd. for all ligands except candesartan, AVE0991 and A-779, the latter two compds. having negligible affinity at either AT1R or AT2R.  The rank order of affinity of ligands at AT2R was CGP42112>AngII≥AngIII>Compd. 21≥PD123319»AngIV [angiotensin IV; angiotensin-(3-8)]>Ang-(1-7) [angiotensin-(1-7)].  Of note, although AngIV and Ang-(1-7) exhibited only modest affinity at AT2R compared with AngII, these two angiotensin peptides, together with AngIII, had substantial AT2R selectivity over AT1R.  Collectively, our results suggest that shorter angiotensin peptides can act as endogenous ligands at AT2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPONK0yiaKCrVg90H21EOLACvtfcHk0ljY-8Kyt3-T3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntlSjsbk%253D&md5=b8e8a22de54c7e39995afecdb18d329c</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1042%2FCS20110036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20110036%26sid%3Dliteratum%253Aachs%26aulast%3DBosnyak%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DE.%2BS.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DAguilar%26aufirst%3DM.%2BI.%26aulast%3DThomas%26aufirst%3DW.%2BG.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DRelative%2520affinity%2520of%2520angiotensin%2520peptides%2520and%2520novel%2520ligands%2520at%2520AT1%2520and%2520AT2%2520receptors%26jtitle%3DClin.%2520Sci.%26date%3D2011%26volume%3D121%26spage%3D297%26epage%3D303%26doi%3D10.1042%2FCS20110036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Targeted gamma-secretase inhibition of Notch signaling activation in acute renal injury</span>. <i>Am. J. Physiol., Renal Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">F736</span>– <span class="NLM_lpage">F746</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.00414.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=10.1152%2Fajprenal.00414.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;key=28971991" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2018&pages=F736-F746&author=J.+C.+Wyssauthor=R.+Kumarauthor=J.+Mikulicauthor=M.+Schneiderauthor=J.+D.+Aebiauthor=L.+Juillerat-Jeanneretauthor=D.+Golshayan&title=Targeted+gamma-secretase+inhibition+of+Notch+signaling+activation+in+acute+renal+injury&doi=10.1152%2Fajprenal.00414.2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00414.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00414.2016%26sid%3Dliteratum%253Aachs%26aulast%3DWyss%26aufirst%3DJ.%2BC.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DMikulic%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DAebi%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DTargeted%2520gamma-secretase%2520inhibition%2520of%2520Notch%2520signaling%2520activation%2520in%2520acute%2520renal%2520injury%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Renal%2520Physiol.%26date%3D2018%26volume%3D314%26spage%3DF736%26epage%3DF746%26doi%3D10.1152%2Fajprenal.00414.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01780&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01780%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-5" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01780" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667989042981d1f3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
